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Preface 
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allowing for fine tuning of physiological functions. This book is a collaborative effort, 
with contribution from experts in their respective fields, reflecting the spirit of 
collaboration - across disciplines and borders - that exists in modern science. Here, we 
review the existing literature and, on occasions, provide novel data on the function of 
protein kinases in various systems. We also discuss the implications of these findings in 
the context of disease, treatment, and drug development. 
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The Target of Rapamycin:  
Structure and Functions 
Chang-Chih Wu, Po-Chien Chou and Estela Jacinto* 
Department of Physiology and Biophysics,  
UMDNJ-Robert Wood Johnson Medical School, Piscataway, Piscataway, NJ 
USA 
1. Introduction  
The target of rapamycin (TOR, also called the mechanistic or mammalian target of 
rapamycin, mTOR) is an atypical protein kinase that is highly conserved in eukaryotes 
(Sarbassov et al. 2005; Wullschleger et al. 2006; Jacinto & Lorberg 2008). It modulates cell 
growth, metabolism, and cell survival in response to diverse extracellular and intracellular 
signals, such as growth factors, energy levels, and nutrient status (Reiling & Sabatini 2006; 
Wullschleger et al. 2006; Jacinto 2008). Inhibition of mTOR activity using rapamycin and 
more recently via mTOR active site inhibitors and disruption of mTOR complexes, has 
revealed important insights on how mTOR functions under physiological and pathological 
conditions (Sarbassov et al. 2005; Proud 2011; Zoncu et al. 2011).  
TOR was first identified as the target of rapamycin, a potent antifungal macrolide originally 
purified from Streptomyces hygroscopicus in an Easter Island soil sample in 1975 (Sehgal et al. 
1975; Vezina et al. 1975). This natural compound was later found to possess 
immunosuppressive and growth inhibitory properties on mammalian cells (Hall 1996; Thomas 
& Hall 1997; Young & Nickerson-Nutter 2005). A genetic screen in the budding yeast, 
Saccharomyces cerevisiae, identified three genes that conferred rapamycin resistance upon 
mutation. These genes include TOR1, TOR2, and FPR1 (Heitman et al. 1991). Whereas TOR1 
and TOR2 are relatively large proteins (around 300 kDa) and display homology to lipid 
kinases, FPR1 (also called FKBP12) is a small protein (about 12 kDa) that has cis-trans prolyl 
isomerase activity (Helliwell et al. 1994; Kunz et al. 2000). The activity of TOR/mTOR becomes 
inhibited by the complex formed by rapamycin and FKBP12. TOR orthologues were also 
discovered in mammalian cells (mTOR) and other higher eukaryotes (eg C. elegans TOR, 
CeTOR; Drosophila TOR, dTOR; Arabidopsis thaliana TOR, At TOR) (Brown et al. 1994; Oldham 
et al. 2000; Long et al. 2002; Menand et al. 2002). In this chapter, we will review the conserved 
structures of TOR, the regulation of the mTOR pathway, and summarize its conserved cellular 
functions. We also discuss the value of targeting mTOR function in therapeutic strategies. 
2. Structure, conserved versus divergent sequences in TOR 
TOR/mTOR is encoded by a single gene in most organisms although in some yeasts there 
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sequence among different species (Wullschleger et al. 2006). TOR belongs to the 
phosphatidylinositol-3 kinase-related kinase (PIKK) family, a subgroup of atypical protein 
kinases (Hanks & Hunter 1995; Manning et al. 2002; Miranda-Saavedra & Barton 2007). 
PIKKs are conserved from yeasts to mammals and have numerous functions in stress 
responses including DNA repair, transcription, and mRNA decay (Keith & Schreiber 1995). 
The PIKKs share some homology in the catalytic domain with lipid kinases including 
phosphatidylinositol-3 kinases (PI3Ks) (Keith & Schreiber 1995; Manning et al. 2002), but 
they possess serine/threonine kinase activity (Figure 1). The large size of PIKK family 
members (from 280 to 470 kDa) has been a major obstacle in studying the structure of these 
molecules (Knutson 2010). In general, these kinases are roughly defined by an -helical N-
terminal region and a catalytic C-terminal region (Choi et al. 1996; Lempiainen & 
Halazonetis 2009). From the structural prediction of amino acid sequences, PIKK family 
members contain HEAT (Huntington, elongation factor 3, alpha-regulatory subunit of 
protein phosphatase 2A and TOR1) repeats at the amino-terminus, FAT (FRAP-ATM- 
TRRAP) domain, kinase domain (KD), the PIKK-regulatory domain (PRD) and the FAT-C- 
 
Fig. 1. Structural domains of mTOR and conserved amino acid sequences between lipid and 
protein kinases. Numbers indicate the residues in mTOR. FAT, FRAP-ATM-TRRAP domain; 
FRB, FKBP12-rapamycin-binding domain; KD, kinase domain; FIT, found in TOR domain; 
PRD, PIKK-regulatory domain; FATC, FAT-C-terminal domain; HEAT repeat, the protein 
domain found in Huntingtin, Elongation factor 3, protein phosphatase 2A, and TOR1; 
mTOR, mammalian target of rapamycin; ATM, Ataxia telangiectasia mutated; DNA-PK, 
DNA-dependent protein kinase; PI3K, Phosphatidylinositol 3-kinases; Akt, protein kinase B; 
CDK1, Cyclin-dependent kinase 1. 
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terminal (FATC) domain, at the carboxyl-terminus (Bosotti et al. 2000; Jacinto 2008; Hardt et al. 
2011). The configuration of these protein motifs contributes to the catalytic activity and 
function of PIKKs, including TORs (Bosotti et al. 2000; Adami et al. 2007; Yip et al. 2010). 
Understanding the regulation of these motifs is key to unravelling the cellular function of 
TOR/mTOR and will provide insights on how we can manipulate the activity of this protein.  
2.1 HEAT repeats 
The amino-terminus of mTOR is characterized by HEAT repeats. This structural motif 
contains varied numbers of two anti-parallel α-helix repeats that are linked by inter-unit 
loops allowing flexibility in this structure (Perry & Kleckner 2003). A recent sequence 
analysis strategy revealed that there are 30 to 32 tandem HEAT repeats predicted in human, 
fly, plant, and yeast TORs (Knutson 2010). HEAT domains confer a curved-tubular shape, 
facilitating multiple protein-protein interactions in the N-terminal half of mTOR (Groves & 
Barford 1999; Adami et al. 2007). Accordingly, this region is shown to provide a platform for 
protein-protein interaction, where mTOR can bind with protein regulators or substrates. In 
the budding yeast, the TORC components, KOG1 (Kontroller Of Growth 1), AVO1 (Adheres 
VOraciously 1), and AVO3 (Adheres VOraciously 3), associate with TOR at the HEAT region 
of the N-terminus (Wullschleger et al. 2005; Adami et al. 2007; Yip et al. 2010). Similarly, 
raptor, the orthologue of KOG1 in mammalian cells, also interacts with the N-terminal 
region of mTOR and that the intact structure of the HEAT domain in mTOR is essential for 
this interaction (Kim et al. 2002; Adami et al. 2007; Yip et al. 2010).  
2.2 FAT domain and FRB domain 
FAT domain is a hallmark of the PIKK family (Bosotti et al. 2000). In mTOR and other PIKK 
members, the FAT domain is adjacent to the N-terminal portion of the catalytic region 
(Lempiainen & Halazonetis 2009; Hardt et al. 2011). Although the overall structure of FAT 
domains in mTOR is still unclear, it is suggested that this domain is composed entirely of -
helices according to sequence analysis and can be viewed as an extension of HEAT repeats. 
This would suggest that it serves as a platform for protein interaction as well (Perry & 
Kleckner 2003; Adami et al. 2007). Furthermore, the FAT domain may associate with another 
domain (FATC) to wedge the KD into a proper configuration and ensure the catalytic 
activity of mTOR (Bosotti et al. 2000).  
The C-terminus of the FAT domain is where rapamycin, in complex with FKBP12, binds 
mTOR (Stan et al. 1994; Chen et al. 1995). This small structural motif, consisting of around 100 
amino acids, has been termed as the FKBP12-rapamycin-binding (FRB) (Veverka et al. 2008). 
Structural and biochemical analyses have revealed that this motif can also bind to 
phosphatidic acid (PA), a lipid secondary messenger (Fang et al. 2001; Veverka et al. 2008). 
Upon mitogen stimulation, the level of PA is enhanced due to the activation of phospholipase 
D (English 1996). Although it is unclear whether PA can activate mTOR directly, it is 
suggested that PA may direct the membrane localization of mTOR (Veverka et al. 2008).  
2.3 FATC domain 
FATC, a protein motif containing around 30 amino acids, is conserved with high sequence 
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these kinases, the FATC domain is at the end of the C-terminal tail and exists in combination 
with the FAT domain to flank the kinase domain (Bosotti et al. 2000; Jacinto & Lorberg 2008) 
(Figure 1). Low-resolution structure of this domain in yeast TOR1, visualized by electron 
microscopy, suggests that this motif protrudes from the catalytic core domain (Adami et al. 
2007; Lempiainen & Halazonetis 2009). However, it is also predicted that the attachment of 
FATC to the KD is required for the proper conformation and activation of the latter. 
Structural studies utilizing NMR spectroscopy uncover that the FATC domain contains an 
-helix followed by a sharp turn, which is stabilized by a disulfide bond between two 
cysteine residues (Dames et al. 2005). The substitution of cysteine with serine increases the 
flexibility of FATC and leads to a lower expression level of TOR2 in budding yeast (Dames 
et al. 2005). Moreover, other mutagenesis assays have implied that the substitution and 
deletion of the hydrophobic residues in this domain abolish the autophosphorylation of 
mTOR and the mTOR-dependent phosphorylation of eukaryotic initiation factor 4E-binding 
protein (4E-BP) and p70 S6 kinase (S6K) (Peterson et al. 2000). Together, these studies 
indicate that the FATC domain modulates both kinase activity and stability of TOR. 
2.4 PRD (FIT) 
The PRD domain is a newly identified motif situated between the kinase and FATC 
domains in PIKK family members (Mordes et al. 2008). Unlike other C-terminal domains, 
this domain is not conserved in all PIKKs and its length varies between 16 to 82 amino acids 
(Mordes et al. 2008). In TOR, this region is also named the Found in TOR (FIT) domain 
(Sturgill & Hall 2009; Hardt et al. 2011). Its N-terminal half, which shows almost no 
sequence homology with other PIKKs, is defined as a suppressor of TOR activity. The 
deletion of residues 2430 to 2450 of rat mTOR enhances kinase activity of both mTOR and its 
downstream targets, in vitro and in vivo respectively (Brunn et al. 1997; Sekulic et al. 2000). 
The mitogen- and nutrient-induced post-translational phosphorylation on several residues 
in the FIT domain, eg Thr 2446, Ser 2448, and Ser 2481 is used as a marker of mTOR 
activation (Chiang & Abraham 2005; Holz & Blenis 2005; Copp et al. 2009). Thus, the 
phosphorylation in this region could relieve the suppressive action conferred by this 
domain. 
2.5 Catalytic domain and kinase activity of mTOR 
In the classification of eukaryotic protein kinases, mTOR belongs to the atypical group, a 
subset of protein kinases lacking sequence similarity to conventional protein kinases (Hanks 
& Hunter 1995) . In fact, the catalytic sequence of mTOR shares high homology with PI3K 
family, a lipid kinase family, but mTOR has been experimentally demonstrated to possess 
Serine/Threonine protein kinase activity (Alarcon et al. 1999). The segment from residues 
Lys2187 to Phe2421 comprises the catalytic region of mTOR (Hardt et al. 2011). Within this 
domain, two conserved structures are proposed to contribute to the kinase activity of 
mTOR: the catalytic loop, which contains the predicted catalytic base (Asp2338) in the triplet 
DRH residues (Hardt et al. 2011), and the activation loop (also called T loop), consisting of 
twenty to thirty amino acids that connects the N- and C-lobes of the kinase domain 
(Lochhead 2009). By general definition, activation loop begins with the DFG sequence and 
ends with the PE sequence (Figure 1). In conventional protein kinases, there is one 
phosphorylatable Ser, Thr, or Tyr residue existing within the region and the 
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phosphorylation at this residue is required for kinase activation. In most cases, either the 
kinase itself (autophosphorylation) or an upstream kinase mediates the phosphorylation of 
this site. However, in atypical protein kinases, such as mTOR, this phosphorylatable residue 
is substituted by an Asp or Glu, which mimics the phosphorylated state of the T loop. 
Hence, instead of the conventional phosphorylation-activation mechanism in the T loop, 
other cis- and trans-acting mechanisms modulate mTOR activity. As discussed above, the 
phosphorylation at the PRD could promote mTOR activity. mTOR could also be potentially 
regulated via FATC domain stability. The formation of disulfide bonds may stabilize the 
FATC structure, or even the whole mTOR protein (Sarbassov & Sabatini 2005). Due to this 
unique structural feature, it has been proposed that the FATC domain could act as a redox-
sensor to regulate mTOR activity (Dames et al. 2005). In this model, the presence of nutrients 
could enhance mitochondria metabolism that alters the intracellular redox environment. 
Although it remains to be examined, this redox change could be sensed by the FATC 
domain and confer a conformation switch in mTOR thereby altering its activity in response 
to intracellular stimuli (Dames et al. 2005). Other regulatory mechanisms such as association 
with regulatory partners and subcellular localization are discussed in Section 4. 
3. mTOR protein complexes 
Forming protein complexes is a common and efficient way to acquire different functional 
modules in a spatial and temporal manner (Hartwell et al. 1999; Pereira-Leal et al. 2006). As 
described in the previous section, the multiple motif conformation and superhelical structure 
of mTOR enables this protein to associate with diverse cofactors. Early studies using gel 
filtration chromatography suggested that TOR could be part of multi-protein complexes (Yang 
& Guan 2007). This was supported by findings that TOR has a rapamycin-insensitive function 
in yeast, implying that two complexes could perform distinct functions (Zheng, 1995; Schmidt, 
1996; Zheng, 1997). Indeed, in a number of organisms with perhaps the exception of plants and 
algae, there are two structurally and functionally distinct TOR complexes (Loewith et al. 2002; 
Wedaman et al. 2003; Matsuo et al. 2007; Diaz-Troya et al. 2008). In this section, both conserved 
and non-conserved components of TOR complexes will be discussed. 
3.1 mTORC1 
3.1.1 Raptor (KOG1) 
KOG1 was first identified to co-purify with TOR1 in budding yeast (Loewith et al. 2002). In 
mammals, the KOG1 orthologue, raptor, was found to associate with mTOR (Hara et al. 
2002; Kim et al. 2002). It is predicted that the C-terminal half of KOG1 and raptor consists of 
four HEAT repeats and seven WD40 repeats (Loewith et al. 2002; Wedaman et al. 2003; 
Adami et al. 2007; Yip et al. 2010). Due to their motif configuration, it is speculated that 
KOG1 and raptor function as scaffold proteins to facilitate the association between TORC1 
(mTORC1) and downstream substrates (Loewith et al. 2002; Adami et al. 2007). Deletion of 
kog1 in budding yeast and knockout of raptor in mice both led to lethality, implying that 
these genes are essential for normal development and cellular functions (Loewith et al. 2002; 
Murakami et al. 2004; Guertin et al. 2006). 
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phosphorylation at this residue is required for kinase activation. In most cases, either the 
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towards its substrates such as S6K and 4E-BP1 in response to insulin and nutrients (Kim et 
al. 2002). Presence of rapamycin/FKBP12 complex diminishes the association between 
raptor and mTOR, which could explain how rapamycin can inhibit mTORC1 function (Kim 
et al. 2002; Kim et al. 2003; Oshiro et al. 2004).  
3.1.2 mLST8 (LST8) 
LST8 is a 34 kDa protein composed of seven WD40 repeats (Chen & Kaiser 2003). Originally, 
LST8 was identified because of its function in the translocation of amino acid permease 
GAP1 from Golgi to cell surface (Roberg et al. 1997; Liu et al. 2001). Later, LST8 (Wat1 in 
fission yeast) was found in both TORC1 and TORC2 complexes (Chen & Kaiser 2003; 
Alvarez & Moreno 2006; Matsuo et al. 2007). Specifically, LST8 binds to the catalytic domain 
in the C-terminal region of TOR2 and regulates its kinase activity. In addition, it has been 
shown that LST8 is required for TORC2 complex integrity (Wullschleger et al. 2005). 
Similarly, mammalian LST8 (mLST8, also known as GL) was first reported to interact with 
raptor and mTOR in a nutrient- and rapamycin- sensitive manner (Kim et al. 2003). mLST8 
is only required for mTORC2 functions in the early development of mice (Guertin et al. 
2006). Knockout of mLST8 in mice revealed that it is required for mTORC2 function but not 
for the mTORC1 function in S6K phosphorylation (Guertin et al. 2006).  
3.2 mTORC2 
3.2.1 Rictor (AVO3) 
AVO3, a 164-kDa protein, is a conserved subunit of TORC2 in budding yeast (Loewith et al. 
2002). It was first identified as a suppressor of sphingolipid biosynthesis mutants in a 
genetic screen (Dunn et al. 1998). The presence of AVO3 is required for the integrity of 
rapamycin-insensitive TOR complex but it is dispensable for the in vitro kinase activity of 
TOR2 (Wullschleger et al. 2005). Therefore, AVO3 is suggested to play a role in recruiting 
TORC2 substrates (Ho et al. 2008).  
Rictor (rapamycin-insensitive companion of mTOR) is the mammalian orthologue of yeast 
AVO3 and is part of mTORC2 (Jacinto et al. 2004; Sarbassov et al. 2004). It lacks common or 
known structural motifs but its C-terminus is conserved among vertebrates. Knockdown or 
ablation of rictor in mammalian cells led to defective phosphorylation of several members of 
the AGC (protein kinase A, G, and C) kinase family, including Akt, SGK1 and PKC, 
decreased cell survival upon stress induction, and impaired reorganization of actin 
cytoskeleton (Jacinto et al. 2004; Sarbassov et al. 2004; Guertin et al. 2006; Shiota et al. 2006; 
Garcia-Martinez & Alessi 2008). In mouse models, rictor knockout is embryonic lethal and 
the rictor-/- MEFs (mouse embryonic fibroblasts) isolated from rictor null embryos display 
slower growth rate compared to wild type MEFs (Guertin et al. 2006; Shiota et al. 2006). 
Substitution of Gly934 in rictor prevented formation of rictor/SIN1 heterodimer and reduced 
mTORC2 activity (Aimbetov et al. 2011). Thus, the interaction between rictor and SIN1 is 
required to form an integral and active mTORC2. 
3.2.2 SIN1 (AVO1) 
AVO1 is another TORC2 component in budding yeast and binds to the N-terminus of TOR2. 
The depletion of AVO1 mimics the defective actin polarization phenotype observed in the 
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tor2 mutant strain (Loewith et al. 2002). Sin1, the orthologue of AVO1 in fission yeast, was 
first identified as a stress-responsive protein that interacts with Sty1/Spc1 mitogen-
activated protein (MAP) kinase, a member of yeast stress-activated MAP kinase (SAPK) 
family (Wilkinson et al. 1999; Yang et al. 2006). Mammalian SIN1 is also implicated in the 
JNK (c-Jun N-terminal kinase) and MAPK (mitogen-activated protein kinase)/ERK 
(extracellular-regulated-protein kinase) pathways (Cheng et al. 2005; Schroder et al. 2005). It 
was later identified as a critical subunit of mTORC2 (Frias et al. 2006; Jacinto et al. 2006; 
Yang et al. 2006). To date, more than five alternatively spliced isoforms of mammalian SIN1 
have been discovered (Schroder et al. 2004; Cheng et al. 2005). Three of these isoforms form 
distinct rapamycin-insensitive mTOR complexes with rictor and mTOR (Frias et al. 2006). 
SIN1 disruption affects both mTORC2 assembly and function. Loss of SIN1 is embryonic 
lethal, indicating an important role for this protein in development (Jacinto et al. 2006; Yang 
et al. 2006). 
3.3 Other interactors 
In addition to the main components of TOR complexes discussed above, there are many 
non-conserved proteins that associate with TOR/mTOR. Some of these mTORC interactors 
can affect mTOR activity. These mTORC-interacting molecules could also mediate crosstalk 
between the mTOR pathway and other signaling pathways (Woo et al. 2007).  
In budding yeast, TCO89 (TOR complex one 89 kDa subunit) has been shown to associate 
with TORC1 (Reinke et al. 2004). Deletion of TOR1 and TCO89 results in rapamycin 
hypersensitivity and defective cell-wall integrity, respectively. AVO2 and BIT61 also 
associate with TORC2 but their roles in regulating TORC2 functions remain to be elucidated 
(Loewith et al. 2002; Reinke et al. 2004). BIT61 can associate with SLM1 and SLM2, which are 
also TORC2-associated proteins mediating actin cytoskeleton organization (Fadri et al. 
2005).  
PRAS40 (proline-rich Akt substrate of 40kDa) is a negative regulator of mTORC1 (Sancak et 
al. 2007; Wang et al. 2007). PRAS40 and mTORC1 substrates, such as 4E-BP-1 and S6K, share 
a similar raptor-binding motif, the TOR signaling (TOS) motif (Wang et al. 2007). Therefore, 
it is speculated that PRAS40 can directly bind to raptor and interfere with the ability of 
mTORC1 to interact with its substrates (Wang et al. 2007). This negative regulation of 
mTORC1 by PRAS40 is inhibited by the insulin signaling pathway, since activated Akt can 
phosphorylate PRAS40 and prevent its binding to raptor (Sancak et al. 2007).  
PRR5 (proline-rich protein 5), also named Protor (protein observed with rictor), and PRR5L 
(PRR5-like) bind to rictor and non-essential subunits of mTORC2 (Pearce et al. 2007; 
Thedieck et al. 2007; Woo et al. 2007). Knockdown of these two proteins did not cause 
significant disruption of both complex integrity and kinase activity of mTORC2. Protor1 is 
required for the phosphorylation of SGK1, but not of Akt and PKC, specifically in mouse 
kidney (Pearce et al. 2011). These findings suggest that this non-conserved interactor might 
regulate mTORC2 function in a tissue- and target- specific manner (Pearce et al. 2011). 
DEPTOR (DEPDC6, DEP domain-containing protein 6), is a negative regulator of mTOR 
that associates with both mTORC1 and mTORC2 (Peterson et al. 2009; Proud 2009). Loss of 
DEPTOR activates S6K1 and Akt, downstream substrates of mTORC1 and mTORC2, 
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DEPTOR activates S6K1 and Akt, downstream substrates of mTORC1 and mTORC2, 





multiple myelomas harboring cyclin D1/D3 or c-MAF/MAFB translocations. The high 
DEPTOR levels in these cells are required for the activation of PI3K/Akt pathway and may 
suppress apoptosis (Peterson et al. 2009). Several studies have characterized how DEPTOR 
levels can be controlled (Duan et al. 2011; Gao et al. 2011; Zhao et al. 2011). DEPTOR is 
recognized and ubiquitinated by an F box protein, SCF (TrCP) and degraded through the 
26S-proteasome pathway (Zhao et al. 2011). Either expressing the dominant-negative 
mutant of TrCP or interfering with the interaction between DEPTOR and TrCP via 
mutagenesis causes the accumulation of DEPTOR and downregulation of mTOR activity 
(Zhao et al. 2011). Furthermore, mTORC1 and mTORC2 could directly phosphorylate 
DEPTOR (Gao et al. 2011). CK1 (casein kinase 1) can generate a phosphodegron on the 
phosphorylated DEPTOR, which is bound by TrCP to induce the degradation of DEPTOR 
(Duan et al. 2011; Gao et al. 2011). The degron mutant and TrCP deletion can inhibit 
DEPTOR degradation and decrease mTOR activities (Gao et al. 2011). Together, these 
studies suggest that DEPTOR can regulate mTORC activity via a positive feedback loop 
involving mTOR itself and CK1. 
4. Mode of regulation of mTOR complexes 
mTOR serves to relay signals from growth cues to downstream events to consequently 
control cell growth and metabolism (Wullschleger et al. 2006; Zhou & Huang 2010). Below, 
we discuss how these growth cues alter mTOR activity via regulation of mTOR complex 
component modification, subcellular localization, and association with other regulatory 
molecules.  
4.1 Phosphorylation 
mTOR itself is regulated via phosphorylation. Ser1261 phosphorylation of mTOR is induced 
by insulin stimulation and is required for mTORC1 activity and mTOR autophosphorylation 
(Acosta-Jaquez et al. 2009). Furthermore, mTOR in the context of intact mTORC1 is 
predominantly phosphorylated at the Ser2448 residue (Copp et al. 2009). This site is 
phosphorylated by S6K in a mitogen- and nutrient-inducible manner (Chiang & Abraham 
2005). The autophosphorylation site at Ser2481 is also growth-signal dependent (Peterson et 
al. 2000). A later report proposed that the Ser2481 phosphorylation event is an indicator of 
functional mTORC2 (Copp et al. 2009). Prolonged but not acute rapamycin treatment, which 
disrupts mTORC2 (Sarbassov et al. 2006), can abolish mTOR phosphorylation at this site 
(Copp et al. 2009). However, mTOR from raptor immunoprecipitates is also phosphorylated 
at Ser2481. Furthermore, inhibition of mTORC1 by acute rapamycin treatment can reduce 
Ser2481 phosphorylation of mTOR that is associated with raptor (Soliman et al. 2010), 
implying that the phosphorylation of Ser2481 residue may also be involved in the regulation 
of mTORC1 functions. Thus, how Ser2481 phosphorylation affects the specific activity of 
mTORC1 vs mTORC2 would need to be clarified.  
mTOR complex components are also phosphorylated at numerous sites. Phosphorylation of 
raptor at different residues may affect the kinase activity of mTOR. For example, AMPK 
mediates phosphorylation of raptor at Ser722/792 upon nutrient depletion and inhibits 
mTORC1 function (Gwinn et al. 2008). In contrast, upon mitogen stimulation, p90 ribosomal 
S6 kinase (RSK) and mTORC1 mediate raptor phosphorylation at Ser719/721/722 and Ser863, 
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respectively, which is essential for mTORC1 activation (Carriere et al. 2008). Rictor is 
predicted to be phosphorylated in at least 37 phosphorylation sites according to MS/MS 
analysis and phospho-proteome database (Dibble et al. 2009; Julien et al. 2010). These 
putative phosphorylation sites mainly localize in the C-terminal region of rictor, which is 
conserved only in vertebrates (Dibble et al. 2009; Julien et al. 2010). Thus, rictor could have 
acquired more diverse functions and complex regulation during evolution . Several studies 
have examined the function of rictor phosphorylation at Thr1135 residue located in the C-
terminal region. This phosphorylation is mediated by S6K1 in an amino acid- and growth 
factor- dependent manner and is suggested to act as a feedback regulation of mTORC2 from 
mTORC1 signals (Dibble et al. 2009; Julien et al. 2010; Treins et al. 2010). Its effect on the 
mTORC2-mediated Akt activation is very minimal if any (Boulbes et al. 2010; Treins et al. 
2010). Moreover, in SIN1-/- MEFs, in which mTORC2 complex integrity is disrupted, this 
phosphorylation is still detectable, suggesting that it might be involved in mTORC2-
independent functions (Boulbes et al. 2010). Rictor is also phosphorylated at Ser1235 by 
GSK3 under ER stress conditions (McDonald et al. 2008). This phosphorylation event 
reduces the binding between mTORC2 and its substrate, Akt, hence negatively regulating 
mTORC2.  
SIN1 can also be phosphorylated at multiple sites although the relevant sites remain to be 
identified. Hypophosphorylation of SIN1 interferes with its association with mTOR (Yang et 
al. 2006), but not with rictor (Rosner & Hengstschlager 2008). mTOR can phosphorylate 
SIN1 in vitro, which may prevent SIN1 degradation from lysosomal pathway in vivo (Chen & 
Sarbassov 2011). Other kinases that can phosphorylate SIN1 to regulate mTORC2 activity 
would need to be investigated. 
4.2 Component stability and complex formation 
The activity and specificity of mTOR can be modulated through complex assembly. 
Disruption of mTOR complexes via gene ablation or knockdown of a specific mTORC 
component has revealed the importance of an intact mTORC for phosphorylation of its 
downstream substrates. For instance, in the adipose-specific raptor knockout mice, which 
carry disrupted mTORC1, S6K phosphorylation in white adipose tissue was diminished 
(Boulbes et al. 2010). Similarly, the deletion of either SIN1 or rictor in MEFs and HeLa cells 
inhibited mTORC2 assembly and abolished Akt HM and TM phosphorylation (Guertin et al. 
2006; Jacinto et al. 2006; Yang et al. 2006). 
In mammalian cells, raptor binds to mTOR in a nutrient- responsive manner (Kim et al. 
2002; Oshiro et al. 2004). Upon nutrient deprivation, raptor and mTOR form a stable 
interaction, which can inhibit mTORC1 activity (Kim et al. 2002). Under growth favorable 
conditions, the association between raptor and mTOR is less tight and presumably can 
promote mTORC1 activity towards its substrates such as S6K and 4E-BP (Kim et al. 2002). 
Instead of affecting the intrinsic kinase activity of mTOR, rapamycin/FKBP12 complex is 
proposed to attenuate the association between mTOR and raptor, thereby inhibiting 
mTORC1 (Chen et al. 1995; Choi et al. 1996; Kim et al. 2002). Supporting this model, mTOR 
purified from rapamycin-treated cells showed no defect of its autophosphorylation ability in 
vivo or kinase activity toward substrates in vitro (Peterson et al. 2000). In addition, recent 
studies revealed that not all mTORC1 functions can be inhibited by rapamycin, suggesting 
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respectively, which is essential for mTORC1 activation (Carriere et al. 2008). Rictor is 
predicted to be phosphorylated in at least 37 phosphorylation sites according to MS/MS 
analysis and phospho-proteome database (Dibble et al. 2009; Julien et al. 2010). These 
putative phosphorylation sites mainly localize in the C-terminal region of rictor, which is 
conserved only in vertebrates (Dibble et al. 2009; Julien et al. 2010). Thus, rictor could have 
acquired more diverse functions and complex regulation during evolution . Several studies 
have examined the function of rictor phosphorylation at Thr1135 residue located in the C-
terminal region. This phosphorylation is mediated by S6K1 in an amino acid- and growth 
factor- dependent manner and is suggested to act as a feedback regulation of mTORC2 from 
mTORC1 signals (Dibble et al. 2009; Julien et al. 2010; Treins et al. 2010). Its effect on the 
mTORC2-mediated Akt activation is very minimal if any (Boulbes et al. 2010; Treins et al. 
2010). Moreover, in SIN1-/- MEFs, in which mTORC2 complex integrity is disrupted, this 
phosphorylation is still detectable, suggesting that it might be involved in mTORC2-
independent functions (Boulbes et al. 2010). Rictor is also phosphorylated at Ser1235 by 
GSK3 under ER stress conditions (McDonald et al. 2008). This phosphorylation event 
reduces the binding between mTORC2 and its substrate, Akt, hence negatively regulating 
mTORC2.  
SIN1 can also be phosphorylated at multiple sites although the relevant sites remain to be 
identified. Hypophosphorylation of SIN1 interferes with its association with mTOR (Yang et 
al. 2006), but not with rictor (Rosner & Hengstschlager 2008). mTOR can phosphorylate 
SIN1 in vitro, which may prevent SIN1 degradation from lysosomal pathway in vivo (Chen & 
Sarbassov 2011). Other kinases that can phosphorylate SIN1 to regulate mTORC2 activity 
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proposed to attenuate the association between mTOR and raptor, thereby inhibiting 
mTORC1 (Chen et al. 1995; Choi et al. 1996; Kim et al. 2002). Supporting this model, mTOR 
purified from rapamycin-treated cells showed no defect of its autophosphorylation ability in 
vivo or kinase activity toward substrates in vitro (Peterson et al. 2000). In addition, recent 
studies revealed that not all mTORC1 functions can be inhibited by rapamycin, suggesting 





While the FKBP12/rapamycin complex binds and inhibits mTORC1, it does not affect 
mTORC2 activity acutely perhaps because it does not bind to mTORC2 (Jacinto et al. 2004). 
However, chronic exposure to rapamycin could disrupt mTORC2 function in some cell lines 
presumably by blocking assembly of newly synthesized mTORC2 subunits (Sarbassov et al. 
2006).  
The integrity of mTORC2 is dependent on stability of the rictor/SIN1 heterodimer. These 
mTORC2 components interact tightly and deficiency in either one leads to destabilization of 
the other, suggesting they require each other for stability (Guertin et al. 2006; Jacinto et al. 
2006; Yang et al. 2006). Other proteins associating with mTORC components have been 
identified that could affect mTORC activity or assembly. The folding chaperone Hsp70 
interacts with rictor and its knockdown reduces rictor level as well as mTOR-rictor 
interaction, resulting in impaired mTORC2 formation and activity (Martin et al. 2008; Martin 
et al. 2008). The maturation and assembly of mTORCs was also shown to be dependent on 
Tel2 and Tti (Takai et al. 2007; Kaizuka et al. 2010 a; Kaizuka et al. 2010 b). Hsp90 was 
shown to mediate the formation of both TORCs, as well as other PIKKs (Horejsi et al. 2010; 
Takai et al. 2010). Whether mTORC signaling can be modulated by these interactors remains 
to be examined.  
mTORC2 components have been found to associate with other proteins independently of 
mTOR. Rictor can form an E3 ligase complex with Cullin-1 and Rbx1 to promote the 
ubiquitination of SGK1 in an mTOR-independent manner (Gao et al. 2010). The interaction 
between rictor, Cullin-1, and Rbx1 is disrupted when rictor is phosphorylated at Thr1135 
residue by multiple AGC kinases (Gao et al. 2010). Whether the phosphorylated rictor 
released from the E3 ligase complexes can affect mTORC2 assembly remains to be 
elucidated. SIN1 also interacts with other proteins independently of mTOR and rictor. The 
function of SIN1 when associated with these proteins remains unclear but these proteins are 
involved in stress responses including ras, MEKK2, JNK, p38, ATF2 and the stress-related 
cytokine receptors IFNAR2, TNFR1/2 (Schroder et al. 2005; Makino et al. 2006; Schroder et 
al. 2007; Ghosh et al. 2008).  Unlike mTORC2 components, so far, the mTORC1 subunit 
raptor has not been found to associate with other proteins in an mTORC1-independent 
manner. 
4.3 Localization of mTOR complexes 
Compartmental localization enables a protein kinase to gain access to its regulators or 
effectors, thereby regulating its function. Supporting this concept, yeast TOR undergoes 
nuclear localization and binds to the 35S rDNA promoter to enhance 35S rRNA synthesis in 
a nutrient-sensitive fashion (Li et al. 2006). The HTH (helix-turn-helix) motif, a region in the 
HEAT domain of TOR, has been demonstrated to be essential for this association since HTH 
deletion interrupts the binding of TOR1 to 35S rDNA (Li et al. 2006). TOR1 and TOR2 also 
localize to membrane compartments that contain actin cytoskeleton and endocytosis 
regulators via their HEAT domain (Kunz et al. 2000; Aronova et al. 2007). Two endoplasmic 
reticulum (ER) and Golgi localization sequences were characterized in the HEAT domain, 
supporting that the TOR complexes may localize at the membrane periphery of these 
organelles (Liu & Zheng 2007). The best example for how mTORC1 can be regulated via 
localization is the recent finding that amino acid stimulation induces shuttling of mTORC1 
to late endosomes and lysosomes (LELs) by interaction with Rag GTPases (Sancak et al. 
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2008). How the presence of amino acids would be sensed by mTORC1 interactors in a 
particular organelle such as the endosomes remain to be further elucidated. 
Less is known on how mTORC2 can be compartmentalized and activated in response to 
growth signals. It co-localizes predominantly in the ER periphery (Boulbes et al. 2011). 
mTORC2 associates with actively translating ribosomes and specifically interacts with the 
proteins from the 80S large ribosomal subunit (Oh et al. 2010; Zinzalla et al. 2011). mTORC2 
components can stably interact with ribosomal proteins that line the tunnel exit of the 80S 
and could function in this site by modifying emerging nascent polypeptides such as Akt (Oh 
et al. 2010). mTORC2 becomes activated upon association with ribosomes although the 
precise mechanism is currently unclear (Zinzalla et al. 2011). Since the protein synthesis 
machinery can physically associate with cell surface receptors (Tcherkezian et al. 2010), it 
can be speculated that mTORC2 could be activated upon nucleation of translation 
machinery with a signaling receptor in the membrane periphery. 
5. Upstream regulators of mTOR complexes 
5.1 Activation of mTORC1 
mTORC1 integrates signals from extracellular and intracellular sources of nutrients with 
other growth, energy and mitogenic cues (Figure 2). mTORC1 activity is sensitive to 
intracellular amino acid concentration, particularly leucine depletion (Hay & Sonenberg 
2004). Previously, intracellular amino acid levels were proposed to modulate mTORC1 
activity via TSC1/2 (tuberous sclerosis complex 1/2) (Gao et al. 2002). However, in TSC2-/- 
cells, attenuated mTORC1 activity upon amino acid withdrawal was still detected (Smith et 
al. 2005), indicating the presence of additional pathways regulating mTORC1 activity in 
response to amino acid levels. Furthermore, hVPS34, a class III PI3K, can signal amino acid 
availability to mTORC1 bypassing the TSC1/2-Rheb axis (Byfield et al. 2005; Nobukuni et al. 
2005). Recently, in both yeast and mammals, TORC1/mTORC1 activity has been shown to 
be regulated by Rag GTPases in response to amino acids. In yeast, Rag orthologues Gtr1 and 
Gtr2, as part of the EGO complex (consisting of EGO1, EGO3, Gtr1 and Gtr2) localize to the 
vacuolar/lysosomal membrane and could mediate amino acid signals to TORC1 (Dubouloz 
et al. 2005; Binda et al. 2009). Mammalian Rags function as heterodimers, wherein Rag A/B 
associates with Rag C/D (Sekiguchi et al. 2001). A protein complex termed the Ragulator 
consisting of MAPK scaffold protein 1, p14, p18 localizes Rag to these membrane 
compartments. In nutrient replete conditions, Rag complexes are fully activated as Rag A/B 
in GTP form and Rag C/D in GDP form (Sekiguchi et al. 2001). Activation of Rag 
heterodimers recruits mTORC1 to the membrane compartment where Rheb (Ras homolog 
enriched in the brain) is enriched, thus promoting mTORC1 activity (Rubio-Texeira & Kaiser 
2006; Meijer & Codogno 2008; Sancak et al. 2008). p62, an adaptor protein that associates 
with mTORC1 and Rag complex was shown to be required for mTORC1 activation (Duran 
et al. 2011). It was proposed that p62 can promote the localization of mTORC1 and Rag 
complex to the lysosomes, which is a critical step of mTORC1 activation, in an amino-acid 
dependent manner (Duran et al. 2011). Rheb is a small GTPase belonging to the Ras family 
(Garami et al. 2003; Manning & Cantley 2003; Long et al. 2005). Upon binding to mTOR, 
GTP-loaded Rheb induces a conformational change in the KD of mTOR to promote its 
activation (Long et al. 2005). In the lysosomes, the amino acid transporter PAT1 (proton-
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lysosomal amino acid transporter (Russnak et al. 2001). This transporter could play a role in 
mTORC1 activation in an amino acid-dependent manner (Heublein et al. 2010). Knockdown 
of PAT1 in MCF-7 cells led to decreased S6K and 4E-BP-1 phosphorylation (Heublein et al. 
2010). Two membrane transporters, SLC7A5 and SLC3A2, were also shown to be required for 
mTORC1 activation (Nicklin et al. 2009). These two transporters function in the cellular uptake 
and the subsequent efflux of glutamine in the presence of essential amino acids (Nicklin et al. 
2009). This process can increase intracellular concentration of leucine and can enhance 
mTORC1 activation via Rag complexes (Sancak et al. 2008). Thus, several regulatory molecules 
in the endosome/lysosomes and membrane compartments could regulate mTORC1 function 
in response to the presence of amino acids. 
Numerous cellular inputs that convey growth or stress conditions are coupled to mTORC1 
via the TSC1/2 tumor suppressor complex (Castro et al. 2003; Garami et al. 2003; Tee et al. 
2003; Hay & Sonenberg 2004; Zoncu et al. 2011). Loss of TSC1 or TSC2 genes, encoding 
hamartin and tuberin respectively, is observed in tuberous sclerosis, a human genetic 
disorder characterized by benign tumors (Green et al. 1994; Onda et al. 1999). Through 
phosphorylation at different residues, the activity of the TSC 1/2 complex can be regulated 
by different upstream signaling pathways (Huang & Houghton 2003). In the presence of 
growth factors, such as insulin, the insulin receptor is activated and recruits the insulin 
receptor substrate (IRS). IRS serves to couple signals to downstream molecules including 
PI3K, which converts phosphatidylinositol-4,5-phosphate (PIP2) into phosphatidylinositol-
3,4,5-phosphate (PIP3) in the plasma membrane. PIP3 can recruit both PDK1 and Akt to the 
membrane, where Akt is phosphorylated and activated by PDK1. The activated Akt can 
directly phosphorylate TSC2 and block the activity of TSC1/2 complex (Huang & Houghton 
2003), which consequently results in the activation of mTORC1 and the phosphorylation of 
S6K and 4E-BP1, the two best-characterized effectors of mTORC1 (Valentinis & Baserga 2001). 
The regulation of mTORC1 activity via Akt can be counteracted by GADD34 (growth arrest 
and DNA damage protein 34) (Minami et al. 2007; Watanabe et al. 2007). By interacting with 
TSC1/2 complexes, GADD34 inhibits phosphorylation of TSC2 at the Akt phosphorylation 
site Thr1462, thus negatively regulating mTORC1 (Minami et al. 2007; Watanabe et al. 2007).  
The mitogen activated protein kinase (MAPK) pathway can also modulate mTORC1 
functions via negative regulation of TSC1/2 in response to growth cues (Ma et al. 2005). In 
the presence of growth factors, receptor tyrosine kinases activate Ras-Erk1/2 signaling 
(Pearson et al. 2001). Activated Erk can phosphorylate TSC2 at Ser664 and induce dissociation 
of TSC1/2 complex, which suppresses TSC1/2 functions toward cell proliferation and 
transformation (Ma et al. 2005). Active Ras can also inactivate TSC via Rsk-mediated 
phosphorylation of TSC2 at Ser1798, resulting in increased mTORC1 signaling (Roux et al. 
2004). 
AMP-activated protein kinase (AMPK) pathway is another well-established regulatory 
input of mTORC1 in response to energy conditions. Under low cellular energy level (high 
AMP/ATP ratio), LKB1, a tumor suppressor, activates AMPK to directly phosphorylate 
TSC2 at Thr1227 and Ser1345 residues (Inoki et al. 2003; Corradetti et al. 2004; Shaw et al. 2004). 
Unlike Akt and Erk, AMPK-mediated phosphorylation enhances the GAP activity of 
TSC1/2 complex and inhibits mTORC1 function. This would provide a mechanism for 
downregulating energy-consuming cellular processes under low ATP levels.  
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5.2 Activation of mTORC2 
Early studies in yeast have elucidated how TORC2 can control actin cytoskeleton 
polarization but the signals that control TORC2 activity has been elusive (Schmidt et al. 
1996; Schmidt et al. 1997; Loewith et al. 2002). Since this function of TORC2 is viewed to 
control growth spatially, it is reasonable to speculate that TORC2 is activated by growth 
signals. In mammals, mTORC2 activity is promoted by growth factors in a PI3K-dependent 
manner. After insulin stimulation, the phosphorylation of Akt at its hydrophobic motif 
(HM; Ser473) mediated by mTORC2 is significantly increased in vivo (Hresko & Mueckler 
2005; Sarbassov et al. 2005). Similar results were also observed in in vitro kinase assays 
(Sarbassov et al. 2005). Since mTORC2 also phosphorylates sites in Akt and PKC in a 
constitutive manner (Facchinetti et al. 2008; Ikenoue et al. 2008), its responsiveness to 
growth factors has been puzzling. However, further studies revealed that mTORC2 could 
phosphorylate the constitutive site in Akt during translation (Oh et al. 2010). This would 
suggest that conditions that enhance translation, such as the presence of growth factors, 
promote mTORC2 activity. Supporting this notion, mTORC2 was found to associate with 
translating ribosomes and this association is enhanced in cells with increased PI3K signaling 
(Oh et al. 2010; Zinzalla et al. 2011). Since nutrients are essential for promoting protein 
synthesis, this would suggest that mTORC2 would also be regulated by nutrients. However, 
it remains to be determined if this is the case and how mTORC2 becomes activated upon 
association with ribosomes.  
6. mTOR functions 
A number of diverse functions have been ascribed to mTOR but it is now emerging that it is 
a central hub to regulate growth and metabolism (Figure 2). In the whole organism, mTOR 
is required during early development. Rapamycin treatment inhibited amino acid 
stimulation of embryo outgrowth in mice at blastocyst stage (Martin & Sutherland 2001). 
Similarly, the embryonic development of mTOR-/- mice is aberrant and arrested at E5.5 
(Gangloff et al. 2004). Conditional knockout strategies have shed light on tissue-specific 
mTOR functions. The inactivation of mTOR in T cells caused defects in differentiation of 
peripheral T lymphocytes (Delgoffe et al. 2009). The muscle-specific mTOR knockout mice 
displayed reduced levels of dystrophin and severe myopathy, which led to premature death 
(Risson et al. 2009). While there was no significant phenotype in mice with specific deletion 
of mTOR in the prostate, tumor initiation and progression in PTEN-/- mice, which possess 
hyperactivated mTORC1, was suppressed (Nardella et al. 2009). These findings support a 
critical role for mTOR itself in organism and organ development as well as disease 
progression.  
The cellular functions of mTOR have surfaced from numerous studies over the years. The 
most well characterized function of mTOR is the rapamycin-sensitive control of protein 
synthesis by mTORC1. More recent studies have revealed that mTOR has rapamycin-
insensitive functions both as part of mTORC1 and mTORC2. Most of the mTOR functions 
that have been elucidated are mediated by the AGC kinases S6K, Akt, SGK, and PKC. 
Another well characterized mTOR substrate is 4E-BP1, a translation regulator. With the 
recent phospho-proteomic studies that identified hundreds of direct and indirect targets of 
mTOR, we can begin to elucidate how the mTOR complexes could perform its wide array of 
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5.2 Activation of mTORC2 
Early studies in yeast have elucidated how TORC2 can control actin cytoskeleton 
polarization but the signals that control TORC2 activity has been elusive (Schmidt et al. 
1996; Schmidt et al. 1997; Loewith et al. 2002). Since this function of TORC2 is viewed to 
control growth spatially, it is reasonable to speculate that TORC2 is activated by growth 
signals. In mammals, mTORC2 activity is promoted by growth factors in a PI3K-dependent 
manner. After insulin stimulation, the phosphorylation of Akt at its hydrophobic motif 
(HM; Ser473) mediated by mTORC2 is significantly increased in vivo (Hresko & Mueckler 
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(Oh et al. 2010; Zinzalla et al. 2011). Since nutrients are essential for promoting protein 
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association with ribosomes.  
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mTOR, we can begin to elucidate how the mTOR complexes could perform its wide array of 






Fig. 2. Overview of mTOR complex signaling and functions. Black arrows and gray lines 
represent activating and inhibitory connections, respectively. Dotted lines indicate possible 
links. 
6.1 Protein synthesis and maturation 
Protein synthesis, ie translation, utilizes huge amounts of energy and machinery (ie. 
ribosomes), and consequently, the entire process is under tight control (Acker & Lorsch 2008; 
Malys & McCarthy 2011). mTOR, primarily mTORC1, is involved in different aspects of 
protein synthesis (Ma & Blenis 2009; Sonenberg & Hinnebusch 2009). Its most well 
characterized function is the phosphorylation of proteins involved in translation initiation, 
namely S6K1 and 4E-BP. 4E-BP is a negative regulator of translation initiation (Pause et al. 
1994). When unphosphorylated, it interacts with eIF-4E (eukaryotic initiation factor 4E) cap-
binding protein, preventing cap-dependent translation. mTORC1-mediated phosphorylation 
dissociates 4E-BP1 from eIF-4F and releases the inhibition of translation (Ma & Blenis 2009; 
Sonenberg & Hinnebusch 2009). However, there are four phosphorylation sites on 4E-BP1 that 
are regulated by mTORC1 but only two of them are sensitive to acute rapamycin treatment 
(Gingras et al. 1999; Gingras et al. 2001; Wang et al. 2003). In the presence of growth signals, 
translation of proteins specifically involved in cell proliferation is upregulated in a 4E-BP-
dependent fashion (Dowling et al. 2010). This would suggest that mTORC1 can specifically 
regulate the translation of a subset of mRNA under a particular growth condition. 
mTORC1 can directly phosphorylate and activate S6K1, which promotes mRNA translation 
by modulating multiple substrates involved in different stages of translation, from mRNA 
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surveillance, initiation to translation elongation (Ma & Blenis 2009). Phosphorylated S6K1 
binds to newly spliced mRNAs through its binding partner, SKAR (S6K1 aly/REF-like 
target) and potentially facilitate translation initiation and/or elongation (Ma et al. 2008). 
This protein complex interacts with EJC (exon junction complex), which monitors the 
quality of newly spliced mRNA (Ma et al. 2008). Active S6K1 also phosphorylates the 40S 
ribosomal protein S6 (rpS6) at several sites. Phosphorylated rpS6 is widely used as a readout 
of mTORC1 activity. Its phosphorylation appears to play a role in the control of cell size but 
is dispensable for translation of mRNA with 5’ terminal oligopyrimidine tract (TOP 
mRNAs) (Ruvinsky et al. 2005). S6K also phosphorylates PDCD4 (programmed cell death 4), 
an inhibitor of RNA helicase eIF4A. PDCD4 levels become downregulated upon 
phosphorylation (Dorrello et al. 2006). The degradation of PDCD4 greatly enhances eIF4A 
helicase activity and facilitates 40S ribosomal subunit scanning to the initiation codon. 
Moreover, S6K can also augment eIF-4A activity through increasing the levels of eIF-4A, 
eIF-4B, and eIF3 complex. The S6K-mediated phosphorylation of eIF4B can enhance its 
binding to eIF3 (Vornlocher et al. 1999). Thus, S6K can modulate a number of proteins 
involved in translation initiation. It could also regulate the elongation phase of translation. 
Phosphorylation of eEF2K (eukaryotic elongation factor 2 kinase) by S6K inhibits its activity 
towards eEF2 and consequently enhances elongation (Wang et al. 2001).  
In addition to the regulation of the translation process, mTORC1 directly affects the 
biosynthesis of the translational machinery as well. The assembly of functional ribosomes is 
an energy-demanding process requiring a series of building components and assembly 
factors (Mayer & Grummt 2006). mTORC1 has been found to regulate ribosome biogenesis 
at different levels, including the production of ribosomal proteins (Cardenas et al. 1999; 
Hardwick et al. 1999), pre-rRNA processing (Powers & Walter 1999), and the rRNA 
synthesis (Hardwick et al. 1999; Hannan et al. 2003). In response to extracellular conditions, 
mTORC1 can coordinate all three nuclear RNA polymerases, Pol I, Pol II and Pol III, to 
control ribosome synthesis (Beck & Hall 1999; Miller et al. 2001; Yuan et al. 2002; Martin et 
al. 2004; White 2005). mTORC1 regulates the nuclear translocation of TIF1A, a transcription 
factor that is essential for Pol I-associated transcription initiation (Mayer et al. 2004). 
Furthermore, mTORC1 activity can enhance the tRNA levels via regulation of the 
transcription of Pol III (Shor et al. 2010). Maf1, a Pol III suppressor, directly associates with 
and inhibits Pol III apparatus (Reina et al. 2006). Under growth-favorable conditions, 
mTORC1 phosphorylates Maf1 to dissociate it from Pol III and promotes its cytoplasmic 
translocation (Shor et al. 2010). mTORC1 also interacts with rDNA (ribosomal DNA) 
promoters to promote Pol I and Pol III transcription in a growth factor-dependent and 
rapamycin-sensitive manner (Tsang et al. 2010). 
mTORC2 is also emerging to play a role in translation. A more pronounced defect in protein 
synthesis and polysome assembly occurs upon mTOR inhibition with active site inhibitors, in 
contrast to rapamycin treatment (Yu et al. 2009; Carayol et al. 2010; Oh et al. 2010; Evangelisti 
et al. 2011). Although it can be argued that the exacerbated defects could be due to inhibition 
of rapamycin-insensitive mTORC1 functions, there is some evidence that mTORC2 inhibition 
could contribute to these defects. First, polysome recovery is somewhat defective in mTORC2-
disrupted cells (Oh et al. 2010; Wu and Jacinto, unpublished results). Second, phosphorylation 
of eEF2 is aberrant in these cells. Most importantly, mTORC2 associates with actively 
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et al. 2010; Zinzalla et al. 2011). mTORC2 components can stably associate with ribosomal 
proteins that are present at the tunnel exit. This would be consistent with the finding that 
mTORC2 can cotranslationally phosphorylate the emerging nascent Akt polypeptide (Oh et al. 
2010). Thus, mTORC2 could function in cotranslational maturation of newly synthesized 
proteins by phosphorylating relevant sites. The maturation of conventional PKC is also 
mediated by mTORC2 via phosphorylation (Facchinetti et al. 2008; Ikenoue et al. 2008).It 
would be interesting to see if mTORC2 could also cotranslationally phosphorylate PKC and 
whether it has additional cotranslational targets other than Akt. 
6.2 Autophagy  
Autophagy is a catabolic process that recycles intracellular components in the lysosomes to 
salvage substrates for energy production when nutrients become limiting (Noda, 1998; 
Janku, 2011). The control of this process by TOR was first discovered in yeast. In yeast, 
active TORC1 correlates with hyperphosphorylation of Atg13, a regulatory component of 
the Atg1 complex. Under this condition, assembly of the Atg1-Atg13 complex is inhibited 
thereby preventing autophagy (Yorimitsu et al. 2009; Kamada et al. 2010; Kijanska et al. 
2010; Yeh et al. 2010). Increased autophagy is observed upon rapamycin treatment, 
supporting the role of TORC1 in regulating this cellular process (Kamada et al. 2000).  
Under nutrient-replete conditions, mTOR negatively regulates autophagy by interacting 
with a protein complex composed of ULK1 (UNC51 like kinase), Atg13, and FIP200 (Ganley 
et al. 2009; Hosokawa et al. 2009; Jung et al. 2009). This complex is involved in the formation 
of the autophagosomes. The phosphorylation of ULK1 and Atg13 is inhibited by rapamycin 
treatment and leucine deprivation, implying the link between mTORC1 and autophagy 
(Hosokawa et al. 2009; Jung et al. 2009).  
mTOR is also involved in regulating expression of genes that are involved in 
autophagosome or lysosome biogenesis. mTORC1 could mediate phosphorylation of the 
transcription factor EB (TFEB), thereby controlling its nuclear shuttling and activity. TFEB 
binds E box related DNA sequences and controls lysosomal gene transcription (Pena-Llopis 
et al. 2011; Settembre et al. 2011). mTORC2 could also be involved in the control of 
autophagy via Akt-FoxO signaling (Mammucari et al. 2007). Disruption of rictor enhanced 
autophagosome formation in skeletal muscle and that this effect was abrogated upon 
expression of constitutively active Akt in the absence or presence of rapamycin, indicating 
that in this cell type, autophagy is dependent on mTORC2 function, not mTORC1 
(Mammucari et al. 2007). Indeed, attenuated Akt activity caused by downregulation of 
mTORC2 leads to decreased phosphorylation and increased nuclear translocation of FoxO3 
(Shiojima & Walsh 2006). FoxO3 induces the expression of many autophagy-related genes, 
such as Atg12l and Ulk2, and increases autophagosome formation in isolated adult mouse 
muscle fibers (Zhao et al. 2007). Together, these results indicate that by directly interacting 
with autophagic proteins or modulating the transcription of autophagy-related genes, 
mTOR complexes regulate autophagy. 
6.3 Metabolism 
Early studies showing reduced fungal amino acid, nucleic acid, and lipid metabolism after 
rapamycin treatment have linked TOR to metabolic functions (Singh et al. 1979). Later 
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transcription profiling screening of lymphoma cells treated with rapamycin revealed a 
tendency towards catabolism and that the levels of many mRNA involved in lipid, 
nucleotide, and protein synthesis were downregulated (Peng et al. 2002). In the whole 
organism, the function of mTOR in metabolism is underscored by findings on the effect of 
rapamycin treatment on insulin-responsive tissues. Inhibition of mTORC1 in mice via 
feeding with rapamycin induced diabetes due to smaller pancreatic islets and abolished 
insulin secretion (Bussiere et al. 2006). This effect could be mediated via S6K and S6 since 
these two mTORC1 pathway effectors are also required for the normal morphology and 
function of pancreatic islet cells and that removal of these two proteins led to a diabetic 
phenotype (Ruvinsky et al. 2005). Corollary to this, hyperactivation of mTORC1 occuring 
in TSC knockout resulted in larger islet size and higher number of -cell (Rachdi et al. 
2008). Together, these findings support a role for mTORC1 in maintaining metabolic 
homeostasis.  
Recent studies, discussed below, that have employed mTORC component gene ablation or 
knockdown further demonstrate the central role of mTOR in cellular and systemic 
metabolism. The critical role of mTORC1 in cellular metabolism is illustrated by its 
involvement in the biogenesis of mitochondria. In muscle-specific raptor knockout mice, 
there are reduced levels of PGC1 (PPAR coactivator 1), which is required for 
mitochondrial gene expression (Cunningham et al. 2007). In these mice, the skeletal muscle 
has lower mitochondria number, reduced oxidative capacity, and elevated glycogen storage, 
which led to muscle dystrophy (Bentzinger et al. 2008). Moreover, by genomic analysis, YY1 
(yin-yang 1), a transcription factor that regulates mitochondrial gene expression and oxygen 
consumption, was identified as a downstream effector of mTORC1 (Cunningham et al. 
2007). Both mTOR and raptor can bind to YY1 while rapamycin treatment inhibited YY1 
activity by preventing its interaction with the coactivator, PGC1 (Cunningham et al. 2007). 
Rapamycin treatment of or knockdown of mTOR or raptor in muscle cells also reduced 
mitochondrial gene transcription and respiratory metabolism (Cunningham et al. 2007). 
Interestingly, this function of mTORC1 appears to be S6K1-independent. In line with these 
findings, enhanced muscular levels of PGC1 and mitochondria were found in S6K1 
knockout mice (Um et al. 2004). Thus, mTORC1, via YY1 and PGC1, could regulate 
mitochondrial gene expression and thereby enhance mitochondrial oxidative functions.  
In addition to skeletal muscle, raptor knockout in other insulin-responsive tissues further 
illustrate the role of mTORC1 in metabolism. In adipose-specific raptor knockout mice, 
adipose tissue was reduced and these mice were protected against diet-induced obesity and 
hypercholesterolemia. There was elevated expression of genes involved in mitochondrial 
respiration in white adipose tissue and the leanness of these mice could be explained by 
enhanced energy expenditure due to mitochondrial uncoupling (Polak et al. 2008).  These 
mice also display higher glucose tolerance and insulin sensitivity. This could be due to 
defective S6K feedback regulation of IRS-1 activity, causing hyperactivated insulin receptor 
signaling (Polak et al. 2008). These findings underscore the role of adipose mTORC1 in 
whole body energy homeostasis. 
In liver, inhibition of mTORC1 promotes hepatic ketogenesis in response to fasting (Sengupta 
et al. 2010). Active mTORC1 negatively regulates PPAR (peroxisome proliferator activated 
receptor ), the master transcriptional activator of ketogenic gene expression, through 
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Thus, mice with hyperactivation of mTORC1 upon loss of TSC1 in the liver manifest defects 
in ketone body production and enlarged liver size during fasting (Sengupta et al. 2010).  
Other effectors of mTORC1 in the control of metabolic processes have emerged in recent 
reports. mTORC1 can modulate sterol and lipid biosynthesis through SREBP-1 (sterol 
regulatory element binding protein-1), a transcription factor that controls lipo- and 
sterolgenic gene transcription (Porstmann et al. 2008; Duvel et al. 2010). The mTORC1 target 
S6K1 can partially promote the activity of SREBP-1 via posttranslational modification. More 
recently, one critical regulator of mTORC1-SREBP-1 pathway has been identified. Lipin 1, 
which is directly phosphorylated and sequestered in the cytoplasm by mTORC1, induces 
the translocation of SREBP-1 into cytoplasm and negatively regulates its activity as a 
transcription factor (Peterson et al. 2011). Under high-fat and –cholesterol diet, mTORC1 
activity is required for SREBP-1 function to promote fat accumulation and 
hypercholesterolemia in mice (Peterson et al. 2011). mTORC1 can also modulate the 
expression level of Hif1 (hypoxia-inducible factor ), which activates numerous hypoxia-
induced genes involved in cellular metabolic processes including those involved in 
glycolysis and glucose uptake (Goldberg et al. 1988; Brugarolas et al. 2003; Duvel et al. 2010).  
There is also accumulating evidence that mTORC2 is required in metabolic processes. 
Knockdown of rictor in MEFs diminished metabolic activity (Shiota et al. 2006). 
Furthermore, deficiency of rictor in Jurkat cells, a leukemic T cell line, increased oxygen 
consumption (Schieke et al. 2006). However, mTORC2 could play a more complex function 
in mitochondrial metabolism since a PTEN-deficient cell line that is mTORC2 addicted/IL3-
independent was shown to require a number of genes involved in mitochondrial functions 
(Colombi et al. 2011). Adipose-specific knockout of rictor in mice revealed that mTORC2 can 
function to control whole body growth (Cybulski et al. 2009). In these mice, there was 
increased size of non-adipose organs, such as heart, kidney, spleen, and pancreas (Cybulski 
et al. 2009). In addition, these mice also displayed hyperinsulinemia and elevated levels of 
IGF (insuline-like growth factor) and IGFBP3 (IGF binding protein 3) (Cybulski et al. 2009). 
Conversely, the deletion of rictor in pancreatic -cells decreased their proliferation and 
mass, which led to reduced insulin secretion, hyperglycemia, and glucose intolerance in 
mice (Gu et al. 2011). Specific effectors of mTORC2 function in metabolism remain to be 
characterized. Future investigation should reveal how mTORC1 and mTORC2 signaling 
pathways impinge on metabolic pathways. This would be important in light of 
understanding how defects in cellular metabolism that occurs in cancer and other 
pathological conditions are linked to aberrant mTOR signaling. 
6.4 Actin cytoskeleton reorganization  
The regulation of actin cytoskeleton reorganization is a conserved function of mTORC2. In 
S. cerevisiae, tor2 mutations or depletion of TORC2 components depolarizes the actin 
cytoskeleton (Schmidt et al. 1996; Loewith et al. 2002). Normal polarization of actin towards 
the growing bud controls spatial growth in yeast. In mammals, mTORC2 can control actin 
polymerization and cell spreading via Rho and Rac, members of the Rho family of GTPases 
that regulates F-actin assembly (Jacinto et al. 2004). Rex1, a Rac GEF, links mTOR signaling 
to Rac activation and regulates cell migration (Hernandez-Negrete et al. 2007). PKC, which 
is phosphorylated by mTORC2, is also linked to actin cytoskeleton reorganization in 
mammalian cells (Sarbassov et al. 2004). However, it remains unclear how the mTORC2-
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dependent phosphorylation of PKC can promote the actin reorganization function of this 
AGC kinase.  
Studies using rapamycin have also linked actin cytoskeleton reorganization to the mTORC1 
pathway. Rapamycin inhibits the reorganization of F-actin and the phosphorylation of focal 
adhesion proteins through S6K1 (Berven et al. 2004; Liu et al. 2008). S6K1 is localized to actin 
stress fibers in fibroblasts (Crouch 1997) and S6K1, Akt, PDK1, and PI3K colocalized with 
the actin arc, a caveolin-enriched cytoskeletal structure located at the leading edge of 
migrating Swiss 3T3 cells (Berven et al. 2004). The mTORC1 pathway is also linked to cell 
motility and migration. Rapamycin inhibits cell motility in several cell types, such as 
neutrophils (Gomez-Cambronero 2003), vascular smooth muscle cells (Poon et al. 1996), and 
T-lymphocytes (Finlay & Cantrell 2010). The mTORC1 target, S6K, mediates cell migration 
via its regulation of focal adhesion formation (Liu et al. 2008), reorganization of F-actin 
(Berven et al. 2004; Liu et al. 2008), as well as the upregulation of the matrix 
metalloproteinase 9 (MM9) (Zhou & Wong 2006), and the activity and expression of RhoA 
(Liu et al. 2010). How mTORC1 or mTORC2 can more directly regulate its effectors in actin 
cytoskeleton reorganization remains to be examined. Future studies on how the mTORC-
mediated function in actin cytoskeleton reorganization is coupled to the other growth-
regulatory functions of mTORCs would need to be addressed. 
7. mTOR inhibitors and therapeutic significance 
Due to the central role of mTOR in cell survival, growth and proliferation, deregulation of 
the mTOR signaling pathway is implicated in many human diseases including benign and 
malignant tumors, neurological and metabolic disorders and cardiovascular diseases (Pei & 
Hugon 2008; Krymskaya & Goncharova 2009; Hwang & Kim 2011; Ibraghimov-Beskrovnaya 
& Natoli 2011). Moreover, its role in organismal aging is highlighted by findings that 
inhibition of the TOR/mTOR pathway can prolong lifespan in several organisms (Vellai et 
al. 2003; Kapahi et al. 2004; Medvedik et al. 2007; Harrison et al. 2009). Drawing lessons from 
rapamycin, numerous mTOR inhibitors have been developed and are currently being 
refined to achieve more specific inhibition. We discuss some recent findings on the use of 
these inhibitors at the bench and in the clinic.  
Rapamycin and its analogs (rapalogs) are allosteric mTOR inhibitors and form a complex 
with FKBP12 and mTOR. By binding at the FRB domain of mTOR, the interaction between 
mTOR and raptor is diminished and can uncouple mTOR from its substrates (Oshiro et al. 
2004). Rapamycin and derivatives such as CCI-779 (temsirolimus, Torisel), RAD001 
(everolimus), and AP23573 (ridaforolimus) act as cytostatic agents that slow down or arrest 
the growth of cells derived from several cancer types such as rhabdomyosarcoma (Hosoi et 
al. 1999), prostate cancer (van der Poel et al. 2003), breast cancer (Pang & Faber 2001), and B-
cell lymphoma (Muthukkumar et al. 1995). Early results from clinical trials reveal that they 
have antiproliferative activity in a subset of cancer, such as endometrial cancer (Oza et al. 
2011), pancreatic neuroendocrine tumors (Goldstein & Meyer 2011), gastric cancer (Doi et al. 
2010), and malignant glioma (Reardon et al. 2011). However, only a subset of mTORC1 
functions is sensitive to rapamycin treatment, hence the antiproliferative properties of this 
drug can be limited (Wang et al. 2005; Choo et al. 2008; Choo & Blenis 2009). In a number of 
cell types, the inhibition of mTORC1 results in the upregulation of the PI3K/Akt pathway. 
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receptor substrate-1 (IRS-1) by phosphorylation at serine residues (Zhande et al. 2002; Shah 
& Hunter 2006; Tzatsos & Kandror 2006). The inhibition of mTORC1 by rapalogs disrupts 
this feedback loop and results in increased IRS1 signaling and Akt activity that may 
compromise the anti-tumor activity of mTOR inhibitors (Harrington et al. 2004; Shah et al. 
2004; Sun et al. 2005; O'Reilly et al. 2006). Since mTORC2 is a positive regulator of Akt, 
several new mTOR inhibitors that can block both mTORC1 and mTORC2 have been 
developed to more effectively inhibit mTOR signaling and cell proliferation. 
The pyrazolopyrimidine analogs PP242 and PP30 are ATP-competitive inhibitors of mTOR 
that bind to its ATP-binding site and as a result, block the kinase activities of both mTORC1 
and mTORC2 (Feldman et al. 2009). PP242 and PP30 both inhibit the mTORC2-induced 
phosphorylation of Akt at Ser473, indicating that these inhibitors can indeed interfere with 
mTORC2 functions. Furthermore, these two mTOR kinase domain inhibitors attenuate 
protein synthesis and proliferation of mouse embryonic fibroblasts (MEFs) (Feldman et al. 
2009). PP242 has been shown to induce cytoreduction and apoptosis in multiple myeloma 
cells (Hoang et al. 2010) and cause death of mouse and human leukemia cells and delay 
leukemia onset in vivo (Janes et al. 2010), highlighting the potential therapeutic application 
of this compound. Another ATP-competitive mTOR inhibitor, Torin1, induces cell cycle 
arrest and inhibits cell growth and proliferation more efficiently than rapamycin (Thoreen et 
al. 2009). Preclinical studies substantiate the therapeutic value of Torin1. For example, 
Torin1 treatment prevented the anti-inflammatory potency of glucocorticoids both in human 
monocytes and myeloid dendritic cells (Weichhart et al. 2011). Moreover, Torin1 
significantly inhibited the translation of viral proteins during human cytomegalovirus 
infection (Clippinger et al. 2011). Recently, Torin2, a novel mTOR inhibitor with improved 
pharmacokinetic properties and synthetic route, has been described (Liu et al. 2011). Torin2 
inhibits mTOR complexes with IC50 of 0.25 nM, compared to Torin1 at IC50 of 2 to 10 nM. 
Therefore, Torin2 is suggested to be a more potent and stable mTORC inhibitor than Torin1.  
Since mTORC1 inhibition leads to upregulation of IRS1 and subsequently PI3K, which in 
turn activates Akt, simultaneously blocking the activities of mTOR complexes and PI3K may 
inhibit cell proliferation and growth more effectively. As a result, several mTOR/PI3K dual 
inhibitors have been developed. NVP-BEZ235 inhibits PI3K and mTOR kinase activity by 
interacting with their ATP-binding domains (Maira et al. 2008). It has been implicated in the 
treatment of non-small cell lung cancer (Konstantinidou et al. 2009), melanoma (Marone et 
al. 2009), pancreatic cancer (Cao et al. 2009), and acute myeloid leukemia (Chapuis et al. 
2010). Given the compensatory mechanisms that cells employ to adapt to growth-inhibitory 
conditions, it would be important to identify signaling pathways that impinge on the 
mTOR/PI3K pathway in order to develop combinatorial therapy for preventing 
malignancy. 
8. Conclusion 
Two decades after the discovery of TOR/mTOR, the function of this protein in orchestrating 
cellular processes in response to growth signals particularly nutrients has been established. 
Some key discoveries in the last few years that allowed more extensive analysis of mTOR 
function and regulation include identification of the mTOR complexes and regulatory 
proteins that link the mTOR pathway to nutrient and energy responses and the 
development of mTOR inhibitors. Studies to dissect the systemic function of mTOR 
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complexes are also gaining momentum with the use of tissue-specific mTORC component 
knockout mice. There are still numerous outstanding questions that need to be addressed 
such as the precise regulation of mTOR complexes by nutrients, how it links signals from 
nutrients to cellular metabolism and other processes, and distinct functions and regulation 
of mTORCs in different cellular compartments. The recent identification of the myriad 
possible direct and indirect targets of the mTORCs should provide clues on the mechanisms 
involved in mTOR functions. Animal models would also provide insights on the role of 
mTOR in physiological and pathological conditions. Finally, development of specific 
mTORC1 and mTORC2 inhibitors would not only be useful to determine the distinct 
functions of these complexes but also would have numerous clinical applications. 
9. Acknowledgements 
We thank Won Jun Oh for comments on this manuscript and acknowledge support from the 
NIH (GM079176), American Cancer Society (RSG0721601TBE), Cancer Research Institute, 
and SU2C-AACR-IRG0311 (E.J.).  
10. References 
Acker, M. G.&Lorsch, J. R. (2008). "Mechanism of ribosomal subunit joining during 
eukaryotic translation initiation." Biochemical Society transactions 36(Pt 4): 653-657. 
Acosta-Jaquez, H. A.; Keller, J. A.; Foster, K. G.; Ekim, B.; Soliman, G. A.; Feener, E. P.; Ballif, 
B. A.&Fingar, D. C. (2009). "Site-specific mTOR phosphorylation promotes 
mTORC1-mediated signaling and cell growth." Molecular and cellular biology 29(15): 
4308-4324. 
Adami, A.; Garcia-Alvarez, B.; Arias-Palomo, E.; Barford, D.&Llorca, O. (2007). "Structure of 
TOR and its complex with KOG1." Molecular cell 27(3): 509-516. 
Aimbetov, R.; Chen, C. H.; Bulgakova, O.; Abetov, D.; Bissenbaev, A. K.; Bersimbaev, R. 
I.&Sarbassov, D. D. (2011). "Integrity of mTORC2 is dependent on the rictor Gly-
934 site." Oncogene. 
Alarcon, C. M.; Heitman, J.&Cardenas, M. E. (1999). "Protein kinase activity and 
identification of a toxic effector domain of the target of rapamycin TOR proteins in 
yeast." Molecular biology of the cell 10(8): 2531-2546. 
Alvarez, B.&Moreno, S. (2006). "Fission yeast Tor2 promotes cell growth and represses cell 
differentiation." Journal of cell science 119(Pt 21): 4475-4485. 
Aronova, S.; Wedaman, K.; Anderson, S.; Yates, J., 3rd&Powers, T. (2007). "Probing the 
membrane environment of the TOR kinases reveals functional interactions between 
TORC1, actin, and membrane trafficking in Saccharomyces cerevisiae." Molecular 
biology of the cell 18(8): 2779-2794. 
Beck, T.&Hall, M. N. (1999). "The TOR signalling pathway controls nuclear localization of 
nutrient-regulated transcription factors." Nature 402(6762): 689-692. 
Bentzinger, C. F.; Romanino, K.; Cloetta, D.; Lin, S.; Mascarenhas, J. B.; Oliveri, F.; Xia, J.; 
Casanova, E.; Costa, C. F.; Brink, M.; Zorzato, F.; Hall, M. N.&Ruegg, M. A. (2008). 
"Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic 
changes and results in muscle dystrophy." Cell metabolism 8(5): 411-424. 
Berven, L. A.; Willard, F. S.&Crouch, M. F. (2004). "Role of the p70(S6K) pathway in 





receptor substrate-1 (IRS-1) by phosphorylation at serine residues (Zhande et al. 2002; Shah 
& Hunter 2006; Tzatsos & Kandror 2006). The inhibition of mTORC1 by rapalogs disrupts 
this feedback loop and results in increased IRS1 signaling and Akt activity that may 
compromise the anti-tumor activity of mTOR inhibitors (Harrington et al. 2004; Shah et al. 
2004; Sun et al. 2005; O'Reilly et al. 2006). Since mTORC2 is a positive regulator of Akt, 
several new mTOR inhibitors that can block both mTORC1 and mTORC2 have been 
developed to more effectively inhibit mTOR signaling and cell proliferation. 
The pyrazolopyrimidine analogs PP242 and PP30 are ATP-competitive inhibitors of mTOR 
that bind to its ATP-binding site and as a result, block the kinase activities of both mTORC1 
and mTORC2 (Feldman et al. 2009). PP242 and PP30 both inhibit the mTORC2-induced 
phosphorylation of Akt at Ser473, indicating that these inhibitors can indeed interfere with 
mTORC2 functions. Furthermore, these two mTOR kinase domain inhibitors attenuate 
protein synthesis and proliferation of mouse embryonic fibroblasts (MEFs) (Feldman et al. 
2009). PP242 has been shown to induce cytoreduction and apoptosis in multiple myeloma 
cells (Hoang et al. 2010) and cause death of mouse and human leukemia cells and delay 
leukemia onset in vivo (Janes et al. 2010), highlighting the potential therapeutic application 
of this compound. Another ATP-competitive mTOR inhibitor, Torin1, induces cell cycle 
arrest and inhibits cell growth and proliferation more efficiently than rapamycin (Thoreen et 
al. 2009). Preclinical studies substantiate the therapeutic value of Torin1. For example, 
Torin1 treatment prevented the anti-inflammatory potency of glucocorticoids both in human 
monocytes and myeloid dendritic cells (Weichhart et al. 2011). Moreover, Torin1 
significantly inhibited the translation of viral proteins during human cytomegalovirus 
infection (Clippinger et al. 2011). Recently, Torin2, a novel mTOR inhibitor with improved 
pharmacokinetic properties and synthetic route, has been described (Liu et al. 2011). Torin2 
inhibits mTOR complexes with IC50 of 0.25 nM, compared to Torin1 at IC50 of 2 to 10 nM. 
Therefore, Torin2 is suggested to be a more potent and stable mTORC inhibitor than Torin1.  
Since mTORC1 inhibition leads to upregulation of IRS1 and subsequently PI3K, which in 
turn activates Akt, simultaneously blocking the activities of mTOR complexes and PI3K may 
inhibit cell proliferation and growth more effectively. As a result, several mTOR/PI3K dual 
inhibitors have been developed. NVP-BEZ235 inhibits PI3K and mTOR kinase activity by 
interacting with their ATP-binding domains (Maira et al. 2008). It has been implicated in the 
treatment of non-small cell lung cancer (Konstantinidou et al. 2009), melanoma (Marone et 
al. 2009), pancreatic cancer (Cao et al. 2009), and acute myeloid leukemia (Chapuis et al. 
2010). Given the compensatory mechanisms that cells employ to adapt to growth-inhibitory 
conditions, it would be important to identify signaling pathways that impinge on the 
mTOR/PI3K pathway in order to develop combinatorial therapy for preventing 
malignancy. 
8. Conclusion 
Two decades after the discovery of TOR/mTOR, the function of this protein in orchestrating 
cellular processes in response to growth signals particularly nutrients has been established. 
Some key discoveries in the last few years that allowed more extensive analysis of mTOR 
function and regulation include identification of the mTOR complexes and regulatory 
proteins that link the mTOR pathway to nutrient and energy responses and the 
development of mTOR inhibitors. Studies to dissect the systemic function of mTOR 
 
The Target of Rapamycin: Structure and Functions 
 
21 
complexes are also gaining momentum with the use of tissue-specific mTORC component 
knockout mice. There are still numerous outstanding questions that need to be addressed 
such as the precise regulation of mTOR complexes by nutrients, how it links signals from 
nutrients to cellular metabolism and other processes, and distinct functions and regulation 
of mTORCs in different cellular compartments. The recent identification of the myriad 
possible direct and indirect targets of the mTORCs should provide clues on the mechanisms 
involved in mTOR functions. Animal models would also provide insights on the role of 
mTOR in physiological and pathological conditions. Finally, development of specific 
mTORC1 and mTORC2 inhibitors would not only be useful to determine the distinct 
functions of these complexes but also would have numerous clinical applications. 
9. Acknowledgements 
We thank Won Jun Oh for comments on this manuscript and acknowledge support from the 
NIH (GM079176), American Cancer Society (RSG0721601TBE), Cancer Research Institute, 
and SU2C-AACR-IRG0311 (E.J.).  
10. References 
Acker, M. G.&Lorsch, J. R. (2008). "Mechanism of ribosomal subunit joining during 
eukaryotic translation initiation." Biochemical Society transactions 36(Pt 4): 653-657. 
Acosta-Jaquez, H. A.; Keller, J. A.; Foster, K. G.; Ekim, B.; Soliman, G. A.; Feener, E. P.; Ballif, 
B. A.&Fingar, D. C. (2009). "Site-specific mTOR phosphorylation promotes 
mTORC1-mediated signaling and cell growth." Molecular and cellular biology 29(15): 
4308-4324. 
Adami, A.; Garcia-Alvarez, B.; Arias-Palomo, E.; Barford, D.&Llorca, O. (2007). "Structure of 
TOR and its complex with KOG1." Molecular cell 27(3): 509-516. 
Aimbetov, R.; Chen, C. H.; Bulgakova, O.; Abetov, D.; Bissenbaev, A. K.; Bersimbaev, R. 
I.&Sarbassov, D. D. (2011). "Integrity of mTORC2 is dependent on the rictor Gly-
934 site." Oncogene. 
Alarcon, C. M.; Heitman, J.&Cardenas, M. E. (1999). "Protein kinase activity and 
identification of a toxic effector domain of the target of rapamycin TOR proteins in 
yeast." Molecular biology of the cell 10(8): 2531-2546. 
Alvarez, B.&Moreno, S. (2006). "Fission yeast Tor2 promotes cell growth and represses cell 
differentiation." Journal of cell science 119(Pt 21): 4475-4485. 
Aronova, S.; Wedaman, K.; Anderson, S.; Yates, J., 3rd&Powers, T. (2007). "Probing the 
membrane environment of the TOR kinases reveals functional interactions between 
TORC1, actin, and membrane trafficking in Saccharomyces cerevisiae." Molecular 
biology of the cell 18(8): 2779-2794. 
Beck, T.&Hall, M. N. (1999). "The TOR signalling pathway controls nuclear localization of 
nutrient-regulated transcription factors." Nature 402(6762): 689-692. 
Bentzinger, C. F.; Romanino, K.; Cloetta, D.; Lin, S.; Mascarenhas, J. B.; Oliveri, F.; Xia, J.; 
Casanova, E.; Costa, C. F.; Brink, M.; Zorzato, F.; Hall, M. N.&Ruegg, M. A. (2008). 
"Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic 
changes and results in muscle dystrophy." Cell metabolism 8(5): 411-424. 
Berven, L. A.; Willard, F. S.&Crouch, M. F. (2004). "Role of the p70(S6K) pathway in 





Binda, M.; Peli-Gulli, M. P.; Bonfils, G.; Panchaud, N.; Urban, J.; Sturgill, T. W.; Loewith, 
R.&De Virgilio, C. (2009). "The Vam6 GEF controls TORC1 by activating the EGO 
complex." Molecular cell 35(5): 563-573. 
Bosotti, R.; Isacchi, A.&Sonnhammer, E. L. (2000). "FAT: a novel domain in PIK-related 
kinases." Trends in biochemical sciences 25(5): 225-227. 
Boulbes, D.; Chen, C. H.; Shaikenov, T.; Agarwal, N. K.; Peterson, T. R.; Addona, T. A.; 
Keshishian, H.; Carr, S. A.; Magnuson, M. A.; Sabatini, D. M.&Sarbassov dos, D. 
(2010). "Rictor phosphorylation on the Thr-1135 site does not require mammalian 
target of rapamycin complex 2." Molecular cancer research : MCR 8(6): 896-906. 
Boulbes, D. R.; Shaiken, T.&Sarbassov dos, D. (2011). "Endoplasmic reticulum is a main 
localization site of mTORC2." Biochemical and biophysical research communications 
413(1): 46-52. 
Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.&Schreiber, S. 
L. (1994). "A mammalian protein targeted by G1-arresting rapamycin-receptor 
complex." Nature 369(6483): 756-758. 
Brugarolas, J. B.; Vazquez, F.; Reddy, A.; Sellers, W. R.&Kaelin, W. G., Jr. (2003). "TSC2 
regulates VEGF through mTOR-dependent and -independent pathways." Cancer 
cell 4(2): 147-158. 
Brunn, G. J.; Fadden, P.; Haystead, T. A.&Lawrence, J. C., Jr. (1997). "The mammalian target 
of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by 
antibodies to a region near its COOH terminus." The Journal of biological chemistry 
272(51): 32547-32550. 
Bussiere, C. T.; Lakey, J. R.; Shapiro, A. M.&Korbutt, G. S. (2006). "The impact of the mTOR 
inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal 
cells." Diabetologia 49(10): 2341-2349. 
Byfield, M. P.; Murray, J. T.&Backer, J. M. (2005). "hVps34 is a nutrient-regulated lipid 
kinase required for activation of p70 S6 kinase." The Journal of biological chemistry 
280(38): 33076-33082. 
Cao, P.; Maira, S. M.; Garcia-Echeverria, C.&Hedley, D. W. (2009). "Activity of a novel, dual 
PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers 
grown as orthotopic xenografts." Br J Cancer 100(8): 1267-1276. 
Carayol, N.; Vakana, E.; Sassano, A.; Kaur, S.; Goussetis, D. J.; Glaser, H.; Druker, B. J.; 
Donato, N. J.; Altman, J. K.; Barr, S.&Platanias, L. C. (2010). "Critical roles for 
mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival 
of BCR-ABL-expressing leukemic cells." Proceedings of the National Academy of 
Sciences of the United States of America 107(28): 12469-12474. 
Cardenas, M. E.; Cutler, N. S.; Lorenz, M. C.; Di Como, C. J.&Heitman, J. (1999). "The TOR 
signaling cascade regulates gene expression in response to nutrients." Genes & 
development 13(24): 3271-3279. 
Carriere, A.; Cargnello, M.; Julien, L. A.; Gao, H.; Bonneil, E.; Thibault, P.&Roux, P. P. (2008). 
"Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-
mediated raptor phosphorylation." Current biology : CB 18(17): 1269-1277. 
Castro, A. F.; Rebhun, J. F.; Clark, G. J.&Quilliam, L. A. (2003). "Rheb binds tuberous 
sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and 
farnesylation-dependent manner." The Journal of biological chemistry 278(35): 32493-
32496. 
 
The Target of Rapamycin: Structure and Functions 
 
23 
Chapuis, N.; Tamburini, J.; Green, A. S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; 
Willems, L.; Park, S.; Macone, A.; Maira, S. M.; Ifrah, N.; Dreyfus, F.; Herault, O.; 
Lacombe, C.; Mayeux, P.&Bouscary, D. (2010). "Dual inhibition of PI3K and 
mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute 
myeloid leukemia." Clin Cancer Res 16(22): 5424-5435. 
Chen, C. H.&Sarbassov, D. D. (2011). "Integrity of mTORC2 is dependent on 
phosphorylation of SIN1 by mTOR." The Journal of biological chemistry. 
Chen, E. J.&Kaiser, C. A. (2003). "LST8 negatively regulates amino acid biosynthesis as a 
component of the TOR pathway." The Journal of cell biology 161(2): 333-347. 
Chen, J.; Zheng, X. F.; Brown, E. J.&Schreiber, S. L. (1995). "Identification of an 11-kDa 
FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-
associated protein and characterization of a critical serine residue." Proceedings of 
the National Academy of Sciences of the United States of America 92(11): 4947-4951. 
Cheng, J.; Zhang, D.; Kim, K.; Zhao, Y.&Su, B. (2005). "Mip1, an MEKK2-interacting protein, 
controls MEKK2 dimerization and activation." Molecular and cellular biology 25(14): 
5955-5964. 
Chiang, G. G.&Abraham, R. T. (2005). "Phosphorylation of mammalian target of rapamycin 
(mTOR) at Ser-2448 is mediated by p70S6 kinase." The Journal of biological chemistry 
280(27): 25485-25490. 
Choi, J.; Chen, J.; Schreiber, S. L.&Clardy, J. (1996). "Structure of the FKBP12-rapamycin 
complex interacting with the binding domain of human FRAP." Science 273(5272): 
239-242. 
Choo, A. Y.&Blenis, J. (2009). "Not all substrates are treated equally: implications for mTOR, 
rapamycin-resistance and cancer therapy." Cell Cycle 8(4): 567-572. 
Choo, A. Y.; Yoon, S. O.; Kim, S. G.; Roux, P. P.&Blenis, J. (2008). "Rapamycin differentially 
inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA 
translation." Proceedings of the National Academy of Sciences of the United States of 
America 105(45): 17414-17419. 
Clippinger, A. J.; Maguire, T. G.&Alwine, J. C. (2011). "The changing role of mTOR kinase in 
the maintenance of protein synthesis during human cytomegalovirus infection." 
Journal of virology 85(8): 3930-3939. 
Colombi, M.; Molle, K. D.; Benjamin, D.; Rattenbacher-Kiser, K.; Schaefer, C.; Betz, C.; 
Thiemeyer, A.; Regenass, U.; Hall, M. N.&Moroni, C. (2011). "Genome-wide shRNA 
screen reveals increased mitochondrial dependence upon mTORC2 addiction." 
Oncogene 30(13): 1551-1565. 
Copp, J.; Manning, G.&Hunter, T. (2009). "TORC-specific phosphorylation of mammalian 
target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR 
signaling complex 2." Cancer research 69(5): 1821-1827. 
Corradetti, M. N.; Inoki, K.; Bardeesy, N.; DePinho, R. A.&Guan, K. L. (2004). "Regulation of 
the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis 
complex and Peutz-Jeghers syndrome." Genes & development 18(13): 1533-1538. 
Crouch, M. F. (1997). "Regulation of thrombin-induced stress fibre formation in Swiss 3T3 
cells by the 70-kDa S6 kinase." Biochem Biophys Res Commun 233(1): 193-199. 
Cunningham, J. T.; Rodgers, J. T.; Arlow, D. H.; Vazquez, F.; Mootha, V. K.&Puigserver, P. 
(2007). "mTOR controls mitochondrial oxidative function through a YY1-PGC-





Binda, M.; Peli-Gulli, M. P.; Bonfils, G.; Panchaud, N.; Urban, J.; Sturgill, T. W.; Loewith, 
R.&De Virgilio, C. (2009). "The Vam6 GEF controls TORC1 by activating the EGO 
complex." Molecular cell 35(5): 563-573. 
Bosotti, R.; Isacchi, A.&Sonnhammer, E. L. (2000). "FAT: a novel domain in PIK-related 
kinases." Trends in biochemical sciences 25(5): 225-227. 
Boulbes, D.; Chen, C. H.; Shaikenov, T.; Agarwal, N. K.; Peterson, T. R.; Addona, T. A.; 
Keshishian, H.; Carr, S. A.; Magnuson, M. A.; Sabatini, D. M.&Sarbassov dos, D. 
(2010). "Rictor phosphorylation on the Thr-1135 site does not require mammalian 
target of rapamycin complex 2." Molecular cancer research : MCR 8(6): 896-906. 
Boulbes, D. R.; Shaiken, T.&Sarbassov dos, D. (2011). "Endoplasmic reticulum is a main 
localization site of mTORC2." Biochemical and biophysical research communications 
413(1): 46-52. 
Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.&Schreiber, S. 
L. (1994). "A mammalian protein targeted by G1-arresting rapamycin-receptor 
complex." Nature 369(6483): 756-758. 
Brugarolas, J. B.; Vazquez, F.; Reddy, A.; Sellers, W. R.&Kaelin, W. G., Jr. (2003). "TSC2 
regulates VEGF through mTOR-dependent and -independent pathways." Cancer 
cell 4(2): 147-158. 
Brunn, G. J.; Fadden, P.; Haystead, T. A.&Lawrence, J. C., Jr. (1997). "The mammalian target 
of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by 
antibodies to a region near its COOH terminus." The Journal of biological chemistry 
272(51): 32547-32550. 
Bussiere, C. T.; Lakey, J. R.; Shapiro, A. M.&Korbutt, G. S. (2006). "The impact of the mTOR 
inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal 
cells." Diabetologia 49(10): 2341-2349. 
Byfield, M. P.; Murray, J. T.&Backer, J. M. (2005). "hVps34 is a nutrient-regulated lipid 
kinase required for activation of p70 S6 kinase." The Journal of biological chemistry 
280(38): 33076-33082. 
Cao, P.; Maira, S. M.; Garcia-Echeverria, C.&Hedley, D. W. (2009). "Activity of a novel, dual 
PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers 
grown as orthotopic xenografts." Br J Cancer 100(8): 1267-1276. 
Carayol, N.; Vakana, E.; Sassano, A.; Kaur, S.; Goussetis, D. J.; Glaser, H.; Druker, B. J.; 
Donato, N. J.; Altman, J. K.; Barr, S.&Platanias, L. C. (2010). "Critical roles for 
mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival 
of BCR-ABL-expressing leukemic cells." Proceedings of the National Academy of 
Sciences of the United States of America 107(28): 12469-12474. 
Cardenas, M. E.; Cutler, N. S.; Lorenz, M. C.; Di Como, C. J.&Heitman, J. (1999). "The TOR 
signaling cascade regulates gene expression in response to nutrients." Genes & 
development 13(24): 3271-3279. 
Carriere, A.; Cargnello, M.; Julien, L. A.; Gao, H.; Bonneil, E.; Thibault, P.&Roux, P. P. (2008). 
"Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-
mediated raptor phosphorylation." Current biology : CB 18(17): 1269-1277. 
Castro, A. F.; Rebhun, J. F.; Clark, G. J.&Quilliam, L. A. (2003). "Rheb binds tuberous 
sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and 
farnesylation-dependent manner." The Journal of biological chemistry 278(35): 32493-
32496. 
 
The Target of Rapamycin: Structure and Functions 
 
23 
Chapuis, N.; Tamburini, J.; Green, A. S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; 
Willems, L.; Park, S.; Macone, A.; Maira, S. M.; Ifrah, N.; Dreyfus, F.; Herault, O.; 
Lacombe, C.; Mayeux, P.&Bouscary, D. (2010). "Dual inhibition of PI3K and 
mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute 
myeloid leukemia." Clin Cancer Res 16(22): 5424-5435. 
Chen, C. H.&Sarbassov, D. D. (2011). "Integrity of mTORC2 is dependent on 
phosphorylation of SIN1 by mTOR." The Journal of biological chemistry. 
Chen, E. J.&Kaiser, C. A. (2003). "LST8 negatively regulates amino acid biosynthesis as a 
component of the TOR pathway." The Journal of cell biology 161(2): 333-347. 
Chen, J.; Zheng, X. F.; Brown, E. J.&Schreiber, S. L. (1995). "Identification of an 11-kDa 
FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-
associated protein and characterization of a critical serine residue." Proceedings of 
the National Academy of Sciences of the United States of America 92(11): 4947-4951. 
Cheng, J.; Zhang, D.; Kim, K.; Zhao, Y.&Su, B. (2005). "Mip1, an MEKK2-interacting protein, 
controls MEKK2 dimerization and activation." Molecular and cellular biology 25(14): 
5955-5964. 
Chiang, G. G.&Abraham, R. T. (2005). "Phosphorylation of mammalian target of rapamycin 
(mTOR) at Ser-2448 is mediated by p70S6 kinase." The Journal of biological chemistry 
280(27): 25485-25490. 
Choi, J.; Chen, J.; Schreiber, S. L.&Clardy, J. (1996). "Structure of the FKBP12-rapamycin 
complex interacting with the binding domain of human FRAP." Science 273(5272): 
239-242. 
Choo, A. Y.&Blenis, J. (2009). "Not all substrates are treated equally: implications for mTOR, 
rapamycin-resistance and cancer therapy." Cell Cycle 8(4): 567-572. 
Choo, A. Y.; Yoon, S. O.; Kim, S. G.; Roux, P. P.&Blenis, J. (2008). "Rapamycin differentially 
inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA 
translation." Proceedings of the National Academy of Sciences of the United States of 
America 105(45): 17414-17419. 
Clippinger, A. J.; Maguire, T. G.&Alwine, J. C. (2011). "The changing role of mTOR kinase in 
the maintenance of protein synthesis during human cytomegalovirus infection." 
Journal of virology 85(8): 3930-3939. 
Colombi, M.; Molle, K. D.; Benjamin, D.; Rattenbacher-Kiser, K.; Schaefer, C.; Betz, C.; 
Thiemeyer, A.; Regenass, U.; Hall, M. N.&Moroni, C. (2011). "Genome-wide shRNA 
screen reveals increased mitochondrial dependence upon mTORC2 addiction." 
Oncogene 30(13): 1551-1565. 
Copp, J.; Manning, G.&Hunter, T. (2009). "TORC-specific phosphorylation of mammalian 
target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR 
signaling complex 2." Cancer research 69(5): 1821-1827. 
Corradetti, M. N.; Inoki, K.; Bardeesy, N.; DePinho, R. A.&Guan, K. L. (2004). "Regulation of 
the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis 
complex and Peutz-Jeghers syndrome." Genes & development 18(13): 1533-1538. 
Crouch, M. F. (1997). "Regulation of thrombin-induced stress fibre formation in Swiss 3T3 
cells by the 70-kDa S6 kinase." Biochem Biophys Res Commun 233(1): 193-199. 
Cunningham, J. T.; Rodgers, J. T.; Arlow, D. H.; Vazquez, F.; Mootha, V. K.&Puigserver, P. 
(2007). "mTOR controls mitochondrial oxidative function through a YY1-PGC-





Cybulski, N.; Polak, P.; Auwerx, J.; Ruegg, M. A.&Hall, M. N. (2009). "mTOR complex 2 in 
adipose tissue negatively controls whole-body growth." Proceedings of the National 
Academy of Sciences of the United States of America 106(24): 9902-9907. 
Dames, S. A.; Mulet, J. M.; Rathgeb-Szabo, K.; Hall, M. N.&Grzesiek, S. (2005). "The solution 
structure of the FATC domain of the protein kinase target of rapamycin suggests a 
role for redox-dependent structural and cellular stability." The Journal of biological 
chemistry 280(21): 20558-20564. 
Delgoffe, G. M.; Kole, T. P.; Zheng, Y.; Zarek, P. E.; Matthews, K. L.; Xiao, B.; Worley, P. F.; 
Kozma, S. C.&Powell, J. D. (2009). "The mTOR kinase differentially regulates 
effector and regulatory T cell lineage commitment." Immunity 30(6): 832-844. 
Diaz-Troya, S.; Perez-Perez, M. E.; Florencio, F. J.&Crespo, J. L. (2008). "The role of TOR in 
autophagy regulation from yeast to plants and mammals." Autophagy 4(7): 851-865. 
Dibble, C. C.; Asara, J. M. & Manning, B. D. (2009). "Characterization of Rictor 
phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1." 
Molecular and cellular biology 29(21): 5657-5670. 
Doi, T.; Muro, K.; Boku, N.; Yamada, Y.; Nishina, T.; Takiuchi, H.; Komatsu, Y.; Hamamoto, 
Y.; Ohno, N.; Fujita, Y.; Robson, M.&Ohtsu, A. (2010). "Multicenter phase II study 
of everolimus in patients with previously treated metastatic gastric cancer." J Clin 
Oncol 28(11): 1904-1910. 
Dorrello, N. V.; Peschiaroli, A.; Guardavaccaro, D.; Colburn, N. H.; Sherman, N. E.&Pagano, 
M. (2006). "S6K1- and betaTRCP-mediated degradation of PDCD4 promotes 
protein translation and cell growth." Science 314(5798): 467-471. 
Dowling, R. J.; Topisirovic, I.; Alain, T.; Bidinosti, M.; Fonseca, B. D.; Petroulakis, E.; Wang, 
X.; Larsson, O.; Selvaraj, A.; Liu, Y.; Kozma, S. C.; Thomas, G.&Sonenberg, N. 
(2010). "mTORC1-mediated cell proliferation, but not cell growth, controlled by the 
4E-BPs." Science 328(5982): 1172-1176. 
Duan, S.; Skaar, J. R.; Kuchay, S.; Toschi, A.; Kanarek, N.; Ben-Neriah, Y.&Pagano, M. (2011). 
"mTOR Generates an Auto-Amplification Loop by Triggering the betaTrCP- and 
CK1alpha-Dependent Degradation of DEPTOR." Molecular cell 44(2): 317-324. 
Dubouloz, F.; Deloche, O.; Wanke, V.; Cameroni, E.&De Virgilio, C. (2005). "The TOR and 
EGO protein complexes orchestrate microautophagy in yeast." Molecular cell 19(1): 
15-26. 
Dunn, T. M.; Haak, D.; Monaghan, E.&Beeler, T. J. (1998). "Synthesis of monohydroxylated 
inositolphosphorylceramide (IPC-C) in Saccharomyces cerevisiae requires Scs7p, a 
protein with both a cytochrome b5-like domain and a hydroxylase/desaturase 
domain." Yeast 14(4): 311-321. 
Duran, A.; Amanchy, R.; Linares, J. F.; Joshi, J.; Abu-Baker, S.; Porollo, A.; Hansen, M.; 
Moscat, J.&Diaz-Meco, M. T. (2011). "p62 Is a Key Regulator of Nutrient Sensing in 
the mTORC1 Pathway." Molecular cell 44(1): 134-146. 
Duvel, K.; Yecies, J. L.; Menon, S.; Raman, P.; Lipovsky, A. I.; Souza, A. L.; Triantafellow, E.; 
Ma, Q.; Gorski, R.; Cleaver, S.; Vander Heiden, M. G.; MacKeigan, J. P.; Finan, P. 
M.; Clish, C. B.; Murphy, L. O.&Manning, B. D. (2010). "Activation of a metabolic 
gene regulatory network downstream of mTOR complex 1." Molecular cell 39(2): 
171-183. 
English, D. (1996). "Phosphatidic acid: a lipid messenger involved in intracellular and 
extracellular signalling." Cellular signalling 8(5): 341-347. 
 
The Target of Rapamycin: Structure and Functions 
 
25 
Evangelisti, C.; Ricci, F.; Tazzari, P.; Tabellini, G.; Battistelli, M.; Falcieri, E.; Chiarini, F.; 
Bortul, R.; Melchionda, F.; Pagliaro, P.; Pession, A.; McCubrey, J. A.&Martelli, A. M. 
(2011). "Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR 
inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia." Leukemia : 
official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 25(5): 
781-791. 
Facchinetti, V.; Ouyang, W.; Wei, H.; Soto, N.; Lazorchak, A.; Gould, C.; Lowry, C.; Newton, 
A. C.; Mao, Y.; Miao, R. Q.; Sessa, W. C.; Qin, J.; Zhang, P.; Su, B.&Jacinto, E. (2008). 
"The mammalian target of rapamycin complex 2 controls folding and stability of 
Akt and protein kinase C." The EMBO journal 27(14): 1932-1943. 
Fadri, M.; Daquinag, A.; Wang, S.; Xue, T.&Kunz, J. (2005). "The pleckstrin homology 
domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in 
yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2." Molecular 
biology of the cell 16(4): 1883-1900. 
Fang, Y.; Vilella-Bach, M.; Bachmann, R.; Flanigan, A.&Chen, J. (2001). "Phosphatidic acid-
mediated mitogenic activation of mTOR signaling." Science 294(5548): 1942-1945. 
Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.&Shokat, K. M. 
(2009). "Active-site inhibitors of mTOR target rapamycin-resistant outputs of 
mTORC1 and mTORC2." PLoS biology 7(2): e38. 
Finlay, D.&Cantrell, D. (2010). "Phosphoinositide 3-kinase and the mammalian target of 
rapamycin pathways control T cell migration." Ann N Y Acad Sci 1183: 149-157. 
Frias, M. A.; Thoreen, C. C.; Jaffe, J. D.; Schroder, W.; Sculley, T.; Carr, S. A.&Sabatini, D. M. 
(2006). "mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define 
three distinct mTORC2s." Current biology : CB 16(18): 1865-1870. 
Gangloff, Y. G.; Mueller, M.; Dann, S. G.; Svoboda, P.; Sticker, M.; Spetz, J. F.; Um, S. H.; 
Brown, E. J.; Cereghini, S.; Thomas, G.&Kozma, S. C. (2004). "Disruption of the 
mouse mTOR gene leads to early postimplantation lethality and prohibits 
embryonic stem cell development." Molecular and cellular biology 24(21): 9508-9516. 
Ganley, I. G.; Lam du, H.; Wang, J.; Ding, X.; Chen, S.&Jiang, X. (2009). 
"ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for 
autophagy." The Journal of biological chemistry 284(18): 12297-12305. 
Gao, D.; Inuzuka, H.; Tan, M. K.; Fukushima, H.; Locasale, J. W.; Liu, P.; Wan, L.; Zhai, B.; 
Chin, Y. R.; Shaik, S.; Lyssiotis, C. A.; Gygi, S. P.; Toker, A.; Cantley, L. C.; Asara, J. 
M.; Harper, J. W.&Wei, W. (2011). "mTOR Drives Its Own Activation via 
SCF(betaTrCP)-Dependent Degradation of the mTOR Inhibitor DEPTOR." 
Molecular cell 44(2): 290-303. 
Gao, D.; Wan, L.; Inuzuka, H.; Berg, A. H.; Tseng, A.; Zhai, B.; Shaik, S.; Bennett, E.; Tron, A. 
E.; Gasser, J. A.; Lau, A.; Gygi, S. P.; Harper, J. W.; DeCaprio, J. A.; Toker, A.&Wei, 
W. (2010). "Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination 
and destruction." Molecular cell 39(5): 797-808. 
Gao, X.; Zhang, Y.; Arrazola, P.; Hino, O.; Kobayashi, T.; Yeung, R. S.; Ru, B.&Pan, D. (2002). 
"Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling." Nature 
cell biology 4(9): 699-704. 
Garami, A.; Zwartkruis, F. J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S. 





Cybulski, N.; Polak, P.; Auwerx, J.; Ruegg, M. A.&Hall, M. N. (2009). "mTOR complex 2 in 
adipose tissue negatively controls whole-body growth." Proceedings of the National 
Academy of Sciences of the United States of America 106(24): 9902-9907. 
Dames, S. A.; Mulet, J. M.; Rathgeb-Szabo, K.; Hall, M. N.&Grzesiek, S. (2005). "The solution 
structure of the FATC domain of the protein kinase target of rapamycin suggests a 
role for redox-dependent structural and cellular stability." The Journal of biological 
chemistry 280(21): 20558-20564. 
Delgoffe, G. M.; Kole, T. P.; Zheng, Y.; Zarek, P. E.; Matthews, K. L.; Xiao, B.; Worley, P. F.; 
Kozma, S. C.&Powell, J. D. (2009). "The mTOR kinase differentially regulates 
effector and regulatory T cell lineage commitment." Immunity 30(6): 832-844. 
Diaz-Troya, S.; Perez-Perez, M. E.; Florencio, F. J.&Crespo, J. L. (2008). "The role of TOR in 
autophagy regulation from yeast to plants and mammals." Autophagy 4(7): 851-865. 
Dibble, C. C.; Asara, J. M. & Manning, B. D. (2009). "Characterization of Rictor 
phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1." 
Molecular and cellular biology 29(21): 5657-5670. 
Doi, T.; Muro, K.; Boku, N.; Yamada, Y.; Nishina, T.; Takiuchi, H.; Komatsu, Y.; Hamamoto, 
Y.; Ohno, N.; Fujita, Y.; Robson, M.&Ohtsu, A. (2010). "Multicenter phase II study 
of everolimus in patients with previously treated metastatic gastric cancer." J Clin 
Oncol 28(11): 1904-1910. 
Dorrello, N. V.; Peschiaroli, A.; Guardavaccaro, D.; Colburn, N. H.; Sherman, N. E.&Pagano, 
M. (2006). "S6K1- and betaTRCP-mediated degradation of PDCD4 promotes 
protein translation and cell growth." Science 314(5798): 467-471. 
Dowling, R. J.; Topisirovic, I.; Alain, T.; Bidinosti, M.; Fonseca, B. D.; Petroulakis, E.; Wang, 
X.; Larsson, O.; Selvaraj, A.; Liu, Y.; Kozma, S. C.; Thomas, G.&Sonenberg, N. 
(2010). "mTORC1-mediated cell proliferation, but not cell growth, controlled by the 
4E-BPs." Science 328(5982): 1172-1176. 
Duan, S.; Skaar, J. R.; Kuchay, S.; Toschi, A.; Kanarek, N.; Ben-Neriah, Y.&Pagano, M. (2011). 
"mTOR Generates an Auto-Amplification Loop by Triggering the betaTrCP- and 
CK1alpha-Dependent Degradation of DEPTOR." Molecular cell 44(2): 317-324. 
Dubouloz, F.; Deloche, O.; Wanke, V.; Cameroni, E.&De Virgilio, C. (2005). "The TOR and 
EGO protein complexes orchestrate microautophagy in yeast." Molecular cell 19(1): 
15-26. 
Dunn, T. M.; Haak, D.; Monaghan, E.&Beeler, T. J. (1998). "Synthesis of monohydroxylated 
inositolphosphorylceramide (IPC-C) in Saccharomyces cerevisiae requires Scs7p, a 
protein with both a cytochrome b5-like domain and a hydroxylase/desaturase 
domain." Yeast 14(4): 311-321. 
Duran, A.; Amanchy, R.; Linares, J. F.; Joshi, J.; Abu-Baker, S.; Porollo, A.; Hansen, M.; 
Moscat, J.&Diaz-Meco, M. T. (2011). "p62 Is a Key Regulator of Nutrient Sensing in 
the mTORC1 Pathway." Molecular cell 44(1): 134-146. 
Duvel, K.; Yecies, J. L.; Menon, S.; Raman, P.; Lipovsky, A. I.; Souza, A. L.; Triantafellow, E.; 
Ma, Q.; Gorski, R.; Cleaver, S.; Vander Heiden, M. G.; MacKeigan, J. P.; Finan, P. 
M.; Clish, C. B.; Murphy, L. O.&Manning, B. D. (2010). "Activation of a metabolic 
gene regulatory network downstream of mTOR complex 1." Molecular cell 39(2): 
171-183. 
English, D. (1996). "Phosphatidic acid: a lipid messenger involved in intracellular and 
extracellular signalling." Cellular signalling 8(5): 341-347. 
 
The Target of Rapamycin: Structure and Functions 
 
25 
Evangelisti, C.; Ricci, F.; Tazzari, P.; Tabellini, G.; Battistelli, M.; Falcieri, E.; Chiarini, F.; 
Bortul, R.; Melchionda, F.; Pagliaro, P.; Pession, A.; McCubrey, J. A.&Martelli, A. M. 
(2011). "Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR 
inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia." Leukemia : 
official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 25(5): 
781-791. 
Facchinetti, V.; Ouyang, W.; Wei, H.; Soto, N.; Lazorchak, A.; Gould, C.; Lowry, C.; Newton, 
A. C.; Mao, Y.; Miao, R. Q.; Sessa, W. C.; Qin, J.; Zhang, P.; Su, B.&Jacinto, E. (2008). 
"The mammalian target of rapamycin complex 2 controls folding and stability of 
Akt and protein kinase C." The EMBO journal 27(14): 1932-1943. 
Fadri, M.; Daquinag, A.; Wang, S.; Xue, T.&Kunz, J. (2005). "The pleckstrin homology 
domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in 
yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2." Molecular 
biology of the cell 16(4): 1883-1900. 
Fang, Y.; Vilella-Bach, M.; Bachmann, R.; Flanigan, A.&Chen, J. (2001). "Phosphatidic acid-
mediated mitogenic activation of mTOR signaling." Science 294(5548): 1942-1945. 
Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.&Shokat, K. M. 
(2009). "Active-site inhibitors of mTOR target rapamycin-resistant outputs of 
mTORC1 and mTORC2." PLoS biology 7(2): e38. 
Finlay, D.&Cantrell, D. (2010). "Phosphoinositide 3-kinase and the mammalian target of 
rapamycin pathways control T cell migration." Ann N Y Acad Sci 1183: 149-157. 
Frias, M. A.; Thoreen, C. C.; Jaffe, J. D.; Schroder, W.; Sculley, T.; Carr, S. A.&Sabatini, D. M. 
(2006). "mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define 
three distinct mTORC2s." Current biology : CB 16(18): 1865-1870. 
Gangloff, Y. G.; Mueller, M.; Dann, S. G.; Svoboda, P.; Sticker, M.; Spetz, J. F.; Um, S. H.; 
Brown, E. J.; Cereghini, S.; Thomas, G.&Kozma, S. C. (2004). "Disruption of the 
mouse mTOR gene leads to early postimplantation lethality and prohibits 
embryonic stem cell development." Molecular and cellular biology 24(21): 9508-9516. 
Ganley, I. G.; Lam du, H.; Wang, J.; Ding, X.; Chen, S.&Jiang, X. (2009). 
"ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for 
autophagy." The Journal of biological chemistry 284(18): 12297-12305. 
Gao, D.; Inuzuka, H.; Tan, M. K.; Fukushima, H.; Locasale, J. W.; Liu, P.; Wan, L.; Zhai, B.; 
Chin, Y. R.; Shaik, S.; Lyssiotis, C. A.; Gygi, S. P.; Toker, A.; Cantley, L. C.; Asara, J. 
M.; Harper, J. W.&Wei, W. (2011). "mTOR Drives Its Own Activation via 
SCF(betaTrCP)-Dependent Degradation of the mTOR Inhibitor DEPTOR." 
Molecular cell 44(2): 290-303. 
Gao, D.; Wan, L.; Inuzuka, H.; Berg, A. H.; Tseng, A.; Zhai, B.; Shaik, S.; Bennett, E.; Tron, A. 
E.; Gasser, J. A.; Lau, A.; Gygi, S. P.; Harper, J. W.; DeCaprio, J. A.; Toker, A.&Wei, 
W. (2010). "Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination 
and destruction." Molecular cell 39(5): 797-808. 
Gao, X.; Zhang, Y.; Arrazola, P.; Hino, O.; Kobayashi, T.; Yeung, R. S.; Ru, B.&Pan, D. (2002). 
"Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling." Nature 
cell biology 4(9): 699-704. 
Garami, A.; Zwartkruis, F. J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S. 





of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2." Molecular cell 11(6): 
1457-1466. 
Garcia-Martinez, J. M.&Alessi, D. R. (2008). "mTOR complex 2 (mTORC2) controls 
hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-
induced protein kinase 1 (SGK1)." The Biochemical journal 416(3): 375-385. 
Ghosh, D.; Srivastava, G. P.; Xu, D.; Schulz, L. C.&Roberts, R. M. (2008). "A link between 
SIN1 (MAPKAP1) and poly(rC) binding protein 2 (PCBP2) in counteracting 
environmental stress." Proceedings of the National Academy of Sciences of the United 
States of America 105(33): 11673-11678. 
Gingras, A. C.; Gygi, S. P.; Raught, B.; Polakiewicz, R. D.; Abraham, R. T.; Hoekstra, M. F.; 
Aebersold, R.&Sonenberg, N. (1999). "Regulation of 4E-BP1 phosphorylation: a 
novel two-step mechanism." Genes & development 13(11): 1422-1437. 
Gingras, A. C.; Raught, B.; Gygi, S. P.; Niedzwiecka, A.; Miron, M.; Burley, S. K.; 
Polakiewicz, R. D.; Wyslouch-Cieszynska, A.; Aebersold, R.&Sonenberg, N. (2001). 
"Hierarchical phosphorylation of the translation inhibitor 4E-BP1." Genes & 
development 15(21): 2852-2864. 
Goldberg, M. A.; Dunning, S. P.&Bunn, H. F. (1988). "Regulation of the erythropoietin gene: 
evidence that the oxygen sensor is a heme protein." Science 242(4884): 1412-1415. 
Goldstein, R.&Meyer, T. (2011). "Role of everolimus in pancreatic neuroendocrine tumors." 
Expert Rev Anticancer Ther 11(11): 1653-1665. 
Gomez-Cambronero, J. (2003). "Rapamycin inhibits GM-CSF-induced neutrophil migration." 
FEBS Lett 550(1-3): 94-100. 
Green, A. J.; Smith, M.&Yates, J. R. (1994). "Loss of heterozygosity on chromosome 16p13.3 
in hamartomas from tuberous sclerosis patients." Nature genetics 6(2): 193-196. 
Groves, M. R.&Barford, D. (1999). "Topological characteristics of helical repeat proteins." 
Current opinion in structural biology 9(3): 383-389. 
Gu, Y.; Lindner, J.; Kumar, A.; Yuan, W.&Magnuson, M. A. (2011). "Rictor/mTORC2 is 
essential for maintaining a balance between beta-cell proliferation and cell size." 
Diabetes 60(3): 827-837. 
Guertin, D. A.; Stevens, D. M.; Thoreen, C. C.; Burds, A. A.; Kalaany, N. Y.; Moffat, J.; 
Brown, M.; Fitzgerald, K. J.&Sabatini, D. M. (2006). "Ablation in mice of the 
mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for 
signaling to Akt-FOXO and PKCalpha, but not S6K1." Developmental cell 11(6): 859-
871. 
Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; 
Turk, B. E.&Shaw, R. J. (2008). "AMPK phosphorylation of raptor mediates a 
metabolic checkpoint." Molecular cell 30(2): 214-226. 
Hall, M. N. (1996). "The TOR signalling pathway and growth control in yeast." Biochemical 
Society transactions 24(1): 234-239. 
Hanks, S. K.&Hunter, T. (1995). "Protein kinases 6. The eukaryotic protein kinase 
superfamily: kinase (catalytic) domain structure and classification." The FASEB 
journal : official publication of the Federation of American Societies for Experimental 
Biology 9(8): 576-596. 
Hannan, K. M.; Brandenburger, Y.; Jenkins, A.; Sharkey, K.; Cavanaugh, A.; Rothblum, L.; 
Moss, T.; Poortinga, G.; McArthur, G. A.; Pearson, R. B.&Hannan, R. D. (2003). 
"mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is 
 
The Target of Rapamycin: Structure and Functions 
 
27 
mediated by phosphorylation of the carboxy-terminal activation domain of the 
nucleolar transcription factor UBF." Molecular and cellular biology 23(23): 8862-8877. 
Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, 
J.&Yonezawa, K. (2002). "Raptor, a binding partner of target of rapamycin (TOR), 
mediates TOR action." Cell 110(2): 177-189. 
Hardt, M.; Chantaravisoot, N.&Tamanoi, F. (2011). "Activating mutations of TOR (target of 
rapamycin)." Genes to cells : devoted to molecular & cellular mechanisms 16(2): 141-151. 
Hardwick, J. S.; Kuruvilla, F. G.; Tong, J. K.; Shamji, A. F.&Schreiber, S. L. (1999). 
"Rapamycin-modulated transcription defines the subset of nutrient-sensitive 
signaling pathways directly controlled by the Tor proteins." Proceedings of the 
National Academy of Sciences of the United States of America 96(26): 14866-14870. 
Harrington, L. S.; Findlay, G. M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, 
J.; Leslie, N. R.; Cheng, S.; Shepherd, P. R.; Gout, I.; Downes, C. P.&Lamb, R. F. 
(2004). "The TSC1-2 tumor suppressor controls insulin-PI3K signaling via 
regulation of IRS proteins." The Journal of cell biology 166(2): 213-223. 
Harrison, D. E.; Strong, R.; Sharp, Z. D.; Nelson, J. F.; Astle, C. M.; Flurkey, K.; Nadon, N. L.; 
Wilkinson, J. E.; Frenkel, K.; Carter, C. S.; Pahor, M.; Javors, M. A.; Fernandez, 
E.&Miller, R. A. (2009). "Rapamycin fed late in life extends lifespan in genetically 
heterogeneous mice." Nature 460(7253): 392-395. 
Hartwell, L. H.; Hopfield, J. J.; Leibler, S.&Murray, A. W. (1999). "From molecular to 
modular cell biology." Nature 402(6761 Suppl): C47-52. 
Hay, N.&Sonenberg, N. (2004). "Upstream and downstream of mTOR." Genes & development 
18(16): 1926-1945. 
Heitman, J.; Movva, N. R.&Hall, M. N. (1991). "Targets for cell cycle arrest by the 
immunosuppressant rapamycin in yeast." Science 253(5022): 905-909. 
Helliwell, S. B.; Wagner, P.; Kunz, J.; Deuter-Reinhard, M.; Henriquez, R.&Hall, M. N. 
(1994). "TOR1 and TOR2 are structurally and functionally similar but not identical 
phosphatidylinositol kinase homologues in yeast." Molecular biology of the cell 5(1): 
105-118. 
Hernandez-Negrete, I.; Carretero-Ortega, J.; Rosenfeldt, H.; Hernandez-Garcia, R.; 
Calderon-Salinas, J. V.; Reyes-Cruz, G.; Gutkind, J. S.&Vazquez-Prado, J. (2007). "P-
Rex1 links mammalian target of rapamycin signaling to Rac activation and cell 
migration." J Biol Chem 282(32): 23708-23715. 
Heublein, S.; Kazi, S.; Ogmundsdottir, M. H.; Attwood, E. V.; Kala, S.; Boyd, C. A.; Wilson, 
C.&Goberdhan, D. C. (2010). "Proton-assisted amino-acid transporters are 
conserved regulators of proliferation and amino-acid-dependent mTORC1 
activation." Oncogene 29(28): 4068-4079. 
Ho, H. L.; Lee, H. Y.; Liao, H. C.&Chen, M. Y. (2008). "Involvement of Saccharomyces 
cerevisiae Avo3p/Tsc11p in maintaining TOR complex 2 integrity and coupling to 
downstream signaling." Eukaryotic cell 7(8): 1328-1343. 
Hoang, B.; Frost, P.; Shi, Y.; Belanger, E.; Benavides, A.; Pezeshkpour, G.; Cappia, S.; 
Guglielmelli, T.; Gera, J.&Lichtenstein, A. (2010). "Targeting TORC2 in multiple 
myeloma with a new mTOR kinase inhibitor." Blood 116(22): 4560-4568. 
Holz, M. K.&Blenis, J. (2005). "Identification of S6 kinase 1 as a novel mammalian target of 






of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2." Molecular cell 11(6): 
1457-1466. 
Garcia-Martinez, J. M.&Alessi, D. R. (2008). "mTOR complex 2 (mTORC2) controls 
hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-
induced protein kinase 1 (SGK1)." The Biochemical journal 416(3): 375-385. 
Ghosh, D.; Srivastava, G. P.; Xu, D.; Schulz, L. C.&Roberts, R. M. (2008). "A link between 
SIN1 (MAPKAP1) and poly(rC) binding protein 2 (PCBP2) in counteracting 
environmental stress." Proceedings of the National Academy of Sciences of the United 
States of America 105(33): 11673-11678. 
Gingras, A. C.; Gygi, S. P.; Raught, B.; Polakiewicz, R. D.; Abraham, R. T.; Hoekstra, M. F.; 
Aebersold, R.&Sonenberg, N. (1999). "Regulation of 4E-BP1 phosphorylation: a 
novel two-step mechanism." Genes & development 13(11): 1422-1437. 
Gingras, A. C.; Raught, B.; Gygi, S. P.; Niedzwiecka, A.; Miron, M.; Burley, S. K.; 
Polakiewicz, R. D.; Wyslouch-Cieszynska, A.; Aebersold, R.&Sonenberg, N. (2001). 
"Hierarchical phosphorylation of the translation inhibitor 4E-BP1." Genes & 
development 15(21): 2852-2864. 
Goldberg, M. A.; Dunning, S. P.&Bunn, H. F. (1988). "Regulation of the erythropoietin gene: 
evidence that the oxygen sensor is a heme protein." Science 242(4884): 1412-1415. 
Goldstein, R.&Meyer, T. (2011). "Role of everolimus in pancreatic neuroendocrine tumors." 
Expert Rev Anticancer Ther 11(11): 1653-1665. 
Gomez-Cambronero, J. (2003). "Rapamycin inhibits GM-CSF-induced neutrophil migration." 
FEBS Lett 550(1-3): 94-100. 
Green, A. J.; Smith, M.&Yates, J. R. (1994). "Loss of heterozygosity on chromosome 16p13.3 
in hamartomas from tuberous sclerosis patients." Nature genetics 6(2): 193-196. 
Groves, M. R.&Barford, D. (1999). "Topological characteristics of helical repeat proteins." 
Current opinion in structural biology 9(3): 383-389. 
Gu, Y.; Lindner, J.; Kumar, A.; Yuan, W.&Magnuson, M. A. (2011). "Rictor/mTORC2 is 
essential for maintaining a balance between beta-cell proliferation and cell size." 
Diabetes 60(3): 827-837. 
Guertin, D. A.; Stevens, D. M.; Thoreen, C. C.; Burds, A. A.; Kalaany, N. Y.; Moffat, J.; 
Brown, M.; Fitzgerald, K. J.&Sabatini, D. M. (2006). "Ablation in mice of the 
mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for 
signaling to Akt-FOXO and PKCalpha, but not S6K1." Developmental cell 11(6): 859-
871. 
Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; 
Turk, B. E.&Shaw, R. J. (2008). "AMPK phosphorylation of raptor mediates a 
metabolic checkpoint." Molecular cell 30(2): 214-226. 
Hall, M. N. (1996). "The TOR signalling pathway and growth control in yeast." Biochemical 
Society transactions 24(1): 234-239. 
Hanks, S. K.&Hunter, T. (1995). "Protein kinases 6. The eukaryotic protein kinase 
superfamily: kinase (catalytic) domain structure and classification." The FASEB 
journal : official publication of the Federation of American Societies for Experimental 
Biology 9(8): 576-596. 
Hannan, K. M.; Brandenburger, Y.; Jenkins, A.; Sharkey, K.; Cavanaugh, A.; Rothblum, L.; 
Moss, T.; Poortinga, G.; McArthur, G. A.; Pearson, R. B.&Hannan, R. D. (2003). 
"mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is 
 
The Target of Rapamycin: Structure and Functions 
 
27 
mediated by phosphorylation of the carboxy-terminal activation domain of the 
nucleolar transcription factor UBF." Molecular and cellular biology 23(23): 8862-8877. 
Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, 
J.&Yonezawa, K. (2002). "Raptor, a binding partner of target of rapamycin (TOR), 
mediates TOR action." Cell 110(2): 177-189. 
Hardt, M.; Chantaravisoot, N.&Tamanoi, F. (2011). "Activating mutations of TOR (target of 
rapamycin)." Genes to cells : devoted to molecular & cellular mechanisms 16(2): 141-151. 
Hardwick, J. S.; Kuruvilla, F. G.; Tong, J. K.; Shamji, A. F.&Schreiber, S. L. (1999). 
"Rapamycin-modulated transcription defines the subset of nutrient-sensitive 
signaling pathways directly controlled by the Tor proteins." Proceedings of the 
National Academy of Sciences of the United States of America 96(26): 14866-14870. 
Harrington, L. S.; Findlay, G. M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, 
J.; Leslie, N. R.; Cheng, S.; Shepherd, P. R.; Gout, I.; Downes, C. P.&Lamb, R. F. 
(2004). "The TSC1-2 tumor suppressor controls insulin-PI3K signaling via 
regulation of IRS proteins." The Journal of cell biology 166(2): 213-223. 
Harrison, D. E.; Strong, R.; Sharp, Z. D.; Nelson, J. F.; Astle, C. M.; Flurkey, K.; Nadon, N. L.; 
Wilkinson, J. E.; Frenkel, K.; Carter, C. S.; Pahor, M.; Javors, M. A.; Fernandez, 
E.&Miller, R. A. (2009). "Rapamycin fed late in life extends lifespan in genetically 
heterogeneous mice." Nature 460(7253): 392-395. 
Hartwell, L. H.; Hopfield, J. J.; Leibler, S.&Murray, A. W. (1999). "From molecular to 
modular cell biology." Nature 402(6761 Suppl): C47-52. 
Hay, N.&Sonenberg, N. (2004). "Upstream and downstream of mTOR." Genes & development 
18(16): 1926-1945. 
Heitman, J.; Movva, N. R.&Hall, M. N. (1991). "Targets for cell cycle arrest by the 
immunosuppressant rapamycin in yeast." Science 253(5022): 905-909. 
Helliwell, S. B.; Wagner, P.; Kunz, J.; Deuter-Reinhard, M.; Henriquez, R.&Hall, M. N. 
(1994). "TOR1 and TOR2 are structurally and functionally similar but not identical 
phosphatidylinositol kinase homologues in yeast." Molecular biology of the cell 5(1): 
105-118. 
Hernandez-Negrete, I.; Carretero-Ortega, J.; Rosenfeldt, H.; Hernandez-Garcia, R.; 
Calderon-Salinas, J. V.; Reyes-Cruz, G.; Gutkind, J. S.&Vazquez-Prado, J. (2007). "P-
Rex1 links mammalian target of rapamycin signaling to Rac activation and cell 
migration." J Biol Chem 282(32): 23708-23715. 
Heublein, S.; Kazi, S.; Ogmundsdottir, M. H.; Attwood, E. V.; Kala, S.; Boyd, C. A.; Wilson, 
C.&Goberdhan, D. C. (2010). "Proton-assisted amino-acid transporters are 
conserved regulators of proliferation and amino-acid-dependent mTORC1 
activation." Oncogene 29(28): 4068-4079. 
Ho, H. L.; Lee, H. Y.; Liao, H. C.&Chen, M. Y. (2008). "Involvement of Saccharomyces 
cerevisiae Avo3p/Tsc11p in maintaining TOR complex 2 integrity and coupling to 
downstream signaling." Eukaryotic cell 7(8): 1328-1343. 
Hoang, B.; Frost, P.; Shi, Y.; Belanger, E.; Benavides, A.; Pezeshkpour, G.; Cappia, S.; 
Guglielmelli, T.; Gera, J.&Lichtenstein, A. (2010). "Targeting TORC2 in multiple 
myeloma with a new mTOR kinase inhibitor." Blood 116(22): 4560-4568. 
Holz, M. K.&Blenis, J. (2005). "Identification of S6 kinase 1 as a novel mammalian target of 






Horejsi, Z.; Takai, H.; Adelman, C. A.; Collis, S. J.; Flynn, H.; Maslen, S.; Skehel, J. M.; de 
Lange, T.&Boulton, S. J. (2010). "CK2 phospho-dependent binding of R2TP complex 
to TEL2 is essential for mTOR and SMG1 stability." Molecular cell 39(6): 839-850. 
Hosoi, H.; Dilling, M. B.; Shikata, T.; Liu, L. N.; Shu, L.; Ashmun, R. A.; Germain, G. S.; 
Abraham, R. T.&Houghton, P. J. (1999). "Rapamycin causes poorly reversible 
inhibition of mTOR and induces p53-independent apoptosis in human 
rhabdomyosarcoma cells." Cancer Res 59(4): 886-894. 
Hosokawa, N.; Hara, T.; Kaizuka, T.; Kishi, C.; Takamura, A.; Miura, Y.; Iemura, S.; 
Natsume, T.; Takehana, K.; Yamada, N.; Guan, J. L.; Oshiro, N.&Mizushima, N. 
(2009). "Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 
complex required for autophagy." Molecular biology of the cell 20(7): 1981-1991. 
Hresko, R. C.&Mueckler, M. (2005). "mTOR.RICTOR is the Ser473 kinase for Akt/protein 
kinase B in 3T3-L1 adipocytes." The Journal of biological chemistry 280(49): 40406-
40416. 
Hsu, P. P.; Kang, S. A.; Rameseder, J.; Zhang, Y.; Ottina, K. A.; Lim, D.; Peterson, T. R.; Choi, 
Y.; Gray, N. S.; Yaffe, M. B.; Marto, J. A.&Sabatini, D. M. (2011). "The mTOR-
regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition 
of growth factor signaling." Science 332(6035): 1317-1322. 
Huang, S.&Houghton, P. J. (2003). "Targeting mTOR signaling for cancer therapy." Current 
opinion in pharmacology 3(4): 371-377. 
Hwang, S. K.&Kim, H. H. (2011). "The functions of mTOR in ischemic diseases." BMB Rep 
44(8): 506-511. 
Ibraghimov-Beskrovnaya, O.&Natoli, T. A. (2011). "mTOR signaling in polycystic kidney 
disease." Trends Mol Med. 
Ikenoue, T.; Inoki, K.; Yang, Q.; Zhou, X.&Guan, K. L. (2008). "Essential function of TORC2 
in PKC and Akt turn motif phosphorylation, maturation and signalling." The EMBO 
journal 27(14): 1919-1931. 
Inoki, K.; Zhu, T.&Guan, K. L. (2003). "TSC2 mediates cellular energy response to control 
cell growth and survival." Cell 115(5): 577-590. 
Jacinto, E. (2008). "What controls TOR?" IUBMB life 60(8): 483-496. 
Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S.; Jung, S. Y.; Huang, Q.; Qin, J.&Su, B. 
(2006). "SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt 
phosphorylation and substrate specificity." Cell 127(1): 125-137. 
Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M. A.; Hall, A.&Hall, M. N. (2004). 
"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive." Nature cell biology 6(11): 1122-1128. 
 Jacinto, E.&Lorberg, A. (2008). "TOR regulation of AGC kinases in yeast and mammals." The 
Biochemical journal 410(1): 19-37. 
Janes, M. R.; Limon, J. J.; So, L.; Chen, J.; Lim, R. J.; Chavez, M. A.; Vu, C.; Lilly, M. B.; 
Mallya, S.; Ong, S. T.; Konopleva, M.; Martin, M. B.; Ren, P.; Liu, Y.; Rommel, 
C.&Fruman, D. A. (2010). "Effective and selective targeting of leukemia cells using 
a TORC1/2 kinase inhibitor." Nat Med 16(2): 205-213. 
Janku, F.; McConkey, D. J.; Hong, D. S.&Kurzrock, R. (2011). "Autophagy as a target for 
anticancer therapy." Nat Rev Clin Oncol 8(9): 528-539. 
 
The Target of Rapamycin: Structure and Functions 
 
29 
Julien, L. A.; Carriere, A.; Moreau, J.&Roux, P. P. (2010). "mTORC1-activated S6K1 
phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling." 
Molecular and cellular biology 30(4): 908-921. 
Jung, C. H.; Jun, C. B.; Ro, S. H.; Kim, Y. M.; Otto, N. M.; Cao, J.; Kundu, M.&Kim, D. H. 
(2009). "ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy 
machinery." Molecular biology of the cell 20(7): 1992-2003. 
Kaizuka, T.; Hara, T.; Oshiro, N.; Kikkawa, U.; Yonezawa, K.; Takehana, K.; Iemura, S.; 
Natsume, T.&Mizushima, N. (2010). "Tti1 and Tel2 are critical factors in 
mammalian target of rapamycin complex assembly." J Biol Chem 285(26): 20109-
20116. 
Kaizuka, T.; Hara, T.; Oshiro, N.; Kikkawa, U.; Yonezawa, K.; Takehana, K.; Iemura, S.; 
Natsume, T.&Mizushima, N. (2010). "Tti1 and Tel2 are critical factors in 
mammalian target of rapamycin complex assembly." The Journal of biological 
chemistry 285(26): 20109-20116. 
Kamada, Y.; Funakoshi, T.; Shintani, T.; Nagano, K.; Ohsumi, M.&Ohsumi, Y. (2000). "Tor-
mediated induction of autophagy via an Apg1 protein kinase complex." The Journal 
of cell biology 150(6): 1507-1513. 
Kamada, Y.; Yoshino, K.; Kondo, C.; Kawamata, T.; Oshiro, N.; Yonezawa, K.&Ohsumi, Y. 
(2010). "Tor directly controls the Atg1 kinase complex to regulate autophagy." 
Molecular and cellular biology 30(4): 1049-1058. 
Kapahi, P.; Zid, B. M.; Harper, T.; Koslover, D.; Sapin, V.&Benzer, S. (2004). "Regulation of 
lifespan in Drosophila by modulation of genes in the TOR signaling pathway." 
Current biology : CB 14(10): 885-890. 
Keith, C. T.&Schreiber, S. L. (1995). "PIK-related kinases: DNA repair, recombination, and 
cell cycle checkpoints." Science 270(5233): 50-51. 
Kijanska, M.; Dohnal, I.; Reiter, W.; Kaspar, S.; Stoffel, I.; Ammerer, G.; Kraft, C.&Peter, M. 
(2010). "Activation of Atg1 kinase in autophagy by regulated phosphorylation." 
Autophagy 6(8): 1168-1178. 
Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; King, J. E.; Latek, R. R.; Erdjument-Bromage, H.; 
Tempst, P.&Sabatini, D. M. (2002). "mTOR interacts with raptor to form a nutrient-
sensitive complex that signals to the cell growth machinery." Cell 110(2): 163-175. 
Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; Latek, R. R.; Guntur, K. V.; Erdjument-Bromage, H.; 
Tempst, P.&Sabatini, D. M. (2003). "GbetaL, a positive regulator of the rapamycin-
sensitive pathway required for the nutrient-sensitive interaction between raptor 
and mTOR." Molecular cell 11(4): 895-904. 
Knutson, B. A. (2010). "Insights into the domain and repeat architecture of target of 
rapamycin." Journal of structural biology 170(2): 354-363. 
Konstantinidou, G.; Bey, E. A.; Rabellino, A.; Schuster, K.; Maira, M. S.; Gazdar, A. F.; Amici, 
A.; Boothman, D. A.&Scaglioni, P. P. (2009). "Dual phosphoinositide 3-
kinase/mammalian target of rapamycin blockade is an effective radiosensitizing 
strategy for the treatment of non-small cell lung cancer harboring K-RAS 
mutations." Cancer Res 69(19): 7644-7652. 
Krymskaya, V. P.&Goncharova, E. A. (2009). "PI3K/mTORC1 activation in hamartoma 





Horejsi, Z.; Takai, H.; Adelman, C. A.; Collis, S. J.; Flynn, H.; Maslen, S.; Skehel, J. M.; de 
Lange, T.&Boulton, S. J. (2010). "CK2 phospho-dependent binding of R2TP complex 
to TEL2 is essential for mTOR and SMG1 stability." Molecular cell 39(6): 839-850. 
Hosoi, H.; Dilling, M. B.; Shikata, T.; Liu, L. N.; Shu, L.; Ashmun, R. A.; Germain, G. S.; 
Abraham, R. T.&Houghton, P. J. (1999). "Rapamycin causes poorly reversible 
inhibition of mTOR and induces p53-independent apoptosis in human 
rhabdomyosarcoma cells." Cancer Res 59(4): 886-894. 
Hosokawa, N.; Hara, T.; Kaizuka, T.; Kishi, C.; Takamura, A.; Miura, Y.; Iemura, S.; 
Natsume, T.; Takehana, K.; Yamada, N.; Guan, J. L.; Oshiro, N.&Mizushima, N. 
(2009). "Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 
complex required for autophagy." Molecular biology of the cell 20(7): 1981-1991. 
Hresko, R. C.&Mueckler, M. (2005). "mTOR.RICTOR is the Ser473 kinase for Akt/protein 
kinase B in 3T3-L1 adipocytes." The Journal of biological chemistry 280(49): 40406-
40416. 
Hsu, P. P.; Kang, S. A.; Rameseder, J.; Zhang, Y.; Ottina, K. A.; Lim, D.; Peterson, T. R.; Choi, 
Y.; Gray, N. S.; Yaffe, M. B.; Marto, J. A.&Sabatini, D. M. (2011). "The mTOR-
regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition 
of growth factor signaling." Science 332(6035): 1317-1322. 
Huang, S.&Houghton, P. J. (2003). "Targeting mTOR signaling for cancer therapy." Current 
opinion in pharmacology 3(4): 371-377. 
Hwang, S. K.&Kim, H. H. (2011). "The functions of mTOR in ischemic diseases." BMB Rep 
44(8): 506-511. 
Ibraghimov-Beskrovnaya, O.&Natoli, T. A. (2011). "mTOR signaling in polycystic kidney 
disease." Trends Mol Med. 
Ikenoue, T.; Inoki, K.; Yang, Q.; Zhou, X.&Guan, K. L. (2008). "Essential function of TORC2 
in PKC and Akt turn motif phosphorylation, maturation and signalling." The EMBO 
journal 27(14): 1919-1931. 
Inoki, K.; Zhu, T.&Guan, K. L. (2003). "TSC2 mediates cellular energy response to control 
cell growth and survival." Cell 115(5): 577-590. 
Jacinto, E. (2008). "What controls TOR?" IUBMB life 60(8): 483-496. 
Jacinto, E.; Facchinetti, V.; Liu, D.; Soto, N.; Wei, S.; Jung, S. Y.; Huang, Q.; Qin, J.&Su, B. 
(2006). "SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt 
phosphorylation and substrate specificity." Cell 127(1): 125-137. 
Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M. A.; Hall, A.&Hall, M. N. (2004). 
"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive." Nature cell biology 6(11): 1122-1128. 
 Jacinto, E.&Lorberg, A. (2008). "TOR regulation of AGC kinases in yeast and mammals." The 
Biochemical journal 410(1): 19-37. 
Janes, M. R.; Limon, J. J.; So, L.; Chen, J.; Lim, R. J.; Chavez, M. A.; Vu, C.; Lilly, M. B.; 
Mallya, S.; Ong, S. T.; Konopleva, M.; Martin, M. B.; Ren, P.; Liu, Y.; Rommel, 
C.&Fruman, D. A. (2010). "Effective and selective targeting of leukemia cells using 
a TORC1/2 kinase inhibitor." Nat Med 16(2): 205-213. 
Janku, F.; McConkey, D. J.; Hong, D. S.&Kurzrock, R. (2011). "Autophagy as a target for 
anticancer therapy." Nat Rev Clin Oncol 8(9): 528-539. 
 
The Target of Rapamycin: Structure and Functions 
 
29 
Julien, L. A.; Carriere, A.; Moreau, J.&Roux, P. P. (2010). "mTORC1-activated S6K1 
phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling." 
Molecular and cellular biology 30(4): 908-921. 
Jung, C. H.; Jun, C. B.; Ro, S. H.; Kim, Y. M.; Otto, N. M.; Cao, J.; Kundu, M.&Kim, D. H. 
(2009). "ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy 
machinery." Molecular biology of the cell 20(7): 1992-2003. 
Kaizuka, T.; Hara, T.; Oshiro, N.; Kikkawa, U.; Yonezawa, K.; Takehana, K.; Iemura, S.; 
Natsume, T.&Mizushima, N. (2010). "Tti1 and Tel2 are critical factors in 
mammalian target of rapamycin complex assembly." J Biol Chem 285(26): 20109-
20116. 
Kaizuka, T.; Hara, T.; Oshiro, N.; Kikkawa, U.; Yonezawa, K.; Takehana, K.; Iemura, S.; 
Natsume, T.&Mizushima, N. (2010). "Tti1 and Tel2 are critical factors in 
mammalian target of rapamycin complex assembly." The Journal of biological 
chemistry 285(26): 20109-20116. 
Kamada, Y.; Funakoshi, T.; Shintani, T.; Nagano, K.; Ohsumi, M.&Ohsumi, Y. (2000). "Tor-
mediated induction of autophagy via an Apg1 protein kinase complex." The Journal 
of cell biology 150(6): 1507-1513. 
Kamada, Y.; Yoshino, K.; Kondo, C.; Kawamata, T.; Oshiro, N.; Yonezawa, K.&Ohsumi, Y. 
(2010). "Tor directly controls the Atg1 kinase complex to regulate autophagy." 
Molecular and cellular biology 30(4): 1049-1058. 
Kapahi, P.; Zid, B. M.; Harper, T.; Koslover, D.; Sapin, V.&Benzer, S. (2004). "Regulation of 
lifespan in Drosophila by modulation of genes in the TOR signaling pathway." 
Current biology : CB 14(10): 885-890. 
Keith, C. T.&Schreiber, S. L. (1995). "PIK-related kinases: DNA repair, recombination, and 
cell cycle checkpoints." Science 270(5233): 50-51. 
Kijanska, M.; Dohnal, I.; Reiter, W.; Kaspar, S.; Stoffel, I.; Ammerer, G.; Kraft, C.&Peter, M. 
(2010). "Activation of Atg1 kinase in autophagy by regulated phosphorylation." 
Autophagy 6(8): 1168-1178. 
Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; King, J. E.; Latek, R. R.; Erdjument-Bromage, H.; 
Tempst, P.&Sabatini, D. M. (2002). "mTOR interacts with raptor to form a nutrient-
sensitive complex that signals to the cell growth machinery." Cell 110(2): 163-175. 
Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; Latek, R. R.; Guntur, K. V.; Erdjument-Bromage, H.; 
Tempst, P.&Sabatini, D. M. (2003). "GbetaL, a positive regulator of the rapamycin-
sensitive pathway required for the nutrient-sensitive interaction between raptor 
and mTOR." Molecular cell 11(4): 895-904. 
Knutson, B. A. (2010). "Insights into the domain and repeat architecture of target of 
rapamycin." Journal of structural biology 170(2): 354-363. 
Konstantinidou, G.; Bey, E. A.; Rabellino, A.; Schuster, K.; Maira, M. S.; Gazdar, A. F.; Amici, 
A.; Boothman, D. A.&Scaglioni, P. P. (2009). "Dual phosphoinositide 3-
kinase/mammalian target of rapamycin blockade is an effective radiosensitizing 
strategy for the treatment of non-small cell lung cancer harboring K-RAS 
mutations." Cancer Res 69(19): 7644-7652. 
Krymskaya, V. P.&Goncharova, E. A. (2009). "PI3K/mTORC1 activation in hamartoma 





Kunz, J.; Loeschmann, A.; Deuter-Reinhard, M.&Hall, M. N. (2000). "FAP1, a homologue of 
human transcription factor NF-X1, competes with rapamycin for binding to 
FKBP12 in yeast." Molecular microbiology 37(6): 1480-1493. 
Kunz, J.; Schneider, U.; Howald, I.; Schmidt, A.&Hall, M. N. (2000). "HEAT repeats mediate 
plasma membrane localization of Tor2p in yeast." The Journal of biological chemistry 
275(47): 37011-37020. 
Lempiainen, H.&Halazonetis, T. D. (2009). "Emerging common themes in regulation of 
PIKKs and PI3Ks." The EMBO journal 28(20): 3067-3073. 
Li, H.; Tsang, C. K.; Watkins, M.; Bertram, P. G.&Zheng, X. F. (2006). "Nutrient regulates 
Tor1 nuclear localization and association with rDNA promoter." Nature 442(7106): 
1058-1061. 
Liu, L.; Chen, L.; Chung, J.&Huang, S. (2008). "Rapamycin inhibits F-actin reorganization 
and phosphorylation of focal adhesion proteins." Oncogene 27(37): 4998-5010. 
Liu, L.; Luo, Y.; Chen, L.; Shen, T.; Xu, B.; Chen, W.; Zhou, H.; Han, X.&Huang, S. (2010). 
"Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing 
RhoA expression and activity." J Biol Chem 285(49): 38362-38373. 
Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.&Gray, N. 
S. (2011). "Discovery of 9-(6-aminopyridin-3-yl)-1-(3-
(trifluoromethyl)phenyl)benzo[h][1,6]naphthyr idin-2(1H)-one (Torin2) as a potent, 
selective, and orally available mammalian target of rapamycin (mTOR) inhibitor 
for treatment of cancer." J Med Chem 54(5): 1473-1480. 
Liu, X.&Zheng, X. F. (2007). "Endoplasmic reticulum and Golgi localization sequences for 
mammalian target of rapamycin." Molecular biology of the cell 18(3): 1073-1082. 
Liu, Z.; Sekito, T.; Epstein, C. B.&Butow, R. A. (2001). "RTG-dependent mitochondria to 
nucleus signaling is negatively regulated by the seven WD-repeat protein Lst8p." 
The EMBO journal 20(24): 7209-7219. 
Lochhead, P. A. (2009). "Protein kinase activation loop autophosphorylation in cis: 
overcoming a Catch-22 situation." Science signaling 2(54): pe4. 
Loewith, R.; Jacinto, E.; Wullschleger, S.; Lorberg, A.; Crespo, J. L.; Bonenfant, D.; Oppliger, 
W.; Jenoe, P.&Hall, M. N. (2002). "Two TOR complexes, only one of which is 
rapamycin sensitive, have distinct roles in cell growth control." Molecular cell 10(3): 
457-468. 
Long, X.; Lin, Y.; Ortiz-Vega, S.; Yonezawa, K.&Avruch, J. (2005). "Rheb binds and regulates 
the mTOR kinase." Current biology : CB 15(8): 702-713. 
Long, X.; Spycher, C.; Han, Z. S.; Rose, A. M.; Muller, F.&Avruch, J. (2002). "TOR deficiency 
in C. elegans causes developmental arrest and intestinal atrophy by inhibition of 
mRNA translation." Current biology : CB 12(17): 1448-1461. 
Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.&Pandolfi, P. P. (2005). 
"Phosphorylation and functional inactivation of TSC2 by Erk implications for 
tuberous sclerosis and cancer pathogenesis." Cell 121(2): 179-193. 
Ma, X. M.&Blenis, J. (2009). "Molecular mechanisms of mTOR-mediated translational 
control." Nature reviews. Molecular cell biology 10(5): 307-318. 
Ma, X. M.; Yoon, S. O.; Richardson, C. J.; Julich, K.&Blenis, J. (2008). "SKAR links pre-mRNA 
splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced 
mRNAs." Cell 133(2): 303-313. 
 
The Target of Rapamycin: Structure and Functions 
 
31 
Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; 
Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; 
Murphy, L.; Finan, P.; Sellers, W.&Garcia-Echeverria, C. (2008). "Identification and 
characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 
3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor 
activity." Mol Cancer Ther 7(7): 1851-1863. 
Makino, C.; Sano, Y.; Shinagawa, T.; Millar, J. B.&Ishii, S. (2006). "Sin1 binds to both ATF-2 
and p38 and enhances ATF-2-dependent transcription in an SAPK signaling 
pathway." Genes to cells : devoted to molecular & cellular mechanisms 11(11): 1239-1251. 
Malys, N.&McCarthy, J. E. (2011). "Translation initiation: variations in the mechanism can be 
anticipated." Cellular and molecular life sciences : CMLS 68(6): 991-1003. 
Mammucari, C.; Milan, G.; Romanello, V.; Masiero, E.; Rudolf, R.; Del Piccolo, P.; Burden, S. 
J.; Di Lisi, R.; Sandri, C.; Zhao, J.; Goldberg, A. L.; Schiaffino, S.&Sandri, M. (2007). 
"FoxO3 controls autophagy in skeletal muscle in vivo." Cell Metab 6(6): 458-471. 
Manning, B. D.&Cantley, L. C. (2003). "Rheb fills a GAP between TSC and TOR." Trends in 
biochemical sciences 28(11): 573-576. 
Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.&Sudarsanam, S. (2002). "The protein 
kinase complement of the human genome." Science 298(5600): 1912-1934. 
Marone, R.; Erhart, D.; Mertz, A. C.; Bohnacker, T.; Schnell, C.; Cmiljanovic, V.; Stauffer, F.; 
Garcia-Echeverria, C.; Giese, B.; Maira, S. M.&Wymann, M. P. (2009). "Targeting 
melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin 
inhibitors." Mol Cancer Res 7(4): 601-613. 
Martin, D. E.; Soulard, A.&Hall, M. N. (2004). "TOR regulates ribosomal protein gene 
expression via PKA and the Forkhead transcription factor FHL1." Cell 119(7): 969-
979. 
Martin, J.; Masri, J.; Bernath, A.; Nishimura, R. N.&Gera, J. (2008). "Hsp70 associates with 
Rictor and is required for mTORC2 formation and activity." Biochem Biophys Res 
Commun 372(4): 578-583. 
Martin, J.; Masri, J.; Bernath, A.; Nishimura, R. N.&Gera, J. (2008). "Hsp70 associates with 
Rictor and is required for mTORC2 formation and activity." Biochemical and 
biophysical research communications 372(4): 578-583. 
Martin, P. M.&Sutherland, A. E. (2001). "Exogenous amino acids regulate trophectoderm 
differentiation in the mouse blastocyst through an mTOR-dependent pathway." 
Developmental biology 240(1): 182-193. 
Matsuo, T.; Otsubo, Y.; Urano, J.; Tamanoi, F.&Yamamoto, M. (2007). "Loss of the TOR 
kinase Tor2 mimics nitrogen starvation and activates the sexual development 
pathway in fission yeast." Molecular and cellular biology 27(8): 3154-3164. 
Mayer, C.&Grummt, I. (2006). "Ribosome biogenesis and cell growth: mTOR coordinates 
transcription by all three classes of nuclear RNA polymerases." Oncogene 25(48): 
6384-6391. 
Mayer, C.; Zhao, J.; Yuan, X.&Grummt, I. (2004). "mTOR-dependent activation of the 
transcription factor TIF-IA links rRNA synthesis to nutrient availability." Genes & 
development 18(4): 423-434. 
McDonald, P. C.; Oloumi, A.; Mills, J.; Dobreva, I.; Maidan, M.; Gray, V.; Wederell, E. D.; 





Kunz, J.; Loeschmann, A.; Deuter-Reinhard, M.&Hall, M. N. (2000). "FAP1, a homologue of 
human transcription factor NF-X1, competes with rapamycin for binding to 
FKBP12 in yeast." Molecular microbiology 37(6): 1480-1493. 
Kunz, J.; Schneider, U.; Howald, I.; Schmidt, A.&Hall, M. N. (2000). "HEAT repeats mediate 
plasma membrane localization of Tor2p in yeast." The Journal of biological chemistry 
275(47): 37011-37020. 
Lempiainen, H.&Halazonetis, T. D. (2009). "Emerging common themes in regulation of 
PIKKs and PI3Ks." The EMBO journal 28(20): 3067-3073. 
Li, H.; Tsang, C. K.; Watkins, M.; Bertram, P. G.&Zheng, X. F. (2006). "Nutrient regulates 
Tor1 nuclear localization and association with rDNA promoter." Nature 442(7106): 
1058-1061. 
Liu, L.; Chen, L.; Chung, J.&Huang, S. (2008). "Rapamycin inhibits F-actin reorganization 
and phosphorylation of focal adhesion proteins." Oncogene 27(37): 4998-5010. 
Liu, L.; Luo, Y.; Chen, L.; Shen, T.; Xu, B.; Chen, W.; Zhou, H.; Han, X.&Huang, S. (2010). 
"Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing 
RhoA expression and activity." J Biol Chem 285(49): 38362-38373. 
Liu, Q.; Wang, J.; Kang, S. A.; Thoreen, C. C.; Hur, W.; Ahmed, T.; Sabatini, D. M.&Gray, N. 
S. (2011). "Discovery of 9-(6-aminopyridin-3-yl)-1-(3-
(trifluoromethyl)phenyl)benzo[h][1,6]naphthyr idin-2(1H)-one (Torin2) as a potent, 
selective, and orally available mammalian target of rapamycin (mTOR) inhibitor 
for treatment of cancer." J Med Chem 54(5): 1473-1480. 
Liu, X.&Zheng, X. F. (2007). "Endoplasmic reticulum and Golgi localization sequences for 
mammalian target of rapamycin." Molecular biology of the cell 18(3): 1073-1082. 
Liu, Z.; Sekito, T.; Epstein, C. B.&Butow, R. A. (2001). "RTG-dependent mitochondria to 
nucleus signaling is negatively regulated by the seven WD-repeat protein Lst8p." 
The EMBO journal 20(24): 7209-7219. 
Lochhead, P. A. (2009). "Protein kinase activation loop autophosphorylation in cis: 
overcoming a Catch-22 situation." Science signaling 2(54): pe4. 
Loewith, R.; Jacinto, E.; Wullschleger, S.; Lorberg, A.; Crespo, J. L.; Bonenfant, D.; Oppliger, 
W.; Jenoe, P.&Hall, M. N. (2002). "Two TOR complexes, only one of which is 
rapamycin sensitive, have distinct roles in cell growth control." Molecular cell 10(3): 
457-468. 
Long, X.; Lin, Y.; Ortiz-Vega, S.; Yonezawa, K.&Avruch, J. (2005). "Rheb binds and regulates 
the mTOR kinase." Current biology : CB 15(8): 702-713. 
Long, X.; Spycher, C.; Han, Z. S.; Rose, A. M.; Muller, F.&Avruch, J. (2002). "TOR deficiency 
in C. elegans causes developmental arrest and intestinal atrophy by inhibition of 
mRNA translation." Current biology : CB 12(17): 1448-1461. 
Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.&Pandolfi, P. P. (2005). 
"Phosphorylation and functional inactivation of TSC2 by Erk implications for 
tuberous sclerosis and cancer pathogenesis." Cell 121(2): 179-193. 
Ma, X. M.&Blenis, J. (2009). "Molecular mechanisms of mTOR-mediated translational 
control." Nature reviews. Molecular cell biology 10(5): 307-318. 
Ma, X. M.; Yoon, S. O.; Richardson, C. J.; Julich, K.&Blenis, J. (2008). "SKAR links pre-mRNA 
splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced 
mRNAs." Cell 133(2): 303-313. 
 
The Target of Rapamycin: Structure and Functions 
 
31 
Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; 
Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; 
Murphy, L.; Finan, P.; Sellers, W.&Garcia-Echeverria, C. (2008). "Identification and 
characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 
3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor 
activity." Mol Cancer Ther 7(7): 1851-1863. 
Makino, C.; Sano, Y.; Shinagawa, T.; Millar, J. B.&Ishii, S. (2006). "Sin1 binds to both ATF-2 
and p38 and enhances ATF-2-dependent transcription in an SAPK signaling 
pathway." Genes to cells : devoted to molecular & cellular mechanisms 11(11): 1239-1251. 
Malys, N.&McCarthy, J. E. (2011). "Translation initiation: variations in the mechanism can be 
anticipated." Cellular and molecular life sciences : CMLS 68(6): 991-1003. 
Mammucari, C.; Milan, G.; Romanello, V.; Masiero, E.; Rudolf, R.; Del Piccolo, P.; Burden, S. 
J.; Di Lisi, R.; Sandri, C.; Zhao, J.; Goldberg, A. L.; Schiaffino, S.&Sandri, M. (2007). 
"FoxO3 controls autophagy in skeletal muscle in vivo." Cell Metab 6(6): 458-471. 
Manning, B. D.&Cantley, L. C. (2003). "Rheb fills a GAP between TSC and TOR." Trends in 
biochemical sciences 28(11): 573-576. 
Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.&Sudarsanam, S. (2002). "The protein 
kinase complement of the human genome." Science 298(5600): 1912-1934. 
Marone, R.; Erhart, D.; Mertz, A. C.; Bohnacker, T.; Schnell, C.; Cmiljanovic, V.; Stauffer, F.; 
Garcia-Echeverria, C.; Giese, B.; Maira, S. M.&Wymann, M. P. (2009). "Targeting 
melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin 
inhibitors." Mol Cancer Res 7(4): 601-613. 
Martin, D. E.; Soulard, A.&Hall, M. N. (2004). "TOR regulates ribosomal protein gene 
expression via PKA and the Forkhead transcription factor FHL1." Cell 119(7): 969-
979. 
Martin, J.; Masri, J.; Bernath, A.; Nishimura, R. N.&Gera, J. (2008). "Hsp70 associates with 
Rictor and is required for mTORC2 formation and activity." Biochem Biophys Res 
Commun 372(4): 578-583. 
Martin, J.; Masri, J.; Bernath, A.; Nishimura, R. N.&Gera, J. (2008). "Hsp70 associates with 
Rictor and is required for mTORC2 formation and activity." Biochemical and 
biophysical research communications 372(4): 578-583. 
Martin, P. M.&Sutherland, A. E. (2001). "Exogenous amino acids regulate trophectoderm 
differentiation in the mouse blastocyst through an mTOR-dependent pathway." 
Developmental biology 240(1): 182-193. 
Matsuo, T.; Otsubo, Y.; Urano, J.; Tamanoi, F.&Yamamoto, M. (2007). "Loss of the TOR 
kinase Tor2 mimics nitrogen starvation and activates the sexual development 
pathway in fission yeast." Molecular and cellular biology 27(8): 3154-3164. 
Mayer, C.&Grummt, I. (2006). "Ribosome biogenesis and cell growth: mTOR coordinates 
transcription by all three classes of nuclear RNA polymerases." Oncogene 25(48): 
6384-6391. 
Mayer, C.; Zhao, J.; Yuan, X.&Grummt, I. (2004). "mTOR-dependent activation of the 
transcription factor TIF-IA links rRNA synthesis to nutrient availability." Genes & 
development 18(4): 423-434. 
McDonald, P. C.; Oloumi, A.; Mills, J.; Dobreva, I.; Maidan, M.; Gray, V.; Wederell, E. D.; 





interact and regulate Akt phosphorylation and cancer cell survival." Cancer research 
68(6): 1618-1624. 
Medvedik, O.; Lamming, D. W.; Kim, K. D.&Sinclair, D. A. (2007). "MSN2 and MSN4 link 
calorie restriction and TOR to sirtuin-mediated lifespan extension in 
Saccharomyces cerevisiae." PLoS biology 5(10): e261. 
Meijer, A. J.&Codogno, P. (2008). "Nutrient sensing: TOR's Ragtime." Nature cell biology 
10(8): 881-883. 
Menand, B.; Desnos, T.; Nussaume, L.; Berger, F.; Bouchez, D.; Meyer, C.&Robaglia, C. 
(2002). "Expression and disruption of the Arabidopsis TOR (target of rapamycin) 
gene." Proceedings of the National Academy of Sciences of the United States of America 
99(9): 6422-6427. 
Miller, G.; Panov, K. I.; Friedrich, J. K.; Trinkle-Mulcahy, L.; Lamond, A. I.&Zomerdijk, J. C. 
(2001). "hRRN3 is essential in the SL1-mediated recruitment of RNA Polymerase I 
to rRNA gene promoters." The EMBO journal 20(6): 1373-1382. 
Minami, K.; Tambe, Y.; Watanabe, R.; Isono, T.; Haneda, M.; Isobe, K.; Kobayashi, T.; Hino, 
O.; Okabe, H.; Chano, T.&Inoue, H. (2007). "Suppression of viral replication by 
stress-inducible GADD34 protein via the mammalian serine/threonine protein 
kinase mTOR pathway." Journal of virology 81(20): 11106-11115. 
Miranda-Saavedra, D.&Barton, G. J. (2007). "Classification and functional annotation of 
eukaryotic protein kinases." Proteins 68(4): 893-914. 
Mordes, D. A.; Glick, G. G.; Zhao, R.&Cortez, D. (2008). "TopBP1 activates ATR through 
ATRIP and a PIKK regulatory domain." Genes & development 22(11): 1478-1489. 
Murakami, M.; Ichisaka, T.; Maeda, M.; Oshiro, N.; Hara, K.; Edenhofer, F.; Kiyama, H.; 
Yonezawa, K.&Yamanaka, S. (2004). "mTOR is essential for growth and 
proliferation in early mouse embryos and embryonic stem cells." Molecular and 
cellular biology 24(15): 6710-6718. 
Muthukkumar, S.; Ramesh, T. M.&Bondada, S. (1995). "Rapamycin, a potent 
immunosuppressive drug, causes programmed cell death in B lymphoma cells." 
Transplantation 60(3): 264-270. 
Nardella, C.; Carracedo, A.; Alimonti, A.; Hobbs, R. M.; Clohessy, J. G.; Chen, Z.; Egia, A.; 
Fornari, A.; Fiorentino, M.; Loda, M.; Kozma, S. C.; Thomas, G.; Cordon-Cardo, 
C.&Pandolfi, P. P. (2009). "Differential requirement of mTOR in postmitotic tissues 
and tumorigenesis." Science signaling 2(55): ra2. 
Nicklin, P.; Bergman, P.; Zhang, B.; Triantafellow, E.; Wang, H.; Nyfeler, B.; Yang, H.; Hild, 
M.; Kung, C.; Wilson, C.; Myer, V. E.; MacKeigan, J. P.; Porter, J. A.; Wang, Y. K.; 
Cantley, L. C.; Finan, P. M.&Murphy, L. O. (2009). "Bidirectional transport of amino 
acids regulates mTOR and autophagy." Cell 136(3): 521-534. 
Nobukuni, T.; Joaquin, M.; Roccio, M.; Dann, S. G.; Kim, S. Y.; Gulati, P.; Byfield, M. P.; 
Backer, J. M.; Natt, F.; Bos, J. L.; Zwartkruis, F. J.&Thomas, G. (2005). "Amino acids 
mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 
3OH-kinase." Proceedings of the National Academy of Sciences of the United States of 
America 102(40): 14238-14243. 
Noda, T & Ohsumi, Y. (1998). "Tor, a phosphatidylinositol kinase homologue, controls 
autophagy in yeast." The Journal of biological chemistry 273(7): 3963-3966. 
O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; 
Hicklin, D. J.; Ludwig, D. L.; Baselga, J.&Rosen, N. (2006). "mTOR inhibition 
 
The Target of Rapamycin: Structure and Functions 
 
33 
induces upstream receptor tyrosine kinase signaling and activates Akt." Cancer Res 
66(3): 1500-1508. 
Oh, W. J.; Wu, C. C.; Kim, S. J.; Facchinetti, V.; Julien, L. A.; Finlan, M.; Roux, P. P.; Su, 
B.&Jacinto, E. (2010). "mTORC2 can associate with ribosomes to promote 
cotranslational phosphorylation and stability of nascent Akt polypeptide." The 
EMBO journal 29(23): 3939-3951. 
Oldham, S.; Montagne, J.; Radimerski, T.; Thomas, G.&Hafen, E. (2000). "Genetic and 
biochemical characterization of dTOR, the Drosophila homolog of the target of 
rapamycin." Genes & development 14(21): 2689-2694. 
Onda, H.; Lueck, A.; Marks, P. W.; Warren, H. B.&Kwiatkowski, D. J. (1999). "Tsc2(+/-) mice 
develop tumors in multiple sites that express gelsolin and are influenced by genetic 
background." The Journal of clinical investigation 104(6): 687-695. 
Oshiro, N.; Yoshino, K.; Hidayat, S.; Tokunaga, C.; Hara, K.; Eguchi, S.; Avruch, 
J.&Yonezawa, K. (2004). "Dissociation of raptor from mTOR is a mechanism of 
rapamycin-induced inhibition of mTOR function." Genes to cells : devoted to molecular 
& cellular mechanisms 9(4): 359-366. 
Oza, A. M.; Elit, L.; Tsao, M. S.; Kamel-Reid, S.; Biagi, J.; Provencher, D. M.; Gotlieb, W. H.; 
Hoskins, P. J.; Ghatage, P.; Tonkin, K. S.; Mackay, H. J.; Mazurka, J.; Sederias, J.; 
Ivy, P.; Dancey, J. E.&Eisenhauer, E. A. (2011). "Phase II study of temsirolimus in 
women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical 
Trials Group." J Clin Oncol 29(24): 3278-3285. 
Pang, H.&Faber, L. E. (2001). "Estrogen and rapamycin effects on cell cycle progression in 
T47D breast cancer cells." Breast Cancer Res Treat 70(1): 21-26. 
Pause, A.; Methot, N.; Svitkin, Y.; Merrick, W. C.&Sonenberg, N. (1994). "Dominant negative 
mutants of mammalian translation initiation factor eIF-4A define a critical role for 
eIF-4F in cap-dependent and cap-independent initiation of translation." The EMBO 
journal 13(5): 1205-1215. 
Pearce, L. R.; Huang, X.; Boudeau, J.; Pawlowski, R.; Wullschleger, S.; Deak, M.; Ibrahim, A. 
F.; Gourlay, R.; Magnuson, M. A.&Alessi, D. R. (2007). "Identification of Protor as a 
novel Rictor-binding component of mTOR complex-2." The Biochemical journal 
405(3): 513-522. 
Pearce, L. R.; Sommer, E. M.; Sakamoto, K.; Wullschleger, S.&Alessi, D. R. (2011). "Protor-1 
is required for efficient mTORC2-mediated activation of SGK1 in the kidney." The 
Biochemical journal 436(1): 169-179. 
Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Berman, K.&Cobb, M. 
H. (2001). "Mitogen-activated protein (MAP) kinase pathways: regulation and 
physiological functions." Endocrine reviews 22(2): 153-183. 
Pei, J. J.&Hugon, J. (2008). "mTOR-dependent signalling in Alzheimer's disease." J Cell Mol 
Med 12(6B): 2525-2532. 
Pena-Llopis, S.; Vega-Rubin-de-Celis, S.; Schwartz, J. C.; Wolff, N. C.; Tran, T. A.; Zou, L.; 
Xie, X. J.; Corey, D. R.&Brugarolas, J. (2011). "Regulation of TFEB and V-ATPases 
by mTORC1." The EMBO journal 30(16): 3242-3258. 
Peng, T.; Golub, T. R.&Sabatini, D. M. (2002). "The immunosuppressant rapamycin mimics a 
starvation-like signal distinct from amino acid and glucose deprivation." Molecular 





interact and regulate Akt phosphorylation and cancer cell survival." Cancer research 
68(6): 1618-1624. 
Medvedik, O.; Lamming, D. W.; Kim, K. D.&Sinclair, D. A. (2007). "MSN2 and MSN4 link 
calorie restriction and TOR to sirtuin-mediated lifespan extension in 
Saccharomyces cerevisiae." PLoS biology 5(10): e261. 
Meijer, A. J.&Codogno, P. (2008). "Nutrient sensing: TOR's Ragtime." Nature cell biology 
10(8): 881-883. 
Menand, B.; Desnos, T.; Nussaume, L.; Berger, F.; Bouchez, D.; Meyer, C.&Robaglia, C. 
(2002). "Expression and disruption of the Arabidopsis TOR (target of rapamycin) 
gene." Proceedings of the National Academy of Sciences of the United States of America 
99(9): 6422-6427. 
Miller, G.; Panov, K. I.; Friedrich, J. K.; Trinkle-Mulcahy, L.; Lamond, A. I.&Zomerdijk, J. C. 
(2001). "hRRN3 is essential in the SL1-mediated recruitment of RNA Polymerase I 
to rRNA gene promoters." The EMBO journal 20(6): 1373-1382. 
Minami, K.; Tambe, Y.; Watanabe, R.; Isono, T.; Haneda, M.; Isobe, K.; Kobayashi, T.; Hino, 
O.; Okabe, H.; Chano, T.&Inoue, H. (2007). "Suppression of viral replication by 
stress-inducible GADD34 protein via the mammalian serine/threonine protein 
kinase mTOR pathway." Journal of virology 81(20): 11106-11115. 
Miranda-Saavedra, D.&Barton, G. J. (2007). "Classification and functional annotation of 
eukaryotic protein kinases." Proteins 68(4): 893-914. 
Mordes, D. A.; Glick, G. G.; Zhao, R.&Cortez, D. (2008). "TopBP1 activates ATR through 
ATRIP and a PIKK regulatory domain." Genes & development 22(11): 1478-1489. 
Murakami, M.; Ichisaka, T.; Maeda, M.; Oshiro, N.; Hara, K.; Edenhofer, F.; Kiyama, H.; 
Yonezawa, K.&Yamanaka, S. (2004). "mTOR is essential for growth and 
proliferation in early mouse embryos and embryonic stem cells." Molecular and 
cellular biology 24(15): 6710-6718. 
Muthukkumar, S.; Ramesh, T. M.&Bondada, S. (1995). "Rapamycin, a potent 
immunosuppressive drug, causes programmed cell death in B lymphoma cells." 
Transplantation 60(3): 264-270. 
Nardella, C.; Carracedo, A.; Alimonti, A.; Hobbs, R. M.; Clohessy, J. G.; Chen, Z.; Egia, A.; 
Fornari, A.; Fiorentino, M.; Loda, M.; Kozma, S. C.; Thomas, G.; Cordon-Cardo, 
C.&Pandolfi, P. P. (2009). "Differential requirement of mTOR in postmitotic tissues 
and tumorigenesis." Science signaling 2(55): ra2. 
Nicklin, P.; Bergman, P.; Zhang, B.; Triantafellow, E.; Wang, H.; Nyfeler, B.; Yang, H.; Hild, 
M.; Kung, C.; Wilson, C.; Myer, V. E.; MacKeigan, J. P.; Porter, J. A.; Wang, Y. K.; 
Cantley, L. C.; Finan, P. M.&Murphy, L. O. (2009). "Bidirectional transport of amino 
acids regulates mTOR and autophagy." Cell 136(3): 521-534. 
Nobukuni, T.; Joaquin, M.; Roccio, M.; Dann, S. G.; Kim, S. Y.; Gulati, P.; Byfield, M. P.; 
Backer, J. M.; Natt, F.; Bos, J. L.; Zwartkruis, F. J.&Thomas, G. (2005). "Amino acids 
mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 
3OH-kinase." Proceedings of the National Academy of Sciences of the United States of 
America 102(40): 14238-14243. 
Noda, T & Ohsumi, Y. (1998). "Tor, a phosphatidylinositol kinase homologue, controls 
autophagy in yeast." The Journal of biological chemistry 273(7): 3963-3966. 
O'Reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; 
Hicklin, D. J.; Ludwig, D. L.; Baselga, J.&Rosen, N. (2006). "mTOR inhibition 
 
The Target of Rapamycin: Structure and Functions 
 
33 
induces upstream receptor tyrosine kinase signaling and activates Akt." Cancer Res 
66(3): 1500-1508. 
Oh, W. J.; Wu, C. C.; Kim, S. J.; Facchinetti, V.; Julien, L. A.; Finlan, M.; Roux, P. P.; Su, 
B.&Jacinto, E. (2010). "mTORC2 can associate with ribosomes to promote 
cotranslational phosphorylation and stability of nascent Akt polypeptide." The 
EMBO journal 29(23): 3939-3951. 
Oldham, S.; Montagne, J.; Radimerski, T.; Thomas, G.&Hafen, E. (2000). "Genetic and 
biochemical characterization of dTOR, the Drosophila homolog of the target of 
rapamycin." Genes & development 14(21): 2689-2694. 
Onda, H.; Lueck, A.; Marks, P. W.; Warren, H. B.&Kwiatkowski, D. J. (1999). "Tsc2(+/-) mice 
develop tumors in multiple sites that express gelsolin and are influenced by genetic 
background." The Journal of clinical investigation 104(6): 687-695. 
Oshiro, N.; Yoshino, K.; Hidayat, S.; Tokunaga, C.; Hara, K.; Eguchi, S.; Avruch, 
J.&Yonezawa, K. (2004). "Dissociation of raptor from mTOR is a mechanism of 
rapamycin-induced inhibition of mTOR function." Genes to cells : devoted to molecular 
& cellular mechanisms 9(4): 359-366. 
Oza, A. M.; Elit, L.; Tsao, M. S.; Kamel-Reid, S.; Biagi, J.; Provencher, D. M.; Gotlieb, W. H.; 
Hoskins, P. J.; Ghatage, P.; Tonkin, K. S.; Mackay, H. J.; Mazurka, J.; Sederias, J.; 
Ivy, P.; Dancey, J. E.&Eisenhauer, E. A. (2011). "Phase II study of temsirolimus in 
women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical 
Trials Group." J Clin Oncol 29(24): 3278-3285. 
Pang, H.&Faber, L. E. (2001). "Estrogen and rapamycin effects on cell cycle progression in 
T47D breast cancer cells." Breast Cancer Res Treat 70(1): 21-26. 
Pause, A.; Methot, N.; Svitkin, Y.; Merrick, W. C.&Sonenberg, N. (1994). "Dominant negative 
mutants of mammalian translation initiation factor eIF-4A define a critical role for 
eIF-4F in cap-dependent and cap-independent initiation of translation." The EMBO 
journal 13(5): 1205-1215. 
Pearce, L. R.; Huang, X.; Boudeau, J.; Pawlowski, R.; Wullschleger, S.; Deak, M.; Ibrahim, A. 
F.; Gourlay, R.; Magnuson, M. A.&Alessi, D. R. (2007). "Identification of Protor as a 
novel Rictor-binding component of mTOR complex-2." The Biochemical journal 
405(3): 513-522. 
Pearce, L. R.; Sommer, E. M.; Sakamoto, K.; Wullschleger, S.&Alessi, D. R. (2011). "Protor-1 
is required for efficient mTORC2-mediated activation of SGK1 in the kidney." The 
Biochemical journal 436(1): 169-179. 
Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Berman, K.&Cobb, M. 
H. (2001). "Mitogen-activated protein (MAP) kinase pathways: regulation and 
physiological functions." Endocrine reviews 22(2): 153-183. 
Pei, J. J.&Hugon, J. (2008). "mTOR-dependent signalling in Alzheimer's disease." J Cell Mol 
Med 12(6B): 2525-2532. 
Pena-Llopis, S.; Vega-Rubin-de-Celis, S.; Schwartz, J. C.; Wolff, N. C.; Tran, T. A.; Zou, L.; 
Xie, X. J.; Corey, D. R.&Brugarolas, J. (2011). "Regulation of TFEB and V-ATPases 
by mTORC1." The EMBO journal 30(16): 3242-3258. 
Peng, T.; Golub, T. R.&Sabatini, D. M. (2002). "The immunosuppressant rapamycin mimics a 
starvation-like signal distinct from amino acid and glucose deprivation." Molecular 





Pereira-Leal, J. B.; Levy, E. D.&Teichmann, S. A. (2006). "The origins and evolution of 
functional modules: lessons from protein complexes." Philosophical transactions of the 
Royal Society of London. Series B, Biological sciences 361(1467): 507-517. 
Perry, J.&Kleckner, N. (2003). "The ATRs, ATMs, and TORs are giant HEAT repeat 
proteins." Cell 112(2): 151-155. 
Peterson, R. T.; Beal, P. A.; Comb, M. J.&Schreiber, S. L. (2000). "FKBP12-rapamycin-
associated protein (FRAP) autophosphorylates at serine 2481 under translationally 
repressive conditions." The Journal of biological chemistry 275(10): 7416-7423. 
Peterson, T. R.; Laplante, M.; Thoreen, C. C.; Sancak, Y.; Kang, S. A.; Kuehl, W. M.; Gray, N. 
S.&Sabatini, D. M. (2009). "DEPTOR is an mTOR inhibitor frequently 
overexpressed in multiple myeloma cells and required for their survival." Cell 
137(5): 873-886. 
Peterson, T. R.; Sengupta, S. S.; Harris, T. E.; Carmack, A. E.; Kang, S. A.; Balderas, E.; 
Guertin, D. A.; Madden, K. L.; Carpenter, A. E.; Finck, B. N.&Sabatini, D. M. (2011). 
"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway." Cell 
146(3): 408-420. 
Polak, P.; Cybulski, N.; Feige, J. N.; Auwerx, J.; Ruegg, M. A.&Hall, M. N. (2008). "Adipose-
specific knockout of raptor results in lean mice with enhanced mitochondrial 
respiration." Cell metabolism 8(5): 399-410. 
Poon, M.; Marx, S. O.; Gallo, R.; Badimon, J. J.; Taubman, M. B.&Marks, A. R. (1996). 
"Rapamycin inhibits vascular smooth muscle cell migration." J Clin Invest 98(10): 
2277-2283. 
Porstmann, T.; Santos, C. R.; Griffiths, B.; Cully, M.; Wu, M.; Leevers, S.; Griffiths, J. R.; 
Chung, Y. L.&Schulze, A. (2008). "SREBP activity is regulated by mTORC1 and 
contributes to Akt-dependent cell growth." Cell metabolism 8(3): 224-236. 
Powers, T.&Walter, P. (1999). "Regulation of ribosome biogenesis by the rapamycin-
sensitive TOR-signaling pathway in Saccharomyces cerevisiae." Molecular biology of 
the cell 10(4): 987-1000. 
Proud, C. G. (2009). "Dynamic balancing: DEPTOR tips the scales." Journal of molecular cell 
biology 1(2): 61-63. 
Proud, C. G. (2011). "mTOR Signalling in Health and Disease." Biochemical Society transactions 
39(2): 431-436. 
Rachdi, L.; Balcazar, N.; Osorio-Duque, F.; Elghazi, L.; Weiss, A.; Gould, A.; Chang-Chen, K. 
J.; Gambello, M. J.&Bernal-Mizrachi, E. (2008). "Disruption of Tsc2 in pancreatic 
beta cells induces beta cell mass expansion and improved glucose tolerance in a 
TORC1-dependent manner." Proceedings of the National Academy of Sciences of the 
United States of America 105(27): 9250-9255. 
Reardon, D. A.; Wen, P. Y.; Alfred Yung, W. K.; Berk, L.; Narasimhan, N.; Turner, C. D.; 
Clackson, T.; Rivera, V. M.&Vogelbaum, M. A. (2011). "Ridaforolimus for patients 
with progressive or recurrent malignant glioma: a perisurgical, sequential, 
ascending-dose trial." Cancer Chemother Pharmacol. 
Reiling, J. H.&Sabatini, D. M. (2006). "Stress and mTORture signaling." Oncogene 25(48): 
6373-6383. 
Reina, J. H.; Azzouz, T. N.&Hernandez, N. (2006). "Maf1, a new player in the regulation of 
human RNA polymerase III transcription." PloS one 1: e134. 
 
The Target of Rapamycin: Structure and Functions 
 
35 
Reinke, A.; Anderson, S.; McCaffery, J. M.; Yates, J., 3rd; Aronova, S.; Chu, S.; Fairclough, S.; 
Iverson, C.; Wedaman, K. P.&Powers, T. (2004). "TOR complex 1 includes a novel 
component, Tco89p (YPL180w), and cooperates with Ssd1p to maintain cellular 
integrity in Saccharomyces cerevisiae." The Journal of biological chemistry 279(15): 
14752-14762. 
Risson, V.; Mazelin, L.; Roceri, M.; Sanchez, H.; Moncollin, V.; Corneloup, C.; Richard-
Bulteau, H.; Vignaud, A.; Baas, D.; Defour, A.; Freyssenet, D.; Tanti, J. F.; Le-
Marchand-Brustel, Y.; Ferrier, B.; Conjard-Duplany, A.; Romanino, K.; Bauche, S.; 
Hantai, D.; Mueller, M.; Kozma, S. C.; Thomas, G.; Ruegg, M. A.; Ferry, A.; Pende, 
M.; Bigard, X.; Koulmann, N.; Schaeffer, L.&Gangloff, Y. G. (2009). "Muscle 
inactivation of mTOR causes metabolic and dystrophin defects leading to severe 
myopathy." The Journal of cell biology 187(6): 859-874. 
Roberg, K. J.; Bickel, S.; Rowley, N.&Kaiser, C. A. (1997). "Control of amino acid permease 
sorting in the late secretory pathway of Saccharomyces cerevisiae by SEC13, LST4, 
LST7 and LST8." Genetics 147(4): 1569-1584. 
Rosner, M.&Hengstschlager, M. (2008). "Cytoplasmic and nuclear distribution of the protein 
complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and 
delocalization of the mTORC2 components rictor and sin1." Human molecular 
genetics 17(19): 2934-2948. 
Roux, P. P.; Ballif, B. A.; Anjum, R.; Gygi, S. P.&Blenis, J. (2004). "Tumor-promoting phorbol 
esters and activated Ras inactivate the tuberous sclerosis tumor suppressor 
complex via p90 ribosomal S6 kinase." Proceedings of the National Academy of Sciences 
of the United States of America 101(37): 13489-13494. 
Rubio-Texeira, M.&Kaiser, C. A. (2006). "Amino acids regulate retrieval of the yeast general 
amino acid permease from the vacuolar targeting pathway." Molecular biology of the 
cell 17(7): 3031-3050. 
Russnak, R.; Konczal, D.&McIntire, S. L. (2001). "A family of yeast proteins mediating 
bidirectional vacuolar amino acid transport." The Journal of biological chemistry 
276(26): 23849-23857. 
Ruvinsky, I.; Sharon, N.; Lerer, T.; Cohen, H.; Stolovich-Rain, M.; Nir, T.; Dor, Y.; Zisman, 
P.&Meyuhas, O. (2005). "Ribosomal protein S6 phosphorylation is a determinant of 
cell size and glucose homeostasis." Genes & development 19(18): 2199-2211. 
Sancak, Y.; Peterson, T. R.; Shaul, Y. D.; Lindquist, R. A.; Thoreen, C. C.; Bar-Peled, 
L.&Sabatini, D. M. (2008). "The Rag GTPases bind raptor and mediate amino acid 
signaling to mTORC1." Science 320(5882): 1496-1501. 
Sancak, Y.; Thoreen, C. C.; Peterson, T. R.; Lindquist, R. A.; Kang, S. A.; Spooner, E.; Carr, S. 
A.&Sabatini, D. M. (2007). "PRAS40 is an insulin-regulated inhibitor of the 
mTORC1 protein kinase." Molecular cell 25(6): 903-915. 
Sarbassov, D. D.; Ali, S. M.; Kim, D. H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; 
Tempst, P.&Sabatini, D. M. (2004). "Rictor, a novel binding partner of mTOR, 
defines a rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton." Current biology : CB 14(14): 1296-1302. 
Sarbassov, D. D.; Ali, S. M.&Sabatini, D. M. (2005). "Growing roles for the mTOR pathway." 





Pereira-Leal, J. B.; Levy, E. D.&Teichmann, S. A. (2006). "The origins and evolution of 
functional modules: lessons from protein complexes." Philosophical transactions of the 
Royal Society of London. Series B, Biological sciences 361(1467): 507-517. 
Perry, J.&Kleckner, N. (2003). "The ATRs, ATMs, and TORs are giant HEAT repeat 
proteins." Cell 112(2): 151-155. 
Peterson, R. T.; Beal, P. A.; Comb, M. J.&Schreiber, S. L. (2000). "FKBP12-rapamycin-
associated protein (FRAP) autophosphorylates at serine 2481 under translationally 
repressive conditions." The Journal of biological chemistry 275(10): 7416-7423. 
Peterson, T. R.; Laplante, M.; Thoreen, C. C.; Sancak, Y.; Kang, S. A.; Kuehl, W. M.; Gray, N. 
S.&Sabatini, D. M. (2009). "DEPTOR is an mTOR inhibitor frequently 
overexpressed in multiple myeloma cells and required for their survival." Cell 
137(5): 873-886. 
Peterson, T. R.; Sengupta, S. S.; Harris, T. E.; Carmack, A. E.; Kang, S. A.; Balderas, E.; 
Guertin, D. A.; Madden, K. L.; Carpenter, A. E.; Finck, B. N.&Sabatini, D. M. (2011). 
"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway." Cell 
146(3): 408-420. 
Polak, P.; Cybulski, N.; Feige, J. N.; Auwerx, J.; Ruegg, M. A.&Hall, M. N. (2008). "Adipose-
specific knockout of raptor results in lean mice with enhanced mitochondrial 
respiration." Cell metabolism 8(5): 399-410. 
Poon, M.; Marx, S. O.; Gallo, R.; Badimon, J. J.; Taubman, M. B.&Marks, A. R. (1996). 
"Rapamycin inhibits vascular smooth muscle cell migration." J Clin Invest 98(10): 
2277-2283. 
Porstmann, T.; Santos, C. R.; Griffiths, B.; Cully, M.; Wu, M.; Leevers, S.; Griffiths, J. R.; 
Chung, Y. L.&Schulze, A. (2008). "SREBP activity is regulated by mTORC1 and 
contributes to Akt-dependent cell growth." Cell metabolism 8(3): 224-236. 
Powers, T.&Walter, P. (1999). "Regulation of ribosome biogenesis by the rapamycin-
sensitive TOR-signaling pathway in Saccharomyces cerevisiae." Molecular biology of 
the cell 10(4): 987-1000. 
Proud, C. G. (2009). "Dynamic balancing: DEPTOR tips the scales." Journal of molecular cell 
biology 1(2): 61-63. 
Proud, C. G. (2011). "mTOR Signalling in Health and Disease." Biochemical Society transactions 
39(2): 431-436. 
Rachdi, L.; Balcazar, N.; Osorio-Duque, F.; Elghazi, L.; Weiss, A.; Gould, A.; Chang-Chen, K. 
J.; Gambello, M. J.&Bernal-Mizrachi, E. (2008). "Disruption of Tsc2 in pancreatic 
beta cells induces beta cell mass expansion and improved glucose tolerance in a 
TORC1-dependent manner." Proceedings of the National Academy of Sciences of the 
United States of America 105(27): 9250-9255. 
Reardon, D. A.; Wen, P. Y.; Alfred Yung, W. K.; Berk, L.; Narasimhan, N.; Turner, C. D.; 
Clackson, T.; Rivera, V. M.&Vogelbaum, M. A. (2011). "Ridaforolimus for patients 
with progressive or recurrent malignant glioma: a perisurgical, sequential, 
ascending-dose trial." Cancer Chemother Pharmacol. 
Reiling, J. H.&Sabatini, D. M. (2006). "Stress and mTORture signaling." Oncogene 25(48): 
6373-6383. 
Reina, J. H.; Azzouz, T. N.&Hernandez, N. (2006). "Maf1, a new player in the regulation of 
human RNA polymerase III transcription." PloS one 1: e134. 
 
The Target of Rapamycin: Structure and Functions 
 
35 
Reinke, A.; Anderson, S.; McCaffery, J. M.; Yates, J., 3rd; Aronova, S.; Chu, S.; Fairclough, S.; 
Iverson, C.; Wedaman, K. P.&Powers, T. (2004). "TOR complex 1 includes a novel 
component, Tco89p (YPL180w), and cooperates with Ssd1p to maintain cellular 
integrity in Saccharomyces cerevisiae." The Journal of biological chemistry 279(15): 
14752-14762. 
Risson, V.; Mazelin, L.; Roceri, M.; Sanchez, H.; Moncollin, V.; Corneloup, C.; Richard-
Bulteau, H.; Vignaud, A.; Baas, D.; Defour, A.; Freyssenet, D.; Tanti, J. F.; Le-
Marchand-Brustel, Y.; Ferrier, B.; Conjard-Duplany, A.; Romanino, K.; Bauche, S.; 
Hantai, D.; Mueller, M.; Kozma, S. C.; Thomas, G.; Ruegg, M. A.; Ferry, A.; Pende, 
M.; Bigard, X.; Koulmann, N.; Schaeffer, L.&Gangloff, Y. G. (2009). "Muscle 
inactivation of mTOR causes metabolic and dystrophin defects leading to severe 
myopathy." The Journal of cell biology 187(6): 859-874. 
Roberg, K. J.; Bickel, S.; Rowley, N.&Kaiser, C. A. (1997). "Control of amino acid permease 
sorting in the late secretory pathway of Saccharomyces cerevisiae by SEC13, LST4, 
LST7 and LST8." Genetics 147(4): 1569-1584. 
Rosner, M.&Hengstschlager, M. (2008). "Cytoplasmic and nuclear distribution of the protein 
complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and 
delocalization of the mTORC2 components rictor and sin1." Human molecular 
genetics 17(19): 2934-2948. 
Roux, P. P.; Ballif, B. A.; Anjum, R.; Gygi, S. P.&Blenis, J. (2004). "Tumor-promoting phorbol 
esters and activated Ras inactivate the tuberous sclerosis tumor suppressor 
complex via p90 ribosomal S6 kinase." Proceedings of the National Academy of Sciences 
of the United States of America 101(37): 13489-13494. 
Rubio-Texeira, M.&Kaiser, C. A. (2006). "Amino acids regulate retrieval of the yeast general 
amino acid permease from the vacuolar targeting pathway." Molecular biology of the 
cell 17(7): 3031-3050. 
Russnak, R.; Konczal, D.&McIntire, S. L. (2001). "A family of yeast proteins mediating 
bidirectional vacuolar amino acid transport." The Journal of biological chemistry 
276(26): 23849-23857. 
Ruvinsky, I.; Sharon, N.; Lerer, T.; Cohen, H.; Stolovich-Rain, M.; Nir, T.; Dor, Y.; Zisman, 
P.&Meyuhas, O. (2005). "Ribosomal protein S6 phosphorylation is a determinant of 
cell size and glucose homeostasis." Genes & development 19(18): 2199-2211. 
Sancak, Y.; Peterson, T. R.; Shaul, Y. D.; Lindquist, R. A.; Thoreen, C. C.; Bar-Peled, 
L.&Sabatini, D. M. (2008). "The Rag GTPases bind raptor and mediate amino acid 
signaling to mTORC1." Science 320(5882): 1496-1501. 
Sancak, Y.; Thoreen, C. C.; Peterson, T. R.; Lindquist, R. A.; Kang, S. A.; Spooner, E.; Carr, S. 
A.&Sabatini, D. M. (2007). "PRAS40 is an insulin-regulated inhibitor of the 
mTORC1 protein kinase." Molecular cell 25(6): 903-915. 
Sarbassov, D. D.; Ali, S. M.; Kim, D. H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; 
Tempst, P.&Sabatini, D. M. (2004). "Rictor, a novel binding partner of mTOR, 
defines a rapamycin-insensitive and raptor-independent pathway that regulates the 
cytoskeleton." Current biology : CB 14(14): 1296-1302. 
Sarbassov, D. D.; Ali, S. M.&Sabatini, D. M. (2005). "Growing roles for the mTOR pathway." 





Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard, A. 
L.&Sabatini, D. M. (2006). "Prolonged rapamycin treatment inhibits mTORC2 
assembly and Akt/PKB." Molecular cell 22(2): 159-168. 
Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.&Sabatini, D. M. (2005). "Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex." Science 307(5712): 1098-1101. 
Sarbassov, D. D.&Sabatini, D. M. (2005). "Redox regulation of the nutrient-sensitive raptor-
mTOR pathway and complex." The Journal of biological chemistry 280(47): 39505-
39509. 
Schieke, S. M.; Phillips, D.; McCoy, J. P., Jr.; Aponte, A. M.; Shen, R. F.; Balaban, R. 
S.&Finkel, T. (2006). "The mammalian target of rapamycin (mTOR) pathway 
regulates mitochondrial oxygen consumption and oxidative capacity." The Journal of 
biological chemistry 281(37): 27643-27652. 
Schmidt, A.; Bickle, M.; Beck, T.&Hall, M. N. (1997). "The yeast phosphatidylinositol kinase 
homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2." Cell 
88(4): 531-542. 
Schmidt, A.; Kunz, J.&Hall, M. N. (1996). "TOR2 is required for organization of the actin 
cytoskeleton in yeast." Proceedings of the National Academy of Sciences of the United 
States of America 93(24): 13780-13785. 
Schroder, W.; Bushell, G.&Sculley, T. (2005). "The human stress-activated protein kinase-
interacting 1 gene encodes JNK-binding proteins." Cellular signalling 17(6): 761-767. 
Schroder, W.; Cloonan, N.; Bushell, G.&Sculley, T. (2004). "Alternative polyadenylation and 
splicing of mRNAs transcribed from the human Sin1 gene." Gene 339: 17-23. 
Schroder, W. A.; Buck, M.; Cloonan, N.; Hancock, J. F.; Suhrbier, A.; Sculley, T.&Bushell, G. 
(2007). "Human Sin1 contains Ras-binding and pleckstrin homology domains and 
suppresses Ras signalling." Cellular signalling 19(6): 1279-1289. 
Sehgal, S. N.; Baker, H.&Vezina, C. (1975). "Rapamycin (AY-22,989), a new antifungal 
antibiotic. II. Fermentation, isolation and characterization." The Journal of antibiotics 
28(10): 727-732. 
Sekiguchi, T.; Hirose, E.; Nakashima, N.; Ii, M.&Nishimoto, T. (2001). "Novel G proteins, 
Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B." The 
Journal of biological chemistry 276(10): 7246-7257. 
Sekulic, A.; Hudson, C. C.; Homme, J. L.; Yin, P.; Otterness, D. M.; Karnitz, L. M.&Abraham, 
R. T. (2000). "A direct linkage between the phosphoinositide 3-kinase-AKT 
signaling pathway and the mammalian target of rapamycin in mitogen-stimulated 
and transformed cells." Cancer research 60(13): 3504-3513. 
Sengupta, S.; Peterson, T. R.; Laplante, M.; Oh, S.&Sabatini, D. M. (2010). "mTORC1 controls 
fasting-induced ketogenesis and its modulation by ageing." Nature 468(7327): 1100-
1104. 
Settembre, C.; Di Malta, C.; Polito, V. A.; Garcia Arencibia, M.; Vetrini, F.; Erdin, S.; Erdin, S. 
U.; Huynh, T.; Medina, D.; Colella, P.; Sardiello, M.; Rubinsztein, D. C.&Ballabio, A. 
(2011). "TFEB links autophagy to lysosomal biogenesis." Science 332(6036): 1429-
1433. 
Shah, O. J.&Hunter, T. (2006). "Turnover of the active fraction of IRS1 involves raptor-
mTOR- and S6K1-dependent serine phosphorylation in cell culture models of 
tuberous sclerosis." Molecular and cellular biology 26(17): 6425-6434. 
 
The Target of Rapamycin: Structure and Functions 
 
37 
Shah, O. J.; Wang, Z.&Hunter, T. (2004). "Inappropriate activation of the 
TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and 
cell survival deficiencies." Current biology : CB 14(18): 1650-1656. 
Shaw, R. J.; Bardeesy, N.; Manning, B. D.; Lopez, L.; Kosmatka, M.; DePinho, R. A.&Cantley, 
L. C. (2004). "The LKB1 tumor suppressor negatively regulates mTOR signaling." 
Cancer cell 6(1): 91-99. 
Shiojima, I.&Walsh, K. (2006). "Regulation of cardiac growth and coronary angiogenesis by 
the Akt/PKB signaling pathway." Genes Dev 20(24): 3347-3365. 
Shiota, C.; Woo, J. T.; Lindner, J.; Shelton, K. D.&Magnuson, M. A. (2006). "Multiallelic 
disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for 
fetal growth and viability." Developmental cell 11(4): 583-589. 
Shor, B.; Wu, J.; Shakey, Q.; Toral-Barza, L.; Shi, C.; Follettie, M.&Yu, K. (2010). 
"Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and 
control of RNA polymerase III-dependent transcription in cancer cells." The Journal 
of biological chemistry 285(20): 15380-15392. 
Singh, K.; Sun, S.&Vezina, C. (1979). "Rapamycin (AY-22,989), a new antifungal antibiotic. 
IV. Mechanism of action." The Journal of antibiotics 32(6): 630-645. 
Smith, E. M.; Finn, S. G.; Tee, A. R.; Browne, G. J.&Proud, C. G. (2005). "The tuberous 
sclerosis protein TSC2 is not required for the regulation of the mammalian target of 
rapamycin by amino acids and certain cellular stresses." The Journal of biological 
chemistry 280(19): 18717-18727. 
Soliman, G. A.; Acosta-Jaquez, H. A.; Dunlop, E. A.; Ekim, B.; Maj, N. E.; Tee, A. R.&Fingar, 
D. C. (2010). "mTOR Ser-2481 autophosphorylation monitors mTORC-specific 
catalytic activity and clarifies rapamycin mechanism of action." The Journal of 
biological chemistry 285(11): 7866-7879. 
Sonenberg, N.&Hinnebusch, A. G. (2009). "Regulation of translation initiation in eukaryotes: 
mechanisms and biological targets." Cell 136(4): 731-745. 
Stan, R.; McLaughlin, M. M.; Cafferkey, R.; Johnson, R. K.; Rosenberg, M.&Livi, G. P. (1994). 
"Interaction between FKBP12-rapamycin and TOR involves a conserved serine 
residue." The Journal of biological chemistry 269(51): 32027-32030. 
Sturgill, T. W.&Hall, M. N. (2009). "Activating mutations in TOR are in similar structures as 
oncogenic mutations in PI3KCalpha." ACS chemical biology 4(12): 999-1015. 
Sun, S. Y.; Rosenberg, L. M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.&Khuri, F. R. (2005). 
"Activation of Akt and eIF4E survival pathways by rapamycin-mediated 
mammalian target of rapamycin inhibition." Cancer research 65(16): 7052-7058. 
Takai, H.; Wang, R. C.; Takai, K. K.; Yang, H.&de Lange, T. (2007). "Tel2 regulates the 
stability of PI3K-related protein kinases." Cell 131(7): 1248-1259. 
Takai, H.; Xie, Y.; de Lange, T.&Pavletich, N. P. (2010). "Tel2 structure and function in the 
Hsp90-dependent maturation of mTOR and ATR complexes." Genes & development 
24(18): 2019-2030. 
Tcherkezian, J.; Brittis, P. A.; Thomas, F.; Roux, P. P.&Flanagan, J. G. (2010). 
"Transmembrane receptor DCC associates with protein synthesis machinery and 
regulates translation." Cell 141(4): 632-644. 
Tee, A. R.; Manning, B. D.; Roux, P. P.; Cantley, L. C.&Blenis, J. (2003). "Tuberous sclerosis 





Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard, A. 
L.&Sabatini, D. M. (2006). "Prolonged rapamycin treatment inhibits mTORC2 
assembly and Akt/PKB." Molecular cell 22(2): 159-168. 
Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.&Sabatini, D. M. (2005). "Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex." Science 307(5712): 1098-1101. 
Sarbassov, D. D.&Sabatini, D. M. (2005). "Redox regulation of the nutrient-sensitive raptor-
mTOR pathway and complex." The Journal of biological chemistry 280(47): 39505-
39509. 
Schieke, S. M.; Phillips, D.; McCoy, J. P., Jr.; Aponte, A. M.; Shen, R. F.; Balaban, R. 
S.&Finkel, T. (2006). "The mammalian target of rapamycin (mTOR) pathway 
regulates mitochondrial oxygen consumption and oxidative capacity." The Journal of 
biological chemistry 281(37): 27643-27652. 
Schmidt, A.; Bickle, M.; Beck, T.&Hall, M. N. (1997). "The yeast phosphatidylinositol kinase 
homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2." Cell 
88(4): 531-542. 
Schmidt, A.; Kunz, J.&Hall, M. N. (1996). "TOR2 is required for organization of the actin 
cytoskeleton in yeast." Proceedings of the National Academy of Sciences of the United 
States of America 93(24): 13780-13785. 
Schroder, W.; Bushell, G.&Sculley, T. (2005). "The human stress-activated protein kinase-
interacting 1 gene encodes JNK-binding proteins." Cellular signalling 17(6): 761-767. 
Schroder, W.; Cloonan, N.; Bushell, G.&Sculley, T. (2004). "Alternative polyadenylation and 
splicing of mRNAs transcribed from the human Sin1 gene." Gene 339: 17-23. 
Schroder, W. A.; Buck, M.; Cloonan, N.; Hancock, J. F.; Suhrbier, A.; Sculley, T.&Bushell, G. 
(2007). "Human Sin1 contains Ras-binding and pleckstrin homology domains and 
suppresses Ras signalling." Cellular signalling 19(6): 1279-1289. 
Sehgal, S. N.; Baker, H.&Vezina, C. (1975). "Rapamycin (AY-22,989), a new antifungal 
antibiotic. II. Fermentation, isolation and characterization." The Journal of antibiotics 
28(10): 727-732. 
Sekiguchi, T.; Hirose, E.; Nakashima, N.; Ii, M.&Nishimoto, T. (2001). "Novel G proteins, 
Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B." The 
Journal of biological chemistry 276(10): 7246-7257. 
Sekulic, A.; Hudson, C. C.; Homme, J. L.; Yin, P.; Otterness, D. M.; Karnitz, L. M.&Abraham, 
R. T. (2000). "A direct linkage between the phosphoinositide 3-kinase-AKT 
signaling pathway and the mammalian target of rapamycin in mitogen-stimulated 
and transformed cells." Cancer research 60(13): 3504-3513. 
Sengupta, S.; Peterson, T. R.; Laplante, M.; Oh, S.&Sabatini, D. M. (2010). "mTORC1 controls 
fasting-induced ketogenesis and its modulation by ageing." Nature 468(7327): 1100-
1104. 
Settembre, C.; Di Malta, C.; Polito, V. A.; Garcia Arencibia, M.; Vetrini, F.; Erdin, S.; Erdin, S. 
U.; Huynh, T.; Medina, D.; Colella, P.; Sardiello, M.; Rubinsztein, D. C.&Ballabio, A. 
(2011). "TFEB links autophagy to lysosomal biogenesis." Science 332(6036): 1429-
1433. 
Shah, O. J.&Hunter, T. (2006). "Turnover of the active fraction of IRS1 involves raptor-
mTOR- and S6K1-dependent serine phosphorylation in cell culture models of 
tuberous sclerosis." Molecular and cellular biology 26(17): 6425-6434. 
 
The Target of Rapamycin: Structure and Functions 
 
37 
Shah, O. J.; Wang, Z.&Hunter, T. (2004). "Inappropriate activation of the 
TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and 
cell survival deficiencies." Current biology : CB 14(18): 1650-1656. 
Shaw, R. J.; Bardeesy, N.; Manning, B. D.; Lopez, L.; Kosmatka, M.; DePinho, R. A.&Cantley, 
L. C. (2004). "The LKB1 tumor suppressor negatively regulates mTOR signaling." 
Cancer cell 6(1): 91-99. 
Shiojima, I.&Walsh, K. (2006). "Regulation of cardiac growth and coronary angiogenesis by 
the Akt/PKB signaling pathway." Genes Dev 20(24): 3347-3365. 
Shiota, C.; Woo, J. T.; Lindner, J.; Shelton, K. D.&Magnuson, M. A. (2006). "Multiallelic 
disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for 
fetal growth and viability." Developmental cell 11(4): 583-589. 
Shor, B.; Wu, J.; Shakey, Q.; Toral-Barza, L.; Shi, C.; Follettie, M.&Yu, K. (2010). 
"Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and 
control of RNA polymerase III-dependent transcription in cancer cells." The Journal 
of biological chemistry 285(20): 15380-15392. 
Singh, K.; Sun, S.&Vezina, C. (1979). "Rapamycin (AY-22,989), a new antifungal antibiotic. 
IV. Mechanism of action." The Journal of antibiotics 32(6): 630-645. 
Smith, E. M.; Finn, S. G.; Tee, A. R.; Browne, G. J.&Proud, C. G. (2005). "The tuberous 
sclerosis protein TSC2 is not required for the regulation of the mammalian target of 
rapamycin by amino acids and certain cellular stresses." The Journal of biological 
chemistry 280(19): 18717-18727. 
Soliman, G. A.; Acosta-Jaquez, H. A.; Dunlop, E. A.; Ekim, B.; Maj, N. E.; Tee, A. R.&Fingar, 
D. C. (2010). "mTOR Ser-2481 autophosphorylation monitors mTORC-specific 
catalytic activity and clarifies rapamycin mechanism of action." The Journal of 
biological chemistry 285(11): 7866-7879. 
Sonenberg, N.&Hinnebusch, A. G. (2009). "Regulation of translation initiation in eukaryotes: 
mechanisms and biological targets." Cell 136(4): 731-745. 
Stan, R.; McLaughlin, M. M.; Cafferkey, R.; Johnson, R. K.; Rosenberg, M.&Livi, G. P. (1994). 
"Interaction between FKBP12-rapamycin and TOR involves a conserved serine 
residue." The Journal of biological chemistry 269(51): 32027-32030. 
Sturgill, T. W.&Hall, M. N. (2009). "Activating mutations in TOR are in similar structures as 
oncogenic mutations in PI3KCalpha." ACS chemical biology 4(12): 999-1015. 
Sun, S. Y.; Rosenberg, L. M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.&Khuri, F. R. (2005). 
"Activation of Akt and eIF4E survival pathways by rapamycin-mediated 
mammalian target of rapamycin inhibition." Cancer research 65(16): 7052-7058. 
Takai, H.; Wang, R. C.; Takai, K. K.; Yang, H.&de Lange, T. (2007). "Tel2 regulates the 
stability of PI3K-related protein kinases." Cell 131(7): 1248-1259. 
Takai, H.; Xie, Y.; de Lange, T.&Pavletich, N. P. (2010). "Tel2 structure and function in the 
Hsp90-dependent maturation of mTOR and ATR complexes." Genes & development 
24(18): 2019-2030. 
Tcherkezian, J.; Brittis, P. A.; Thomas, F.; Roux, P. P.&Flanagan, J. G. (2010). 
"Transmembrane receptor DCC associates with protein synthesis machinery and 
regulates translation." Cell 141(4): 632-644. 
Tee, A. R.; Manning, B. D.; Roux, P. P.; Cantley, L. C.&Blenis, J. (2003). "Tuberous sclerosis 





as a GTPase-activating protein complex toward Rheb." Current biology : CB 13(15): 
1259-1268. 
Thedieck, K.; Polak, P.; Kim, M. L.; Molle, K. D.; Cohen, A.; Jeno, P.; Arrieumerlou, C.&Hall, 
M. N. (2007). "PRAS40 and PRR5-like protein are new mTOR interactors that 
regulate apoptosis." PloS one 2(11): e1217. 
Thomas, G.&Hall, M. N. (1997). "TOR signalling and control of cell growth." Current opinion 
in cell biology 9(6): 782-787. 
Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; 
Sabatini, D. M.&Gray, N. S. (2009). "An ATP-competitive mammalian target of 
rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1." The Journal 
of biological chemistry 284(12): 8023-8032. 
Treins, C.; Warne, P. H.; Magnuson, M. A.; Pende, M.&Downward, J. (2010). "Rictor is a 
novel target of p70 S6 kinase-1." Oncogene 29(7): 1003-1016. 
Tsang, C. K.; Liu, H.&Zheng, X. F. (2010). "mTOR binds to the promoters of RNA 
polymerase I- and III-transcribed genes." Cell Cycle 9(5): 953-957. 
Tzatsos, A.&Kandror, K. V. (2006). "Nutrients suppress phosphatidylinositol 3-kinase/Akt 
signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 
phosphorylation." Molecular and cellular biology 26(1): 63-76. 
Um, S. H.; Frigerio, F.; Watanabe, M.; Picard, F.; Joaquin, M.; Sticker, M.; Fumagalli, S.; 
Allegrini, P. R.; Kozma, S. C.; Auwerx, J.&Thomas, G. (2004). "Absence of S6K1 
protects against age- and diet-induced obesity while enhancing insulin sensitivity." 
Nature 431(7005): 200-205. 
Valentinis, B.&Baserga, R. (2001). "IGF-I receptor signalling in transformation and 
differentiation." Molecular pathology : MP 54(3): 133-137. 
van der Poel, H. G.; Hanrahan, C.; Zhong, H.&Simons, J. W. (2003). "Rapamycin induces 
Smad activity in prostate cancer cell lines." Urol Res 30(6): 380-386. 
Vellai, T.; Takacs-Vellai, K.; Zhang, Y.; Kovacs, A. L.; Orosz, L.&Muller, F. (2003). "Genetics: 
influence of TOR kinase on lifespan in C. elegans." Nature 426(6967): 620. 
Veverka, V.; Crabbe, T.; Bird, I.; Lennie, G.; Muskett, F. W.; Taylor, R. J.&Carr, M. D. (2008). 
"Structural characterization of the interaction of mTOR with phosphatidic acid and 
a novel class of inhibitor: compelling evidence for a central role of the FRB domain 
in small molecule-mediated regulation of mTOR." Oncogene 27(5): 585-595. 
Vezina, C.; Kudelski, A.&Sehgal, S. N. (1975). "Rapamycin (AY-22,989), a new antifungal 
antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active 
principle." The Journal of antibiotics 28(10): 721-726. 
Vornlocher, H. P.; Hanachi, P.; Ribeiro, S.&Hershey, J. W. (1999). "A 110-kilodalton subunit 
of translation initiation factor eIF3 and an associated 135-kilodalton protein are 
encoded by the Saccharomyces cerevisiae TIF32 and TIF31 genes." The Journal of 
biological chemistry 274(24): 16802-16812. 
Wang, L.; Harris, T. E.; Roth, R. A.&Lawrence, J. C., Jr. (2007). "PRAS40 regulates mTORC1 
kinase activity by functioning as a direct inhibitor of substrate binding." The Journal 
of biological chemistry 282(27): 20036-20044. 
Wang, X.; Beugnet, A.; Murakami, M.; Yamanaka, S.&Proud, C. G. (2005). "Distinct signaling 
events downstream of mTOR cooperate to mediate the effects of amino acids and 
insulin on initiation factor 4E-binding proteins." Molecular and cellular biology 25(7): 
2558-2572. 
 
The Target of Rapamycin: Structure and Functions 
 
39 
Wang, X.; Li, W.; Parra, J. L.; Beugnet, A.&Proud, C. G. (2003). "The C terminus of initiation 
factor 4E-binding protein 1 contains multiple regulatory features that influence its 
function and phosphorylation." Molecular and cellular biology 23(5): 1546-1557. 
Wang, X.; Li, W.; Williams, M.; Terada, N.; Alessi, D. R.&Proud, C. G. (2001). "Regulation of 
elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase." The EMBO journal 
20(16): 4370-4379. 
Watanabe, R.; Tambe, Y.; Inoue, H.; Isono, T.; Haneda, M.; Isobe, K.; Kobayashi, T.; Hino, O.; 
Okabe, H.&Chano, T. (2007). "GADD34 inhibits mammalian target of rapamycin 
signaling via tuberous sclerosis complex and controls cell survival under 
bioenergetic stress." International journal of molecular medicine 19(3): 475-483. 
Wedaman, K. P.; Reinke, A.; Anderson, S.; Yates, J., 3rd; McCaffery, J. M.&Powers, T. (2003). 
"Tor kinases are in distinct membrane-associated protein complexes in 
Saccharomyces cerevisiae." Molecular biology of the cell 14(3): 1204-1220. 
Weichhart, T.; Haidinger, M.; Katholnig, K.; Kopecky, C.; Poglitsch, M.; Lassnig, C.; Rosner, 
M.; Zlabinger, G. J.; Hengstschlager, M.; Muller, M.; Horl, W. H.&Saemann, M. D. 
(2011). "Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids 
in myeloid immune cells." Blood 117(16): 4273-4283. 
White, R. J. (2005). "RNA polymerases I and III, growth control and cancer." Nature reviews. 
Molecular cell biology 6(1): 69-78. 
Wilkinson, M. G.; Pino, T. S.; Tournier, S.; Buck, V.; Martin, H.; Christiansen, J.; Wilkinson, 
D. G.&Millar, J. B. (1999). "Sin1: an evolutionarily conserved component of the 
eukaryotic SAPK pathway." The EMBO journal 18(15): 4210-4221. 
Woo, S. Y.; Kim, D. H.; Jun, C. B.; Kim, Y. M.; Haar, E. V.; Lee, S. I.; Hegg, J. W.; Bandhakavi, 
S.&Griffin, T. J. (2007). "PRR5, a novel component of mTOR complex 2, regulates 
platelet-derived growth factor receptor beta expression and signaling." The Journal 
of biological chemistry 282(35): 25604-25612. 
Wullschleger, S.; Loewith, R.&Hall, M. N. (2006). "TOR signaling in growth and 
metabolism." Cell 124(3): 471-484. 
Wullschleger, S.; Loewith, R.; Oppliger, W.&Hall, M. N. (2005). "Molecular organization of 
target of rapamycin complex 2." The Journal of biological chemistry 280(35): 30697-
30704. 
Yang, Q.&Guan, K. L. (2007). "Expanding mTOR signaling." Cell research 17(8): 666-681. 
Yang, Q.; Inoki, K.; Ikenoue, T.&Guan, K. L. (2006). "Identification of Sin1 as an essential 
TORC2 component required for complex formation and kinase activity." Genes & 
development 20(20): 2820-2832. 
Yeh, Y. Y.; Wrasman, K.&Herman, P. K. (2010). "Autophosphorylation within the Atg1 
activation loop is required for both kinase activity and the induction of autophagy 
in Saccharomyces cerevisiae." Genetics 185(3): 871-882. 
Yip, C. K.; Murata, K.; Walz, T.; Sabatini, D. M.&Kang, S. A. (2010). "Structure of the human 
mTOR complex I and its implications for rapamycin inhibition." Molecular cell 38(5): 
768-774. 
Yorimitsu, T.; He, C.; Wang, K.&Klionsky, D. J. (2009). "Tap42-associated protein 
phosphatase type 2A negatively regulates induction of autophagy." Autophagy 5(5): 
616-624. 
Young, D. A.&Nickerson-Nutter, C. L. (2005). "mTOR--beyond transplantation." Current 





as a GTPase-activating protein complex toward Rheb." Current biology : CB 13(15): 
1259-1268. 
Thedieck, K.; Polak, P.; Kim, M. L.; Molle, K. D.; Cohen, A.; Jeno, P.; Arrieumerlou, C.&Hall, 
M. N. (2007). "PRAS40 and PRR5-like protein are new mTOR interactors that 
regulate apoptosis." PloS one 2(11): e1217. 
Thomas, G.&Hall, M. N. (1997). "TOR signalling and control of cell growth." Current opinion 
in cell biology 9(6): 782-787. 
Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; 
Sabatini, D. M.&Gray, N. S. (2009). "An ATP-competitive mammalian target of 
rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1." The Journal 
of biological chemistry 284(12): 8023-8032. 
Treins, C.; Warne, P. H.; Magnuson, M. A.; Pende, M.&Downward, J. (2010). "Rictor is a 
novel target of p70 S6 kinase-1." Oncogene 29(7): 1003-1016. 
Tsang, C. K.; Liu, H.&Zheng, X. F. (2010). "mTOR binds to the promoters of RNA 
polymerase I- and III-transcribed genes." Cell Cycle 9(5): 953-957. 
Tzatsos, A.&Kandror, K. V. (2006). "Nutrients suppress phosphatidylinositol 3-kinase/Akt 
signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 
phosphorylation." Molecular and cellular biology 26(1): 63-76. 
Um, S. H.; Frigerio, F.; Watanabe, M.; Picard, F.; Joaquin, M.; Sticker, M.; Fumagalli, S.; 
Allegrini, P. R.; Kozma, S. C.; Auwerx, J.&Thomas, G. (2004). "Absence of S6K1 
protects against age- and diet-induced obesity while enhancing insulin sensitivity." 
Nature 431(7005): 200-205. 
Valentinis, B.&Baserga, R. (2001). "IGF-I receptor signalling in transformation and 
differentiation." Molecular pathology : MP 54(3): 133-137. 
van der Poel, H. G.; Hanrahan, C.; Zhong, H.&Simons, J. W. (2003). "Rapamycin induces 
Smad activity in prostate cancer cell lines." Urol Res 30(6): 380-386. 
Vellai, T.; Takacs-Vellai, K.; Zhang, Y.; Kovacs, A. L.; Orosz, L.&Muller, F. (2003). "Genetics: 
influence of TOR kinase on lifespan in C. elegans." Nature 426(6967): 620. 
Veverka, V.; Crabbe, T.; Bird, I.; Lennie, G.; Muskett, F. W.; Taylor, R. J.&Carr, M. D. (2008). 
"Structural characterization of the interaction of mTOR with phosphatidic acid and 
a novel class of inhibitor: compelling evidence for a central role of the FRB domain 
in small molecule-mediated regulation of mTOR." Oncogene 27(5): 585-595. 
Vezina, C.; Kudelski, A.&Sehgal, S. N. (1975). "Rapamycin (AY-22,989), a new antifungal 
antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active 
principle." The Journal of antibiotics 28(10): 721-726. 
Vornlocher, H. P.; Hanachi, P.; Ribeiro, S.&Hershey, J. W. (1999). "A 110-kilodalton subunit 
of translation initiation factor eIF3 and an associated 135-kilodalton protein are 
encoded by the Saccharomyces cerevisiae TIF32 and TIF31 genes." The Journal of 
biological chemistry 274(24): 16802-16812. 
Wang, L.; Harris, T. E.; Roth, R. A.&Lawrence, J. C., Jr. (2007). "PRAS40 regulates mTORC1 
kinase activity by functioning as a direct inhibitor of substrate binding." The Journal 
of biological chemistry 282(27): 20036-20044. 
Wang, X.; Beugnet, A.; Murakami, M.; Yamanaka, S.&Proud, C. G. (2005). "Distinct signaling 
events downstream of mTOR cooperate to mediate the effects of amino acids and 
insulin on initiation factor 4E-binding proteins." Molecular and cellular biology 25(7): 
2558-2572. 
 
The Target of Rapamycin: Structure and Functions 
 
39 
Wang, X.; Li, W.; Parra, J. L.; Beugnet, A.&Proud, C. G. (2003). "The C terminus of initiation 
factor 4E-binding protein 1 contains multiple regulatory features that influence its 
function and phosphorylation." Molecular and cellular biology 23(5): 1546-1557. 
Wang, X.; Li, W.; Williams, M.; Terada, N.; Alessi, D. R.&Proud, C. G. (2001). "Regulation of 
elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase." The EMBO journal 
20(16): 4370-4379. 
Watanabe, R.; Tambe, Y.; Inoue, H.; Isono, T.; Haneda, M.; Isobe, K.; Kobayashi, T.; Hino, O.; 
Okabe, H.&Chano, T. (2007). "GADD34 inhibits mammalian target of rapamycin 
signaling via tuberous sclerosis complex and controls cell survival under 
bioenergetic stress." International journal of molecular medicine 19(3): 475-483. 
Wedaman, K. P.; Reinke, A.; Anderson, S.; Yates, J., 3rd; McCaffery, J. M.&Powers, T. (2003). 
"Tor kinases are in distinct membrane-associated protein complexes in 
Saccharomyces cerevisiae." Molecular biology of the cell 14(3): 1204-1220. 
Weichhart, T.; Haidinger, M.; Katholnig, K.; Kopecky, C.; Poglitsch, M.; Lassnig, C.; Rosner, 
M.; Zlabinger, G. J.; Hengstschlager, M.; Muller, M.; Horl, W. H.&Saemann, M. D. 
(2011). "Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids 
in myeloid immune cells." Blood 117(16): 4273-4283. 
White, R. J. (2005). "RNA polymerases I and III, growth control and cancer." Nature reviews. 
Molecular cell biology 6(1): 69-78. 
Wilkinson, M. G.; Pino, T. S.; Tournier, S.; Buck, V.; Martin, H.; Christiansen, J.; Wilkinson, 
D. G.&Millar, J. B. (1999). "Sin1: an evolutionarily conserved component of the 
eukaryotic SAPK pathway." The EMBO journal 18(15): 4210-4221. 
Woo, S. Y.; Kim, D. H.; Jun, C. B.; Kim, Y. M.; Haar, E. V.; Lee, S. I.; Hegg, J. W.; Bandhakavi, 
S.&Griffin, T. J. (2007). "PRR5, a novel component of mTOR complex 2, regulates 
platelet-derived growth factor receptor beta expression and signaling." The Journal 
of biological chemistry 282(35): 25604-25612. 
Wullschleger, S.; Loewith, R.&Hall, M. N. (2006). "TOR signaling in growth and 
metabolism." Cell 124(3): 471-484. 
Wullschleger, S.; Loewith, R.; Oppliger, W.&Hall, M. N. (2005). "Molecular organization of 
target of rapamycin complex 2." The Journal of biological chemistry 280(35): 30697-
30704. 
Yang, Q.&Guan, K. L. (2007). "Expanding mTOR signaling." Cell research 17(8): 666-681. 
Yang, Q.; Inoki, K.; Ikenoue, T.&Guan, K. L. (2006). "Identification of Sin1 as an essential 
TORC2 component required for complex formation and kinase activity." Genes & 
development 20(20): 2820-2832. 
Yeh, Y. Y.; Wrasman, K.&Herman, P. K. (2010). "Autophosphorylation within the Atg1 
activation loop is required for both kinase activity and the induction of autophagy 
in Saccharomyces cerevisiae." Genetics 185(3): 871-882. 
Yip, C. K.; Murata, K.; Walz, T.; Sabatini, D. M.&Kang, S. A. (2010). "Structure of the human 
mTOR complex I and its implications for rapamycin inhibition." Molecular cell 38(5): 
768-774. 
Yorimitsu, T.; He, C.; Wang, K.&Klionsky, D. J. (2009). "Tap42-associated protein 
phosphatase type 2A negatively regulates induction of autophagy." Autophagy 5(5): 
616-624. 
Young, D. A.&Nickerson-Nutter, C. L. (2005). "mTOR--beyond transplantation." Current 





Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W. G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, 
K.; Malwitz, D. J.; Cole, D. C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T. S.; 
Gibbons, J. J.; Abraham, R. T.; Nowak, P.&Zask, A. (2009). "Biochemical, cellular, 
and in vivo activity of novel ATP-competitive and selective inhibitors of the 
mammalian target of rapamycin." Cancer research 69(15): 6232-6240. 
Yu, Y.; Yoon, S. O.; Poulogiannis, G.; Yang, Q.; Ma, X. M.; Villen, J.; Kubica, N.; Hoffman, G. 
R.; Cantley, L. C.; Gygi, S. P.&Blenis, J. (2011). "Phosphoproteomic analysis 
identifies Grb10 as an mTORC1 substrate that negatively regulates insulin 
signaling." Science 332(6035): 1322-1326. 
Yuan, X.; Zhao, J.; Zentgraf, H.; Hoffmann-Rohrer, U.&Grummt, I. (2002). "Multiple 
interactions between RNA polymerase I, TIF-IA and TAF(I) subunits regulate 
preinitiation complex assembly at the ribosomal gene promoter." EMBO reports 
3(11): 1082-1087. 
Zhande, R.; Mitchell, J. J.; Wu, J.&Sun, X. J. (2002). "Molecular mechanism of insulin-induced 
degradation of insulin receptor substrate 1." Molecular and cellular biology 22(4): 
1016-1026. 
Zhao, J.; Brault, J. J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S. H.&Goldberg, A. 
L. (2007). "FoxO3 coordinately activates protein degradation by the 
autophagic/lysosomal and proteasomal pathways in atrophying muscle cells." Cell 
Metab 6(6): 472-483. 
Zhao, Y.; Xiong, X.&Sun, Y. (2011). "DEPTOR, an mTOR Inhibitor, Is a Physiological 
Substrate of SCF(betaTrCP) E3 Ubiquitin Ligase and Regulates Survival and 
Autophagy." Molecular cell 44(2): 304-316. 
Zheng, X. F.; Florentino, D.; Chen, J.; Crabtree, G. R.&Schreiber, S. L. (1995). "TOR kinase 
domains are required for two distinct functions, only one of which is inhibited by 
rapamycin." Cell 82(1): 121-130. 
Zheng, X. F.&Schreiber, S. L. (1997). "Target of rapamycin proteins and their kinase activities 
are required for meiosis." Proceedings of the National Academy of Sciences of the United 
States of America 94(7): 3070-3075. 
Zhou, H.&Huang, S. (2010). "The complexes of mammalian target of rapamycin." Current 
protein & peptide science 11(6): 409-424. 
Zhou, H. Y.&Wong, A. S. (2006). "Activation of p70S6K induces expression of matrix 
metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in 
human ovarian cancer cells." Endocrinology 147(5): 2557-2566. 
Zinzalla, V.; Stracka, D.; Oppliger, W.&Hall, M. N. (2011). "Activation of mTORC2 by 
association with the ribosome." Cell 144(5): 757-768. 
Zoncu, R.; Efeyan, A.&Sabatini, D. M. (2011). "mTOR: from growth signal integration to 
cancer, diabetes and ageing." Nature reviews. Molecular cell biology 12(1): 21-35. 
2 
SNF1/AMP-Activated Protein Kinases:  
Genes, Expression and Biological Role  
Dmytro O. Minchenko1,2 and Oleksandr H. Minchenko1 
1Department of Molecular Biology, Palladin Institute of Biochemistry, 
National Academy of Sciences of Ukraine, 
2National Bogomolets Medical University, Kyiv,  
Ukraine 
1. Introduction  
Most of the physiological and metabolic processes in any organism are controlled by a 
regulatory factor network, which includes a lot of protein kinases, protein phosphatases and 
transcription factors. Protein kinases and phosphatases are key regulators of the majority of 
transcription factors which control metabolism both in normal and in different pathological 
conditions; it is a circadian type of regulation [1–5]. AMPK-related kinases SNARK and 
NUAK1 as well as many others AMPK-related kinases represent molecular components of 
signalling cascades that control metabolism, gene expression and perhaps cell proliferation 
in response to cellular, metabolic and environmental stresses [6–8].  
The sucrose-non-fermenting protein kinase (SNF1) from Saccharomyces cerevisiae and its 
mammalian counterpart, AMP-activated protein kinase (AMPK), form a family of 
serine/threonine kinases that acts as a master sensor and regulator of the energy balance at 
the cellular level as well as the stress response systems, has been critical to our understanding 
of the whole body energy homeostasis [9]. This family of protein kinases is highly conserved 
between animals, fungi and plants and is commonly activated in response to cellular and 
environmental stresses such as nutrient deprivation. Yeast SNF1 responds to glucose 
deprivation by derepressing genes implicated in carbon source utilization and by 
modulating the transcription of glucose-regulated genes involved in gluconeogenesis, 
respiration, sporulation, thermotolerance, peroxisome biogenesis and cell cycle regulation. 
Activated by environmental stresses AMPK switches off anabolic pathways (e.g. fatty acid 
and cholesterol synthesis) and induces ATP generating catabolic pathways [9]. Twelve protein 
kinases (NUAK1, NUAK2, BRSK1, BRSK2, SIK, QIK, QSK, MARK1, MARK2, MARK3, 
MARK4 and MELK) in the human kinome are closely related to AMPKα1 and AMPKα2, thus 
forming a 14 kinase phylogenetic tree known as “AMPK-related kinases” which represent 
components of signalling cascades that control metabolism, gene expression and perhaps cell 
proliferation in response to cellular, metabolic and environmental stresses [9].  
The AMP-activated protein kinase system acts as a sensor of cellular energy status that is 
conserved in all eukaryotic cells. It is activated by a large variety of cellular stresses that 
increase cellular AMP and decrease ATP levels and also by physiological stimuli, such as 
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increase cellular AMP and decrease ATP levels and also by physiological stimuli, such as 





metabolic stresses that either interferes with ATP production or that accelerate ATP 
consumption [10]. AMPK modulates multiple metabolic pathways. Activation in response to 
an increase in AMP involves phosphorylation by an upstream kinase, the tumour 
suppressor LKB1. Once activated, AMPK switches on catabolic pathways that generate ATP, 
while switching off ATP-consuming processes such as biosynthesis and cell growth and 
proliferation. Thus, it is a key player in the development of new treatments for obesity, the 
metabolic syndrome, type 2 diabetes or even cancer. In fact, it has been recently reported 
that drugs used in the treatment of diabetes, such as metformin and thiazolidinediones, 
exert their beneficial effects through the activation of AMPK. 
The sucrose-non-fermenting protein kinase (SNF1)/AMP-activated protein kinase-related 
kinase (SNF1/AMP-activated protein kinase; SNARK) is a member of AMPK kinases 
(NUAK family SNF1-like kinase 2) which is related to serine/threonine protein kinases [7, 
9]. SNARK activity is regulated by glucose- or glutamine-deprivation, induction of 
endoplasmic reticulum stress by dithyothreitol or homocysteine, elevation of cellular AMP 
and/or depletion of ATP, hyperosmotic stress, salt stress and oxidative stress caused by 
hydrogen peroxide. However, the regulation of SNARK activity in response to cellular 
stresses depends greatly upon cell type. It was also shown that SNARK is also regulated by 
metabolic stress and diabetes [11]. Nuclear localization of SNARK has shown its impact on 
gene expression [12].  
Tsuchihara et al. [13] demonstrated that SNARK(+/-) mice exhibit mature-onset obesity and 
related metabolic disorders. Moreover, the incidence of both adenomas and aberrant crypt 
foci were significantly higher in SNARK(+/-) mice than in their wild-type counterparts, 
suggesting that SNARK deficiency contributed to the early phase of tumourigenesis via 
obesity-dependent and obesity-independent mechanisms [14]. Recently, Namiki et al. [14] 
have shown that AMP kinase-related kinase SNARK affects tumour growth, migration, and 
clinical outcome of human melanoma, further supporting the importance of this protein 
kinase in cancer development and tumour progression, while AMPK has antioncogenic 
properties. We have also shown that the SNF1/AMP-activated protein kinase-related kinase 
is a sensitive marker for the action of ecotoxicant methyl tert-butyl ether (MTBE) as well as 
silver nanoparticles [15, 16]. These observations support a role for SNARK as a molecular 
component of the cellular stress response. 
SNF1-like kinase 1 (NUAK1) is an AMP-activated protein kinase family member 5, ARK5, 
which regulates ploidy and senescence, tumour cell survival, malignancy and invasion 
downstream of Akt signaling, acts as an ATM kinase under the conditions of nutrient 
starvation [17–20]. Moreover, NUAK1 suppresses the apoptosis, induced by nutrient 
starvation, and death receptors via inhibition of caspase-8 and caspase-6 activation [21, 22]. 
Importantly, AMPK-related kinase NUAK1 as well as many others AMPK kinases 
(including MARK/PAR-1) is regulated by protein kinase LKB1 and USP9X [23, 24]. 
2. NUAK family SNF1-like kinase 2 (NUAK2), Sucrose nonfermenting AMPK-
related kinase (SNARK)  
Human NUAK family SNF1-like kinase 2 (NUAK2; EC_number "2.7.11.1") also known as 
sucrose nonfermenting AMPK-related kinase or skeletal muscle sucrose, nonfermenting 
1/adenosine monophosphate activated protein kinase-related kinase (SNARK) is an AMP-
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activated protein kinase family member 4, which was identified 10 years ago as an potential 
mediator of cellular response to metabolic stress [9].  
2.1 NUAK2 gene, transcripts and encoded proteins 
The human NUAK2 (SNARK) gene (geneID: 81788) is localized on chromosome 1 (1q32,1). 
The SNARK gene encodes mRNA (GenBank accession number NM_030952) of seven exons. 
Northern blotting demonstrated that mRNA transcripts (at least two variants) for the 
SNARK were widely expressed in rodent tissues, but most abundant in rat kidney. Reverse-
transcriptase-mediated PCR detected two SNARK cDNA products in RNA from rat heart, 
skin, spleen, lung, uterus, liver and a neonatal rat keratinocyte cell line, NRKC. The two 
different SNARK PCR products were cloned, sequenced and found to encode either 
authentic SNARK (1437 bp) or an internally deleted SNARK transcript (1247 bp) [9]. 
Whereas rat kidney contained predominantly the intact SNARK transcript and testes 
expressed only the 1247 bp SNARK transcript, both intact and internally deleted SNARK 
transcripts were detected in other tested tissues. The ORF encodes a putative protein of 630 
amino acid residues with a predicted molecular mass of 70 kDa and a theoretical pI of 9.35. 
Translation of the SNARK-deleted transcript is predicted to give rise to a prematurely 
terminated protein of approximately 415 amino acid residues [9].  
Although no autophosphorylated products were detected in samples of immunoprecipitated 
endogenous SNARK from wild type BHK cells, one major phosphorylated band, possibly a 
protein doublet, was detected in the immunoprecipitates from SNARK-transfected BHK 
cells [9]. The size of the phosphorylated band(s) corresponds to the size of SNARK detected 
in these cell lines by Western blot analysis. Thus, these results demonstrate that SNARK is a 
protein kinase capable of autophosphorylation in vitro. Besides that, immunoprecipitated 
SNARK protein exhibits phosphotransferase activity with the synthetic peptide substrate 
HMRSAMSGLHLVKRR as a kinase substrate [9]. SNARK was translated in vitro to yield a 
single protein band of approximately 76 kDa, possibly a protein doublet, however, Western 
analysis of transfected BHK (baby hamster kidney) cells detected two SNARK-
immunoreactive bands of approximately 76 – 80 kDa.  
The NUAK family SNF1-like kinase 2 (NUAK2 or SNARK) is a member 4 of AMPK kinases 
which are related to serine/threonine protein kinases and contains all 11 catalytic 
subdomains conserved in these protein kinases. Analysis of the catalytic domain of SNARK 
with the Prosite program revealed a protein kinase ATP-binding region signature (residues 
63 – 89) and a serine/threonine protein kinase active-site signature (residues 175 – 187). The 
sequences at the C-terminus of SNARK were distinct and not well conserved with C-
terminal sequences of other SNF1/AMPK family members. The instability index is 
computed to be 58.40 with the Protparam Tool program, classifying protein kinase SNARK 
as an unstable protein [9]. 
Comparison of the SNARK catalytic subdomains I – XI to other SNF-1/AMPK family 
members demonstrates that protein kinase SNARK originated very early in eukaryotic 
evolution, diverging before the divergence of yeast and humans [9]. On the basis of the 
phylogeny of the catalytic subdomains, SNARK is no more closely related to SNF1 than it is 
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activated protein kinase family member 4, which was identified 10 years ago as an potential 
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2.2 Protein kinase SNARK, its activity and regulation 
The NUAK family SNF1-like kinase 2 is a member of AMPK kinases, it is commonly 
activated in response to cellular and environmental stresses, and it is a molecular 
component of the cellular stress response, but its precise mechanisms remain unclear [7, 9, 
11, 25]. Its activity is regulated by glucose- or glutamine-deprivation, induction of 
endoplasmic reticulum stress by homocysteine or dithiothreitol, hyperosmotic stress, salt 
stress, elevation of cellular AMP and/or depletion of ATP, ultraviolet B radiation and 
oxidative stress caused by hydrogen peroxide. However, the regulation of protein kinase 
SNARK activity in response to cellular stresses depends greatly upon cell type. Several 
aspects of SNARK activation and regulation are broadly similar to AMPK [8]. For example, 
SNARK and AMPK are both AMP-responsive and activated by treatments known to 
increase the AMP:ATP ratio, including glucose deprivation and chemical ATP production 
[9, 12]. Nevertheless, the metabolic role of SNARK at the cellular level, particularly in 
humans, especially in skeletal muscle, is incompletely resolved. 
Kuga et al. [12] identified the subcellular localization of SNARK protein. Unlike cytoplasmic 
localizing AMPK, SNARK was predominantly localized in the nucleus. This protein kinase 
is constitutively distributed in the nucleus; even when SNARK is activated by metabolic 
stimuli such as the AMP-mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR) 
or glucose-deprivation. Conserved nuclear localization signal was identified at the N-
terminal portion (68KKAR71) of protein kinase SNARK. Deletion and point mutation of this 
part resulted in the cytoplasmic translocation of mutant proteins. Furthermore, GFP fused 
with the SNARK fragment containing 68KKAR71 translocated to the nucleus.  
A microarray analysis revealed that nuclear localized SNARK alteres transcriptome profiles 
and a considerable part of these alterations were canceled by the mutation of nuclear 
localization signal (first two core lysine residues of 68KKAR71 were altered to alanine 
(68AAAR71)), suggesting the ability of SNARK to modulate gene expression is dependent on 
its nuclear localization. It has been shown that overexpression of protein kinase SNARK in 
human liver hepatoma cells results in the upregulation (more than 2.0-fold) of 76 mRNA 
targets and in the downregulation (more than 2.0-fold) of 32 mRNA targets, suggesting that 
this protein kinase can work as a stress-responsive transcriptional modulator in the nucleus 
[12].  
Moreover, transcriptome profiles of wild-type and nuclear localized signal-mutant SNARK 
expressing cells were compared to identify the impact of the nuclear localization of SNARK 
on the regulation of mRNA levels of potential downstream genes. Among the 76 up-
regulated probe sets by overexpressed SNARK, only eight probe sets increased more than 
2.0-fold in 68AAAR71-overexpressing cells compared with vector-transfected cells. On the 
other hand, among the 32 down-regulated probe sets by overexpressed SNARK, only 13 
probe sets decreased more than 2.0-fold in 68AAAR71-overexpressing cells compared with 
vector-transfected cells. Thus, overexpressed SNARK altered the gene expression profiles 
more than nuclear localization signal-mutant SNARK. This result implied that protein 
kinase SNARK in the nucleus, but not the cytoplasm, has a remarkable impact on gene 
expression and can work in the nucleus as a transcriptional modulator in response to stress. 
This data may become a platform to elucidate the molecular mechanism and the 
physiological signification of protein kinase SNARK.  
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AMPK and AMPK-related kinases are believed to be activated by increased AMP:ATP ratio 
through a direct activation mechanism of the allosteric effect and/or indirectly activated by 
phosphorylation at threonine residue in the activation loop by upstream kinases, LKB1 
(serine/threonine protein kinase 11, STK11), CaMKK (calcium/calmodulin-dependent 
protein kinase kinase 1, alpha), and TAK1 (mitogen-activated protein kinase kinase kinase 7; 
MAP3K7) [25]. CaMKK and TAK1 are localized in the cytoplasm, but LKB1 is localized in 
both nucleus and cytoplasm. Therefore SNARK might be phosphorylated in the nucleus by 
protein kinase LKB1 [12]. 
Rune et al. [11] showed that skeletal muscle SNARK expression is also regulated by 
metabolic stress and increases in human obesity, and in response to metabolic stressors. This 
increase in SNARK mRNA expression may occur as a consequence of systemic factors 
associated with metabolic impairments in obesity, since exposure of myotubes to elevated 
levels of TNF-α or palmitate acutely increased SNARK mRNA expression. siRNA against 
SNARK failed to rescue TNFα- or palmitate-induced insulin resistance, indicating that 
changes in SNARK expression occur as a consequence, rather than a cause of insulin 
resistance. Based on this data in human skeletal muscle, in the insulin-resistant and obesity 
phenotype in whole-body SNARK-haploinsufficient mice [13], SNARK expression in 
metabolically active tissues beyond skeletal muscle may play a role in whole body energy 
and glucose homeostasis. 
Interestingly, SNARK has anti-apoptotic properties, acting through a TNF-α-sensitive 
nuclear NF-κB-mediated mechanism. Thus, the SNF1/AMP kinase-related kinase 2, which 
is induced in response to various forms of metabolic stress, was identified as an NF-B-
regulated anti-apoptotic kinase that contributes to the tumour-promoting activity of death 
receptor CD95 (APO-1/Fas) in apoptosis-resistant tumour cells [26]. The death receptor 
CD95 induces apoptosis in many tissues. However, in apoptosis-resistant tumour cells, 
stimulation of CD95 induces up-regulation of a defined number of mostly anti-apoptotic 
genes, resulting in increased motility and invasiveness of tumour cells. The majority of these 
genes are known NF-B target genes. One of the CD95-regulated genes is the 
serine/threonine kinase (SNARK). It was shown that up-regulation of SNARK in response 
to CD95 ligand and tumour necrosis factor  depends on activation of NF-B. 
Overexpression of SNARK rendered tumour cells more resistant, whereas a kinase-inactive 
mutant of SNARK sensitizes cells to CD95-mediated apoptosis. Furthermore, small 
interfering RNA-mediated knockdown of SNARK increases the sensitivity of tumour cells to 
death receptor CD95 ligand- and TRAIL-induced apoptosis. Importantly, cells with reduced 
expression of SNARK also showed reduced motility and invasiveness in response to CD95 
engagement. SNARK therefore represents an NF-B-regulated anti-apoptotic gene that 
contributes to the tumour-promoting activity of CD95 in apoptosis-resistant tumour cells 
[26]. 
Kim et al. [27] have investigated the effect of Epstein-Barr virus (EBV) latent membrane 
protein 1 (LMP1) on human cancer cells for identification of potential target genes. It was 
found that LMP1 upregulated the expression of protein kinase SNARK compared with the 
empty vector transfected control cells. Moreover, SNARK expression increased drug 
resistance in response to doxorubicin, whereas knockdown of SNARK by siRNA effectively 
inhibited LMP-1-mediated increase of cell survival. SNARK stimulates the expression of 
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mediated increase of cell survival. These results suggest that SNARK is a downstream 
cellular target of LMP1 in malignant cells [27]. 
2.3 Protein kinase SNARK and tumourigenesis 
Members of the AMP kinase family play an important role in tumourigenesis [6]. This 
activity is believed to be due to their activation by various forms of metabolic stress such as 
glucose deprivation, a condition to be expected within solid tumours [28]. Recently, Namiki 
et al. [14] showed that AMP kinase-related kinase NUAK2 affects tumour growth, 
migration, and clinical outcome of human melanoma. This study further supports the 
importance of NUAK2 in cancer development and tumour progression, while AMPK has 
antioncogenic properties.  
Although several in vitro studies have suggested that metabolic stress as well as genotoxic or 
osmotic stresses induce SNARK activation, the physiological roles of protein kinase SNARK 
remain uncertain. Using SNARK-deficient mice helps to clarify the in vivo function of this 
kinase. Interestingly, SNARK(+/-) mice exhibited mature-onset obesity and related 
metabolic disorders [13]. Thus, an increased bodyweight in these mice is accompanied by fat 
deposition, fatty changes of the liver, and increased serum triglyceride concentration. These 
mice also exhibited hyperinsulinemia, hyperglycemia, and glucose intolerance, symptoms 
which are similar to those of human type II diabetes mellitus accompanied with obesity. 
Obesity is regarded as a risk factor for colorectal cancer. To investigate whether SNARK 
deficiency is involved in tumorigenesis in the large intestine, obese SNARK(+/-) mice were 
treated with a chemical carcinogen, azoxymethane, a chemical carcinogen that induces 
aberrant crypt foci, colorectal adenoma, and adenocarcinoma. The incidences of both 
adenomas and aberrant crypt foci were significantly higher in SNARK(+/-) mice than in 
their wild-type counterparts, suggesting that SNARK deficiency contributed to the early 
phase of tumourigenesis via obesity-dependent and -independent mechanisms [13]. 
2.4 Activation of protein kinase SNARK during muscle contraction 
Sakamoto  et al. [29] have shown that deficiency of LKB1 in skeletal muscle prevents AMPK 
activation and glucose uptake during contraction. In LKB1-lacking muscle, the basal activity 
of the AMPKalpha2 isoform was greatly reduced and was not increased by the AMP-
mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug 
phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-
2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by 
AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. 
Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than 
in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating 
AMPK activity and cellular energy levels in response to contraction and phenformin.  
Recently, Koh et al. [30] showed that muscle contraction also increases protein kinase 
SNARK activity and that this effect blunted in the muscle-specific LKB1 knockout mice. It is 
known that the signaling mechanisms that mediate the important effects of contraction, to 
increase glucose transport in skeletal muscle, occur through an insulin-independent 
mechanism. Moreover, muscle-specific knockout of protein kinase LKB1, an upstream 
kinase for AMPK and AMPK-related protein kinases, significantly inhibited contraction-
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
47 
stimulated glucose transport, suggests that one or more AMPK-related protein kinases are 
important for this process. It has been shown that expression of a mutant SNARK in mouse 
tibialis anterior muscle impaired contraction-stimulated, but not insulin-stimulated, glucose 
transport. The impaired contraction-stimulated glucose transport was also observed in 
skeletal muscle of whole-body SNARK heterozygotic knockout mice [30]. Thus, SNARK, the 
fourth member of the AMP-activated protein kinase catalytic subunit family, is activated by 
muscle contraction and is a unique mediator of contraction-stimulated glucose transport in 
skeletal muscle.  
There is data that NUAK2 is a TNFalpha-induced kinase which regulates myosin phosphatase 
target subunit 1 (MYPT1) activity by phosphorylation at a site other than known Rho-kinase 
phosphorylation sites (Thr696 or Thr853) responsible for inhibition of myosin phosphatase 
activity [31]. Moreover, Suzuki et al. [32] observed the induction of cell-cell detachment 
during glucose starvation through F-actin conversion by protein kinase SNARK. Recently, 
Vallenius et al. [33] have shown that an association between AMP kinase-related kinase 
SNARK and myosin phosphatase Rho-interacting protein (MRIP) reveals a novel 
mechanism for regulation of actin stress fibers via activation of MLCP (myosin light chain 
phosphatase). Moreover, new roles for the LKB1-NUAK pathway in controlling myosin 
phosphatase complexes and cell adhesion have been shown [34]. 
2.5 Protein kinase SNARK as a regulator of whole-body metabolism 
Ichinoseki-Sekine et al. [35] provide evidence for a robust effect on whole body metabolism 
by hemiallelic SNARK deficiency, suggesting that this AMPK-related kinase is a previously 
unrecognized important regulator of whole-body metabolism. They have investigated the in 
vivo effects of altering expression of SNARK by using hemiallelic loss of SNARK on whole 
body metabolic homeostasis and physical activity behaviour. Homozygous SNARK-
deficient mice have a high incidence of embryonic lethality, whereas the heterozygous 
SNARK-deficient mice have an obvious metabolic phenotype with mature-onset obesity and 
increased white adipose tissue mass evident after the age of 4 month.  
Activation of SNARK by upstream kinase LKB1 occurs by phosphorylation of Thr208, a 
conserved threonine residue equivalent in position to Thr172 within the activation loop of 
AMPKα2 [36]. LKB1 is attractive as a regulator of SNARK activity by virtue of its nuclear 
localization, which is coincident with the predominant nuclear localization of SNARK [12], 
but SNARK may also directly mediate some physiological effects of LKB1. Several aspects of 
SNARK regulation and activity are broadly similar to those of AMPK, which can be 
summarized as follows. First, SNARK possesses AMPK-like phosphotransferase activity; 
second, activation of SNARK is AMP responsive; third, SNARK activity is increased by 
AICAR, albeit in a cell-specific manner; and fourth, SNARK is activated by treatments 
known to increase AMP/ATP ratio or disrupt ATP production, including glucose 
deprivation and chemical ATP depletion among others [36].  
Possible AMPK activation of SNARK, secondary to the activation of AMPK by these 
treatments, has not been investigated but raises the possibility that one or more activities 
previously attributed to the AMPK-signaling cascade may be attributable, in part, to 
SNARK activation. In addition, similarities between AMPK and SNARK regulation do not 





mediated increase of cell survival. These results suggest that SNARK is a downstream 
cellular target of LMP1 in malignant cells [27]. 
2.3 Protein kinase SNARK and tumourigenesis 
Members of the AMP kinase family play an important role in tumourigenesis [6]. This 
activity is believed to be due to their activation by various forms of metabolic stress such as 
glucose deprivation, a condition to be expected within solid tumours [28]. Recently, Namiki 
et al. [14] showed that AMP kinase-related kinase NUAK2 affects tumour growth, 
migration, and clinical outcome of human melanoma. This study further supports the 
importance of NUAK2 in cancer development and tumour progression, while AMPK has 
antioncogenic properties.  
Although several in vitro studies have suggested that metabolic stress as well as genotoxic or 
osmotic stresses induce SNARK activation, the physiological roles of protein kinase SNARK 
remain uncertain. Using SNARK-deficient mice helps to clarify the in vivo function of this 
kinase. Interestingly, SNARK(+/-) mice exhibited mature-onset obesity and related 
metabolic disorders [13]. Thus, an increased bodyweight in these mice is accompanied by fat 
deposition, fatty changes of the liver, and increased serum triglyceride concentration. These 
mice also exhibited hyperinsulinemia, hyperglycemia, and glucose intolerance, symptoms 
which are similar to those of human type II diabetes mellitus accompanied with obesity. 
Obesity is regarded as a risk factor for colorectal cancer. To investigate whether SNARK 
deficiency is involved in tumorigenesis in the large intestine, obese SNARK(+/-) mice were 
treated with a chemical carcinogen, azoxymethane, a chemical carcinogen that induces 
aberrant crypt foci, colorectal adenoma, and adenocarcinoma. The incidences of both 
adenomas and aberrant crypt foci were significantly higher in SNARK(+/-) mice than in 
their wild-type counterparts, suggesting that SNARK deficiency contributed to the early 
phase of tumourigenesis via obesity-dependent and -independent mechanisms [13]. 
2.4 Activation of protein kinase SNARK during muscle contraction 
Sakamoto  et al. [29] have shown that deficiency of LKB1 in skeletal muscle prevents AMPK 
activation and glucose uptake during contraction. In LKB1-lacking muscle, the basal activity 
of the AMPKalpha2 isoform was greatly reduced and was not increased by the AMP-
mimetic agent, 5-aminoimidazole-4-carboxamide riboside (AICAR), by the antidiabetic drug 
phenformin, or by muscle contraction. Moreover, phosphorylation of acetyl CoA carboxylase-
2, a downstream target of AMPK, was profoundly reduced. Glucose uptake stimulated by 
AICAR or muscle contraction, but not by insulin, was inhibited in the absence of LKB1. 
Contraction increased the AMP:ATP ratio to a greater extent in LKB1-deficient muscles than 
in LKB1-expressing muscles. These studies establish the importance of LKB1 in regulating 
AMPK activity and cellular energy levels in response to contraction and phenformin.  
Recently, Koh et al. [30] showed that muscle contraction also increases protein kinase 
SNARK activity and that this effect blunted in the muscle-specific LKB1 knockout mice. It is 
known that the signaling mechanisms that mediate the important effects of contraction, to 
increase glucose transport in skeletal muscle, occur through an insulin-independent 
mechanism. Moreover, muscle-specific knockout of protein kinase LKB1, an upstream 
kinase for AMPK and AMPK-related protein kinases, significantly inhibited contraction-
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
47 
stimulated glucose transport, suggests that one or more AMPK-related protein kinases are 
important for this process. It has been shown that expression of a mutant SNARK in mouse 
tibialis anterior muscle impaired contraction-stimulated, but not insulin-stimulated, glucose 
transport. The impaired contraction-stimulated glucose transport was also observed in 
skeletal muscle of whole-body SNARK heterozygotic knockout mice [30]. Thus, SNARK, the 
fourth member of the AMP-activated protein kinase catalytic subunit family, is activated by 
muscle contraction and is a unique mediator of contraction-stimulated glucose transport in 
skeletal muscle.  
There is data that NUAK2 is a TNFalpha-induced kinase which regulates myosin phosphatase 
target subunit 1 (MYPT1) activity by phosphorylation at a site other than known Rho-kinase 
phosphorylation sites (Thr696 or Thr853) responsible for inhibition of myosin phosphatase 
activity [31]. Moreover, Suzuki et al. [32] observed the induction of cell-cell detachment 
during glucose starvation through F-actin conversion by protein kinase SNARK. Recently, 
Vallenius et al. [33] have shown that an association between AMP kinase-related kinase 
SNARK and myosin phosphatase Rho-interacting protein (MRIP) reveals a novel 
mechanism for regulation of actin stress fibers via activation of MLCP (myosin light chain 
phosphatase). Moreover, new roles for the LKB1-NUAK pathway in controlling myosin 
phosphatase complexes and cell adhesion have been shown [34]. 
2.5 Protein kinase SNARK as a regulator of whole-body metabolism 
Ichinoseki-Sekine et al. [35] provide evidence for a robust effect on whole body metabolism 
by hemiallelic SNARK deficiency, suggesting that this AMPK-related kinase is a previously 
unrecognized important regulator of whole-body metabolism. They have investigated the in 
vivo effects of altering expression of SNARK by using hemiallelic loss of SNARK on whole 
body metabolic homeostasis and physical activity behaviour. Homozygous SNARK-
deficient mice have a high incidence of embryonic lethality, whereas the heterozygous 
SNARK-deficient mice have an obvious metabolic phenotype with mature-onset obesity and 
increased white adipose tissue mass evident after the age of 4 month.  
Activation of SNARK by upstream kinase LKB1 occurs by phosphorylation of Thr208, a 
conserved threonine residue equivalent in position to Thr172 within the activation loop of 
AMPKα2 [36]. LKB1 is attractive as a regulator of SNARK activity by virtue of its nuclear 
localization, which is coincident with the predominant nuclear localization of SNARK [12], 
but SNARK may also directly mediate some physiological effects of LKB1. Several aspects of 
SNARK regulation and activity are broadly similar to those of AMPK, which can be 
summarized as follows. First, SNARK possesses AMPK-like phosphotransferase activity; 
second, activation of SNARK is AMP responsive; third, SNARK activity is increased by 
AICAR, albeit in a cell-specific manner; and fourth, SNARK is activated by treatments 
known to increase AMP/ATP ratio or disrupt ATP production, including glucose 
deprivation and chemical ATP depletion among others [36].  
Possible AMPK activation of SNARK, secondary to the activation of AMPK by these 
treatments, has not been investigated but raises the possibility that one or more activities 
previously attributed to the AMPK-signaling cascade may be attributable, in part, to 
SNARK activation. In addition, similarities between AMPK and SNARK regulation do not 





cellular metabolism. Cell-specific differences are reported between SNARK and AMPK 
activity and pharmacological activation as well as in the relative rates of phosphorylation 
and peptide substrates phosphorylated [36]. 
Examining metabolic and anthropometric effects of SNARK deficiency, the core finding in 
Ichinoseki-Sekine et al. [35] investigation is that the provision of voluntary exercise 
opportunities to SNARK(+/-) mice results in habitually increased daily physical activity 
(∼2-fold) compared with SNARK(+/+) mice, commensurate with the prevention of mature-
onset obesity to which these animals are genetically predisposed. Physical activity resulted 
in a reduction in total body mass, liver mass, and white and brown adipose tissue mass in 
both exercise groups compared with sedentary controls. At termination of the study, body 
mass was similar between genotypes in the physically active mice. The prevention of weight 
gain in the active SNARK(+/-) mice occurred despite a 10% increase in food intake. 
Differences in physical activity were not attributable to sex, age, or disrupted circadian 
rhythm, nor were they attributable to any intrinsic deficit in forced exercise capacity/muscle 
energetic associated with SNARK deficiency. Direct SNARK-dependent modulation of 
whole body metabolism, similar to AMPK effects in the context of carbohydrate and lipid 
metabolism has not been demonstrated yet. However, SNARK is predominantly and 
constitutively localized in the nucleus, where it is likely to be regulated by protein kinase 
LKB1 or other unidentified kinases [12].  
Interestingly, the SNARK gene expression and kinase activity is tissue specific, and its 
activity profile differs significantly from the AMPKα2 activity profile. Therefore, targeting 
SNARK could potentially affect whole body metabolic homeostasis, and a more thorough 
examination of the physiological role of SNARK is warranted. Thus, protein kinase SNARK 
is a novel regulator of whole body metabolic homeostasis and highlights yet another protein 
kinase as an exciting new addition to the already extensive paradigm of homeostatic 
regulation by cellular energy sensors.  
2.6 Protein kinase SNARK and PFKFB-3 alternative splicing 
The new aspect of the biological role of protein kinase SNARK was demonstrated in 
SNARK-deficient mice by investigation of the expression of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-3 (PFKFB-3) mRNA and its alternative splice variants in 
the liver, lungs, testes, heart, and skeletal muscle [37]. Bifunctional enzyme PFKFB is a key 
regulatory enzyme of glycolysis which also participates in glucose phosphorylation [38, 39]. 
The PFKFB-3 expression significantly increased due to hypoxia in different normal and 
cancer cell lines via hypoxia inducible transcription factor (HIF)-dependent mechanism [40, 
41]. Hypoxia also induces expression of PFKFB-3 in different mouse organs in vivo, except 
skeletal muscle [42]. High expression level and phosphorylation status of PFKFB-3 as an 
important glycolytic regulator was determined in different malignant tumours [43–47]. 
Because SNARK deficiency contributed to the early phase of tumourigenesis and is important 
in cancer development and tumour progression [13, 14], investigation of the expression of 
PFKFB-3 and its alternative splice variants, which have different proliferative properties [48], 
is necessary for understanding the role of SNARK deficiency in tumourigenesis.  
As shown in Fig. 1, the expression levels of PFKFB-3 mRNA significantly increases in the 
liver and lung of SNARK(-/-) knockout mice as compared to corresponding tissues of 
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control C57BL/6 mice [37]. At the same time, PFKFB-3 mRNA expression level in skeletal 
muscle of SNARK knockout mice decreases without significant changes in the heart as 
compared to control animals. Thus, SNARK deficiency leads to variable changes of PFKFB-3 
mRNA expression in different mouse tissues.  
Reverse-transcriptase-mediated PCR of the carboxyl-terminus of PFKFB-3 mRNA detected 
three – four cDNA products in RNA from the liver, lung, testis, heart, and skeletal muscle of 
control C57BL/6 and SNARK knockout mice (Fig. 2). This heterogeneity is a result of 
alternative splicing of the PFKFB-3 mRNA in tissue specific manner. Alternative splice 
variants of PFKFB-3 mRNA were identified by sequence analysis of cloned fragments. The 
major difference among the members of these bifunctional enzyme alternative splice 
variants is the length and composition of the carboxyl-terminal region (Fig. 3 and 4), 
supporting the idea that this terminus of the various enzyme isoforms serve to adapt the 
kinetic properties of the catalytic core to metabolic exigencies of a particular tissue. 
Alternative splice variants of PFKFB-3 also have different amounts and sequence positions 
of serine residues which are very important in the regulation of isozyme activity via 
phosphorylation [39, 46]. It was shown that the pattern of alternative splice variants of the 
PFKFB-3 mRNA differs in different mouse organs (Fig. 2). 
Results of this study strongly support the SNARK dependent regulation of PFKFB 
alternative splicing. Thus, the level of smallest alternative splice variant increases in the 
heart and liver of SNARK knockout mice compared with control mice. However, the level of 
longest alternative splice variant decreases in the skeletal muscle of SNARK knockout mice 
compared with control mice (Fig, 2). Therefore, investigation of different alternative splice 
variants of PFBFB-3 isozymes is important for comprehension of tissue-specific regulation 
mechanisms of glycolysis. The precise molecular mechanisms, whereby SNARK participates 
in the splicing of PFKFB as well as a role of different isoenzymes in the regulation of 
glycolysis, await further study. 
 
Fig. 1. Real time PCR analysis of PFKFB-3 mRNA expression in liver, lung, heart and 
skeletal muscle of control C57BL/6 male mice (C) and SNARK(-/-) knockout mice (KO). 
Amplification of PFKFB-3 mRNA was carried out using M4 forward and M5 reverse 
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Fig. 1. Real time PCR analysis of PFKFB-3 mRNA expression in liver, lung, heart and 
skeletal muscle of control C57BL/6 male mice (C) and SNARK(-/-) knockout mice (KO). 
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Fig. 2. RT-PCR analysis of PFKFB-3 mRNA expression in the heart, liver, lung, testis and 
skeletal muscle of control C57BL/6 (+/+) and SNARK knockout mice (-/-). Amplification of 
PFKFB-3 mRNA was carried out using M3 forward and M6 reverse primers. The amplified 
PCR products were run on an agarose gel. Intensities of PFKFB-3 mRNA bands were 
normalized to -actin mRNA [37]. 
 
Fig. 3. Schematic representation of exon structure of mouse PFKFB-3 mRNA alternative 
splice variants. Most of these splice variants do not have exon 13th. Some of splice variants 
have 15th and 15tha exons which alters the reading frame, amino acid sequence and length of 
C-terminus. One splice variant is shortest because it does not have exon 14th. Position of 
three possible stop codons for the different alternative splice variants of PFKFB-3 mRNA are 
shown by asterisk. The GenBank accession number of alternative splice variants of mouse 
PFKFB-3 is noted on the left [38]. 
2.7 SNARK kinase as a stress sensor and sensitive marker of silver nanoparticles and 
methyl tert-butyl ether action  
Recently we have shown that the expression of SNF1/AMP-activated protein kinase 
(SNARK) increases in different organs of male Wistar rats intratracheally instilled by 30% 
silver nanoparticles (28-30 nm) in sodium chloride matrix aerosol in dose 50 g/kg (or  0.05 
mg/kg) body weight (=15 g of silver) [15]. Silver nanoparticles were prepared in the 
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Laboratory No. 84 of the Paton Electric Welding Institute of The National Academy of 
Sciences of Ukraine. The expression levels of the SNARK mRNA were analyzed in the lung, 
liver, brain, heart, kidney and testis using quantitative polymerase chain reaction on the 1st, 
3rd or 14th day after one-time intratracheally treated rats with silver nanoparticles. 
 
Fig. 4. Amino acid sequence of alternative splice variants of mouse PFKFB-3. Differences in 
amino acid sequences and length of C-terminus of different alternative splice variants of 
mouse PFKFB-3 are shown. Serine residues are underlined. The GenBank accession number 
of alternative splice variants of mouse PFKFB-3 is noted on the left [38]. 
It was shown that the expression of protein kinase SNARK mRNA increases in the liver, 
lung and brain on the 1st, 3rd and 14th day after one-time treatment of rats with silver 
nanoparticles, being more intense (more than 2 fold) on the 3rd and 14th day in the brain and 
liver and on the 1st day in the lung (Fig. 5 and 6). Results of Fig. 6 and 7 also indicated that 
SNARK mRNA expression does not change significantly in the heart and testes on the 1st  
 
Fig. 5. The effect of silver nanoparticles on the expression of protein kinase SNARK mRNA in 
the liver and lung in 1, 3 or 14 days (d) after treatment. Values of SNARK mRNA expressions 
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Fig. 6. The effect of silver nanoparticles on the expression of protein kinase SNARK mRNA 
in the brain and testis in 1, 3 or 14 days (d) after treatment. Values of SNARK mRNA 
expressions were normalized to -actin mRNA expression; C – control; n = 3; * - P < 0.05 
[15]. 
and 14th days after treatment of rats with silver nanoparticles, but there is a clear increase of 
SNARK expression on the 3rd day as compared to control animals. Results of Fig. 7 show 
that SNARK mRNA expression also increases in the kidney on the 1st, 3rd and 14th day after 
treatment of rats with silver nanoparticles, being more intense on the 3rd and 14th days; 
however, this induction is significantly less when compared to the liver, lung or brain.  
Thus, one-time intratracheally instilled silver nanoparticles change the expression of the 
protein kinase SNARK in different rat organs, not only in the lung tissue. Moreover, this 
effect of silver nanoparticles on the expression of the protein kinase SNARK strongly 
depends on time after the treatment of rats with these nanoparticles in a tissue-specific 
manner. These results correlate to data from Lefebvre and Rosen [7] whom have shown that 
the regulation of protein kinase SNARK activity in response to cellular stresses greatly 
depends upon cell type.  
 
Fig. 7. The effect of silver nanoparticles on the expression of protein kinase SNARK mRNA in 
the kidney and heart in 1, 3 or 14 days (d) after treatment. Values of SNARK mRNA 
expressions were normalized to -actin mRNA expression; C – control; n = 3; * - P < 0.05 [15]. 
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Shimada et al. [49] demonstrated that the intratracheally instilled ultrafine nanoparticles are 
able to translocate from the mouse lung into systemic circulation. Precise mechanisms of the 
anatomical translocation (crossing the air-blood barrier) of inhaled nanoparticles at the 
alveolar wall are not fully understood. Silver nanoparticles are widely used in the field of 
biomedicine, but a comprehensive understanding of how silver nanoparticles distribute in 
the body and the induced toxicity remains largely unknown. Tang et al. [50] investigated the 
distribution and accumulation of silver nanoparticles in rats with subcutaneous injection. 
Rats were injected with either silver nanoparticles SNPs or silver microparticles (SMPs) at 
62.8 mg/kg, and then sacrificed at predetermined time points. Silver content analysis by 
Inductively coupled plasma mass spectrometry was used for determination of silver content 
in different organs. Results indicated that silver nanoparticles translocated into the blood 
circulation and distributed throughout the main organs, especially in the kidney, liver, 
spleen, brain and lung in the form of particles. Ultrastructural observations indicate that 
those silver nanoparticles that had accumulated in organs could enter different kinds of 
cells. Moreover, silver nanoparticles also induced blood-brain barrier (BBB) destruction and 
astrocyte swelling, and caused neuronal degeneration [50].  
There is data that silver nanoparticles are more toxic than silver microparticles or ions [51–
53]. Powers et al. [53] have shown that silver nanoparticles have the potential to evoke 
developmental neurotoxicity even more potently than known neurotoxicants. Silver ions 
inhibited replication and increased cell death in undifferentiated cells, and selectively 
impaired neurite formation. Silver nanoparticles in D. melanogaster induce heat shock 
stress, oxidative stress, DNA damage and apoptosis [54]. Thus, silver nanoparticles up-
regulate the expression of heat shock protein 70, the cell cycle checkpoint p53 and cell 
signaling protein p38 all of which are involved in the DNA damage repair pathway. 
Moreover, the activity of caspase-3 and caspase-9, markers of apoptosis was significantly 
higher in silver nanoparticles exposed organisms. 
It is possible that silver nanoparticles create stress conditions which affect the expression of 
protein kinase SNARK mRNA via unfolded protein response signals through activation of 
inositol requiring enzyme-1 (endoplasmic reticulum–nuclei-1) and alternative splicing of 
XBP-1 [55 – 57]. Endoplasmic reticulum stress signalling activates inositol requiring enzyme-
1 and XBP-1 which control diverse cell type- and condition-specific transcriptional 
regulatory networks. However, the cellular mechanism for survival under stress conditions 
is complex and further investigation of the mechanism by which silver nanoparticles affects 
protein kinase SNARK expression as well as biologic significance of silver nanoparticles 
induced alteration in the expression of these genes is needed. The stage is now set for the 
elucidation of the molecular mechanisms responsible for these important SNARK responses 
to silver nanoparticles action.  
Results of investigations clearly demonstrate that silver nanoparticles have a significant 
effect on important regulatory mechanisms which control metabolic processes in different 
tissues via SNARK gene expression, which can be considered as a sensitive marker for silver 
nanoparticles action. These results suggest that more caution is needed in biomedical 
applications of silver nanoparticles as well as higher level of safety in the silver 
nanoparticles production industry. 
We have also studied the effect of different doses of ecotoxicant methyl tertbutyl ether on 
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investigation demonstrated that methyl tertbutyl ether affects the expression protein kinase 
SNARK in the liver, lung and heart in dose dependent and tissue specific manner and that 
very small dose induce the expression of protein kinase SNARK in all tested vital organs in 
rats (Fig. 8 and 9). There is data that methyl tertbutyl ether can initiate the variety of 
neurotoxic, allergic and respiratory illnesses, liver hypertrophy and leukaemia in humans as 
well as the following cancers in rats and mice: kidney, liver, testicular and lymph nodes, 
initiate development of leukemia [58, 59]. We have recently shown that methyl tertbutyl 
ether affects the expression of PFKFB-4 mRNA and its alternative splicing [60]. Thus, 
SNARK gene expression can be considered as sensitive markers for the methyl tertbutyl 
ether action. 
 
Fig. 8. Effect of methyl tertbutyl ether [0.5 (M 0,5); 5 (M 5); 50 (M 50) та 500 (M 500) mg/kg 
body weight during two months] on SNARK mRNA expression in the liver, lung and heart 
by reverse-transcriptase-mediated PCR. C – control rats. 
 
Fig. 9. Effect of methyl tertbutyl ether [0.5 (M 0,5); 5 (M 5); 50 (M 50) та 500 (M 500) mg/kg 
body weight during two months] on the expression levels of SNARK mRNA in the liver, 
lung and heart by quantitative PCR. C – control rats. 
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3. SNF1-like kinase, 1 (NUAK1) AMP-activated protein kinase family member 
5, ARK5 
Human NUAK family SNF1-like kinase 1 (NUAK1; EC_number "2.7.11.1") is an 
AMP-activated protein kinase family member, ARK5. AMP-activated protein 
kinases (AMPKs) are a class of serine/threonine protein kinases that are activated 
by an increase in intracellular AMP concentration. They are a sensitive indicator of 
cellular energy status and have been found to promote tumor cell survival during 
nutrient starvation. The human gene encoded protein kinase NUAK1 (ARK5) is 
located on chromosome 12 ("12q23.3"; GeneID: 9891). This gene encodes a protein 
of 661 amino acid residues. ARK5, which is the fifth member of the AMPK catalytic 
subunit family, is a tumor malignancy-associated factor at the downstream of Akt 
[19]. ARK5 is a tumour cell survival and invasion-associated factor. The activated 
ARK5 induces cell survival during nutrient starvation and death receptor 
activation, and tumor cell invasion and metastasis [18–21]. 
However, the precise mechanisms of how ARK5 activity inhibits caspase dependent cell 
death remains to be determined. Both cell death and cell survival are important for cellular 
homeostasis; therefore, an imbalance of their signalling causes several disease states, 
including tumourogenesis.  
ARK5, as an AMP-activated protein kinase family member 5, is a tumour progression-
associated factor that is directly phosphorylated by AKT at serine 600 in the regulatory 
domain, but phosphorylation at the conserved threonine residue on the active T loop has 
been found to be required for its full activation [18, 19]. Suzuki et al. [61] identified 
serine/threonine protein kinase NDR2 as a protein kinase that also phosphorylates and 
activates ARK5 during insulin-like growth factor-1 (IGF-1) signalling. Upon stimulation 
with IGF-1, protein kinase NDR2 was found to directly phosphorylate the conserved 
threonine 211 on the active T loop of protein kinase ARK5 and to promote cell survival and 
invasion of colorectal cancer cell lines through ARK5.  
During IGF-1 signaling, phosphorylation at three residues (threonine 75, serine 282 and 
threonine 442) was also found to be required for NDR2 activation. Among these three 
residues, phosphorylation of serine 282 seemed to be most important for NDR2 activation 
(the same as for the mouse homologue) because its aspartic acid-converted mutant 
(NDR2/S282D) induced ARK5-mediated cell survival and invasion activities even in the 
absence of IGF-1. Threonine 75 in protein kinase NDR2 was required for interaction with 
protein S100B, and binding was in a calcium ion-dependent and phospholipase C-gamma-
dependent manner [61]. Thus, protein kinase NDR2 is an upstream kinase of ARK5 that 
plays an essential role in tumour progression through an AMP-activated protein kinase 
ARK5. 
NUAK1 acts as an ATM kinase under the conditions of nutrient starvation and plays a key 
role in tumour malignancy downstream of Akt signalling [19]. Matrigel invasion assays 
demonstrated that both overexpressed and endogenous ARK5 showed strong Akt 
dependent activity. In addition, ARK5 expression induced activation of matrix 
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3. SNF1-like kinase, 1 (NUAK1) AMP-activated protein kinase family member 
5, ARK5 
Human NUAK family SNF1-like kinase 1 (NUAK1; EC_number "2.7.11.1") is an 
AMP-activated protein kinase family member, ARK5. AMP-activated protein 
kinases (AMPKs) are a class of serine/threonine protein kinases that are activated 
by an increase in intracellular AMP concentration. They are a sensitive indicator of 
cellular energy status and have been found to promote tumor cell survival during 
nutrient starvation. The human gene encoded protein kinase NUAK1 (ARK5) is 
located on chromosome 12 ("12q23.3"; GeneID: 9891). This gene encodes a protein 
of 661 amino acid residues. ARK5, which is the fifth member of the AMPK catalytic 
subunit family, is a tumor malignancy-associated factor at the downstream of Akt 
[19]. ARK5 is a tumour cell survival and invasion-associated factor. The activated 
ARK5 induces cell survival during nutrient starvation and death receptor 
activation, and tumor cell invasion and metastasis [18–21]. 
However, the precise mechanisms of how ARK5 activity inhibits caspase dependent cell 
death remains to be determined. Both cell death and cell survival are important for cellular 
homeostasis; therefore, an imbalance of their signalling causes several disease states, 
including tumourogenesis.  
ARK5, as an AMP-activated protein kinase family member 5, is a tumour progression-
associated factor that is directly phosphorylated by AKT at serine 600 in the regulatory 
domain, but phosphorylation at the conserved threonine residue on the active T loop has 
been found to be required for its full activation [18, 19]. Suzuki et al. [61] identified 
serine/threonine protein kinase NDR2 as a protein kinase that also phosphorylates and 
activates ARK5 during insulin-like growth factor-1 (IGF-1) signalling. Upon stimulation 
with IGF-1, protein kinase NDR2 was found to directly phosphorylate the conserved 
threonine 211 on the active T loop of protein kinase ARK5 and to promote cell survival and 
invasion of colorectal cancer cell lines through ARK5.  
During IGF-1 signaling, phosphorylation at three residues (threonine 75, serine 282 and 
threonine 442) was also found to be required for NDR2 activation. Among these three 
residues, phosphorylation of serine 282 seemed to be most important for NDR2 activation 
(the same as for the mouse homologue) because its aspartic acid-converted mutant 
(NDR2/S282D) induced ARK5-mediated cell survival and invasion activities even in the 
absence of IGF-1. Threonine 75 in protein kinase NDR2 was required for interaction with 
protein S100B, and binding was in a calcium ion-dependent and phospholipase C-gamma-
dependent manner [61]. Thus, protein kinase NDR2 is an upstream kinase of ARK5 that 
plays an essential role in tumour progression through an AMP-activated protein kinase 
ARK5. 
NUAK1 acts as an ATM kinase under the conditions of nutrient starvation and plays a key 
role in tumour malignancy downstream of Akt signalling [19]. Matrigel invasion assays 
demonstrated that both overexpressed and endogenous ARK5 showed strong Akt 
dependent activity. In addition, ARK5 expression induced activation of matrix 





with a significant increase in tumour growth and significant suppression of necrosis in 
tumour tissue. Interestingly, only the ARK5-overexpressing PANC-1 cell line tumour 
showed invasion and metastasis in nude mice, although Akt was activated in tumours 
derived from both PANC-1 and ARK5-overexpressing PANC-1 cell lines. 
Suzuki et al. [21] have investigated the mechanisms of induction of cell survival by protein 
kinase ARK5 and have shown that ARK5 suppresses the apoptosis induced by nutrient 
starvation and death receptors via inhibition of caspase 8 activation. Thus, human hepatoma 
HepG2 cells undergo necrotic cell death within 24 h after the start of glucose starvation, and 
the cell death signaling has been found to be mediated by death-receptor-independent 
activation of caspase 8. When HepG2 cells were transfected with ARK5 expression vector 
and subjected to several cell death stimuli, ARK5 was found to suppress cell death by 
glucose starvation and TNF-alpha, but not by camptothecin or doxorubicin. Western 
blotting analysis revealed that glucose starvation induced Bid cleavage and FLIP 
degradation following caspase 8 activation in a time-dependent manner, and ARK5 
overexpression clearly delayed Bid cleavage, FLIP degradation, and caspase 8 activation. 
These results demonstrated that cell survival induced by ARK5 is, at least in part, due to 
inhibition of caspase 8 activation. 
AMP-activated protein kinase family member 5 also negatively regulates procaspase-6 by 
phosphorylation at serine 257, leading to resistance to the FasL/Fas system the key 
regulator promoting cell death and cell survival [22]. Fas is a type I transmembrane protein 
mediating intracellular cell death signalling upon the stimulation of Fas ligand (FasL). When 
Fas is activated by the ligation of FasL, an intracellular interaction of Fas death domain (Fas-
DD), FADD, and caspase-8 (death inducing signalling complex (DISC) recruitment) is 
initiated for the activation of executioner caspase; and cellular FLIP is well known as the 
inhibitor of DISC recruitment. The serine/threonine protein kinase Akt induces cell survival 
as a result of phosphorylation and several cell death-associated factors, such as Bad, 
caspase-9 and Forkhead, upon the stimulation of growth factor receptor and integrin-
induced cell signaling. Although active caspase-6 overexpression induced cell death in 
SW480 and DLD-1 cell lines, SW480 cells, but not DLD-1 cells, exhibite strong resistance to 
procaspase-6 overexpression. Moreover, mutant caspase-6, in which the serine 257 was 
substituted by alanine (caspase-6/SA), induced cell death and FLIP degradation, even in 
SW480 cells. Active ARK5 was found to phosphorylate wild-type caspase-6 in vitro, but not 
caspase-6/SA, and the prevented activation of caspase-6 was promoted due to its 
phosphorylation by active ARK5 in vitro.  
AMPK-related kinases NUAK1 and many others (including MARK/PAR-1) are regulated 
by protein kinase LKB1 and USP9X [23, 24]. Moreover, there is data that the LKB1-NUAK 
pathway plays important role in controlling myosin phosphatase complexes and cell 
adhesion [34]. NUAK1 regulates ploidy and senescence; cells that constitutively express 
NUAK1 suffer gross aneuploidies and show diminished expression of the genomic stability 
regulator LATS1, whereas depletion of NUAK1 with shRNA exerts opposite effects [17].  
AMP-activated protein kinase-related kinase 5 (ARK5/NUAK1) is expressed in rat skeletal 
muscle and phosphorylated by electrically elicited contractions and 5-aminoimidazole-4-
carboxamide-1-beta-d-ribofuranoside (AICAR). Increased phosphorylation of ARK5 by 
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muscle contractions or exposure to AICAR, however, is insufficient to activate this protein 
kinase in skeletal muscle, suggesting that some other modification (e.g., phosphorylation on 
tyrosine or by Akt) may be necessary for its activity in muscle [62]. 
4. Conclusions 
NUAK family SNF1-like kinase includes two kinases, NUAK1 and NUAK2; both are 
members of AMP-activated protein kinases which are related to serine/threonine protein 
kinases. The sucrose-non-fermenting protein kinase (SNF1)/AMP-activated protein kinase-
related kinase (SNF1/AMP-activated protein kinase; SNARK) is a member 4 of AMPK 
kinases (NUAK family SNF1-like kinase 2; NUAK2). SNF1-like kinase 1 (NUAK1) is an 
AMP-activated protein kinase family member 5, ARK5. Protein kinase NUAK2 (SNARK) is 
a molecular component of the cellular stress response and an important regulator of whole-
body metabolism. Protein kinase SNARK was consistently localized in the nuclei. It has 
been shown that the nuclear localizing SNARK alters transcriptome profiles. It therefore 
represents a NF-B-regulated anti-apoptotic gene that contributes to the tumour-promoting 
activity of death receptor CD95 in apoptosis-resistant tumour cells and plays an important 
role in cancer development and tumour progression. SNARK affects tumour growth, 
migration, and clinical outcome of human melanoma. Protein kinase SNARK is also 
activated by muscle contraction and is a unique mediator of contraction-stimulated glucose 
transport in skeletal muscle. Moreover, association between AMP kinase-related kinase 
SNARK and myosin phosphatase Rho-interacting protein reveals a novel mechanism for 
regulation of actin stress fibers via activation of myosin light chain phosphatase. Protein 
kinase NUAK1 (ARK5) regulates ploidy and senescence, tumour cell survival, malignancy 
and invasion downstream of Akt signalling and suppresses apoptosis induced by nutrient 
starvation and death receptors via inhibition of caspase-8 and caspase-6 activation. It is 
interesting to note that the expression of SNARK is a sensitive marker of silver nanoparticles 
and methyl tert-butyl ether toxic effect.  
5. References 
[1] Mizoguchi, T., Putterill, J. and Ohkoshi, Y. (2006) Kinase and phosphatase: the cog and 
spring of the circadian clock. Int. Rev. Cytol., 250, 47–72.  
[2] Walton, K.M., Fisher, K., Rubitski, D., Marconi, M., Meng, Q.J., Sládek, M., Adams, J., 
Bass, M., Chandrasekaran, R., Butler, T., Griffor, M., Rajamohan, F., Serpa, M., 
Chen, Y., Claffey, M., Hastings, M., Loudon, A., Maywood, E., Ohren, J., Doran, A. 
and Wager, T.T. (2009) Selective inhibition of casein kinase 1 epsilon minimally 
alters circadian clock period. J. Pharmacol. Ex. Ther., 330, 430–439. 
[3] Meng, Q.J., Maywood, E.S., Bechtold, D.A., Lu, W.Q., Li, J., Gibbs, J.E., Dupré, S.M., 
Chesham, J.E., Rajamohan, F., Knafels, J., Sneed, B., Zawadzke, L.E., Ohren, J.F., 
Walton, K.M., Wager, T.T., Hastings, M.H. and Loudon, A.S. (2010) Entrainment of 
disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. 
Proc. Natl. Acad. Sci. U.S.A., 107, 15240–15245.  
[4] Huang, W., Ramsey, K.M. and Marcheva, B. (2011) Circadian rhythms, sleep, and 
metabolism. J. Clin. Invest., 121, 2133–2141. 
[5] Kovac J., Husse J., Oster H. (2009) A time to fast, a time to feast: the crosstalk between 





with a significant increase in tumour growth and significant suppression of necrosis in 
tumour tissue. Interestingly, only the ARK5-overexpressing PANC-1 cell line tumour 
showed invasion and metastasis in nude mice, although Akt was activated in tumours 
derived from both PANC-1 and ARK5-overexpressing PANC-1 cell lines. 
Suzuki et al. [21] have investigated the mechanisms of induction of cell survival by protein 
kinase ARK5 and have shown that ARK5 suppresses the apoptosis induced by nutrient 
starvation and death receptors via inhibition of caspase 8 activation. Thus, human hepatoma 
HepG2 cells undergo necrotic cell death within 24 h after the start of glucose starvation, and 
the cell death signaling has been found to be mediated by death-receptor-independent 
activation of caspase 8. When HepG2 cells were transfected with ARK5 expression vector 
and subjected to several cell death stimuli, ARK5 was found to suppress cell death by 
glucose starvation and TNF-alpha, but not by camptothecin or doxorubicin. Western 
blotting analysis revealed that glucose starvation induced Bid cleavage and FLIP 
degradation following caspase 8 activation in a time-dependent manner, and ARK5 
overexpression clearly delayed Bid cleavage, FLIP degradation, and caspase 8 activation. 
These results demonstrated that cell survival induced by ARK5 is, at least in part, due to 
inhibition of caspase 8 activation. 
AMP-activated protein kinase family member 5 also negatively regulates procaspase-6 by 
phosphorylation at serine 257, leading to resistance to the FasL/Fas system the key 
regulator promoting cell death and cell survival [22]. Fas is a type I transmembrane protein 
mediating intracellular cell death signalling upon the stimulation of Fas ligand (FasL). When 
Fas is activated by the ligation of FasL, an intracellular interaction of Fas death domain (Fas-
DD), FADD, and caspase-8 (death inducing signalling complex (DISC) recruitment) is 
initiated for the activation of executioner caspase; and cellular FLIP is well known as the 
inhibitor of DISC recruitment. The serine/threonine protein kinase Akt induces cell survival 
as a result of phosphorylation and several cell death-associated factors, such as Bad, 
caspase-9 and Forkhead, upon the stimulation of growth factor receptor and integrin-
induced cell signaling. Although active caspase-6 overexpression induced cell death in 
SW480 and DLD-1 cell lines, SW480 cells, but not DLD-1 cells, exhibite strong resistance to 
procaspase-6 overexpression. Moreover, mutant caspase-6, in which the serine 257 was 
substituted by alanine (caspase-6/SA), induced cell death and FLIP degradation, even in 
SW480 cells. Active ARK5 was found to phosphorylate wild-type caspase-6 in vitro, but not 
caspase-6/SA, and the prevented activation of caspase-6 was promoted due to its 
phosphorylation by active ARK5 in vitro.  
AMPK-related kinases NUAK1 and many others (including MARK/PAR-1) are regulated 
by protein kinase LKB1 and USP9X [23, 24]. Moreover, there is data that the LKB1-NUAK 
pathway plays important role in controlling myosin phosphatase complexes and cell 
adhesion [34]. NUAK1 regulates ploidy and senescence; cells that constitutively express 
NUAK1 suffer gross aneuploidies and show diminished expression of the genomic stability 
regulator LATS1, whereas depletion of NUAK1 with shRNA exerts opposite effects [17].  
AMP-activated protein kinase-related kinase 5 (ARK5/NUAK1) is expressed in rat skeletal 
muscle and phosphorylated by electrically elicited contractions and 5-aminoimidazole-4-
carboxamide-1-beta-d-ribofuranoside (AICAR). Increased phosphorylation of ARK5 by 
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
57 
muscle contractions or exposure to AICAR, however, is insufficient to activate this protein 
kinase in skeletal muscle, suggesting that some other modification (e.g., phosphorylation on 
tyrosine or by Akt) may be necessary for its activity in muscle [62]. 
4. Conclusions 
NUAK family SNF1-like kinase includes two kinases, NUAK1 and NUAK2; both are 
members of AMP-activated protein kinases which are related to serine/threonine protein 
kinases. The sucrose-non-fermenting protein kinase (SNF1)/AMP-activated protein kinase-
related kinase (SNF1/AMP-activated protein kinase; SNARK) is a member 4 of AMPK 
kinases (NUAK family SNF1-like kinase 2; NUAK2). SNF1-like kinase 1 (NUAK1) is an 
AMP-activated protein kinase family member 5, ARK5. Protein kinase NUAK2 (SNARK) is 
a molecular component of the cellular stress response and an important regulator of whole-
body metabolism. Protein kinase SNARK was consistently localized in the nuclei. It has 
been shown that the nuclear localizing SNARK alters transcriptome profiles. It therefore 
represents a NF-B-regulated anti-apoptotic gene that contributes to the tumour-promoting 
activity of death receptor CD95 in apoptosis-resistant tumour cells and plays an important 
role in cancer development and tumour progression. SNARK affects tumour growth, 
migration, and clinical outcome of human melanoma. Protein kinase SNARK is also 
activated by muscle contraction and is a unique mediator of contraction-stimulated glucose 
transport in skeletal muscle. Moreover, association between AMP kinase-related kinase 
SNARK and myosin phosphatase Rho-interacting protein reveals a novel mechanism for 
regulation of actin stress fibers via activation of myosin light chain phosphatase. Protein 
kinase NUAK1 (ARK5) regulates ploidy and senescence, tumour cell survival, malignancy 
and invasion downstream of Akt signalling and suppresses apoptosis induced by nutrient 
starvation and death receptors via inhibition of caspase-8 and caspase-6 activation. It is 
interesting to note that the expression of SNARK is a sensitive marker of silver nanoparticles 
and methyl tert-butyl ether toxic effect.  
5. References 
[1] Mizoguchi, T., Putterill, J. and Ohkoshi, Y. (2006) Kinase and phosphatase: the cog and 
spring of the circadian clock. Int. Rev. Cytol., 250, 47–72.  
[2] Walton, K.M., Fisher, K., Rubitski, D., Marconi, M., Meng, Q.J., Sládek, M., Adams, J., 
Bass, M., Chandrasekaran, R., Butler, T., Griffor, M., Rajamohan, F., Serpa, M., 
Chen, Y., Claffey, M., Hastings, M., Loudon, A., Maywood, E., Ohren, J., Doran, A. 
and Wager, T.T. (2009) Selective inhibition of casein kinase 1 epsilon minimally 
alters circadian clock period. J. Pharmacol. Ex. Ther., 330, 430–439. 
[3] Meng, Q.J., Maywood, E.S., Bechtold, D.A., Lu, W.Q., Li, J., Gibbs, J.E., Dupré, S.M., 
Chesham, J.E., Rajamohan, F., Knafels, J., Sneed, B., Zawadzke, L.E., Ohren, J.F., 
Walton, K.M., Wager, T.T., Hastings, M.H. and Loudon, A.S. (2010) Entrainment of 
disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. 
Proc. Natl. Acad. Sci. U.S.A., 107, 15240–15245.  
[4] Huang, W., Ramsey, K.M. and Marcheva, B. (2011) Circadian rhythms, sleep, and 
metabolism. J. Clin. Invest., 121, 2133–2141. 
[5] Kovac J., Husse J., Oster H. (2009) A time to fast, a time to feast: the crosstalk between 





[6] Hardie, G. D., Carling, D. and Carlson, M. (1998) The AMP-activated/SNF1 protein 
kinase subfamily : metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 
821-855. 
[7] Lefebvre, D.L. and Rosen, C.F. (2005) Regulation of SNARK activity in response to 
cellular stresses. Biochim. Biophys. Acta, 1724, 71–85. 
[8] Egan, B. and Zierath, J.R. (2009) Hunting for the SNARK in metabolic disease. Am. J. 
Physiol. Endocrinol. Metab., 296, E969–E972.  
[9] Lefebvre, D.L., Bai, Y., Shahmolky, N., Sharma, M., Poon, R., Drucker, D.J. and Rosen, 
C.F. (2001) Identification and characterization of a novel sucrose-non-fermenting 
protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. 
Biochem. J., 355, 297–305.  
[10] Sanz, P. (2008) AMP-activated protein kinase: structure and regulation. Curr. Protein 
Pept. Sci., 9, 478–492.  
[11] Rune, A., Osler, M.E., Fritz, T. and Zierath, J.R. (2009) Regulation of skeletal muscle 
sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) 
by metabolic stress and diabetes. Diabetologia, 52, 2182–2189.  
[12] Kuga, W., Tsuchihara, K., Ogura, T., Kanehara, S., Saito, M., Suzuki, A. and Esumi, H. 
(2008) Nuclear localization of SNARK; its impact on gene expression. Biochem. 
Biophys. Res. Commun., 377, 1062–1066. 
[13] Tsuchihara, K., Ogura, T., Fujioka, R., Fujii, S., Kuga, W., Saito, M., Ochiya, T., Ochiai, 
A., Esumi, H. (2008) Susceptibility of Snark-deficient mice to azoxymethaneinduced 
colorectal tumorigenesis and the formation of aberrant crypt foci. Cancer Sci., 99, 
677–682. 
[14] Namiki, T., Tanemura, A., Valencia, J.C., Coelho, S.G., Passeron, T., Kawaguchi, M., 
Vieira, W.D., Ishikawa, M., Nishijima, W., Izumo, T., Kaneko, Y., Katayama, I., 
Yamaguchi, Y., Yin, L., Polley, E.C., Liu, H., Kawakami, Y., Eishi, Y., Takahashi, E., 
Yokozeki, H. and Hearing, V.J. (2011) AMP kinase-related kinase NUAK2 affects 
tumor growth, migration, and clinical outcome of human melanoma. Proc. Natl. 
Acad. Sci. U.S.A., 108, 6597–6602.  
[15] Minchenko, D., Bozhko, I., Zinchenko, T., Yavorovsky, O., Minchenko, O. (2011) 
Expression of SNF1/AMP-activated protein kinase and casein kinase-1epsilon in 
different rat tissues is a sensitive marker of in vivo silver nanoparticles action. 
Materialwissenschaft und Werkstofftechnik, 42, N 2, 21–25.  
[16] Minchenko, O.H., Minchenko, D.O., Yavorovsky, O.P., Zavhorodny, I.V., Paustovsky, 
Y.O., Tsuchihara, K., Esumi, H. (2008) Expression of casein kinase-1� and SNARK 
in the liver, lung and heart as a marker of methyl tertbutyl ether action on the 
organism of laboratory animals. Scientific Bulletin National Bogomolets Medical 
University, 21, 21–27. 
[17] Humbert, N., Navaratnam, N., Augert, A., Da Costa, M., Martien, S., Wang, J., Martinez, 
D., Abbadie, C., Carling, D., de Launoit, Y., Gil, J. and Bernard, D. (2010) 
Regulation of ploidy and senescence by the AMPK-related kinase NUAK1. EMBO 
J., 29, 376–386.  
[18] Suzuki, A., Kusakai, G., Kishimoto, A., Lu, J., Ogura, T., Lavin, M.F. and Esumi, H. 
(2003) Identification of a novel protein kinase mediating Akt survival signaling to 
the ATM protein. J. Biol. Chem., 278, 48-–53.  
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
59 
[19] Suzuki, A., Lu, J., Kusakai, G., Kishimoto, A., Ogura, T. and Esumi, H. (2004) ARK5 is a 
tumor invasion-associated factor downstream of Akt signaling. Mol. Cell. Biol., 24, 
3526–3535.  
[20] Kusakai, G., Suzuki, A., Ogura, T., Kaminishi, M. and Esumi, H. (2004) Strong 
association of ARK5 with tumor invasion and metastasis. J. Exp. Clin. Cancer Res., 
23, 263–268. 
[21] Suzuki, A., Kusakai, G., Kishimoto, A., Lu, J., Ogura, T. and Esumi, H. (2003) ARK5 
suppresses the cell death induced by nutrient starvation and death receptors via 
inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV 
irradiation. Oncogene, 22, 6177–6182.  
[22] Suzuki, A., Kusakai, G., Kishimoto, A., Shimojo, Y., Miyamoto, S., Ogura, T., Ochiai, A. 
and Esumi, H. (2004) Regulation of caspase-6 and FLIP by the AMPK family 
member ARK5. Oncogene, 23, 7067–7075. 
[23] Al-Hakim, A.K., Zagorska, A., Chapman, L., Deak, M., Peggie, M. and Alessi, D.R. 
(2008) Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-
linked polyubiquitin chains. Biochem. J., 411, 249–260.  
[24] Lizcano, J.M., Goransson, O., Toth, R., Deak, M., Morrice, N.A., Boudeau, J., Hawley, 
S.A., Udd, L., Makela, T.P., Hardie, D.G. and Alessi, D.R. (2004) LKB1 is a master 
kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. 
EMBO J., 23, 833–843.  
[25] Williams, T. and Brenman, J.E. (2008) LKB1 and AMPK in cell polarity and division, 
Trends Cell. Biol., 18, 193–198. 
[26] Legembre, P., Schickel, R., Barnhart, B.C. and Peter, M.E. (2004) Identification of 
SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase 
involved in CD95-induced motility and invasiveness. J. Biol. Chem., 279, 46742–
46747.  
[27] Kim, J.H., Kim, W.S. and Park, C. (2008) SNARK, a novel downstream molecule of EBV 
latent membrane protein 1, is associated with resistance to cancer cell death. Leuk. 
Lymphoma, 49, 1392–1398. 
[28] Denko, N.C. (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature 
Reviews Cancer, 8, 705–713. 
[29] Sakamoto, K., McCarthy, A., Smith, D., Green, K.A., Grahame Hardie, D., Ashworth, A. 
and Alessi, D.R. (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK 
activation and glucose uptake during contraction. EMBO J., 24, 1810–1820.  
[30] Koh, H.J., Toyoda, T., Fujii, N., Jung, M.M., Rathod, A., Middelbeek, R.J., Lessard, S.J., 
Treebak, J.T., Tsuchihara, K., Esumi, H., Richter, E.A., Wojtaszewski, J.F., 
Hirshman, M.F. and Goodyear, L.J. (2010) Sucrose nonfermenting AMPK-related 
kinase (SNARK) mediates contraction-stimulated glucose transport in mouse 
skeletal muscle. Proc. Natl. Acad. Sci. U.S.A., 107, 15541–15546.  
[31] Yamamoto,H., Takashima,S., Shintani,Y., Yamazaki,S., Seguchi,O., Nakano,A., Higo,S., 
Kato,H., Liao, Y., Asano, Y., Minamino, T., Matsumura, Y., Takeda, H. and 
Kitakaze, M. (2008) Identification of a novel substrate for TNFalpha-induced kinase 
NUAK2. Biochem. Biophys. Res. Commun., 365, 541–547.  
[32] Suzuki, A., Kusakai, G., Kishimoto, A., Minegichi, Y., Ogura, T. and Esumi, H. (2003) 





[6] Hardie, G. D., Carling, D. and Carlson, M. (1998) The AMP-activated/SNF1 protein 
kinase subfamily : metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 
821-855. 
[7] Lefebvre, D.L. and Rosen, C.F. (2005) Regulation of SNARK activity in response to 
cellular stresses. Biochim. Biophys. Acta, 1724, 71–85. 
[8] Egan, B. and Zierath, J.R. (2009) Hunting for the SNARK in metabolic disease. Am. J. 
Physiol. Endocrinol. Metab., 296, E969–E972.  
[9] Lefebvre, D.L., Bai, Y., Shahmolky, N., Sharma, M., Poon, R., Drucker, D.J. and Rosen, 
C.F. (2001) Identification and characterization of a novel sucrose-non-fermenting 
protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. 
Biochem. J., 355, 297–305.  
[10] Sanz, P. (2008) AMP-activated protein kinase: structure and regulation. Curr. Protein 
Pept. Sci., 9, 478–492.  
[11] Rune, A., Osler, M.E., Fritz, T. and Zierath, J.R. (2009) Regulation of skeletal muscle 
sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) 
by metabolic stress and diabetes. Diabetologia, 52, 2182–2189.  
[12] Kuga, W., Tsuchihara, K., Ogura, T., Kanehara, S., Saito, M., Suzuki, A. and Esumi, H. 
(2008) Nuclear localization of SNARK; its impact on gene expression. Biochem. 
Biophys. Res. Commun., 377, 1062–1066. 
[13] Tsuchihara, K., Ogura, T., Fujioka, R., Fujii, S., Kuga, W., Saito, M., Ochiya, T., Ochiai, 
A., Esumi, H. (2008) Susceptibility of Snark-deficient mice to azoxymethaneinduced 
colorectal tumorigenesis and the formation of aberrant crypt foci. Cancer Sci., 99, 
677–682. 
[14] Namiki, T., Tanemura, A., Valencia, J.C., Coelho, S.G., Passeron, T., Kawaguchi, M., 
Vieira, W.D., Ishikawa, M., Nishijima, W., Izumo, T., Kaneko, Y., Katayama, I., 
Yamaguchi, Y., Yin, L., Polley, E.C., Liu, H., Kawakami, Y., Eishi, Y., Takahashi, E., 
Yokozeki, H. and Hearing, V.J. (2011) AMP kinase-related kinase NUAK2 affects 
tumor growth, migration, and clinical outcome of human melanoma. Proc. Natl. 
Acad. Sci. U.S.A., 108, 6597–6602.  
[15] Minchenko, D., Bozhko, I., Zinchenko, T., Yavorovsky, O., Minchenko, O. (2011) 
Expression of SNF1/AMP-activated protein kinase and casein kinase-1epsilon in 
different rat tissues is a sensitive marker of in vivo silver nanoparticles action. 
Materialwissenschaft und Werkstofftechnik, 42, N 2, 21–25.  
[16] Minchenko, O.H., Minchenko, D.O., Yavorovsky, O.P., Zavhorodny, I.V., Paustovsky, 
Y.O., Tsuchihara, K., Esumi, H. (2008) Expression of casein kinase-1� and SNARK 
in the liver, lung and heart as a marker of methyl tertbutyl ether action on the 
organism of laboratory animals. Scientific Bulletin National Bogomolets Medical 
University, 21, 21–27. 
[17] Humbert, N., Navaratnam, N., Augert, A., Da Costa, M., Martien, S., Wang, J., Martinez, 
D., Abbadie, C., Carling, D., de Launoit, Y., Gil, J. and Bernard, D. (2010) 
Regulation of ploidy and senescence by the AMPK-related kinase NUAK1. EMBO 
J., 29, 376–386.  
[18] Suzuki, A., Kusakai, G., Kishimoto, A., Lu, J., Ogura, T., Lavin, M.F. and Esumi, H. 
(2003) Identification of a novel protein kinase mediating Akt survival signaling to 
the ATM protein. J. Biol. Chem., 278, 48-–53.  
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
59 
[19] Suzuki, A., Lu, J., Kusakai, G., Kishimoto, A., Ogura, T. and Esumi, H. (2004) ARK5 is a 
tumor invasion-associated factor downstream of Akt signaling. Mol. Cell. Biol., 24, 
3526–3535.  
[20] Kusakai, G., Suzuki, A., Ogura, T., Kaminishi, M. and Esumi, H. (2004) Strong 
association of ARK5 with tumor invasion and metastasis. J. Exp. Clin. Cancer Res., 
23, 263–268. 
[21] Suzuki, A., Kusakai, G., Kishimoto, A., Lu, J., Ogura, T. and Esumi, H. (2003) ARK5 
suppresses the cell death induced by nutrient starvation and death receptors via 
inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV 
irradiation. Oncogene, 22, 6177–6182.  
[22] Suzuki, A., Kusakai, G., Kishimoto, A., Shimojo, Y., Miyamoto, S., Ogura, T., Ochiai, A. 
and Esumi, H. (2004) Regulation of caspase-6 and FLIP by the AMPK family 
member ARK5. Oncogene, 23, 7067–7075. 
[23] Al-Hakim, A.K., Zagorska, A., Chapman, L., Deak, M., Peggie, M. and Alessi, D.R. 
(2008) Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-
linked polyubiquitin chains. Biochem. J., 411, 249–260.  
[24] Lizcano, J.M., Goransson, O., Toth, R., Deak, M., Morrice, N.A., Boudeau, J., Hawley, 
S.A., Udd, L., Makela, T.P., Hardie, D.G. and Alessi, D.R. (2004) LKB1 is a master 
kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. 
EMBO J., 23, 833–843.  
[25] Williams, T. and Brenman, J.E. (2008) LKB1 and AMPK in cell polarity and division, 
Trends Cell. Biol., 18, 193–198. 
[26] Legembre, P., Schickel, R., Barnhart, B.C. and Peter, M.E. (2004) Identification of 
SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase 
involved in CD95-induced motility and invasiveness. J. Biol. Chem., 279, 46742–
46747.  
[27] Kim, J.H., Kim, W.S. and Park, C. (2008) SNARK, a novel downstream molecule of EBV 
latent membrane protein 1, is associated with resistance to cancer cell death. Leuk. 
Lymphoma, 49, 1392–1398. 
[28] Denko, N.C. (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature 
Reviews Cancer, 8, 705–713. 
[29] Sakamoto, K., McCarthy, A., Smith, D., Green, K.A., Grahame Hardie, D., Ashworth, A. 
and Alessi, D.R. (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK 
activation and glucose uptake during contraction. EMBO J., 24, 1810–1820.  
[30] Koh, H.J., Toyoda, T., Fujii, N., Jung, M.M., Rathod, A., Middelbeek, R.J., Lessard, S.J., 
Treebak, J.T., Tsuchihara, K., Esumi, H., Richter, E.A., Wojtaszewski, J.F., 
Hirshman, M.F. and Goodyear, L.J. (2010) Sucrose nonfermenting AMPK-related 
kinase (SNARK) mediates contraction-stimulated glucose transport in mouse 
skeletal muscle. Proc. Natl. Acad. Sci. U.S.A., 107, 15541–15546.  
[31] Yamamoto,H., Takashima,S., Shintani,Y., Yamazaki,S., Seguchi,O., Nakano,A., Higo,S., 
Kato,H., Liao, Y., Asano, Y., Minamino, T., Matsumura, Y., Takeda, H. and 
Kitakaze, M. (2008) Identification of a novel substrate for TNFalpha-induced kinase 
NUAK2. Biochem. Biophys. Res. Commun., 365, 541–547.  
[32] Suzuki, A., Kusakai, G., Kishimoto, A., Minegichi, Y., Ogura, T. and Esumi, H. (2003) 





conversion by SNARK, the fourth member of the AMP-activated protein kinase 
catalytic subunit family. Biochem. Biophys. Res. Commun., 311, 156–161.  
[33] Vallenius, T., Vaahtomeri, K., Kovac, B., Osiceanu, A.M., Viljanen, M. and Makela, T.P. 
(2011) An association between NUAK2 and MRIP reveals a novel mechanism for 
regulation of actin stress fibers. J. Cell. Sci., 124, 384–393.  
[34] Zagorska, A., Deak, M., Campbell, D.G., Banerjee, S., Hirano, M. Aizawa, S., Prescott, 
A.R. and Alessi, D.R. (2010) New roles for the LKB1-NUAK pathway in controlling 
myosin phosphatase complexes and cell adhesion. Sci. Signal, 3, RA25.  
[35] Ichinoseki-Sekine, N., Naito, H., Tsuchihara, K., Kobayashi, I., Ogura Y., Kakigi, R., 
Kurosaka, M., Fujioka, R. and Esumi, H. (2009) Provision of a voluntary exercise 
environment enhances running activity and prevents obesity in Snark-deficient 
mice. Am. J. Physiol. Endocrinol. Metab., 296, E1013–E1021. 
[36] Kahn, B.B., Alquier, T., Carling, D. and Hardie, D.G. (2005) AMP-activated protein 
kinase: ancient energy gauge provides clues to modern understanding of 
metabolism. Cell Metab., 1, 15–25.  
[37] Minchenko, D.O., Tsuchihara, K., Komisarenko, S.V., Moenner, M., Bikfalvi, A., Esumi, 
H., Minchenko O.H. (2008) Unique alternative splice variants of mouse PFKFB-3 
mRNA: tissue specific expression. Scientific Bulletin National Bogomolets Medical 
University, 20, 22–31. 
[38] Minchenko, D.О., Bobarykina, A.Y., Kundieva, A.V., Lypova N.M., Bozhko, І.V., 
Ratushna, О.О. and Minchenko O.H. (2009) 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase genes: structural organization, expression and regulation of the 
expression. Studia Biologica, 3(3), 123–140. 
[39] Rider, M.H., Bertrand, L., Vertommen, D., Michels, P.A., Rousseau, G.G. and Hue, L. 
(2004) 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase: head-head with a 
bifunctional enzyme that controls glycolysis. Biochem. J., 381, 561–579. 
[40] Minchenko, A.G., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V.E. 
and Caro, J. (2002) Hypoxia-inducible factor-1-mediated expression of the 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible 
role in the Warburg effect. J. Biol. Chem., 277, 6183–6187. 
[41] Bobarykina, A.Y., Minchenko, D.O., Opentanova, I.L., Moenner, M., Caro, J., Esumi, H. 
and Minchenko, O.H. (2006) Hypoxic regulation of PFKFB-3 and PFKFB-4 gene 
expression in gastric and pancreatic cancer cell lines and expression of PFKFB 
genes in gastric cancers. Acta Biochim. Pol., 53, 789–799. 
[42] Minchenko, O., Opentanova, I. and Caro, J. (2003) Hypoxic regulation of the 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) 
expression in vivo. FEBS Lett., 554, 264–270. 
[43] Minchenko, O.H., Ochiai, A., Opentanova, I.L., Ogura, T., Minchenko, D.O., Caro, J., 
Komisarenko, S.V. and Esumi, H. (2005) Overexpression of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant 
tumors. Biochimie, 87, 1005–1010.  
[44] Minchenko, D.O., Bobarykina, A.Y., Senchenko, T.Y., Hubenya, O.V., Tsuchihara, K., 
Ochiai, A., Moenner, M., Esumi, H. and Minchenko, O.H. (2009) Expression of the 
VEGF, Glut1 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 
in human cancers of the lung, colon and stomach. Studia Biologica, 3(1), 25–34. 
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
61 
[45] Atsumi, T., Chesney, J., Metz, C., Leng, L., Donnelly, S., Makita, Z., Mitchell, R. and 
Bucala, R. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase-3 (iPFK-2; PFKFB3) in human cancers. Cancer Res., 62, 5881–
5887. 
[46] Bando, H., Atsumi, T., Nishio, T., Niwa, H., Mishima, S., Shimizu, C., Yoshioka, N., 
Bucala, R. and Koike, T. (2005) Phosphorylation of the 6-phosphofructo-2-
kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in 
human cancer. Clin. Cancer Res., 11, 5784–5792.  
[47] Kessler, R., Bleichert, F., Warnke, J.P. and Eschrich, K. (2008) 6-Phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade 
astrocytomas. J. Neurooncol., 86, 257–264.  
[48] Duran, J., Gómez, M., Navarro-Sabate, A., Riera-Sans, L., Obach, M., Manzano, A., 
Perales, J.C. and Bartrons, R. (2008) Characterization of a new liver- and kidney-
specific pfkfb3 isozyme that is downregulated by cell proliferation and 
dedifferentiation. Biochem. Biophys. Res. Commun., 367, 748–754.  
[49] Shimada, A., Kawamura, N., Okajima, M., Kaewamatawong, T., Inoue, H. and Morita, 
T. (2006) Translocation pathway of the intratracheally instilled ultrafine particles 
from the lung into the blood circulation in the mouse. Toxicol. Pathol., 34, 949–957.  
[50] Tang, J., Xiong, L., Wang, S., Wang, J., Liu, L., Li, J., Yuan, F. and Xi, T. (2009) 
Distribution, translocation and accumulation of silver nanoparticles in rats. J. 
Nanosci. Nanotechnol., 9, 4924–4932. 
[51] Gaiser, B.K., Fernandes, T.F., Jepson, M., Lead, J.R., Tyler, C.R. and Stone, V. (2009) 
Assessing exposure, uptake and toxicity of silver and cerium dioxide nanoparticles 
from contaminated environments. Environ. Health., 8, Suppl. 1, S2. 
[52] Lubick, N. (2008) Nanosilver toxicity: ions, nanoparticles or both? Environ. Sci. Technol., 
42, 8617. 
[53] Powers, C.M., Wrench, N., Ryde, I.T., Smith, A.M., Seidler, F.J. and Slotkin, T.A. (2010) 
Silver impairs neurodevelopment: studies in PC12 cells. Environ Health Perspect., 
118, 73–79.  
[54] Ahamed, M., Posgai, R., Gorey, T.J., Nielsen, M., Hussain, S.M. and Rowe, J.J. (2010) 
Silver nanoparticles induced heat shock protein 70, oxidative stress and apoptosis 
in Drosophila melanogaster. Toxicol. Appl. Pharmacol., 242, 263–269. 
[55] Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., Shokat, K.M., 
Lavail, M.M. and Walter, P. (2007) IRE1 signaling affects cell fate during the 
unfolded protein response. Science, 318, 944–949.  
[56] Aragón, T., van Anken, E., Pincus, D., Serafimova, I.M., Korennykh, A.V., Rubio, C.A. 
and Walter, P. (2009) Messenger RNA targeting to endoplasmic reticulum stress 
signalling sites. Nature, 457, 736–740. 
[57] Acosta-Alvear, D., Zhou, Y., Blais, A., Tsikitis, M., Lents, N.H., Arias, C., Lennon, C.J., 
Kluger, Y. and Dynlacht, D.D. (2007) XBP1 controls diverse cell type- and 
condition-specific transcriptional regulatory networks. Mol. Cell, 27, 53–66.  
[58] McGregor, D. (2007) Ethyl tertiary-butyl ether: a toxicological review. Critical Review 
Toxicol., 2007; 37(4): 287–312. 
[59] Hutcheon, D. E., Arnold, J. D., Hove, W. and Boyle, J. 3rd. (1996) Disposition, 
metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for 





conversion by SNARK, the fourth member of the AMP-activated protein kinase 
catalytic subunit family. Biochem. Biophys. Res. Commun., 311, 156–161.  
[33] Vallenius, T., Vaahtomeri, K., Kovac, B., Osiceanu, A.M., Viljanen, M. and Makela, T.P. 
(2011) An association between NUAK2 and MRIP reveals a novel mechanism for 
regulation of actin stress fibers. J. Cell. Sci., 124, 384–393.  
[34] Zagorska, A., Deak, M., Campbell, D.G., Banerjee, S., Hirano, M. Aizawa, S., Prescott, 
A.R. and Alessi, D.R. (2010) New roles for the LKB1-NUAK pathway in controlling 
myosin phosphatase complexes and cell adhesion. Sci. Signal, 3, RA25.  
[35] Ichinoseki-Sekine, N., Naito, H., Tsuchihara, K., Kobayashi, I., Ogura Y., Kakigi, R., 
Kurosaka, M., Fujioka, R. and Esumi, H. (2009) Provision of a voluntary exercise 
environment enhances running activity and prevents obesity in Snark-deficient 
mice. Am. J. Physiol. Endocrinol. Metab., 296, E1013–E1021. 
[36] Kahn, B.B., Alquier, T., Carling, D. and Hardie, D.G. (2005) AMP-activated protein 
kinase: ancient energy gauge provides clues to modern understanding of 
metabolism. Cell Metab., 1, 15–25.  
[37] Minchenko, D.O., Tsuchihara, K., Komisarenko, S.V., Moenner, M., Bikfalvi, A., Esumi, 
H., Minchenko O.H. (2008) Unique alternative splice variants of mouse PFKFB-3 
mRNA: tissue specific expression. Scientific Bulletin National Bogomolets Medical 
University, 20, 22–31. 
[38] Minchenko, D.О., Bobarykina, A.Y., Kundieva, A.V., Lypova N.M., Bozhko, І.V., 
Ratushna, О.О. and Minchenko O.H. (2009) 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase genes: structural organization, expression and regulation of the 
expression. Studia Biologica, 3(3), 123–140. 
[39] Rider, M.H., Bertrand, L., Vertommen, D., Michels, P.A., Rousseau, G.G. and Hue, L. 
(2004) 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase: head-head with a 
bifunctional enzyme that controls glycolysis. Biochem. J., 381, 561–579. 
[40] Minchenko, A.G., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V.E. 
and Caro, J. (2002) Hypoxia-inducible factor-1-mediated expression of the 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible 
role in the Warburg effect. J. Biol. Chem., 277, 6183–6187. 
[41] Bobarykina, A.Y., Minchenko, D.O., Opentanova, I.L., Moenner, M., Caro, J., Esumi, H. 
and Minchenko, O.H. (2006) Hypoxic regulation of PFKFB-3 and PFKFB-4 gene 
expression in gastric and pancreatic cancer cell lines and expression of PFKFB 
genes in gastric cancers. Acta Biochim. Pol., 53, 789–799. 
[42] Minchenko, O., Opentanova, I. and Caro, J. (2003) Hypoxic regulation of the 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) 
expression in vivo. FEBS Lett., 554, 264–270. 
[43] Minchenko, O.H., Ochiai, A., Opentanova, I.L., Ogura, T., Minchenko, D.O., Caro, J., 
Komisarenko, S.V. and Esumi, H. (2005) Overexpression of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant 
tumors. Biochimie, 87, 1005–1010.  
[44] Minchenko, D.O., Bobarykina, A.Y., Senchenko, T.Y., Hubenya, O.V., Tsuchihara, K., 
Ochiai, A., Moenner, M., Esumi, H. and Minchenko, O.H. (2009) Expression of the 
VEGF, Glut1 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 
in human cancers of the lung, colon and stomach. Studia Biologica, 3(1), 25–34. 
 
SNF1/AMP-Activated Protein Kinases: Genes, Expression and Biological Role 
 
61 
[45] Atsumi, T., Chesney, J., Metz, C., Leng, L., Donnelly, S., Makita, Z., Mitchell, R. and 
Bucala, R. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase-3 (iPFK-2; PFKFB3) in human cancers. Cancer Res., 62, 5881–
5887. 
[46] Bando, H., Atsumi, T., Nishio, T., Niwa, H., Mishima, S., Shimizu, C., Yoshioka, N., 
Bucala, R. and Koike, T. (2005) Phosphorylation of the 6-phosphofructo-2-
kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in 
human cancer. Clin. Cancer Res., 11, 5784–5792.  
[47] Kessler, R., Bleichert, F., Warnke, J.P. and Eschrich, K. (2008) 6-Phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade 
astrocytomas. J. Neurooncol., 86, 257–264.  
[48] Duran, J., Gómez, M., Navarro-Sabate, A., Riera-Sans, L., Obach, M., Manzano, A., 
Perales, J.C. and Bartrons, R. (2008) Characterization of a new liver- and kidney-
specific pfkfb3 isozyme that is downregulated by cell proliferation and 
dedifferentiation. Biochem. Biophys. Res. Commun., 367, 748–754.  
[49] Shimada, A., Kawamura, N., Okajima, M., Kaewamatawong, T., Inoue, H. and Morita, 
T. (2006) Translocation pathway of the intratracheally instilled ultrafine particles 
from the lung into the blood circulation in the mouse. Toxicol. Pathol., 34, 949–957.  
[50] Tang, J., Xiong, L., Wang, S., Wang, J., Liu, L., Li, J., Yuan, F. and Xi, T. (2009) 
Distribution, translocation and accumulation of silver nanoparticles in rats. J. 
Nanosci. Nanotechnol., 9, 4924–4932. 
[51] Gaiser, B.K., Fernandes, T.F., Jepson, M., Lead, J.R., Tyler, C.R. and Stone, V. (2009) 
Assessing exposure, uptake and toxicity of silver and cerium dioxide nanoparticles 
from contaminated environments. Environ. Health., 8, Suppl. 1, S2. 
[52] Lubick, N. (2008) Nanosilver toxicity: ions, nanoparticles or both? Environ. Sci. Technol., 
42, 8617. 
[53] Powers, C.M., Wrench, N., Ryde, I.T., Smith, A.M., Seidler, F.J. and Slotkin, T.A. (2010) 
Silver impairs neurodevelopment: studies in PC12 cells. Environ Health Perspect., 
118, 73–79.  
[54] Ahamed, M., Posgai, R., Gorey, T.J., Nielsen, M., Hussain, S.M. and Rowe, J.J. (2010) 
Silver nanoparticles induced heat shock protein 70, oxidative stress and apoptosis 
in Drosophila melanogaster. Toxicol. Appl. Pharmacol., 242, 263–269. 
[55] Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., Shokat, K.M., 
Lavail, M.M. and Walter, P. (2007) IRE1 signaling affects cell fate during the 
unfolded protein response. Science, 318, 944–949.  
[56] Aragón, T., van Anken, E., Pincus, D., Serafimova, I.M., Korennykh, A.V., Rubio, C.A. 
and Walter, P. (2009) Messenger RNA targeting to endoplasmic reticulum stress 
signalling sites. Nature, 457, 736–740. 
[57] Acosta-Alvear, D., Zhou, Y., Blais, A., Tsikitis, M., Lents, N.H., Arias, C., Lennon, C.J., 
Kluger, Y. and Dynlacht, D.D. (2007) XBP1 controls diverse cell type- and 
condition-specific transcriptional regulatory networks. Mol. Cell, 27, 53–66.  
[58] McGregor, D. (2007) Ethyl tertiary-butyl ether: a toxicological review. Critical Review 
Toxicol., 2007; 37(4): 287–312. 
[59] Hutcheon, D. E., Arnold, J. D., Hove, W. and Boyle, J. 3rd. (1996) Disposition, 
metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for 





[60] Minchenko, D.O., Mykhalchenko, V.G., Tsuchihara, K., Kanehara, S., Yavorovsky, O.P., 
Zavgorodny, I.V., Paustovsky, Y.O., Komisarenko, S.V., Esumi, H. and Minchenko, 
O.H. (2008) Unique alternative splice variants of rat 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-4 mRNA. Ukr. Biochem. J., 80(4), 66–73. 
[61] Suzuki, A., Ogura T. and Esumi, H. (2006) NDR2 acts as the upstream kinase of ARK5 
during insulin-like growth factor-1 signaling. J. Biol. Chem., 281, 13915–13921.  
[62] Fisher, J.S., Ju, J.S., Oppelt, P.J., Smith, J.L., Suzuki, A. and Esumi, H. (2005) Muscle 
contractions, AICAR, and insulin cause phosphorylation of an AMPK-related 
kinase. Am. J. Physiol. Endocrinol. Metab., 289, E986-E992. 
3 
Alternating Phosphorylation  
with O-GlcNAc Modification:  
Another Way to Control Protein Function 
Victor V. Lima and Rita C. Tostes* 
Department of Pharmacology, School of Medicine of Ribeirao Preto,  
University of Sao Paulo, Ribeirao Preto-SP,  
Brazil 
1. Introduction 
As widely known, reversible phosphorylation of proteins, or the addition of a phosphate 
(PO43-) molecule to a polar R group of an amino acid residue, is an important regulatory 
mechanism that switches many enzymes and receptors "on" or "off" and therefore controls a 
range of cellular functions. Regulatory roles of phosphorylation include biological 
thermodynamics of energy-requiring reactions, enzyme and receptors’ activation or inhibition, 
protein-protein interaction via recognition domains, protein degradation. 
Kinases and phosphatases are involved in this process and these enzymes induce 
phosphorylation and dephosphorylation, respectively, of target proteins. Phosphorylation 
usually occurs on serine, threonine, and tyrosine (O-linked), or histidine (N-linked) residues 
of proteins, although arginine and lysine residues can also be phosphorylated. 
O-GlcNAcylation, or glycosylation with O-linked β-N-acetylglucosamine, is similar to 
protein phosphorylation in that both modifications occur on serine and threonine residues, 
both are dynamically added and removed in response to cellular signals, and both alter the 
function and associations of the modified protein. O-GlcNAcylation also modulates many 
cellular functions by mechanisms that include protein targeting to specific substrates, 
transient complex formation with other proteins, subcellular compartmentalization upon 
glycosylation of specific proteins and a complex interplay with protein O-phosphorylation, 
the main topic of this chapter. Accordingly, in this chapter we will discuss the biology of the 
O-GlcNAc modification, the interplay between O-GlcNAcylation and O-phosphorylation, 
signaling pathways modified by O-GlcNAcylation, and the physiological implications of 
alternating O-GlcNAcylation and O-phosphorylation. 
2. The biology of the O-GlcNAc  
Glycosylation is the site-specific enzymatic addition of saccharides [from the Greek word 
sákkharon (meaning sugar); also known in biochemistry as carbohydrates or hydrates of 
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thermodynamics of energy-requiring reactions, enzyme and receptors’ activation or inhibition, 
protein-protein interaction via recognition domains, protein degradation. 
Kinases and phosphatases are involved in this process and these enzymes induce 
phosphorylation and dephosphorylation, respectively, of target proteins. Phosphorylation 
usually occurs on serine, threonine, and tyrosine (O-linked), or histidine (N-linked) residues 
of proteins, although arginine and lysine residues can also be phosphorylated. 
O-GlcNAcylation, or glycosylation with O-linked β-N-acetylglucosamine, is similar to 
protein phosphorylation in that both modifications occur on serine and threonine residues, 
both are dynamically added and removed in response to cellular signals, and both alter the 
function and associations of the modified protein. O-GlcNAcylation also modulates many 
cellular functions by mechanisms that include protein targeting to specific substrates, 
transient complex formation with other proteins, subcellular compartmentalization upon 
glycosylation of specific proteins and a complex interplay with protein O-phosphorylation, 
the main topic of this chapter. Accordingly, in this chapter we will discuss the biology of the 
O-GlcNAc modification, the interplay between O-GlcNAcylation and O-phosphorylation, 
signaling pathways modified by O-GlcNAcylation, and the physiological implications of 
alternating O-GlcNAcylation and O-phosphorylation. 
2. The biology of the O-GlcNAc  
Glycosylation is the site-specific enzymatic addition of saccharides [from the Greek word 
sákkharon (meaning sugar); also known in biochemistry as carbohydrates or hydrates of 
                                                 





carbon due to the chemical empirical formula Cm(H2O)n] to proteins and lipids. 
Glycosylation has many functions in a cell: it allows correct folding of proteins (some 
proteins do not fold correctly unless they are glycosylated first); confers stability (some 
unglycosylated proteins are more rapidly degraded); allows cell-cell adhesion (e.g. surface 
glycoproteins are directly involved in the biological functions of lymphocytes); and 
modulates intracellular signaling pathways (glycosylation of proteins may enhance or 
inhibit enzymes’ activities) (Spiro, 2002; Taylor & Drickamer, 2006; Varki et al., 2009). 
There are many types of glycosylation: N-linked, where the carbohydrate is attached to a 
nitrogen of asparagine or arginine side-chains; O-linked, where glycans are attached to the 
hydroxy oxygen of serine, threonine, tyrosine, hydroxylysine, or hydroxyproline side-
chains; phospho-linked, where the sugar is attached via the phosphate of a phospho-serine; 
C-linked, where the carbohydrate is added to a carbon on a tryptophan side-chain; the 
formation of a glycosylphosphatidylinositol (GPI) anchor (glypiation), where the sugar is 
linked to phosphoethanolamine, which in turn is attached to the terminal carboxyl group of 
the protein (Spiro, 2002; Taylor & Drickamer, 2006; Varki et al., 2009). However, great 
interest has been directed to O-GlcNAcylation, or glycosylation of proteins with O-linked β-
N-acetylglucosamine.  
Cellular glycoproteins were initially thought to be targeted, after their synthesis, only to 
luminal or extracellular compartments. However, in 1984, Torres and Hart, who were 
interested in characterizing the role of cell-surface saccharides in the development and 
functions of lymphocytes, described a novel carbohydrate (N-acetylglucosamine, GlcNAc)-
peptide linkage, which was present on proteins localized in the cytosol and the cyto- and 
nucleoplasmic faces of membranous organelles (Torres & Hart, 1984). In 1989, Kelly and 
Hart described that Drosophila polytene chromosomes (i.e., polytene chromosome spreads 
prepared from the salivary glands of third instar stage Drosophila melanogaster larvae) 
contained a surprisingly large amount of terminal GlcNAc residues along their lengths. 
Nearly all of the chromatin-associated GlcNAc moieties existed as single monosaccharide 
residues attached to protein by an O-linkage (O-GlcNAc) (Kelly & Hart, 1989). Also in the 
late 80’s, the glycosyltransferase responsible for the addition of GlcNAc to proteins was 
found to be oriented with its active site in the cytoplasm and the first proteins modified with 
O-GlcNAc were described (Hart et al., 1988, 1989; Hart, 1997). These initial observations, 
which indicated a functional or biological significance for the O-linkage of GlcNAc to 
proteins, led to the term O-GlcNAcylation. Accordingly, O-GlcNAcylation is currently 
defined as an unusual form of protein glycosylation, where a single-sugar [N-
acetylglucosamine (O-GlcNAc)] is added (β-attachment) to the hydroxyl moiety of serine 
(Ser) and threonine (Thr) residues of nuclear and cytoplasmic proteins.  
It is unusual in that it is found in nuclear and cytoplasmic proteins, representing the first 
reported example of glycosylated proteins found outside of the secretory channels. Unlike 
other peptide-linked monosaccharides, the β-linked GlcNAc-Ser/Thr does not become 
further substituted by other sugars, remaining a single monosaccharide modification of the 
protein to which it is attached. O-GlcNAcylation is widely dispersed among eukaryotes, 
from protozoa to higher mammals. The amino acid consensus sequence or glycosylation 
motifs for the formation of O-GlcNAc bonds have not yet been found. However, 
information relating to the polypeptide domains that favors O-GlcNAc attachment has been 
obtained and seems to involve PEST [proline (P), glutamic acid (E), serine (S), and threonine 
(T)] sequences (Haltiwanger et al., 1997; Rogers et al., 1986). 
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Results from recent proteomic studies, from different laboratories, suggest that more than 
1500 proteins in the cell are modified by O-GlcNAc. These proteins belong to almost every 
functional class of proteins including transcription or translation factors, cytoskeletal 
proteins, nuclear pore proteins, RNA polymerase II, tumor suppressors, hormone receptors, 
phosphatases, and kinases (Khidekel et al., 2007; Nandi et al., 2006; Wang et al., 2008; 
Vosseller et al., 2006). A database of O-GlcNAcylated proteins and sites, dbOGAP, was 
recently created and is primarily based on literature published since O-GlcNAcylation was 
first described in 1984. The database currently contains ~800 proteins with experimental O-
GlcNAcylation information. The O-GlcNAcylated proteins are primarily nucleocytoplasmic, 
and include membrane- and non-membrane bounded organelle-associated proteins (Wang 
et al., 2011). An O-GlcNAcylation site prediction system (O-GlcNAcScan) based on nearly 
400 O-GlcNAcylation sites was also developed (Hu, 2010). Both the database and the 
prediction system are publicly available at http://cbsb.lombardi.georgetown.edu/OGAP.html and 
http://cbsb.lombardi.georgetown.edu/filedown.php, respectively. 
The attachment of the single-sugar ß-N-acetylglucosamine via an O-linkage to Ser/Thr 
residues is controlled by two highly conserved enzymes, O-GlcNAc transferase (OGT or 
uridine diphospho-N-acetyl glucosamine; polypeptide β-N-acetylglucosaminyl transferase; 
UDP-NAc transferase) and β-N-acetylglucosaminidase (OGA or O-GlcNAcase). Whereas 
OGT catalyses the addition of O-GlcNAc to the hydroxyl group of Ser and Thr residues of a 
target protein using UDP-GlcNAc as the obligatory substrate, OGA catalyses the hydrolytic 
cleavage of O-GlcNAc from post-translationally-modified proteins (Hart et a;, 2007; Zachara 
& Hart, 2006) (Figure 1). 
A single OGT gene is located on the X chromosome in humans and mice (Kreppel et al., 
1997; Nolte & Muller, 2002). In some tissues, such as skeletal muscle, kidney, and liver, three 
distinct isoforms of OGT have been identified, including two 110-kDa subunits and one 78-
kDa subunit, which can assemble into multimers, and smaller mitochondrial isoforms 
(Kreppel & Hart, 1999, Lazarus et al., 2006; Lubas & Hanover, 2000). Each variant contains a 
C-terminal catalytic domain, but differs in the number of tetratricopeptide repeats (TPRs) 
within its N-terminal domain. The TPRs serve as protein-protein interaction modules that 
appear to target OGT to accessory proteins and potential substrates, such as the related O-
GlcNAc transferase interacting protein (OIP106) and protein phosphatase-1 (PP1) (Wells et 
al., 2004). Phylogenetic analysis of eukaryotic OGTs indicate that plants have two distinct 
OGTs, SEC (secret agent)- and SPY (spindly)-like, that originated in prokaryotes and that are 
involved in diverse plant processes, including response to hormones and environmental 
signals, circadian rhythms, development, intercellular transport and virus infection 
(Olszewski et al., 2009; Swain et al, 2001). Animals and some fungi have a SEC-like enzyme 
while plants have both. Green algae and some members of the Apicomplexa and amoebozoa 
have the SPY-like enzyme (Olszewski et al., 2009). 
The donor substrate for OGT activity, UDP-GlcNAc or uridine-diphosphate-N-
acetylglucosamine, is a terminal product of the hexosamine biosynthesis pathway (HBP – 
Figure 1). Flux through the HBP and UDP-GlcNAc levels changes rapidly in response to 
many different nutrients, such as glucose, fatty acids, and amino acids (Hanover et al., 2009) 
altering the extent of O-GlcNAcylation of many proteins. It is estimated that 2–5% of total 
cellular glucose is funneled into the HBP, although the glucose flux is potentially different in 
various cell types (Hart et al., 2007, Hanover et al., 2009). Free fatty acids can increase HBP 
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produced by fatty acid metabolism, serves as the donor for the acetylation of glucosamine in 
the formation of UDP-GlcNAc (Wang et al., 1998). Exogenously, small amounts of 
glucosamine can dramatically increase UDP-GlcNAc pools in cells (Zou et al., 2009).  
The HBP shares its first two steps with glycolysis. First, hexokinase phosphorylates glucose 
to produce glucose 6-phosphate, which is then converted into fructose 6-phosphate. At this 
point the pathways diverge, fructose 6-phosphate is converted by the HBP rate-limiting 
enzyme glutamine fructose-6-phosphate transferase (GFAT) into glucosamine 6-phosphate 
(Slawson et al., 2010). Because OGT activity is exquisitely sensitive to UDP-GlcNAc 
concentrations (Haltiwanger et al., 1992) (Figure 1), O-GlcNAcylation may act as a sensor for 
the general metabolic state of the cell. 
 
Fig. 1. The hexosamine biosynthesis pathway. After entering the cell via a glucose transporter 
and being converted to glucose-6-phosphate (glucose-6P) by a hexokinase and to fructose-6-
phosphate (fructose-6P), glucose can either be used in the glycolytic or the hexosamine 
biosynthesis (HBP) pathways. The HBP uses fructose-6P to form glucosamine-6-phosphate 
(glucosamine-6P), with glutamine serving as the donor of the aminogroup. The reaction is 
catalyzed by the rate-limiting enzyme glutamine:fructose-6-phosphate transferase (GFAT). 
Glucosamine-6P is rapidly acetylated through the action of acetyl-CoA:d-glucosamine-6-
phosphate N-acetyltransferase (GAT), and isomerized to N-Acetylglucosamine-1-phosphate 
(GlcNAc-1-P) and activated, via the action of UDP-GlcNAc pyrophosphorylase (AGX), to 
UDP-N-acetylglucosamine (UDP-GlcNAc) that serves as the donor of O-GlcNAc for OGT 
activity. Glucosamine can also enter the cell through the glucose transporter and is rapidly 
phosphorylated by hexokinase yielding glucosamine-6P, thereby bypassing the rate-limiting 
first step of the HBP. S, serine; T, threonine, OGT, O-GlcNAc transferase; OGA, O-GlcNAcase. 
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O-GlcNAcase or OGA was initially identified as hexosaminidase C. However, OGA activity 
is specific for N-acetyl-β-D-glucosaminides and, unlike hexosaminidase, has an optimum 
pH near neutral and mainly a cytosolic localization (Dong & Hart, 1994; Zachara & Hart, 
2006). OGA appears to use substrate catalysis involving the 2-acetamido group and contains 
an N-terminal glycosidase domain and a putative C-terminal histone acetyltransferase 
domain (Macauley et al., 2005; Toleman et a., 2004). To date, two distinct isoforms of OGA 
have been described, a 130-kDa and a 75-kDa variant, which differ in their C terminus. 
Whereas the 130-kDa or "long OGA" contains a distinct N-terminal glycosidase domain and 
the C-terminal histone acetyltransferase domain, the 75-kDa or "short OGA" lacks the C-
terminal domain. One important functional aspect in the existence of these two splices is 
their differential sensitivity to previously described potent OGA inhibitors. For example, the 
short OGA exhibits comparative resistance to PugNAc and NAG-thiazoline, but is very 
sensitive to alpha-GlcNAc thiolsulfonate (Zachara & Hart, 2006). Inhibition of OGT and 
OGA represents an area of great interest on O-GlcNAcylation research, which is evident 
from the increasing number of studies addressing the enzymes molecular mechanisms for 
the addition and removal of O-GlcNAc (Borodkin & van Aalten, 2010; Dorfmueller et al., 
2010, 2011; Dorfmueller & van Aalten, 2010; Gloster et al., 2011; Gloster & Vocadlo, 2010; 
Lameira et al., 2011; Lazarus et al., 2011; Li et al., 2011; Macauley & Vocadlo, 2010; Martinez-
Fleites et al., 2010).  
3. The interplay between O-GlcNAcylation and Protein O-Phosphorylation  
The dynamic addition of O-GlcNAc to proteins has been implicated in modulating protein 
behavior via one potential mechanism that includes a complex interplay between O-
GlcNAcylation and phosphorylation. Many phosphorylation sites are also known 
glycosylation sites, and this reciprocal occupancy may produce different activities or alter 
stability in the target protein (Hu et al., 2010; Zeidan & Hart, 2010) (Figure 2). In support of 
this model, an earlier report has shown that activation of PKC and PKA reduced 
glycosylation in a detergent insoluble cytoskeletal and cytoskeleton-associated protein 
fraction. Conversely, inhibition of PKC and PKA increased O-GlcNAc protein modification 
in this fraction (Griffith & Schmitz, 1999). The competition between O-GlcNAcylation and 
phosphorylation for the same or neighboring residues has been termed the “yin-yang” 
hypothesis and has been reported in a variety of proteins (Hart et al., 1995).  
However, it should be emphasized that the interplay between these two PTMs is not always 
reciprocal. For example, some proteins, such as p53 and vimentin, can be concomitantly 
phosphorylated and O-GlcNAcylated, and the adjacent phosphorylation or O-
GlcNAcylation can regulate the addition of either moiety (Wang et al., 2007; Yang et al., 
2006).  
In addition to the reciprocal crosstalk at same or proximal sites of the proteins, crosstalk 
between O-GlcNAcylation and phosphorylation also exists among distantly located sites, 
such as on the C-terminal domain of RNA polymerase II and on cytokeratins (Chou et al., 
1992; Comer & Hart, 2001). Furthermore, the crosstalk between phosphorylation and O-
GlcNAcylation also influences each other by regulating the activities or localization of other 
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Fig. 2. The interplay between O-GlcNAcylation and O-phosphorylation of proteins. Both 
phosphorylation and O-GlcNAcylation occur on serine/threonine (Ser/Thr) residues of 
proteins. In specific proteins, there is a competitive relationship between O-GlcNAc and O-
phosphate for the same Ser/Thr residues, although there can be adjacent or multiple 
occupancy for phosphorylation and O-GlcNAcylation on the same protein. The interplay 
between phosphorylation and O-GlcNAcylation creates molecular diversity by altering 
specific protein sites that regulate protein functions and signaling events. OGT, O-GlcNAc 
transferase; OGA, O-GlcNAcase; Tyr, tyrosine. Reproduced with permission, from Lima et 
al., 2012, Clinical Science, vol__, pp__-__.  © the Biochemical Society. 
itself O-GlcNAc-modified [49]. OGT also forms a stable and active complex with protein 
phosphatase-1 (PP1β and PP1γ) in rat brain [50]. The association between OGT and PP1 is 
particularly intriguing, as it may provide a direct mechanism to couple O-GlcNAc to 
dephosphorylation of specific substrates. As with OGT, OGA has been shown to interact 
with specific proteins, including protein phosphatase-2β (Wells et al., 2002).  
A recent report showed that rat brain assembly protein AP180, which is involved in the 
assembly of clathrin-coated vesicles in synaptic vesicle endocytosis, contains a 
phosphorylated O-GlcNAc (O-GlcNAc-P) within a highly conserved sequence (O-GlcNAc 
or O-GlcNAc-P, but not phosphorylation alone, was found at Thr310) (Graham et al., 2011). 
O-GlcNAcylation was thought to be a terminal modification, i.e. the O-GlcNAc was not 
found to be additionally modified. The existence of protein glycosyl phosphorylation (O-
GlcNAc-P) adds further complexity to the phosphorylation-O-GlcNAcylation interplay.  
Lastly, the interplay between O-GlcNAc modification and phosphorylation may not be 
limited to Ser/Thr phosphorylation, but may also include tyrosine (Tyr) phosphorylation. 
Based on the higher prevalence of Tyr phosphorylation among O-GlcNAc-modified proteins 
(~68% vs. ~2% in non-O-GlcNAc-modified proteins), Mishra and colleagues suggested that 
Tyr phosphorylation plays a role in the interplay between O-GlcNAc modification and 
Ser/Thr phosphorylation in proteins (Mishra et al., 2011).  
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This clearly shows that the interplay between O-GlcNAcylation and phosphorylation is both 
complex and very extensive. As with any PTM, mapping the attachment sites is a 
prerequisite toward understanding the biological functions of O-GlcNAcylation. With the 
development of sample enrichment methods and new mass spectrometry fragmentation 
methods, such as electron capture dissociation and electron transfer dissociation, now 
hundreds of O-GlcNAc sites have been mapped, and some cellular stimuli were shown to 
increase both modifications. For further information on the complex interplay between O-
GlcNAcylation and phosphorylation, please refer to the following comprehensive and 
excellent reviews (Copeland et al., 2008; Hart et al., 2011; Hu et al., 2010; Wang et al., 2008; 
Zeidan & Hart 2010). 
4. Signaling pathways modified by O-GlcNAcylation  
Many proteins, mainly kinases, involved in signaling pathways that regulate cell growth, 
apoptosis, ion channel activities, and actin cytoskeleton are target for O-GlcNAc 
modification (Lima et al., 2009, 2011). In this section we will briefly comment general aspects 
of some of the signaling proteins that have been identified as targets for O-GlcNAcylation. 
The protein kinase C (PKC) family constitutes a group of multifunctional Ser/Thr protein 
kinases that are classified into three groups: the classic PKCs [PKCalpha(), PKCbeta(βI), 
PKCbeta(βII), PKCgamma(γ)], the novel PKCs [PKCdelta(δ), PKCepsilon(ε), PKCeta(η), 
PKCmu(μ), PKCtheta(θ)], and the atypical PKCs [PKCzeta(ζ), PKCiota/lambda(ι/λ)] 
(Salamanca & Khalil, 2005). 
Functional studies have demonstrated that interaction of PKC with its protein substrate 
triggers activation of a cascade of kinases that ultimately stimulate many cellular functions, 
including contraction, hypertrophy, growth, proliferation and cell survival. As an example, 
PKC phosphorylates CPI-17, which in turn inhibits myosin light chain (MLC) phosphatase, 
increases MLC phosphorylation and enhances vascular smooth muscle contraction. PKC 
also phosphorylates the actin-binding protein calponin, and thereby reverses its inhibition 
of actin-activated myosin ATPase, allowing more actin to interact with myosin and increases 
vascular contraction (Budzyn et al., 2006; Salamanca & Khalil, 2005; Woodsome et al, 2001). 
Initial studies indicated that activation of PKC or cAMP-dependent protein kinase significantly 
decreased overall O-GlcNAcylation in neuronal cytoskeletal proteins. Conversely, inhibition 
of PKC, cAMP-dependent protein kinase, cyclin-dependent protein kinases, or S6 kinase 
increased overall O-GlcNAc levels in fractions from these cells (Griffith et al., 1995). 
Stimulation of the transactivation of Sp1, which is O-GlcNAcylation–dependent, can be 
blocked by molecular and pharmacological inhibition of PKC (Fantus et al., 2006). In 
cerebellar neurons from early postnatal mice, activation of cAMP-dependent protein kinase 
or PKC results in reduced levels of O-GlcNAc specifically in the fraction of cytoskeletal and 
cytoskeleton-associated proteins, whereas inhibition of the same kinases results in increased 
levels of O-GlcNAc (Griffith & Schmitz, 1999). 
In the reverse direction, all PKC isoforms expressed in rat hepatocytes are dynamically 
modified by O-GlcNAc. O-GlcNAcylation of PKC-α negatively correlates with enzyme 
activity (Robles-Flores et al., 2008). Increased O-GlcNAc modification in a human astroglial 
cell line, in response to glucosamine (which increases the production of glucosamine 6-






Fig. 2. The interplay between O-GlcNAcylation and O-phosphorylation of proteins. Both 
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al., 2012, Clinical Science, vol__, pp__-__.  © the Biochemical Society. 
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GlcNAcase activity, mimicking the enzyme-stabilized transition state), results in a decrease 
in membrane-associated PKC-ε and PKC-α, but not PKC-ι, indicating that increased levels of 
the O-GlcNAc modification regulates specific PKC isoforms (Matthews et al., 2005). 
Therefore, it is likely that O-GlcNAc modification of PKC isoforms, such as PKC-α, PKC-β, 
PKC-γ, PKC-ε, and PKC-ζ can interfere with cellular processes regulated by these enzymes. 
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases which 
are classically associated with cell contraction, migration, adhesion, collagen deposition, cell 
growth, differentiation, and survival (Pearson et al., 2001). Of the major MAPKs, 
extracellular signal-regulated kinases (ERK1/2), p38 MAPK, and stress-activated protein 
kinase/c-Jun N-terminal kinases (SAPK/JNK) are the best characterized. The complex 
signaling networks that underlie MAPK activation typically require phosphorylation by a 
MAPK kinase also known as MEK. The ERK1/2 phosphorylation cascade involves MEK1/2 
(MAP/ERK kinase) whereas the signaling processes leading to SAPK/JNK and p38 MAPK 
activation involve MEK4/7 and MEK3/6, respectively (Pearson et al., 2001). Activation of 
MAPKs has been reported to be primarily dependent on the nonreceptor tyrosine kinase c-
Src in different cell types. To date, at least 14 Src-related kinases have been identified, of 
which the 60 kDa c-Src is the most abundantly expressed isoform in vascular smooth muscle 
cells and rapidly activated by G protein-coupled receptors. Other proximal regulators of 
MEK include the Ras-Raf pathway, which may not necessarily involve c-Src (Kolch, 2005; 
Martin, 2001; Oda et al., 1999). 
The MAPKs p38 and ERK1/2 have been reported to be phosphorylated in response to 
increased O-GlcNAc levels (Laczy et al., 2009). A positive correlation between phosphorylation 
of the MAPK cascade (ERK1/2 and p38) and nuclear O-GlcNAcylation was observed in fetal 
human cardiac myocytes exposed to high glucose (Gross et al., 2005). In isolated rat hearts, 
perfusion with 5 mM glucosamine increases O-GlcNAc levels and confers cardioprotection 
after ischemia-reperfusion (Zou et al., 2009). Interestingly, although glucosamine does not 
alter the response of either ERK1/2 or Akt (protein kinase B) to ischemia-reperfusion, it 
significantly attenuates the ischemia-induced increase in p38 phosphorylation, as well as the 
increased p38 phosphorylation at the end of reperfusion, suggesting that glucosamine-
induced cardioprotection may be mediated via the p38 MAPK pathway (Jones et al., 2008). 
Augmented O-GlcNAc levels in mouse hippocampal synapses increases phosphorylation of 
synapsin I/II at Ser9 (cAMP-dependent protein kinase substrate site), Ser62/67 (ERK1/2 
[MAPK 1/2] substrate site), and Ser603 (calmodulin kinase II site). Activation-specific 
phosphorylation events on ERK1/2 and calmodulin kinase II are also increased in response 
to elevation of O-GlcNAc levels (Rexach et al., 2008). 
Advanced glycation end-products induce ROS accumulation, apoptosis, MAPK activation, 
and nuclear O-GlcNAcylation in human cardiac myocytes (Li et al., 2007). In addition, 
exposure of neutrophils to PUGNAc or glucosamine also stimulates the small GTPase Rac, 
which is an important upstream regulatory element in p38 and ERK1/2 MAPK signaling in 
neutrophils, and these MAPKs are implicated in chemotactic signal transduction. 
Conversely, alterations in MAPK pathways can also have effects on the enzymes responsible 
for the regulation of O-GlcNAc (Laczy et al., 2009, Lima et al., 2011). In neuro-2a 
neuroblastoma cells, increased OGT expression on glucose deprivation occurs in an AMP-
activated protein kinase–dependent manner, whereas OGT enzymatic activity is regulated 
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in a p38 MAPK-dependent manner. OGT is not phosphorylated by p38, but rather it 
interacts directly with p38 through its C terminus. The interaction with p38 does not change 
the catalytic activity of OGT, but p38 regulates OGT activity within the cell by recruiting it 
to specific targets (Cheung & Hart, 2008). 
Together, these data indicate that O-GlcNAcylation is an important signaling element and it 
modulates the activities of several critical signaling kinases (Kneass & Marchase, 2005). 
Thus, it is possible that signaling kinases, such as proteins from MAPK, PKC, and 
RhoA/Rho kinase pathways, are also regulated by O-GlcNAc modifications and that this 
post-translational modification not only modulates many cellular responses, but also may 
play a role in the abnormal function of kinases observed in various pathological conditions. 
Ca+2 sensitization in smooth muscle cells is a well known process mediated by the small 
GTPase Rho and its downstream target Rho-kinase. The exchange of bound guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP) activates Rho and stimulates its 
translocation from the cytosol to the plasma membrane. Rho-GTP phosphorylates Rho-
kinase, which inhibits MLC phosphatase activity by phosphorylation of the MLC 
phosphatase target subunit (MYPT1). A decrease in MLC phosphatase activity increases 
phosphorylation of myosin and therefore contributes to smooth muscle contraction at low 
levels of intracellular Ca+2 (Somlyo & Somlyo, 2000). RhoA/Rho kinase signaling has been 
implicated in many cellular processes including contraction, reactive oxygen species 
generation, inflammation, and cell migration (Calo & Pessina, 2007).  
Rho-kinase activation also suppresses eNOS activity/expression, and decreased sensitivity 
of contractile proteins to Ca2+ is considered a key mechanism in NO-induced relaxation of 
vascular smooth muscle cells. Accordingly, NO also induces vasodilation through the 
inhibition of the RhoA/Rho-kinase signaling pathway. Accordingly, NO-mediated increases 
in cGMP and activation of cGMP-dependent protein kinase (cGK) lead to inhibition of RhoA 
(Chitaley & Webb, 2002; Sauzeau et al., 2001; Sawada et al., 2001).  
The small G-protein RhoA and its downstream target, Rho-kinase, play a direct role in the 
regulation of MLC phosphatase activity. In the active state, RhoA engages downstream 
effectors, such as Rho-kinase, which then phosphorylates the myosin binding subunit of 
MLC phosphatase (MYPT1 Thr853), inhibiting its activity, and thus promoting the 
phosphorylated state of MLC (Chitaley et al., 2001). Data from our laboratory and others 
indicate that increased O-GlcNAcylation augments vascular reactivity to constrictor stimuli 
via changes in the RhoA/Rho-kinase pathway (Lima et al, 2011; Kim et al, 2011). 
Since increased O-GlcNAcylation decreases eNOS/NO signaling (Musick et al., 2005) and 
NO inhibits RhoA/Rho-kinase signaling, increased RhoA/Rho-kinase activity observed in 
many pathological conditions may be associated with augmented O-GlcNAc levels.  
5. Physiological implications of alternating O-GlcNAcylation and O-
phosphorylation 
The physiological significance of the crosstalk between O-GlcNAcylation and O-
phosphorylation certainly warrants further investigation. However, data available so far 
indicate that the “on” or “off” state of many enzymes and receptors are not simply determined 
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MLC phosphatase (MYPT1 Thr853), inhibiting its activity, and thus promoting the 
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NO inhibits RhoA/Rho-kinase signaling, increased RhoA/Rho-kinase activity observed in 
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complex interplay between O-GlcNAcylation and O-phosphorylation, within reciprocal or 
proximal sites, makes the activation/deactivation or the “on”/”off” switch of enzymes and 
receptors a much more elaborated process. Since both post-translational modifications 
modulate many cellular functions via protein targeting to specific substrates, transient 
complex formation with other proteins, subcellular compartmentalization of specific proteins, 
activation/inhibition of many signaling pathways, the interplay between O-GlcNAcylation 
and O-phosphorylation adds great complexity to our knowledge of protein activity 
regulation. 
New techniques allowing the recognition of several O-GlcNAc sites will further clarify how 
different cellular stimuli interfere with these post-translational modifications. One big 
challenge in the field has been to map the sites where the attachments are simultaneously 
occurring. The development and improvement of some techniques such as electron capture 
dissociation and electron transfer dissociation has opened new possibilities to map O-
GlcNAcylation and O-phosphorylation sites. Please, refer to the following comprehensive 
and excellent reviews for further information regarding O-GlcNAc enrichment methods 
(Macauley & Vocadlo, 2009; 120. Peter-Katalinic, 2005; Wang et al, 2010; Zachara, 2009). 
6. Conclusions 
Our understanding of the O-GlcNAcylation process (enzymatic regulation, cellular targets 
and sites for O-GlcNAc addition, modulation by other pathways) as well as of its functional 
importance and its contribution to (dys)regulation of many cellular processes is rapidly 
increasing. It is also evident that the direct interactions between O-GlcNAcylation and O-
phosphorylation and the fact that both post-translational modifications can interfere with 
many signaling pathways and cellular processes, not only add great complexity to our 
knowledge of protein activity regulation, but warrant intense research in the field. 
Future investigations focusing on the characterization of specific O-GlcNAcylated and O-
phosphorylated sites/proteins, as well as studies addressing and identifying the factors 
involved in the regulation of OGT and OGA activity are needed. They will provide a greater 
understanding as to how O-GlcNAc modulates cellular function and potentially provide an 
avenue for targeted interventions and therapies. 
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complex interplay between O-GlcNAcylation and O-phosphorylation, within reciprocal or 
proximal sites, makes the activation/deactivation or the “on”/”off” switch of enzymes and 
receptors a much more elaborated process. Since both post-translational modifications 
modulate many cellular functions via protein targeting to specific substrates, transient 
complex formation with other proteins, subcellular compartmentalization of specific proteins, 
activation/inhibition of many signaling pathways, the interplay between O-GlcNAcylation 
and O-phosphorylation adds great complexity to our knowledge of protein activity 
regulation. 
New techniques allowing the recognition of several O-GlcNAc sites will further clarify how 
different cellular stimuli interfere with these post-translational modifications. One big 
challenge in the field has been to map the sites where the attachments are simultaneously 
occurring. The development and improvement of some techniques such as electron capture 
dissociation and electron transfer dissociation has opened new possibilities to map O-
GlcNAcylation and O-phosphorylation sites. Please, refer to the following comprehensive 
and excellent reviews for further information regarding O-GlcNAc enrichment methods 
(Macauley & Vocadlo, 2009; 120. Peter-Katalinic, 2005; Wang et al, 2010; Zachara, 2009). 
6. Conclusions 
Our understanding of the O-GlcNAcylation process (enzymatic regulation, cellular targets 
and sites for O-GlcNAc addition, modulation by other pathways) as well as of its functional 
importance and its contribution to (dys)regulation of many cellular processes is rapidly 
increasing. It is also evident that the direct interactions between O-GlcNAcylation and O-
phosphorylation and the fact that both post-translational modifications can interfere with 
many signaling pathways and cellular processes, not only add great complexity to our 
knowledge of protein activity regulation, but warrant intense research in the field. 
Future investigations focusing on the characterization of specific O-GlcNAcylated and O-
phosphorylated sites/proteins, as well as studies addressing and identifying the factors 
involved in the regulation of OGT and OGA activity are needed. They will provide a greater 
understanding as to how O-GlcNAc modulates cellular function and potentially provide an 
avenue for targeted interventions and therapies. 
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Living systems continuously monitor and respond to the surrounding environment. These 
processes are made possible by cellular signal transduction systems. When particular 
information reaches the cell (in many cases to the surface of cells), corresponding molecular 
networks are activated to process the information. These cascade-type reactions change 
many enzymes in the cell and ultimately the enzymatic reactions taking place determine the 
cellular response. Although the system includes a large number of enzymes, protein kinases 
are the most important group of enzymes and play key roles of signal transduction events. 
The human genome encodes nearly 500 types of protein kinases (Cohen, 2001). One-third of 
all cellular proteins act as substrates of protein kinases. Therefore, the monitoring of the 
activities of protein kinases is a crucial technology not only for understanding life processes, 
but also for the development of efficient diagnostics or effective drug discovery programs. 
Modification of certain protein kinase activities will also be an important medical 
technology for therapy against many diseases. In this context, this chapter will introduce 
recent technologies that have been developed to monitor protein kinases. In addition, if we 
use the activity of the protein kinases as a tool for medical engineering, we may be able to 
control cellular function when needed. In this category, new technologies that use protein 
kinase activities for controlling transgene regulation will also be introduced. 
2. Overview of kinase assays 
The activity of protein kinases is easily detected through the incorporation of a radioactive 
phosphate to a protein or peptide substrate using 32P- or 33P-ATP (Schutkowski et al., 2004; 
Panse et al., 2004; Diks et al., 2004). Although such assays are highly sensitive and 
quantitative, there are some important drawbacks such as the requirement of a special 
facility to handle radioactive materials, production of radioactive waste, the short half-lives 
(14 days) of the radioactive phosphate, and the potential risk to health. Thus, many types of 
non-radioactive protein kinase assays have been developed. In these assays, fluorescence-
based approaches represent a promising way for high-throughput analysis of protein kinase 
activities. Alternatively, colorimetry may be easier to handle and cheaper when compared 
with fluorimetry; however, the sensitivity is generally lower. Mass spectrometry represents 
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When fluorescence techniques are used for the design of protein kinase assays, many useful 
properties of the fluorescence phenomena can be used such as fluorescence intensity, 
fluorescence polarization, fluorescence energy transfer and the fluorescence life-time. 
What is important in assay design is the ability of the system to distinguish between 
phosphorylated and non-phosphorylated forms of the substrate. An anti-phospho antibody 
is a convenient way to recognize phosphorylation of a substrate. However, antibody with 
sufficient affinity for phorsporykated Ser/Thr is not commercially available. Therefore, 
other artificial molecules such as metal complexes, polycationic polymers or beads are used 
for the recognition of phosphor-serine or –threonine. Phos-Tag (Kinoshita et al., 2006; 
Inamori et al., 2005) or Pro-Q Diamond dye (Steinberg et al., 2003) are typical examples for 
this category (Fig. 1). Phos-Tag is a zinc complex that was designed by using the alkaline 
phosphatase structure, and this compound binds to phosphor-amino acids. The molecule 
also possesses a biotin moiety so that avidin derivatives can also bind tightly. Pro-Q 
Diamond dye is a gallium complex of a fluorescent molecule. Phosphorylation of a peptide 
or protein can be detected by agarose gel electrophoresis using this probe. Instead of 
binding other molecules to the phosphorylation site, phosphorylated amino acid residues 
may be derivatized to other chemical groups by attaching a marker molecule to detect the 
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3. Protein kinase assay with measurement of fluorescence intensity 
Probably, the simplest way of using fluorimetry in kinase assays is the design of a 
fluorescent substrate that changes its fluorescence intensity upon phosphorylation. 
However, it is not so easy to change the fluorescence intensity of a single fluorescent 
molecule through phosphorylation. The first example was an acrylodan-labeled peptide 
substrate of protein kinase C (PKC) (McIlroy et al., 1991). The molecule, Acrylodan-
CKKKKRFSFKKSFKLSGFSFKKNKK-OH, decreased its fluorescence intensity by 20% upon 
phosphorylation by PKC. The time course of the fluorescence decrease was found to 
correlate well with that of [32P]phosphate incorporation. The assay detected 0.02 nM of PKC. 
Although the assay cannot be applied to living cells, the PKC activity in a brain homogenate 
was easily detected. On the other hand,  Higashi et al, 1996. reported a cell permeable 
acrylodan-labeled peptide (syntide 2) for the detection of calcium calmodulin dependent 
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activity in mice hippocampus slices. However, this type of assay using simply fluorescence-
labeled substrates provides only a small change in the fluorescence intensity following 
phosphorylation. Consequently, the sensitivity of this approach is generally low.  
Generally it is difficult to obtain large changes in fluorescence intensity if the fluorophore 
involves the simple labeling of a peptide. Kupcho et al, 2003. reported a unique fluorescent 
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the substrate peptide of PKA was introduced into the both sides of rhodamine 110 through 
amide bonds. The molecule is practically non-fluorescent due to the formation of a lactone ring 
in the rhodamine structure. Peptidase degrades the peptide moieties from their amino termini. 
When the peptides were completely digested, the fluorescence of the rhodamine 110 recovers. 
However, if the peptide is phosphorylated with PKA, digestion by peptidase is inhibited at the 
phosphor-serine such that the fluorescence never recovers. This method can clearly detect 
PKA activity with an ‘on-off’ strategy; however, the molecular design is not versatile and 
therefore not suitable for many kinases. In addition, the method cannot be applied to living 
cells and in vivo. It often requires the design of a complicated probe molecule to obtain large 
changes in the fluorescence intensity with phosphorylation when using small probe molecules. 
However, if we use a molecular assembly system such as micelles or polyionic complexes, it 
becomes easier to obtain larger changes in the fluorescence intensity when probing 
phosphorylation. Sun et al. 2005 reported a micelle system for the detection of protein kinase 
activity (Sun et al., 2005) (Fig. 2b). In this system, an aliphatic chain was connected to a peptide 
substrate of a target kinase that was labeled with a fluorescent molecule. If the length of the 
hydrocarbon chain is optimized, the material forms a micelle-like assembly. The fluorescence 
is then quenched due to the concentrating of the fluorophores. However, if the substrate is 
phosphorylated by a target kinase the fluorescence intensity increases several fold because of 
the decomposition of the micelle. Phosphorylation of the peptide moiety dramatically changes 
the hydrophilic-hydrophobic balance of the alkylated peptide substrate. We also developed a 
polyion complex consisting of an alkylated cationic peptide substrate and a fluorescein-labeled 
polyaspartic acid for monitoring protein kinase A or protein kinase C activity (Koga et al. 
2011) (Fig. 2c). Such a polyion complex formed a nano-particle with a size of 100-200 nm. In 
this particle, the fluorescence is quenched because of the high concentration. Phosphorylation 
of the peptide moiety decreases the cationic net charges of the peptide so that an electrostatic 
interaction between the lipid-type peptide and the fluorescence-labeled polyanion decreases 
and this leads to the disintegration of the polyion complex. Such an event leads to an increase 
in the fluorescence intensity by several fold. In this system, the peptide substrate does not 
require the direct labeling of a fluorophore, which sometimes affects the ability of the molecule 
to act as a kinase substrate. This system was successfully applied to validate kinase inhibitors.  
4. Protein kinase assay based on fluorescent polarization 
Fluorescence polarization is a technique to detect the rotational property of a target 
molecule. When a fluorescent molecule is excited with polarized light, the extent of the 
remaining polarization of the emitted light depends on the rotation of the molecule. If the 
molecule rotates within the period of its excitation, the emitted light loses the polarization in 
the plane of excited light. Since the molecular rotation is dependent on the molecular weight 
of the protein, the technique can detect the binding of a large molecule to the target 
molecule. This strategy can be applied in the design of protein kinase assays. Seethala et al. 
1997 reported the first kinase assay based on a fluorescence polarization experiment 
(Seethala, 1997). Once a fluorescently labeled peptide substrate is phosphorylated with a 
protein kinase, an anti-phospo-amino acid antibody binds to the substrate (Fig. 3a). Due to 
the dramatic increase of the molecular size, the fluorescence polarization signal was 
observed to increase because of a reduction in the rate of rotation. This direct monitoring of 
fluorescence polarization is simple, but it usually requires a relatively large amount of anti-
phospho antibody. The method also needs a small substrate such as a peptide and the 
 
Technologies for the Use of Protein Kinases into Medical Applications 
 
83 
technique cannot be applied using a protein substrate. On the other hand, if the strategy 
involves a competition assay, the protein substrate can also be available (Seethala et al., 
1998; Kristjansdottir et al., 2003) (Fig. 3b). In this system, after the protein substrate is 
phosphorylated by the protein kinase, it is added into the complex of the fluorescence-
labeled phosphorpeptide and anti-phopho antibody to compete for binding to the antibody. 
Thereafter, we can evaluate the kinase activity by evaluating the decrease in the fluorescence 
polarization signal. The advantage of the fluorescence polarization assay is that this 
approach is independent of the concentration or fluorescence intensity of the fluorophore 
used. However, only an anti-phospho antibody for tyrosine is available. Therefore, another 
molecule that can bind to phosphoserine or threonine is needed if this type of assay is to be 
applied to monitor the activity of serine/threonine protein kinases. Polycationic peptides 
and trivalent cation-containing particles can be used for this purpose (Coffin et al., 2000). 
However, such compounds have poor specificity. Moreover, polycationic peptides are also 
limited to the use of neutral substrate peptides and trivalent cation-containing particles 
sometimes suffer from weak binding to phosphorylated sites. The Phos-Tag may be another 
practical possibility because of its relatively high specificity and binding constant. Recently, 
a fluorescent polarization assay was applied to a high-throughput assay for screening 
inhibitors of a protein kinase (Kumar et al., 2011). 
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two different fluorophores. If the emission spectrum of the donor fluorophore and the 
excitation spectrum of the acceptor fluorophore overlap and these two fluorophores exist in 





the acceptor. This phenomenon can be observed when the two molecules exist within 10 nm. 
Consequently, FRET is highly sensitive to distances between donors and acceptors. This 
methodology can be applied to similar systems characterized by fluorescence polarization-
based assays using peptide substrates and an anti-phospho antibody. If the peptide 
substrate and the antibody are labeled with acceptor and donor molecules, respectively, 
binding of the antibody to the phosphorylated substrate generates FRET between the donor 
and acceptor. Therefore, protein kinase activity can be detected by monitoring the ratio of 
the fluorescence intensity at two emission wavelengths for the donor and acceptor. FRET 
measurements are sometimes disturbed by background fluorescence derived from other 
biomaterials and are also affected by direct excitation of the acceptor with excitation light for 
the donor molecule. To avoid such disturbances, time-resolve FRET is often used. Riddle et 
al. 2006 reported a FRET system using a GFP-fused peptide substrate and an anti-
phosphotyrosine antibody labeled with a terbium ion complex (Riddle et al. 2006 (fig.4a)). 
The time-resolved FRET technique can be applied because rare earth metal complexes, such 
as terbium or europium complexes, produce long life-time fluorescences. However, a GFP 
fusion sometimes disturbs the phosphorylation of the substrate because of its large size. To 
avoid this effect, small organic fluorophores such as Alexa dyes are also used as acceptors 
(Zhang et al., 2005). A microplate based-high throughput assay has also been reported using 
a FRET-based kinase assay (Gratz et al., 2010) (Fig. 4b). In this assay, the substrate peptide of 
casein kinase 2 was labeled with fluorophore (EDANS) and the quencher (DABSYL) at the C 
and N terminus, respectively. The fluorescence of EDANS was quenched due to the FRET 
with DABSYL. Phosphorylation of the peptide by CK2 prohibited the cleavage of the 
peptide with elastase. Thus, CK2 activity was evaluated by the decrease in fluorescence. 
This approach was applied to a microplate-based assay and CK2 inhibitors were screened.     
Although these systems are applied only to solution samples, if a FRET system can be 
applied to living cells, it has an advantage of ratiometry, in which, the assay can be 
performed independent of the thickness of the sample. Phocus is a good example of such a 
system. In this probe, CFP and YFP are fused with a kinase substrate, linker and phosphor-
recognition domain (Sato & Umezawa, 2004) (Fig. 4c). In the free form, FRET between CFP 
and YFP does not occur because of the long distance between the two molecules. On the 
other hand, phosphorylation of the substrate domain causes the binding of the phosphor-
recognition domain. This moves the two fluorophores into close proximity to cause FRET. 
Using this probe, activities of c-Jun and Src were observed successfully in living cells. The 
advantage of this probe is that the probe can be expressed in living cell spontaneously after 
the transfection of the encoding genes. On the other hand, optimization of the construct is 
required to design the probe for each kinase, and the large fluorescence moieties, CFP and 
YFP, may disturb the access of the protein kinase to the substrate domain in some cases. The 
method is also inconvenient for HTS systems. 
An additional monitoring system of protein kinases uses an alpha-screen assay (Pedro et al., 
2010). Alpha-screening is not exactly a FRET system, but the excitation energy of a donor 
bead transfers to an acceptor bead indirectly via singlet oxygen. Excitation of the donor 
produces singlet oxygen with a photodynamic effect. Although the lifetime of singlet 
oxygen is very short, 4 sec, if the acceptor exists within 200 nm from the donor, the singlet 
oxygen can reach the acceptor. The acceptor then produces an emission light with singlet 
oxygen. Pedro et al. 2010 reported the monitoring of a leucine-rich repeat kinase (LRRK2), 
which is sometimes active in Parkinson’s disease, using the alpha-screen system. Moesin is a 
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substrate of LRRK2 fused with a GST tag. Donor and acceptor beads were modified with 
GST and protein A, respectively. An antiphospho-antibody was then introduced onto the 
acceptor bead through protein A. After the phosphorylation of moecine with LRRK2, the 
donor and acceptor beads bound the moecine through GST and the phosphorylation site, 
respectively. In this case, excitation of the donor bead with 680 nm light produced an 
emission light at 520600 nm from the acceptor bead through singlet oxygen. The system 
was applied to HTS analysis using a 384-well plate. 
The QTL Light Speed Kinase Activity AssayTM is also a sensitive detection system for detecting 
protein kinase activity (Moon et al., 2007). This assay uses a highly fluorescent microsphere 
and quencher-labeled substrate peptide. The peptide can bind to the microsphere if the 
peptide is phosphorylated by the target kinase, because its surface is modified with a gallium 
complex. The fluorescence of the microsphere is then quenched with the quencher on the 
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(e) Protein kinase assay based on QTL system 
Fig. 4. FRET-based protein kinase assays 
6. HTS assay using Gold Nano-Particle (GNP) with colorimetry 
Although fluorimetry is sensitive and flexible, it can be affected by factors such as 
background substances, temperature, pH and the concentration of the fluorophore. 
Colorimetry, on the other hand, is simple and robust. We reported a label-free kinase assay 
using gold nano-particle (GNP) (Oishi et al., 2007; Oishi et al., 2008) (Fig. 5). Cationic 
peptides causes an aggregation of anionic GNP prepared by citrate reducing. This changes 
the color of the GNP dispersion from red to blue. This aggregation is highly sensitive to the 
peptide. Cationic peptide aggregates are 1000-fold more effective than inorganic cations that 
have same cationic charges. However, if the peptide is phosphorylated by the target kinase, 
the ability to aggregate is reduced dramatically so that the color of the dispersion remains 
red upon the addition of the peptide. Thus, phosphorylation of the peptide can easily be 
detected by monitoring the absorbance at 670 nm. The assay has been sufficiently sensitive 
to detect PKA, PKC, MAPK, p38 and Src activity in solution, cell lysates and tissue 
extracts. Detection of PKC activity in tumor and normal tissues from human patients 
suggests that the assay can be applied as a diagnostic of breast cancer (Kang et al., 2010). The 
assay was also used to screen for protein kinase inhibitors using a micro-titer plate format 
(Oishi et al., 2008; Asami et al., 2011). Using a chemical library containing 3000 chemicals, 
new PKA inhibitors, which have similar inhibitory activity to current PKA inhibitors, were 
actually identified using this assay. The aggregation of GNP is affected by the cationic net 
charges of the peptide and ionic strength. Therefore, the ionic concentration of the detecting 
solution has to be optimized for each peptide sequence. However, such conditions can be 
optimized easily, because the conditions of the phosphorylation and detection steps can be 
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set independently. In addition, this assay does not require any labeling steps to the substrate 
peptide and is simple, rapid and widely applicable from solution to tissue samples. Since 
the assay depends on decreasing net charge of the substrate peptide, the original net charge 
has to be cationic. On the other hand, some protein kinases require anionic peptide 
sequences as their substrates. This issue can be overcome by the addition of some cationic 
amino acids at one end of the peptide through a flexible triethylene glycol linker. If gold 
nano-rods are covered with a cationic surfactant, Cetyltrimethylammonium bromide 
(CTAB) is used instead of GNP, and an anionic substrate can be used without any addition 
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Fig. 5. Concept of colorimetrical assay of protein kinase using gold nano-particle 
7. Peptide array 
Genomic and post-genomic research has enabled us to understand life at the molecular 
level. Many aspects of molecular processes have been elucidated. As a result, evolutionary 
changes have been made in methodologies in drug discovery, diagnostics and other medical 
technologies. Developments of molecular targeted drugs that primarily target tyrosine 
kinases for cancer therapy represent a typical example. However, life was not constructed 
through a simple combination of such pieces, but involves many pieces that interact with 
each other to generate a complicated network system. Therefore, diseases are not simply 
treated by inhibiting a single target molecule. For example, cancer cells often acquire a 
tolerance against molecular targeted drugs during their applications, even though the drugs 
continue to inhibit the target protein kinases. Therefore, we have to clarify the condition of 
entire signal network to know the cellular condition exactly. From research using gene chip 
technology, it has been clarified that a major part of the transcriptome is necessary to 
maintain the basic functions of living cells, and only a part of the transcriptome relates to 
each cell-specific function. Tiny fluctuations of the transcriptome sometimes cause a 
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set independently. In addition, this assay does not require any labeling steps to the substrate 
peptide and is simple, rapid and widely applicable from solution to tissue samples. Since 
the assay depends on decreasing net charge of the substrate peptide, the original net charge 
has to be cationic. On the other hand, some protein kinases require anionic peptide 
sequences as their substrates. This issue can be overcome by the addition of some cationic 
amino acids at one end of the peptide through a flexible triethylene glycol linker. If gold 
nano-rods are covered with a cationic surfactant, Cetyltrimethylammonium bromide 
(CTAB) is used instead of GNP, and an anionic substrate can be used without any addition 
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Fig. 5. Concept of colorimetrical assay of protein kinase using gold nano-particle 
7. Peptide array 
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each other to generate a complicated network system. Therefore, diseases are not simply 
treated by inhibiting a single target molecule. For example, cancer cells often acquire a 
tolerance against molecular targeted drugs during their applications, even though the drugs 
continue to inhibit the target protein kinases. Therefore, we have to clarify the condition of 
entire signal network to know the cellular condition exactly. From research using gene chip 
technology, it has been clarified that a major part of the transcriptome is necessary to 
maintain the basic functions of living cells, and only a part of the transcriptome relates to 
each cell-specific function. Tiny fluctuations of the transcriptome sometimes cause a 





This indicates that monitoring enzymatic activities in cellular signal transduction events 
must be efficient and effective for precisely evaluating cell conditions. Kinome, the entire 
profile of protein kinases in cells, is a new concept presented in this issue. The most practical 
format of the kinome analysis is peptide array. Peptide array involves chip technology, in 
which many peptide substrates of protein kinases are immobilized on a solid support. Some 
peptide array systems are now commercially available. The PepScan array is probably the 
first example in which kinome analysis was carried out using a peptide array (Diks et al., 
2004). In this array, many peptide substrates are immobilized onto a glass slide and 
phosphorylation is detected with the incorporation of [33P]-phosphate from RI-labeled ATP. 
Using the array immobilizing 192 peptides, changes in the activities in particular kinases 
after LPS stimulation was analyzed. Following this report, kinome in Barrett’s esophagus, 
endothelial cells and also c-Met activity in colon cancer after the inhibition of 
cycloocygenase-2 were monitored using more than 1000 peptides (van Baal et al., 2011). 
Although the array seems to give reasonable evaluations in activation of particular kinases, 
the system assumes that one peptide is phosphorylated by a single kinase; however, such 
short peptides may be phosphorylated by plural protein kinases. The CelluSpot system is 
another similar peptide array format (Olaussen et al., 2009). In this array, peptide substrates 
that were synthesized on a nitrocellulose membrane are cleaved and set on a solid support. 
The effect of tyrosine kinase inhibitors on the kinome in a carcinoma cell line was evaluated 
using this system with 144 peptides. Phosphorylation of the peptides was detected using a 
fluorescence-labeled anti-phosphotyrosine antibody. Although this system is simple and 
does not use radio-active material, the size of each spot is large (1 mm) such that a relatively 
large amount of sample is required.  
Enzymatic reactions are sometimes inconvenient to perform on solid surfaces. The Pamchip is 
an array to address this issue (Jinnin et al., 2008; Maat et al., 2009). In this system, peptides are 
immobilized in a well consisting of porous material. The porous material is 60 m thick and 
has long branched interconnected capillaries with a diameter of 200 nm. It results in a 500-fold 
increase in the reactive surface and the reaction and washing steps can also be performed by 
pulsing back and forth through the porous material many times. The profile of tyrosine kinase 
activities in a pediatric brain tumor was evaluated and compared with kinomes from other 
various cancer cell lines in 144 peptides (Sikkema et al., 2009). A group of peptides that were 
phosphorylated by all cancer cell lines and by particular cell lines were identified. However, it 
is relatively difficult to identify each kinase from such profiles. Activation of vascular 
endothelial growth factor receptor type2 (VEGEFR2) and Src signaling were also confirmed 
in infantile hemangioma and melanoma cells, respectively, with this system. 
The above mentioned peptide arrays are useful for kinome analysis. However, it is unclear 
whether they can be used for quantitative analysis. For monitoring kinase activity, it is 
important to know how much activity has changed. In many cases, cellular function will be 
influenced by the degree of activation of particular kinases. Recently we developed a peptide 
array in which peptide substrates are immobilized onto gold or glass support for surface 
Plasmon resonance (SPR) and fluorescence detection, respectively (Shigaki et al., 2007; Inamori 
et al. 2005) (Fig. 6a). By careful optimization of the surface chemistry, these arrays secured 
quantitative data describing the detection of the phosphorylation ratio in each peptide (Han et 
al., 2008; Shimomura et al., 2011). For example, the efficiency of peptide immobilization 
influenced the results from the methodology (Inamori et al., 2008) (Fig. 6b).  
 






























In the case of SPR detection, no fluoresence
labeling material is used.  
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(b) Correlation between immobilized peptide density and immobilization protocol 
Fig. 6. Quantitative peptide array: concept and immobilization method of peptide substrate 
Figure 6b shows the efficiency of peptides immobilized onto a gold chip. Although the 
polyethylene glycol (PEG) moiety is effective in suppressing non-specific adsorption of bio-
substances, peptide immobilization was also suppressed if the PEG moiety was modified on 
the chip in advance. On the other hand, when the PEG-linked peptide was reacted with a 
rigid group on the chip, the amount of the immobilized peptide increased dramatically. In 
our system, phosphorylation of the peptide was achieved by using an anti-phosphotyrosine 
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activities of particular protein kinases were detected using the SPR chip in solution and a 
cell lysate after the cell was stimulated with NGF (Han et al., 2009). An advantage of the SPR 
detection system is that it does not require any labeling for detection. However, this 
advantage contains a risk that binding of any other substances gives rise to a detectable 
signal at the same time. In this case, fluorescence detection will be more practical. In the 
quantitative detection of the kinome on a peptide array, peptides that have cysteines at the 
amino terminus were immobilized through a formyl group or maleimide. In the former 
case, high-density amino-modified glass surfaces were treated with glutaraldehyde, and 
then the peptide was linked to the formyl group at the thiol group of the cysteine residue by 
forming a thiazoline ring (Mori et al., 2009). The surface of the chip was then blocked from 
unspecific adsorption with Blocking One-P, which is a commercial cocktail. We recently 
used a plastic plate that was modified, called the ‘S-Bio’ system, to avoid the adsorption of 
biomacromolecules. In this case, cysteine-containing peptides were immobilized on the chip 
using maleimide chemistry. Detection of phosphorylation was achieved using a Cy-3 
labeled anti-phosphotyrosine antibody or a PhosTag and Alexa647-labeled streptavidin. 
After the optimization of the conditions of immobilization, the obtained chip provides 
quantitative phosphorylation ratios of the peptide. This quantitative analysis is sufficient for 
measuring peptide phosphorylation immobilized on a single chip. However, an internal 
standard is required for the inter-plate comparison. Alexa647 labeled peptide is used for this 
purpose. Using this array, Src activity in various cancer cell lines and mouse tissues was 
successfully monitored. Changes in the kinome profile with drug stimulation such as NGF 
or Iressa was also obtained (Han et al., 2010). Such arrays were also applied to screen kinase 
inhibitors (Inamori et al., 2009). 
Kinome analysis using peptide array has not been a well-establish technology. Especially, 
bio-informatics technique which converts obtained phosphorylation profile into actual 
signal network of protein kinases. Reproducibility of peptide array has also to be improved. 
8. New technology using protein kinase activity in artificial bio-regulation 
As mentioned above, many technologies for monitoring protein kinase activity have been 
developed. On the other hand, any technology that uses protein kinase activity should also 
be useful for medicine, because protein kinases play key roles in determining cellular 
functions. Abnormal activation of particular kinases is often observed in many diseases. For 
example, hyper-activation of EGFR, c-MET, bcl-Abl, PKC, or Src has been reported in 
many types of tumors. In myocardiac infarction, over expression of Rho kinase is also 
reported. Activation of I--kinase is a key signal to initiate inflammation. Therefore, 
abnormal activity of such kinases can be markers to distinguish disease cells. In this context, 
if these signals can be converted to other information artificially, such signal conversion 
should identify disease cells specifically. Such artificial signal converters will offer a new 
strategy for cell-specific medicines. We recently reported some artificial gene regulators that 
activated transgene expression in response to target protein kinase activity (Oishi et al., 2006; 
Sonoda et al., 2005; Kawamura et al., 2005) (Fig.7). The regulators consist of polymer 
backbone and some cationic peptide side-chains. The peptide is also designed as a specific 
substrate of a target protein kinase. Since the polymer-peptide conjugates are polycationic, 
they can form electrostatic complexes with DNA such as an expression vector. In the 
complex, this type of conjugate suppresses the gene transcription much more efficiently  
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Fig. 7. Structure of artificial gene regulator (left) and concept of its gene regulation in 
response to protein kinase 
than ordinary polycations such as polyethyleneimine, or poly-L-lysine. When the complex is 
taken up by target disease cells in which target protein kinases are hyper-activated, the 
peptide side-chains are phosphorylated. This introduction of anionic charges decreases the 
net cationic charges of the conjugate, and the electrostatic interaction between the conjugate 
and DNA is attenuated. As a result, the gene can be expressed due to the disintegration of 
the complex. This system is the first strategy for cell-specific gene therapy using kinase 
activity as a marker of cellular identification. Using this strategy, various gene regulators 
have been developed for Src, PKC, I--kinase, Rho kinase and PKA as target signals (Sato 
et al., 2010; Kang et al., 2010; Asai et al., 2009; Tsuchiya et al., 2011; Oishi et al., 2006). These 
materials realize highly cell-specific gene expression. Figure 8b indicates examples of such 
signal-responsive gene expression in I--kinase and PKC-responsive systems (Asai et al., 
2009). The I--kinase responsive system activated expression of a GFP encoding gene only 
following stimulation of NHI 3T3 cells with LPS or TNF-, thereby initiating inflammation. 
However, if the serine residue in the peptide side-chain, which is a phosphorylation site, 
was replaced with alanine, such gene expression was not observed even following 
stimulation by LPS or TNF-. PLC is another important kinase for the proliferation of 
many types of cancer cells (Kang et al., 2009). Therefore, transfection of GFP encoding 
plasmid as a complex with the PKC responsive regulator gave massive expression of GFP 
in various cancer cell lines (Asai et al., 2009). Conversely, a negative control-regulator, in 
which the serine residue was replaced with alanine, did not show any expression in such 
cell lines. In addition, no activation of GFP expression was observed when such cells were 
pre-treated with an inhibitor of PKC. These results clearly indicate that such systems 
regulated gene expression in response to target kinases (Toita et al., 2009). In particular, the 
PKC responsive system worked also in tumor bearing mice (Kang et al., 2008; Toita et al., 
2009; Kang et al., 2010) (fig. 8c). When a complex between a PKC-responsive conjugate and 
the luciferase encoding gene was injected into a tumor directly, expression of luciferase was 
observed successfully. On the other hand, injection of the complex in normal subcutaneous 
tissue or injection of the complex using a negative control conjugate into a tumor did not 
show any expression of luciferase. The obtained image of luciferase indicates a proliferation 
activity, because the enzymatic activity regulates cancer proliferation directly and is closely 
related to the cancer malignancy. Thus, this system will be useful for cancer imaging, 
because this is the first functional imaging of cancer in contrast to ordinary imaging 
techniques of cancer that mainly visualize the existence of a tumor. Such functional images 
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imaging technologies. Such a system can also be applied to cancer cell-specific gene therapy 
(Tomiyama et al., 2010 and 2009). Using the caspase-8 encoding gene as a therapeutic gene, 
shrinkage of the tumor was also observed in HepG2 tumor bearing mice. HSV thymidine 
kinase encoding gene and the gancyclovir system also worked well in this system. Since this 
method is highly disease cell-specific, gene activity can be masked in other normal tissues or 
organs due to the absence of continuous target kinase activity (Kang et al., 2010). Therefore, 
many therapeutic genes, which were abandoned as clinical targets because of their side 
effects derived from undesired activation of such genes in non-target organs, should be 
revived using this methodology. These techniques are potentially useful for future 
medicines; although the gene complex has to be stabilized in blood flow. By covering the 
complex with sugar chains such as chondroitin sulfate or hyaluronic acid offers a promising 


















a) Chemical structure of I--kinase and PKC reponsive regulator
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Fig. 8. Intracellular protein kinase-responsive gene regulation system 
9. Conclusion and future prospective 
Recent technologies for the monitoring or handling of protein kinase activities have been 
described. Monitoring protein kinase activities using current technologies offers a way to 
understand basic biological processes of life. Such technologies are becoming significant in 
medical and medicinal fields, because protein kinases represent major drug targets and can 
also be used as diagnostic markers. However, such technologies have to be high-throughput 
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to satisfy medical or pharmaceutical demands. Detecting dysfunctional activity of particular 
kinases and relating this to a disease condition will require the development of simple and 
rapid assays. Fluorescence polarization, bead techniques using fluorimetry and colorimetric 
assays offer a way to reach this goal. Mass spectrometry is also a promising approach (Kang 
et al., 2008; Kang et al., 2007; Shigaki et al., 2006). Peptide arrays are another promising 
technology for detail evaluation of cellular conditions. Since cellular function is determined 
by a network of signaling reactions governed by enzymes including protein kinases, the 
exact state of living cells in various diseases cannot be evaluated by a single protein kinase 
assay. In this context, kinome analysis will be crucial for providing a detailed diagnosis 
before medication, prognosis after medication and validation of drugs in pharmaceutical 
testing. However, problems with the current peptide array systems, including their low 
reproducibility of obtaining similar phosphorylation profiles on chips, are hampering 
progress towards fully accurate kinome analysis. Relatively low specificity of peptide 
substrates is another issue. It is difficult to convert the obtained phosphorylation profile into 
a profile that represents the actual protein kinase activity. Bioinformatics and mathematical 
technology should be combined with array technologies in the future. 
Protein kinases are also attractive as a marker to distinguish between disease cells and 
normal cells. Our gene regulation system that responds to target protein kinase activity is 
the first artificial system that uses intracellular signaling as a trigger to output another 
biological signal. Such signal engineering represents a new cell-specific medicine approach. 
We need such a new technological field, termed “Cell Signalomics”, to link basic biological 
findings to clinical approaches. Protein kinases will be one of the most important elements 
for such a technology. 
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medical and medicinal fields, because protein kinases represent major drug targets and can 
also be used as diagnostic markers. However, such technologies have to be high-throughput 
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to satisfy medical or pharmaceutical demands. Detecting dysfunctional activity of particular 
kinases and relating this to a disease condition will require the development of simple and 
rapid assays. Fluorescence polarization, bead techniques using fluorimetry and colorimetric 
assays offer a way to reach this goal. Mass spectrometry is also a promising approach (Kang 
et al., 2008; Kang et al., 2007; Shigaki et al., 2006). Peptide arrays are another promising 
technology for detail evaluation of cellular conditions. Since cellular function is determined 
by a network of signaling reactions governed by enzymes including protein kinases, the 
exact state of living cells in various diseases cannot be evaluated by a single protein kinase 
assay. In this context, kinome analysis will be crucial for providing a detailed diagnosis 
before medication, prognosis after medication and validation of drugs in pharmaceutical 
testing. However, problems with the current peptide array systems, including their low 
reproducibility of obtaining similar phosphorylation profiles on chips, are hampering 
progress towards fully accurate kinome analysis. Relatively low specificity of peptide 
substrates is another issue. It is difficult to convert the obtained phosphorylation profile into 
a profile that represents the actual protein kinase activity. Bioinformatics and mathematical 
technology should be combined with array technologies in the future. 
Protein kinases are also attractive as a marker to distinguish between disease cells and 
normal cells. Our gene regulation system that responds to target protein kinase activity is 
the first artificial system that uses intracellular signaling as a trigger to output another 
biological signal. Such signal engineering represents a new cell-specific medicine approach. 
We need such a new technological field, termed “Cell Signalomics”, to link basic biological 
findings to clinical approaches. Protein kinases will be one of the most important elements 
for such a technology. 
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1. Introduction  
Living organisms are constantly exposed to changing environmental stimuli and insults; 
dynamic adaptation is crucial for survival. The ability of cells to sense their surrounding 
environment and respond in an appropriate manner is essential for the normal functioning 
of every living organism, and although cells are constantly exposed to numerous stimuli, 
they are usually able to accurately identify them and respond accordingly. These correct 
responses are based on a multitude of intracellular signalling networks that are able to 
decode and translate the incoming stimuli. 
Rapid adaptation to a changing environment requires a fast response from the organism. 
Thus, organisms have developed specific pathways based on cascades of chemical reactions, 
which culminate in gene transcription and a fast metabolic adaptation. These rapid changes 
are important especially when responses have to be orchestrated from different cellular 
compartments. Thus it is not surprising, given the importance of signalling in the normal 
functioning of the host cell, that pathogens exploit host cellular signalling networks in order 
to optimize their infectious cycles. The final goal of pathogens is to erode host-cell functions 
and therefore establish a permissive niche in which they can successfully survive and 
replicate. Although most microorganisms invading the human body are contained by an 
efficient immune response, some microbes have evolved to successfully establish infection 
by bypassing defensive hostile environments mounted by the host.  
Professional phagocytes, such as macrophages, neutrophils and dendritic cells are 
uniquely qualified to engulf and destroy microorganisms. These cells initiate immune 
responses and respond to microorganisms based on signal transduction pathways which 
are largely dependant on phosphorylation/dephosphorylation processes mediated by 
kinases/phosphatases. These signalling pathways are versatile and sophisticated regulatory 
mechanisms that play a central role in forming an integrated, information-processing 
network capable of coordinating multiple cellular processes in response to a wide spectrum 
of internal and external signals. Thus, this ubiquitous mechanism is responsible for the 
adaptation of cells to changes in the environment and is based on a cascade of events 
involving protein kinases. 
This chapter will focus on: (a) the effects of secreted bacterial kinases and phosphatases on 
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factors used by bacterial pathogens to modulate signal transduction pathways associated 
with the immunological response of the host. Only in the interaction of macrophages with 
pathogens will be explored. Mechanisms of signal transduction activated within bacteria in 
response to infection will not be discussed. 
2. Proteins and phospholipids involved in signalling  
2.1 Protein kinases 
Protein kinases are enzymes that phosphorylate a protein substrate by transferring a 
phosphate group from a high-energy donor, such as ATP or GTP onto specific serine, 
threonine, and tyrosine residues of a protein substrate. As a result, the phosphorylated 
substrate is activated to perform either a specific activity or to continue with the transfer of 
the phosphate group downstream to another protein substrate initiating a cascade of 
reactions. To suppress the activity of phosphorylated proteins, phosphatases catalyze the 
reverse reaction by dephosphorylating the phosphorylated substrate, turning the protein 
substrates to their initial inactivated state (not phosphorylated) preparing the system for the 
next signalling event. Thus, kinases and phosphatases function as ON/OFF switches 
modulating specific signal transduction pathways. 
2.2 Phosphatidylinositol (PI) signalling  
PIs are small lipids derived from inositol and are key components of cell membranes. They 
participate in essential roles in a wide range of cellular processes, such as membrane 
dynamics, actin cytoskeleton arrangements and vesicle trafficking (Di Paolo & De Camilli, 
2006) (Table 1). The differential distribution of PIs in cell membranes is tightly regulated by 
localized PI kinases and phosphatases, which convert diverse PI species (Fig. 1). This 
dynamic diversity enables effective temporal and spatial regulation of membrane-associated 
signalling events.  
 
PI Distribution Functions 
PI(3P) Endosomes Endocytic membane traffic, phagosome maturation, autophagy 
PI(4P) Golgi Golgi trafficking 
PI(5P) Nucleus Apoptosis 
PI(3,4)P2 Plasma membrane Signalling, cytoskeleton dynamics 
PI(3,5)P2 Endosomes Signalling, vacuole homeostasis 
PI(4,5)P2 Nucleus and plasma membrane Endocytosis, cytoskeleton dynamics 
PI(3,4,5)P3 Plasma membrane Signalling, cytoskeleton dynamics 
Table 1. Functions and distribution of PIs (adapted from Rusten & Stenmark, 2006) 
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Since PIs are involved in a wide range of cellular functions, their metabolism is often 
targeted by bacterial virulence factors that act as PI phosphatases or PI adaptor proteins. 
The signalling pathway of PIs is based on the well-established hydrolysis of 
phosphatidylinositol 4,5-bisphosphate PI-(4,5)P giving rise to the second messengers 
diacylglycerol and inositol 1,4,5-trisphosphate and the phosphorylation of PI(4,5)P2 
yielding the novel lipid phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) (Fig. 1). PIs 
often act in concert with small GTPases to recruit cytosolic proteins to host membranes. 
This allows PIs and small GTPases to exert regulatory control on each other (Di Paolo & 
De Camilli, 2006). PIs can bind GTPase-activating proteins (GAPs) and guanine nucleotide 
exchange factors (GEFs), whereas GTPases control PI metabolism by regulating PI kinases 
and phosphatases (Di Paolo & De Camilli, 2006). Manipulation of this close functional 
interplay between PI metabolism and GTPase signalling can be observed in many 
bacterial infections. 
 
Fig. 1. Biochemical activities of PI 3-kinases. 
2.3 Small GTPases  
Proteins that hydrolyse GTP to GDP, called GTPases or G proteins, use this hydrolysis to 
serve a multitude of functions in the eukaryotic cells, such as actin dynamics, vesicle 
trafficking, phagocytosis, cell growth and cell differentiation. The Ras superfamily of small 
GTPases consists of several subfamilies, including the Rab, Rho, ADP-ribosylation factor 
(Arf), Ran, and Ras families (Sprang, 1997). Small GTPases function as molecular switches 
that cycle between an inactive guanosine dihosphate (GDP-bound state) and an active GTP-
bound state. In the active GTP-bound conformation, each small GTPase binds to a subset of 
downstream effectors, which in turn activate downstream proteins to generate the 
appropriate outcome. This cycle is facilitated by two classes of regulatory proteins: GAPs 
and GEFs. GAPs turn the GTPase 'off' by accelerating the intrinsic rate of GTP hydrolysis, 
resulting in the formation of GDP and phosphate. By contrast, GEFs turn the switch 'on' by 
facilitating the dissociation of GDP and allowing the more abundant GTP to bind. 
2.4 Src family  
The regulation and activity of Src family kinases (SFKs) in response to external and internal 
cues is important during many cellular processes including cell adhesion, migration, 
polarity, and division (Bromann et al., 2004). SFKs are membrane-associated enzymes that 
can recognize and bind their specific substrates and transfer a phosphate group onto a target 
protein’s tyrosine residues. SKFs are regulated themselves by tyrosine phosphorylation, 
which controls intramolecular interactions within the molecule that fix the kinase in an 
inactive closed conformation, or allow the kinase to adopt an active conformation.  
SFKs also activate the cytoplasmic domain of tyrosine-based immunoreceptors (Fc 
receptors and complement receptor 3) once the extracellular domain binds opsonins, such as 
immunoglobulins G (IgG).  
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3. Microbial pattern recognition  
Since macrophages need to recognize a plethora of foreign microbes rapidly, they express a 
diverse repertoire of receptors that bind conserved microbial molecular patterns. These 
receptors have evolved to recognize molecular patterns that have remained unchanged over 
the evolution of the microbes. Signalling that is initiated as a result of these pattern 
recognition receptors increases the macrophages antimicrobial abilities. To provide a fast 
response against microbe invasion, mammals have developed an early immune response 
defined as the innate response, which does not provide a long-lasting protection, but is an 
essential first line of defence against bacterial pathogens. 
3.1 Pathogen-Associated Molecular Patterns (PAMPs) and receptors 
Since unchangeable molecular patterns, such as the bacterial cell wall, is essentially conserved 
across Gram-positive and Gram-negative bacteria, eukaryotic organisms evolved specific 
receptors which recognize these molecular patterns. These specific receptors are encoded by 
germlines and termed pattern recognition receptors (PRRs) (Ishii et al., 2008). Recognition of 
Pathogen-Associated Molecular patterns (PAMPs) stimulates intracellular signalling leading to 
gene expression and ultimately the activation of antimicrobial and inflammatory activities. 
Therefore, the innate response exerts two functions: (a) a rapid line of defence against 
pathogens, and (b) the initiation of a signalling process leading to the development of adaptive 
immune responses and the establishment of an immunological memory.  
To avoid detection by macrophages, some bacteria have evolved to modify their cellular 
surface and avoid the stimulation of receptors on phagocyte membranes. For example, many 
Gram-negative bacteria can alter their lipopolysaccharide structure during infection, to avoid 
recognition or to protect themselves from antibacterial products generated by the host, such as 
antibacterial peptides. In parallel, the innate recognition of microbes activates a cascade of 
kinase reactions, which in turn, will activate a cellular response capable of eliminating the 
invading microorganism. Since this innate immune response can be accompanied by tissue 
damage, tissue repair mechanisms are also activated (Medzhitov, 2008). In addition, the 
activation of transcription factors represents the culmination or endpoint of many signal 
transduction pathways activated in response to microbial recognition. These transcription 
factors can access the nucleus and bind to specific DNA sequences activating gene 
transcription upon binding to the respective promoters or, as in the case of the IFN-B 
promoter, activating different transcription factors such as nuclear factor kappa B (NF-kB), 
interferon (IFN)-regulatory factors (IRFs) and AP-1 (Honda & Taniguchi, 2006).  
Most PRRs able to recognize bacterial patterns are Toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain containing proteins (NOD)-like receptors (NLRs) (Table 2). 
TLRs are transmembrane receptors able to recognize PAMPs in the extracellular space and in 
the cytoplasm or endosomes. In humans, ten TLRs have been identified (Takeuchi & Akira, 
2010). Structurally, TLRs comprise of a single membrane-spanning domain separating the 
cytoplasmic domain involved in signalling from the recognizing receptor able to bind the 
ligand. The extracellular domain is involved in PAMP recognition, whereas the cytoplasmic 
domain is essential for downstream signalling (O’Neill & Bowie, 2007). TLRs are highly 
expressed by professional phagocytes such as macrophages and dendritic cells, but can also be 
expressed by other cell types, such as epithelial cells (Iwasaki & Medzhitov, 2004).  
 
Role of Kinases and Phosphatases in Host-Pathogen Interactions 103 
NLRs consist of an N’-terminal effector domain, responsible for downstream signalling and 
a C’-terminal region similar to TLRs, which are involved in the PAMP recognition (Inohara 
& Nunez, 2003). NOD1 and NOD2 are the best-characterized NLRs and are involved in the 
detection of intracellular bacteria (Chamaillard et al., 2003; Girardin et al., 2003). For 
instance, peptidoglycans (PGNs) are structural units of cell walls common to all bacteria 
(Gay & Gangloff, 2007). Degradation of PGNs leads to the release of several structural units 
including muramyl dipeptide, which is sensed in the cytosol by the NLR NOD2, which in 








TLR9 Unmethylated CpG DNA 
Diaminopimelic acid NOD1 
Muramyl dipeptide NOD2 
 Table 2. Receptors involved in bacterial pattern recognition 
3.2 Major signalling pathways involved in host-pathogen interaction 
Upon the perception of bacterial patterns, the immune response activates an intricate and 
complex network of kinases, which will ultimately result in the transcription of genes. The 
products of these genes will generate the immune response. Then, PRRs are able to activate a 
sequence of three major signalling pathways in mammals: mitogen-activated protein kinases 
(MAPKs), IRFs, and the nucler factor NF-kB, which will culminate in the transcription and 
release of proteins involved in the immune response.  
The MAPKs are a group of protein serine/threonine kinases that are activated in 
mammalian cells in response to a variety of extracellular stimuli and mediate signal 
transduction from the cell surface to the nucleus where they can alter the phosphorylation 
status of specific transcription factors (Johnson & Lapadat, 2002). Three major types of 
MAPK pathways have been reported so far in mammalian cells. The extracellular signal-
related kinases (ERKs 1 and 2) pathway is involved in cell proliferation and differentiation, 
whereas the c-Jun N-terminal kinases (JNKs 1, 2 and 3), and p38 MAPK (p38 , β, γ and δ) 
pathways are involved in response to stress stimuli. These three factors -ERK, JNK and p38- 
dictate the fate of cells in concert (Johnson & Lapadat, 2002). As an illustration, TLR4 
recognizes lipopolysaccharides (LPSs) of Gram-negative bacteria. Then, when TLR4 
recognizes this pattern, an activation of the MAPKs’ cascade is initiated. At the onset of this 
process, the cytoplasmic TIR domain of TLR4 mediates the activation of the cascade through 
the four adaptor proteins: (a) myeloid differentiation primary response protein 88 (MyD88), 
(b) TIR-domain-containing adaptor inducing IFN-B (TRIF), (3) TRIF related adaptor, and (4) 
MyD88-adaptor-like (Mal) (Fitzgerald et al., 2001, 2003; Yamamoto et al., 2003a; 2003b). 
Upon activation, these adaptor proteins communicate the signal via the kinases IL-1 
receptor associated kinase (IRAK)-4, IRAK-1/2, and RIPI, which in collaboration with TNF 
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3. Microbial pattern recognition  
Since macrophages need to recognize a plethora of foreign microbes rapidly, they express a 
diverse repertoire of receptors that bind conserved microbial molecular patterns. These 
receptors have evolved to recognize molecular patterns that have remained unchanged over 
the evolution of the microbes. Signalling that is initiated as a result of these pattern 
recognition receptors increases the macrophages antimicrobial abilities. To provide a fast 
response against microbe invasion, mammals have developed an early immune response 
defined as the innate response, which does not provide a long-lasting protection, but is an 
essential first line of defence against bacterial pathogens. 
3.1 Pathogen-Associated Molecular Patterns (PAMPs) and receptors 
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receptors which recognize these molecular patterns. These specific receptors are encoded by 
germlines and termed pattern recognition receptors (PRRs) (Ishii et al., 2008). Recognition of 
Pathogen-Associated Molecular patterns (PAMPs) stimulates intracellular signalling leading to 
gene expression and ultimately the activation of antimicrobial and inflammatory activities. 
Therefore, the innate response exerts two functions: (a) a rapid line of defence against 
pathogens, and (b) the initiation of a signalling process leading to the development of adaptive 
immune responses and the establishment of an immunological memory.  
To avoid detection by macrophages, some bacteria have evolved to modify their cellular 
surface and avoid the stimulation of receptors on phagocyte membranes. For example, many 
Gram-negative bacteria can alter their lipopolysaccharide structure during infection, to avoid 
recognition or to protect themselves from antibacterial products generated by the host, such as 
antibacterial peptides. In parallel, the innate recognition of microbes activates a cascade of 
kinase reactions, which in turn, will activate a cellular response capable of eliminating the 
invading microorganism. Since this innate immune response can be accompanied by tissue 
damage, tissue repair mechanisms are also activated (Medzhitov, 2008). In addition, the 
activation of transcription factors represents the culmination or endpoint of many signal 
transduction pathways activated in response to microbial recognition. These transcription 
factors can access the nucleus and bind to specific DNA sequences activating gene 
transcription upon binding to the respective promoters or, as in the case of the IFN-B 
promoter, activating different transcription factors such as nuclear factor kappa B (NF-kB), 
interferon (IFN)-regulatory factors (IRFs) and AP-1 (Honda & Taniguchi, 2006).  
Most PRRs able to recognize bacterial patterns are Toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain containing proteins (NOD)-like receptors (NLRs) (Table 2). 
TLRs are transmembrane receptors able to recognize PAMPs in the extracellular space and in 
the cytoplasm or endosomes. In humans, ten TLRs have been identified (Takeuchi & Akira, 
2010). Structurally, TLRs comprise of a single membrane-spanning domain separating the 
cytoplasmic domain involved in signalling from the recognizing receptor able to bind the 
ligand. The extracellular domain is involved in PAMP recognition, whereas the cytoplasmic 
domain is essential for downstream signalling (O’Neill & Bowie, 2007). TLRs are highly 
expressed by professional phagocytes such as macrophages and dendritic cells, but can also be 
expressed by other cell types, such as epithelial cells (Iwasaki & Medzhitov, 2004).  
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NLRs consist of an N’-terminal effector domain, responsible for downstream signalling and 
a C’-terminal region similar to TLRs, which are involved in the PAMP recognition (Inohara 
& Nunez, 2003). NOD1 and NOD2 are the best-characterized NLRs and are involved in the 
detection of intracellular bacteria (Chamaillard et al., 2003; Girardin et al., 2003). For 
instance, peptidoglycans (PGNs) are structural units of cell walls common to all bacteria 
(Gay & Gangloff, 2007). Degradation of PGNs leads to the release of several structural units 
including muramyl dipeptide, which is sensed in the cytosol by the NLR NOD2, which in 








TLR9 Unmethylated CpG DNA 
Diaminopimelic acid NOD1 
Muramyl dipeptide NOD2 
 Table 2. Receptors involved in bacterial pattern recognition 
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whereas the c-Jun N-terminal kinases (JNKs 1, 2 and 3), and p38 MAPK (p38 , β, γ and δ) 
pathways are involved in response to stress stimuli. These three factors -ERK, JNK and p38- 
dictate the fate of cells in concert (Johnson & Lapadat, 2002). As an illustration, TLR4 
recognizes lipopolysaccharides (LPSs) of Gram-negative bacteria. Then, when TLR4 
recognizes this pattern, an activation of the MAPKs’ cascade is initiated. At the onset of this 
process, the cytoplasmic TIR domain of TLR4 mediates the activation of the cascade through 
the four adaptor proteins: (a) myeloid differentiation primary response protein 88 (MyD88), 
(b) TIR-domain-containing adaptor inducing IFN-B (TRIF), (3) TRIF related adaptor, and (4) 
MyD88-adaptor-like (Mal) (Fitzgerald et al., 2001, 2003; Yamamoto et al., 2003a; 2003b). 
Upon activation, these adaptor proteins communicate the signal via the kinases IL-1 
receptor associated kinase (IRAK)-4, IRAK-1/2, and RIPI, which in collaboration with TNF 
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receptor-associated factor (TRAF) 6, activate transforming growth factor B-activated kinase 
(TAK) 1 in association with TAB2/3, through a mechanism dependent on the E3 ubiquitin 
ligase activity of the TRAF molecules (Akira & Takeda 2004; Kawagoe et al., 2008, Sato et al., 
2005). TAK1 activates IkB kinase (IKK)-alfa/beta to release NF-kB from the inhibitory 
subunit of IkB, as well as MAPKs (Sato et al., 2005).  
4. Phagocytosis and intracellular survival 
Upon infection, bacterial pathogens interact with host membranes through different 
mechanisms. The interaction between the bacterium and the host plasma membrane (and its 
embedded receptors) results in the activation of multiple host-signalling pathways that can 
alter actin cytoskeleton dynamics or vesicle trafficking. Three membrane-associated sig-
nalling events are targeted by bacterial pathogens: phosphoinositide (PI) metabolism, 
GTPase signalling and autophagy. 
4.1 Avoiding phagocytosis  
Some bacteria evolved to remain in the extracellular milieu to avoid being killed within the 
macrophage. This advantage also minimizes bacteria–macrophage interactions and as a 
consequence, the macrophage signalling required to activate an adaptive immune response 
is impaired. To avoid their engulfment, extracellular pathogens have to interfere with 
phagocytosis. One of the best study pathogens is Yersinia, which interferes with 
phagocytosis by a set of virulence proteins with an array of enzymatic activities that is 
delivered into macrophages. Some of the bacterial proteins interfere with the signal 
transduction of macrophages. For instance, YopH is a protein tyrosine phosphatase that 
targets host focal adhesion proteins, such as p130cas, paxillin, and focal adhesion kinase 
(FAK). Then, by dephosphorylating these substrates, YopH prevents uptake of bacteria by 
the host immune cells by destabilizing the focal adhesions involved in the internalization of 
bacteria by eukaryotic cells (Black et al., 1997), and allowing the pathogen to proliferate 
extracellularly. Yersinia also secretes YopE, a GTPase-activating protein that inactivates the 
small GTPases RhoA, Rac, and Cdc42 to prevent the actin polymerization that is required 
for phagocytosis (von Pawel-Rammingen, 2000). YopT is a papain-like cysteine protease that 
cleaves the lipid moiety of RhoA to depolymerize actin filaments, leading to their 
irreversible detachment from the plasma membrane and their inactivation (Shao et al., 2002). 
Thus, YopT contributes to the inhibition of bacterial phagocytosis by preventing 
rearrangements of the actin cytoskeleton. Yersinia also secretes the kinase YpkA into the host 
cytoplasm, where it phosphorylates specific proteins to prevent bacterial uptake and the 
killing by macrophages (Hakansson et al., 1996). Finally, YopO, a serine/threonine kinase 
activated by actin, contributes to the antiphagocytic activity in Y. enterocolitica by binding to 
Rho GTPases (Grosdent et al., 2002).  
Other microorganisms such as enteropathogenic Escherichia coli (EPEC), target a different 
signalling pathway by secreting an unidentified bacterial protein into macrophages to 
inhibit the activity of phosphatidylinositol 3-kinase (PI3K) (Celi et al., 2001). Although 
pathogens that subvert macrophage phagocytic signalling remain outside the cell to avoid 
phagolysosomal degradation, they still have mechanisms to cope with extracellular 
defences, such as killing by complement or antimicrobial peptides (Wurzner, 1999). 
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4.2 Modulating the interacting membrane by disruption of PI signalling  
PIs are key players in maintaining cell membrane structure by regulating the actin 
cytoskeleton underneath the plasma membrane and by tagging and targeting vesicles inside 
the cell. The disruption of PI homeostasis at the plasma membrane can destabilize actin 
dynamics changing membrane morphologies, and then intracellular pathogens can 
modulate the membrane integrity. 
The inositol phosphate phosphatase IpgD is an effector from the facultative intracellular 
pathogen Shigella flexneri that is directly translocated into host cells through a type III 
secretion system (Niebuhr et al., 2000). IpgD hydrolyses PI(4,5)P2 to produce PI5P, at an 
early stage in the infection (Niebuhr et al., 2002). The removement of PI(4,5)P2 causes a 
rearrangement in the cytoskeleton by changing the extent of interaction of membrane 
visualized as a massive cell blebbing, facilitating the invasion of bacteria (Charras & Paluch, 
2008).  
Listeria invasion is mediated by interaction of the bacterial surface protein InlB with the host 
receptor Met receptor tyrosine kinase (Shen et al., 2000). InlB-Met interaction triggers 
activation, by tyrosine phosphorylation, of the Met receptor and subsequent rearrangements 
in the actin cytoskeleton of the mammalian cell (Mostowy & Cossart, 2009). Ultimately, 
these cytoskeletal changes remodel the host cell surface, resulting in the engulfment of 
adherent Listeria. The human GAP ARAP2 is required for InlB-mediated cytoskeletal 
changes and entry of the pathogen. ARAP2 is known to bind PI(3,4,5)P3, resulting in 
upregulation of a GAP domain that inactivates the mammalian GTPase Arf6 (Wong & 
Isberg, 2003). Then, one of the likely ways that PI3-kinase controls entry of Listeria is 
through regulation of ARAP2. In addition, cholesterol-rich lipid rafts at the plasma 
membrane are needed for InlB-mediated uptake of Listeria (Seveau et al., 2004).  
Small GTPases Sar1, Rab1 and Arf1 are required for the Legionella-containing vesicles to 
acquire vesicle trafficking protein Sec22b (Kagan & Roy, 2002). Legionella secretes the 
effectors DrrA/SidM and LepB, which impaire the recruitment of Rab1 (Ingmundson et al., 
2007). The association of these secreted effectors with the Legionella-containing vesicles 
surface is mediated by their affinity for the abundant lipid PI4P on the Legionella-containing 
vesicles surface (Brombacher et al., 2009; Ragaz et al., 2008). 
SopB, a type III secretion system effector from Salmonella typhimurium, is a PI phosphatase 
that affects multiple processes during the course of infection, including bacterial invasion, 
Salmonella-containing vesicle formation and maturation (Hernandez et al., 2004). SopB 
hydrolyses PI(4,5)P2 both at the plasma membrane and on the Salmonella-containing vesicle 
membrane surface (Bakowski et al., 2010). Decreased levels of PI(4,5)P2 at the plasma 
membrane promote membrane fission by reorganizing the actin cytoskeleton during 
bacterial internalization (Mason et al., 2007).  
SopB also mediates the production and maintenance of high levels of PI3P on the Salmonella-
containing vesicle surface through an indirect effect of its phosphatase activity. SopB 
recruits Rab5 and its effector VPS34, a PI3-kinase (that generates PI3P), to the Salmonella-
containing vesicle through a process that is dependent on the reduction of PI(4,5)P2 (Mallo 
et al., 2008). Then, by manipulating the lipid composition of the Salmonella-containing 
vesicle, SopB impairs the recruitment of Rabs avoiding lysosomal degradation.  
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vesicle, SopB impairs the recruitment of Rabs avoiding lysosomal degradation.  
 
Protein Kinases 106 
4.3 Surviving and living within the host  
The ability to survive intracellularly is crucial for several pathogenic bacteria after they 
invade their eukaryotic target cells. Following engulfment by macrophages, bacteria are 
internalized within a membrane–bound vacuole termed a phagosome. Phagosomes are 
pivotal organelles in the ability of mammalian cells, including professional and non-
professional phagocytes, to restrict the establishment and spread of infectious diseases.  
Rapidly after their formation, phagosomes modify their composition by recycling plasma 
membrane molecules, and by acquiring markers of the early endocytic pathway such as 
Rab5 and EEA1 (Steele-Mortimer et al., 1999). Phagosomes have been shown to fuse 
sequentially with endosomes of increasing age or of increasing maturation level (Jahraus et 
al., 1994). A variety of Rab proteins have been identified on phagosomes, including Rab5, 
Rab7, and Rab11 (Desjardins et al., 1994; Cox et al., 2000).  
Under normal circumstances, the phagosome progressively acidifies and ultimately, in a 
tightly regulated process, will fuse with the lysosome, in an event known as phagosome-
lysosome (phagolysosome) fusion. 
The process of phagocytosis itself determines some of the characteristics of the first 
compartment in which pathogens are going to reside within the host cells. Newly formed 
phagosomes are immature organelles unable to kill and degrade microorganisms. In order 
to acquire and exert their microbicidal function, phagosomes must engage in a maturation 
process referred to as phagolysosome biogenesis. Then, to successfully invade and replicate 
intracellularly, pathogens must find ways to avoid the harsh environment of lysosomes, 
organelles containing an arsenal of potent microbicidal compounds. Therefore, the final goal 
of the majority of intracellular pathogens is to prevent their arrival to lysosomes, where their 
killing is dictated.  
While the majority of bacteria grow outside of eukaryotic cells, some bacteria are facultative 
or even obligate intracellular pathogens; such is the case with L. monocytogenes, 
Mycobacterium tuberculosis, and Chlamydia trachomatis. Bacterial replication, therefore, takes 
place in the endosomal compartments, or in the case of Listeria in the cytoplasm due to a 
mechanism of escape from the phagosomes.  
The life style of cytosolic bacteria can be divided into three main stages: (a) escape from the 
phagosome, (b) replication within the cytosol, and (c) manipulation of the innate immune 
responses triggered in the cytosol. The escape from the phagosome is a crucial step in the 
life cycle of cytosolic pathogens. This occurs rapidly following invasion, and most 
pathogens are detected free in the cytosol within 30 minutes of invasion. In order to evade 
the lysosome, a process lasting between 30-45 minutes post-engulfment (Yates et al., 2005), 
pathogens must escape before the fusion with lysosomes (Haas, 2007).  
4.4 Disruption of MAPK signalling pathways  
MAPK signalling is crucial for many responses to infection, representing a strategic target 
for bacterial subversion strategies. The extent of MAPK phosphorylation (kinase signalling 
kinetics) may influence the responses of macrophages. For instance, the duration of 
signalling through MAPK pathways determines whether a macrophage proliferates or 
activates in response to a stimulus (Velledor et al., 2000). Likewise, modification of MAPK 
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pathways by bacteria may contribute to induction of host cell death, which is an important 
feature of bacterial pathogenesis, promoting bacterial tissue colonization.  
In the case of S. enterica serovar Typhi, the tyrosine phosphatase SptP, a translocated protein 
from the pathogen within the host, inhibits the activation of the MAPK pathway by 
dephosphorylating Raf, an intermediate in this pathway (Lin et al., 2003).  
A way to alter the MAPK pathway is the degradation of members involved in the response 
cascade. For example, Bacillus anthracis interrupts several MAPK signalling pathways by 
proteolytically degrading all MAPK kinases (MAPKKs) except MAPKK5. This interference 
is mediated by the delivery of a metalloproteinase to the cytosol, where it deactivates MEK1 
by cleaving between its amino terminus and catalytic domain. Cleavage of the MAPKK that 
activates p38 MAPK, which is mediated by lethal factor, induces macrophage apoptosis, 
possibly by interfering with the p38-dependent expression of NF-κB target genes that are 
necessary for cell survival (Park et al., 2002). 
Other pathogens interfere by blocking or inhibiting post-translational modifications, such as 
prevention of phosphorylation. Members of the genus Yersinia use an alternative mechanism 
to disrupt MAPK signalling and, as a result of this disruption, the downstream activation of 
NF-κB in macrophages is impaired. Specifically, Y. pseudotuberculosis delivers YopJ, a 
cysteine protease, which inhibits kinase activity by preventing phosphorylation (Orth et al., 
1999). YopJ also interferes with the post-translational modification of proteins that are 
involved in MAPK signalling by disturbing the ubiquitin-like protein SUMO-1, and then 
inhibiting its conjugation to target proteins for degradation (Orth et al., 2000).  
In conclusion, pathogens can modify the antibacterial response of macrophages not only 
towards a targeted kinase pathway, but also by the timing of the activation or inhibition. 
An important downstream response of normal macrophage signalling is the production of 
cytokines. Cytokines are essential for modulation of inflammation, recruitment of other cells 
to the site of infection, and mediation of the link between innate and adaptive immune 
responses. As mentioned above, macrophages must control signalling that leads to 
inflammatory responses tightly, to avoid an inflammation dysregulation. One level of 
control is to regulate the intensity and duration of signalling, which often originates from 
TLRs. For example, the macrophage protein IRAK-M has a pivotal role in downregulating 
macrophage responses to LPS by inducing tolerance. Without IRAK-M, Salmonella infection 
causes increased tissue damage (Kobayashi et al., 2002). Another level of control is the 
balance between proinflammatory cytokines, such as TNF- and IL-12, and predominantly 
anti-inflammatory cytokines, such as IL-10 and transforming growth factor-β (TGF-β), 
which are produced during infection. Bacterial pathogens target signalling that leads to the 
expression of cytokine genes or their post-translational modifications that perturb the 
balance of cytokines to their advantage. Macrophages and bacteria can therefore both 
control the extent of the immune response through cytokine production. 
One effector protein secreted intracellularly by Shigella is OspF, which possesses 
phosphothreonine lyase activity. Once translocated into the nucleus, OspF irreversibly 
dephosphorylates host MAPKs, and therefore prevents the phosphorylation of histone H3 
(Li et al., 2007; Arbibe et al., 2007). Interestingly, other bacterial virulence factors, such as 
SpvC from S. typhimurium possess the same phosphothreonine lyase activity as OspF and 
also target MAP kinases of their hosts (Mazurkiewicz et al., 2008). In addition to these 
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cascade. For example, Bacillus anthracis interrupts several MAPK signalling pathways by 
proteolytically degrading all MAPK kinases (MAPKKs) except MAPKK5. This interference 
is mediated by the delivery of a metalloproteinase to the cytosol, where it deactivates MEK1 
by cleaving between its amino terminus and catalytic domain. Cleavage of the MAPKK that 
activates p38 MAPK, which is mediated by lethal factor, induces macrophage apoptosis, 
possibly by interfering with the p38-dependent expression of NF-κB target genes that are 
necessary for cell survival (Park et al., 2002). 
Other pathogens interfere by blocking or inhibiting post-translational modifications, such as 
prevention of phosphorylation. Members of the genus Yersinia use an alternative mechanism 
to disrupt MAPK signalling and, as a result of this disruption, the downstream activation of 
NF-κB in macrophages is impaired. Specifically, Y. pseudotuberculosis delivers YopJ, a 
cysteine protease, which inhibits kinase activity by preventing phosphorylation (Orth et al., 
1999). YopJ also interferes with the post-translational modification of proteins that are 
involved in MAPK signalling by disturbing the ubiquitin-like protein SUMO-1, and then 
inhibiting its conjugation to target proteins for degradation (Orth et al., 2000).  
In conclusion, pathogens can modify the antibacterial response of macrophages not only 
towards a targeted kinase pathway, but also by the timing of the activation or inhibition. 
An important downstream response of normal macrophage signalling is the production of 
cytokines. Cytokines are essential for modulation of inflammation, recruitment of other cells 
to the site of infection, and mediation of the link between innate and adaptive immune 
responses. As mentioned above, macrophages must control signalling that leads to 
inflammatory responses tightly, to avoid an inflammation dysregulation. One level of 
control is to regulate the intensity and duration of signalling, which often originates from 
TLRs. For example, the macrophage protein IRAK-M has a pivotal role in downregulating 
macrophage responses to LPS by inducing tolerance. Without IRAK-M, Salmonella infection 
causes increased tissue damage (Kobayashi et al., 2002). Another level of control is the 
balance between proinflammatory cytokines, such as TNF- and IL-12, and predominantly 
anti-inflammatory cytokines, such as IL-10 and transforming growth factor-β (TGF-β), 
which are produced during infection. Bacterial pathogens target signalling that leads to the 
expression of cytokine genes or their post-translational modifications that perturb the 
balance of cytokines to their advantage. Macrophages and bacteria can therefore both 
control the extent of the immune response through cytokine production. 
One effector protein secreted intracellularly by Shigella is OspF, which possesses 
phosphothreonine lyase activity. Once translocated into the nucleus, OspF irreversibly 
dephosphorylates host MAPKs, and therefore prevents the phosphorylation of histone H3 
(Li et al., 2007; Arbibe et al., 2007). Interestingly, other bacterial virulence factors, such as 
SpvC from S. typhimurium possess the same phosphothreonine lyase activity as OspF and 
also target MAP kinases of their hosts (Mazurkiewicz et al., 2008). In addition to these 
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factors, the Yersinia YopJ/P effector can inactivate host MAP kinases by catalyzing their 
acetylation (Mittal et al., 2006; Mukherjee et al., 2006). Finally, the anthrax lethal factor, a 
subunit of the anthrax toxin encoded by B. anthracis, cleaves host MAP kinases, leading to 
their irreversible inactivation (Turk, 2007). 
Helicobacter pylori has been reported to activate MAPK3 enzymes (Asim et al., 2010). When 
invading the human-derived monocyte cell line THP-1, H. pylori-stimulates the extression of 
IL-18 that was reduced by either ERK or p38 inhibitors (Yamauchi et al., 2008). Inhibition of 
ERK and, to a greater degree, inhibition of p38 have been shown to reduce H. pylori-
stimulated IL-8 expression in THP-1 cells (Bhattacharyya et al., 2002). Taken together, these 
studies suggested that at least MAPKs are involved in biological effects of H. pylori infection 
in macrophages.  
4.5 Disruption of interferon signalling  
Macrophages possess a robust tyrosine kinase signalling network that includes the Janus 
kinase (JAK) and the signal transducer and activator of transcription (STAT). Both pathways 
are activated as a result of IFN binding to their receptors on the cell surface. IFN-γ amplifies 
the antibactericidal activity of macrophages (Boehm et al., 1997) by activating various 
enzymes within the macrophage that increase the production of damaging reactive oxygen 
and nitrogen species, starve the bacteria of tryptophan within the phagolysosome, and 
increase lysosomal degradation of the bacteria. In addition, IFN-γ enhances the adaptive 
response of the organism by increasing the Major Histocompatibility Complex (MHC) class I 
and II antigen presentation and synthesis of cytokines such as IL-12 and TNF-α (Shtrichman 
& Samuel, 2001). In conclusion, the IFN-γ signalling network allows macrophages to 
respond more rapidly to bacterial infection. Bacterial impairment of IFN-γ signalling is best 
characterized in macrophages infected by Mycobacteria species. M. avium infection causes a 
decreased transcription of the IFN-γ receptor leading to impaired downstream STAT 
activation (Hussain et al., 1999). M. tuberculosis uses an uncharacterized mycobacterial 
surface component to affect a later step in IFN-γ signalling. Although STAT 
phosphorylation, dimerization, nuclear translocation and DNA binding is intact in M. 
tuberculosis-infected macrophages, there is still a decrease in the association of STAT with 
transcriptional co-activators, causing an impaired transcription of IFN-γ-responsive genes 
(Ting et al., 1999). 
4.6 Disruption and amplification of NF-κB signalling  
NF-κB signalling relies on the targeting of its inhibitor IκB. As a result of binding to IκB, NF-
κB avoid translocation from the cytosol to the nucleus where it activates gene transcription. 
Inhibition of NF-κB signalling leads to the decreased release of proinflammatory cytokines, 
such as TNF-, and increased apoptosis, both of which can protect pathogens from the 
immune response.Virulence proteins secreted by pathogens such as Y. enterocolitica bind to 
the IKK to prevent the phosphorylation of IκB, which is essential for its degradation, thereby 
trapping NF-κB in the cytosol and avoiding its gene target interactions (Schesser et al., 1998). 
M. ulcerans inhibits nuclear translocation of NF-κB independently of IκB, possibly by 
altering the phosphorylation of NF-κB or interfering with its DNA-binding ability (Pehleven 
et al., 1999).  
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On the other hand, pathogens can use an opposite strategy by actively increasing the NF-κB 
activity. In this way, the production of proinflammatory cytokines can recruit more host 
cells to the site of infection, facilitating the bacterial spread. For instance, listeriolysin O and 
InlB, two virulence proteins secreted by L. monocytogenes, activate NF-κB in a PI3K-
dependent manner. As a result of an increase in the inflammatory response, pathogens 
spread by recruiting more monocyte to the site of infection (Kayaal et al., 2002). Another 
advantage for the pathogen is a protective environment because of the anti-apoptotic 
signalling activated by NF-κB.  
L. monocytogenes secretes InlC intracellularly, which directly interacts with the IKKa protein 
to block the phosphorylation of IkBa (Gouin et al., 2010). Similarly, YopJ/P, an effector 
produced by pathogenic Yersinia species, mediates the acetylation of the IKKa and b 
proteins, which prevents their activation and subsequent IkBa phosphorylation (Mittal et al., 
2006).  
The effectors NleH1 and NleH2 of the enterohaemorrhagic E. coli (EHEC) are 
autophosphorylated serine/threonine kinases translocated by the pathogen. Both effectors 
bind directly to RPS3, a NF-κB non-Rel subunit. Although autophosphorylated, their 
binding to RPS3 is independent of kinase activity (Gao et al., 2009).  
4.7 Disruption of small GTPase signalling 
After initial attachment to the host cell membrane, many pathogens Gram-negative bacteria 
use a type III secretion system to inject virulence proteins into the host cell cytoplasm 
(Ghosh, 2004). A number of injected proteins bind directly to actin to modulate its dynamic 
leading to changes in the organization of the actin cytoskeleton (Patel & Galan, 2005) by 
regulating small GTPases. In a variety of pathogens, a family of conserved type III secreted 
proteins influences the actin cytoskeleton dynamic by mimicking the GTP-bound form of 
the Rho GTPases (Alto et al., 2006). These proteins, which share no obvious sequences 
homology with Rho GTPases, use a conserved WxxE motif to directly activate downstream 
effectors of Cdc42, Rac1, and Rho (Alto et al., 2006). 
Several bacterial pathogens also use the type IV secretion systems to inject effector proteins 
into the cytoplasm of host cells (Cascales & Christie, 2003; Galan & Wolf-Watz, 2006). After 
translocation, these effectors target various components of eukaryotic signal transduction 
pathways, which subvert host cell functions for the benefit of the pathogen. 
Rho-family GTPases, such as Rho, Rac1, and Cdc42, regulate actin dynamics by induction of 
actin, lamellipodia, and filopodia formation, respectively. Inactivation of these GTPases 
leads to a decrease in F-actin and increase in monomeric actin (G-actin), resulting in loss of 
cell shape, motility, and ability to phagocytose or endocytose pathogens.  
S. typhimurium manipulates this members using the effectors SopE and SptP. SopE acts as a 
GEF for Cdc42 and Rac1, whereas SptP acts as a GAP for Cdc42 and Rac1 (Fu & Galan, 
1999). SopE is translocated into the cell to induce actin rearrangement and membrane 
disruption to facilitate pathogen entry into the cell and formation of Salmonella-containing 
vesicles, while SptP disrupts these actin filaments to restore actin organization in the cell 
(Hardt et al., 1998). SptP possesses both a GAP and tyrosine phosphatase activities (Fu & 
Galan, 1999). It disrupts the actin cytoskeleton by binding to Rac1 and catalysing the 
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factors, the Yersinia YopJ/P effector can inactivate host MAP kinases by catalyzing their 
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increase lysosomal degradation of the bacteria. In addition, IFN-γ enhances the adaptive 
response of the organism by increasing the Major Histocompatibility Complex (MHC) class I 
and II antigen presentation and synthesis of cytokines such as IL-12 and TNF-α (Shtrichman 
& Samuel, 2001). In conclusion, the IFN-γ signalling network allows macrophages to 
respond more rapidly to bacterial infection. Bacterial impairment of IFN-γ signalling is best 
characterized in macrophages infected by Mycobacteria species. M. avium infection causes a 
decreased transcription of the IFN-γ receptor leading to impaired downstream STAT 
activation (Hussain et al., 1999). M. tuberculosis uses an uncharacterized mycobacterial 
surface component to affect a later step in IFN-γ signalling. Although STAT 
phosphorylation, dimerization, nuclear translocation and DNA binding is intact in M. 
tuberculosis-infected macrophages, there is still a decrease in the association of STAT with 
transcriptional co-activators, causing an impaired transcription of IFN-γ-responsive genes 
(Ting et al., 1999). 
4.6 Disruption and amplification of NF-κB signalling  
NF-κB signalling relies on the targeting of its inhibitor IκB. As a result of binding to IκB, NF-
κB avoid translocation from the cytosol to the nucleus where it activates gene transcription. 
Inhibition of NF-κB signalling leads to the decreased release of proinflammatory cytokines, 
such as TNF-, and increased apoptosis, both of which can protect pathogens from the 
immune response.Virulence proteins secreted by pathogens such as Y. enterocolitica bind to 
the IKK to prevent the phosphorylation of IκB, which is essential for its degradation, thereby 
trapping NF-κB in the cytosol and avoiding its gene target interactions (Schesser et al., 1998). 
M. ulcerans inhibits nuclear translocation of NF-κB independently of IκB, possibly by 
altering the phosphorylation of NF-κB or interfering with its DNA-binding ability (Pehleven 
et al., 1999).  
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On the other hand, pathogens can use an opposite strategy by actively increasing the NF-κB 
activity. In this way, the production of proinflammatory cytokines can recruit more host 
cells to the site of infection, facilitating the bacterial spread. For instance, listeriolysin O and 
InlB, two virulence proteins secreted by L. monocytogenes, activate NF-κB in a PI3K-
dependent manner. As a result of an increase in the inflammatory response, pathogens 
spread by recruiting more monocyte to the site of infection (Kayaal et al., 2002). Another 
advantage for the pathogen is a protective environment because of the anti-apoptotic 
signalling activated by NF-κB.  
L. monocytogenes secretes InlC intracellularly, which directly interacts with the IKKa protein 
to block the phosphorylation of IkBa (Gouin et al., 2010). Similarly, YopJ/P, an effector 
produced by pathogenic Yersinia species, mediates the acetylation of the IKKa and b 
proteins, which prevents their activation and subsequent IkBa phosphorylation (Mittal et al., 
2006).  
The effectors NleH1 and NleH2 of the enterohaemorrhagic E. coli (EHEC) are 
autophosphorylated serine/threonine kinases translocated by the pathogen. Both effectors 
bind directly to RPS3, a NF-κB non-Rel subunit. Although autophosphorylated, their 
binding to RPS3 is independent of kinase activity (Gao et al., 2009).  
4.7 Disruption of small GTPase signalling 
After initial attachment to the host cell membrane, many pathogens Gram-negative bacteria 
use a type III secretion system to inject virulence proteins into the host cell cytoplasm 
(Ghosh, 2004). A number of injected proteins bind directly to actin to modulate its dynamic 
leading to changes in the organization of the actin cytoskeleton (Patel & Galan, 2005) by 
regulating small GTPases. In a variety of pathogens, a family of conserved type III secreted 
proteins influences the actin cytoskeleton dynamic by mimicking the GTP-bound form of 
the Rho GTPases (Alto et al., 2006). These proteins, which share no obvious sequences 
homology with Rho GTPases, use a conserved WxxE motif to directly activate downstream 
effectors of Cdc42, Rac1, and Rho (Alto et al., 2006). 
Several bacterial pathogens also use the type IV secretion systems to inject effector proteins 
into the cytoplasm of host cells (Cascales & Christie, 2003; Galan & Wolf-Watz, 2006). After 
translocation, these effectors target various components of eukaryotic signal transduction 
pathways, which subvert host cell functions for the benefit of the pathogen. 
Rho-family GTPases, such as Rho, Rac1, and Cdc42, regulate actin dynamics by induction of 
actin, lamellipodia, and filopodia formation, respectively. Inactivation of these GTPases 
leads to a decrease in F-actin and increase in monomeric actin (G-actin), resulting in loss of 
cell shape, motility, and ability to phagocytose or endocytose pathogens.  
S. typhimurium manipulates this members using the effectors SopE and SptP. SopE acts as a 
GEF for Cdc42 and Rac1, whereas SptP acts as a GAP for Cdc42 and Rac1 (Fu & Galan, 
1999). SopE is translocated into the cell to induce actin rearrangement and membrane 
disruption to facilitate pathogen entry into the cell and formation of Salmonella-containing 
vesicles, while SptP disrupts these actin filaments to restore actin organization in the cell 
(Hardt et al., 1998). SptP possesses both a GAP and tyrosine phosphatase activities (Fu & 
Galan, 1999). It disrupts the actin cytoskeleton by binding to Rac1 and catalysing the 
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hydrolysis of GTP to GDP. Although SopE and SptP are antagonists, they are coordinately 
regulated. While SopE acts early in the infection to facilitate the uptake of the pathogen, 
SptP disasssembles F-actin organization, allowing the pathogen to proliferate in the vesicle 
(Kubori & Galan, 2003). 
IpgB1, a type III secretion system effector of S. flexneri, binds to the host cell engulfment and 
cell motility ELMO–DOCK180 complex activating Rac1 (Handa et al., 2007). As a result, 
IpgB1 increases infection efficiency. Another effector secreted by the same pathogen, IpgB2, 
induces membrane disruption by mimicking the Rho-GEF (Klink et al., 2010).  
The effectors YopE and YopT secreted by Yersinia inhibit actin rearrangements by 
inactivating host Rho GTPases. YopE is known to act as a GAP (Black & Bliska, 2000) 
inhibiting RhoA, Rac-1 and Cdc42 by accelerating the conversion of the GTP-bound form of 
the Rho GTPase to the GDP-bound inactive form. The GAP activity of YopE is also needed 
to prevent the formation of pores generated by insertion of the translocation machinery in 
the host cell plasma membrane (Viboud & Bliska, 2001). YopT has been found previously to 
inhibit Rho GTPases by releasing them from the membrane (Zumbihl et al., 1999). YopT acts 
as a cysteine protease that cleaves the prenyl group of lipid-modified Rho GTPases (Shao et 
al., 2002).  
The effector SidM from L. pneumophila targets Rab1 proteins involved in ER–Golgi transport. 
SidM is a bifunctional enzyme; the C’-terminus possesses a RAB/GEF activity, whereas the 
N’-terminus catalyses AMPylation. Then, SidM catalyses the exchange of GDP for GTP by 
changing the conformation of Rab1 residues that are important for nucleotide stabilization 
(Murata et al., 2006). AMPylation induces cell rounding and shrinkage, which contribute to 
the disruption of cell homeostasis and to cytotoxicity (Muller et al., 2010). SidM is localized 
to the membrane through its interaction with PI4P (see above), and recruits Rab1/GTP to 
the Legionella-containing vesicles, mimicking a Rab1/GEF and delaying GAP activity by 
AMPylation. SidM-mediated Rab1 activation and recruitment to the Legionella-containing 
vesicles promotes fusion of ER-derived vesicle with the Legionella-containing vesicles. 
Another L. pneumophila effector is LepB, that functions as a GAP for Rab1 (Ingmundson et 
al., 2007), inactivating the GTPase and releasing it from the Legionella-containing vesicles, 
promoting ist fusion with the ER. During the initial phase of infection, L. pneumophila resides 
in the ER-derived vesicle that interacts with the secretory pathway, whereas during the later 
stages of infection, when bacterial replication occurs, these vesicles acquire lysosomal 
markers (Sturgill-Koszycki & Swanson, 2000). 
4.8 A unique infection model: Mycobacterium tuberculosis  
The infection of a macrophage by M. tuberculosis is complex, and since a variety of pathways 
are orchestrated by the pathogen, a separated section is dedicated to analyze this pathogen. 
M. tuberculosis is able to survive, reside, and multiply in macrophages as an intracellular 
parasite, circumventing all defence pathways of the host. The hallmarks of Mycobacterium 
infection are (a) the manipulation of phagolysosome maturation (Koul et al., 2004; Hestvik et 
al., 2005), (b) the prevention of antigen presentation (Moreno et al., 1988), (c) a decrease in 
stimulators of apoptosis (Balcewicz-Sablinska et al., 1998), (d) alteration of IFN- activity 
(Sibley et al., 1988), and (e) modulation of MAPK and JAK/STAT signalling pathways (Koul 
et al., 2004).  
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Upon internalization by macrophage phagocytosis, M. tuberculosis is able to arrest 
phagolysosome fusion (Pethe et al., 2004) and modulate other macrophage defences to 
promote its survival (Gan et al., 2008). Arrested M. tuberculosis-containing phagosomes are 
characterized by the presence of Rab5a, but the recruitment of its effectors, such as EEA1 
and hVPS34, is impaired (Fratti et al., 2001). M. tuberculosis uses a range of protein and lipid 
effectors to alter the PI(3)P signalling (Vergne et al., 2005) and the concentration of cytosolic 
Ca2+, both events essential for the proper phagosomal maturation (Jaconi et al., 1990). The 
mycobacterial mannosylated lipoarabinomanan (Man-LAM), a shed component of the cell 
wall, is distributed throughout the endocytic network (Beatty et al., 2000), preventing the 
increase in cytosolic [Ca2+], a process necessary for phagocytosis upon activation of hVPS34 
by calmodulin (Vergne et al., 2003). Inhibition of the PI3K pathway by Man-LAM also 
blocks the delivery of lysosomal proteins, such as hydrolases (e.g. cathepsin D) and the 
membrane-docking fusion protein syntaxin 6, from the trans-Golgi network to phagosomes 
(Fratti et al., 2003). In addition, the pathogen further impairs cytosolic Ca2+ flux by inhibiting 
sphingosine kinase, which converts sphingosine to sphingosine-1–phosphate, which in turn 
promotes Ca2+ efflux from the endoplasmic reticulum (Malik et al., 2003). M. tuberculosis also 
produces the phosphatase SapM, which has been shown to specifically inhibit hydrolysis of 
PI(3)P in vitro (Vergne et al., 2005). These findings indicate that Man-LAM blocks 
phagosome maturation by inhibiting a signalling cascade based on [Ca2+], calmodulin, and 
PI3K. Mycobacterial phagosomes also recruit early phagosomal proteins such as coronin-1 
(Ferrari et al., 1999), but avoid acidification as the bacteria specifically exclude the vesicular 
proton ATPase from the phagosomal membrane (Sturgill-Koezycki et al., 1994, Wong et al., 
2011).  
Macrophages infected with harmful bacteria activate their own apoptotic program when the 
infected cell cannot resolve its infection. However, many bacterial pathogens alter host 
apoptotic pathways (Spira et al., 2003). Mycobacteria-induced macrophage apoptosis is a 
complex mechanism that is modulated by mycobacterial virulence factors (Nigou et al., 
2002). Ca2+ is thought to facilitate apoptosis by increasing the permeability of mitochondrial 
membranes, and then promoting the release of pro-apoptotic factors such as cytochrome c 
(Szalai et al., 1999). Interestingly, Man-LAM also stimulates the phosphorylation of the 
apoptotic protein Bad, preventing it from binding to the anti-apoptotic proteins Bcl-2 and 
Bcl-XL (Maiti et al., 2001).  
Pro-inflammatory cytokines, such as IL-1, IL-6, TNF-α, and IFNs, are able to induce a 
cellular innate immune response when macrophages sense invading bacteria.  
The activation of MAPK signalling in macrophages that are infected with non-pathogenic 
mycobacteria leads to the synthesis of various microbicidal molecules, including TNF-, 
which mediate antibacterial and inflammatory immune responses (Roach & Schorey, 2002). 
These observations are supported by a study that demonstrated that the secretion of TNF- 
by macrophages infected with M. avium is dependent on MEK1 and ERK1 and 2 activation 
(Reiling et al., 2001). A high level of TNF- is a crucial factor for controlling primary 
infection, as it induces the expression of other pro-inflammatory cytokines, such as IL-1, and 
of several chemotactic cytokines, which attract immune cells to the site of infection.  
Tyrosine phosphorylation of JAK and STAT has been shown to be essential for the 
antibacterial response of macrophages (Decker et al., 2002). Pathogenic mycobacteria have 
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cellular innate immune response when macrophages sense invading bacteria.  
The activation of MAPK signalling in macrophages that are infected with non-pathogenic 
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which mediate antibacterial and inflammatory immune responses (Roach & Schorey, 2002). 
These observations are supported by a study that demonstrated that the secretion of TNF- 
by macrophages infected with M. avium is dependent on MEK1 and ERK1 and 2 activation 
(Reiling et al., 2001). A high level of TNF- is a crucial factor for controlling primary 
infection, as it induces the expression of other pro-inflammatory cytokines, such as IL-1, and 
of several chemotactic cytokines, which attract immune cells to the site of infection.  
Tyrosine phosphorylation of JAK and STAT has been shown to be essential for the 
antibacterial response of macrophages (Decker et al., 2002). Pathogenic mycobacteria have 
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evolved mechanisms to suppress the IFN-γ and JAK/STAT signalling pathways (Hussain et 
al., 1999) by mechanisms not yet elucidated.  
Surprisingly, two protein tyrosine phosphatases PtpA and PtpB are annotated in the 
genome sequence of M. tuberculosis (Cole et al., 1998). The presence of such proteins is 
interesting, since their partners, protein tyrosine kinases, are not predicted from the genome 
sequence, which suggests they play a role in the survival of the pathogen in host 
macrophages. The role of PtpA has been elucidated (Bach et al., 2008). This phosphatase is 
secreted within human macrophages upon infection and translocates into the cytosol to 
dephosphorylate VPS33B, an ubiquitously expressed protein essential for vesicle trafficking. 
Then, by dephosphorylating VPS33B, the pathogen prevents the maturation of the 
phagosome. Interestingly, a study reported the first protein tyrosine kinase, PtkA, in M. 
tuberculosis (Bach et al., 2009). This tyrosine kinase phosphorylates PtpA. although the role of 
this activity remains to be elucidated. The second protein tyrosine phosphatase annotated in 
the M. tuberculosis genome is PtpB. Interestingly, PtpB orthologs are restricted to pathogenic 
Mycobacteria. It has been reported that PtpB blocks the ERK1 and 2 pathways in murine 
macrophages, but its mechanism has not yet been elucidated (Zhou et al., 2010).  
Another virulence protein secreted by M. tuberculosis is the protein kinase G. Although this 
protein has been shown to participate in the inhibition of phagolysosome fusion in M. bovis 
strain BCG (Walburger et al., 2004), its mechanism has not yet been elucidated.  
5. Conclusion  
In this chapter, the mechanisms through which virulence proteins and conserved microbial 
structures can initiate macrophage signalling were discussed. Macrophages can use specific 
receptors and common signalling pathways to integrate this information to mount an 
immunological response, but they are still vulnerable to subversion by bacterial pathogens 
that can interfere with crucial kinase, trafficking or transcriptional networks. However, there 
are redundancies in macrophage signalling pathways, and the recent discovery of a 
cytosolic detection system in macrophages is a good example of how avoiding one 
component of a macrophage’s arsenal makes pathogens vulnerable to another. It seems that 
the combination of mechanisms that a pathogen has to modify specific macrophage 
signalling cascades dictates their most successful niche. 
Genome sequencing projects have identified an overwhelming number of host and bacterial 
genes that encode proteins with unknown functions. The characterization of the biological 
functions of these proteins will probably add to the ever-increasing number and diversity of 
strategies that are used by macrophages to detect and contain the invaders and by bacterial 
pathogens to subvert and evade host responses. 
Finally, the development of new technologies, such as improvements in mass spectrometry 
techniques, will undoubtedly increase the currently known post-translational modification 
and facilitate the understanding of their roles in host-pathogen interactions. Identifying 
pathogen-encoded enzymes that catalyze specific post-translational modification critical for 
infection will provide valuable new targets for drug development. Indeed, the selective 
inhibition of these enzymes may constitute a promising strategy to contain and restrict the 
proliferation of pathogens. However, only few interaction partners have been identified so 
far. Systematic mapping of protein-protein interactions can provide valuable insights into 
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biological systems. However, current large-scale screening methods fail to provide 
information about these interactions.  
6. Acknowledgment  
The author thanks Jeffrey Helm and Eviatar Bach for helpful discussions and technical 
support. 
7. References  
Akira, S. & Takeda, K. (2004). Toll-like receptor signalling. Nature Reviews Immunology, Vol.4, 
No.7, (July 2004), pp. 499-511 
Alto, N.; Shao, F.; Lazar, C.; Brost, R.; Chua, G.; Mattoo, S.; McMahon, S.; Ghosh, P.; Hughes, 
T.; Boone, C. & Dixon, J. (2006). Identification of a bacterial type III effector family 
with G protein mimicry funcions. Cell, Vol.124, No.1, (January 2006), pp. 133-145  
Arbibe, L.; Kim, D.; Batsche, E.; Pedron, T.; Mateescu, B.; Muchardt, C.; Parsot, C. & 
Sansonetti, P. (2007). An injected bacterial effector targets chromatin access for 
transcription factor NF-kappaB to alter transcription of host genes involved in 
immune responses. Nature Immunology, Vol.8, No.1, (January 2007), pp. 47-56 
Asim, M.; Chaturvedi, R.; Hoge, S.; Lewis, N.; Singh, K.; Barry, D.; Algood, H.; de Sablet, T.; 
Gobert, A. & Wilson, K. (2010). Helicobacter pylori induces ERK-dependent 
formation of a phospho-c-Fos.c-Jun activator protein-1 complex that causes 
apoptosis in macrophages. Journal of Biological Chemistry, Vol.285, No.26, (June 
2010), pp. 20343-20357 
Bach, H.; Papavinasasundaram, K.; Wong, D.; Hmama, Z. & Av-Gay, Y. (2008). 
Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of 
human vacuolar protein sorting 33B. Cell Host Microbe, Vol.15, No.3, (May 2008), 
pp. 316-322 
Bach, H.; Wong, D. & Av-Gay, Y. (2009). Mycobacterium tuberculosis PtkA is a novel protein 
tyrosine kinase whose substrate is PtpA. Biochemical Journal, Vol.420, No.2, (May 
2009), pp. 155-160 
Balcewicz-Sablinska, M.; Keane, J.; Kornfeld, H. & Remold, H. (1998). Pathogenic 
Mycobacterium tuberculosis evades apoptosis of host macrophages by release of 
TNF-R2, resulting in inactivation of TNF-alpha. Journal of Immunology, Vol.161, No. 
5, (September 1998), pp. 2636-2641 
Bakowsky, M.; Braun, V.; Lam, G.; Yeung, T.; Heo, W.; Meyer, T.; Finlay, B.; Grinstein, S. & 
Brumell, J. (2010). The phosphoinositide phosphatase SopB manipulates membrane 
surface charge and trafficking of the Salmonella-containing vacuole. Cell Host 
Microbe, Vol.7, No.6, (June 2010), pp. 453-462 
Bhattacharyya, A.; Pathak, S.; Datta, S.; Chattopadhyay, S.; Basu, J. & Kundu, M. (2002). 
Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter 
pylori-mediated interleukin-8 release from macrophages. Biochemical Journal, 
Vol.368, No.1, (November 2002), pp. 121-129 
 
Protein Kinases 112 
evolved mechanisms to suppress the IFN-γ and JAK/STAT signalling pathways (Hussain et 
al., 1999) by mechanisms not yet elucidated.  
Surprisingly, two protein tyrosine phosphatases PtpA and PtpB are annotated in the 
genome sequence of M. tuberculosis (Cole et al., 1998). The presence of such proteins is 
interesting, since their partners, protein tyrosine kinases, are not predicted from the genome 
sequence, which suggests they play a role in the survival of the pathogen in host 
macrophages. The role of PtpA has been elucidated (Bach et al., 2008). This phosphatase is 
secreted within human macrophages upon infection and translocates into the cytosol to 
dephosphorylate VPS33B, an ubiquitously expressed protein essential for vesicle trafficking. 
Then, by dephosphorylating VPS33B, the pathogen prevents the maturation of the 
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this activity remains to be elucidated. The second protein tyrosine phosphatase annotated in 
the M. tuberculosis genome is PtpB. Interestingly, PtpB orthologs are restricted to pathogenic 
Mycobacteria. It has been reported that PtpB blocks the ERK1 and 2 pathways in murine 
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protein has been shown to participate in the inhibition of phagolysosome fusion in M. bovis 
strain BCG (Walburger et al., 2004), its mechanism has not yet been elucidated.  
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structures can initiate macrophage signalling were discussed. Macrophages can use specific 
receptors and common signalling pathways to integrate this information to mount an 
immunological response, but they are still vulnerable to subversion by bacterial pathogens 
that can interfere with crucial kinase, trafficking or transcriptional networks. However, there 
are redundancies in macrophage signalling pathways, and the recent discovery of a 
cytosolic detection system in macrophages is a good example of how avoiding one 
component of a macrophage’s arsenal makes pathogens vulnerable to another. It seems that 
the combination of mechanisms that a pathogen has to modify specific macrophage 
signalling cascades dictates their most successful niche. 
Genome sequencing projects have identified an overwhelming number of host and bacterial 
genes that encode proteins with unknown functions. The characterization of the biological 
functions of these proteins will probably add to the ever-increasing number and diversity of 
strategies that are used by macrophages to detect and contain the invaders and by bacterial 
pathogens to subvert and evade host responses. 
Finally, the development of new technologies, such as improvements in mass spectrometry 
techniques, will undoubtedly increase the currently known post-translational modification 
and facilitate the understanding of their roles in host-pathogen interactions. Identifying 
pathogen-encoded enzymes that catalyze specific post-translational modification critical for 
infection will provide valuable new targets for drug development. Indeed, the selective 
inhibition of these enzymes may constitute a promising strategy to contain and restrict the 
proliferation of pathogens. However, only few interaction partners have been identified so 
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1. Introduction 
An effective host defense against pathogens requires appropriate recognition of the 
invading microorganism by immune cells, conducing to an inflammatory process that 
involves recruitment of leukocytes to the site of infection, activation of antimicrobial effector 
mechanisms and induction of an adaptive immune response that ultimately will promote 
the clearance of infection. All these events require the coordination of multiple signaling 
pathways, initially triggered by the contact of the pathogen with innate immune cells. The 
“signal alarm” is normally triggered by ligation of microorganism, or microorganism’s 
components, to pattern-recognition receptors, causing their phosphorylation and recruitment 
of adapter molecules, which in turn will activate second messengers within the cytosol of the 
cells, allowing the transduction of the signal. The second messengers are often protein 
kinases that in a cascade process ultimately activate the transcription factors responsible for 
the expression of effector molecules like, cytokines, chemokines and reactive oxygen species, 
crucial elements to mount an adequate immune response. The activity of such critical 
intracellular signaling pathways is a process extremely well controlled by a balance of 
positive and negative regulation, being the activation of a given protein kinase normally 
counterbalanced by the activation of its opposing phosphatase. However, as part of their 
pathogenic strategies, several microorganisms exploit host cell signaling mechanisms by 
distorting this balance between positive and negative signals. They hijack crucial immune-
cell signaling pathways, subverting the immunogenic abilities of these cells and evading this 
way the host immune response. In the last few years a great effort has gone into 
understanding the molecular mechanisms behind this subversion, and various signaling 
cascades were identified as main targets of pathogens and virulence factors. Among these 
targets, assume particular importance the transcription factor nuclear factor-κB (NF-κB), a 
cornerstone of innate immunity and inflammatory responses, as well as the mitogen 
activated protein kinases (MAPKs), signaling cascades implicated in the regulation of 
crucial aspects of immunity. Overall in this chapter, we will provide an overview of the 
current understanding of how pathogens interact with host cells and how these 
microorganisms exploit host immune response in a signaling point of view.  
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2. Immune response to invading microorganisms  
In mammals, immune system can be subdivided into two branches: innate and adaptive 
immunity. Following infection, innate immune cells like macrophages, dendritic cells (DCs) 
and neutrophils (collectively called phagocytes) engulf and destroy microorganisms, 
representing that way a rapid first defense barrier against infection. In turn, adaptive 
immunity is mediated via the generation of antigen-specific B and T lymphocytes, through a 
process of gene rearrangement resulting in the production and development of specific 
antibodies and killer T cell, respectively. Adaptive immunity is also behind immunological 
memory, allowing the host to rapidly respond when exposed again to the same pathogen. 
Contrarily to the originally thought, the innate immune response is not completely 
nonspecific, but rather is able to discriminate between self antigens and a variety of 
pathogens (Akira et al., 2006). Furthermore, much evidence has demonstrated that 
pathogen-specific innate immune recognition is a prerequisite to the induction of antigen-
specific adaptive immune responses (Hoebe et al., 2004; Iwasaki & Medzhitov, 2010), being 
dendritic cells central players in this linking (Steinman, 2006). DCs are specialized antigen-
presenting cells that function as sentinels, scanning changes in their local microenvironment 
and transferring the information to the cells of the adaptive immune system (Banchereau & 
Steinman, 1998; Banchereau et al., 2000). Upon activation by microorganisms or 
microorganism components, immature DCs suffer a complex process of morphological, 
phenotypical and functional modifications to become mature DCs that enter draining 
lymphatic vessels and migrate to the T-cell zones of draining lymph nodes where they 
present antigens to T lymphocytes. Depending on their maturation/activation profile, DCs  
 
Fig. 1. Dendritic cells link innate to adaptive immunity. Once in contact with microbial 
antigens, DCs mature and migrate to draining lymph nodes where they present antigens to 
naïve T lymphocytes. Different pathogens trigger disticnt DCs maturation profiles, leading 
to the polarization of different T-cell subsets. The adaptive immune response is therefore 
modulated, in some extent, to match the nature of the pathogen. Ag: antigen; CTL: cytotoxic 
T cell; DC: dendritic cell; Mφ: macrophage. 
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will polarize and expand distinct T-cell subsets (T-helper cells [Th1, Th2, and Th17], regulatory 
T cells, and cytotoxic T cells) (Sporri & Reis e Sousa, 2005; Diebold, 2009) and given that the 
recognition of different microorganisms lead to distinct DC maturation/activation profiles, the 
adaptive immune response is, therefore, modulated to match the nature of the pathogen 
(Figure 1) 
2.1 Recognition of microorganisms by innate immune cells 
To a rational understanding of molecular mechanisms by which pathogens escape the 
immune system, we need first to know how our immune cells sense microorganisms and 
spread the “alarm”.  
Innate immune cells, like macrophages and DCs, recognize microorganisms through 
sensing conserved microbial components, globally designated as pathogen associated 
molecular patterns (PAMPs) (Kawai & Akira, 2010; Takeuchi & Akira, 2010; Medzhitov, 
2007). These molecular patterns are normally essential components of microbial 
metabolism, including proteins, lipids, carbohydrates and nucleic acids, not subjected to 
antigenic variability. Another important feature of PAMPs is that they are markedly 
distinct from self-antigens, allowing the innate immune system to discriminate between 
self and non-self. 
The recognition of PAMPs is mediated by constitutively expressed host´s germline-encoded 
pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs), C-type lectin receptors 
(CLRs), retinoic acid-inducible gene-1(RIG-1)-like receptors and nucleotide-oligomerization 
domain (NOD)-like receptors. The beauty of this evolutionary sensor mechanism is that 
different PRRs react with specific PAMPs, triggering a signaling pathway profile that 
ultimately lead to distinct anti-pathogen responses (Akira, 2009). Therefore, innate immunity 
is a key element in the infection-induced non specific inflammatory response as well as in the 
conditioning of the specific adaptive immunity to the invading pathogens (Akira et al., 2001; 
Iwasaki & Medzhitov, 2004). 
2.1.1 Toll-like receptors 
Among PPRs, TLRs are by far the most intensively studied and the more expressive group, 
being considered the primary sensors of pathogen components. TLRs are type I membrane 
glycoproteins formed by extracellular leucine rich repeats involved in PAMP recognition, 
and a cytoplasmic signaling domain homologous to that of the interleukin 1 receptor (IL-
1R), know as Toll/IL-1R homology (TIR) domain. These receptors were originally identified 
in Drosophila as essential elements for the establishment of the dorso-ventral pattern in 
developing embryos (Hashimoto et al., 1988). However, in 1996, Hoffmann and colleagues 
would initiate a novel era in our understanding of innate immunity, demonstrating that 
Toll-mutant flies were highly susceptible to fungal infection, showing that way that TLRs 
were involved in the defense against invading microorganisms (Lemaitre et al., 1996). 
Afterward, mammalian homologues of Toll receptor were progressively identified, and 
actually most mammalian species are believed to have between ten and thirteen types of 
TLRs. In human, ten functional receptors (TLR1-10) have been identified so far and an  
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Fig. 1. Dendritic cells link innate to adaptive immunity. Once in contact with microbial 
antigens, DCs mature and migrate to draining lymph nodes where they present antigens to 
naïve T lymphocytes. Different pathogens trigger disticnt DCs maturation profiles, leading 
to the polarization of different T-cell subsets. The adaptive immune response is therefore 
modulated, in some extent, to match the nature of the pathogen. Ag: antigen; CTL: cytotoxic 
T cell; DC: dendritic cell; Mφ: macrophage. 
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will polarize and expand distinct T-cell subsets (T-helper cells [Th1, Th2, and Th17], regulatory 
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TLR family Cellular location Microbial components Pathogens 
TLR1/2 Cell surface Tri-acyl lipopeptides Soluble factors 
Bacteria, mycobacteria 
Neisseria meningitides 
TLR2 Cell surface 
Diacyl lipopeptides  
Triacyl lipopeptides  
Peptidoglycan  
Lipoteichoic acid  
Porins 
Lipoarabinomannan  
Phenol-soluble modulin  
tGPI-mutin  
Glycolipids 

























TLR4 Cell surface 
LPS  
Fusion protein  













TLR5 Cell surface Flagellin Flagellated bacteria 
TLR6/2 Cell surface 
Diacyl lipopeptides  
Lipoteichoic acid  
Zymosan  
Mycoplasma  
Group B Streptococcus 
Saccharomyces cerevisiae 
TLR7 Endolysosome 
Viral single-stranded RNA 
RNA 
Several virus 
Bacteria from group B 
Streptococcus 
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TLR family Cellular location Microbial components Pathogens 
TLR8 (only 
human) Endolysosome 
Viral single-stranded RNA Several virus 
TLR9 Endolysosome 
CpG-DNA  








TLR10 Cell surface Unknown Unknown 
TLR11 (only 
mouse) Endosome 
Profilin-like molecule  Toxoplasma gondii  
Uropathogenic E. coli 
TLR12 (only 
mouse) Cell surface 
ND Unknown 
TLR13 (only 
mouse) Cell surface 
ND Virus 
Table 1. Toll-like receptors cellular location and microbial ligands. ND: not determined. 
eleventh has been found to be encoded at gene level but, as it contains several stop codons, 
protein is not expressed (Zhang et al., 2004). TLRs are involved in sensing a wide panel of 
microbial products (Kawai & Akira, 2010), including lipids, peptidoglycans, proteins, and 
nucleic acids (Table 1). Regarding their cellular location, these receptors are either found at  
cell surface membrane or within intracellular compartments. A growing body of data 
suggests that TLRs involved in sensing bacterial chemical structures (TLR1, TLR2, TLR4 and 
TLR5) are located on the cell surface, while nucleic acid-recognizing TLRs (TLR3, TLR7, 
TLR8 and TLR9) are uniquely positioned intracellularly (McGettrick & O'Neill, ; Barton & 
Kagan, 2009). 
2.1.1.1 Signaling through TLRs 
Recognition of microbial components by TLRs leads to the activation of an intricate network 
of intracellular signaling pathways that ultimately result in the induction of molecules 
crucial to the resolution of infection such, proinflammatory cytokines, type I interferon 
(IFN), chemokines, and co-stimulatory molecules (Takeuchi & Akira, 2010 ; Kumar et al., 
2010). These signaling cascades originate from cytoplasmic TIR domains and are meditated 
via the recruitment of different TIR domain-containing adaptor molecules, such as myeloid 
differentiation primary response gene 88 (MyD88), TIR-containing adaptor protein/ 
MyD88-adaptor-like (TIRAP/MAL), TIR-containing adaptor inducing interferon-β (IFN-
β)/TIR-domain-containing adaptor molecule 1 (TRIF/TICAM1) and TIR-domain-containing 
adaptor molecule/TRIF-related adaptor molecule 2 (TRAM/TICAM2) (Fitzgerald et al., 
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2001; Horng et al., 2001; Yamamoto et al., 2002; Takeda & Akira, 2004; Yamamoto et al., 
2004).  
In the signaling pathways downstream of the TIR domain, the TIR domain-containing 
adaptor MyD88 assumes a crucial role. With exception for TLR3, all TLRs recruit MyD88 
and initiate MyD88-dependent signaling cascades to activate NF-κB and MAP kinases. 
MyD88 is used as the sole adapter in TLR5, TLR7 and TLR9 signaling, while TLR1, TLR2, 
and TLR6, additionally recruit the adaptor TIRAP. TLR4 uses the four adaptors, including 
MyD88, TIRAP, TRIF and TRAM (Yamamoto et al., 2002; Yamamoto et al., 2003)  
In a general point of view, TLR signaling could be divided into two major pathways: 
MyD88-dependent and TRIF-dependent pathways. 
MyD88-dependent pathway 
Following stimulation, MyD88 recruits IL-1 receptor-associated kinase proteins (IRAK) to 
TLRs, resulting in IRAK phosphorylation and subsequent association and activation of 
tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) (Swantek et al., 2000; 
Suzuki et al., 2002). The IRAK-1/TRAF6 complex dissociates from the TLR receptor and 
associates with TGF-β-activated kinase 1 (TAK1) and TAK1 binding proteins, TAB1 and 
TAB2. From this new formed complex, IRAK-1 is degraded, whereas the remaining complex 
of TRAF6, TAK1, TAB1, and TAB2 is transported across the cytosol where it forms large 
complexes with E2 protein ligases such as the Ubc13 and Uev1A. As result, TRAF6 is 
polyubiquitinated and thereby induces TAK1 activation (Deng et al., 2000) which, in turn, 
activates the IκB kinases complex (IKK). The active IKK complex promotes the 
phosphorylation and subsequent ubiquitination of the NF-κB inhibitory protein IκB-α, 
leading to its proteosomal degradation. This allows the NF-κB subunits to be translocated to 
the nucleus, where they initiate the transcription of genes involved in inflammatory 
response (Wang et al., 2001). Additionally to NF-κB activation, MyD88-dependent signaling 
cascade also culminates into the activation of the three MAPK pathways (extracellular 
signal–regulated kinase (ERK), Jun N-terminal kinase (JNK) and p38), regulating both, the 
transcription of inflammatory genes and the mRNA stability of those transcripts (Figure 2). 
TRIF-dependent pathway  
Besides this MyD88-dependent pathway, NF-κB could also be activated follow TLR3 and 
TLR4 engagement in a TRIF-dependent manner. In TLR3 signaling, TRIF interacts directly 
with the TIR domain of the receptor, whereas for TLR4 another TIR domain containing 
adaptor, TRAM/TICAM-2, acts as a bridging between TLR4 and TRIF (Oshiumi et al., 2003; 
Oshiumi et al., 2003). In this pathway, TRIF recruits TRAF-6 and RIP1, molecules that 
cooperate in TAK1 activation, and lead to robust NF-κB activation. 
TRIF-dependent signaling cascade also assumes a crucial role in the expression of type I IFN 
and IFN-inducible genes (ISGs). These genes are mainly potent antiviral molecules and their 
expression, follow TLR3 sensing of viral double stranded RNA, is of critical importance for 
the control of viral infections (review by Taniguchi et al., 2001). In this pathway, TRIF 
associates with TBK1 and IKKi, which in turn phosphorylate IRF3 and IRF7, leading to their 
nuclear translocation and induction of type I IFN genes and co-stimulatory molecules 
(Figure 2). 
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Fig. 2. Schematic representation of TLRs-mediated signaling. TLR signaling pathways were 
triggered by recognition of PAMPs by plasma membrane-localized TLRs, such as TLR4, 
TLR5, and TLR2 (TLR1 and TLR6 form heterodimers with TLR2 becoming functional 
receptor complexes) and endosomal-localized TLRs, such as TLR3, TLR7, and TLR9. 
Depending on the adaptor molecules involved, two major pathways could be established: 
the MyD88-dependent pathway (black arrows) and the TRIF-dependent pathway (blue 
arrows). MyD88-dependent signaling is initiated through the recruitment and activation of 
IRAK that associates and activates TRAF6. The IRAK-1/TRAF6 complex subsequently 
activates the TAK1 kinase, which in turn activates the IKK complex. The active IKK complex 
activates NF-κB subunits leading to their translocation to nucleus where they initiate the 
transcription of inflammatory cytokines/chemokines genes. In the TRIF-dependent 
signaling pathway, TRIF recruits TRAF-6 and RIP1, molecules that cooperate in TAK1 
activation, leading to NF-κB activation. Besides, TRIF also recruits TBK1 and IKKi, leading 
to phosphorylation and nuclear translocation of IRF3 and IRF7, which results in 
transcription of type I IFN genes and co-stimulatory molecules 
2.1.2 C-Type lectin receptors  
C-type lectin receptors are a large superfamily of proteins characterized by the presence of 
one or more C-type lectin-like domains (CTLDs) that were originally described as Ca2+-
dependent, carbohydrate binding proteins (Weis et al., 1998). Over the past decade more 
than 60 CLRs have been identified in human immune cells (van Vliet et al., 2008). In recent 
years, some of these CLRs have emerged as PRRs with important roles in the induction of 
immune responses against numerous pathogens. Although the TLRs have a well defined 
role in alerting innate immune cells to the presence of pathogens, CLRs are mainly involved 
in the recognition and subsequent endocytosis or phagocytosis of microorganisms. These 
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receptors have also crucial functions in recognizing glycan structures expressed by the host, 
facilitating this way cellular interaction between DCs and other immune cells, like T-cells 
and neutrophils (Geijtenbeek et al., 2000; van Gisbergen et al., 2005; Bogoevska et al., 2006). 
Based on their structural features, C-type lectin receptors are sorted into two major groups: 
type I and type II receptors. Type I receptors are transmembrane proteins with multiple 
carbohydrate recognition domains (CRDs), being members of this group the mannose 
receptor (MR), DEC-205 (CD205), and Endo 180 (CD280), among others. Type II receptors 
are also transmembrane proteins, but in contrast, they have just a single CRD. DC-specific 
intercellular adhesion molecule (ICAM)-3 grabbing nonintegrin (DC-SIGN), Langerin, DC-
associated C-type lectin-1 (Dectin 1), Dectin 2, DC-immunoreceptor (DCIR) and 
macrophage-inducible C-type lectin (Mincle) are examples of type II CLRs.  
Originally, CLRs were thought to be predominantly involved in antifungal immunity, but 
are currently recognized to participate in immune responses induced by a wide spectrum of 
other pathogens, including bacteria, viruses and nematodes (Table 2). 
2.1.2.1- Signaling through C-Type lectin receptors 
Besides its roles in recognition and uptake of antigens, CLRs have also important signaling 
functions, shaping the immune responses to innumerous pathogens. Whereas some CLRs 
possess intrinsic signaling properties and are thus capable of directly activate transcription 
factors leading to cytokines expression, others predominantly act as modulators of 
responses to other PRRs, such as TLRs. This crosstalk between groups of PRRs is actually 
seen as a crucial event by which immune responses are balanced through collaborative 
induction of positive or negative feedback mechanisms. While TLRs engagement triggers   
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Leishmania spp. 
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Table 2. Major C-type lectin receptors involved in pathogen recognition. BCG: Bacillus 
Calmette-Guérin; HIV-1: Human immunodeficiency virus type 1; ND: not determined. 
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intracellular signaling cascades that result in macrophage activation, DC maturation and 
ultimately T cell activation, binding of ligands to CLRs normally results in tolerogenic 
signals. Therefore the cross talk between TLRs and CLRs may fine-tune the balance 
between immune activation and tolerance. In terms of immunity this represents a paradox: 
if crucial to maintain tolerance to self-antigens, CLRs could be used by pathogens to escape 
immune system. Several pathogens exploit this “security breach”, taking part of their 
capacity to activate C-type lectin receptors to promote an unresponsive state against their 
antigens recognized by other PPRs and increasing, this way, their chances of survival in 
host.  
2.1.2.1.1 Mannose receptor  
The mannose receptor is a type I transmembrane protein expressed on the surface of 
macrophages and immature dendritic cells. This receptor is primarily involved in 
recognition, phagocytosis and processing of glycans structures containing mannose, fucose 
and N-acetylglucosamine, molecules commonly found on the cell walls of pathogenic micro-
organisms, such as mycobacteria, fungus, parasites and yeast (East & Isacke, 2002).  
While MR has been shown to be involved in the expression of several pro and anti-
inflammatory cytokines, the lack of an intracellular signaling motif on its cytoplasmic tail 
indicates that it requires an interaction with other PPRs in order to trigger any signaling 
cascade (Gazi & Martinez-Pomares, 2009). In fact, it was recently showed an intriguing 
interplay between the mannose receptor and another main CLR, Dectin-1. The recognition 
of fungi species, like Candida albicans, Aspergillus fumigates and Pneumocystis carinii by 
Dectin-1 enhances MR shedding in a serine/threonine protein kinase Raf-1 and 
phosphatidylinositol 3-kinase (PI3K)-dependent pathways. As these cleaved MR-cysteine-
rich domains are capable of binding fungi particles and are recognized by tissues lacking 
mannose receptors this could represent a system delivery of MR-ligands to organs that do 
not possess MR receptors. 
2.1.2.1.2 DC-SIGN 
DC-SIGN is one of the most extensively studied type II CLRs. This receptor is primarily 
expressed in myeloid DCs being involved in numerous functions, like egress of DC-
precursors from blood to tissues, DC-T-cell interactions and antigen recognition 
(Geijtenbeek et al., 2000; van Kooyk & Geijtenbeek, 2003). The receptor is involved in 
recognition of carbohydrate antigens of viruses, bacteria and protozoa, modulating the TLR 
signaling triggered by these pathogens. 
Binding of several pathogens, including M. tuberculosis, C. albicans and HIV-1, to DC-SIGN 
triggers three routes that converge to activate Raf-1: the activation of the small GTPase Ras 
protein leads to its association with Raf-1 allowing Raf-1 phosphorylation at residues 
Ser338, Tyr340 and Tyr341, by p21-activated kinases (PAKs) and Src kinases, respectively. 
Raf-1 activation leads in turn to the modulation of TLR-induced NF-κB activation. After 
TLR-induced nuclear translocation of NF-κB, activated Raf-1 mediates the phosphorylation 
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Fig. 3. Signaling through DC-SIGN. a) Carbohydrate antigens of HIV-1, Mycobacterium 
tuberculosis and Candida albicans are recognized by DC-SIGN, leading to activation of the 
small GTPase Ras proteins which associate with the serine/threonine protein kinase RAF1. 
RAF1 is then phosphorylated at residues Ser338, and Tyr340 and Tyr341 by PAKs and Src 
kinases, respectively. RAF1 activation leads to modulation of TLR-induced NF-κB activation 
by inducing the phosphorylation of p65 at Ser276 and its subsequent acetylation (Ac). 
Acetylated p65 exhibits enhanced transcriptional activity, particularly for Il-10 gene, thereby 
increasing the production of IL-10. b) Binding of the salivary protein Salp15 from the tick 
Ixodes scapularis to DC-SIGN activates RAF1, and by a yet unknown co-receptor, changes 
downstream effectors of RAF1, leading to MEK activation. MEK-dependent signaling 
modulates B. burgdorferi-induced TLR1–TLR2-dependent pro-inflammatory cytokine 
production by enhancing the decay of Il-6 and Tnf mRNA. 
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intracellular signaling cascades that result in macrophage activation, DC maturation and 
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2.1.2.1.3 Dectin 1 
In humans, Dectin-1 is mainly expressed in myeloid cells, such as macrophages, neutrophils 
and dendritic cells (Taylor et al., 2002), although it was also been found in other cell types, 
like B-cells, eosinophiles and mast cells (Ahren et al., 2003; Olynych et al., 2006). Unlike 
many other CLRs, Dectin-1 recognizes β-glucans in a Ca2+-independent fashion (Brown & 
Gordon, 2001) and it lacks the conserved residues within its CRD that are typically 
necessary for binding carbohydrate ligands (Weis et al., 1998). The receptor contains a single 
CRD in the extracellular region and an immunoreceptor tyrosine-based activation (ITAM)-
like motif within its intracellular tail.  
It was the first non-TLR PPR shown to possess intrinsic signaling properties, being able to 
signal through both, spleen tyrosine kinase (Syk)-dependent and Syk-independent pathways 
(Brown, 2006) (Figure 4).  
In the Syk-dependent pathway, and upon binding to Dectin-1, the ITAM-like motif is 
phosphorylated in tyrosine residues via Src kinases, promoting the recruitment of the 
signaling protein Syk (Rogers et al., 2005). Activated Syk then signals through the downstream 
transducer caspase recruitment domain protein (Card)9, that forms a complex with the B cell 
lymphoma 10 (Bcl10) and the mucosa associated lymphoid tissue translocation protein 1 
(Malt1) (Gross et al., 2006). This activated CARD9–BCL10–MALT1 (CBM) complex controls 
NF-B activation and subsequent expression of cytokines/chemokines, like TNF-α, IL-1β, IL-
10, IL-6, IL-23, CCL2 and CCL3 (LeibundGut-Landmann et al., 2007). Dendritic cells, trough 
this Dectin-1-Syk-Card9 axis and by orchestration of the cytokines IL-1β, IL-6 and IL-23, 
promote the differentiation of Th17 helper cells, establishing this way a crucial host response 
against extracellular bacteria and fungi (Osorio et al., 2008). Moreover, there are evidences of a 
collaborative Dectin-1/TLR2 pathway for the induction of a specific Candida albicans-Th17 
response, by the induction of prostaglandin E2, which in turn up-regulates the Th17 polarizing 
cytokines IL-6 and IL-23 (Smeekens et al., 2010). Besides the canonical NF-kB activation, Detin-
1 can also activate, through Syk, the NIK-dependent non-canonical RelB subunit of NF-kB 
(Gringhuis et al., 2009). Another Syk downstream signal recently described, points to the 
activation of phospholipase C gamma-2, which in turn activates several calcium-dependent 
and MAPKs-dependent pathways (Xu et al., 2009). One of these calcium-mediated responses 
involves the calcineurin activation of the nuclear factor of activated T-cells (NFAT), leading to 
the expression of the cytokines IL-2 and IL-10 and of inflammatory mediators, like 
cyclooxygenase-2 (COX-2) (Suram et al., 2006; Goodridge et al., 2007). Recently, another 
calcium-dependent pathway downstream of Dectin-1 and Syk was described. In this pathway, 
activated calmodulin-dependent kinase II and Pyk2 promote the activation of the ERK–MAPK 
pathway and CREB, resulting in the generation of an oxidative burst and in the production of 
IL-2 and IL-10 (Slack et al., 2007; Kelly et al., 2010). The generated reactive oxygen species act 
through NLRP3 inflammasome and are essential to IL-1β production in response to fungal 
infections (Gross et al., 2009; Kumar et al., 2009; Said-Sadier et al., 2010). 
The Syk-independent pathway downstream Dectin-1 is not fully characterized; however, 
recent findings suggest that Dectin 1 activation leads to the phosphorylation and activation 
of RAF1 by Ras proteins, which promotes the phosphorylation of p65, at Ser276 residue, 
facilitating its acetylation by the histone acetyltransferases CREB-binding protein. Similarly 
to that described for DC-SIGN, acetylated p65 prolongs and increases the transcription of IL-
10 gene. 
 
Pathogen Strategies to Evade Innate Immune Response: A Signaling Point of View 135 
 
Fig. 4. Signaling through Dectin 1. Recognition of microorganisms by Dectin 1 leads to 
signal through both, Syk-dependent (black arrows) and Syk-independent pathways (blue 
arrows). In the Syk-dependent pathway, binding of glucans to Dectin-1 causes the 
phosphorylation of ITAM-like motifs in its tyrosine residues. Syk is then recruited to the 
two phosphorylated receptors, leading to the formation of a complex involving CARD9, 
BCL-10 and MALT1. This activated complex controls NF-B activation and subsequent 
expression of cytokines/chemokines, like TNF-α, IL-1β, IL-10, and IL-6. Activation of Syk 
also leads to the activation of the non-canonical NF-B pathway, a process mediated by NIK 
and IKK, and in which RelB-p52 dimers were translocated to nucleus. Another Syk 
downstream signal leads to activation of PLC2, which in turn activates MAPKs-dependent 
and calcineurin-dependent pathways. Activation of calcineurin promotes the activation of 
NFAT, leading to the expression of the cytokines IL-2 and IL-10 and COX-2. In turn, 
activation of ERK, results in the generation of an oxidative burst that acting through the 
NLRP3 inflammasome, is essential to IL-1β production. In the Syk-independent pathway, 
Dectin 1 activation leads to the phosphorylation and activation of RAF1 by Ras proteins, 
leading in turn to the phosphorylation and acetylation of p65. Binding of acetylated p65 to 
the Il-10 enhancer, increases the transcription of the gene. C1: caspase 1; pC1: pro-caspase. 
2.1.2.1.4 Dectin 2  
Dectin 2 was originally found in DCs (Ariizumi et al., 2000), although it is also expressed in 
tissue macrophages, inflammatory monocytes, B cells, and neutrophils (Fernandes et al., 
1999). The receptor has been shown to be involved in recognition of mannan-like or 
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mannan-containing glycoproteins, glycolipids or oligomannosides present in fungi hyphae, 
being critical for the establishment of Th17 antifungal responses (Sato et al., 2006; Robinson 
et al., 2009). Furthermore, murine Dectin-2 was also associated with helminth infections by 
recognition of soluble components derived from the eggs of Schistosoma mansoni (Ritter et 
al., 2010). In contrast to Dectin-1, Dectin-2 does not contain defined signaling motifs in its 
cytoplasmic tail and is therefore incapable of inducing intracellular signaling on its own. 
However, the receptor associates with the adaptor molecule Fc receptor γ chain (FcRγ) to 
transduce intracellular signals, through a Dectin 2-FcRγ-Syk-dependent pathway. FcRγ 
chain contains an ITAM motif that is dually phosphorylated by Src kinases, promoting the 
recruitment and activation of Syk. Syk activates, in turn, the NF-κB and MAPKs pathways in 
a CARD9-dependent or independent fashion, respectively (Saijo et al., 2010) (Figure 5a).  
2.1.2.1.5 Mincle 
Mincle is a type II transmembrane protein with a highly conserved C-type lectin domain, 
predominantly expressed in macrophages. It has been implicated in the recognition of 
Saccharomyces cerevisiae, C. albicans and mycobacteria, and was shown to be responsible for 
specific recognition of α-mannose residues in Malassezia species (Bugarcic et al., 2008; Wells 
et al., 2008; Ishikawa et al., 2009; Yamasaki et al., 2009). Similarly to Dectin-2, it lacks a 
signaling motif but couples to FcRγ to transduce intracellular signals. Ligation to Mincle of 
trehalose-6,6-dimycolate, an abundant mycobacterial cell wall glycolipid, was shown to 
trigger a FcRγ-Syk-CARD9 dependent pathway, leading to protective Th1 and Th17 
immune responses (Werninghaus et al., 2009) (Figure 5b). 
2.1.2.1.6 BDCA2 
BDCA2 is a type II C-type lectin receptor primarily expressed in human plasmacytoid 
dendritic cells (Dzionek et al., 2001). As endogenous or microbial ligands for BDCA2 have 
not yet been identified, it is difficult to understand the pathophysiological implications of 
this CLR. However, it has been shown, by treatment with anti-BDCA-2 monoclonal 
antibodies, that the receptor crosstalk with other PPARs, namely TLR-9, decreasing the 
induced IFN-I expression (Jahn et al., 2010). As for Dectin-2 and Mincle, BDCA2 signals 
through the ITAM motifs of the FcRγ chain. Activation of BDCA2 results in phosphorylation 
of ITAM motifs of FcRγ, followed by the recruitment and activation of Syk. Activated Syk 
leads to the formation of a complex, consisting of B cell linker (BLNK), Bruton's tyrosine 
kinase (BTK) and phospholipase C2 (PLC2), which induces calcium mobilization. This 
calcium increase appears to be involved in the inhibition of MYD88 adapter recruitment to 
TLR9 and, thereby, in the reduction of the induced expression of IFN-I, TNF-α and IL-6 
(Figure 5c).  
2.1.2.1.7 CLEC5A 
CLEC5A, also known as Myeloid DNAX activation protein 12 (DAP12)-associating lectin-1 
(MDL-1), is a type II C-type lectin receptor expressed in cells of myeloid origin, like 
monocytes and macrophages, and in human CD66-positive neutrophils (Aoki et al., 2009). 
Contrarily to other CLRs predominantly involved in fungal and micobacterial recognition, 
CLEC5A was the first CLRs directly linked to viral recognition. It has been shown that this 
receptor plays a crucial role in the pathophysiology of dengue virus infection, being directly 
involved in the production of proinflammatory cytokines by infected macrophages (Chen et  
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Fig. 5. Signaling through ITAM-coupled C-type lectin receptors. Dectin-2, Mincle and 
BDCA2 do not contain defined signaling motifs in their cytoplasmic tail being incapable of 
inducing intracellular signaling on their own. Following ligand binding, these receptors 
associate with FcRγ leading to recruitment of Syk and subsequent activation of downstream 
signaling cascades (black arrows). CLEC5a also lacks a citoplasmatic catalytic domain. 
Recognition of Dengue virions by CLEC5a, results in the association and phosphorylation of 
DAP12, leading to recruitment of Syk and activation of Syk-dependent downstream 
signaling.  
al., 2008; Watson et al., 2011). CLEC5A has a very short cytoplasmic region lacking a defined 
signaling motif, yet it transduces intracellular signals trough non-covalent association with 
the ITAM-bearing adapters DAP10 and DAP12 (Bakker et al., 1999; Inui et al., 2009). DAP10 
ITAM motif contains a cytoplasmic sequence that facilitates PI3K recruitment and 
activation, being possible that it cooperates with DAP12-associated receptors to mediate co-
stimulatory signals (Kerrigan & Brown, 2010). Moreover, it was showed that the interaction 
of dengue virus with CLEC5A causes the phosphorylation of the coupled DAP12 ITAM 
motif (Chen et al., 2008). Although not formally demonstrated, this molecular event may 
result in Syk recruitment and activation, followed by downstream signaling that leads to the 
observed induction of proinflammatory cytokines (Figure 5d)  
2.1.2.1.8 DCIR 
DCIR was found to be expressed at high levels in blood monocytes, myeloid and 
plasmacytoid DCs, macrophages and in a less extent in B cells (Bates et al., 1999). Although 
no endogenous or exogenous specific ligands were yet identified, the receptor was recently 
shown to play an important role in HIV-1 infection by acting as an attachment factor for the 
virus (Lambert et al., 2008). DCIR and DC-associated C-type lectin-2 (DCAL-2) are, among 
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the presently identified human CLRs, the only ones containing intracellular immune 
receptor tyrosine-based inhibition motifs (ITIMs). These ITIMs motifs are responsible, in a 
phosphatase dependent fashion, for the negative signals that result in repressed activation 
of neutrophils and dendritic cells (Kanazawa et al., 2002; Richard et al., 2006).  
At the molecular level, the activation of DCIR by anti-DCIR antibodies leads to receptor 
internalization into endosomal compartments in a clathrin-dependent process. As in these 
endosomal structures are also located TLR8 and TLR9, it is likely that internalized DCIR will 
interact with them, modulating their signaling. Supporting this hypothesis, recent data 
shows that the phosphorylation of ITIM promotes the recruitment of the phosphatases SH2-
domain-containing protein tyrosine phosphatase 1 (SHP1) or SHP2, which, by an 
unidentified mechanism, leads to the downregulation of TLR8-induced IL-12 and TNF 
production in myeloid DCs (Meyer-Wentrup et al., 2009), and to the down-modulation of 
TLR9-induced IFN and TNF production in plasmacytoid DCs (Meyer-Wentrup et al., 2008). 
2.1.3 RIG-I-Like receptors 
RIG-I-like receptors (RLRs) constitute a family of three cytoplasmic RNA helicases: retinoic 
acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and 
laboratory of genetics and physiology 2 (LGP2). These receptors share a common functional 
RNA helicase domain near the C terminus (HELICc) that specifically binds to the RNA of 
viral origin and are, therefore, crucial for antiviral host responses (Yoneyama et al., 2004; 
Wilkins & Gale, 2010). These responses result from the action of induced inflammatory 
cytokines and type I interferons over the cells of the innate and adaptive immune system. 
Inflammatory cytokines primarily promote the recruitment of macrophages and dendritic 
cells, while type I interferons inhibit viral replication, promote the apoptosis of infected cells 
and increase the lytic capacity of natural killer cells (Takahasi et al., 2008). 
RIG-I is involved in the recognition of a wide variety of RNA viruses belonging to the 
paramyxovirus and rhabdovirus families, as well as Japanese encephalitis virus, while 
MDA5 specifically detect, Picornaviruses, such as encephalomyocarditis virus, mengovirus 
and poliovirus. Somme virus such as dengue virus and West Nile Virus, require, however, 
the activation of both RIG-I and MDA5 to generate a robust innate immune responses. 
Despite structural similarity, RIG-I and MDA5 have been shown to bind distinct types of 
viral RNAs (Kato et al., 2006). MDA5 preferentially binds long dsRNAs, whilst RIG-I has 
high affinity for 5′-triphosphate ssRNAs and short dsRNAs without a 5′-triphosphate end 
(Pichlmair et al., 2006; Kato et al., 2008; Lu et al., 2010). The RIG-I distinction of self from 
viral ssRNAs is ensured by the predominantly nuclear localization of cellular 5′-
triphosphate ssRNAs that even if present in the cytoplasm are normally capped or 
processed. Recently, the notion that 5′-triphosphate ssRNAs were sufficient to bind to and 
activate RIG-I was challenged by data obtained with synthetic single-stranded 5´- 
triphosphate oligoribonucleotides (Schlee et al., 2009). In these experiments, the synthetic 5′-
triphosphate ssRNAs were unable to activate RIG-I and only the addition of the synthetic 
complementary strand resulted in optimal binding and activation of the receptor. The 
authors hypothesized that this newly data explains how RIG-I detects negative-strand RNA 
viruses lacking long dsRNA but containing blunt short double strand 5´-triphosphate RNA 
in the panhandle region of their single-stranded genome. 
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2.1.3.1 Signaling through RIG-I-Like receptors 
RIG-I and MDA5 contain a DExD/H-box helicase domain that recognizes the viral RNA, 
inducing conformational changes and exposing the caspase-recruitment domains (CARDs) 
responsible for downstream signaling of these cytoplasmic sensors. CARDs interact with a 
CARD-containing adaptor, IFN-β promoter stimulator-1 (IPS-1), located in the outer 
mitochondrial membrane and on peroxisomes (Kawai et al., 2005; Dixit et al., 2010). While 
peroxisomal IPS-1 induces early expression of interferon-stimulating genes (ISGs) via 
transcription factor IRF1, mitochondrial IPS-1 induces delayed responses via IRF3/IRF7-
controled expression of ISGs and type I interferons. Therefore, signaling through 
mitochondrial and peroxisomal IPS-1 is essential to an effective antiviral response. From the 
interaction of IPS-1 with RIG-I and MDA5 CARDs also results the activation of NF-κB, a 
process that involves the recruitment of TRADD, FADD, caspase-8, and caspase-10 and 
leads to the induction of proinflammatory cytokines (Takahashi et al., 2006) (Figure 6a). The 
third member of this cytoplasmic PRRs family, LGP2, similarly to RIG-I and MDA5, 
possesses a DExD/H-box helicase domain but is devoid of a CARD domain (Yoneyama et 
al., 2005) and was therefore considered as a negative regulator of RIG-I- and MDA5-
mediated signaling (Rothenfusser et al., 2005; Komuro & Horvath, 2006; Saito et al., 2007). 
Recent in vivo experiment showed, however, precisely the opposite, suggesting that LPG2 
could contribute to a robust antiviral response, acting as a facilitator of the interaction 
between viral RNA, RIG-I and MDA5 (Satoh et al., 2010).  
2.1.4 NOD-like receptors 
Nucleotide-oligomerization domain (NOD)-like receptors (NLRs) are cytosolic sensors of 
microbial components highly conserved trough evolution. A great number of homologs of 
these receptors have been described in animals and plants, attesting their importance as 
ancestral host defense mechanisms. In humans, 23 members of the NLR family were 
identified, being primarily expressed in immune cells, such lymphocytes, macrophages and 
dendritic cells, although also found in epithelial and mesothelial cells (Franchi et al., 2009). 
NLRs contain tree characteristic domains: a) a C-terminal leucine-rich repeat (LRR) domain, 
responsible for ligand sensing and autoregulation, b) a central nucleotide-binding 
oligomerization (NOD) domain, required for nucleotide binding and self-oligomerization 
upon activation and c) a N-terminal effector domain responsible for downstream signal 
propagation. To date, four different N-terminal domains have been identified: acidic 
transactivation domain, caspase-recruitment domain (CARD), pyrin domain (PYD), and 
baculoviral inhibitory repeat (BIR)-like domain (Chen et al., 2009). NOD1 and NOD2, the 
most studied NLRs, both sense bacterial molecules produced during peptidoglycan 
synthesis and remodeling. Peptidoglycan is a major component of the bacterial cell wall, 
formed by alternated residues of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc), which are crosslinked by short peptide chains. The bridging aminoacids inside 
these peptide chains are differentially found in gram-negative and gram-positive bacteria, 
being responsible for the differential recognition abilities of NOD1 and NOD2 (McDonald et 
al., 2005). Therefore, NOD2 senses muramyl dipeptide (MDP), which is found in the 
peptidoglycan of nearly all gram-positive and gram-negative bacteria, while NOD1 sense γ -
D-glutamyl-meso-diaminopimelic acid (iE-DAP), an amino acid that is predominantly 
found in gram-negative bacteria and in some gram-positive bacteria, such as Listeria 
monocytogenes and Bacillus spp (Chamaillard et al., 2003). 
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2.1.4.1 Signaling through NOD-like receptors 
The intracellular NLR proteins organize signaling platforms, such as NOD signalosomes 
and inflammasomes that trigger NF-κB and MAPKs pathways and control the activation of 
inflammatory caspases (Chen et al., 2009). Upon recognition of their respective ligands, both 
NOD1 and NOD2 self-oligomerize to recruit and activate the serine-threonine kinase RICK 
that becomes polyubiquitinated. RICK directly interacts with the regulatory subunit of IKK, 
the inhibitor of NF-κB kinase γ (IKKγ), promoting the activation of the catalytic subunits 
IKKα and IKKβ (Inohara et al., 2000). These activated subunits phosphorylate the inhibitor 
IκB-α, leading to its ubiquitination and subsequent degradation via the proteasome. The 
released NF-κB translocates to the nucleus, where it promotes the expression of 
proinflammatory cytokines and chemokines (Masumoto et al., 2006; Werts et al., 2007; 
Buchholz & Stephens, 2008). Additionally, RICK also promotes the K63-linked 
polyubiquitination of IKKγ, which facilitates the recruitment of transforming growth factor 
β-activated kinase (TAK1) (Hasegawa et al., 2008). TAK1 forms a complex with the ubiquitin 
binding proteins TAK1-binding protein 1 (Tab1), Tab2, and/or Tab3, promoting the 
phosphorylation of the IKKβ subunit of IKK, that in turn leads to the phosphorylation and 
degradation of IκB-α. Signaling through NOD1 and NOD2 also results in MAPK activation 
by a process not fully characterized, but dependent of TAK1 and RICK (Shim et al., 2005) 
(Figure 6b).  
Another process by which NLRs participate in host response to microbial infections is 
through their involvement in inflammasome formation. Inflammasomes are large protein 
complexes that includes NLRs proteins, the adapter ASC (apoptosis-associated speck-like 
protein containing a C-terminal CARD) and pro-caspase-1. This molecular platform is 
crucial for caspase-1 activation and subsequent processing of pro-IL-1β and pro-IL-18, 
resulting in the secretion of their mature biologically active forms (Lamkanfi et al., 2007). 
NLR family members, such as NLRP1, NLRP3 and NLRP4, have shown to be critical factors 
in the activation of proinflammatory caspase-1 and IL-1β secretion in response to several 
microbial stimuli (Pedra et al., 2009) (Figure 6b). 
NLR signaling: NOD1 senses iE-DAP, an amino acid predominantly found in gram-negative 
bacteria while NOD2 senses MDP, which is found in the peptidoglycan of nearly all gram-
positive and gram negative bacteria. Following recognition of their respective ligands, both 
NOD1 and NOD2 self oligomerize to recruit and activate RICK, which in turn activates NF-κB 
via the IKK complex. Signaling through NOD1 and NOD2 also results in MAPK activation by 
a process not fully characterized but dependent of TAK1 and RICK. Another member of the 
NLR family constitutes the inflammasome, a multi-protein complex that includes NLRs 
proteins, the adapter ASC and pro-caspase-1(pC1). In this complex pro-caspase 1 is activated, 
promoting in turn the maturation of pro-IL-1 cytokine to its bioactive form. 
3. Molecular mechanisms by which microorganisms subvert the innate 
immune system 
Common features of pathogenic microorganisms are the exploitation of cytoskeleton and 
membranous structures to invade/or to gain motility inside the host cell, and also the 
manipulation of key signaling pathways. In this section, we will specially focus on the 
mechanisms by which pathogens manipulate signaling pathways in immune cells. 
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Fig. 6. Signaling through RLRs and NLRs. RLR signaling: RIG-I and MDA5 function as 
cytosolic sensors of viral RNA, recognizing preferentially 5′-triphosphate ssRNAs and long 
dsRNAs, respectively. Binding of viral RNAs to these receptors activates signaling through 
the adaptor protein IPS-1, located in the outer mitochondrial membrane or on in 
peroxisomes. Mitochondrial IPS-1 leads to activation of NF-κB and IRF3/IRF7 through the 
IKK complex and TBK1/IKKi, respectively, which results in the production of inflammatory 
cytokines, type I interferons and interferon-stimulating genes (ISGs). In turn, peroxisomal 
IPS-1 induces early expression of ISGs via transcription factor IRF1. 
As stated in above sections, pattern-recognition receptors confer to mammals an extremely 
efficient “detection system” of invading microorganism, triggering an intricate signaling 
network that ultimately orchestrates the establishment of an adequate immune response. 
However, as part of their pathogenic strategies, several microorganisms evade immune 
system by circumventing, or distorting, these signaling pathways and creating, therefore, 
conditions that facilitate their replication and spreading in the host. In the last few years 
great efforts have been made to understand the molecular mechanisms behind this 
subversion, and various signaling cascades were identified as main targets of pathogens and 
virulence factors. When globally analyzed, cascade signals downstream PPRs activation 
mainly converge to two key signaling pathways: the transcription factor nuclear factor-κB 
(NF-κB) and the mitogen activated protein kinases (MAPKs). NF-κB is a cornerstone of 
innate immunity and inflammatory responses, controlling the expression of effector 
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molecules, such as proinflammatory cytokines/chemokines, anti-apoptotic factors and 
defensins; MAPKs are also signaling cascades intimately connected to the regulation of 
innumerous aspects of immunity. Therefore is expectable that pathogens try to circumvent, 
or manipulate, these pathways. This manipulation can be achieved by directly targeting 
signaling intermediates (through cleavage or dephosphorylation), or by distorting the 
balance between immunogenic and tolerogenic signals. The later mechanism mostly results 
from the exploitation of signaling crosstalk between several receptors of innate immune 
system (Hajishengallis & Lambris, 2011). A classical example is the crosstalk between TLRs 
and DC-SIGN: while antigen recognition by TLRs triggers a deleterious response, 
recognition of another antigen of the same pathogen by DC-SIGN negatively modulates the 
TLR signal, promoting an unresponsive state. In the present chapter we do not intent to 
cover the general immune evasion strategies of pathogens, but rather focus on the 
mechanisms by which the microorganisms directly, or by “crosstalk manipulation”, 
interfere with key immune signaling pathways. 
3.1 Exploiting CLRs signaling and their crosstalk with other receptors 
Mycobacterium tuberculosis, the causative agent of tuberculosis, has been a major world-wide 
threat for centuries. In 2009 the disease was responsible for 1.8 million deaths and a recent 
estimative suggests that a third of the world’s population is infected (WHO 2010). 
Macrophages are the primary targets for M. tuberculosis and mainly drive the initial innate 
immune response against the pathogen, while dendritic cells play a central role in the 
establishment of a subsequent cellular response (Fenton & Vermeulen, 1996; Demangel & 
Britton, 2000). In this process, DCs capture and process the pathogen, migrate to draining 
lymph nodes and present the antigenic peptides to naïve T cell, initiating an adaptive 
immune response. M. tuberculosis was shown to modulate the functions of both 
macrophages and DCs (Balboa et al., 2010; Geijtenbeek et al., 2003), promoting immune 
conditions that allow a latent infection. Macrophages phagocyte bacteria into phagosomes, 
which then mature by acquiring low pH, degradative enzymes and reactive 
oxygen/nitrogen species. Phagosomes fuse with lysosomes to form phagolysosomes, 
exposing the engulfed microorganism to the lethal action of hydrolases, proteases, super 
oxide dismutase and lysozymes. However, M. tuberculosis escapes death by blocking the 
maturation of phagosomes and preventing their fusion with lysosomes (Fratti et al., 2003; 
Hmama et al., 2004). This process was shown to be partially mediated by the binding of 
mannosylated lipoarabinomannan (ManLAM) to the mannose receptor in macrophages 
(Kang et al., 2005). ManLAM is a major mannose-containing lipoglycan present in M. 
tuberculosis cell wall that downregulates calmodulin-dependent signal transduction and 
inhibits sphingosine kinase, preventing the conversion of macrophage sphingosine to 
sphingosine-1 phosphate (S-1P) (Malik et al., 2003). This arrests the S-1P-dependent increase 
in Ca2+ concentration, disrupting the PI-3K signaling and the subsequent recruitment of 
Rab5 effector early endosomal antigen 1 (EEA1) to phagosomes (Fratti et al., 2001). EEA1 is 
crucial for the delivery of lysosomal components from the trans-Golgi network to the 
phagosome and regulates fusion of phagosomes with lysosomal vesicles. Therefore the MR-
mediated phagocytosis of ManLAM-containing M. tuberculosis prevents phagosomes to 
mature and to fuse with lisosomes, allowing bacteria to survive.  
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One of the most ingenious mechanisms used by microorganisms to escape host immune 
response is to subvert or disrupt the molecular signaling crosstalk between receptors of the 
innate immune system (Hajishengallis & Lambris, 2011). 
This signaling hijacking frequently leads to an augmented production of immunosuppressive 
molecules, such as IL-10 and/or to a decreased expression of proinflammatory molecules, such 
IL-12 and IFN. 
Both M. tuberculosis and M. bovis BCG are able to induce DC maturation through TLR2- and 
TLR4-mediated signaling (Henderson et al., 1997; Tsuji et al., 2000). However, the 
concomitant engagement of ManLAM to the C-type lectin receptor DC-SIGN modulates the 
TLR-induced NF-κB activation, blocking the expression of co-stimulatory molecules CD80, 
CD83 and CD86 and inducing the production of the immunosuppressive cytokine IL-10 
(Geijtenbeek et al., 2003; Gringhuis et al., 2007). Immature mycobacteria-infected DCs and 
IL-10 dependent blockage of IL-12 production impair the generation of a protective Th1 
response, contributing therefore to the establishment of a latent infection. Besides M. 
tuberculosis, other important human pathogens, such M. leprae, Candida albicans, measles 
virus and HIV-1, were shown to explore TLR-DC-SIGN crosstalk to induce the expression of 
the immunosuppressive cytokine IL-10 (Bergman et al., 2004; Gringhuis et al., 2007; 
Gringhuis et al., 2009). Similarly to M. tuberculosis, HIV-1 activates the Raf-1 pathway 
through DC-SIGN, modulating TLR signaling, and leading to IL-10 increased production, 
impairment of TLR-induced dendritic cell maturation and reduced T-cell proliferation. In a 
process independent of TLR activation, DC-SIGN interacts with HIV-1 envelope 
glycoprotein gp120, and regulates the gene expression profile of DCs (Hodges et al., 2007). 
Among the modulated genes, activating transcription factor 3 (ATF3) is of particular 
importance since it acts as a negative regulator of TLR4-induced expression of 
proinflammatory cytokines IL-6 and IL-12 (Gilchrist et al., 2006). This is therefore suggestive 
that DC-SIGN, besides modulating, also represses TLR4 signaling (den Dunnen et al., 2009). 
Additionally, HIV-1 also exploits the crosstalk between DCIR and TLR8/TLR9 to promote 
DC infection and to evade host immune response. Binding of the virus to DCIR was shown 
to down-modulate the production of TLR8-induced IL-12 and TLR9-induced IFN-α, in 
myeloid and in plasmacytoid DCs, respectively. 
In contrast to the above referred mannose-containing pathogens (mycobacteria, C. albicans 
and HIV-1), Helicobacter pylori induces IL-10 production and Th1 inhibition, through a Raf-1 
independent mechanism. In fact, binding of the fucose-containing LPS Lewis antigens from 
Helicobacter pylori to DC-SIGN actively dissociated the KSR1–CNK–Raf-1 complex from the 
DC-SIGN signalosome, modifying downstream signal transduction (Gringhuis et al., 2009). 
Recently, a new form of crosstalk between DC-SIGN and TLRs was described in dendritic 
cells (Hovius et al., 2008). In this process, Borrelia burgdorferi lipoproteins trigger TLR2 
activation, while Salp15, a salivary protein from Ixodes scapularis, the human vector of 
B.burgdorferi, binds to DC-SIGN and leads to RAF1-mediated MEK activation. MEK-
dependent signaling attenuates, in turn, the TLR2-induced proinflammatory cytokine 
production, by enhancing the decay of Il6 and Tnf mRNA and decreasing IL-12p70 cytokine 
production. Additionally, this crosstalk synergistically enhances IL-10 production. This 
immunosuppression reveals to be advantageous for both, the vector and the bacteria, given 
that it impairs the establishment of an effective adaptive immune response against tick 
and/or B. burgdorferi antigens (Hovius et al., 2008). 
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molecules, such as proinflammatory cytokines/chemokines, anti-apoptotic factors and 
defensins; MAPKs are also signaling cascades intimately connected to the regulation of 
innumerous aspects of immunity. Therefore is expectable that pathogens try to circumvent, 
or manipulate, these pathways. This manipulation can be achieved by directly targeting 
signaling intermediates (through cleavage or dephosphorylation), or by distorting the 
balance between immunogenic and tolerogenic signals. The later mechanism mostly results 
from the exploitation of signaling crosstalk between several receptors of innate immune 
system (Hajishengallis & Lambris, 2011). A classical example is the crosstalk between TLRs 
and DC-SIGN: while antigen recognition by TLRs triggers a deleterious response, 
recognition of another antigen of the same pathogen by DC-SIGN negatively modulates the 
TLR signal, promoting an unresponsive state. In the present chapter we do not intent to 
cover the general immune evasion strategies of pathogens, but rather focus on the 
mechanisms by which the microorganisms directly, or by “crosstalk manipulation”, 
interfere with key immune signaling pathways. 
3.1 Exploiting CLRs signaling and their crosstalk with other receptors 
Mycobacterium tuberculosis, the causative agent of tuberculosis, has been a major world-wide 
threat for centuries. In 2009 the disease was responsible for 1.8 million deaths and a recent 
estimative suggests that a third of the world’s population is infected (WHO 2010). 
Macrophages are the primary targets for M. tuberculosis and mainly drive the initial innate 
immune response against the pathogen, while dendritic cells play a central role in the 
establishment of a subsequent cellular response (Fenton & Vermeulen, 1996; Demangel & 
Britton, 2000). In this process, DCs capture and process the pathogen, migrate to draining 
lymph nodes and present the antigenic peptides to naïve T cell, initiating an adaptive 
immune response. M. tuberculosis was shown to modulate the functions of both 
macrophages and DCs (Balboa et al., 2010; Geijtenbeek et al., 2003), promoting immune 
conditions that allow a latent infection. Macrophages phagocyte bacteria into phagosomes, 
which then mature by acquiring low pH, degradative enzymes and reactive 
oxygen/nitrogen species. Phagosomes fuse with lysosomes to form phagolysosomes, 
exposing the engulfed microorganism to the lethal action of hydrolases, proteases, super 
oxide dismutase and lysozymes. However, M. tuberculosis escapes death by blocking the 
maturation of phagosomes and preventing their fusion with lysosomes (Fratti et al., 2003; 
Hmama et al., 2004). This process was shown to be partially mediated by the binding of 
mannosylated lipoarabinomannan (ManLAM) to the mannose receptor in macrophages 
(Kang et al., 2005). ManLAM is a major mannose-containing lipoglycan present in M. 
tuberculosis cell wall that downregulates calmodulin-dependent signal transduction and 
inhibits sphingosine kinase, preventing the conversion of macrophage sphingosine to 
sphingosine-1 phosphate (S-1P) (Malik et al., 2003). This arrests the S-1P-dependent increase 
in Ca2+ concentration, disrupting the PI-3K signaling and the subsequent recruitment of 
Rab5 effector early endosomal antigen 1 (EEA1) to phagosomes (Fratti et al., 2001). EEA1 is 
crucial for the delivery of lysosomal components from the trans-Golgi network to the 
phagosome and regulates fusion of phagosomes with lysosomal vesicles. Therefore the MR-
mediated phagocytosis of ManLAM-containing M. tuberculosis prevents phagosomes to 
mature and to fuse with lisosomes, allowing bacteria to survive.  
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One of the most ingenious mechanisms used by microorganisms to escape host immune 
response is to subvert or disrupt the molecular signaling crosstalk between receptors of the 
innate immune system (Hajishengallis & Lambris, 2011). 
This signaling hijacking frequently leads to an augmented production of immunosuppressive 
molecules, such as IL-10 and/or to a decreased expression of proinflammatory molecules, such 
IL-12 and IFN. 
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TLR4-mediated signaling (Henderson et al., 1997; Tsuji et al., 2000). However, the 
concomitant engagement of ManLAM to the C-type lectin receptor DC-SIGN modulates the 
TLR-induced NF-κB activation, blocking the expression of co-stimulatory molecules CD80, 
CD83 and CD86 and inducing the production of the immunosuppressive cytokine IL-10 
(Geijtenbeek et al., 2003; Gringhuis et al., 2007). Immature mycobacteria-infected DCs and 
IL-10 dependent blockage of IL-12 production impair the generation of a protective Th1 
response, contributing therefore to the establishment of a latent infection. Besides M. 
tuberculosis, other important human pathogens, such M. leprae, Candida albicans, measles 
virus and HIV-1, were shown to explore TLR-DC-SIGN crosstalk to induce the expression of 
the immunosuppressive cytokine IL-10 (Bergman et al., 2004; Gringhuis et al., 2007; 
Gringhuis et al., 2009). Similarly to M. tuberculosis, HIV-1 activates the Raf-1 pathway 
through DC-SIGN, modulating TLR signaling, and leading to IL-10 increased production, 
impairment of TLR-induced dendritic cell maturation and reduced T-cell proliferation. In a 
process independent of TLR activation, DC-SIGN interacts with HIV-1 envelope 
glycoprotein gp120, and regulates the gene expression profile of DCs (Hodges et al., 2007). 
Among the modulated genes, activating transcription factor 3 (ATF3) is of particular 
importance since it acts as a negative regulator of TLR4-induced expression of 
proinflammatory cytokines IL-6 and IL-12 (Gilchrist et al., 2006). This is therefore suggestive 
that DC-SIGN, besides modulating, also represses TLR4 signaling (den Dunnen et al., 2009). 
Additionally, HIV-1 also exploits the crosstalk between DCIR and TLR8/TLR9 to promote 
DC infection and to evade host immune response. Binding of the virus to DCIR was shown 
to down-modulate the production of TLR8-induced IL-12 and TLR9-induced IFN-α, in 
myeloid and in plasmacytoid DCs, respectively. 
In contrast to the above referred mannose-containing pathogens (mycobacteria, C. albicans 
and HIV-1), Helicobacter pylori induces IL-10 production and Th1 inhibition, through a Raf-1 
independent mechanism. In fact, binding of the fucose-containing LPS Lewis antigens from 
Helicobacter pylori to DC-SIGN actively dissociated the KSR1–CNK–Raf-1 complex from the 
DC-SIGN signalosome, modifying downstream signal transduction (Gringhuis et al., 2009). 
Recently, a new form of crosstalk between DC-SIGN and TLRs was described in dendritic 
cells (Hovius et al., 2008). In this process, Borrelia burgdorferi lipoproteins trigger TLR2 
activation, while Salp15, a salivary protein from Ixodes scapularis, the human vector of 
B.burgdorferi, binds to DC-SIGN and leads to RAF1-mediated MEK activation. MEK-
dependent signaling attenuates, in turn, the TLR2-induced proinflammatory cytokine 
production, by enhancing the decay of Il6 and Tnf mRNA and decreasing IL-12p70 cytokine 
production. Additionally, this crosstalk synergistically enhances IL-10 production. This 
immunosuppression reveals to be advantageous for both, the vector and the bacteria, given 
that it impairs the establishment of an effective adaptive immune response against tick 
and/or B. burgdorferi antigens (Hovius et al., 2008). 
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In neutrophils, mycobacteria bind, to a yet unidentified C-type lectin receptor (potentially 
CLEC5A) and induce, via Syk, a crosstalk with the TLR2 adapter molecule MYD88. This 
results in a rapid and synergistic phosphorylation of Akt and p38 MAK, leading to 
increased IL-10 production, that in turn contributs to the persistence of high mycobacterial 
burden (Zhang et al., 2009). Finally, another example of CLRs-TLRs crosstalk that could 
contribute to the successes of invading pathogens was recently characterized (Goodridge et 
al., 2007). The C-type lectin receptor Dectin-1 is, in DCs and macrophages, crucial for the 
detection of the pathogenic fungi Candida albicans, Aspergillus fumigates and Pneumocystis 
carinii. Traditionally, regarded as inflammatory stimuli, ligands of Dectin-1 induce 
significant amounts of the anti-inflammatory cytokine IL-10, conditioning inflammatory 
cytokine production and Th subsets polarization. The receptor collaborates with TLR2 in 
NF-κB activation, inducing proinflammatory cytokines, such as IL-6 and TNF-α (Gantner et 
al., 2003). However, engagement of Dectin 1 was also shown to activate the nuclear factor of 
activated T-cells (NFAT) that, directly and/or by interference with TLR2, regulates the 
expression of the immunosuppressive cytokine IL-10 (Goodridge et al., 2007). Moreover, 
Dectin-1, due to its cytoplasmic adapter ITAM, signals in an autonomous manner, leading to 
IL-10 production through a calcium-dependent calmodulin (CaM) dependent kinase 
(CaMK)–Pyk2–ERK signaling pathway (Kelly et al., 2010). Accordingly, the genetic deletion 
of Dectin-1 only partially blocks inflammatory cytokine production, while severely impairs 
IL-10 expression (Taylor et al., 2007).  
3.2 Exploiting TLRs signaling and their crosstalk with other receptors 
Among pattern recognition receptors, TLRs are, by excellence, the orchestrators of innate 
immunity. However, pathogens might have evolved to interact with, and exploit, TLRs 
signaling cascades, inducing conflicting signals by distinct pathogen-expressed TLR ligands. 
TLR2-induced responses represent a paradigm of this TLR-TLR interplay. Signaling through 
this receptor leads to an overall proinflammatory response, however it also induces the 
production of substantial levels of the immunosuppressive cytokine IL-10. It was 
hypothesized that this probably results from the crosstalk between TLR2 and particular co-
receptors such CLRs (Zhang et al., 2009). 
Several microorganisms exploit TLR2 crosstalk with other TLRs to evade immune system. 
For example, in macrophages, C. albicans was shown to trigger both TLR4 and TLR2 signals. 
While TLR4 signaling confers protection against infection, TLR2 signaling promotes host 
susceptibility to invasive candidiasis, through the induction of high levels of IL-10 (Netea et 
al., 2004). Lipoproteins from M. tuberculosis cell wall bind TLR2 and down-regulate the 
bacterial CpG DnA-TLR9 induced production of IFNα and IFNβ (Simmons et al., 2010). 
Similarly, in human monocytes, Hepatitis C virus induces TLR2-mediated expression of IL-
10, which in turn suppresses TLR9-induced IFNα production by plasmacytoid DCs 
(Dolganiuc et al., 2006). The pathogens M. tuberculosis and Toxoplasma gondii promote their 
survival in macrophages, through TLR2-MYD88-dependent induction of IL-6, IL-10 and 
granulocyte colony-stimulating factor (GCSF) (El Kasmi et al., 2008). These cytokines, 
through signal transducer and activator of transcription 3 (STAT3), increase the expression 
of arginase 1 (ARG1), which by competing with inducible Nitric Oxide Synthase (iNOS) for 
the common substrate arginine, inhibits the TLR4-mediated production of nitric oxide (NO) 
(Qualls et al., 2010). 
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Additionally to interfering with PPR signaling crosstalk, microorganisms also exploit the 
interplay between other immune receptors, such as TLRs and complement receptors. 
Normally, complement receptors and TLRs are rapidly activated in response to infection, 
and their signals synergistically converge to activate ERK and JNK, promoting an effective 
early innate immune response. However, in macrophages this crosstalk between TLRs and 
complement receptors is frequently subversive, particularly by reducing the cytokines of IL-
12 family (IL-12, IL-23, and IL-27). This decreased cytokine expression translates into a 
limited polarization of protective Th1 responses (Hawlisch et al., 2005). The molecular 
mechanisms of this crosstalk are not fully known, but anaphylatoxin receptor C5aR was 
shown to interfere with TLR-induced cytokine expression, by ERK and PI3K-dependent 
pathways. The C5aR-ERk-IRF1 pathway preferentially inhibits IL-12p70 production, while 
the C5aR–PI3k–IRF8 pathway mainly decreases the production of IL-23 (Hawlisch et al., 
2005). Several other complement receptors, such as gC1qR, CD46 and CR3, limit the TLR4 
and TLR2-induced IL-12 production (Karp et al., 1996; Marth & Kelsall, 1997). HCV core 
protein has been shown to associate with the putative gC1q receptor expressed in host 
immune cells, specifically inhibiting TLR-induced production of IL-12. Therefore, 
engagement of gC1qR on DCs by HCV depresses Th1 immunity and contributes to viral 
persistence (Waggoner et al., 2007). L. monocytogenes and S. aureus were also shown to 
interact with gC1qR, leading probably to a similar evasion mechanism (Braun et al., 2000; 
Nguyen et al., 2000). Other human pathogens, such as P. gingivalis, Histoplasma capsulatum 
and B. pertussis inhibit IL-12 release through CR3-TLR-dependent crosstalk. The fimbriae of 
Porphyromonas gingivalis interacts with complement receptor 3, activating ERK1 and ERK2, 
and thereby limiting TLR2-induced IL-12 production (Hajishengallis et al., 2007).  
These are only some examples of molecular mechanisms by which microorganisms disrupt, 
or subvert, signaling crosstalk between innate immune receptors, being particularly 
emphasized in this review the PPRs interplay. This is an exciting and dynamic Immunology 
field that in last decade brought considerable advances to the understanding of the 
pathophysiology of several human infectious diseases.  
3.3 Direct targeting of signaling intermediates 
Another common evasive maneuver used by pathogens is to directly impair signal 
transduction, through cleavage or dephosphorylation of intermediate molecules in signaling 
cascades. Cascade signals downstream PPRs activation mainly converge to NF-κB and 
MAPKs pathways to establish effective immune responses, making the intermediates of 
these pathways main targets of microorganism hijacking strategies.  
Phosphorylation is the most frequent intracellular modification for signal transduction and 
many pathogens modulate host cell phosphorylation machinery, in order to block or 
circumvent deleterious signals. Yersinia species, causative agents of human diseases, such as 
bubonic and pneumonic plagues and gastrointestinal disorders, use a wide spectrum of 
strategies to circumvent immune response. Through a type III secretion system, bacteria can 
inject into the cytosol of the host cell six different Yersinia outer proteins (Yop). These 
effector proteins interfere with signaling pathways involved in the regulation of the actin 
cytoskeleton, phagocytosis, apoptosis and the inflammatory response, thus favoring 
survival of the bacteria (Viboud & Bliska, 2005). The protein YopP/J was shown to be the 
main antiinflammatory effector protein of Yersinia, by inactivating MAPKs and NF-κB 
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In neutrophils, mycobacteria bind, to a yet unidentified C-type lectin receptor (potentially 
CLEC5A) and induce, via Syk, a crosstalk with the TLR2 adapter molecule MYD88. This 
results in a rapid and synergistic phosphorylation of Akt and p38 MAK, leading to 
increased IL-10 production, that in turn contributs to the persistence of high mycobacterial 
burden (Zhang et al., 2009). Finally, another example of CLRs-TLRs crosstalk that could 
contribute to the successes of invading pathogens was recently characterized (Goodridge et 
al., 2007). The C-type lectin receptor Dectin-1 is, in DCs and macrophages, crucial for the 
detection of the pathogenic fungi Candida albicans, Aspergillus fumigates and Pneumocystis 
carinii. Traditionally, regarded as inflammatory stimuli, ligands of Dectin-1 induce 
significant amounts of the anti-inflammatory cytokine IL-10, conditioning inflammatory 
cytokine production and Th subsets polarization. The receptor collaborates with TLR2 in 
NF-κB activation, inducing proinflammatory cytokines, such as IL-6 and TNF-α (Gantner et 
al., 2003). However, engagement of Dectin 1 was also shown to activate the nuclear factor of 
activated T-cells (NFAT) that, directly and/or by interference with TLR2, regulates the 
expression of the immunosuppressive cytokine IL-10 (Goodridge et al., 2007). Moreover, 
Dectin-1, due to its cytoplasmic adapter ITAM, signals in an autonomous manner, leading to 
IL-10 production through a calcium-dependent calmodulin (CaM) dependent kinase 
(CaMK)–Pyk2–ERK signaling pathway (Kelly et al., 2010). Accordingly, the genetic deletion 
of Dectin-1 only partially blocks inflammatory cytokine production, while severely impairs 
IL-10 expression (Taylor et al., 2007).  
3.2 Exploiting TLRs signaling and their crosstalk with other receptors 
Among pattern recognition receptors, TLRs are, by excellence, the orchestrators of innate 
immunity. However, pathogens might have evolved to interact with, and exploit, TLRs 
signaling cascades, inducing conflicting signals by distinct pathogen-expressed TLR ligands. 
TLR2-induced responses represent a paradigm of this TLR-TLR interplay. Signaling through 
this receptor leads to an overall proinflammatory response, however it also induces the 
production of substantial levels of the immunosuppressive cytokine IL-10. It was 
hypothesized that this probably results from the crosstalk between TLR2 and particular co-
receptors such CLRs (Zhang et al., 2009). 
Several microorganisms exploit TLR2 crosstalk with other TLRs to evade immune system. 
For example, in macrophages, C. albicans was shown to trigger both TLR4 and TLR2 signals. 
While TLR4 signaling confers protection against infection, TLR2 signaling promotes host 
susceptibility to invasive candidiasis, through the induction of high levels of IL-10 (Netea et 
al., 2004). Lipoproteins from M. tuberculosis cell wall bind TLR2 and down-regulate the 
bacterial CpG DnA-TLR9 induced production of IFNα and IFNβ (Simmons et al., 2010). 
Similarly, in human monocytes, Hepatitis C virus induces TLR2-mediated expression of IL-
10, which in turn suppresses TLR9-induced IFNα production by plasmacytoid DCs 
(Dolganiuc et al., 2006). The pathogens M. tuberculosis and Toxoplasma gondii promote their 
survival in macrophages, through TLR2-MYD88-dependent induction of IL-6, IL-10 and 
granulocyte colony-stimulating factor (GCSF) (El Kasmi et al., 2008). These cytokines, 
through signal transducer and activator of transcription 3 (STAT3), increase the expression 
of arginase 1 (ARG1), which by competing with inducible Nitric Oxide Synthase (iNOS) for 
the common substrate arginine, inhibits the TLR4-mediated production of nitric oxide (NO) 
(Qualls et al., 2010). 
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Additionally to interfering with PPR signaling crosstalk, microorganisms also exploit the 
interplay between other immune receptors, such as TLRs and complement receptors. 
Normally, complement receptors and TLRs are rapidly activated in response to infection, 
and their signals synergistically converge to activate ERK and JNK, promoting an effective 
early innate immune response. However, in macrophages this crosstalk between TLRs and 
complement receptors is frequently subversive, particularly by reducing the cytokines of IL-
12 family (IL-12, IL-23, and IL-27). This decreased cytokine expression translates into a 
limited polarization of protective Th1 responses (Hawlisch et al., 2005). The molecular 
mechanisms of this crosstalk are not fully known, but anaphylatoxin receptor C5aR was 
shown to interfere with TLR-induced cytokine expression, by ERK and PI3K-dependent 
pathways. The C5aR-ERk-IRF1 pathway preferentially inhibits IL-12p70 production, while 
the C5aR–PI3k–IRF8 pathway mainly decreases the production of IL-23 (Hawlisch et al., 
2005). Several other complement receptors, such as gC1qR, CD46 and CR3, limit the TLR4 
and TLR2-induced IL-12 production (Karp et al., 1996; Marth & Kelsall, 1997). HCV core 
protein has been shown to associate with the putative gC1q receptor expressed in host 
immune cells, specifically inhibiting TLR-induced production of IL-12. Therefore, 
engagement of gC1qR on DCs by HCV depresses Th1 immunity and contributes to viral 
persistence (Waggoner et al., 2007). L. monocytogenes and S. aureus were also shown to 
interact with gC1qR, leading probably to a similar evasion mechanism (Braun et al., 2000; 
Nguyen et al., 2000). Other human pathogens, such as P. gingivalis, Histoplasma capsulatum 
and B. pertussis inhibit IL-12 release through CR3-TLR-dependent crosstalk. The fimbriae of 
Porphyromonas gingivalis interacts with complement receptor 3, activating ERK1 and ERK2, 
and thereby limiting TLR2-induced IL-12 production (Hajishengallis et al., 2007).  
These are only some examples of molecular mechanisms by which microorganisms disrupt, 
or subvert, signaling crosstalk between innate immune receptors, being particularly 
emphasized in this review the PPRs interplay. This is an exciting and dynamic Immunology 
field that in last decade brought considerable advances to the understanding of the 
pathophysiology of several human infectious diseases.  
3.3 Direct targeting of signaling intermediates 
Another common evasive maneuver used by pathogens is to directly impair signal 
transduction, through cleavage or dephosphorylation of intermediate molecules in signaling 
cascades. Cascade signals downstream PPRs activation mainly converge to NF-κB and 
MAPKs pathways to establish effective immune responses, making the intermediates of 
these pathways main targets of microorganism hijacking strategies.  
Phosphorylation is the most frequent intracellular modification for signal transduction and 
many pathogens modulate host cell phosphorylation machinery, in order to block or 
circumvent deleterious signals. Yersinia species, causative agents of human diseases, such as 
bubonic and pneumonic plagues and gastrointestinal disorders, use a wide spectrum of 
strategies to circumvent immune response. Through a type III secretion system, bacteria can 
inject into the cytosol of the host cell six different Yersinia outer proteins (Yop). These 
effector proteins interfere with signaling pathways involved in the regulation of the actin 
cytoskeleton, phagocytosis, apoptosis and the inflammatory response, thus favoring 
survival of the bacteria (Viboud & Bliska, 2005). The protein YopP/J was shown to be the 
main antiinflammatory effector protein of Yersinia, by inactivating MAPKs and NF-κB 
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pathways. NF-κB pathway inhibition was initially clearly associated to the de-ubiquitinating 
activity of YopP/J. IκB-α de-ubiquitination impairs its targeting for proteosomal 
degradation, effectively sequestering NF-κB into the cytoplasm (Zhou et al., 2005). However, 
this ubiquitin-like protease activity was unable to explain the effects of YopP/J over 
MAPKs, as ubiquitination is not known to play a direct role in MAPK signaling. Recent data 
demonstrate that YopP/J has acetyltranferase activity, transferring acetyl moieties to 
Ser/Thr residues in the activation loop of MKKs and IKKs (Mittal et al., 2006). It was 
suggested that acetylation competes effectively with phosphorylation at these sites, thereby 
blocking signal transduction. Vibrio outer protein A (VopA), an YopJ-like protein from 
Vibrio parahaemolyticus, was also shown to selectively inhibit MAPKs signaling by 
acetylating a conserved lysine in the ATP-binding pocket of MKKs. This not only prevents 
MKKs activation but also decreases the activity of activated MKKs (Trosky et al., 2007).  
Salmonella, another important human pathogen, delivers effector proteins into host cell, 
suppressing cellular immune response through blockade of NF-κB and MAPKs cascades 
(McGhie et al., 2009). The effector protein SptP, by its GTPase-activating protein and tyrosine 
phosphatase activities, reverses MAPKs activation (Murli et al., 2001; Lin et al., 2003) and 
AvrA, through its acetyltransferase activity toward specific mitogen-activated protein kinase 
kinases (MAPKKs), potently inhibits JNK (Jones et al., 2008). Other Salmonella effector proteins, 
such SpvC, a phosphothreonine lyase, directly dephosphorylates ERK, JNK and p38 MAPKs 
(Mazurkiewicz et al., 2008) and Avra and SseL proteins suppress NF-κB activation by 
impairing IκB-α ubiquitination and degradation (Ye et al., 2007; Le Negrate et al., 2008).  
Similarly, as a strategy for repressing innate immunity, Shigella flexneri has evolved the 
capacity to precisely modulate host cell epigenetic “information”, interfering with MAPKs 
and NF-κB pathways at several points. This is mainly drived by the effector protein OspF. 
OspF is remarkable not only for its biochemistry but also for the fact that is one of the few 
bacterial effectors that is known to translocate to the host-cell nucleus. At the cytosol level, 
the protein binds to the ubiquitylated form of the E2 ubiquitin-conjugating enzyme 
UBCH5B, and independently of IκB phosphorylation, prevents the transfer of ubiquitin to IκB 
by an E3 ubiquitin–protein ligase (Kim et al., 2005). Additionally, OspF dephosphorylates ERK 
and p38 MAPKs by either phosphatase (Arbibe et al., 2007) or phosphothreonine lyase (Li et 
al., 2007) activities. Recent data showed that this protein also manipulates the physical and 
spatial context of DNA encoding NF-κB-responsive genes (Arbibe et al., 2007). At the host-
cell nucleus, OspF dephosphorylates the MAPK ERK2, impairing the activation of mitogen- 
and stress-activated kinase 1 (MSK1) and MSK2. This prevents subsequent histone 
phosphorylation, which is necessary for NF-κB-dependent transcription. Therefore, several 
innate immune-related genes under control of NF-κB remain silent, allowing S. flexneri to 
avoid a deleterious response. 
The mechanisms used by microorganisms to modulate NF-κB signaling are diverse and, as 
exemplified above, a common strategy is to target the steps that lead to IκB degradation. 
However, several pathogens, such Toxoplasma gondii and Leishmania spp have evolved 
distinct processes to block this central signaling pathway. Infection by T. gondii provides 
potent signals for IL-12 production and for induction of strong Th1 immunity, being NF-κB 
an important player in this process (Caamano & Hunter, 2002). However, at early times of 
infection (up to 24h) the parasite impairs in macrophages, the NF-κB signaling, limiting the 
production of IL-12, TNF-α and NO. This blockage was shown to occur independently of 
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infection-induced IKK-dependent degradation of IκB-α, resulting in specific impairment of 
NF-κB nuclear translocation. The termination of NF-κB signaling was therefore associated 
with reduced phosphorylation of p65/RelA subunit, an event involved in the ability of NF-
κB to translocate to the nucleus and to bind DNA (Shapira et al., 2005). 
Regarding Leishmania, the infection by this protozoan parasite has long been regarded as the 
paradigm of a Th2 immune response. Extensive studies have been conducted to disclose the 
molecular mechanism by which Leishmania modulate intracellular signaling events in 
infected macrophages and dendritic cells. Obtained data indicate that the parasite use an 
extensive “arsenal” of strategies and virulence factors to alter the host cell signaling, 
favoring its survival. Infection of macrophages with L. donovani promastigotes was shown to 
increase intracellular ceramide content causing a downregulation of classical PKC activity, 
up-regulation of calcium independent atypical PKC-zeta and dephosphorylation of ERK. 
Downregulation of ERK signaling was subsequently found to be associated with the 
inhibition of activated protein 1 (AP-1) and NF-κB transactivation (Ghosh et al., 2002). Other 
studies whit the same infection model showed that Leishmania alters signal transduction 
upstream of c-Fos and c-Jun, by inhibiting ERK, JNK and p38 MAP Kinases, resulting in a 
reduction of AP-1 nuclear translocation (Prive & Descoteaux, 2000). Until recently, little was 
known about the intervenients and molecular mechanisms behind these immunosuppressive 
abilities of Leishmania. In macrophages infected with Leishmania mexicana amastigotes, 
Cameron and co-workers showed that cysteine peptidase B (CPB) is the virulence factor 
responsible for proteolytic degradation of NF-κB, ERK and JNK (Cameron et al., 2004). 
Additionally, CPB is also involved in the activation of host protein tyrosine phosphatase 1B 
(PTP-1B), inhibition of AP-1 and cleavage of STAT-1α (Abu-Dayyeh et al., 2010). Another 
Leishmania virulence factor, the surface metalloprotease GP63, was shown to cleave host 
protein tyrosine phosphatases PTP-1B, TCPTP, and SHP-1, resulting in the stimulation of 
their phosphatase activity and consequent dephosphorylation of key kinases, such as 
JAK/STAT, IRAK-1 and MAPKs (Gomez et al., 2009). Moreover, GP63 is also responsible for 
the observed cleavage of NF-κB p65RelA subunit in L. mexicana and L.infantum -infected 
macrophages and dendritic cells (Gregory et al., 2008; Neves et al., 2010). From this cleavage 
results a fragment of approximately 35 kDa that is rapidly translocated into the nucleus 
where it has some transcriptional activity. It was postulated that the resulting p35RelA 
fragment may represent an important mediator by which Leishmania promastigotes induce 
several chemokines without inducing other NF-κB-regulated genes, such as iNOS and IL-12 
that are detrimental for parasite survival. 
Recently, the metalloprotease GP63 was shown to be involved in the decreased general 
translation observed in macrophages infected with L.major (Jaramillo et al., 2011). The parasite 
protease cleaves the serine/threonine kinase mammalian/ mechanistic target of rapamycin 
(mTOR), impairing the formation of mTOR complex 1 (mTORC1) and the downstream 
phosphorylation of translational repressor 4E-binding protein 1/2 (4E-BP1/2). The activity of 
the translational repressors 4E-BPs is controlled through their phosphorylation state and, in 
normal conditions, mTORC1 formation leads to hyperphosphorylation of 4E-binding proteins 
(4E-BPs), causing their dissociation from eukaryotic initiation factor 4F, facilitating this way 
the translation of mRNA (Gingras et al., 1999). mTORC1, through its downstream targets p70 
ribosomal S6 protein kinases 1 and 2 (S6K1/2) and 4E-BPs controls the translation of key 
innate immune effector molecules, such as type I IFN (Cao et al., 2008; Costa-Mattioli & 
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pathways. NF-κB pathway inhibition was initially clearly associated to the de-ubiquitinating 
activity of YopP/J. IκB-α de-ubiquitination impairs its targeting for proteosomal 
degradation, effectively sequestering NF-κB into the cytoplasm (Zhou et al., 2005). However, 
this ubiquitin-like protease activity was unable to explain the effects of YopP/J over 
MAPKs, as ubiquitination is not known to play a direct role in MAPK signaling. Recent data 
demonstrate that YopP/J has acetyltranferase activity, transferring acetyl moieties to 
Ser/Thr residues in the activation loop of MKKs and IKKs (Mittal et al., 2006). It was 
suggested that acetylation competes effectively with phosphorylation at these sites, thereby 
blocking signal transduction. Vibrio outer protein A (VopA), an YopJ-like protein from 
Vibrio parahaemolyticus, was also shown to selectively inhibit MAPKs signaling by 
acetylating a conserved lysine in the ATP-binding pocket of MKKs. This not only prevents 
MKKs activation but also decreases the activity of activated MKKs (Trosky et al., 2007).  
Salmonella, another important human pathogen, delivers effector proteins into host cell, 
suppressing cellular immune response through blockade of NF-κB and MAPKs cascades 
(McGhie et al., 2009). The effector protein SptP, by its GTPase-activating protein and tyrosine 
phosphatase activities, reverses MAPKs activation (Murli et al., 2001; Lin et al., 2003) and 
AvrA, through its acetyltransferase activity toward specific mitogen-activated protein kinase 
kinases (MAPKKs), potently inhibits JNK (Jones et al., 2008). Other Salmonella effector proteins, 
such SpvC, a phosphothreonine lyase, directly dephosphorylates ERK, JNK and p38 MAPKs 
(Mazurkiewicz et al., 2008) and Avra and SseL proteins suppress NF-κB activation by 
impairing IκB-α ubiquitination and degradation (Ye et al., 2007; Le Negrate et al., 2008).  
Similarly, as a strategy for repressing innate immunity, Shigella flexneri has evolved the 
capacity to precisely modulate host cell epigenetic “information”, interfering with MAPKs 
and NF-κB pathways at several points. This is mainly drived by the effector protein OspF. 
OspF is remarkable not only for its biochemistry but also for the fact that is one of the few 
bacterial effectors that is known to translocate to the host-cell nucleus. At the cytosol level, 
the protein binds to the ubiquitylated form of the E2 ubiquitin-conjugating enzyme 
UBCH5B, and independently of IκB phosphorylation, prevents the transfer of ubiquitin to IκB 
by an E3 ubiquitin–protein ligase (Kim et al., 2005). Additionally, OspF dephosphorylates ERK 
and p38 MAPKs by either phosphatase (Arbibe et al., 2007) or phosphothreonine lyase (Li et 
al., 2007) activities. Recent data showed that this protein also manipulates the physical and 
spatial context of DNA encoding NF-κB-responsive genes (Arbibe et al., 2007). At the host-
cell nucleus, OspF dephosphorylates the MAPK ERK2, impairing the activation of mitogen- 
and stress-activated kinase 1 (MSK1) and MSK2. This prevents subsequent histone 
phosphorylation, which is necessary for NF-κB-dependent transcription. Therefore, several 
innate immune-related genes under control of NF-κB remain silent, allowing S. flexneri to 
avoid a deleterious response. 
The mechanisms used by microorganisms to modulate NF-κB signaling are diverse and, as 
exemplified above, a common strategy is to target the steps that lead to IκB degradation. 
However, several pathogens, such Toxoplasma gondii and Leishmania spp have evolved 
distinct processes to block this central signaling pathway. Infection by T. gondii provides 
potent signals for IL-12 production and for induction of strong Th1 immunity, being NF-κB 
an important player in this process (Caamano & Hunter, 2002). However, at early times of 
infection (up to 24h) the parasite impairs in macrophages, the NF-κB signaling, limiting the 
production of IL-12, TNF-α and NO. This blockage was shown to occur independently of 
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infection-induced IKK-dependent degradation of IκB-α, resulting in specific impairment of 
NF-κB nuclear translocation. The termination of NF-κB signaling was therefore associated 
with reduced phosphorylation of p65/RelA subunit, an event involved in the ability of NF-
κB to translocate to the nucleus and to bind DNA (Shapira et al., 2005). 
Regarding Leishmania, the infection by this protozoan parasite has long been regarded as the 
paradigm of a Th2 immune response. Extensive studies have been conducted to disclose the 
molecular mechanism by which Leishmania modulate intracellular signaling events in 
infected macrophages and dendritic cells. Obtained data indicate that the parasite use an 
extensive “arsenal” of strategies and virulence factors to alter the host cell signaling, 
favoring its survival. Infection of macrophages with L. donovani promastigotes was shown to 
increase intracellular ceramide content causing a downregulation of classical PKC activity, 
up-regulation of calcium independent atypical PKC-zeta and dephosphorylation of ERK. 
Downregulation of ERK signaling was subsequently found to be associated with the 
inhibition of activated protein 1 (AP-1) and NF-κB transactivation (Ghosh et al., 2002). Other 
studies whit the same infection model showed that Leishmania alters signal transduction 
upstream of c-Fos and c-Jun, by inhibiting ERK, JNK and p38 MAP Kinases, resulting in a 
reduction of AP-1 nuclear translocation (Prive & Descoteaux, 2000). Until recently, little was 
known about the intervenients and molecular mechanisms behind these immunosuppressive 
abilities of Leishmania. In macrophages infected with Leishmania mexicana amastigotes, 
Cameron and co-workers showed that cysteine peptidase B (CPB) is the virulence factor 
responsible for proteolytic degradation of NF-κB, ERK and JNK (Cameron et al., 2004). 
Additionally, CPB is also involved in the activation of host protein tyrosine phosphatase 1B 
(PTP-1B), inhibition of AP-1 and cleavage of STAT-1α (Abu-Dayyeh et al., 2010). Another 
Leishmania virulence factor, the surface metalloprotease GP63, was shown to cleave host 
protein tyrosine phosphatases PTP-1B, TCPTP, and SHP-1, resulting in the stimulation of 
their phosphatase activity and consequent dephosphorylation of key kinases, such as 
JAK/STAT, IRAK-1 and MAPKs (Gomez et al., 2009). Moreover, GP63 is also responsible for 
the observed cleavage of NF-κB p65RelA subunit in L. mexicana and L.infantum -infected 
macrophages and dendritic cells (Gregory et al., 2008; Neves et al., 2010). From this cleavage 
results a fragment of approximately 35 kDa that is rapidly translocated into the nucleus 
where it has some transcriptional activity. It was postulated that the resulting p35RelA 
fragment may represent an important mediator by which Leishmania promastigotes induce 
several chemokines without inducing other NF-κB-regulated genes, such as iNOS and IL-12 
that are detrimental for parasite survival. 
Recently, the metalloprotease GP63 was shown to be involved in the decreased general 
translation observed in macrophages infected with L.major (Jaramillo et al., 2011). The parasite 
protease cleaves the serine/threonine kinase mammalian/ mechanistic target of rapamycin 
(mTOR), impairing the formation of mTOR complex 1 (mTORC1) and the downstream 
phosphorylation of translational repressor 4E-binding protein 1/2 (4E-BP1/2). The activity of 
the translational repressors 4E-BPs is controlled through their phosphorylation state and, in 
normal conditions, mTORC1 formation leads to hyperphosphorylation of 4E-binding proteins 
(4E-BPs), causing their dissociation from eukaryotic initiation factor 4F, facilitating this way 
the translation of mRNA (Gingras et al., 1999). mTORC1, through its downstream targets p70 
ribosomal S6 protein kinases 1 and 2 (S6K1/2) and 4E-BPs controls the translation of key 
innate immune effector molecules, such as type I IFN (Cao et al., 2008; Costa-Mattioli & 
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Sonenberg, 2008). This cleavage of mTOR by Leishamania GP63 represents, therefore, a 
survival mechanism where the parasite directly targets the host translational machinery. This 
strategy is also a common feature of several human viruses. Lytic viruses, such members of the 
picornavirus group (enterovirus, rhinovirus and aphtovirus) inhibit overall host cellular 
translation, redirecting the translational apparatus to viral protein synthesis. This effect was 
shown to be due to the poliovirus 2A protease-mediated cleavage of the translation initiation 
factor eIF4G (Borman et al., 1997). 
Bacillus anthracis, Chlamydia and Escherichia coli are examples of other human pathogens that 
directly cleave intermediate molecules from NF-κB and MAPKs signaling cascades. Bacillus 
anthracis, a spore-forming encapsulated gram-positive bacterium kwon to cause anthrax 
disease, produces innumerous virulence factors critical for the establishment of infection 
and pathogenesis (Turnbull, 2002). Among these factors, the plasmid-encoded enzymes 
lethal factor (LF) and oedema factor (OF) are of major importance for the evasion abilities of 
B. anthracis. LF is a particularly selective metalloproteinase that cleaves MKKs at specific 
sites outside of their catalytic domains, impairing the downstream MAPK activation 
(Duesbery et al., 1998). In addition, it blocks the p38 MAPK-dependent activation of IRF3 
(Dang et al., 2004) and, although not directly affecting NF-κB activity, it causes the 
downregulation of NF-κB target genes that simultaneously require p38 activity for induction 
(Park et al., 2002). Consequently, macrophage production of proinflammatory cytokines, 
such as TNF-α, IL-1β and IL-6, is severely impaired. In turn, OF is an active Ca2+ and 
calmodulin-dependent adenylate cyclase that increases cAMP in the cytosol of host cells 
(Drum et al., 2002). Raised intracellular levels of cAMP activate PKA, causing downstream 
inhibition of ERK and JNK pathways, as well as a decreased NADPH oxidase activity, 
resulting in impaired TNF-α and microbicidal superoxide production (Hoover et al., 1994). 
The obligate intracellular bacterial parasite Chlamydia is the leading cause of preventable 
blindness worldwide and urogenital tract infection remains the most prevalent cause of 
sexually transmitted diseases in developed countries. The parasite avoids host inflammatory 
response, partially by disrupting the NF-κB signal resultant from the PPR recognition of 
bacterial component such LPS. This blockage was shown to result from the selective 
cleavage of the p65RelA subunit of NF-κB by the chlamydial protease-like activity factor 
(CPAF) (Christian et al., 2010). Similarly, E.coli decreases production of proinflammatory 
cytokines and reduces macrophage bactericidal activity, by targeting NF-κB signal 
transduction at multiple points. Infection by E coli induces a host caspase 3-mediated 
cleavage of p65RelA, by a mechanism not completely defined, but thought to be mediated 
through the mitochondrial pathway of apoptosis (Albee & Perlman, 2006). In addition, 
several studies have recently demonstrated that E. coli also downregulates NF-κB-mediated 
gene expression by injecting into host-cells several non-LEE encoded (Nle) effector proteins, 
such as NleB, NleC and NleE. NleB and NleE prevent IKKβ activation and consequently the 
degradation of IκB-α, thus limiting p65 translocation to the nucleus (Nadler et al., 2010; 
Newton et al., 2010) while the zinc-dependent metalloprotease NleC was shown to 
enzymatically degrade p65RelA and JNK (Yen et al., ; Baruch et al., 2010). 
Although more frequent in bacteria, the shutdown of PPR signaling by direct cleavage of 
cascade intermediates is also a strategy used by some relevant human viral pathogens. As 
an example, hepatitis C virus-host interactions have revealed several evasion mechanisms 
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used by the virus to control PPRs signaling, providing a molecular basis for viral 
persistence. In viral infections, recognition of pathogen associated molecular patterns by 
TLRs and RLRs leads, through independent signaling cascades, to the activation of 
transcription factors, such as IRF1, IRF3, IRF5, IRF7 and NF-κB. The activity of these 
transcription factors is crucial for an effective antiviral innate immune response, given that 
they control the expression of interferon-stimulated genes (ISGs) and type I interferons. 
Hepatitis C virus (HCV) has evolved to disrupt RLRs signaling by impairing RIG-I pathway, 
through NS3/4A-mediated cleavage of IPS-1 (Malmgaard, 2004). NS3/4A is formed by a 
complex of the NS3 and NS4A HCV proteins and has been shown to be an essential viral 
protein with serine protease activity (Brass et al., 2008). In HCV infection, cleavage of IPS-1 
by NS3/4A impairs downstream activation of IRF-3 and NF-κB, blocking the production of 
IFN-β, as well as the expression of ISGs (Li et al., 2005). This results in a strongly compromised 
innate immune response, potentiating the propagation of chronic HCV infection. 
4. Conclusions 
Millenary host–microbe co-evolution has resulted in the development of ingenious 
strategies by pathogens in order to successfully evade host immune response. Besides the 
manipulation of host-cell cytoskeleton to gain entry and/or to gain motility in the cell, 
immune-cell signaling pathways are frequent targets of invading pathogens. Within the past 
decades, remarkable progress has been made in our understanding on how immune cells 
sense microorganisms and how microbial effectors counteract innate immune responses. 
Recognition of conserved microorganism patterns by PRRs activates, in immune cells, an 
intricate signaling network that culminates in the expression of effector molecules, such as 
cytokines, chemokines and reactive oxygen species, crucial elements to mount an adequate 
immune response. A common strategy of pathogens is to disrupt these signaling cascades, 
by promoting contradictory signals through engagement of distinct PRRs and/or by directly 
target intermediate components of these signaling pathways. Therefore, understanding the 
molecular mechanisms used by pathogens to exploit the host signaling networks is of 
crucial importance for the development of rational interventions in which host response will 
be redirect to achieve protective immunity. 
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factor eIF4G (Borman et al., 1997). 
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by NS3/4A impairs downstream activation of IRF-3 and NF-κB, blocking the production of 
IFN-β, as well as the expression of ISGs (Li et al., 2005). This results in a strongly compromised 
innate immune response, potentiating the propagation of chronic HCV infection. 
4. Conclusions 
Millenary host–microbe co-evolution has resulted in the development of ingenious 
strategies by pathogens in order to successfully evade host immune response. Besides the 
manipulation of host-cell cytoskeleton to gain entry and/or to gain motility in the cell, 
immune-cell signaling pathways are frequent targets of invading pathogens. Within the past 
decades, remarkable progress has been made in our understanding on how immune cells 
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Recognition of conserved microorganism patterns by PRRs activates, in immune cells, an 
intricate signaling network that culminates in the expression of effector molecules, such as 
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immune response. A common strategy of pathogens is to disrupt these signaling cascades, 
by promoting contradictory signals through engagement of distinct PRRs and/or by directly 
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1. Introduction 
To maintain its functional integrity, a cell senses and reacts to the acute or chronic changes 
in the environment under physiological and pathological conditions. This typically involves 
cell surface membrane proteins such as receptors, ion channels, and structural proteins, 
whose surface expression level is regulated at multiple different steps of their biosynthesis 
and trafficking. Protein trafficking is mediated by a series of dynamic interactions between 
the sorting motifs of cargo proteins and the cellular machineries that recognize these motifs. 
While the constitutive trafficking of many cargo proteins relies on intrinsic sorting signals, 
post-translational modification of cargo proteins often serves as a key switch that enables 
the spatio-temporal regulation of their trafficking. Protein phosphorylation is one of the 
most intensively studied post-translational modifications that control the membrane 
trafficking. However, molecular mechanisms by which phosphorylation signal regulates the 
protein localization are diverse and remain not fully understood. The 14-3-3 proteins had 
been identified to specifically recognize phosphorylated serine or threonine residues, and 
thus represents one of the most distinct effector molecules that function downstream of the 
phosphorylation signal by kinases. This chapter will focus on the emerging role of 14-3-3 
proteins in the phosphorylation-dependent control of cell surface membrane protein 
trafficking. 
2. Control of cell surface expression by phosphorylation signal 
A typical mechanism by which phosphorylation signal controls protein trafficking is that 
phosphorylation of cargo proteins creates docking sites for the interacting proteins. A well 
studied example is the internalization of G protein-coupled receptors (GPCRs), where 
ligand binding induces the conformational change of the receptor and subsequent 
recruitment of GPCR kinases (GRKs) to the receptor. Receptor phosphorylation by GRKs 
recruits arrestin that couples the receptor to the adaptor protein of clathrin coat, thereby 
initiating the internalization of the cargo vesicles (Drake et al., 2006; Tobin, 2008). This way 
phosphorylation signal leads to the desensitization of ligand stimulus by reducing the cell 
surface density of GPCRs. On the other hand, phosphorylation signalling can also regulate 
localization of membrane proteins by attenuating the sorting signal activity. In the neuron, 
ligand stimulation of N-methyl-D-aspartate (NMDA) receptor leads to receptor 
phosphorylation by casein kinase II (CK2) at the serine residue within the C-terminal PDZ 
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phosphorylation of cargo proteins creates docking sites for the interacting proteins. A well 
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ligand binding induces the conformational change of the receptor and subsequent 
recruitment of GPCR kinases (GRKs) to the receptor. Receptor phosphorylation by GRKs 
recruits arrestin that couples the receptor to the adaptor protein of clathrin coat, thereby 
initiating the internalization of the cargo vesicles (Drake et al., 2006; Tobin, 2008). This way 
phosphorylation signal leads to the desensitization of ligand stimulus by reducing the cell 
surface density of GPCRs. On the other hand, phosphorylation signalling can also regulate 
localization of membrane proteins by attenuating the sorting signal activity. In the neuron, 
ligand stimulation of N-methyl-D-aspartate (NMDA) receptor leads to receptor 
phosphorylation by casein kinase II (CK2) at the serine residue within the C-terminal PDZ 
 
Protein Kinases 166 
[postsynaptic density-95 (PSD-95)/Discs large/zona occludens-1] binding motif (IESDV-
COOH) of NMDA receptor subunit 2B (NR2B). CK2 phosphorylation disrupts the 
interaction of NR2B with the PDZ domains of PSD-95 and SAP102 and thereby decreases 
cell surface NR2B expression (Chung et al., 2004). This represents the regulatory role of 
phosphorylation in excitatory synaptic function and plasticity.  
In contrast to the downregulation of surface expression, the molecular basis for the role of 
phosphorylation in promoting cell surface trafficking has been less well understood. 
However, studies in the past decade have revealed that 14-3-3s are the key class of phospho- 
sensing proteins which mediate cell surface trafficking of various membrane proteins. Here 
we will review recent findings on the emerging role of 14-3-3 in cell surface protein 
trafficking, with particular focus on their mechanisms of action and relevant kinases. 
2.1 14-3-3 proteins and 14-3-3 binding sites 
The 14-3-3 proteins were first discovered in 1967 as brain-rich, acidic protein (Moore & Perez, 
1967). The name 14-3-3 refers to the elution and migration profile of these proteins on DEAE-
cellulose chromatography and starch gel electrophoresis. They are highly conserved and 
expressed in all eukaryotic cells, with seven isoforms in mammals (β, γ, ε, ζ, η, τ, σ) and two in 
yeast (Bmh1 and Bmh2). 14-3-3 proteins participate in fundamental biological processes such 
as signal transduction, metabolism, protein degradation, and trafficking (Tzivion & Avruch, 
2002; van Hemert et al., 2001). All the 14-3-3 proteins, except for the sigma isoform, are able to 
form stable homo- and heterodimers (Benzinger et al., 2005; Gardino et al., 2006; Wilker et al., 
2005). The dimeric structure of the 14-3-3 protein allows it to simultaneously bind two binding 
sites through an amphipathic ligand-binding groove present in each monomer. In the majority 
of cases, 14-3-3 proteins recognize phosphorylated peptides in their binding partners. 
Screening of phosphoserine-oriented peptide libraries has identified two consensus 14-3-3 
binding motifs that are present in many of known 14-3-3 binding proteins (Yaffe et al., 1997). 
These are R-[S/]-X-pS/pT-X-P (mode I) and R-X-[S/]-X-pS/pT-X-P (mode II) binding sites 
where pS/pT is phosphoserine or phosphothreonine,  is an aromatic residue, and X is any 
residue (typically leucine, glutamate, alanine, and methionine). However, it should be noted 
that 14-3-3-binding sites in numerous proteins do not conform to these optimal motifs, 
presumably because other structural features also contribute to the interactions. For instance, 
proline located at position +2 of the phosphorylation site occurs in only about half of known 
14-3-3 binding motifs in mammalian proteins (Johnson et al., 2010).  
The C-terminal 14-3-3 binding motifs have recently become a newly recognized group with 
a distinct mode of interaction (see Table 1). Based on the similarity between the C-terminal 
14-3-3 binding motifs of the oAANAT (RRNpSDR-COOH) and H+-ATPase (QQXYpTV-
COOH) proteins, a new mode III consensus for 14-3-3 binding (pSX1–2-COOH) had been 
proposed (Ganguly et al., 2005). The focal points of this consensus are that the motif is at the 
extreme C-terminus in contrast to the canonical mode I and II internal binding sites, and that 
the binding is phosphorylation-dependent. Mode III sequences interact with the same 
ligand-binding groove of 14-3-3 as do the mode I and mode II motifs (Coblitz et al., 2005). 
Amino acid selectivity upstream of the phosphorylated residue is conspicuously absent 
from the proposed mode III motif, presumably due to the discrepancy between the 
oAANAT and H+-ATPase motifs. However, upstream arginine residues are preferred for 
modes I and II 14-3-3 binding as determined by random synthetic peptide library screening  
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Table 1. 14-3-3 binding sequences. Consensus mode I and mode II motifs and the reported 
C-terminal mode III binding sequences are shown. S/T: phosphorylated serine or threonine 
required for 14-3-3 binding, : aromatic residue, Reference#1: (Bodnar et al., 1999) , #2: (Sliva 
et al., 2000), #3 and #4: (O'Kelly et al., 2002):, #5 and #6: (Shikano et al., 2005), #7:(Rong et al., 
2007), #8: (Wurtele et al., 2003), #9: (Ganguly et al., 2005), #10: (Fujita et al., 2003).  
(Yaffe et al., 1997) and by random C-terminal peptide selection in a cell-based genetic screen 
(Shikano et al., 2005). Indeed, the majority of the so far identified C-terminal 14-3-3 binding 
sequences contain arginine residues upstream of the phosphorylated serine or threonine 
(Table 1). Recent mutagenesis study of the C-terminal 14-3-3 binding site in GPR15 
demonstrated the importance of the upstream arginine residue for phosphorylation-
dependent 14-3-3 binding (Okamoto & Shikano, 2011). In a crystal structure with 14-3-3, a 
mode II peptide displayed an arginine in the -4 position from phosphorylated serine 
(RLYHpSLPA) that was looped back to interact with the phosphate on the peptide (Rittinger 
et al., 1999). These lines of evidence support significant contribution of upstream arginine 
residues to the 14-3-3 affinity. Thus, Mode III would be better defined as RXXpS/pTX-
COOH. For all three modes of 14-3-3 binding, phosphorylation is a prerequisite and arginine 
residues located upstream of the phospho-serine/threonine are also important for 
recognition by a number of kinases (Kobe et al., 2005). Thus, the absence of an arginine 
residue in the C-terminal 14-3-3 binding sequence in plant H+-ATPase (QQXYpTV-COOH) 
suggests the possibility that plant and animal differ significantly in kinase recognition. As 
more C-terminal 14-3-3 binding proteins become available, it would be valuable to revisit 
the issue of upstream sequence requirements both in terms of 14-3-3 binding per se and in 
terms of kinase recognition.  
2.2 Protein kinases that phosphorylate 14-3-3 target sites 
Proteomic screens have identified over 200 phosphoproteins which interact with 14-3-3 
(Chang et al., 2009; Ichimura et al., 2002; Kakiuchi et al., 2007; Meek et al., 2004; Pozuelo 
Rubio et al., 2004). Understanding when and how 14-3-3 proteins impact on these targets 
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COOH) of NMDA receptor subunit 2B (NR2B). CK2 phosphorylation disrupts the 
interaction of NR2B with the PDZ domains of PSD-95 and SAP102 and thereby decreases 
cell surface NR2B expression (Chung et al., 2004). This represents the regulatory role of 
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trafficking, with particular focus on their mechanisms of action and relevant kinases. 
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1967). The name 14-3-3 refers to the elution and migration profile of these proteins on DEAE-
cellulose chromatography and starch gel electrophoresis. They are highly conserved and 
expressed in all eukaryotic cells, with seven isoforms in mammals (β, γ, ε, ζ, η, τ, σ) and two in 
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proposed (Ganguly et al., 2005). The focal points of this consensus are that the motif is at the 
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Table 1. 14-3-3 binding sequences. Consensus mode I and mode II motifs and the reported 
C-terminal mode III binding sequences are shown. S/T: phosphorylated serine or threonine 
required for 14-3-3 binding, : aromatic residue, Reference#1: (Bodnar et al., 1999) , #2: (Sliva 
et al., 2000), #3 and #4: (O'Kelly et al., 2002):, #5 and #6: (Shikano et al., 2005), #7:(Rong et al., 
2007), #8: (Wurtele et al., 2003), #9: (Ganguly et al., 2005), #10: (Fujita et al., 2003).  
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(Chang et al., 2009; Ichimura et al., 2002; Kakiuchi et al., 2007; Meek et al., 2004; Pozuelo 
Rubio et al., 2004). Understanding when and how 14-3-3 proteins impact on these targets 
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offers a great opportunity to gain mechanistic insights into many phosphorylation-regulated 
biological pathways. Since 14-3-3 target sites in proteins must satisfy the specificity 
requirements for both 14-3-3s and the protein kinases that create the sites in the first place, 
identification of kinases that phosphorylate 14-3-3 target sites is crucial for elucidating the 
physiological roles of 14-3-3 binding. Unfortunately, in the majority of cases the identity of 
the physiologically relevant kinases that phosphorylate the mode I, II or III 14-3-3 binding 
motifs is still unknown. This is largely due to the high similarities between different 
serine/threonine protein kinase recognition sites (Table 2) and their likely redundant 
activities. One reasonable approach to overcome such obstacles and gain better 
understanding of the physiological kinases for 14-3-3 target proteins would be the global 
analysis of the actual 14-3-3-binding phosphoproteins. Based on the proteomics data and 
other available literature on 14-3-3, Johnson et al. have recently attempted to define 14-3-3 
specificity and identify relevant protein kinases (Johnson et al., 2010). This study points out 
several features that are distinctive of 14-3-3-binding sequences as compared with other 
protein phosphorylation sites. For instance, few reported 14-3-3-binding sites have a +1 
(relative to phosphorylated serine/threonine) proline residue, which contrasts with 
phosphoproteomic studies of cell lysates and subcellular fractions where phosphoserine-
proline is the most commonly reported phosphorylation motif overall (Ubersax & Ferrell, 
2007). This indicates that proline-directed kinases do not phosphorylate 14-3-3-binding sites. 
Similarly, no reported 14-3-3-binding sites conform to the canonical consensus site for casein 
kinase II (pS/pT-X-X-D/S/pS), which is probably the second most common type of motif in 
the entire mammalian phosphoproteome (Salvi et al., 2009). Another interesting notion is 
that, while the optimal mode I (R-[S/]-X-pS/pT-X-P) and mode II (R-X-[S/]-X-pS/pT-X-P) 
14-3-3-binding motifs were defined using phosphopeptides, many 14-3-3-binding sites in 
mammalian proteins (but not in plant 14-3-3-binding proteins) have basic residues in 
position -5 (and -4) in addition to -3. This creates a motif RXRXXS/T, which is a good target 
for the basophilic AGC kinase family (cAMP-dependent protein kinases A, cGMP-
dependent protein kinases G, and phospholipid-dependent protein kinases) and the 
calcium/calmodulin-dependent kinase (CaMK) family (Pearson & Kemp, 1991). Indeed, 
members of these kinase families, including protein kinase A (PKA), protein kinase C (PKC), 
CaMKI, checkpoint kinases 1 and 2 (Chk1 and 2), Akt/protein kinase B (PKB) and p90 
ribosomal S6 kinase (p90Rsk), are all known to phosphorylate sites that mediate 14-3-3 
binding (Dougherty & Morrison, 2004). Among these, Akt is one of the most well 
documented kinases in phosphorylating 14-3-3 client proteins (Mackintosh, 2004).  
 
Table 2. Consensus recognition sequences of major serine/threonine kinases that are known 
to phosphorylate 14-3-3 binding site. 
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2.3 Molecular mechanism for the 14-3-3 effects on membrane protein trafficking 
The phospho-binding ability of 14-3-3 proteins is reminiscent of other proteins carrying 
specific modules that recognize phosphorylated sites. Such modules include FHA (Durocher 
et al., 2000), WD40 (Yaffe & Elia, 2001), Polo-box (Lowery et al., 2005), and BRCT (BRCA-1 C-
terminal) repeat domains (Manke et al., 2003), which target serine and threonine 
phosphorylation, as well as SH2 (Src-homology 2) domains which target phosphorylated 
tyrosine residues in specific sequence contexts (Bradshaw & Waksman, 2002). These 
domains are found in a large number of proteins involved in a wide range of signaling 
processes. 14-3-3s are distinct from those proteins in that 14-3-3s are not modular 
components of other proteins. They are discrete binding proteins with no intrinsic enzyme 
activities, except for the nucleoside diphosphate (NDP) kinase-like activity (Yano et al., 
1997) and chaperonic activity toward selected substrates (Yano et al., 2006). So, how do 14-3-
3s exert their effects? Several excellent reviews discuss different models of 14-3-3 action as 
masking, scaffolding, or clamping of proteins (Dougherty & Morrison, 2004; Mackintosh, 
2004; Mrowiec & Schwappach, 2006). Recruitment of proteins may be regulated by masking 
of functional signals by 14-3-3 binding. Alternatively, the scaffolding model suggests that 
14-3-3 proteins tether different molecules together and form a platform for complex 
assembly. Clamping describes the idea that 14-3-3 binding alters the functional property of 
the client protein by stabilizing a certain conformation (Figure 1). It should be noted that 
combinations of these 'masking', 'scaffolding', and 'clamping' types of 14-3-3 action may 
occur together. As far as membrane proteins are concerned, very few examples exist where 
the interactions of 14-3-3 with client proteins are sufficiently well understood to ascribe a 
particular mode of action. Nevertheless, 14-3-3s may be considered as general switch 
proteins, of which effect of binding depends on the client protein. In most cases, 
phosphorylation at a serine or threonine residue activates the switch, and the subsequent 
binding of 14-3-3 proteins is thought to prevent rapid dephosphorylation. Recent studies 
have firmly demonstrated that 14-3-3 proteins are involved in controlling cell surface 
expression level of various cargo membrane proteins. We will discuss the pertinent evidence 
and hypothetical molecular mechanisms explaining these observations, with attention to the 
relevant kinases that regulate 14-3-3 binding. 
2.3.1 Masking  
14-3-3s are implicated in regulating the subcellular localization of many phosphorylated 
target proteins. The majority of the cases seem to involve the mechanism where 14-3-3 
binding blocks the access of other proteins to the sorting signal of target proteins. Such a 
'masking' role of 14-3-3 was first implicated in the mitochondria-cytoplasm translocation of 
the pro-apoptotic protein BAD. BAD interferes with the anti-apoptotic function of Bcl-2 and 
Bcl-xL in the mitochondria by binding to those proteins via its BH3 domain (Zha et al., 1996). 
BH3 domain is located immediately adjacent to the serine136, of which phosphoryaltion by 
Akt (Datta et al., 1997) is required for the binding of BAD to 14-3-3 in the cytoplasm (Zha et 
al., 1997). These results suggested that 14-3-3 binding obscures the BH3 domain and 
prevents the targeting of BAD to mitochondria. A similar mechanism was found for the 
nuclear-cytoplasmic shuttling of various proteins including tyrosine phosphatase Cdc25C 
(Kumagai & Dunphy, 1999), transcription factor FKHRL1 (Brunet  et al., 1999), 
glucocorticoidreceptor (Kino et al., 2003), CDK (cyclin-dependent kinase) inhibitor p27  
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2.3 Molecular mechanism for the 14-3-3 effects on membrane protein trafficking 
The phospho-binding ability of 14-3-3 proteins is reminiscent of other proteins carrying 
specific modules that recognize phosphorylated sites. Such modules include FHA (Durocher 
et al., 2000), WD40 (Yaffe & Elia, 2001), Polo-box (Lowery et al., 2005), and BRCT (BRCA-1 C-
terminal) repeat domains (Manke et al., 2003), which target serine and threonine 
phosphorylation, as well as SH2 (Src-homology 2) domains which target phosphorylated 
tyrosine residues in specific sequence contexts (Bradshaw & Waksman, 2002). These 
domains are found in a large number of proteins involved in a wide range of signaling 
processes. 14-3-3s are distinct from those proteins in that 14-3-3s are not modular 
components of other proteins. They are discrete binding proteins with no intrinsic enzyme 
activities, except for the nucleoside diphosphate (NDP) kinase-like activity (Yano et al., 
1997) and chaperonic activity toward selected substrates (Yano et al., 2006). So, how do 14-3-
3s exert their effects? Several excellent reviews discuss different models of 14-3-3 action as 
masking, scaffolding, or clamping of proteins (Dougherty & Morrison, 2004; Mackintosh, 
2004; Mrowiec & Schwappach, 2006). Recruitment of proteins may be regulated by masking 
of functional signals by 14-3-3 binding. Alternatively, the scaffolding model suggests that 
14-3-3 proteins tether different molecules together and form a platform for complex 
assembly. Clamping describes the idea that 14-3-3 binding alters the functional property of 
the client protein by stabilizing a certain conformation (Figure 1). It should be noted that 
combinations of these 'masking', 'scaffolding', and 'clamping' types of 14-3-3 action may 
occur together. As far as membrane proteins are concerned, very few examples exist where 
the interactions of 14-3-3 with client proteins are sufficiently well understood to ascribe a 
particular mode of action. Nevertheless, 14-3-3s may be considered as general switch 
proteins, of which effect of binding depends on the client protein. In most cases, 
phosphorylation at a serine or threonine residue activates the switch, and the subsequent 
binding of 14-3-3 proteins is thought to prevent rapid dephosphorylation. Recent studies 
have firmly demonstrated that 14-3-3 proteins are involved in controlling cell surface 
expression level of various cargo membrane proteins. We will discuss the pertinent evidence 
and hypothetical molecular mechanisms explaining these observations, with attention to the 
relevant kinases that regulate 14-3-3 binding. 
2.3.1 Masking  
14-3-3s are implicated in regulating the subcellular localization of many phosphorylated 
target proteins. The majority of the cases seem to involve the mechanism where 14-3-3 
binding blocks the access of other proteins to the sorting signal of target proteins. Such a 
'masking' role of 14-3-3 was first implicated in the mitochondria-cytoplasm translocation of 
the pro-apoptotic protein BAD. BAD interferes with the anti-apoptotic function of Bcl-2 and 
Bcl-xL in the mitochondria by binding to those proteins via its BH3 domain (Zha et al., 1996). 
BH3 domain is located immediately adjacent to the serine136, of which phosphoryaltion by 
Akt (Datta et al., 1997) is required for the binding of BAD to 14-3-3 in the cytoplasm (Zha et 
al., 1997). These results suggested that 14-3-3 binding obscures the BH3 domain and 
prevents the targeting of BAD to mitochondria. A similar mechanism was found for the 
nuclear-cytoplasmic shuttling of various proteins including tyrosine phosphatase Cdc25C 
(Kumagai & Dunphy, 1999), transcription factor FKHRL1 (Brunet  et al., 1999), 
glucocorticoidreceptor (Kino et al., 2003), CDK (cyclin-dependent kinase) inhibitor p27  
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Fig. 1. Hypothetical models for the effects of 14-3-3 binding on the trafficking of membrane 
proteins. (A) Masking. Sorting signals (e.g., RXR motif) are physically masked by 14-3-3 
binding to the nearby phosphorylated target site (shown as ○P). This blocks the access of 
transport machineries (e.g., COPI proteins) to the sorting signal. Only the action of one 14-3-
3 monomer is drawn here. (B) Scaffolding. Dimeric 14-3-3 facilitates the interaction of cargo 
proteins with transport machineries (e.g., motor proteins and microtubules). Binding of 14-
3-3 dimer to two different targets might involve phosphorylation-independent and/or outer 
surface-mediated interaction (see main text). (C) Clamping. Binding of a 14-3-3 dimer 
induces a conformation that is unfavorable for sorting signals (e.g., RXR motif), which can 
be achieved by clustering of targets or relocation from active zones (e.g., proximity to the 
transmembrane region (see main text)). This could result in reduced accessibility by 
transport machineries (e.g., COPI proteins).  
(Fujita et al., 2003), and catalytic subunit of telomerase TERT (Seimiya et al., 2000). In most 
cases, 14-3-3 binding promotes the cytoplasmic localization of target proteins. For instance, 
14-3-3 binding to serine287 of Cdc25C leads to the cytoplasmic retention of Cdc25C. This 
seems to be due to the occlusion of the closely located bipartite nuclear localization sequence 
(NLS) at amino acids 298-316 of Cdc25C from importin-, a receptor for bipartite NLS 
(Kumagai & Dunphy, 1999). These observations are consistent with the predominant 
cytoplasmic localization of 14-3-3 proteins at the steady-state, which has led to the 
hypothesis that they might serve as a universal cytoplasmic anchor that blocks import into 
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the nucleus or other organelles. However, this model of 14-3-3 action is contradicted by the 
observation that 14-3-3 can also promote the nuclear localization of other binding partners. 
Seimiya et al. found that 14-3-3 binding to human TERT, which requires threonine1030, 
serine1037 and serine1041, lead to the nuclear localization of hTERT. This was attributed to the 
blocking of the nearby leucine-rich nuclear export sequence (NES) present at residues 970–
981 of hTERT, which is otherwise recognized by the nuclear export receptor CRM1 (Seimiya 
et al., 2000). So, how does 14-3-3 regulate nuclear-cytoplasmic shuttling of different proteins 
in two opposing directions? One simple hypothesis may be that 14-3-3 itself bears no 
specific information about protein sorting and the effect of 14-3-3 binding on the subcellular 
localization of a client protein depends entirely on sorting signals encoded within the client 
protein and the proximity of those signals to a 14-3-3 binding motif. If so, 14-3-3 binding 
could possibly affect any other protein sorting pathways.  
Consistent with this idea, recent studies report a critical role of 14-3-3 in controlling the cell 
surface expression level of membrane proteins of different functions, including ion channels, 
receptors, and adhesion molecules. In many cases, the underlying mechanism seems to 
involve 'masking' of a short sequence motif, namely a di-arginine or di-basic (RXR) ER 
localization signal. The RXR-type ER-localisation signals were first identified in ATP-
sensitive potassium channels (KATP channels) (Zerangue et al., 1999). These channels 
assemble as octameric complexes consisting of four Kir6 channel subunits and four 
sulphonylurea receptor (SUR) subunits, and each of these subunits carries an RXR signal in 
the cytoplasmic tail. It is believed that the ER-localisation activity of these motifs is mediated 
by the retrieval of cargo proteins from the post-ER compartments such as ER-Golgi 
intermediate compartment (ERGIC) and cis-Glogi through their interaction with the 
retrograde transport coatomer protein, COPI (Michelsen et al., 2007; Zerangue et al., 1999). 
Although the RXR motif resembles the C-terminal di-lysine (KKXX) motif which also 
mediates ER retrieval of membrane protein cargos through direct interaction with COPI 
(Michelsen et al., 2007), RXR motif is distinct in that it is present almost exclusively in the 
multimeric cell surface membrane proteins (Michelsen et al., 2005), while KKXX motif is 
found in the membrane proteins that are resident to the ER such as nucleotide sugar 
transporters (Jackson et al., 1990, 1993).  
Efficient cell surface transport of proteins harbouring RXR motifs will be allowed only when 
the motif becomes inaccessible to COPI probably by multiple different mechanisms including 
folding, subunit assembly, post-translational modification, and protein recruitment. 14-3-3 
proteins have been implicated in the masking of RXR motif in several instances. The first 
evidence that 14-3-3 proteins control cell surface transport of membrane protein was shown 
for two-pore-domain potassium (K2P) channels TASK1 and TASK3 (O'Kelly et al., 2002). 
These channels bound to 14-3-3 via a mode III C-terminal binding motif (RRSSV-COOH and 
RRKSV-COOH for TASK1 and TASK3, respectively), where phosphorylation of the 
penultimate serine and the upstream arginine residues were critically required. In the 
absence of phosphorylation on the penultimate serine, COPI proteins bind to the adjacent 
RXR-like sequence (KRR) which shares two arginine residues with the 14-3-3 binding motif. 
It is thought that phosphorylation switch allows 14-3-3 binding that occludes the partially 
overlapping RXR-like COPI binding motif. A very recent study by Mant et al. reports that 
PKA, which recognizes a consensus sequence of RXXS/T, phosphorylates the penultimate 
serine residue in TASK1 and TASK3 channels and promote their expression on cell surface, 
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the nucleus or other organelles. However, this model of 14-3-3 action is contradicted by the 
observation that 14-3-3 can also promote the nuclear localization of other binding partners. 
Seimiya et al. found that 14-3-3 binding to human TERT, which requires threonine1030, 
serine1037 and serine1041, lead to the nuclear localization of hTERT. This was attributed to the 
blocking of the nearby leucine-rich nuclear export sequence (NES) present at residues 970–
981 of hTERT, which is otherwise recognized by the nuclear export receptor CRM1 (Seimiya 
et al., 2000). So, how does 14-3-3 regulate nuclear-cytoplasmic shuttling of different proteins 
in two opposing directions? One simple hypothesis may be that 14-3-3 itself bears no 
specific information about protein sorting and the effect of 14-3-3 binding on the subcellular 
localization of a client protein depends entirely on sorting signals encoded within the client 
protein and the proximity of those signals to a 14-3-3 binding motif. If so, 14-3-3 binding 
could possibly affect any other protein sorting pathways.  
Consistent with this idea, recent studies report a critical role of 14-3-3 in controlling the cell 
surface expression level of membrane proteins of different functions, including ion channels, 
receptors, and adhesion molecules. In many cases, the underlying mechanism seems to 
involve 'masking' of a short sequence motif, namely a di-arginine or di-basic (RXR) ER 
localization signal. The RXR-type ER-localisation signals were first identified in ATP-
sensitive potassium channels (KATP channels) (Zerangue et al., 1999). These channels 
assemble as octameric complexes consisting of four Kir6 channel subunits and four 
sulphonylurea receptor (SUR) subunits, and each of these subunits carries an RXR signal in 
the cytoplasmic tail. It is believed that the ER-localisation activity of these motifs is mediated 
by the retrieval of cargo proteins from the post-ER compartments such as ER-Golgi 
intermediate compartment (ERGIC) and cis-Glogi through their interaction with the 
retrograde transport coatomer protein, COPI (Michelsen et al., 2007; Zerangue et al., 1999). 
Although the RXR motif resembles the C-terminal di-lysine (KKXX) motif which also 
mediates ER retrieval of membrane protein cargos through direct interaction with COPI 
(Michelsen et al., 2007), RXR motif is distinct in that it is present almost exclusively in the 
multimeric cell surface membrane proteins (Michelsen et al., 2005), while KKXX motif is 
found in the membrane proteins that are resident to the ER such as nucleotide sugar 
transporters (Jackson et al., 1990, 1993).  
Efficient cell surface transport of proteins harbouring RXR motifs will be allowed only when 
the motif becomes inaccessible to COPI probably by multiple different mechanisms including 
folding, subunit assembly, post-translational modification, and protein recruitment. 14-3-3 
proteins have been implicated in the masking of RXR motif in several instances. The first 
evidence that 14-3-3 proteins control cell surface transport of membrane protein was shown 
for two-pore-domain potassium (K2P) channels TASK1 and TASK3 (O'Kelly et al., 2002). 
These channels bound to 14-3-3 via a mode III C-terminal binding motif (RRSSV-COOH and 
RRKSV-COOH for TASK1 and TASK3, respectively), where phosphorylation of the 
penultimate serine and the upstream arginine residues were critically required. In the 
absence of phosphorylation on the penultimate serine, COPI proteins bind to the adjacent 
RXR-like sequence (KRR) which shares two arginine residues with the 14-3-3 binding motif. 
It is thought that phosphorylation switch allows 14-3-3 binding that occludes the partially 
overlapping RXR-like COPI binding motif. A very recent study by Mant et al. reports that 
PKA, which recognizes a consensus sequence of RXXS/T, phosphorylates the penultimate 
serine residue in TASK1 and TASK3 channels and promote their expression on cell surface, 
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although it was not shown in the literature whether this phosphorylation actually promotes 
the binding of 14-3-3 proteins to these sites (Mant et al., 2011).  
A similar masking mechanism was suggested for the ER-export of Iip35 isoform of major 
histocompatibility complex (MHC) class-II-associated invariant chain (O'Kelly et al., 2002). 
During their assembly in the ER, MHC class-II αβ dimers associate with preformed trimers 
of the invariant chains (Iip33, Iip35, Iip41, Iip43), to form nonameric (αβIi)3 oligomers. It had 
been known that phosphorylation of an N-terminal serine8, present exclusively in the Iip35 
cytoplasmic tail (NH3-MHRRRSRS…), is a prerequisite for efficient ER exit and sorting of 
class-II/Iip35 complexes to the cell surface. Phosphorylation of serine8 leads to the 14-3-3 
binding to Iip35 and the alanine mutation on this residue inhibits the ER exit of class-
II/Iip35 complex (Kuwana et al., 1998). Together with the fact that 14-3-3 and COPI bound to 
the N-terminal sequence of Iip35 in a mutually exclusive manner, it was concluded that the 
cell surface transport of MHC class-II complex is promoted by 'masking' effect of 14-3-3 
(O'Kelly et al., 2002). However, as Khalil et al. pointed out (Khalil et al., 2005), this model 
seems to require further investigation, since it is not consistent with the fact that, even when 
associated with a 14-3-3 protein, Iip35 will not leave the ER in the absence of class-II 
molecules and that mutation of serine8 to asparagine prevents 14-3-3 protein binding but 
still allows ER export if class-II molecules are present (Kuwana et al., 1998).  
The effect of 14-3-3 binding on promoting cell surface transport was also found by a 
completely different approach. Shikano et al. screened a random peptide library to identify 
C-terminal peptide signals that would functionally override the ER localization activity of 
the RXR motif (Shikano et al., 2005). The screening was based on the yeast growth 
complementation assay using a mutant Saccharomyces cerevisiae SGY1528 which cannot 
survive in low potassium media due to the lack of endogenous potassium uptake 
transporters. However, SGY1528 growth in low potassium media can be rescued by 
heterologous expression of mammalian inward rectifying potassium channel Kir2.1, but not 
when Kir2.1 was artificially fused with the RXR motif (RKR) due to the efficient retention of 
channel in the ER (Shikano et al., 2005). In the screen, SGY1528 cells were transformed with 
Kir2.1 constructs where random peptide library of 8-mer sequences was placed at the 
extreme C-terminus, downstream of the implanted RXR motif. By selecting the transformed 
cells that survived in low potassium media, the authors searched for the sequence that were 
able to override the ER localization activity of the RXR motif and restored the surface 
expression of the chimeric Kir2.1 channel. The screen of about 2x106 clones yielded several 
sequences that showed robust surface expression of Kir2.1 as tested in mammalian cell. 
Those sequences shared a minimum consensus of RXXS/TX-COOH and showed strong 
binding to 14-3-3, which required penultimate serine or threonine and the upstream 
arginine residues (Shikano et al., 2005). By using one of the identified C-terminal sequences, 
namely RGRSWTY-COOH, Chung et al. investigated the relevant kinases. Using in vitro 
phosphorylation assay using recombinant proteins and in vivo studies using reporter Kir2.1 
channel bearing both RXR motif and downstream C-terminal RGRSWTY sequence, the 
authors found that Akt, but not PKA or CamKII, is responsible for direct phosphorylation of 
the RGRSWTY sequence which recruits 14-3-3 proteins to this site (Chung et al., 2009). 
Importantly, the extracellular stimulation that activates Akt pathway, such as insulin and 
platelet-derived growth factor (PDGF), enhanced 14-3-3 binding and promoted the cell 
surface transport of the reporter Kir2.1 channel (Chung et al., 2009). These results 
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demonstrate that, despite high similarity in the recognition sequences of basophilic 
serine/threonine protein kinases, specific kinase signaling can modulate membrane protein 
trafficking through 14-3-3 binding. Further search of the human protein database for this C-
terminal 14-3-3-binding motif has identified several candidate membrane proteins that 
would interact with 14-3-3. These include GPR15, an orphan GPCR that serves for a co-
receptor for human immunodeficiency virus (HIV) entry (Farzan et al., 1997). GPR15, which 
has a C-terminal sequence of RRRKRSVSL-COOH, was indeed confirmed to bind 14-3-3 and 
this binding absolutely required phosphorylation of penultimate serine359. A recent study by 
Okamoto and Shikano reported that alanine mutation of the serine359 resulted in substantial 
ER localization of GPR15 and this was mediated by the upstream arginine residues at amino 
acids 352 and 354, which constitute a COPI-binding RXR motif (Okamoto & Shikano, 2011). 
These results suggested that mode III binding of 14-3-3 to the receptor C-terminus 
physically occludes the adjacent RXR motif from the access by COPI, similar to the cases for 
TASK channels. Thus, a non-biased screening has led to the identification of 14-3-3 function 
as a key switch that converts phosphorylation signal to the sorting of membrane proteins by 
modulating the activity of an ER localization signal.  
The masking effect of 14-3-3 on the cell surface transport is not restricted to the mode III C-
terminal binding. The cytoplasmic tail of ADAM22, a member of ADAM (a disintegrin and 
metalloprotease domain) protein family, contains two internal 14-3-3 binding sites and three 
RXR-type ER-localization signals that overlap with both of the 14-3-3 protein binding sites. 
Mutations in both 14-3-3 binding sites inhibited surface expression of ADAM22, while 
deletion of both RXR motif and 14-3-3 binding sites restored the surface expression (Godde 
et al., 2006). Although this study did not investigate COPI interaction with ADAM22, the 
results suggest the possibility that 14-3-3 binding inhibited the COPI-dependent ER 
localization activity of RXR signal.  
The cell surface transport of a gap junction protein connexin 43 is also promoted by 14-3-3 
binding to its internal mode I binding site (RASSRP) (Park et al., 2007). The authors have 
found that Akt phosphorylates the serine373 in this site in the epidermal growth factor (EGF)-
stimulated cell. Although not characterized yet, the existence of an overlapping RXR motif 
(RPR) suggests a possible masking effect of 14-3-3 on the cell surface transport of connexin 43. 
NMDA receptors are tetramers composed of homologous subunits (NR1; NR2A-D; NR3A-B 
(Cull-Candy & Leszkiewicz, 2004). There are multiple NR2 subunits, each with unique 
spatio-temporal expression patterns, ensuring functional diversity of NMDA receptors. 
Recently, cerebellar NR2C subunit was found to be directly phosphorylated by Akt at the 
sequence that conforms to mode I 14-3-3 binding motif (RPRHASLP) (Chen & Roche, 2009). 
The Akt phosphorylation induced by insulin growth factor (IGF-1) results in the recruitment 
of 14-3-3 and the increase of cell surface expression of NMDA receptors. Although the 
causative role of 14-3-3 in surface transport remains unclear in this study, the presence of ER 
localization signals (Horak & Wenthold, 2009) in the NR1 subunit and the obligatory 
assembly of NR2 with NR1 for functional NMDA receptor suggest a possible mechanism 
where Akt-induced 14-3-3 binding to NR2C attenuates the activity of ER localization signals 
in NR1 by physically occluding them. 
Interestingly, 14-3-3s have also been reported to bind directly to the RXR motif itself in a 
phosphorylation-independent manner. By using an artificial multimer of the distal C-
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although it was not shown in the literature whether this phosphorylation actually promotes 
the binding of 14-3-3 proteins to these sites (Mant et al., 2011).  
A similar masking mechanism was suggested for the ER-export of Iip35 isoform of major 
histocompatibility complex (MHC) class-II-associated invariant chain (O'Kelly et al., 2002). 
During their assembly in the ER, MHC class-II αβ dimers associate with preformed trimers 
of the invariant chains (Iip33, Iip35, Iip41, Iip43), to form nonameric (αβIi)3 oligomers. It had 
been known that phosphorylation of an N-terminal serine8, present exclusively in the Iip35 
cytoplasmic tail (NH3-MHRRRSRS…), is a prerequisite for efficient ER exit and sorting of 
class-II/Iip35 complexes to the cell surface. Phosphorylation of serine8 leads to the 14-3-3 
binding to Iip35 and the alanine mutation on this residue inhibits the ER exit of class-
II/Iip35 complex (Kuwana et al., 1998). Together with the fact that 14-3-3 and COPI bound to 
the N-terminal sequence of Iip35 in a mutually exclusive manner, it was concluded that the 
cell surface transport of MHC class-II complex is promoted by 'masking' effect of 14-3-3 
(O'Kelly et al., 2002). However, as Khalil et al. pointed out (Khalil et al., 2005), this model 
seems to require further investigation, since it is not consistent with the fact that, even when 
associated with a 14-3-3 protein, Iip35 will not leave the ER in the absence of class-II 
molecules and that mutation of serine8 to asparagine prevents 14-3-3 protein binding but 
still allows ER export if class-II molecules are present (Kuwana et al., 1998).  
The effect of 14-3-3 binding on promoting cell surface transport was also found by a 
completely different approach. Shikano et al. screened a random peptide library to identify 
C-terminal peptide signals that would functionally override the ER localization activity of 
the RXR motif (Shikano et al., 2005). The screening was based on the yeast growth 
complementation assay using a mutant Saccharomyces cerevisiae SGY1528 which cannot 
survive in low potassium media due to the lack of endogenous potassium uptake 
transporters. However, SGY1528 growth in low potassium media can be rescued by 
heterologous expression of mammalian inward rectifying potassium channel Kir2.1, but not 
when Kir2.1 was artificially fused with the RXR motif (RKR) due to the efficient retention of 
channel in the ER (Shikano et al., 2005). In the screen, SGY1528 cells were transformed with 
Kir2.1 constructs where random peptide library of 8-mer sequences was placed at the 
extreme C-terminus, downstream of the implanted RXR motif. By selecting the transformed 
cells that survived in low potassium media, the authors searched for the sequence that were 
able to override the ER localization activity of the RXR motif and restored the surface 
expression of the chimeric Kir2.1 channel. The screen of about 2x106 clones yielded several 
sequences that showed robust surface expression of Kir2.1 as tested in mammalian cell. 
Those sequences shared a minimum consensus of RXXS/TX-COOH and showed strong 
binding to 14-3-3, which required penultimate serine or threonine and the upstream 
arginine residues (Shikano et al., 2005). By using one of the identified C-terminal sequences, 
namely RGRSWTY-COOH, Chung et al. investigated the relevant kinases. Using in vitro 
phosphorylation assay using recombinant proteins and in vivo studies using reporter Kir2.1 
channel bearing both RXR motif and downstream C-terminal RGRSWTY sequence, the 
authors found that Akt, but not PKA or CamKII, is responsible for direct phosphorylation of 
the RGRSWTY sequence which recruits 14-3-3 proteins to this site (Chung et al., 2009). 
Importantly, the extracellular stimulation that activates Akt pathway, such as insulin and 
platelet-derived growth factor (PDGF), enhanced 14-3-3 binding and promoted the cell 
surface transport of the reporter Kir2.1 channel (Chung et al., 2009). These results 
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demonstrate that, despite high similarity in the recognition sequences of basophilic 
serine/threonine protein kinases, specific kinase signaling can modulate membrane protein 
trafficking through 14-3-3 binding. Further search of the human protein database for this C-
terminal 14-3-3-binding motif has identified several candidate membrane proteins that 
would interact with 14-3-3. These include GPR15, an orphan GPCR that serves for a co-
receptor for human immunodeficiency virus (HIV) entry (Farzan et al., 1997). GPR15, which 
has a C-terminal sequence of RRRKRSVSL-COOH, was indeed confirmed to bind 14-3-3 and 
this binding absolutely required phosphorylation of penultimate serine359. A recent study by 
Okamoto and Shikano reported that alanine mutation of the serine359 resulted in substantial 
ER localization of GPR15 and this was mediated by the upstream arginine residues at amino 
acids 352 and 354, which constitute a COPI-binding RXR motif (Okamoto & Shikano, 2011). 
These results suggested that mode III binding of 14-3-3 to the receptor C-terminus 
physically occludes the adjacent RXR motif from the access by COPI, similar to the cases for 
TASK channels. Thus, a non-biased screening has led to the identification of 14-3-3 function 
as a key switch that converts phosphorylation signal to the sorting of membrane proteins by 
modulating the activity of an ER localization signal.  
The masking effect of 14-3-3 on the cell surface transport is not restricted to the mode III C-
terminal binding. The cytoplasmic tail of ADAM22, a member of ADAM (a disintegrin and 
metalloprotease domain) protein family, contains two internal 14-3-3 binding sites and three 
RXR-type ER-localization signals that overlap with both of the 14-3-3 protein binding sites. 
Mutations in both 14-3-3 binding sites inhibited surface expression of ADAM22, while 
deletion of both RXR motif and 14-3-3 binding sites restored the surface expression (Godde 
et al., 2006). Although this study did not investigate COPI interaction with ADAM22, the 
results suggest the possibility that 14-3-3 binding inhibited the COPI-dependent ER 
localization activity of RXR signal.  
The cell surface transport of a gap junction protein connexin 43 is also promoted by 14-3-3 
binding to its internal mode I binding site (RASSRP) (Park et al., 2007). The authors have 
found that Akt phosphorylates the serine373 in this site in the epidermal growth factor (EGF)-
stimulated cell. Although not characterized yet, the existence of an overlapping RXR motif 
(RPR) suggests a possible masking effect of 14-3-3 on the cell surface transport of connexin 43. 
NMDA receptors are tetramers composed of homologous subunits (NR1; NR2A-D; NR3A-B 
(Cull-Candy & Leszkiewicz, 2004). There are multiple NR2 subunits, each with unique 
spatio-temporal expression patterns, ensuring functional diversity of NMDA receptors. 
Recently, cerebellar NR2C subunit was found to be directly phosphorylated by Akt at the 
sequence that conforms to mode I 14-3-3 binding motif (RPRHASLP) (Chen & Roche, 2009). 
The Akt phosphorylation induced by insulin growth factor (IGF-1) results in the recruitment 
of 14-3-3 and the increase of cell surface expression of NMDA receptors. Although the 
causative role of 14-3-3 in surface transport remains unclear in this study, the presence of ER 
localization signals (Horak & Wenthold, 2009) in the NR1 subunit and the obligatory 
assembly of NR2 with NR1 for functional NMDA receptor suggest a possible mechanism 
where Akt-induced 14-3-3 binding to NR2C attenuates the activity of ER localization signals 
in NR1 by physically occluding them. 
Interestingly, 14-3-3s have also been reported to bind directly to the RXR motif itself in a 
phosphorylation-independent manner. By using an artificial multimer of the distal C-
 
Protein Kinases 174 
terminus of Kir6.2 channel in pull-down assays from cytosolic cellular extracts, Yuan et al. 
showed that 14-3-3 proteins preferentially bound to the RXR motif (RSRR) in the 
oligomerized form (Yuan et al., 2003). This interaction was sufficient to allow the exit of a 
multimeric reporter protein carrying this motif from the ER and promote the subsequent 
transport to the cell surface. Although the precise role of the 14-3-3 binding in the cell 
surface transport of octameric KATP channel consisting of four Kir6.2 and four SUR1 seems 
to require further investigation (Heusser et al., 2006), this study demonstrated the possibility 
that 14-3-3 serves for a constitutive check point of ER protein quality control which ensures 
the cell surface delivery of functional multimeric membrane proteins by preferentially 
inactivating the ER localisation signals on the properly oligomerized subunits. 
2.3.2 Scaffolding  
The stable dimeric structure immediately suggests that 14-3-3s might serve as a simple 
'scaffold', where two different target proteins bind simultaneously to each monomer of the 
same 14-3-3 dimer. Indeed, 14-3-3 proteins are often referred to as 'scaffolding proteins' in 
the literature. However, while 14-3-3s are components of multiprotein complexes (Munday 
et al., 2000; Pnueli et al., 2001; Widen et al., 2000), the evidence showing the 14-3-3 dimers 
acting as an intermolecular bridge between two different substrates had been limited to 
several earlier studies including those reporting the pairings involving Raf-1, namely Raf-1 
and Bcr (B-cell receptor) (Braselmann & McCormick, 1995), Raf-1 and A20 (Vincenz & Dixit, 
1996) and Raf-1 and PKCζ (Van Der Hoeven et al., 2000). Nevertheless, in the context of 
membrane protein trafficking, some recent studies implicate the scaffolding role of 14-3-3 in 
promoting the cell surface expression of membrane proteins.  
14-3-3 promotes the ER export of N-cadherin through coupling the N-cadherin/-catenin/PX-
RICS complex to the microtubule-based motor proteins dynein/dynactin (Nakamura et al., 
2010). 14-3-3ζ or 14-3-3θ directly interacts in a phosphorylation-dependent manner with a 
mode I site (RSKSDP) of PX-RICS, a β-catenin-interacting GTPase-activating protein for 
Cdc42, and this seems to facilitate ER to Golgi trafficking by association of N-cadherin/β-
catenin cargo with minus-end motor proteins dynein/dynactin. This results in the increased 
localization of N-cadherin/β-catenin at cell-cell contact sites. The authors have also shown 
that CaMKII is responsible for direct phosphorylation of PX-RICS and the subsequent 14-3-3 
binding by using in vitro phosphorylation assay and siRNA knockdown of CaMKII 
(Nakamura et al., 2010). It is of note that a similar scaffolding function has been reported for 
a PDZ protein that couples a cargo receptor and a motor protein which mediates 
microtubule-based trafficking. PDZ domain of mLin-10 directly interacts with the C-
terminal PDZ-binding motif of a neuron-specific plus-end molecular motor KIF-17. mLin-10 
also forms a complex with its family members mLin-2 and mLin-7, which in turn interact 
with PDZ-binding motif of NMDA receptor subunit 2B (Setou et al., 2000).  
The interactions between the α3 subunit of the nicotinic acetylcholine receptor (nAChR) and 
a multi-subunit cytoskeletal-anchoring complex provide another evidence suggesting 
possible scaffolding role of 14-3-3 (Rosenberg et al., 2008). APC (adenomatous polyposis coli) 
organizes a multi-protein postsynaptic complex that targets α3nAChRs to synapses. APC 
interaction with the microtubule plus-end binding protein EB1 is essential for α3nAChR 
surface membrane insertion and stabilization. 14-3-3 directly interacts with α3 subunit in a 
phosphorylation-dependent manner and also forms complex with APC. Thus, 14-3-3 
 
Phosphorylation-Regulated Cell Surface Expression of Membrane Proteins 175 
proteins may provide for a mechanism by which nAChRs containing only specific subunits 
are recruited to postsynaptic clusters and may stabilise them there. In both of the above 
studies, it is still not clear whether and how a 14-3-3 dimer binds to two separate targets 
with each monomer. Multiple proteomic screenings have revealed that 14-3-3s form 
complex with a large number of proteins closely involved in vesicular trafficking such as 
motor proteins, coat proteins, and GTPase regulators (Mrowiec & Schwappach, 2006). 
Therefore it is conceivable that 14-3-3 proteins do modulate membrane trafficking by 
serving as a scaffold that connects cargo proteins with cellular transport machineries.  
Then, does a 14-3-3 dimer really bind to two different proteins at the same time? It seems 
somewhat unlikely that there would be frequent occasions where a 14-3-3 dimer binds two 
separate targets via each canonical ligand-binding groove, unless those target proteins 
happen to be already close enough to each other and in such position that both of their 
phosphorylated binding sites can be accommodated by the binding grooves of the same 14-
3-3 dimer, whose core is a rigid and unyielding structure (Obsil et al., 2001), but not by the 
neighboring 14-3-3 dimers. Crystal structure of 14-3-3ζ : AANAT revealed that in addition to 
the phosphorylation-dependent interaction through its canonical ligand-binding groove, 14-
3-3 also makes extensive contacts with AANAT via other regions of the 14-3-3 channel, 
although these contacts must be insufficient to form a stable complex (Obsil et al., 2001). 
Moreover, a recent finding by Barry et al. demonstrated that 14-3-3 can directly interact with 
other proteins outside of the canonical binding groove, providing a possible molecular basis 
for the scaffolding function of 14-3-3 (Barry et al., 2009). 14-3-3 undergoes phosphorylation 
at tyrosine179 upon cytokine stimulation and this leads to the binding of Shc protein through 
its SH2 domain that recognizes phosphorylated tyrosine. This 14-3-3/Shc complex is 
required for the recruitment of a phosphatidylinositol 3-kinase (PI3K) signaling complex 
and the regulation of cell survival in response to cytokine. Although this study did not 
describe whether Shc-bound 14-3-3 proteins bind to any serine/threonine-phosphorylated 
targets, the result suggests that 14-3-3/Shc scaffolds can act as multivalent signaling nodes 
for the integration of both phosphoserine/threonine and phosphotyrosine pathways to 
regulate specific cellular responses. Thus, interaction of 14-3-3 with proteins via non-
canonical binding sites of 14-3-3 should contribute to the diversity of its roles in a wide 
variety of biological pathways including membrane trafficking.  
In addition, the propensity of the different 14-3-3 isoforms to form homo- or hetero-dimers 
may confer additional specificity to the scaffolding roles. Those regions of the 14-3-3 protein 
which vary between the isoforms are primarily located on the surface of the protein. 
Therefore, the specificity of interaction of 14-3-3 isoforms with diverse target proteins may 
involve the outer surface of the protein. For instance, C-termini of 14-3-3 proteins are most 
divergent and hence most likely to contain isoform-specific structural determinants 
(Williams et al., 2011). Identification of more protein complexes whose assembly requires 14-
3-3 is necessary to gain more mechanistic insights into the scaffolding function of 14-3-3. 
2.3.3 Clamping  
Another mechanism by which 14-3-3 proteins are thought to exert their effect on their 
targets are conformational 'clamping'. Clamping can occur when a 14-3-3 dimer binds two 
sites on the same target protein. A synthetic phosphopeptide with two tandem 14-3-3 
consensus motifs binds over 30-fold more tightly than the same peptide containing only a 
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terminus of Kir6.2 channel in pull-down assays from cytosolic cellular extracts, Yuan et al. 
showed that 14-3-3 proteins preferentially bound to the RXR motif (RSRR) in the 
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multimeric reporter protein carrying this motif from the ER and promote the subsequent 
transport to the cell surface. Although the precise role of the 14-3-3 binding in the cell 
surface transport of octameric KATP channel consisting of four Kir6.2 and four SUR1 seems 
to require further investigation (Heusser et al., 2006), this study demonstrated the possibility 
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acting as an intermolecular bridge between two different substrates had been limited to 
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Cdc42, and this seems to facilitate ER to Golgi trafficking by association of N-cadherin/β-
catenin cargo with minus-end motor proteins dynein/dynactin. This results in the increased 
localization of N-cadherin/β-catenin at cell-cell contact sites. The authors have also shown 
that CaMKII is responsible for direct phosphorylation of PX-RICS and the subsequent 14-3-3 
binding by using in vitro phosphorylation assay and siRNA knockdown of CaMKII 
(Nakamura et al., 2010). It is of note that a similar scaffolding function has been reported for 
a PDZ protein that couples a cargo receptor and a motor protein which mediates 
microtubule-based trafficking. PDZ domain of mLin-10 directly interacts with the C-
terminal PDZ-binding motif of a neuron-specific plus-end molecular motor KIF-17. mLin-10 
also forms a complex with its family members mLin-2 and mLin-7, which in turn interact 
with PDZ-binding motif of NMDA receptor subunit 2B (Setou et al., 2000).  
The interactions between the α3 subunit of the nicotinic acetylcholine receptor (nAChR) and 
a multi-subunit cytoskeletal-anchoring complex provide another evidence suggesting 
possible scaffolding role of 14-3-3 (Rosenberg et al., 2008). APC (adenomatous polyposis coli) 
organizes a multi-protein postsynaptic complex that targets α3nAChRs to synapses. APC 
interaction with the microtubule plus-end binding protein EB1 is essential for α3nAChR 
surface membrane insertion and stabilization. 14-3-3 directly interacts with α3 subunit in a 
phosphorylation-dependent manner and also forms complex with APC. Thus, 14-3-3 
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proteins may provide for a mechanism by which nAChRs containing only specific subunits 
are recruited to postsynaptic clusters and may stabilise them there. In both of the above 
studies, it is still not clear whether and how a 14-3-3 dimer binds to two separate targets 
with each monomer. Multiple proteomic screenings have revealed that 14-3-3s form 
complex with a large number of proteins closely involved in vesicular trafficking such as 
motor proteins, coat proteins, and GTPase regulators (Mrowiec & Schwappach, 2006). 
Therefore it is conceivable that 14-3-3 proteins do modulate membrane trafficking by 
serving as a scaffold that connects cargo proteins with cellular transport machineries.  
Then, does a 14-3-3 dimer really bind to two different proteins at the same time? It seems 
somewhat unlikely that there would be frequent occasions where a 14-3-3 dimer binds two 
separate targets via each canonical ligand-binding groove, unless those target proteins 
happen to be already close enough to each other and in such position that both of their 
phosphorylated binding sites can be accommodated by the binding grooves of the same 14-
3-3 dimer, whose core is a rigid and unyielding structure (Obsil et al., 2001), but not by the 
neighboring 14-3-3 dimers. Crystal structure of 14-3-3ζ : AANAT revealed that in addition to 
the phosphorylation-dependent interaction through its canonical ligand-binding groove, 14-
3-3 also makes extensive contacts with AANAT via other regions of the 14-3-3 channel, 
although these contacts must be insufficient to form a stable complex (Obsil et al., 2001). 
Moreover, a recent finding by Barry et al. demonstrated that 14-3-3 can directly interact with 
other proteins outside of the canonical binding groove, providing a possible molecular basis 
for the scaffolding function of 14-3-3 (Barry et al., 2009). 14-3-3 undergoes phosphorylation 
at tyrosine179 upon cytokine stimulation and this leads to the binding of Shc protein through 
its SH2 domain that recognizes phosphorylated tyrosine. This 14-3-3/Shc complex is 
required for the recruitment of a phosphatidylinositol 3-kinase (PI3K) signaling complex 
and the regulation of cell survival in response to cytokine. Although this study did not 
describe whether Shc-bound 14-3-3 proteins bind to any serine/threonine-phosphorylated 
targets, the result suggests that 14-3-3/Shc scaffolds can act as multivalent signaling nodes 
for the integration of both phosphoserine/threonine and phosphotyrosine pathways to 
regulate specific cellular responses. Thus, interaction of 14-3-3 with proteins via non-
canonical binding sites of 14-3-3 should contribute to the diversity of its roles in a wide 
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involve the outer surface of the protein. For instance, C-termini of 14-3-3 proteins are most 
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2.3.3 Clamping  
Another mechanism by which 14-3-3 proteins are thought to exert their effect on their 
targets are conformational 'clamping'. Clamping can occur when a 14-3-3 dimer binds two 
sites on the same target protein. A synthetic phosphopeptide with two tandem 14-3-3 
consensus motifs binds over 30-fold more tightly than the same peptide containing only a 
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single motif (Yaffe et al., 1997). A number of 14-3-3-binding proteins, including Raf-1 (Muslin 
et al., 1996), AANAT (Ganguly et al., 2005), ADAM22 (Godde et al., 2006), tyrosine hydroxylase 
(Toska et al., 2002), and Ndel1 (Johnson et al., 2010), contain two phosphorylated sites that are 
implicated in 14-3-3 binding, and are separated by polypeptides of various lengths. It has been 
postulated that one site called the 'gatekeeper' is indispensable for a stable 14-3-3 interaction, 
whereas a second site 'enhances' the interaction, but has too weak an affinity to bind 14-3-3 
alone (Yaffe, 2002). In the case of AANAT, the gatekeeper residue is phosphorylated 
threonine31. Binding of the gatekeeper leads to binding of a second low-affinity site, in this 
case phosphorylated serine205, which reflects both the intrinsic affinity of that site and the 
'high local concentration induced by its proximity' (Ganguly et al., 2005; Yaffe, 2002). This 
dual-site binding of AANAT to 14-3-3 provides optimal conformation of the enzyme for 
high-affinity binding of the substrate arylalkylamine.  
14-3-3 clamping can also occur when a 14-3-3 dimer binds two neighboring target proteins. 
14-3-3 proteins activate the plant plasma membrane H(+)-ATPase (PMA2) by binding to its 
C-terminal autoinhibitory domain. This interaction requires phosphorylation of a C-terminal 
mode III recognition motif as well as an adjacent span of 52 amino acids. X-ray diffraction 
studies using crystals of 14-3-3 in complex with the entire binding motif of the PMA2 have 
shown that each 14-3-3 dimer simultaneously binds to two H+-ATPase molecules. The 3D 
reconstruction of the purified H(+)-ATPase/14-3-3 complex demonstrated a hexagonal 
structure consisting of six PMA2 subunits and six 14-3-3 proteins (Ottmann et al., 2007). 
Thus, a rigid 14-3-3 'clamps' stabilize the dodecameric compex in the active conformation 
where C-terminal auto-inhibitory domain of PMA would be displaced.  
With regards to membrane protein trafficking, clamping activity of 14-3-3 proteins has 
been much less well understood. This is largely due to the, as yet, small number of studies 
in this research area and the lack of high-resolution structure of the 14-3-3/target 
membrane protein complex, which are also true for 'masking' and 'scaffolding' 
mechanisms. However, the ability of 14-3-3 to change conformation of target proteins 
suggests the possibility that such conformational change will lead to a new interaction of 
the target with proteins that are involved in protein trafficking. This way 14-3-3 might 
indirectly exert the scaffolding function that eventually modulates the protein sorting of 
the client protein. Alternatively, instead of direct 'masking' of RXR motif by 14-3-3, 14-3-3 
binding might force the target protein into the conformation where the RXR motif will be 
occluded. The RXR motif was previously found to have its functional 'zoning' in relation to 
the transmembrane region in the context of a reporter CD4 protein (Shikano & Li, 2003). 
This notion was based on the observation that the ER localization activity of RXR motif was 
lost when it was positioned proximal to the transmembrane region of CD4. This zoning 
model was supported by the later study on the gamma-aminobutyric acid type B (GABAB) 
receptor (Gassmann et al., 2005). An RXR motif (RSRR) is responsible for the ER retrieval of 
the GABAB1 subunits that were not properly assembled with GABAB2 subunits. It had 
been thought that coiled-coil interaction of the GABAB1 with GABAB2 will shield RSRR 
signal on GABAB1. However, closer positioning of RSRR signal to the membrane region 
drastically reduced its effectiveness and also functional ectopic RSRR signals in GABAB1 
were efficiently inactivated by the GABAB2 subunit in the absence of coiled-coil 
dimerization (Gassmann et al., 2005). These results were consistent with a model in which 
removal of RSRR from its functionally active zone, rather than its direct shielding by 
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coiled-coil dimerization, triggers cell surface trafficking of GABAB receptors. Thus, it is 
interesting to speculate that clamping of two different 14-3-3 binding sites, either within 
the same target protein or in two neighboring proteins, might lead to the placement of RXR 
motifs in a non-functional zone such as membrane proximity and suppress ER localization 
of target membrane proteins. 
2.3.4 Other mechanisms by which 14-3-3s modulate membrane protein trafficking  
Modulation of membrane protein localization by 14-3-3s is not necessarily mediated by their 
binding to the cargo protein itself. It is not surprising that 14-3-3 binding to any cellular 
machinery proteins involved in biosynthetic pathways would affect their functions and 
thereby affect the sorting of the cargo protein.  
The best characterized mechanism of this type involves the interaction of 14-3-3 with AS160, a 
Rab GTPase-activating protein (Rab-GAP). AS160 is an Akt substrate whose phosphorylation 
contributes to the recruitment of GLUT4 transporters to adipocyte plasma membrane in 
response to insulin (Watson & Pessin, 2006). It maintains Rab proteins with which it 
associates in their inactive, GDP-bound states. Several evidences implicate Akt-mediated 
AS160 phosphorylation and the subsequent 14-3-3 binding in the recruitment of the GLUT4 
glucose transporter to the cell surface of adipocytes (Ramm et al., 2006; Watson & Pessin, 
2006). Insulin stimulation leads to the recruitment of Akt to the plasma membrane where it 
gets activated and then phosphorylate AS160 at serine341 and threonine642. It is thought that 
the binding of 14-3-3 to AS160 inhibits its Rab-GAP activity toward substrate Rabs (Ishikura 
et al., 2007), which stabilizes them at GTP-bound active form and thereby facilitate the 
trafficking of cargo vesicles. Interestingly, insulin-dependent cell surface transport of GLUT4 
is known to be primarily mediated by Akt isoform 2 (Akt2) but not Akt1 in adipocytes (Bae et 
al., 2003; Cho et al., 2001). A recent study by Gonzalez and McGraw demonstrated that upon 
insulin stimulation, Akt2 is able to remain associated with plasma membrane longer than 
Akt1 does and this leads to the Akt2-specific phosphorylation of AS160, which is necessary 
for GLUT4 trafficking (Gonzalez & McGraw, 2009). It will be interesting to investigate 
whether and how this Akt isoform-specific phosphorylation of AS160 regulates 14-3-3 
binding. 
The surface expression of the epithelial sodium channel (ENaC) seems to be regulated in a 
similar manner that involves AS160-14-3-3 interaction (Liang et al., 2010). Aldosterone 
stimulation of renal epithelial cell induces the expression of serum- and glucocorticoid-
induced kinase (SGK1) that increases the cell surface expression of ENaC and Na 
absorption (Bhalla et al., 2006). Aldosterone also induces the expression of two 14-3-3 
protein isoforms, β and ε (Liang et al., 2006). Liang et al. reported that SGK1, which is the 
downstream kinase of PI3K and shares with Akt the recognition motif of RXRXXS/T 
(Tessier & Woodgett, 2006), phosphorylates AS160 upon aldosterone stimulation and this 
recruits the induced 14-3-3 isoforms (Liang et al., 2010), similar to the insulin-induced Akt 
phosphorylation of AS160. Inhibition of ENaC surface transport by expression of AS160 
carrying mutations in SGK1 target sites suggests that 14-3-3 downregulates AS160 function 
to eventually promote surface transport of ENaC and augment Na absorption in response 
to aldosterone.  
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Furthermore, 14-3-3 also controls the surface expression level of ENaC by regulating its 
degradation machinery. Ubiquitination of ENaC by ubiquitin-E3 protein ligase Nedd4-2 
leads to an increased rate of protein degradation. The activation of SGK1 by aldosterone 
results in the phosphorylation of Nedd4-2 and recruitment of 14-3-3 proteins to Nedd4-2. 
This 14-3-3 binding inhibits the interaction of Nedd4-2 with ENaC and thereby suppresses 
the ubiquitin-dependent degradation of ENaC (Ichimura et al., 2005; Liang et al., 2006). This 
results in the longer stability of ENaC on the cell surface. 
14-3-3s also bind to another transport machinery protein, phosphofurin acidic cluster sorting 
protein (PACS)-2 (Aslan et al., 2009). PACS-2 recognizes an acidic cluster in the cytoplasmic 
tail of TRPP2 cation channel and localize the channel in the ER through interaction with the 
COPI complex (Kottgen et al., 2005). The 14-3-3 binding to PACS-2 is dependent on the 
phosphorylation of PACS-2 by AKt, and this 14-3-3 binding was found to be required for the 
ER targeting of the PACS-2 substrate cargo protein TRPP2 (Aslan et al., 2009). How binding 
of PACS-2 to 14-3-3 and COPI cooperate to mediate cargo traffic remains to be determined. 
Cell surface expression of membrane proteins could be also regulated by 14-3-3 through 
modulation of endocytic processes. Recent study demonstrates the interaction of 14-3-3 with 
transferrin receptor trafficking protein (TTP) (Chiba et al., 2009). TTP specifically promotes 
the internalization of transferrin receptor (TfR), but not other receptors such as epidermal 
growth factor receptor (EGFR) and low-density lipoprotein receptor (LDLR), through the 
clathrin-dependent pathway (Tosoni et al., 2005). 14-3-3 proteins directly bind to TTP in the 
Akt-dependent manner and this interaction was enhanced by oxidative stress (Chiba et al., 
2009). Although the in vivo role of this 14-3-3 binding in TTP transport was not shown in this 
study, it suggests another possible mechanism where kinase signaling utilizes 14-3-3 as an 
effector molecule to control the cell surface density of proteins. 
3. Conclusion 
The requirement of phosphorylation for 14-3-3 binding confers 14-3-3 proteins a primary 
role in regulating protein-protein interactions that are under the control of specific kinases 
and phosphatases. Accordingly, 14-3-3 constitutes a key player which stands at a point of 
cross-talk between a plethora of vital biological processes including signaling, metabolism, 
cell cycle, and protein trafficking. Although available data from biochemical, structural, and 
bioinformatics studies have provided substantial amounts of information that characterize 
14-3-3/client interaction, several fundamental questions regarding 14-3-3 protein biology 
remain to be addressed.  
Although proteomics have revealed over 200 proteins forming complex with 14-3-3, the 
information regarding kinases and phosphatases that regulate these interactions are limited. 
The relevant kinase is not known for the majority of 14-3-3-binding proteins and the 
substantial overlap between the recognition sites of numerous basophilic serine/threonine 
kinases and 14-3-3 binding sites make their identification very difficult. Equally important 
but even less well studied are the phosphatases relevant for 14-3-3 binding. When and how 
the 14-3-3 proteins dissociate from the client proteins is very poorly understood. Does it 
require dephosphorylation of the 14-3-3 binding site by phosphatases? If so, how can the 
phosphatases do that when the phosphorylated serine/threonine of a target protein is 
buried in the amphipathic ligand-binding groove of 14-3-3? Alternatively, does some other 
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signaling event facilitate the release of 14-3-3s from client proteins? In the context of protein 
trafficking, 14-3-3 is known to modulate sorting of the client proteins by various different 
mechanisms. In many of the cases where surface membrane transport is promoted by 14-3-3 
binding, 14-3-3 seems to impinge on the early step of ER-to-Golgi trafficking. However, 
except for a very small number of studies (Godde et al., 2006; Okamoto & Shikano, 2011), it 
is not understood if 14-3-3 proteins remain bound to the client all along the trip to the cell 
surface or dissociate in any particular step of the vesicular trafficking by phosphatase 
activity. These problems make us realize that we still do not know enough about the biology 
of kinases and phosphatases, especially the spatio-temporal regulation of their activities in 
different cellular compartments.  
Another important question that has been long discussed but not fully addressed is whether 
and how 14-3-3 isoforms play specific roles. The complete sequence conservation in the 
observed ligand-binding regions of 14-3-3 would support the hypothesis that there may be 
little isoform specificity in the interaction between 14-3-3 and client proteins; therefore 
isoform-specific function of 14-3-3 may result either from subcellular localization (Paul et al., 
2005; van Hemert et al., 2004) or transcriptional regulation (Liang et al., 2006) of particular 
isotypes rather than from inherent differences in their ability to bind to particular ligands. 
However, several findings (Dubois et al., 1997; Gu & Du, 1998; Ichimura et al., 1995) suggest 
that additional interactions may occur on the outer surface of 14-3-3. This may confer 
isoform specificity, since residues that are variable between 14-3-3 isoforms are located on 
the surface of the protein. It is also conceivable that due to the common occurrence of two 
14-3-3 binding sites within the target protein, the synergy between the two may also lead to 
isoform preference of interaction. Studies have shown that 14-3-3 isoforms form hetero-
dimers in vivo (Alvarez et al., 2003; Liang et al., 2008). The isoform-specific interaction with 
client proteins may become most relevant in a 'scaffolding' model, where a hetero-dimer 
consisting of different isoforms would bind to two separate targets via each isoform. Thus, it 
is likely that its propensity to form homo- and various heterodimeric combinations is crucial 
for the specificity of 14-3-3 isoform functions. Many apparent conclusions of 14-3-3 function 
within particular cell types are based on observations of a single isoform, and comparative 
data among isoforms are still limited. More analysis of the exact combinations of homo- and 
hetero-dimers of 14-3-3 isoforms that are present within cell compartments and that are 
involved in interactions with particular proteins will be important. 
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1. Introduction 
Our genome contains a higher amount of endogenous retroelements (〜42 %) than mouse (
〜37 %) or fruit fly (〜3.6 %) (1-3). Long interspersed element-1 (L1) is the most abundant of 
transposable elements, comprising 〜17% of the genome (1-4). L1 is an autonomous 
endogenous retroelement that has evolved in a single, unbroken lineage for the past 40 
million years in primates (5). A single human cell has more than 5x105 copies of L1 (2,4), and 
most of them are functionally defective (6). However, 80 to 100 copies of L1 are competent 
for retrotransposition (L1-RTP) (7), and approximately 10 % of these are highly active for 
“copy and paste” (7). L1 is actively expressed in embryonal stem cells (8) and L1-RTP is 
induced in oocytes or early embryonic development (9-11). L1-RTP occurring in germ lines 
would function an intrinsic factor responsible for allelic variants among individuals (12,13). 
However, aberrant L1-RTP alternates critical gene structures, leading to the development of 
inborn errors (14). At the moment, at least 17 genetic diseases have been reported as 
sporadic cases of inheritable disorders caused by aberrant insertion of L1 (14). On the other 
hand, recent observations suggest that L1-RTP occurs in somatic cells. Strikingly, it was 
shown that copy numbers of L1 is increased in human brain tissues (15,16). Aberrant L1 
insertions have been detected in c-myc gene and the APC gene in breast carcinoma and colon 
carcinoma, respectively (17,18). Moreover recent analysis demonstrated that L1 is frequently 
mobilized in human lung cancers and pancreatic carcinomas (19,20). These observations 
indicate that it is important to understand the mode of L1-RTP, but little is known about the 
cellular factors for the induction of L1-RTP in somatic cells. We herein summarize our 
current understanding of L1-RTP induction, with an emphasis on mitogen-activated protein 
kinases (MAPKs), which are activated by environmental compounds, and we discuss their 
roles in genome shuffling.  
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1. Introduction 
Our genome contains a higher amount of endogenous retroelements (〜42 %) than mouse (
〜37 %) or fruit fly (〜3.6 %) (1-3). Long interspersed element-1 (L1) is the most abundant of 
transposable elements, comprising 〜17% of the genome (1-4). L1 is an autonomous 
endogenous retroelement that has evolved in a single, unbroken lineage for the past 40 
million years in primates (5). A single human cell has more than 5x105 copies of L1 (2,4), and 
most of them are functionally defective (6). However, 80 to 100 copies of L1 are competent 
for retrotransposition (L1-RTP) (7), and approximately 10 % of these are highly active for 
“copy and paste” (7). L1 is actively expressed in embryonal stem cells (8) and L1-RTP is 
induced in oocytes or early embryonic development (9-11). L1-RTP occurring in germ lines 
would function an intrinsic factor responsible for allelic variants among individuals (12,13). 
However, aberrant L1-RTP alternates critical gene structures, leading to the development of 
inborn errors (14). At the moment, at least 17 genetic diseases have been reported as 
sporadic cases of inheritable disorders caused by aberrant insertion of L1 (14). On the other 
hand, recent observations suggest that L1-RTP occurs in somatic cells. Strikingly, it was 
shown that copy numbers of L1 is increased in human brain tissues (15,16). Aberrant L1 
insertions have been detected in c-myc gene and the APC gene in breast carcinoma and colon 
carcinoma, respectively (17,18). Moreover recent analysis demonstrated that L1 is frequently 
mobilized in human lung cancers and pancreatic carcinomas (19,20). These observations 
indicate that it is important to understand the mode of L1-RTP, but little is known about the 
cellular factors for the induction of L1-RTP in somatic cells. We herein summarize our 
current understanding of L1-RTP induction, with an emphasis on mitogen-activated protein 
kinases (MAPKs), which are activated by environmental compounds, and we discuss their 
roles in genome shuffling.  
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2. Biology of L1-RTP  
L1, a non-long terminal repeat (non-LTR)-type endogenous retroelement, encodes two 
proteins: open reading frames 1 and 2 (ORF1 and 2) (3). ORF1 is a cytoplasmic 40 kDa 
protein that is present within ribonucleoprotein complexes (21-23). ORF1 associates in cis 
with L1-mRNA (24) and functions as a chaperone of L1-mRNA (25). ORF2 is a protein of 
about 150 kDa with dual activities as reverse transcriptase (RT) (26) and an endonuclease 
(27). ORF2 recognizes the 5′-TTAAAA hexanucleotide in the genome and induces a nick 
between 3′-AA and TTTT in the complementary strand (28,29). It has been proposed that the 
first-strand DNA is synthesized by target site-primed reverse transcription (3,29). ORF1 and 
2 complete the entire process of L1-RTP and are competent for the induction of 
retrotransposition of Alu, a non-autonomous retroelements (30, 31). 
3. Reported triggers of L1-RTP  
As to the environmental factors that induce L1-RTP in somatic cells, Farkash et al. reported 
that gamma irradiation at 4.5 Gy induced L1-RTP (32). Independently, Deiniger’s group 
reported that heavy metals of such as mercury, cadmium and nickel also induced L1-RTP 
(33,34). They also reported that nickel-induced L1-RTP is induced by a post-transcriptional 
mechanism (34). As to an environmental carcinogen, Stribinskis and Ramos found that 
benzo[a]pyrene (B[a]P) induced L1-RTP (35). An extensive analysis revealed that aryl 
hydrocarbon receptor (AhR), which serves as a receptor for such environmental pollutants 
as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (36), was required for the B[a]P-induced L1-
RTP (35). Because TCDD, a non-genotoxic hydrocarbon carcinogen, did not induce L1-RTP, 
it was proposed that as one of the its mechanisms an AhR-dependent cellular response 
converts B[a]P into an active genotoxic compound, which in turn induces L1-RTP (35). 
Although the exact modes of L1-RTP are unclear, these studies inspired us to investigate the 
possibility that various environmental compounds can induce L1-RTP.   
4. Induction of L1-RTP by an environmental compound and identification of 
p38 as a pivotal cellular factor  
First, we found that 6-formylindolo[3,2-b]carbazole (FICZ), a tryptophan photoproduct, 
induced L1-RTP (37). FICZ is highly active, and even picomolar comncentratiom of the 
compound induced L1-RTP. In mammalian cells, six groups of MAPKs, namely extracellular 
signal-regulated protein kinase (ERK)1/2, ERK5, JNK, p38, ERK3/4 and ERK7/8, are 
identified, and are activated by intracellular and extracellular stimuli (38). Among these, 
cellular signal cascades of ERK1/2, p38 and JNK have been well characterized, because of 
the availability of inhibitors, including PD98,059, SB202190 and SP600125, respectively. 
Using these MAPK inhibitors, we found that FICZ-induced L1-RTP was dependent on p38 
(37). Interestingly, the compound induced phosphorylation of cyclic-AMP responsive 
element binding protein (CREB), and the down-regulation of endogenous CREB by short 
interference RNA (siRNA) attenuated the induction of L1-RTP by FICZ. Moreover, a 
transfection-back experiment of cDNA that encoded a siRNA-resistant CREB restored the 
induction of L1-RTP. These data indicate that the induction of L1-RTP by FICZ depended on 
p38-CREB-dependent signaling. Intriguingly, L1-RTP by FICZ was not dependent on AhR, 
although FICZ is a candidate physiological ligand of AhR (39). In contrast, L1-RTP by FICZ 
was dependent on AhR nuclear translocator 1 (ARNT1), a binding partner of AhR (40).  
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AhR and ARNT1 are members of the basic helix-loop-helix/per-arnt-sim (bHLH/PAS) 
family, which are transcription factors involved in a variety of biological functions (41). 
Recently, it was shown that the bHLH/PAS family is functionally linked with 
environmental adaptation of living organisms (42). When AhR binds environmental 
compounds, it forms a heterodimer with ARNT1, which is recruited from the cytoplasm to 
chromatin and recognizes a xenobiotic responsive element (XRE) (36). It has been shown 
that the chromatin recruitment of ligand-bound AhR depends on the nuclear localization 
signal of ARNT1 (43), but there are no reports showing that ARNT1 functions as a receptor 
for environmental compounds. A cellular factor that cooperates with ARNT1 in FICZ-
induced L1-RTP has yet to be identified.    
5. MAPKs required for L1-RTP by FICZ 
To explore the involvement of MAPKs in L1-RTP, we extended our experiments to explore 
whether environmental carcinogens induce L1-RTP. In two-stage chemical carcinogenesis, it 
has been shown that skin tumors develop by treatment with 7,12-dimethylbenz[a]anthracene 
(DMBA) plus 12-O-tetradecanoylphorbol-13-acetate (TPA) (44). DMBA functions as an 
initiator and activates H-ras gene, whereas TPA functions as a tumor promoter thorough non-
genotoxic effects (45). However, how TPA induces tumor progression remains to be clarified. 
We first analyzed whether L1-RTP is involved under skin carcinogenesis. When transgenic 
mice harboring human L1 as a transgene (hL1-EGFP mouse) were subjected to DMBA/TPA-
induced skin carcinogenesis, L1-RTP was frequently observed in the DMBA/TPA-induced 
skin tumors (46). Interestingly, in vitro experiments revealed that both DMBA and TPA were 
active for the induction of L1-RTP. On the other hand, in vivo experiments, in which hL1-EGFP 
mice were transiently treated with DMBA or TPA suggested that L1-RTP in the skin tumors 
was attributable to the effects of the repeated treatment with TPA. Notably, we observed that 
the mode of L1-RTP by DMBA and TPA was different. DMBA-induced L1-RTP was 
dependent on both AhR and ARNT1, whereas TPA-induced L1-RTP required neither protein. 
Instead, it depended on ERK1/2 and epidermal growth factor receptor (EGFR). Since Balmain 
et al (44) originally reported on DMBA/TPA-induced two-stage carcinogenesis, a major issue 
of cancer research is to clarify the mechanism of the TPA-induced tumor promotion. Using 
genetically-engineered mice, it has been proven that TPA-induced tumor promotion depends 
on ERK1/2 and EGFR (47,48). Interestingly, TPA-induced L1-RTP was shown to be dependent 
on these molecules, suggesting that the genome shuffling by L1-RTP is linked with the mode 
of TPA-dependent tumor promotion.  
6. MAPKs are involved in the induction of L1-RTP by carcinogens 
Given that environmental compounds seemed to induce L1-RTP by involving different 
cellular proteins, we investigated other carcinogens such as B[a]P and 3-methylcholanthrene 
(3-MC). Consistent with a previous report (35), B[a]P induced L1-RTP in an AhR-dependent 
manner (46). Additionally, 3-MC also induced L1-RTP in an AhR-dependent manner (46). 
However, we found that the L1-RTP was induced even when siRNA against ARNT1 was 
transfected into the cell (Fig. 1b, lanes 9 and 18). The siRNA clearly suppressed the mRNA 
expression of CYP1A1 (Fig. 1c, lanes 11 and 12), indicating that the siRNA effectively 
abrogated the function of endogenous ARNT1 protein. These data support the idea that 
ARNT1 is dispensable for the induction of L1-RTP by these compounds. Because it has been  
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Fig. 1. B[a]P and 3-MC induced L1-RTP depending on AhR and ER, but not on ARNT1. An 
L1-RTP assay was performed according to the procedures described (37,46). Briefly, HuH-7 
cells from a human hepatoma cell line were transfected with pEF06R on day 0, then treated 
with 0.5 g/mL puromycin for two days (days 1-3). The cells were then trypsinized and 
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replated for treatment with the compounds. Two days after the addition of 3 M B[a]P or 1 
M 3-MC, the cells were harvested and their DNA extracted. No cytotoxicity was caused by 
3 M B[a]P or 1 M 3-MC (data not shown). For the PCR-based assay, a spliced form of 
EGFP cDNA (140 bp in length) was amplified by PCR with primers specific for the 
separated exons of EGFP cDNA. The amplified DNA was then loaded onto an agarose gel 
and detected after staining with SYBR Green. As an internal control, the same samples were 
used as templates for the amplification of -actin. a. Effects of ARNT1 siRNA on the down-
regulation of endogenous ARNT1. Western blot analysis was performed on day 2 after the 
transfection of ARNT1 siRNA. U, untreated; C, control siRNA; ARNT1, ARNT1 siRNA. b. L1-
RTP caused by B[a]P and 3-MC was independent of ARNT1. The PCR-based assay of the 
effects of ARNT1 siRNA is shown. HuH-7 cells were transfected with pEF06R on day 0 and 
then selected from days 1-3. On day 3, the cells were trypsinized, replated, and further 
transfected with control (Cont.) or ARNT1 siRNA. On day 4, the cells were again divided into 
three groups and treated with DMSO, 3-MC (left panel), or B[a]P (right panel). After two days, 
DNA was extracted and subjected to a PCR-based assay. The arrowhead indicates the PCR-
amplified band corresponding to the induction of L1-RTP. c. ARNT1 siRNA effectively 
blocked the mRNA expression of CYP1A1, which was induced by the compounds. HuH-7 
cells were first transfected with control or ARNT1 siRNAs. On day 2 after transfection, the cells 
were trypsinized, replated, and treated with B[a]P or 3-MC. RT-PCR analysis was performed 
on day 2 after the addition of the compounds. d. ER is required for the induction of L1-RTP 
by B[a]P or 3-MC. In this experiment, MCF-7 cells from a human breast carcinoma cell line 
were used. Using a similar experimental protocol, the effect of ER siRNA on the induction of 
L1-RTP was examined. As an internal control, -actin was amplified.  
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SB202190 ○ ○ ○ - - 
SP600125 - ○ ○ - - 
PD98,059 N.T. N.T. N.T. - ○ 
○, dependent; -, independent; N.T., not tested. 
The induction of L1-RTP was examined by a PCR-based assay (see legend for Fig. 1). 
Table 1. Summary of cellular factors required for L1-RTP by environmental compounds 
shown that AhR forms a complex with estrogen receptor  (ER we further tested the 
involvement of ER in the induction of L1-RTP. Interestingly, the transfection of ERsiRNA 
attenuated L1-RTP induced by these compounds (Fig. 1d, lanes 5 and 6). In addition, we 
found that CREB was definitely phorphorylated (Fig. 2a, lane 4), and checked the effects of 
MAPK inhibitors on the induction of L1-RTP by 3-MC. As shown in Fig. 2b, SB202190 
attenuated the induction of L1-RTP (lane 8), whereas SP600125 did not (lane 10). To further 
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identify a candidate substrate of p38, we examined the effects of CREB siRNA. The 
transfection of CREB siRNA abrogated the induction of L1-RTP by 3-MC (Fig. 2c). These 
data suggest that L1-RTP by 3-MC is induced by the cooperative function of AhR and ER 
depending on a signal cascade involving the p38-CREB pathway. Our data also indicate that 
the induction of L1-RTP by B[a]P is dependent on p38 and JNK (Fig. 2d, lanes 8 and 10). 
Although further study is required, our current understanding is that various environmental 
compounds induce L1-RTP by combinations of the bHLH/PAS family and MAPKs (Table 
1). L1-RTP was differentially induced by FICZ, DMBA, B[a]P, 3-MC and TPA. Most of the 
compounds examined, with the exception of DMBA, depended on MAPKs. Moreover, the 
L1-RTP by carcinogens depended on AhR, whereas FICZ did not. It is important to collect 
more information about chemical compounds active in the induction of L1-RTP and to 
elucidate the involvement of MAPKs.  
It has been proposed that L1-RTP is controlled at the transcriptional and post-transcriptional 
levels. In vitro experiments revealed that that the expression of L1 is tightly regulated by 
methytlation of CpG in the region of 5’-LTR. In normal somatic cells, the 5’-LTR of L1 is 
methylated at CpG (50,51), but it is hypomethylated in transformed cells (52). It has been 
consistently reported that treatment with B[a]P induced the hypomethylation of CpG in 
HeLa cells (53). Moreover, it was reported that L1-5’UTR has a ubiquitously active antisense 
promoter that encodes small interfering RNAs, which effectively suppressed the 
retrotransposition of L1 (54). These observations indicate that epigenetic alternation of the 
5’-UTR was proposed as the activation mode of L1-UTR by the compound. However, the 
following in vitro experiments suggested the presence of another regulatory system of L1-
RTP. A reporter construct was transfected into cultured cells, and treatment with the 
compounds increased the frequency of L1-RTP. Because the reporter construct (e.g., pEF06R, 
which carries EGFP cDNA as a reporter gene) contained a potent CMV promoter (32,34), L1-
mRNA was strongly expressed when it was transfected into cultured cells. Even under such 
conditions, remarkable effects on the induction of L1-RTP were detectable by additing 
inducers such as FICZ, B[a]P, and 3-MC (37,46). Data indicate the presence of an additional 
regulatory system in which cellular proteins regulate the induction of L1-RTP. One possible 
mode of regulation is the chromatin recruitment of ORF1. 
7. The chromatin recruitment of ORF1 is MAPK-dependent  
Because it has been postulated that ORF1 is present in the cytoplasm (21-23) and carcinogen-
induced L1-RTP was dependent on AhR, it is plausible that ORF1 is functionally associated 
with the bHLH/PAS family. To prove this, we evaluated the association of ORF1 and AhR 
by an immunoprecipitation followed by Western blot analysis with a polyclonal antibody to 
human ORF1. Intriguingly, ORF1 and AhR were associated even under normal conditions 
(Okudaira N, submitted). More importantly, we detected that recruitment of ORF1 into the 
chromatin-rich fraction was coupled with L1-RTP. As reported, chromatin recruitment of 
ORF1 was induced by FICZ in a MAPK-dependent manner. It is interesting that the 
chromatin recruitment of ORF1 was induced by FICZ, although FICZ-induced L1-RTP was 
not dependent on AhR (37). Interestingly, ARNT1 was associated with ORF1 when FICZ 
was added to the culture medium (37). Although the precise role of the MAPK is unclear, 
these data suggest that the chromatin recruitment of ORF1 is the important regulatory step 
in L1-RTP, where at least p38 is involved as a crucial cellular factor.  
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chromatin recruitment of ORF1 was induced by FICZ, although FICZ-induced L1-RTP was 
not dependent on AhR (37). Interestingly, ARNT1 was associated with ORF1 when FICZ 
was added to the culture medium (37). Although the precise role of the MAPK is unclear, 
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SB202190 and SP600125, respectively. U, untreated; D, DMSO; F, FICZ; M, 3-MC; H, H2O2. 
Of note, L1-RTP caused by 3-MC was attenuated by SB (lane 8), but not by SP (lane 10). The 
arrowhead indicates the induction of L1-RTP. c. CREB is required for L1-RTP induced by 3-
MC. Left panel: Western blot analysis detected efficient down-regulation of the endogenous 
protein by CREB siRNA. U, untreated; N, non-transfected; C, control siRNA; CREB, CREB 
siRNA. Right panel: PCR-based assay after the transfection of CREB siRNA. CREB siRNA 
attenuated L1-RTP induced by 3-MC (lane 9). d. Effects of MAPK inhibitors on L1-RTP 
induced by B[a]P. Reagents similar to those described in Fig. 2b were used. L1-RTP by B[a]P 
was attenuated by both SB (lane 8) and SP (lane 10). 
8. Roles of MAPK on L1-RTP  
It has been supposed that the increase of transposable elements coupled with evolution (7). 
Even in Candida albicans, an L1-like structure is present as a functional gene (55). On the other 
hand, the bHLH/PAS family, which has a variety of biological functions including the 
metabolism of xenobiotics, maintenance of the circadian rhythm, cellular responses to hypoxia, 
and neuronal differentiation (41,42), is also well conserved from lower species to mammals 
(56). Interestingly, AhR homologs are also present in the genomes of Drosophila melanogaster 
and Caenorhabditis elegans (56). Although no direct evidence on the functional relationship 
between these two biological phenomena has been claimed, our observation is the first to 
demonstrate the functional link of these biological events. Moreover, data suggest that MAPKs 
are involved in the bHLH/PAS-dependent L1-RTP. MAPKs are involved in cellular response 
to intracellular and extracellular stress (38,57), and it is plausible that MAPKs mediate various 
stresses in the induction of L1-RTP, resulting in genome shuffling. Random mutagenesis by 
L1-RTP may give emerging novel organisms to survive in altered environments.  
It is important to clarify the roles of MAPKs in the induction of L1-RTP. At present, at least 
two functions of MAPKs can be postulated. As explained, environmental compounds 
activate MAPKs, by which the chromatin recruitment of ORF1 is induced as a necessary step 
in L1-RTP. ORF1 functions in cis with L1- mRNA and functions as a chaperon of L1-mRNA 
(24,25). Using MAPK inhibitors, we observed that L1-RTP was abrogated concomitantly 
with the reduced chromatin recruitment of ORF1. These observations suggest that MAPK 
activation drives the mobilization of ORF1 to chromatin, by which retroelements are 
translocated to chromtin.  
Another possible role for MAPKs is related to the activity of the APOBEC family. It has been 
proposed that APOBEC family functions as innate restriction factors that suppress the 
activity of endogenous retroelements (58). Originally, it was postulated that the APOBEC 
family inhibits HIV-1 infection by editing C to T via deaminase activity (58). Vif, a gene 
product of HIV-1, degrades APOBEC proteins, causing infected cells to become permissive 
for HIV-1 infection (59). We previously showed that all members of the APOBEC family 
exhibit inhibitory activity toward L1-RTP (60). However, it was recently postulated that the 
APOBEC has dual activity (61) and inhibits the activity of RT (62). In in vitro experiments in 
which APOBEC3G were added to the reaction of RT in the synthesis of viral DNA, APOBEC 
interfered with elongation of the viral DNA (62). Interestingly, it has been shown that 
C/EBP- bound APOBEC3G and attenuate the inhibitory activity of APOBEC3G (63). 
Moreover, it was demonstrated that the mutation of serine at 228 (S228),the phosphorylation 
of which is correlated with the cytoplasmic localization of the molecule (63), abolished both 
binding and inhibitory activity on APOBEC3G (64). Given that C/EBP-is a substrate of p38 
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(38), a plausible model is that p38 augments the blocking activity of C/EBP- on APOBEC3G 
via phosphorylation.  
9. Further implications 
Ataxia telangiectasis mutated (ATM), a phosphoinositide 3-kinase, has a functional link with 
L1-RTP (16). In an intriguing recent observation, the copy number of L1 increased in the 
brain tissues of patients with ATM (16). L1-RTP is consistently increased in the brain tissue 
of ATM-knock out mouse. Although these observations suggest that ATM functions as a 
negative regulator of L1-RTP, Gasior et al. originally reported that ATM was required for the 
induction of L1-RTP (65). Because of controversial observations regarding the role of ATM 
in L1-RTP, we focused on MAPKs in the current study.  
Recent observations revealed that genome shuffling by L1-RTP in human somatic cells is a 
source of interindividual genomic heterogeneity (12,13). In addition, independent research 
groups reported that L1-RTP is frequently induced in tumors (19,20), suggesting the 
involvement of L1-RTP in the development of carcinogenesis. Importantly, L1 proteins are 
active on the retrotransposition of Alu (30,31), a non-autonomous retoroelement. On the other 
hand, it has been shown that Alu induces genomic instability via non-allelic homologous 
recombination (66). Thus, it is important to understand the activation mechanisms of L1. Our 
current observations support the idea that the chromatin recruitment of ORF1, which is 
controlled by cooperative regulation by members of the bHLH/PAS family and MAPKs, is a 
critical step in the regulation of L1-RTP. If this is the case, L1-RTP induction in the genome is 
selectively determined by cellular factors. Because AhR is a transcription factor that 
recognizes specific nucleotide element (36), carcinogens possibly induce L1-RTP in the 
genomes in the vicinity of the cis-element.  
As observed in the analysis of L1-RTP by B[a]P and 3-MC, L1-RTP was not induced via the 
classical pathway controlled by both AhR and ARNT1. Our data suggest that L1-RTP is not 
necessarily induced by genotoxic activities of these compounds, further implying that L1-RTP 
is a novel type of genomic instability by which cellular cascades activated by environmental 
compounds lead to genome shuffling and generate stable phenotypes of the affected cells. The 
suppression of L1-RTP in somatic cells by targeting MAPK activity may be a novel strategy to 
protect the development of intractable diseases that include carcinogenesis.    
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1.1 Mammalian connexins 
Connexins are protein subunits expressed by cordates that form gap junction channels 
(GJCs) and hemichannels (HCs) (Goodenough, 1974; Makowski et al., 1977). A GJC is 
formed by the head-to-head docking of two HCs, each contributed by one of the two 
contacting cells (Meşe et al., 2007). Each HC is an oligomeric assembly of six identical 
(homomeric) or six different (heteromeric) Cx subunits (Sáez et al., 2005). GJCs and HCs 
subserve different functions; while GJCs communicate the cytoplasm of contacting cells, 
HCs provide a pathway for communication between the intracellular and extracellular 
compartments (Bruzzone and Dermietzel, 2006). Although both types of channels are 
permeable to ions and small molecules, GJCs and HCs composed of the same Cx subtype 
are likely to present differences in permeability and regulatory properties (Sáez et al., 2003; 
Meşe et al., 2007; Sáez et al., 2010). 
The family of connexin genes has 20 members in the mouse genome and 21 members in the 
human genome (Eiberger et al., 2001; Willecke et al., 2002; Söhl and Willecke, 2003; 2004). 
Most Cx genes have a similar structure and contain the protein coding region as a single 
exon (Willecke et al., 2002; Söhl and Willecke, 2003; 2004; Pfenniger et al., 2011). Cxs were 
initially denoted according to the tissue of origin or the apparent size of a polypeptide as 
determined by SDS-PAGE. Shortly thereafter, it became clear that such designations were 
inappropriate, because many of these proteins are expressed in more than one tissue (Beyer 
et al., 1987) and their apparent molecular mass may vary with electrophoresis conditions 
(Green et al., 1988). Therefore, a standard nomenclature was developed to distinguish 
members of this family. The current nomenclature uses the abbreviated symbol “Cx” (for 
connexin) followed by a suffix that indicates the molecular mass of the Cx amino acid 
sequence (in kDa) predicted from its cDNA. In some cases, a prefix is added to indicate the 
species of origin. Hydropathicity plots of the Cx amino acid sequences have been used to 
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predict their membrane topology. These analyses predicted the presence of four 
hydrophobic domains, three hydrophilic cytoplasmic domains (the amino and carboxyl 
termini and an intracellular loop) and two extracellular loops (Heynkes et al., 1986; Paul, 
1986; Beyer et al., 1987). This topology was supported by experiments that studied the 
binding of site-specific antibodies and protease sensitive sites (Zimmer et al., 1987; 
Hertzberg et al., 1988; Milks et al., 1988; Yancey et al., 1989; Zhang and Nicholson, 1994; 
Quist et al., 2000). The cytoplasmic loop and the carboxyl terminus vary extensively in 
length and amino acid composition and probably contain most of the regulatory sites of 
GJCs and HCs. 
1.2 Mammalian protein kinases and phosphoprotein phosphatases 
Most Cxs contain putative phosphorylation sites (Lampe and Lau, 2004). As with all 
phosphoproteins, their phosphorylation state will depend on the activities of protein kinases 
and phosphoprotein phosphatases. Mammalian cells express several different types of 
protein kinases and phosphoprotein phosphatases with more than 500 putative kinase genes 
in the human and mouse genome (Manning et al., 2002; Caenepeel et al., 2004). Protein 
kinases and phosphoprotein phosphatases have been subdivided according to their 
substrate specificities, activators, cofactors and/or amino acid sequence homology. It would 
be beyond the scope of this chapter to attempt to review them here and thus, we will briefly 
summarize the characteristics of the kinases and phosphatases that have most frequently 
been studied as possible effectors of the phosphorylation state of connexins. 
1.3 Serine/threonine protein kinases 
cAMP- and cGMP-dependent protein kinases (PKA and PKG, respectively) can be activated 
by increasing the concentration of the corresponding cyclic nucleotide (e.g., treatment with 
membrane permeable analogs of cAMP or cGMP such as 8-Bromo-cAMP and 8-Bromo-
cGMP or forskolin, which activates adenylyl cyclase). The CAMKII isoenzymes are activated 
by binding of Ca2+/calmodulin but other protein binding partners can also regulate their 
activity (Griffith, 2004). Casein kinase I (CK1) is a family of monomeric serine/threonine 
kinases that are constitutively active. This family shows a strong preference for pre-
phosphorylated substrates. Several inhibitors for members of this family have been 
described including CKI-7 and IC261 (Perez et al., 2011). Protein kinase C (PKC) has several 
isoforms that have been subdivided in three subtypes: conventional, novel and atypical. 
They differ in their activation by Ca2+, binding of diacylglycerol (DAG) and in their response 
to phorbol esters. Conventional PKCs bind Ca2+ and DAG. Novel PKCs lack amino acids 
involved in Ca2+ binding, but bind DAG. The catalytic activity of atypical PKCs is 
independent of Ca2+ and DAG; these PKC isoforms do not bind phorbol esters (Newton, 
1995). The phorbol ester tumor promoter, 12-O-tetradecanoylphorbol 13-acetate (TPA) and 
1-oleoyl-2-acetyl-sn-glycerol (OAG), an analog of diacylglycerol have been commonly used 
as activators of PKC. MAPKs are subdivided in three subfamilies: the extracellular signal-
regulated kinases (ERKs), the c-Jun amino-terminal kinases (JNKs) and the p38 MAPKs. 
They are activated by protein kinase cascades [MKKK-MKK(or MEK for ERKs)-MAPK], 
although MKK-independent activation of p38α has been reported (Johnson and Lapadat, 
2002). Finally, cyclin-dependent kinases (Cdks) constitute a family of serine/threonine 
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kinases that regulate proliferation, differentiation, senescence and apoptosis. In post-mitotic 
neurons, all Cdks, with the exception of Cdk5, are silenced.  
1.4 Tyrosine kinases 
The tyrosine kinases can be divided in two groups: receptor tyrosine kinases (RPTKs; e.g, 
growth factor receptors, ephrin receptors) and non-receptor (cytoplasmic) tyrosine kinases 
(NRPTKs; e.g., Src, FAK, JAK). RPTKs can be further subdivided into 20 subfamilies and 
NRPTKs into 10 subfamilies.  In the case of RPTKs, ligand-induced oligomerization and 
conformational changes result in tyrosine autophosphorylation of the receptor subunits 
which activates the catalytic activity and mediate the specific binding of cytoplasmic 
signaling proteins containing Src homology-2 (SH2) and protein tyrosine-binding domains. 
The NRPTK, c-Src, contains an SH2 domain through which it can bind to specific tyrosine 
autophosphorylation sites in ligand-stimulated RPTKs and mediate mitogenic signaling. c-
Src can also be activated by binding to proline-rich sequences in target proteins through its 
SH3 domain or by dephophorylation of Tyr527 (Blume-Jensen and Hunter, 2001). The viral 
form of Src, v-Src, is constitutively active and oncogenic. It contains a shorter sequence at 
the carboxyl terminus that lacks Tyr527, which is required for inactivation. v-Src has been 
extensively studied in relation to connexins for its effects on gap junction function. 
1.5 Serine/threonine phosphoprotein phosphatases 
The phosphoserine/phosphothreonine protein phosphatases have been classified in three 
subfamilies (PPM, FCP and PPP). Members of the PPP (PP1, PP2A and PP2B) and PPM 
(PP2C) subfamilies which use a metal ion-catalyzed reaction account for most of the 
serine/phosphothreonine phosphatase activity in vivo (Barford et al., 1998). Several 
phosphatase inhibitors with different specificities are available including calyculin A (which 
inhibits PP1 and PP2A), cyclosporine A (an inhibitor of PP2B), FK506 (an inhibitor of PP2B) 
and okadaic acid (which inhibits PP1).  
1.6 Phosphotyrosine phosphatases 
The phosphotyrosine phosphatases (PTPs) have been classified in class I-IV based on the 
amino acid sequence of their catalytic domains (class I-III are cysteine-based PTPs and class 
IV are aspartic-based PTPs). The cysteine-based family can be subdivided in classical PTPs, 
dual-specificity PTPs, cdc25 PTPs, and low-molecular weight PTPs.  Classical PTPs can be 
further subdivided into transmembrane receptor-like enzymes and intracellular non-
receptor PTPs. Eighty one of the 107 PTP genes in the human genome are active protein 
phosphatases (Alonso et al., 2004). 
2. Methods used to demonstrate that connexins are phosphoproteins 
The most frequently used experimental approaches to demonstrate that a particular Cx is a 
phosphoprotein include metabolic labeling of cultured cells with 32P followed by 
immunoprecipitation and alkaline phosphatase treatment, phosphoamino acid analysis (Sáez 
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(PP2C) subfamilies which use a metal ion-catalyzed reaction account for most of the 
serine/phosphothreonine phosphatase activity in vivo (Barford et al., 1998). Several 
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inhibits PP1 and PP2A), cyclosporine A (an inhibitor of PP2B), FK506 (an inhibitor of PP2B) 
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amino acid sequence of their catalytic domains (class I-III are cysteine-based PTPs and class 
IV are aspartic-based PTPs). The cysteine-based family can be subdivided in classical PTPs, 
dual-specificity PTPs, cdc25 PTPs, and low-molecular weight PTPs.  Classical PTPs can be 
further subdivided into transmembrane receptor-like enzymes and intracellular non-
receptor PTPs. Eighty one of the 107 PTP genes in the human genome are active protein 
phosphatases (Alonso et al., 2004). 
2. Methods used to demonstrate that connexins are phosphoproteins 
The most frequently used experimental approaches to demonstrate that a particular Cx is a 
phosphoprotein include metabolic labeling of cultured cells with 32P followed by 
immunoprecipitation and alkaline phosphatase treatment, phosphoamino acid analysis (Sáez 





1992; Goldberg and Lau, 1993; Kurata and Lau, 1994; Doble et al., 1996; Warn-Cramer et al., 
1996; Mikalsen et al., 1997; Cheng and Louis, 1999) or two-dimensional phosphopeptide 
mapping (Sáez et al., 1990; Kurata and Lau, 1994; Díez et al., 1995; Loo et al., 1995; Warn-
Cramer et al., 1996; Berthoud et al., 1997; Díez et al., 1998; Kanemitsu et al., 1998) in vitro 
phosphorylation assays using fusion proteins or synthetic peptides containing the putative 
phosphorylation site(s) and purified protein kinases (Sáez et al., 1990; Loo et al., 1995; Warn-
Cramer et al., 1996; Berthoud et al., 1997; Kanemitsu et al., 1998; Shah et al., 2002; O'Brien et 
al., 2004; Ouyang et al., 2005; Yogo et al., 2006; Alev et al., 2008; Morel et al., 2010); treatment 
of cultured cells with specific protein kinase or phosphoprotein phosphatase activators or 
inhibitors to alter 32P incorporation or the immunoblot pattern of connexins (Lau et al., 1992; 
Husøy et al., 1993; Guan et al., 1996; Berthoud et al., 1997; Cruciani et al., 1999; Duthe et al., 
2000; Li and Nagy, 2000; Sirnes et al., 2009; Morley et al., 2010); overexpression or knockdown 
of a specific protein kinase or phosphoprotein phosphatase (Kanemitsu et al., 1998; Lampe et 
al., 1998; Doble et al., 2000; Lin et al., 2001; Chu et al., 2002; Petrich et al., 2002; Doble et al., 
2004; Peterson-Roth et al., 2009; Ai et al., 2011); mass spectrometry (MS) analyses of 
immunoprecipitated connexins or in vitro phosphorylated fusion proteins containing a Cx 
intracellular domain (Cooper et al., 2000; Yin et al., 2000; TenBroek et al., 2001; Cooper and 
Lampe, 2002; Cameron et al., 2003; Axelsen et al., 2006; Locke et al., 2006; Solan et al., 2007; 
Shearer et al., 2008; Locke et al., 2009; Wang and Schey, 2009; Huang et al., 2011) and more 
recently, luminescence resonance energy transfer (Bao et al., 2007). Mutagenesis of the 
identified phosphorylation sites has been used to determine the functional consequences of 
their phosphorylation/dephosphorylation in cultured cells as well as in vivo after 
transfection or knock-in of a phosphosite-directed mutant Cx (Lampe et al., 1998; Remo et 
al., 2011). 
3. Metabolic labeling with 32P  
The first reports that demonstrated a particular Cx to be a phosphoprotein using metabolic 
labeling with 32P showed phosphorylation of Cx32 in hepatocytes (treated with phorbol 
esters, OAG, forskolin or cAMP analogs)((Sáez et a., 1986; Takeda et al., 1989; Sáez et al., 
1990) and phosphorylation of Cx43 in uninfected and Rous sarcoma virus (RSV)-transformed 
fibroblasts (Crow et al., 1990). Phosphoamino acid analysis indicated that hepatocyte Cx32 
and Cx43 in uninfected fibroblasts were phosphorylated on seryl residues (Takeda et al., 
1989; Crow et al., 1990; Sáez et al., 1990), but Cx43 was also phosphorylated in tyrosyl 
residues in RSV-transformed fibroblasts (Crow et al., 1990). Using metabolic labeling with 32P, 
other studies described that EGF-induced phosphorylation of Cx43 on serine residues in T51B 
cells through activation of mitogen-activated protein kinase (MAPK) (Lau et al., 1992; Warn-
Cramer et al., 1996), FGF-2 induced phosphorylation of Cx43 in cardiomyocytes (Doble et al., 
1996), tyrosine phosphorylation of Cx43 in early passage hamster embryo fibroblast 
(Mikalsen et al., 1997), phosphorylation of Cx56 by PKC and Cx49 by casein kinase 1 (CK1) in 
lens fiber cells (Berthoud et al., 1997; Cheng and Louis, 1999). In some cases, the specific 
phosphorylation site has been identified in reconstituted connexons expressed in Xenopus 
laevis oocytes. Using this approach, it has been demonstrated that v-Src induces tyrosine 
phosphorylation of Cx43 but not Cx32 (Swenson et al., 1990), and that serine368 of Cx43 (but 
not serine372) is directly phosphorylated by PKC (Bao et al., 2004a; 2004b). 
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3.1 In vitro phosphorylation 
Another widely used approach to identify putative phosphorylation sites is in vitro 
phosphorylation assays. In this case, a polypeptide, fusion protein or synthetic peptide 
(corresponding to a fragment of the connexin that includes the putative phosphorylation 
site(s)) is incubated with a purified protein kinase in the presence of [γ-32P]ATP and its 
ability to be a substrate for that protein kinase is evaluated by the incorporation of 32P. Sáez 
and collaborators (1990) also performed in vitro kinase assays using the catalytic subunits of 
PKA, PKC or CaMK II and purified gap junctions or synthetic peptides as substrates, and 
compared their two-dimensional pattern of phosphopeptides with those obtained from 
metabolically labeled cells. Using glutathione S-transferase (GST) fusion proteins of Cx56 
containing the carboxyl terminus or the intracellular loop, in vitro phosphorylation of Cx56 
by PKC and PKA have been demonstrated in serine118 (in the intracellular loop) and 
serine493 (in the carboxyl terminus)(Berthoud et al., 1997). 
Phosphorylation of Cx43 is among the best characterized. Polypeptides, fusion proteins and 
several synthetic peptides containing putative phosphorylation sites within the carboxyl 
terminus of Cx43 have been used to carry out in vitro phosphorylation and identify 
phosphorylation sites. These experiments have demonstrated that Cx43 is a substrate of 
p34cdc2 kinase (cell division cycle 2 kinase also known as cyclin dependent kinase 1) which 
mediates phosphorylation of Cx43 on Ser255 and possibly Ser262 (Kanemitsu et al., 1998). 
Cx43 is also a substrate for PKC and PKA. Kinetic analyses of wild type and mutant (S364P 
and S365N) Cx43 peptides (containing amino acid residues 359-376) in vitro phosphorylated 
by PKA and PKC have suggested that phosphorylation of Ser364 may be required for 
subsequent phosphorylation by PKC (Shah et al., 2002). In vitro phosphorylation of Ser365, 
Ser368, Ser369, and Ser373 by PKA has been described using a His-tagged Cx43-CT 
(containing amino acid residues E227-I382)(Yogo et al., 2006). 
Other studies have shown in vitro phosphorylation of perch Cx35 by PKA and mouse Cx36 
by CaMKII using fusion proteins containing the carboxyl terminus or the intracellular loop 
(O'Brien et al., 2004; Ouyang et al., 2005; Alev et al., 2008). A polypeptide containing the 
polymorphic variants S319 and P319 of the carboxyl terminus of human Cx37 (amino acid 
residues 233-333) was in vitro phosphorylated by glycogen synthase kinase-3β (Morel et al., 
2010). In vitro kinase assays have also been used to demonstrate that phosphorylation of 
Cx32 by PKC prevents its proteolysis by calpains (Elvira et al., 1993). 
Analyses of two dimensional maps of mixes of tryptic phosphopeptides from a connexin 
immunoprecipitated after metabolic labeling and from a (poly)peptide after in vitro 
phosphorylation together with phosphopeptide sequencing have been used often to identify 
the phosphorylated sites of the immunoprecipitated connexin and changes in their 
phosphorylation state under different experimental conditions.  
4. Pharmacological modulation of phosphoprotein phosphatases 
Changes in the phosphorylation state of Cxs can be induced by activating or inhibiting a 
specific intracellular phosphoprotein phosphatase. This type of approach allows 
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Using this approach, it has been demonstrated that treatment of V79 fibroblasts with several 
phosphoprotein phosphatase inhibitors (i.e., calyculin A, cyclosporin A or FK506) does not 
change the immunoblot pattern of Cx43 (Husøy et al., 1993; Cruciani et al., 1999). However, 
the dephosphorylation of immunoprecipitated Cx43 from TPA-exposed V79 cells is more 
efficiently reduced by PP2A than by PP1, PP2B or PP2C inhibitors (Cruciani et al., 1999). In 
WB-F344 cells, a rat liver epithelial cell line, calyculin A prevents the dephosphorylation of 
Cx43 induced by 18β-glycyrrhetinic acid (Guan et al., 1996). However, in primary cultures of 
astrocytes, calyculin A had little effect on hypoxia-induced Cx43 dephosphorylation; in this 
cell type, inhibition of PP2B with cyclosporin A or FK506 reduced Cx43 dephosphorylation 
after hypoxia (Li and Nagy, 2000). Calyculin A significantly retarded the loss of channel 
activity seen in ventricular myocytes in ATP-deprived conditions; conversely, stimulation of 
endogenous PP1 activity by treatment with p-nitrophenyl phosphate or 2,3-butanedione 
monoxime (a dephosphorylating chemical agent) induced a reversible interruption of cell-
to-cell communication (Duthe et al., 2000; 2001). 
The effect of okadaic acid on Cx43 also varies depending on cell type. It inhibits 
dephosphorylation of Cx43 in untreated and EGF-treated T5lB rat liver epithelial cells and 
prevents the dephosphorylation of Cx43 induced by 18β-glycyrrhetinic acid in WB-F344 rat 
liver epithelial cells (Lau et al., 1992; Guan et al., 1996). Okadaic acid also significantly 
retards the loss of gap junction channel activity seen in ventricular myocytes in ATP-
deprived conditions (Duthe et al., 2000; 2001). In other cell types, it has little or no effect on 
the immunoblot pattern of Cx43 (Berthoud et al., 1992; Husøy et al., 1993; Cruciani et al., 
1999), and has little effect on hypoxia-induced Cx43 dephosphorylation in primary cultures 
of astrocytes (Li and Nagy, 2000). Altogether these results suggest the involvement of 
different protein phosphatases in the phosphorylation state of Cx43 in different cell types 
under various experimental conditions. 
5. Genetic activation or inhibition of a protein kinase or phosphatase 
In some studies, changes in the phosphorylation state of Cxs have been induced by genetic 
manipulation through chemical-induced mutagenesis of genomic DNA or transfection with 
mammalian expression vectors and/or infection with virus containing cDNAs coding for a 
protein of interest. These methods can be used to modify the kinase activity using cDNAs 
encoding active or dominant negative mutant forms of a specific kinase. Lampe et al. used 
the FT210 cell line which contains a temperature-sensitive mutant of p34cdc2/cyclin B kinase 
to demonstrate that the formation of the phosphoform of Cx43 present in mitotic cells was 
dependent on the activity of this kinase.  However, the two-dimensional tryptic 
phosphopeptide map of immunoprecipitated Cx43 from mitotic cells had many major and 
minor tryptic phosphopeptides that could not be attributed to direct p34cdc2/cyclin B kinase 
phosphorylation of the Cx43CT (Lampe et al., 1998). Doble et al. (2000) used transient 
tranfection and adenoviral infection of truncated or dominant-negative forms of PKCε to 
demonstrate that this kinase is required for Cx43 phosphorylation in cardiomyocytes (Doble 
et al., 2000). 
The mechanism by which v-Src affects Cx43 phosphorylation and function has been 
extensively explored. Several studies have shown that expression of v-Src in mammalian 
fibroblasts leads to phosphorylation of Cx43 in tyrosyl residues (Crow et al., 1990). Mutants 
of Cx43 and v-Src SH2 and SH3 domains have been used to demonstrate that the SH2 and 
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SH3 domains of v-Src interact with Cx43; the SH3 domain binds to a proline-rich motif and 
the SH2 domain binds to a phosphorylated tyrosyl residue in the carboxyl terminus of Cx43 
(Kanemitsu et al., 1997). Two specific phosphorylation sites for v-Src have been identified in 
Cx43, Tyr247 and Tyr265, by stably re-expressing wild type or mutant Cx43 with v-Src in 
Cx43 knockout cells (Lin et al., 2001). Moreover, using a triple serine-to-alanine mutant at 
the MAPK sites (S255/279/282A) it has been shown that phosphorylation of Cx43 by MAPK 
is not required for v-Src-induced disruption of gap junctional intercellular communication 
(Lin et al., 2006). 
Several studies have been carried out on cardiac cells. Phosphorylation of Cx43 in Ser262 
regulates DNA synthesis in cardiomyocytes forming cell-cell contact (Doble et al., 2004). 
Expression of an activated mutant of mitogen-activated protein kinase kinase 7 (a JNK-
specific upstream activator) in cultured cardiomyocytes and in the heart in vivo demonstrated 
that Cx43 expression is regulated by JNK, although this effect may not be mediated by direct 
phosphorylation of Cx43 (Petrich et al., 2002). Transgenic mice with cardiac-specific 
overexpression of a constitutively active form of calcineurin (a calcium-dependent 
serine/threonine phosphatase) showed differences in the distribution of Cx43 in the 
ventricles, and Cx43 was mainly present in the nonphosphorylated form (Chu et al., 2002). 
Overexpression of p21-activated kinase 1 (PAK1, an activator of PP2A) increased PP2A 
activity and induced dephosphorylation of Cx43 in rabbit myocytes and Cx43-overexpressing 
HEK293 cells (Ai et al., 2011).  
6. Genetic modification of a phosphosite-specific mutant connexin 
A more recent approach is the generation of connexin knock-in mice in which the coding 
region of the wild type protein is replaced by DNA encoding a phosphosite-specific mutant. 
The only available report to date using this approach showed that mice in which Cx43 was 
replaced by a Cx43 mutant at the CK1 sites in which serines 325/328/330 were replaced 
with phosphomimetic glutamic acids (S3E) were resistant to gap junction remodeling and 
less susceptible to the induction of arrhythmias. In contrast, mice in which a Cx43 mutant 
with serines 325/328/330 mutated to non-phosphorylatable alanines (S3A) was knocked-in 
in place of Cx43 had severe alterations in gap junction formation and function, and had a 
proarrhythmic phenotype (Remo et al., 2011). This report shows a mechanistic link between 
the phosphorylation state of Cx43 and arrhythmic susceptibility (Remo et al., 2011). 
7. Phosphospecific antibodies 
Antibodies that recognize a specific phosphorylated (or dephosphorylated) site in a 
connexin have been developed. These have been extensively used to identify the state of 
phosphorylation of the phosphosite they recognize and to determine associated changes in 
connexin distribution in cells under different physiological and pathological conditions. 
Using this approach, it has been described that ischemic preconditioning prevents the 
changes in the phosphorylation state of Cx43 observed in a model of ischemia/reperfusion 
in pig hearts (Schulz et al., 2003). It has also been reported that PKC phosphorylates Cx43 in 
Ser368 (Solan et al., 2003), and that scratch wounding of primary human keratinocytes 
causes a PKC-dependent increase in phosphorylation at this site in cells adjacent to the 
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PSer282 of Cx43 to demonstrate that different phosphorylated forms of Cx43 coexist at the 
plasma membrane (Leykauf et al., 2003). Two antibodies recognizing the same phosphosites 
were used to show that EGF and activation of its receptor with quinones induce 
phosphorylation of Cx43 in these serine residues (Abdelmohsen et al., 2003; Leykauf et al., 
2003). Using an antibody that specifically recognizes Cx43 phosphorylated at serines 325, 
328 and/or 330 (PS325/328/330), Lampe and colleagues showed that while Cx43 relocalizes 
to the lateral edges in ischemic hearts, Cx43 phosphorylated at these residues remained 
mostly at the intercalated disk (Lampe et al., 2006). An antibody that recognizes 
dephosphorylated Ser364/Ser365 and binds preferentially to Golgi-localized Cx43 in 
cultured cells has been used to demonstrate conformational changes in Cx43 (Sosinsky et al., 
2007). Other studies have described that phosphorylation of connexin 43 at Ser262 is 
associated with a cardiac injury-resistant state (Srisakuldee et al., 2009). 
Phosphospecific antibodies have been used in combination with PKC or MEK inhibitors to 
determine the protein kinase pathway involved in the effects observed. Sirnes et al. reported 
that TPA induces phosphorylation of Ser255 and Ser262 of Cx43 in a MAPK-dependent 
manner (Sirnes et al., 2009). A MAPK-dependent phosphorylation of serines 255, 262 and 
279/282 of Cx43 has also been demonstrated using phosphospecific antibodies and a MEK 
inhibitor in follicles exposed to luteinizing hormone (Norris et al., 2008). In MC3T3-E1 
osteoblasts, treatment with fibroblast growth factor 2 induces a PKCδ-dependent increase in 
phosphorylation at Ser368 of Cx43 (Niger et al., 2010). Solan and Lampe used several anti-
Cx43 phosphospecific antibodies that recognize Src, MAPK or PKC sites and LA-25 cells 
(which express a temperature-sensitive v-Src) grown at the permissive and non-permissive 
temperatures to show that distinct tyrosine and serine residues are phosphorylated in 
response to v-Src activity (Solan and Lampe, 2008). Li et al. used antibodies that specifically 
recognize PSer110 and PSer276 in Cx35 to demonstrate that the level of phosphorylation of 
these serines depends on PKA activity and regulates photoreceptor coupling in zebrafish 
retina (Li et al., 2009). 
8. Mass spectrometry analyses 
Another technique that has been used to identify putative phosphorylation sites is mass 
spectrometry (MS) analysis of connexins isolated from tissue or cultured cells or in vitro 
phosphorylated (poly)peptides. For this purpose, the immunoprecipitated/isolated 
connexin or in vitro phosphorylated polypeptide is digested with a protease or a mix of 
proteases, the sample is enriched in phosphopeptides and subjected to MS. This technique is 
highly sensitive and it does not require the use of radioactivity. 
The first studies using this technique to identify phosphorylation sites in Cxs were reported 
several years ago (Cooper et al., 2000; Yin et al., 2000). Cooper et al. showed that in vitro 
phosphorylation of the carboxyl terminus of Cx43 with p34cdc2/cyclin B kinase resulted in 
phosphorylation of Ser255 using liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) (Cooper et al., 2000). Yin et al. demonstrated that lens Cx45.6 is 
phosphorylated in the chicken lens in vivo at Ser363 using nanoelectrospray and tandem 
mass spectrometry (Yin et al., 2000). 
Several studies using mass spectrometry analysis have been performed on Cx43. Ser364 was 
identified as a phosphorylation site in Cx43 using matrix-assisted laser 
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desorption/ionization-time of flight (MALDI-TOF MS) and LC-MS/MS (TenBroek et al., 
2001). MALDI-TOF MS in combination with metabolic labeling of normal rat kidney (NRK) 
epithelial cells (in the presence and absence of a casein kinase 1 inhibitor) and in vitro 
phosphorylation of Cx43CT fusion proteins with casein kinase 1δ (CK1δ) have been used to 
determine that serines 325, 328 or 330 are potential sites of CK1 phosphorylation in these 
cells (Cooper and Lampe, 2002). Cameron et al. (2003) used MALDI-TOF MS to identify 
Ser255 of Cx43 as the preferred site for big MAPK 1 (BMK1)/ERK5 phosphorylation.  This 
finding was further supported by the lack of phosphorylation of GST fusion proteins 
containing mutant carboxyl termini of Cx43 in which Ser255 had been mutated to alanine 
(S255A and S255A/S279A/ S282A). Axelsen et al. (2006) reported the time course of changes 
in phosphorylation of Cx43 immunopurified from perfused rat hearts under non-ischemic 
and ischemic conditions. These authors identified thirteen phosphorylation sites using 
MALDI MS and LC-MS/MS in non-ischemic conditions and detected site-specific changes  
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in Cx43 phosphorylation during the course of ischemia. Phosphorylation of Ser365 has also 
been demonstrated in Cx43 immunoprecipitated from NRK cells using liquid 
chromatography coupled to electrospray ionization tandem mass spectrometry (LC/ESI 
MS/MS) (Solan et al., 2007). Fifteen putative phosphorylation sites on Cx43 have also been 
identified after in vitro phosphorylation of a GST fusion protein containing the Cx43CT with 
CaMK II by high-resolution mass spectrometry (Huang et al., 2011). 
Post-translational modification by phosphate has also been identified by mass spectrometry 
in Cx26 and Cx32; Cx26 is phosphorylated in the intracellular loop and the second 
extracellular loop, and Cx32 is phosphorylated in the amino and carboxyl termini (Locke et 
al., 2006). Two studies have used mass spectrometry to identify phosphorylation sites in the 
bovine lens fiber connexins, Cx44 and Cx49. While phosphorylation sites were identified 
only on the carboxyl terminus of Cx44, phosphosites were identified in both the intracellular 
loop and carboxyl terminus of Cx49 (Shearer et al., 2008; Wang and Schey, 2009). 
9. Luminescence resonance energy transfer 
Another recent approach used to evaluate the functional effect(s) of phosphorylation of Cxs 
is the generation of hemichannels of known composition, stoichiometry that can be assessed 
by luminescence resonance energy transfer (LRET)(Bao et al., 2007). This method uses 
terbium ions (Tb3+), which have a long lifetime emission as donor and fluorescein as acceptor. 
The technique is based on the detection of LRET between Cx43 subunits labeled with Tb3+ 
and those labeled with fluorescein. The composition of the HCs can be determined based on 
the number of acceptor-labeled monomers per HC. Using HC of known composition, Bao 
and colleagues have determined that in a Cx43 HC all six subunits have to be 
phosphorylated by PKC at Ser368 to abolish sucrose permeability, although the HC pore 
still has a sizable diameter and allows permeation of smaller molecules (Bao et al., 2007). 
10. Conclusions and future directions 
In summary, connexins are substrates for various protein kinases and phosphoprotein 
phosphatases. Several of the phosphorylation sites have been identified, and the effect of 
phosphorylation at many of these sites on connexin channel activity has been studied. In some 
cases, pathophysiological conditions that alter their phosphorylation state have been reported. 
Although significant progress has been made in the area of connexin phosphorylation, there 
are many associated aspects that require further investigation. 
A question that remains unanswered is whether all connexins are phosphoproteins. Does 
phosphorylation affect connexin channel function in all members? Does phosphorylation at a 
specific site induce consistent functional changes in gap junction channels and hemichannels? 
Or, can phosphorylation at a specific site induce changes in one channel type, and not in the 
other?. Because phosphorylation has been implicated in several steps of the connexin’s life 
cycle, it is also important to determine which phosphorylation events are associated with 
proper trafficking to the plasma membrane, formation of gap junctional plaques or 
internalization and degradation. Are connexins sorted/targeted to different compartments 
depending on their cohort of phosphorylated sites? Where do these phosphorylation events 
take place? Since some hierarchy in the phosphorylation events has been shown for Cx43, it is 
interesting to know whether changes in phosphorylation are also associated with other post-
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translational modifications. Do these have a hierarchical sequence? Because connexins and 
changes in the activity of protein kinases/phosphoprotein phosphatases have been associated 
with disease, it would be important to know how the phosphorylation state of connexins is 
affected in disease. What are the intracellular signals and mechanisms of regulation of 
phosphorylation/dephosphorylation of connexins? What are the endogenous activators of 
the protein kinases/phosphoprotein phosphatases involved? Although the answers to some 
of these questions are known for some of the phosphorylation sites identified, especially in 
the case of Cx43, these questions have not been addressed for most connexins. 
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1. Introduction 
Mitosis is the final stage of the cell cycle that results in the formation of two independent 
daughter cells with an equal and identical complement of chromosomes (Figure 1). This 
requires a complex series of events such as nuclear envelope breakdown, spindle formation, 
equal chromosome segregation, packaging of chromosomes into daughter nuclei and 
constriction of the plasma membrane at the cell equator, which is subsequently abscised to 
generate two independent daughter cells. For mitosis to be successful, these events need to 
occur in a strict order and be spatiotemporally controlled, which is primarily mediated by 
protein phosphorylation (Dephoure et al., 2008). In human cells more than one thousand 
proteins show increased phosphorylation during mitosis (Dephoure et al., 2008). These 
phosphorylation events are mediated by mitotic protein kinases such as cyclin-dependent 
kinases (Cdks), Auroras, Polo-like kinases (Plks), Mps1, Neks and NimA (Ma and Poon, 
2011). In mammalian cells, the majority of phosphorylation events and thus mitotic 
progression is driven by the activity of Cdk1, which is the main subtype of Cdks (Dephoure 
et al., 2008). Its activity during mitosis is due to binding cyclin B1 and phosphorylation of a 
residue in the T-loop. 
Mitotic exit involves two stages: (1) membrane ingression, which begins during anaphase 
following chromosome segregation and involves the breakdown of mitotic structures 
including the mitotic spindle. It also involves the physical constriction of the cell membrane 
between segregating chromosomes at the cell equator to generate a thin intracellular bridge 
between nascent daughter cells. This is followed by (2) membrane abscission at a specific 
location along the intracellular bridge to generate two independent daughter cells (Figure 1). 
During mitotic exit, cells also decondense their chromosomes and re-assemble interphase 
structures such as the nuclear envelope and endoplasmic reticulum. Again, these events 
need to occur in a strict ordered sequence and requires the reversal of Cdk1-mediated 
phosphorylation events. Cdk1 is inactivated upon anaphase and is largely dependent on 
proteasomal-mediated degradation of cyclin B1 by the anaphase promoting 
complex/cyclosome (APCCdc20) (Peters, 2006). However, downregulation of Cdk is not 
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1. Introduction 
Mitosis is the final stage of the cell cycle that results in the formation of two independent 
daughter cells with an equal and identical complement of chromosomes (Figure 1). This 
requires a complex series of events such as nuclear envelope breakdown, spindle formation, 
equal chromosome segregation, packaging of chromosomes into daughter nuclei and 
constriction of the plasma membrane at the cell equator, which is subsequently abscised to 
generate two independent daughter cells. For mitosis to be successful, these events need to 
occur in a strict order and be spatiotemporally controlled, which is primarily mediated by 
protein phosphorylation (Dephoure et al., 2008). In human cells more than one thousand 
proteins show increased phosphorylation during mitosis (Dephoure et al., 2008). These 
phosphorylation events are mediated by mitotic protein kinases such as cyclin-dependent 
kinases (Cdks), Auroras, Polo-like kinases (Plks), Mps1, Neks and NimA (Ma and Poon, 
2011). In mammalian cells, the majority of phosphorylation events and thus mitotic 
progression is driven by the activity of Cdk1, which is the main subtype of Cdks (Dephoure 
et al., 2008). Its activity during mitosis is due to binding cyclin B1 and phosphorylation of a 
residue in the T-loop. 
Mitotic exit involves two stages: (1) membrane ingression, which begins during anaphase 
following chromosome segregation and involves the breakdown of mitotic structures 
including the mitotic spindle. It also involves the physical constriction of the cell membrane 
between segregating chromosomes at the cell equator to generate a thin intracellular bridge 
between nascent daughter cells. This is followed by (2) membrane abscission at a specific 
location along the intracellular bridge to generate two independent daughter cells (Figure 1). 
During mitotic exit, cells also decondense their chromosomes and re-assemble interphase 
structures such as the nuclear envelope and endoplasmic reticulum. Again, these events 
need to occur in a strict ordered sequence and requires the reversal of Cdk1-mediated 
phosphorylation events. Cdk1 is inactivated upon anaphase and is largely dependent on 
proteasomal-mediated degradation of cyclin B1 by the anaphase promoting 
complex/cyclosome (APCCdc20) (Peters, 2006). However, downregulation of Cdk is not 
sufficient for mitotic exit in human cells. Thus, mitotic phosphatases are also thought to 
contribute to both the inactivation of Cdk1 at the onset of anaphase and to the mitotic exit 
process in higher eukaryotes. Consistent with this idea, in the early stages of mitotic exit, 
Cdk1 is transiently inhibited by phosphorylation prior to the degradation of cyclin B1 
(D'Angiolella et al., 2007). It is possible that the transient phosphorylation of Cdk1 is also 
due to inhibition of the Cdc25C phosphatase by the PP2A phosphatase, which is the same 
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phosphatase that keeps Cdc25C inactive during interphase (Forester et al., 2007). However, 
recent evidence indicates that the Cdc14B phosphatase dephosphorylates Cdc25C resulting 
in its inhibition and consequent phosphorylation of Cdk1 (Tumurbaatar et al., 2011). 
Moreover, Cdk substrates are dephosphorylated in an ordered sequence from anaphase to 
cytokinesis (Bouchoux and Uhlmann, 2011). Thus, mitotic exit further depends on the 
activation of protein phosphatase(s). Indeed, mitotic exit is blocked in cells lacking Cdk1 
activity when protein phosphatase activity is suppressed (Skoufias et al., 2007).  
 
Fig. 1. Schematic illustration of the stages of mitosis. The relative abundance of 
phosphorylation events is shown above each mitotic stage and the major cellular events 
occurring at each stage are shown below. These events are known to be regulated by 
phosphorylation/dephosphorylation. Mitotic exit begins during anaphase and involves two 
sequential stages: (1) membrane ingression that generates a cleavage furrow followed by (2) 
membrane abscission of the intracellular bridge that connects the two nascent daughter 
cells. Chromosomes/nuclei shown in blue. Midbody shown in red. 
Although there is a large body of knowledge about the phosphoproteins and protein kinases 
involved in mitosis and how they are regulated, the specific dephosphorylation events and 
the involvement of specific phosphatases in mitosis has only recently become appreciated. 
Studies are now revealing how the timely execution of mitotic events depends on the 
delicate interplay between protein kinases and phosphatases. To date, most reviews have 
focused on the role of protein dephosphorylation at the mitotic spindle and specifically how 
it regulates chromosome alignment (metaphase) and segregation (anaphase) (Bollen et al., 
2009, De et al., 2009). This chapter will focus on providing an updated overview of the 
protein dephosphorylation events that occur during the later stages of mitosis (anaphase – 
cytokinesis) that contribute to driving mitotic exit and the generation of two independent 
daughter cells. More specifically, this chapter will provide insights into the protein 
phosphatases responsible for these dephosphorylation events and how they are regulated in 
mammalian cells. 
2. Mitotic phosphatases in mammalian cells 
In Saccharomyces cerevisiae (Shou et al., 1999, Visintin et al., 1999) and Schizosaccharomyces 
pombe (Cueille et al., 2001, Trautmann et al., 2001), mitotic exit and co-ordination of the final 
stage of mitosis, cytokinesis, are driven by the dual serine-threonine and tyrosine-protein 
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phosphatase, Cdc14. Thus the action of Cdc14 is, in part, to counteract Cdk activity by 
dephosphorylating Cdk substrates (Visintin et al., 1998). Cdc14 is tightly regulated both 
spatially and temporally (Stegmeier and Amon, 2004, Queralt and Uhlmann, 2008) as well as 
being a part of several feedback loops that contribute to a rapid metaphase-anaphase 
transition (Holt et al., 2008). We have gained a detailed molecular picture of the way that the 
Cdc14 phosphatase orchestrates mitotic exit in yeast (reviewed in (Stegmeier and Amon, 
2004, Queralt and Uhlmann, 2008)). However, much less is known about the protein 
dephosphorylation events and the responsible phosphatases that reverse Cdk 
phosphorylation and thus drive mitotic exit in eukaryotes. Homologues of Cdc14 exist in 
most if not all eukaryotes, but they do not seem to have the same central function in late 
mitosis as in budding yeast (Trautmann and McCollum, 2002). In Caenorhabditis elegans, 
depletion of CeCDC-14 by RNAi causes defects in cytokinesis; however, this is most likely 
due to failure to form an intact central spindle (Gruneberg et al., 2002). The human genome 
encodes two Cdcl4 homologues, Cdc14A and Cdc14B and both can rescue Cdc14 yeast 
phenotypes (Queralt and Uhlmann, 2008), suggesting functional conservation. However, 
neither Cdc14A nor Cdc14B are required for mitotic exit in higher eukaryotes (Berdougo et 
al., 2008) although they do seem to be required to generally dephosphorylate Cdk targets 
(Mocciaro and Schiebel, 2010). This indicates that they have overlapping functions or that 
additional mitotic exit phosphatases are required. Instead, recent reports suggest that 
Cdc14s might act by reversing the activating phosphorylations on Cdc25 phosphatases, 
thereby indirectly contributing to the regulation of Cdk activity in human cells (Krasinska et 
al., 2007, Vazquez-Novelle et al., 2010, Tumurbaatar et al., 2011). A survey of phosphatase 
contribution to cell cycle progression in Drosophila failed to identify a specific candidate for 
a mitotic exit phosphatase (Chen et al., 2007), suggesting that more than one phosphatase 
may act redundantly, or that its involvement in mitotic exit is not the only function of the 
phosphatase. Recent efforts into identifying phosphatases other than Cdc14 that drive 
mitotic exit have revealed the serine-threonine calcium- and calmodulin-activated 
phosphatase, calcineurin (CaN or PP2B) (Chircop et al., 2010a), the protein tyrosine 
phosphatase containing domain 1 (Ptpcd-1) (Zineldeen et al., 2009), PP1 (Wu et al., 2009), 
PP2A (Mochida et al., 2009, Schmitz et al., 2010) and oculocerebrorenal syndrome of Lowe 1 
(OCRL1) (Ben El et al., 2011) as being required for mitotic exit in mammalian cells (Table 1). 
2.1 Cdc14A and Cdc14B 
Although the roles of human Cdc14A and Cdc14B are poorly understood, Cdc14A has been 
linked to centrosome separation and cytokinesis (Kaiser et al., 2002, Yuan et al., 2007), while 
Cdc14B participates in centrosome duplication and microtubule stabilization (Cho et al., 
2005).  
2.1.1 Cdc14A 
The role of Cdc14A in cytokinesis has been linked to the membrane abscission stage. 
Ectopically expressed Xenopus Cdc14A localizes to the midbody of cytokinetic cells. Xenopus 
oocytes overexpressing wild-type or phosphatase-dead Cdc14A arrests cells in late stage 
cytokinesis, whereby the nascent daughter cells are connected by a thin intracellular bridge. 
Neither central spindle formation, nor the re-localization of passenger proteins and 
centralspindlin complexes to the midbody are affected. Instead targeting of the essential 
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phosphatase that keeps Cdc25C inactive during interphase (Forester et al., 2007). However, 
recent evidence indicates that the Cdc14B phosphatase dephosphorylates Cdc25C resulting 
in its inhibition and consequent phosphorylation of Cdk1 (Tumurbaatar et al., 2011). 
Moreover, Cdk substrates are dephosphorylated in an ordered sequence from anaphase to 
cytokinesis (Bouchoux and Uhlmann, 2011). Thus, mitotic exit further depends on the 
activation of protein phosphatase(s). Indeed, mitotic exit is blocked in cells lacking Cdk1 
activity when protein phosphatase activity is suppressed (Skoufias et al., 2007).  
 
Fig. 1. Schematic illustration of the stages of mitosis. The relative abundance of 
phosphorylation events is shown above each mitotic stage and the major cellular events 
occurring at each stage are shown below. These events are known to be regulated by 
phosphorylation/dephosphorylation. Mitotic exit begins during anaphase and involves two 
sequential stages: (1) membrane ingression that generates a cleavage furrow followed by (2) 
membrane abscission of the intracellular bridge that connects the two nascent daughter 
cells. Chromosomes/nuclei shown in blue. Midbody shown in red. 
Although there is a large body of knowledge about the phosphoproteins and protein kinases 
involved in mitosis and how they are regulated, the specific dephosphorylation events and 
the involvement of specific phosphatases in mitosis has only recently become appreciated. 
Studies are now revealing how the timely execution of mitotic events depends on the 
delicate interplay between protein kinases and phosphatases. To date, most reviews have 
focused on the role of protein dephosphorylation at the mitotic spindle and specifically how 
it regulates chromosome alignment (metaphase) and segregation (anaphase) (Bollen et al., 
2009, De et al., 2009). This chapter will focus on providing an updated overview of the 
protein dephosphorylation events that occur during the later stages of mitosis (anaphase – 
cytokinesis) that contribute to driving mitotic exit and the generation of two independent 
daughter cells. More specifically, this chapter will provide insights into the protein 
phosphatases responsible for these dephosphorylation events and how they are regulated in 
mammalian cells. 
2. Mitotic phosphatases in mammalian cells 
In Saccharomyces cerevisiae (Shou et al., 1999, Visintin et al., 1999) and Schizosaccharomyces 
pombe (Cueille et al., 2001, Trautmann et al., 2001), mitotic exit and co-ordination of the final 
stage of mitosis, cytokinesis, are driven by the dual serine-threonine and tyrosine-protein 
 
Protein Phosphatases Drive Mitotic Exit 217 
phosphatase, Cdc14. Thus the action of Cdc14 is, in part, to counteract Cdk activity by 
dephosphorylating Cdk substrates (Visintin et al., 1998). Cdc14 is tightly regulated both 
spatially and temporally (Stegmeier and Amon, 2004, Queralt and Uhlmann, 2008) as well as 
being a part of several feedback loops that contribute to a rapid metaphase-anaphase 
transition (Holt et al., 2008). We have gained a detailed molecular picture of the way that the 
Cdc14 phosphatase orchestrates mitotic exit in yeast (reviewed in (Stegmeier and Amon, 
2004, Queralt and Uhlmann, 2008)). However, much less is known about the protein 
dephosphorylation events and the responsible phosphatases that reverse Cdk 
phosphorylation and thus drive mitotic exit in eukaryotes. Homologues of Cdc14 exist in 
most if not all eukaryotes, but they do not seem to have the same central function in late 
mitosis as in budding yeast (Trautmann and McCollum, 2002). In Caenorhabditis elegans, 
depletion of CeCDC-14 by RNAi causes defects in cytokinesis; however, this is most likely 
due to failure to form an intact central spindle (Gruneberg et al., 2002). The human genome 
encodes two Cdcl4 homologues, Cdc14A and Cdc14B and both can rescue Cdc14 yeast 
phenotypes (Queralt and Uhlmann, 2008), suggesting functional conservation. However, 
neither Cdc14A nor Cdc14B are required for mitotic exit in higher eukaryotes (Berdougo et 
al., 2008) although they do seem to be required to generally dephosphorylate Cdk targets 
(Mocciaro and Schiebel, 2010). This indicates that they have overlapping functions or that 
additional mitotic exit phosphatases are required. Instead, recent reports suggest that 
Cdc14s might act by reversing the activating phosphorylations on Cdc25 phosphatases, 
thereby indirectly contributing to the regulation of Cdk activity in human cells (Krasinska et 
al., 2007, Vazquez-Novelle et al., 2010, Tumurbaatar et al., 2011). A survey of phosphatase 
contribution to cell cycle progression in Drosophila failed to identify a specific candidate for 
a mitotic exit phosphatase (Chen et al., 2007), suggesting that more than one phosphatase 
may act redundantly, or that its involvement in mitotic exit is not the only function of the 
phosphatase. Recent efforts into identifying phosphatases other than Cdc14 that drive 
mitotic exit have revealed the serine-threonine calcium- and calmodulin-activated 
phosphatase, calcineurin (CaN or PP2B) (Chircop et al., 2010a), the protein tyrosine 
phosphatase containing domain 1 (Ptpcd-1) (Zineldeen et al., 2009), PP1 (Wu et al., 2009), 
PP2A (Mochida et al., 2009, Schmitz et al., 2010) and oculocerebrorenal syndrome of Lowe 1 
(OCRL1) (Ben El et al., 2011) as being required for mitotic exit in mammalian cells (Table 1). 
2.1 Cdc14A and Cdc14B 
Although the roles of human Cdc14A and Cdc14B are poorly understood, Cdc14A has been 
linked to centrosome separation and cytokinesis (Kaiser et al., 2002, Yuan et al., 2007), while 
Cdc14B participates in centrosome duplication and microtubule stabilization (Cho et al., 
2005).  
2.1.1 Cdc14A 
The role of Cdc14A in cytokinesis has been linked to the membrane abscission stage. 
Ectopically expressed Xenopus Cdc14A localizes to the midbody of cytokinetic cells. Xenopus 
oocytes overexpressing wild-type or phosphatase-dead Cdc14A arrests cells in late stage 
cytokinesis, whereby the nascent daughter cells are connected by a thin intracellular bridge. 
Neither central spindle formation, nor the re-localization of passenger proteins and 
centralspindlin complexes to the midbody are affected. Instead targeting of the essential 
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midbody abscission components, exocyst and SNARE complexes to the midbody, are 
disrupted in these cells (Krasinska et al., 2007), indicating that Cdc14 midbody localization 
and more specifically its phosphatase activity is required for abscission. 
 
Phosphatase Substrates Function(s) References 
Cdc14A    
 Unidentified Cdk 
substrates 
Centrosome separation, 
chromosome segregation and 
cytokinesis 
(Kaiser et al., 2002, 
Mailand et al., 2002, 
Yuan et al., 2007) 
 Cdc25 Inhibition of Cdk1 (Krasinska et al., 
2007) 
Cdc14B    
 N.D. Stabilisation and bundling of 
MTs 
(Cho et al., 2005) 
 SIRT2 Downregulation of SIRT2 
deacetylase activity by 
promoting its degradation 
(Dryden et al., 2003) 
Ptpcd-1    
 Unidentified Cdk 
substrates 
Cytokinesis (Zineldeen et al., 
2009) 
PP1    
 I2 Chromosome segregation (Wu et al., 2009) 
 Moesin Cell shape changes for 
anaphase elongation 
(Kunda et al., 2011) 
 AIB1 Relocate AIB1 to chromatin 
for transcription 
(Ferrero et al., 2011) 
 PNUTS Chromosome decondensation (Landsverk et al., 
2005) 
 B-type lamins Targeting ER to chromatin 
and nuclear envelop 
reformation 
(Steen et al., 2000, Ito 
et al., 2007) 
 Histone H3 Chromsomal reorganisation 
and nuclear envelope 
reformation 
(Vagnarelli et al., 
2011) 
PP2A    
 Unidentified Cdk 
substrates 
Mitotic exit (Schmitz et al., 2010, 
Burgess et al., 2010) 
CaN (PP2B)    
 Dynamin II Membrane abscission (Chircop et al., 2010a, 
Chircop et al., 2010b) 
OCRL    
 PI(4,5)P2 Cleavage furrow formation 
and membrane ingression 
(Ben El et al., 2011) 
Table 1. The substrates and function of mitotic phosphatases required for mitotic exit in 
mammalian cells. N.D. not determined. 
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Biochemical studies in human HeLa cells suggests that Plk1 regulates the phosphatase 
activity of Cdc14A during mitosis (Yuan et al., 2007). Plk1 interacts with and phosphorylates 
Cdc14A resulting in release of Cdc14 auto-inhibited phosphatase activity in vitro. This is 
likely to occur during anaphase. Indeed, overexpression of a phospho-mimetic mutant of 
Cdc14A in HeLa cells results in aberrant chromosome alignment with delay in 
prometaphase (Yuan et al., 2007). This suggests that Cdc14A activity is associated with 
metaphase-anaphase progression and chromosome segregation. 
2.1.2 Cdc14B 
Although Cdc14B is not required for mitotic exit in mammalian cells, it does appear to play 
a role in mitosis during the latter stages. The SIRT2 protein is a NAD-dependent deacetylase 
(NDAC) that is a member of the SIR2 gene family with roles in chromatin structure, 
transcriptional silencing, DNA repair, and control of cellular life span. SIRT2 abundance and 
phosphorylation status increase upon mitotic entry. During late stages of mitosis, Cdc14B, 
but not Cdc14A, mediates SIRT2 dephosphorylation, which in turn targets it for degradation 
by the 26S proteasome (Dryden et al., 2003). Cells stably overexpressing wildtype SIRT2 but 
not missense mutants lacking NDAC activity have a prolonged mitotic phase (Dryden et al., 
2003). Thus, Cdc14B may contribute to chromatin changes during mitotic exit such as 
chromosome decondensation by targeting SIRT2 for destruction. 
2.2 Ptpcd-1 
Of all the phosphatases implicated in mammalian cell mitotic exit to date, the dual-
specificity phosphatase, Ptpcd-1, is structurally the most related to Cdc14 (Zineldeen et al., 
2009). It is suggested to be a functional isozyme of mammalian Cdc14A (Zineldeen et al., 
2009). Like Cdc14A, Ptpcd-1 associates with and co-localises with Plk1 at the midbody of 
cells in cytokinesis. Both overexpression of Ptpcd-1 and Plk1 cause cytokinesis failure and 
multinucleate cell formation. No Ptpcd-1 substrates have yet been identified, however like 
Cdc14B its function is most likely regulated by Plk1. Ptpcd-1 possesses four Plk1 consensus 
phosphorylation sites and its overexpression could not rescue cytokinesis failure induced by 
Plk1 depletion (Zineldeen et al., 2009), suggesting that it lies downstream of Plk1. In support 
of this idea, the yeast homolog of Plk1, Cdc5, regulates Cdc14 phosphorylation and its 
subcellular localization for mitotic exit (Visintin et al., 2003, Visintin et al., 2008). Based on 
their midbody co-localization, it is possible that this Plk1/Ptpcd-1 signalling pathway 
contributes to membrane abscission. 
2.3 PP1 and PP2A 
The phosphatase inhibitor, okadaic acid, can induce mitotic entry in interphase cells 
(Yamashita et al., 1990) and this mitotic state can be maintained if Cdk1 activity is inhibited 
(Skoufias et al., 2007). Okadaic acid inhibits the activity of the protein phosphatase (PP)1 
and PP2A. Consequently, both phosphatases have been implicated in reversing mitotic 
phosphorylation events in Xenopus egg extracts (Wu et al., 2009, Mochida et al., 2009). Not 
surprisingly, both phosphatases are inactivated during mitosis and their reactivation is 
important for mitotic exit (Wu et al., 2009, Mochida et al., 2009). However, both 
phosphatases have distinct substrates and are regulated via different mechanisms, which is 
in line with these enzymes being structurally diverse (Virshup and Shenolikar, 2009).  
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midbody abscission components, exocyst and SNARE complexes to the midbody, are 
disrupted in these cells (Krasinska et al., 2007), indicating that Cdc14 midbody localization 
and more specifically its phosphatase activity is required for abscission. 
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Biochemical studies in human HeLa cells suggests that Plk1 regulates the phosphatase 
activity of Cdc14A during mitosis (Yuan et al., 2007). Plk1 interacts with and phosphorylates 
Cdc14A resulting in release of Cdc14 auto-inhibited phosphatase activity in vitro. This is 
likely to occur during anaphase. Indeed, overexpression of a phospho-mimetic mutant of 
Cdc14A in HeLa cells results in aberrant chromosome alignment with delay in 
prometaphase (Yuan et al., 2007). This suggests that Cdc14A activity is associated with 
metaphase-anaphase progression and chromosome segregation. 
2.1.2 Cdc14B 
Although Cdc14B is not required for mitotic exit in mammalian cells, it does appear to play 
a role in mitosis during the latter stages. The SIRT2 protein is a NAD-dependent deacetylase 
(NDAC) that is a member of the SIR2 gene family with roles in chromatin structure, 
transcriptional silencing, DNA repair, and control of cellular life span. SIRT2 abundance and 
phosphorylation status increase upon mitotic entry. During late stages of mitosis, Cdc14B, 
but not Cdc14A, mediates SIRT2 dephosphorylation, which in turn targets it for degradation 
by the 26S proteasome (Dryden et al., 2003). Cells stably overexpressing wildtype SIRT2 but 
not missense mutants lacking NDAC activity have a prolonged mitotic phase (Dryden et al., 
2003). Thus, Cdc14B may contribute to chromatin changes during mitotic exit such as 
chromosome decondensation by targeting SIRT2 for destruction. 
2.2 Ptpcd-1 
Of all the phosphatases implicated in mammalian cell mitotic exit to date, the dual-
specificity phosphatase, Ptpcd-1, is structurally the most related to Cdc14 (Zineldeen et al., 
2009). It is suggested to be a functional isozyme of mammalian Cdc14A (Zineldeen et al., 
2009). Like Cdc14A, Ptpcd-1 associates with and co-localises with Plk1 at the midbody of 
cells in cytokinesis. Both overexpression of Ptpcd-1 and Plk1 cause cytokinesis failure and 
multinucleate cell formation. No Ptpcd-1 substrates have yet been identified, however like 
Cdc14B its function is most likely regulated by Plk1. Ptpcd-1 possesses four Plk1 consensus 
phosphorylation sites and its overexpression could not rescue cytokinesis failure induced by 
Plk1 depletion (Zineldeen et al., 2009), suggesting that it lies downstream of Plk1. In support 
of this idea, the yeast homolog of Plk1, Cdc5, regulates Cdc14 phosphorylation and its 
subcellular localization for mitotic exit (Visintin et al., 2003, Visintin et al., 2008). Based on 
their midbody co-localization, it is possible that this Plk1/Ptpcd-1 signalling pathway 
contributes to membrane abscission. 
2.3 PP1 and PP2A 
The phosphatase inhibitor, okadaic acid, can induce mitotic entry in interphase cells 
(Yamashita et al., 1990) and this mitotic state can be maintained if Cdk1 activity is inhibited 
(Skoufias et al., 2007). Okadaic acid inhibits the activity of the protein phosphatase (PP)1 
and PP2A. Consequently, both phosphatases have been implicated in reversing mitotic 
phosphorylation events in Xenopus egg extracts (Wu et al., 2009, Mochida et al., 2009). Not 
surprisingly, both phosphatases are inactivated during mitosis and their reactivation is 
important for mitotic exit (Wu et al., 2009, Mochida et al., 2009). However, both 
phosphatases have distinct substrates and are regulated via different mechanisms, which is 
in line with these enzymes being structurally diverse (Virshup and Shenolikar, 2009).  
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2.3.1 PP1 
PP1 is activated at the metaphase-anaphase transition by a mechanism involving both 
inactivation of Cdk1 and proteasome-dependent degradation of an unknown protein 
(Mochida and Hunt, 2007, Skoufias et al., 2007). During early stages of mitosis, PP1 activity 
is suppressed and this supression is maintained through dual inhibition by Cdk1 
phosphorylation and the binding of inhibitor-1 (I1) (Wu et al., 2009). Protein kinase A 
phosphorylates I1, mediating its binding to PP1. Partial PP1 activation is achieved during 
anaphase following a drop in Cdk1 levels due to cyclin B degradation. This shifts the 
Cdk1/PP1 ratio in favour of PP1 allowing auto-dephosphorylation of PP1 at its Cdk1-
mediated phosphorylation site. PP1 subsequently mediates the dephosphorylation of I2 at 
the I2 activating site, resulting in dissociation of the PP1-I2 inhibitor complex. This results in 
full activation of PP1 and initiation of mitotic exit. During anaphase, when the outer 
kinetochore is dis-assembled, I2 levels drop and this may also contribute to the up-
regulation of PP1 (Li et al., 2007, Wang et al., 2008). PP1 itself participates in outer 
kinetochore dis-assembly and chromosome segregation and this may be due to its ability 
to dephosphorylate Aurora B substrates (Emanuele et al., 2008). Thus, several feedback 
loops exist and involve protein kinases to initiate and maintain PP1 activity for mitotic 
exit. 
PP1 plays roles in several mitotic events that need to occur in a sequential order and include 
cell elongation, chromosome segregation, chromosome decondensation and nuclear 
envelope re-formation. At the onset of mitosis, the cell rounds up and forms a stiff, rounded 
metaphase cortex. Moesin, the sole Drosophila Ezrin-Radixin-Moesin (ERM)-family protein 
which functions to regulate actin dynamics and cytoskeleton organization (Fehon et al., 
2010), plays a critical role in this process and is dependent on the phospho-form of moesin 
(Kunda and Baum, 2009, Roch et al., 2010, Roubinet et al., 2011). Consequently, 
dephosphorylation of moesin at the cell poles is required to dismantle this rigid cortex to 
allow for anaphase elongation and cytokinesis. An RNAi screen for phosphatases involved 
in the temporal and spatial control of moesin identified PP1 as the responsible phosphatase 
(Kunda et al., 2011). Overexpression of phosphomimetic-moesin and PP1 depletion blocks 
proper anaphase elongation of the cell (Kunda et al., 2011). 
PP1 is involved in the first step of nuclear envelope re-formation by stimulating the 
targeting of endoplasmic reticulum to chromatin (Ito et al., 2007). The assembly of the 
nuclear lamina depends on the dephosphorylation of B-type lamins, which is catalyzed by a 
PP1/AKAP149 complex that is associated with the nuclear envelope (Steen et al., 2000). 
The role of PP1 in chromosome decondensation involves its association with Repo-Man and 
the PP1 nuclear targeting subunit (PNUTS). During anaphase, a Repo-Man/PP1 complex 
forms following Repo-Man dephosphorylation. Repo-Man targets the complex to 
chromosomes to allow PP1 to mediate the dephosphorylation of histone H3 (Vagnarelli et 
al., 2011). This contributes to the loss of chromosome architecture (Vagnarelli et al., 2006, 
Trinkle-Mulcahy and Lamond, 2006, Trinkle-Mulcahy et al., 2006). During telophase, PP1 
targets PNUTS to the reforming nuclei following the assembly of nuclear membranes 
concomitant with chromatin decondensation. Here, PNUTS enhances in vitro chromosome 
decondensation in a PP1-dependent manner (Landsverk et al., 2005). Thus, targeting of 
PNUTS to the reforming nuclei in telophase may be part of a signalling event promoting 
chromatin decondensation as cells re-enter interphase.  
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Finally, PP1 appears to play a role in the initiation of transcription upon entry into the next 
cell cycle, as it is responsible for reversing the inhibitory Cdk1-mediated phosphorylation 
events of the transcription factor, AIB1 (Ferrero et al., 2011). AIB1 phosphorylation does not 
appear to affect its transcriptional activity but instead excludes it from condensed chromatin 
during mitosis to prevent its access to the promoters of AIB1-dependent genes. Its 
dephosphorylation by PP1 would presumably allow AIB1 to relocate to decondensed 
chromatin upon entry into the next cell cycle to re-initiate gene transcription. 
2.3.2 PP2A 
PP2A forms a complex with B-type regulatory subunits and these subunits contribute to 
PP2A localisation and substrate specificity. As such, PP2A-B55α and PP2A-B55δ were 
considered strong mitotic exit phosphatase candidates since these B55 regulatory subunits 
are substrate specifiers for Cdk substrates (Janssens et al., 2008). Indeed, both have been 
shown to be regulators of mitotic exit in human cells (Mochida et al., 2009, Schmitz et al., 
2010). In Xenopus egg extracts, PP2A-B55δ is negatively regulated by the kinase greatwall 
(MASTL in humans) during early mitotic stages to allow the accumulation of mitotically 
phosphorylated proteins. This is achieved by greatwall-mediated phosphorylation of the 
small protein ARPP-19, which converts it into a potent PP2A inhibitor (Burgess et al., 2010). 
PP2A activation induced by MASTL knockdown leads to premature mitotic exit in human 
cells (Burgess et al., 2010). How PP2A is reactivated once Cdk1 activity decreases to drive 
mitotic exit remains unclear. Presumably greatwall needs to be inactivated and this is likely 
to involve an as yet unidentified phosphatase. Alternatively or in addition to this, PP2A 
may be activated via auto-phosphorylation in a similar manner to PP1 (Wu et al., 2009). 
Moreover, the identification of PP2A substrates and the role of PP2A for mitotic exit remain 
key questions for future investigation. 
2.4 CaN (PP2B) 
Endocytosis is thought to shut down during mitosis then resume during the final stage, 
cytokinesis (Schweitzer et al., 2005). Endocytosis is required for cytokinesis (Feng et al., 
2002) and thought to contribute to the pool of recycling endosomes that are eventually 
delivered to the site of abscission. Here, they are proposed to (i) provide extra total cell 
surface area, an increase of at least 25% is required to complete division (Boucrot and 
Kirchhausen, 2007), (ii) deliver critical cytokinetic proteins to the abscission site (Low et al., 
2003), and/or (iii) be directly involved in compound fusion, whereby numerous vesicles 
fuse with the plasma membrane during abscission to separate the daughter cells (Low et al., 
2003, Gromley et al., 2005, Goss and Toomre, 2008, Prekeris and Gould, 2008). 
The calcium- and calmodulin-dependent phosphatase, calcineurin (CaN) is an excellent 
candidate phosphatase for restarting endocytosis during cytokinesis, since it initiates 
endocytosis in neurons (Liu et al., 1994). In support of this idea, the fission yeast CaN gene is 
required for cytokinesis and the CaN inhibitors cyclosporin A (CsA) and FK506 block yeast 
cytokinesis (Yoshida et al., 1994). CaN is required for calcium-induced mitotic exit in 
cytostatic factor-arrested Xenopus oocytes (Mochida and Hunt, 2007, Nishiyama et al., 2007). 
CaN is upregulated in Xenopus oocytes from metaphase of meiosis II. An increase in 
cytoplasmic calcium upon fertilisation triggers meiosis II exit in these oocytes, which 
involves calmodulin-activating kinase-dependent activation of the APC. APC-mediated 
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inactivation of Cdk is not sufficient to drive Cdk substrate dephosphorylation and meiotic 
exit in these oocytes and thus activation of CaN is likely to occur in parrallel to drive this 
process. A recent report has indicated that CaN is also required for completion of abscission 
in human cells (Chircop et al., 2010a). During cytokinesis CaN locates to two 1.1 m 
diameter flanking midbody rings (FMRs) that reside on either side of the 1.6 m diameter γ-
tubulin midbody ring (MR) within the centre of the intracellular bridge. The endocytic 
protein, dynamin II (dynII), is mitotically phosphorylated by Cdk1/cyclin B1 upon mitotic 
entry and co-localises with CaN at the FMRs during cytokinesis (Chircop et al., 2010a, 
Chircop et al., 2010b). CaN inhibition by CsA, dynII depletion, phospho-mimetic dynII 
phosphopeptides and small molecule dynamin inhibitors lead to aborted cytokinesis and 
multinucleation (Joshi et al., 2010, Chircop et al., 2010a, Chircop et al., 2010b, Chircop et al., 
2011). At the FMRs, a calcium influx activates CaN resulting in dephosphorylation of dynII. 
This is one of the last molecular events known to occur prior to abscission. Thus, it is 
possible that CaN-mediated dynII dephosphorylation may be the trigger for cellular 
abscission to complete cytokinesis. 
In the brain, for clathrin-mediated endocytosis (CME) and activity-dependent bulk 
endocytosis (ADBE), CaN not only targets dynI but also -adaptin, epsin and eps15 (Cousin 
and Robinson, 2001). Like dynII, epsin and -adaptin are mitotically phosphorylated (Chen 
et al., 1999, Kariya et al., 2000, Dephoure et al., 2008). Thus, they represent additional 
potential CaN substrates during cytokinesis. Once dephosphorylated they may contribute to 
the recruitment of the dephosphorylated form of dynII to the abscission site or directly in 
CME within the intracellular bridge. 
2.5 Oculocerebrorenal syndrome of Lowe 1 (OCRL), an inositol 5-phosphatase 
Generation of the cleavage furrow during the membrane ingression stage of cytokinesis 
involves an actin-myosin II contractile ring. At the cleavage furrow, the phosphoinositide 
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) plays an important role in this process by 
recruiting and regulating essential proteins of the cytokinesis machinery (Janetopoulos and 
Devreotes, 2006). PI(4,5)P2 mis-regulation blocks cleavage furrow formation leading to 
generation of a multinucleated cell (Emoto et al., 2005, Field et al., 2005, Wong et al., 2005). 
In Drosophila, the localization of PI(4,5)P2 is restricted at the cleavage furrow by the 
Drosophila ortholog of human oculocerebrorenal syndrome of Lowe 1 (OCRL1) (Ben El et 
al., 2011), an inositol 5-phosphatase mutated in the X-linked disorder oculocerebrorenal 
Lowe syndrome. Depletion of this phosphatase results in cytokinesis failure due to mis-
localization of several essential cleavage furrow components to giant cytoplasmic vacuoles 
that are rich in PI(4,5)P2 and endocytic markers (Ben El et al., 2011). dOCRL is associated 
with endosomes and mediates PI(4,5)P2 dephosphorylation on internal membranes to 
restrict this phosphoinositide at the plasma membrane and thereby regulate cleavage 
furrow formation and ingression.  
3. Conclusion 
Here, the role of Cdc14A and Cdc14B, PP1, PP2A-B55, CaN, Ptpcd-1 and OCRL in 
regulating and driving mitotic exit in mammalian cells was reviewed. It is clear that we have 
only scraped the surface in our investigations into understanding the role and regulation of 
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protein phophatases in mitosis. The identification of all protein phosphatases involved in 
driving mitotic exit in mammalian cells, their relevant substrates and function as well as 
how their action is spatio- and temporal regulated in vivo remain key questions for future 
investigation. 
Understanding how protein dephosphorylation regulates mitotic exit and how the 
responsible protein phosphatases are regulated will provide an improved understanding to 
how two independent daughter cells are generated. Mitotic exit failure results in 
aneuploidy, which leads to genomic instability and thus contributes to the initiation and 
progression of tumourigenesis. Thus, an understanding of the molecular pathways that 
drive mitotic exit may highlight molecular targets for the development of new anti-cancer 
chemotherapeutic agents. In line with this idea, a recent publication has identified the CaN 
substrate, dynII, as a molecular target for the treatment of cancer (Chircop et al., 2010a, 
Chircop et al., 2010b). Inhibitors of dynII possess anti-cancer properties due to their ability 
to cause cytokinesis failure and subsequent cell growth arrest or apoptotic cell death (Joshi 
et al., 2010). It will be interesting to pursue the development of other targeted inhibitors to 
determine if they also possess anti-cancer properties as well as being useful molecular tools 
to unravel the signalling pathways required for mitotic exit in mammalian cells. 
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1. Introduction 
The RCK (the tyrosine kinase gene v-ros cross-hybridizing kinase) family within the CMGC 
(CDK/MAPK/GSK3/CLK) group of the human kinome consists of ICK/MRK (Intestinal cell 
kinase/MAK-related kinase) (Abe, Yagi et al. 1995; Togawa, Yan et al. 2000), MAK (male germ 
cell-associated kinase) (Matsushime, Jinno et al. 1990), and MOK (MAPK/MAK/MRK-
overlapping kinase) (Miyata, Akashi et al. 1999) (Fig. 1). In the N-terminal catalytic domain, 
they all share significant sequence homology with MAPK (mitogen-activated protein kinase) 
and contain a MAPK-like TXY motif in the activation T-loop. However, they display 
significant divergence in the composition of their C-terminal non-catalytic domains which may 
determine their functional specificity and confer distinct regulatory mechanisms. 
The biological functions of the ICK/MAK/MOK family have been elusive until recently. 
MAK is highly expressed in testis, however the MAK null mouse is viable and fertile, 
suggesting the existence of functional redundancy or compensation for the lack of MAK in 
testis (Shinkai, Satoh et al. 2002). In the MAK-null retina, photoreceptors exhibit elongated 
cilia and progressive degeneration, suggesting that MAK is required for regulation of ciliary 
length and retinal photoreceptor survival (Omori, Chaya et al. 2010). Exome sequencing has 
identified multiple point mutations in the kinase domain (Fig. 1) or an Alu-insertion in exon 
9 of MAK as potential causes of retinitis pigmentosa (RP), a genetically heritable and 
autosomal recessive disease (Ozgul, Siemiatkowska et al. 2011; Tucker, Scheetz et al. 2011). 
MAK is a co-activator for androgen receptor (AR) in prostate cancer cells and is required for 
AR-mediated signaling and cell proliferation (Xia, Robinson et al. 2002; Ma, Xia et al. 2006). 
A loss-of-function point mutation R272Q of ICK (Fig. 1) has been recently identified as the 
causative mutation in a neonatal lethal multiplex human syndrome ECO (endocrine-
cerebro-osteodysplasia), implicating a key role for ICK in development of multiple organ 
systems (Lahiry, Wang et al. 2009). Using shRNA knockdown, we have shown that 
suppression of ICK expression in intestinal epithelial cells markedly impaired cell 
proliferation and G1 cell cycle progression (Fu, Kim et al. 2009). Furthermore, ICK 
deficiency led to a significant decrease in the mTORC1 (mammalian target of rapamycin 
complex 1) activity, concomitant with reduced expression of specific mTORC1 downstream 
targets cyclinD1 and c-Myc (Fu, Kim et al. 2009). These results suggest that ICK may target  
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Fig. 1. Schematic illustration of structural organization and features of human ICK, MAK 
and MOK; Sequence alignment of their catalytic domains. ECO, endocrine-cerebro-
osteodysplasia syndrome; RP, retinitis pigmentosa 
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the mTORC1 signaling pathway to regulate cell proliferation and cell cycle progression. The 
biological functions of MOK are the least understood in the ICK/MAK/MOK family, except 
that a previous study indicated that MOK may be involved in growth arrest and 
differentiation in the intestinal epithelium (Uesaka and Kageyama 2004). 
In this chapter, the current knowledge about the regulations and functions of this novel group 
of serine/threonine protein kinases will be reviewed. Furthermore, and more importantly, the 
many “unknowns” about the biology of ICK/MAK/MOK will be identified and discussed, 
the answers to which should provide new insights into their unique regulatory mechanisms, 
diverse biological substrates and physiological functions.  
2. ICK signaling cascade 
ICK was separately cloned from a rat heart cDNA library (Abe, Yagi et al. 1995) and a 
mouse small intestinal crypt cDNA library (Togawa, Yan et al. 2000) by using degenerate 
oligonucleotide primers recognizing sequences from highly conserved subdomains of 
serine-threonine kinases. ICK, named after its cloning origin the intestine, is actually a 
ubiquitously expressed Ser/Thr protein kinase. Northern analysis with specific ICK probes 
detected ICK mRNAs in most mouse, rat and human tissues examined (Abe, Yagi et al. 
1995; Togawa, Yan et al. 2000). ICK and MAK contain nearly identical N-terminal catalytic 
domains (87% identity) but more divergent C-terminal noncatalytic domains. The 
ICK/MAK catalytic domain is related to both mitogen-activated protein kinases (MAPKs) 
and cyclin-dependent protein kinases (CDKs), with a MAPK-like TDY motif in the 
activation loop and the CDK-like regulatory sites T14Y15, but lacking the PSTAIRE cyclin-
binding motif found in most CDKs. ICK and MAK are also conserved from yeast to humans. 
Saccharomyces cerevisiae has one closely related kinase, Ime2p (inducer of meiosis) that is a 
meiosis-specific homolog of human CDK2 and required for timing meiotic S phase (Foiani, 
Nadjar-Boger et al. 1996; Clifford, Stark et al. 2005). Caenorhabditis elegans has one homolog 
DYF5, a dye-filling defective mutant identified from a forward genetic screen that plays an 
important role in the control of cilia length and the docking and undocking of kinesin-2 
motors from IFT (intraflagellar transport) particles (Burghoorn, Dekkers et al. 2007). Danio 
rerio (zebrafish) also has one homologous gene whose in situ expression at the basal level 
was detected in the retinal photoreceptor cell layer (http://zfin.org). 
2.1 Regulation of activity by the TDY motif phosphorylation through a pair of yin-yang 
regulators 
So far, we have established ICK as the prototype for a new group of kinases with MAPK-like 
regulation at TDY motifs (Fu, Schroeder et al. 2005). By mass spectrometry, we have shown 
that ICK can be specifically phosphorylated in the TDY motif in vivo. ICK requires an intact 
and doubly phosphorylated TDY motif for maximum activity. Autophosphorylation on Tyr-
159 in the TDY motif only confers basal kinase activity. Full activation of ICK requires 
additional phosphorylation of Thr-157 in the TDY motif. Furthermore, we have identified 
PP5 (protein phosphatase 5) and CCRK (cell cycle related kinase) as a pair of yin-yang 
regulators for Thr-157 phosphorylation (Fu, Larson et al. 2006). 
CCRK (Cell Cycle-Related Kinase): Since the catalytic domain of ICK is similar to those of both 
ERK2 (extracellular signal-regulated kinase) and CDK2 (cyclin-dependent protein kinase 2), 
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Fig. 2. Working model of the ICK signaling cascade. CCRK, cell cycle-related kinase; PP5, 
protein phosphatase 5; Bromi, broad-minded; AR, androgen receptor; mTOR, mammalian 
target of rapamycin; Raptor, regulatory associated protein of mTOR; Scythe/BAT3, HLA-b-
associated transcript 3.  
activator CAK (Cdk activating kinase) activates ICK. Surprisingly, neither MEK1/2 nor the 
Cdk7 complex (CDK7/cyclin H/MAT1) phosphorylates ICK in the T-loop, instead our data 
implicated ICK as a physiologic downstream target of CCRK (Fu, Schroeder et al. 2005; Fu, 
Larson et al. 2006). CCRK is most closely related to yeast CAK based on sequence homology, 
however it is a point of controversy as to whether CCRK has the intrinsic CAK activity (Liu, 
Wu et al. 2004; Wohlbold, Larochelle et al. 2006). CCRK may support a role for ICK in the 
regulation of proliferation and/or apoptosis. CCRK was identified in a large scale siRNA 
screen for suppressors of apoptosis (MacKeigan, Murphy et al. 2005). CCRK was also shown 
to be important for cell growth in HeLa, HCT116 and U2OS cells (Liu, Wu et al. 2004; 
Wohlbold, Larochelle et al. 2006). CCRK is a novel candidate oncogene in human 
glioblastoma (Ng, Cheung et al. 2007), colon cancer (An, Ng et al. 2010) and hepatocellular 
carcinoma (Feng, Cheng et al. 2011). The heart expresses a splice variant of CCRK, which 
promotes cardiac cell growth and survival; differs from the generic isoform in terms of 
protein-protein interactions, substrate specificity and regulation of the cell cycle; and is 
down-regulated significantly in heart failure (Qiu, Dai et al. 2008). Recently, CCRK was 
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shown to interact with Broad-minded (Bromi) to control cilia assembly and mammalian 
Sonic hedgehog (Shh) signaling transduction (Ko, Norman et al. 2010). The endogenous 
CCRK protein level was significantly reduced in Bromi mutant embryos and fibroblasts, 
while the CCRK mRNA level was unaffected, suggesting that Bromi promotes CCRK 
stability. CCRK was also implicated as a downstream mediator of AR (androgen receptor) 
signaling that drives hepatocarcinogenesis through a β-catenin and TCF (T cell receptor)-
dependent pathway (Feng, Cheng et al. 2011). Ligand-bound AR is able to up-regulate 
CCRK transcription and protein expression through direct binding to the AR-responsive 
element of its promoter. What remains unknown is how the activity of CCRK is regulated 
independent of its expression level. Given CCRK is localized in both nuclear and 
cytoplasmic compartments, it will be important to know whether CCRK is differentially 
regulated and performs distinct biological functions in two different locations. It is also 
worth pointing out that a previous gel filtration study demonstrated the presence of at least 
two different CAK activities in human cells, with the second CAK activity detected at 30-40 
KDa resembling the biochemical properties of Cak1p (Kaldis and Solomon 2000). This 
observation raises the possibility that a “small” CAK other than CCRK may be an upstream 
activator of ICK and MAK.  
PP5 (Protein Phosphatase 5): PP5 plays important roles in cell cycle checkpoints, DNA 
damage response and proliferation (Golden, Swingle et al. 2008; Hinds and Sanchez 2008). 
Inhibition of PP5 expression results in a marked antiproliferative effect through the 
activation of the p53-dependent G1 checkpoint (Zuo, Dean et al. 1998). PP5 is required for 
both ATM (Ataxia telangiectasia mutated) and ATR (Ataxia telangiectasia and Rad3-related 
protein) checkpoint signaling, operant in S and G2/M (Ali, Zhang et al. 2004; Zhang, Bao et 
al. 2005). Hydrogen peroxide treatment induces activation of PP5 leading to the negative 
regulation of ASK1 (apoptosis signal-regulating kinase 1) and inhibition of apoptosis 
(Morita, Saitoh et al. 2001). PP5 dephosphorylates two functional sites in DNA-PKc (DNA-
dependent protein kinase, catalytic subunit) that are required for functions in the DNA 
repair of double strand breaks (Wechsler, Chen et al. 2004). PP5 also dephosphorylates Raf1 
(proto-oncogene c-Raf) at Ser-338 to inhibit Raf1 activity and its downstream signaling to 
MEK and ERK (von Kriegsheim, Pitt et al. 2006). Similarly, PP5 can inactivate ICK by 
dephosphorylating the essential phospho-threonine residue within the T-loop (Fu, Larson et 
al. 2006). We also showed that hydrogen peroxide treatment induces activation of the 
endogenous PP5 to negatively regulate ICK phosphorylation in the T-loop (Fu, Larson et al. 
2006). Identifying ICK as a new downstream target of PP5 leads to our hypothesis that PP5 
may modulate some branch of checkpoint signaling in response to stress and DNA-damage 
through the inactivation of ICK.  
2.2 Regulation of activity by nuclear targeting 
Prior studies from us and others have shown that GFP-tagged ICK is predominantly nuclear 
(Yang, Jiang et al. 2002; Fu, Schroeder et al. 2005). Our studies further established that the 
catalytic domain, but not the C-terminal domain, of ICK is required for nuclear localization. 
Neither the kinase activity nor the TDY phosphorylation appears to be necessary. Instead, 
an intact subdomain XI is required as well as the conserved arginine, R272, in the PKKRP 
motif and its interacting networks including W184 and E169. Loss of nuclear localization 






Fig. 2. Working model of the ICK signaling cascade. CCRK, cell cycle-related kinase; PP5, 
protein phosphatase 5; Bromi, broad-minded; AR, androgen receptor; mTOR, mammalian 
target of rapamycin; Raptor, regulatory associated protein of mTOR; Scythe/BAT3, HLA-b-
associated transcript 3.  
activator CAK (Cdk activating kinase) activates ICK. Surprisingly, neither MEK1/2 nor the 
Cdk7 complex (CDK7/cyclin H/MAT1) phosphorylates ICK in the T-loop, instead our data 
implicated ICK as a physiologic downstream target of CCRK (Fu, Schroeder et al. 2005; Fu, 
Larson et al. 2006). CCRK is most closely related to yeast CAK based on sequence homology, 
however it is a point of controversy as to whether CCRK has the intrinsic CAK activity (Liu, 
Wu et al. 2004; Wohlbold, Larochelle et al. 2006). CCRK may support a role for ICK in the 
regulation of proliferation and/or apoptosis. CCRK was identified in a large scale siRNA 
screen for suppressors of apoptosis (MacKeigan, Murphy et al. 2005). CCRK was also shown 
to be important for cell growth in HeLa, HCT116 and U2OS cells (Liu, Wu et al. 2004; 
Wohlbold, Larochelle et al. 2006). CCRK is a novel candidate oncogene in human 
glioblastoma (Ng, Cheung et al. 2007), colon cancer (An, Ng et al. 2010) and hepatocellular 
carcinoma (Feng, Cheng et al. 2011). The heart expresses a splice variant of CCRK, which 
promotes cardiac cell growth and survival; differs from the generic isoform in terms of 
protein-protein interactions, substrate specificity and regulation of the cell cycle; and is 
down-regulated significantly in heart failure (Qiu, Dai et al. 2008). Recently, CCRK was 
Regulations and Functions of ICK/MAK/MOK  
– A Novel MAPK-Related Kinase Family Linked to Human Diseases 
 
233 
shown to interact with Broad-minded (Bromi) to control cilia assembly and mammalian 
Sonic hedgehog (Shh) signaling transduction (Ko, Norman et al. 2010). The endogenous 
CCRK protein level was significantly reduced in Bromi mutant embryos and fibroblasts, 
while the CCRK mRNA level was unaffected, suggesting that Bromi promotes CCRK 
stability. CCRK was also implicated as a downstream mediator of AR (androgen receptor) 
signaling that drives hepatocarcinogenesis through a β-catenin and TCF (T cell receptor)-
dependent pathway (Feng, Cheng et al. 2011). Ligand-bound AR is able to up-regulate 
CCRK transcription and protein expression through direct binding to the AR-responsive 
element of its promoter. What remains unknown is how the activity of CCRK is regulated 
independent of its expression level. Given CCRK is localized in both nuclear and 
cytoplasmic compartments, it will be important to know whether CCRK is differentially 
regulated and performs distinct biological functions in two different locations. It is also 
worth pointing out that a previous gel filtration study demonstrated the presence of at least 
two different CAK activities in human cells, with the second CAK activity detected at 30-40 
KDa resembling the biochemical properties of Cak1p (Kaldis and Solomon 2000). This 
observation raises the possibility that a “small” CAK other than CCRK may be an upstream 
activator of ICK and MAK.  
PP5 (Protein Phosphatase 5): PP5 plays important roles in cell cycle checkpoints, DNA 
damage response and proliferation (Golden, Swingle et al. 2008; Hinds and Sanchez 2008). 
Inhibition of PP5 expression results in a marked antiproliferative effect through the 
activation of the p53-dependent G1 checkpoint (Zuo, Dean et al. 1998). PP5 is required for 
both ATM (Ataxia telangiectasia mutated) and ATR (Ataxia telangiectasia and Rad3-related 
protein) checkpoint signaling, operant in S and G2/M (Ali, Zhang et al. 2004; Zhang, Bao et 
al. 2005). Hydrogen peroxide treatment induces activation of PP5 leading to the negative 
regulation of ASK1 (apoptosis signal-regulating kinase 1) and inhibition of apoptosis 
(Morita, Saitoh et al. 2001). PP5 dephosphorylates two functional sites in DNA-PKc (DNA-
dependent protein kinase, catalytic subunit) that are required for functions in the DNA 
repair of double strand breaks (Wechsler, Chen et al. 2004). PP5 also dephosphorylates Raf1 
(proto-oncogene c-Raf) at Ser-338 to inhibit Raf1 activity and its downstream signaling to 
MEK and ERK (von Kriegsheim, Pitt et al. 2006). Similarly, PP5 can inactivate ICK by 
dephosphorylating the essential phospho-threonine residue within the T-loop (Fu, Larson et 
al. 2006). We also showed that hydrogen peroxide treatment induces activation of the 
endogenous PP5 to negatively regulate ICK phosphorylation in the T-loop (Fu, Larson et al. 
2006). Identifying ICK as a new downstream target of PP5 leads to our hypothesis that PP5 
may modulate some branch of checkpoint signaling in response to stress and DNA-damage 
through the inactivation of ICK.  
2.2 Regulation of activity by nuclear targeting 
Prior studies from us and others have shown that GFP-tagged ICK is predominantly nuclear 
(Yang, Jiang et al. 2002; Fu, Schroeder et al. 2005). Our studies further established that the 
catalytic domain, but not the C-terminal domain, of ICK is required for nuclear localization. 
Neither the kinase activity nor the TDY phosphorylation appears to be necessary. Instead, 
an intact subdomain XI is required as well as the conserved arginine, R272, in the PKKRP 
motif and its interacting networks including W184 and E169. Loss of nuclear localization 





targeting is important for the maximal activation of ICK, consistent with the predominant 
nuclear localization of its upstream activator CCRK.  
It still remains elusive how the endogenous ICK is distributed in cells. Our unpublished 
data implicate the presence of endogenous ICK signals in the cytoplasm. Given that ICK has 
multiple splicing variants, it is possible that different isoforms of ICK may exhibit 
differential subcellular localization. Although CCRK is mainly localized to the nucleus, it is 
also present in the cytoplasm (Liu, Wu et al. 2004; An, Ng et al. 2010; Ko, Norman et al. 
2010), thus capable of phosphorylating and activating cytoplasmic ICK as well. It remains to 
be determined whether cytoplasmic ICK and nuclear ICK have distinct biological activities.  
2.3 The ICK substrate phosphorylation consensus 
In order to identify putative substrates for ICK, a positional scanning peptide array method 
was used to determine the sequence specificity surrounding the ICK phosphorylation site 
(Fu, Larson et al. 2006). The phosphorylation consensus for ICK is [R]-[P]-[X]-[S/T]-
[P/A/T/S], with the strongest selection for arginine at P-3 and proline at P-2. A preference 
for proline at P+1 was observed and was expected, given the similarity of ICK to ERK2 in 
the catalytic domain. However, the selection for proline at P+1 position is not absolutely 
stringent because alanine, threonine, and serine were also selected albeit less well. Despite 
some similarities, the ICK phosphorylation consensus is distinct from that of ERK2 due to 
the lack of absolute stringency for proline at P+1 or that of CDK2 due to the lack of a strong 
preference for basic residues (K/R) at P+3.  
Due to the difficulty in obtaining a large quantity of highly purified and active full-length 
ICK protein, we were only able to use the catalytic domain of ICK as the kinase source in the 
peptide library scan (Fu, Larson et al. 2006). Therefore, despite our recent successes in using 
this consensus motif to identify several candidate physiological substrates for ICK (see Fig. 
2), there still is the possibility that the full-length ICK including the long C-terminal domain 
may add additional features or modifications to the current substrate consensus sequence 
for ICK.  
Given that ICK and MAK are essentially identical in the catalytic domain, we anticipate that 
this consensus sequence for ICK may also be useful for selecting putative substrates and/or 
phosphorylation sites for MAK. For example, we have identified Scythe/BAT3 as a 
candidate physiological substrate for ICK (Fu, Larson et al. 2006). Scythe/BAT3 is especially 
enriched in testis and abundant in male germ cells (Wang and Liew 1994), an expression 
pattern very similar to that of MAK (Matsushime, Jinno et al. 1990). In addition, both MAK 
and Scythe/BAT3 mRNAs increase dramatically in the mouse testis at around 14 to 20 days 
after birth. These correlations suggest an interesting hypothesis that Scythe may be a direct 
substrate downstream of MAK to function in some aspects of spermatogenesis.  
2.4 Candidate physiological substrates  
Scythe/BAT3 (HLA-b-associated transcript 3): We have established, in vitro, that ICK can 
phosphorylate Scythe (Fu, Larson et al. 2006), an important mediator of apoptosis and 
proliferation during mammalian development (Desmots, Russell et al. 2005). Scythe was 
originally identified as a novel reaper-binding apoptotic regulator in Drosophila melanogaster 
(Thress, Henzel et al. 1998; Thress, Evans et al. 1999). Recently, Scythe was identified as the 
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key interacting partner of the human small glutamine-rich TPR-containing protein (hSGT) 
that is required for progression through cell division (Winnefeld, Grewenig et al. 2006). 
Findings from studies of Scythe-deficient mice indicated that Scythe is a novel and essential 
regulator of p53-mediated responses to genotoxic stress by controlling DNA-damage 
induced acetylation of p53 (Sasaki, Gan et al. 2007). As a possible link of ICK to colon cancer, 
Scythe was a newly identified candidate tumor suppressor gene in colon cancer cells 
(Ivanov, Lo et al. 2007). Scythe is also essential for selective elimination of defective 
proteasomal substrate as a ubiquitin-like protein (Minami, Hayakawa et al. 2010) and acts as 
a tansmembrane domain (TMD)-selective chaperon that effectively channels tail-anchored 
(TA) proteins into the ER membrane (Mariappan, Li et al. 2010). Using the ICK 
phosphorylation consensus sequence R-P-X-S/T, we reported that an in vivo phosphorylation 
site, Thr-1080, in Scythe is a major ICK phosphorylation site in vitro (Fu, Larson et al. 2006). 
Functions are yet to be defined for this ICK phosphorylation site in Scythe-regulated 
biological events such as proliferation, apoptosis and DNA damage control in response to 
genotoxic stress. 
Raptor (Regulatory associated protein of mTOR): The serine/threonine protein kinase mammalian 
target of rapamycin (mTOR) is the core catalytic component of two structurally and 
functionally distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2), which collectively integrates nutrient, hormonal, and energy signal inputs to 
control cell growth, proliferation and survival (Bhaskar and Hay 2007; Hall 2008; Laplante 
and Sabatini 2009). mTORC1, when activated by growth factors and nutrients, stimulate cell 
growth and proliferation by phosphorylating two key regulators of mRNA translation and 
ribosome biogenesis, S6K1 (ribosomal protein S6 kinase) and 4EBP1 (eukaryotic initiation 
factor 4E-binding protein 1) (Hara, Yonezawa et al. 1997; Fingar, Richardson et al. 2004; 
Proud 2004; Ma and Blenis 2009). In addition to the catalytic subunit mTOR, mTORC1 also 
contains four associated components, Raptor, mLST8/GβL, PRAS40, and Deptor (Kim, 
Sarbassov et al. 2002; Loewith, Jacinto et al. 2002; Kim, Sarbassov et al. 2003; Kim and 
Sabatini 2004; Vander Haar, Lee et al. 2007; Wang, Harris et al. 2008; Peterson, Laplante et al. 
2009). Raptor plays an important role as a scaffolding protein to recruit substrates S6K1 and 
4EBP1 to mTOR (Nojima, Tokunaga et al. 2003). Upon growth factor stimulation, Raptor 
binding to substrates can be enhanced by the dissociation of the competitive inhibitor 
PRAS40 (the proline-rich Akt substrate of 40KDa) from mTORC1 (Fonseca, Smith et al. 2007; 
Sancak, Thoreen et al. 2007; Wang, Harris et al. 2008; Nascimento and Ouwens 2009). Raptor 
can also positively regulate mTOR activity in response to nutrient sufficiency by directly 
interacting with Rag family GTPases to induce mTORC1 re-localization to an intracellular 
vesicular compartment containing RheB, a Ras-like GTP-binding protein that activates 
mTOR via an unknown mechanism (Hanrahan and Blenis 2006; Kim, Goraksha-Hicks et al. 
2008; Sancak, Peterson et al. 2008). 
Recently, multiple phosphorylation sites of Raptor have been identified, several of which 
are critical for the regulation of mTORC1 activity in response to insulin, nutrients or energy 
stress. Phosphorylation of Raptor Ser-722 and Ser-792 by AMPK is required for the 
inhibition of mTORC1 and cell cycle arrest induced by energy stress (Gwinn, Shackelford et 
al. 2008). RSK mediated phosphorylation of Ser-719/721/722 enhances mTORC1 activity 
stimulated by Ras/MAPK pathway (Carriere, Cargnello et al. 2008). Phosphorylation of Ser-





targeting is important for the maximal activation of ICK, consistent with the predominant 
nuclear localization of its upstream activator CCRK.  
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key interacting partner of the human small glutamine-rich TPR-containing protein (hSGT) 
that is required for progression through cell division (Winnefeld, Grewenig et al. 2006). 
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regulator of p53-mediated responses to genotoxic stress by controlling DNA-damage 
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proteasomal substrate as a ubiquitin-like protein (Minami, Hayakawa et al. 2010) and acts as 
a tansmembrane domain (TMD)-selective chaperon that effectively channels tail-anchored 
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(mTORC2), which collectively integrates nutrient, hormonal, and energy signal inputs to 
control cell growth, proliferation and survival (Bhaskar and Hay 2007; Hall 2008; Laplante 
and Sabatini 2009). mTORC1, when activated by growth factors and nutrients, stimulate cell 
growth and proliferation by phosphorylating two key regulators of mRNA translation and 
ribosome biogenesis, S6K1 (ribosomal protein S6 kinase) and 4EBP1 (eukaryotic initiation 
factor 4E-binding protein 1) (Hara, Yonezawa et al. 1997; Fingar, Richardson et al. 2004; 
Proud 2004; Ma and Blenis 2009). In addition to the catalytic subunit mTOR, mTORC1 also 
contains four associated components, Raptor, mLST8/GβL, PRAS40, and Deptor (Kim, 
Sarbassov et al. 2002; Loewith, Jacinto et al. 2002; Kim, Sarbassov et al. 2003; Kim and 
Sabatini 2004; Vander Haar, Lee et al. 2007; Wang, Harris et al. 2008; Peterson, Laplante et al. 
2009). Raptor plays an important role as a scaffolding protein to recruit substrates S6K1 and 
4EBP1 to mTOR (Nojima, Tokunaga et al. 2003). Upon growth factor stimulation, Raptor 
binding to substrates can be enhanced by the dissociation of the competitive inhibitor 
PRAS40 (the proline-rich Akt substrate of 40KDa) from mTORC1 (Fonseca, Smith et al. 2007; 
Sancak, Thoreen et al. 2007; Wang, Harris et al. 2008; Nascimento and Ouwens 2009). Raptor 
can also positively regulate mTOR activity in response to nutrient sufficiency by directly 
interacting with Rag family GTPases to induce mTORC1 re-localization to an intracellular 
vesicular compartment containing RheB, a Ras-like GTP-binding protein that activates 
mTOR via an unknown mechanism (Hanrahan and Blenis 2006; Kim, Goraksha-Hicks et al. 
2008; Sancak, Peterson et al. 2008). 
Recently, multiple phosphorylation sites of Raptor have been identified, several of which 
are critical for the regulation of mTORC1 activity in response to insulin, nutrients or energy 
stress. Phosphorylation of Raptor Ser-722 and Ser-792 by AMPK is required for the 
inhibition of mTORC1 and cell cycle arrest induced by energy stress (Gwinn, Shackelford et 
al. 2008). RSK mediated phosphorylation of Ser-719/721/722 enhances mTORC1 activity 
stimulated by Ras/MAPK pathway (Carriere, Cargnello et al. 2008). Phosphorylation of Ser-





including growth factors, nutrients and cellular energy (Wang, Lawrence et al. 2009; Foster, 
Acosta-Jaquez et al. 2010; Carriere, Romeo et al. 2011). Taken together, a plethora of 
emerging evidence indicates that the complex phosphorylation status of Raptor is tightly 
associated with the activity of mTORC1. Our data indicated that ICK associates with Raptor 
and phosphorylates Raptor at Thr-908 (Fu, Kim et al. 2009). More importantly, knockdown 
the ICK expression significantly reduced the phosphorylation of S6K1 at Thr-389 targeted by 
the mTORC1, suggesting that ICK is an upstream regulator of the mTORC1 activity in the 
regulation of cell growth and proliferation (Fu, Kim et al. 2009).  
2.5 Role of ICK in ECO and multiple organ development during embryogenesis 
Protein kinases comprise one of the largest and most abundant gene families in humans. 
Both inherited germ-line and somatic mutations in kinase genes have been associated with 
many human diseases including developmental and metabolic disorders and neoplastic 
malignancies (Lahiry, Torkamani et al. 2010). The human endocrine-cerebro-osteodysplasia 
(ECO) syndrome is a newly identified congenital neonatal-lethal disorder whose clinical 
manifestations include osteodysplasia, cerebral anomalies, and endocrine gland hypoplasia. 
A homozygous missense mutation R272Q in ICK was identified as the causative mutation 
for ECO. ICK, named after its cloning origin the intestine, is a misnomer because it is highly 
conserved and ubiquitously expressed in human tissues, which may explain why the R272Q 
mutation in ICK causes developmental defects in multiple organs. Previously we have 
established that the R272A mutation in ICK impairs the nuclear targeting and the catalytic 
activity of ICK; this result was confirmed with the R272Q mutation as well. Many of the 
malformations observed in ECO involve a defect in apoptosis, especially the cleft lip and 
palate, syndactyly, prolonged persistence of fusion of the eyelids, and unfused urogenital 
folds. ECO-affected infants also develop phenotypes observed with Scythe deficiency, 
including hydrocephalus, dilated and hypoplastic kidneys. Given the role of scythe in 
apoptosis, these observations support the hypothesis that ICK targets scythe to regulate 
apoptosis during mammalian organ development.  
2.6 Role of ICK in the intestinal epithelium  
A delicate balance of cell renewal, differentiation and cell death is crucial to maintain the 
gastrointestinal tissue architecture that forms the basis for the normal function of the gut. 
An early study using in situ hybridization showed that the expression of ICK mRNA was 
localized specifically to the crypt compartment of the small intestine (Togawa, Yan et al. 
2000). The crypt is the compartment of the intestinal epithelium where stem cells, progenitor 
cells and rapidly replicating transit-amplifying cells reside raising the hypothesis that ICK 
may play a role in epithelial replication, lineage specification and cell fate determination in 
crypt epithelium. Using a conditional ICK knockout mouse model, we are currently 
addressing whether intestine-specific ablation of the ICK gene affects cell proliferation, 
differentiation, migration and lineage allocation in the intestinal epithelium during normal 
development and homeostasis, and whether the ICK expression is important for the 
expansion and proliferation of the intestinal stem cell population and their progenitors in 
the restoration of the normal epithelial architecture after mucosal injury. 
Recently, we reported that suppression of ICK expression in cultured colorectal carcinoma 
and intestinal epithelial cell lines by short hairpin RNA (shRNA) interference significantly 
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impaired cellular proliferation and induced features of gene expression characteristic of 
colonic or enterocytic differentiation (Fu, Kim et al. 2009). Downregulation of ICK altered 
expression of cell cycle regulators (cyclin D1, c-Myc, and p21Cip1/WAF1) of G1-S transition, 
consistent with the G1 cell cycle delay induced by ICK shRNA. ICK deficiency also led to a 
significant decrease in the expression and/or activity of S6K1, indicating that disrupting 
ICK function downregulates the mTORC1 signaling pathway. Our prior studies also 
provided biochemical evidence that ICK interacts with the mTOR/Raptor complex in cells 
and Raptor is an in vitro substrate for ICK (Fu, Kim et al. 2009). Recently, we investigated 
whether and how ICK targets Raptor to regulate the activity of mTORC1. Our results 
indicate that ICK is able to promote mTORC1 activation through phosphorylation of Raptor 
Thr-908 (Wu D et al., J Biol Chem, in press).   
2.7 Role of ICK in cardiac development and hypertrophy  
Abe, S and colleagues (Abe, Yagi et al. 1995) observed the ICK/MRK protein signals in the 
cytosol of cardiomyocytes at day 11 rat embryos, and the ICK/MRK immunohistological 
staining appeared to be weaker and in a patchy, speckled pattern in adult rat hearts, 
suggesting downregulation of the ICK/MRK signals during cardiac development. 
Furthermore, the intensity of the ICK/MRK staining and the number of ICK positive 
cardiomyocytes were both increased in hypertrophic hearts with experimentally induced 
stenosis of the abdominal aorta, implicating that the ICK/MRK expression is inducible by 
external stress such as pressure overload.  
3. MAK signaling cascade 
In 1990, MAK was first isolated from a human genomic DNA library by using weak cross-
hybridization with a tyrosine kinase gene (v-ros) in Professor Masabumi Shibuya’s 
laboratory. This gene was designated as MAK (male germ cell-associated kinase) because it 
is highly expressed in testicular germ cells. In contrast to the ubiquitous expression pattern 
of ICK, MAK expression is more restricted. MAK mRNAs are enriched in testis and 
expressed in male germ cells during and after meiosis (Matsushime, Jinno et al. 1990). MAK 
expression was also detected in prostate and retina. MAK was identified as an androgen-
inducible gene in LNCaP prostate epithelial cells and as a co-activator of androgen receptor 
signaling in prostate cancer (Ma, Xia et al. 2006). Recently, MAK expression was detected in 
cilia of the retina where it was suggested to be involved in photoreceptor cell survival 
(Omori, Chaya et al. 2010). 
3.1 cell cycle-dependent localization and regulation in the TDY motif 
The subcellular localization of MAK is dynamic during cell cycle (Wang and Kung 2011). 
MAK displays uniform localization in the nucleus during interphase, and associates with 
mitotic spindles and centrosomes at metaphase and anaphase. This dynamic nuclear 
localization of MAK is associated with its cell cycle-related role (see 3.4). Similar to ICK, 
MAK also requires an intact and dually phosphorylated TDY motif for full activation. 
CCRK, but not MEK, is the upstream activating kinase for MAK in the TDY motif (Wang 
and Kung 2011). More interestingly, although the expression level of MAK remained 
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Protein kinases comprise one of the largest and most abundant gene families in humans. 
Both inherited germ-line and somatic mutations in kinase genes have been associated with 
many human diseases including developmental and metabolic disorders and neoplastic 
malignancies (Lahiry, Torkamani et al. 2010). The human endocrine-cerebro-osteodysplasia 
(ECO) syndrome is a newly identified congenital neonatal-lethal disorder whose clinical 
manifestations include osteodysplasia, cerebral anomalies, and endocrine gland hypoplasia. 
A homozygous missense mutation R272Q in ICK was identified as the causative mutation 
for ECO. ICK, named after its cloning origin the intestine, is a misnomer because it is highly 
conserved and ubiquitously expressed in human tissues, which may explain why the R272Q 
mutation in ICK causes developmental defects in multiple organs. Previously we have 
established that the R272A mutation in ICK impairs the nuclear targeting and the catalytic 
activity of ICK; this result was confirmed with the R272Q mutation as well. Many of the 
malformations observed in ECO involve a defect in apoptosis, especially the cleft lip and 
palate, syndactyly, prolonged persistence of fusion of the eyelids, and unfused urogenital 
folds. ECO-affected infants also develop phenotypes observed with Scythe deficiency, 
including hydrocephalus, dilated and hypoplastic kidneys. Given the role of scythe in 
apoptosis, these observations support the hypothesis that ICK targets scythe to regulate 
apoptosis during mammalian organ development.  
2.6 Role of ICK in the intestinal epithelium  
A delicate balance of cell renewal, differentiation and cell death is crucial to maintain the 
gastrointestinal tissue architecture that forms the basis for the normal function of the gut. 
An early study using in situ hybridization showed that the expression of ICK mRNA was 
localized specifically to the crypt compartment of the small intestine (Togawa, Yan et al. 
2000). The crypt is the compartment of the intestinal epithelium where stem cells, progenitor 
cells and rapidly replicating transit-amplifying cells reside raising the hypothesis that ICK 
may play a role in epithelial replication, lineage specification and cell fate determination in 
crypt epithelium. Using a conditional ICK knockout mouse model, we are currently 
addressing whether intestine-specific ablation of the ICK gene affects cell proliferation, 
differentiation, migration and lineage allocation in the intestinal epithelium during normal 
development and homeostasis, and whether the ICK expression is important for the 
expansion and proliferation of the intestinal stem cell population and their progenitors in 
the restoration of the normal epithelial architecture after mucosal injury. 
Recently, we reported that suppression of ICK expression in cultured colorectal carcinoma 
and intestinal epithelial cell lines by short hairpin RNA (shRNA) interference significantly 
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impaired cellular proliferation and induced features of gene expression characteristic of 
colonic or enterocytic differentiation (Fu, Kim et al. 2009). Downregulation of ICK altered 
expression of cell cycle regulators (cyclin D1, c-Myc, and p21Cip1/WAF1) of G1-S transition, 
consistent with the G1 cell cycle delay induced by ICK shRNA. ICK deficiency also led to a 
significant decrease in the expression and/or activity of S6K1, indicating that disrupting 
ICK function downregulates the mTORC1 signaling pathway. Our prior studies also 
provided biochemical evidence that ICK interacts with the mTOR/Raptor complex in cells 
and Raptor is an in vitro substrate for ICK (Fu, Kim et al. 2009). Recently, we investigated 
whether and how ICK targets Raptor to regulate the activity of mTORC1. Our results 
indicate that ICK is able to promote mTORC1 activation through phosphorylation of Raptor 
Thr-908 (Wu D et al., J Biol Chem, in press).   
2.7 Role of ICK in cardiac development and hypertrophy  
Abe, S and colleagues (Abe, Yagi et al. 1995) observed the ICK/MRK protein signals in the 
cytosol of cardiomyocytes at day 11 rat embryos, and the ICK/MRK immunohistological 
staining appeared to be weaker and in a patchy, speckled pattern in adult rat hearts, 
suggesting downregulation of the ICK/MRK signals during cardiac development. 
Furthermore, the intensity of the ICK/MRK staining and the number of ICK positive 
cardiomyocytes were both increased in hypertrophic hearts with experimentally induced 
stenosis of the abdominal aorta, implicating that the ICK/MRK expression is inducible by 
external stress such as pressure overload.  
3. MAK signaling cascade 
In 1990, MAK was first isolated from a human genomic DNA library by using weak cross-
hybridization with a tyrosine kinase gene (v-ros) in Professor Masabumi Shibuya’s 
laboratory. This gene was designated as MAK (male germ cell-associated kinase) because it 
is highly expressed in testicular germ cells. In contrast to the ubiquitous expression pattern 
of ICK, MAK expression is more restricted. MAK mRNAs are enriched in testis and 
expressed in male germ cells during and after meiosis (Matsushime, Jinno et al. 1990). MAK 
expression was also detected in prostate and retina. MAK was identified as an androgen-
inducible gene in LNCaP prostate epithelial cells and as a co-activator of androgen receptor 
signaling in prostate cancer (Ma, Xia et al. 2006). Recently, MAK expression was detected in 
cilia of the retina where it was suggested to be involved in photoreceptor cell survival 
(Omori, Chaya et al. 2010). 
3.1 cell cycle-dependent localization and regulation in the TDY motif 
The subcellular localization of MAK is dynamic during cell cycle (Wang and Kung 2011). 
MAK displays uniform localization in the nucleus during interphase, and associates with 
mitotic spindles and centrosomes at metaphase and anaphase. This dynamic nuclear 
localization of MAK is associated with its cell cycle-related role (see 3.4). Similar to ICK, 
MAK also requires an intact and dually phosphorylated TDY motif for full activation. 
CCRK, but not MEK, is the upstream activating kinase for MAK in the TDY motif (Wang 
and Kung 2011). More interestingly, although the expression level of MAK remained 





2011). It increased at S phase, peaked at G2 to early M phase, and decreased at late M phase. 
It is not clear, however, whether this oscillation of the TDY-dual phosphorylation of MAK 
during cell cycle is associated with the expression and/or activity levels of CCRK. The high 
level TDY-phosphorylation of MAK at G2/M does provide the molecular basis for an 
important role of MAK during the metaphase-anaphase transition (see 3.4).    
3.2 MAK in testis and spermatogenesis 
Northern blot analysis revealed two discrete transcripts (2.6 and 3.8 kb) of the mak gene that 
are mainly expressed in germ cells at and/or after the pachytene stage (Matsushime, Jinno 
et al. 1990). Since these two mak transcripts display differential temporal expression patterns 
during spermatogenesis, it was speculated that they may have distinct physiological 
functions in germ cells differentiation. Subsequent studies from Professor Shibuya’s lab 
identified two MAK protein products that are mainly localized in the cytoplasm and a 
phosphorylated 210-KDa protein as a candidate physiological substrate for MAK. The true 
identify of this MAK-associated 210-KDa protein still remains a mystery.  
In 2002, phenotypic analysis of the MAK knockout mouse was reported by Yoichi Shinkai 
and colleagues. Overall, MAK-deficient mice developed normally with no gross 
abnormalities (Shinkai, Satoh et al. 2002). Surprisingly, most of the MAK null mice were 
fertile, suggesting no major defects in spermatogenesis in the absence of MAK gene in mice. 
The only mild phenotype in MAK-deficient male mice is reduced sperm motility. These data 
suggest that MAK is not essential for spermatogenesis and male fertility, raising the 
possibility that ICK may compensate for the role of MAK in spermatogenesis. Our studies 
indicate that both ICK and MAK, proteins are abundantly expressed in mouse testis, and in 
primary spermatocytes and sertoli cell lines (Fu Z et al., unpublished data), providing 
further molecular basis for the speculation that ICK and MAK may have redundant 
biological functions in testis. Knockout of both MAK and ICK genes in mice will be required 
to test this hypothesis.  
3.3 MAK in retina, ciliogenesis and retinitis pigmentosa  
A potential role of MAK and ICK in regulating cilia structure and functions has long been 
speculated based on the observations that loss of functions of their homologs in 
Chlamydomonas reinhardtii (LF4p) (Berman, Wilson et al. 2003), in Caenorhabditis elegans (Dyf-
5) (Burghoorn, Dekkers et al. 2007), and in Leishmania Mexicana (LmxMPK9) (Bengs, Scholz et 
al. 2005) causes elongated cilia or flagella to various degrees. During a microarray screening 
to identify photoreceptor cell-specific genes involved in the conversion of photoreceptors to 
amacrine-like cells, Takahisa Furukawa and colleagues found a retina-specific isoform of 
MAK cDNA containing a 75-bp in-frame insertion to the originally reported form of MAK in 
testis. Using the same MAK-null mice that display no major phenotype in spermatogenesis, 
Furukawa’s lab investigated whether MAK has any important functions in retina where 
MAK is predominantly expressed in photoreceptor cells and localized in the photoreceptor 
connecting cilia and outer segment axonemes. The MAK-null retina appears to be normal 
until the completion of retinogenesis at postnatal day 14, suggesting that MAK gene is not 
essential for cell fate determination in retina. However, photoreceptor cells in the MAK-null 
retina do exhibit progressive degeneration associated with two major hallmarks: elongated 
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cilia and aberrant outer-segment disk formation. The role of MAK in regulating cilia length 
was also confirmed in serum starved NIH 3T3 cells where MAK is mainly localized in the 
nuclei and in the cilia as well. Both the kinase activity and the C-terminal region of MAK are 
essential for the regulation of the cilia length. However, only the C-terminal noncatalytic 
domain, but not the kinase activity, of MAK is required for its ciliary localization.  
Retinitis pigmentosa 1 (RP1) was implicated as a candidate physiological substrate for MAK 
in regulating ciliary structure and organization in that RP1 induces ciliary elongation and 
reduces the effect of MAK overexpression, and furthermore MAK physically interacts with 
RP1 and directly phosphorylates RP1 in vitro (Omori, Chaya et al. 2010). Scythe may be 
another candidate substrate for MAK related to its role in RP for the following reasons. 
Scythe was identified from a yeast two-hybrid screen using ICK kinase domain as the bait 
and was confirmed to be an in vitro and in vivo substrate for ICK (Fu, Larson et al. 2006). ICK 
and MAK are essentially identical in the kinase domain, therefore Scythe maybe a common 
substrate for both. RP is characterized by apoptotic death of photoreceptor cells and scythe 
is known to be important for regulating apoptosis and is abundantly expressed in retina. 
MAK was found in two cell types involved in sensory transduction, photoreceptors and 
olfactory receptors as well as epithelial of the respiratory tract and choroid plexus (Bladt 
and Birchmeier 1993). Interestingly, Furukawa and his colleagues also noted the reduced 
MAK expression in respiratory epithelia of the nasal cavity and in epididymal sperm cells of 
the testis, yet the ciliary length of neither cell types differ in wild-type and MAK-KO mice 
(Omori, Chaya et al. 2010). One possible explaination for this retina-specific phenotype in 
MAK-KO mice is the tissue-specific functional redundancy/compensation. Our studies 
indicate that both ICK and MAK are expressed in respiratory systems and testis, but very 
little of ICK or MOK protein is detected in retina where MAK is highly expressed (Fu Z et 
al., unpublished data), consistent with the notion that functional redundancy may exist 
between MAK, ICK and MOK in testis and lung but not in retina.  
The essential role of MAK in supporting the biological functions of retina was further 
substantiated recently by similar findings from two independent studies (Ozgul, 
Siemiatkowska et al. 2011; Tucker, Scheetz et al. 2011). Exome sequencing and cis-regulatory 
mapping identified six missense point mutations of highly conserved residues within the 
catalytic domain of MAK as a cause of retinitis pigmentosa (RP) (Fig. 1). Also by exome 
sequencing, a 353-bp Alu repeat insertion was found to disrupt the correct splicing of exon 9 
of Mak gene, thereby preventing mature retinal cells from expressing the correct MAK 
isoform in retina. In either case, a lack of active form of MAK gene product in retina was 
implicated as a cause of RP. Interestingly, as pointed out in (Ozgul, Siemiatkowska et al. 
2011), all of the MAK mutations identified in the retinal isoform should also be present in 
testis isoform, yet there were no reports of infertility in the identified male objects, 
consistent with the phenotype of the Mak knockout mice. This finding again raises the 
possibility that ICK may be able to compensate for the lack of MAK in testis where both 
genes are abundantly expressed.       
3.4 MAK in prostate cancer, AR signaling and mitosis 
In contrast to ICK, expression of its closely related kinase MAK is more restricted. However, 





2011). It increased at S phase, peaked at G2 to early M phase, and decreased at late M phase. 
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Robinson et al. 2002). MAK was identified as an androgen-inducible co-activator of 
androgen receptor (AR) in prostate cancer cells (Ma, Xia et al. 2006). Similar to the role of 
ICK in intestinal epithelial cells, MAK is also required for prostate epithelial cell replication 
(Ma, Xia et al. 2006). A recent study from Kung’s lab indicated that over-expression of MAK 
in prostate cancer cells caused mitotic defects that are independent of AR signaling but are 
associated with deregulation of the APC/C(CDH1) (Wang and Kung 2011). 
Unpublished data from Kung’s lab and our own data have suggested that AR is not the 
substrate for MAK in vitro or in vivo. Given the tight physical association of MAK with AR 
complex in cells and the significant biological effect of MAK knockdown on AR signaling 
events, it is quite possible that an AR-associated protein within the AR complex serves as 
the direct target of MAK in regulating the AR signaling. 
Recently, Kung’s lab demonstrated that MAK is over-expressed in prostate cancer cells and 
causes mitotic defects such as centrosome amplification and lagging chromosomes via 
deregulation of APC/CCDH1, thus providing an AR-independent mechanism to promote 
prostate cancer development (Wang and Kung 2011). This report also indicated that CDH1 
is an in vitro substrate for MAK and MAK can negatively regulate APC/CCDH1 through 
phosphorylation of CDH1 at the same CDK-dependent sites. It requires further studies to 
determine whether CDH1 is a true physiologic substrate for MAK and how MAK and CDK 
coordinate to target the same sites to regulate APC/CCDH1 activities.   
4. MOK signaling cascade 
MOK was identified through in silico computer screening of the GENBANK EST database 
using MAP kinase consensus sequences as probes (Miyata, Akashi et al. 1999). MOK 
encodes a protein of 419 (human) and 420 (mouse) amino acids, containing the conserved 
kinase subdomains I-XI and the TEY motif in the activation loop. Structurally, MOK belongs 
to the MAP kinase superfamily, and is closely related to MAK and ICK/MRK, thus termed 
as MOK (MAPK/MAK/MRK overlapping kinase). Although MOK shares highest 
homologies to MAK and ICK, especially in the catalytic domains (41-43% identity), it also 
displays certain structural features that are distinct from MAK and ICK. MAK and ICK have 
the TDY motif in the activation loop, as compared with the TEY motif for MOK. Similar to 
Cdk2, MAK and ICK possess T14Y15 motif in the N-terminal end of their catalytic domains, 
while MOK exhibits T14F15 motif instead in the same position. More significantly, the C-
terminal noncatalytic domain of MOK is much shorter than that of either MAK or ICK (Fig. 
1) and show very little sequence homology to MAK and ICK or any other known protein 
kinases.  
Interestingly, MOK was also isolated from a blast search to analyze homologies to the RAGE 
(renal cell carcinoma antigen)-gene family that encodes antigens of human renal carcinoma 
cells recognized by autologous cytolytic T lymphocytes (Eichmuller, Usener et al. 2002). 
Sequence alignment indicates MOK is identical to RAGE-1, -2, -3 at the 3’-region, but is 
completely different at the 5’-region, suggesting that MOK and RAGE genes may be the 
splicing products from the same gene or MOK may be aberrantly inserted into RAGE genes 
by translocation. What is the molecular genetic basis for this observation and whether MOK 
is involved in RAGE-gene family associated tumorigenesis are interesting questions that 
will motivate further studies.  
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4.1 Regulation of MOK activity in the TEY motif and by TPA 
MOK possesses protein kinase activity towards exogenous substrates for MAPK such as c-
Jun, MBP, cyclin B1 and c-Myc and undergoes autophosphorylation (Miyata, Akashi et al. 
1999). Similar to ICK and MAK, an intact TEY motif in the activation loop of MOK is 
essential for its kinase activity (Miyata, Akashi et al. 1999). The autokinase activity of MOK 
was almost completely abolished when the TEY motif was mutated to AEF, although it is 
not clear whether the Thr and/or the Tyr in the TEY motif are the phosphor-acceptor sites 
by autophosphorylation. 
Similar to ICK and MAK, MOK could not be significantly activated by many extracellular 
stimuli (serum, anisomycin, and hyperosmotic shock) that stimulate MAP kinases (Miyata, 
Akashi et al. 1999). TPA (phorbol 12-myristate 13-acetate), however, at a concentration of 
100 ng/ml, was able to stimulate the MOK activity up to about threefold, albeit at a much 
longer time point after treatment (15-20 min) than that required to maximally activate 
ERK1/2 and p38 MAPK (5 min) (Miyata, Akashi et al. 1999). These results suggest that the 
activation mechanism of MOK by TPA is different from that of MAP kinases. The identity of 
the upstream activating kinase for MOK remains unknown.  
4.2 Regulation of MOK activity and/or functional specificity by subcellular localization 
Recombinant MOK is predominantly cytoplasmic (Miyata, Akashi et al. 1999). In our 
subcellular fractionation studies, we observed both cytoplasmic and nuclear localization of 
endogenous MOK in human cell lines, suggesting that MOK may shuttle between these two 
compartments (Fu, Z et al., unpublished data). The molecular size (48 KDa) of MOK allows 
its nuclear entry by diffusion. In addition, there is a consensus bipartite NLS located in its C-
terminal domain (Fig. 1), possibly permitting selective nuclear targeting as well. Further 
studies are required to elucidate the molecular mechanisms underlying its subcellular 
distribution and to address whether MOK targets different subsets of substrates in different 
locations and thus performs distinct biological functions.  
4.3 Regulation of MOK stability by chaperone proteins 
Work from Professor Eisuke Nishida’s lab suggested specific association of MOK with a set 
of molecular chaperones including HSP90, HSP70 and Cdc37 (Miyata, Ikawa et al. 2001). 
Inhibition of HSP90 chaperone activity caused rapid degradation of MOK through 
proteasome-dependent pathways, suggesting that chaperone association is required to 
stabilize MOK. Interestingly, in the same study both MAK and ICK/MRK were also 
reported to associate with HSP90, although the biological effects of HSP90 association with 
MAK and ICK/MRK were not examined. In our unpublished studies, we also observed 
robust association of chaperones (HSP70 and Cdc37) with ICK and its upstream activating 
kinase CCRK. These results taken together suggest that ICK/MAK/MOK may require the 
presence of chaperone proteins in the same protein complexes for assistance in folding and 
stabilization, a biochemical property that is strikingly different from classic MAP kinases 
that do not specifically associate with chaperones (Miyata, Ikawa et al. 2001).  
4.4 MOK in testis and germ cell development  
MOK (T/STK30, testis-derived serine/threonine kinase 30) was isolated from adult testis 
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(Gopalan, Centanni et al. 1999). T/STK30 transcripts are most abundantly expressed in testis 
and ovary, and were not detected in a sterile mutant testis that lacks germ cells, further 
demonstrating that T/STK30 expression in testis is restricted to germ cells. By in situ 
hybridization, Donovan P.J. and colleagues further demonstrated that T/STK30 transcripts 
were detected in pachytene spermatocytes and round spermatids, but not in spermatogonia 
or testicular somatic cells. Similarly, T/STK30 is highly expressed in female germ cells, but 
not in the surrounding somatic cells that are mostly proliferating. These results, taken 
together, suggest T/STK30 is involved in some aspects of germ cell differentiation and 
maturation. Functional studies (targeted gene disruption and/or over-expression) will be 
required to address the role of MOK (T/STK30) in mammalian gametogenesis.  
4.5 MOK in intestinal cell differentiation 
Although MOK is closely related to ICK in the N-terminal catalytic domain, they differ 
significantly in the structural organization of the C-terminal non-catalytic domain. While 
MOK mRNA appears to be restricted to the crypt compartment of the small intestine, MOK 
protein was detected in the upper crypt and lower villus epithelial cells (Uesaka and 
Kageyama 2004). In HT-29 cells, MOK activity was reported to be elevated by sodium 
butyrate, which is known to inhibit growth and induce differentiation of HT-29 cells 
(Uesaka and Kageyama 2004). This observation suggests a possible role for MOK in the 
regulation of intestinal epithelial differentiation. Does MOK play an important role in the 
induction of growth arrest and differentiation in the intestinal epithelium, which could be 
directly opposite to the role of ICK? What are the upstream modulators and the downstream 
physiological substrates of MOK? Does MOK crosstalk with ICK during the regulation of 
gastrointestinal proliferation and differentiation? If so, what is the molecular basis for this 
interaction? These questions about MOK and its relationship to ICK remain to be clarified. 
5. Conclusion and significant questions 
The ICK/MAK/MOK family shares significant sequence and structural homology to 
MAPKs and CDKs. They all contain a TXY motif in the activation loop that is required for 
full activity. ICK and MAK also possess a CDK-like TY motif, but so far it is unknown 
whether these sites are phosphorylated in vivo and be able to regulate the catalytic activity. 
The regulatory mechanisms of ICK/MAK/MOK appear to be very different from that of 
MAPKs. Unlike classic MAPKs, they are not acutely activated by growth factors or stress. 
The upstream activating kinase for ICK and MAK is CCRK, not MEK or CDK7 complex. 
Both ICK and MAK have a long C-terminal non-catalytic domain with postulated functions 
in protein-protein and protein-DNA interactions, enabling them to operate through 
signaling pathways distinct from that of classic MAPKs.  
Emerging evidence strongly suggest that this group of kinases have important biological 
functions in mammalian development and human diseases. They are involved in regulating 
many fundamental biological processes including cell proliferation, differentiation, 
apoptosis and cell cycle. Yet the molecular basis underlying these regulations is still largely 
elusive.  
Even though tremendous progress has been made to elucidate the regulations and functions 
of ICK/MAK/MOK since their discoveries some 20 years ago, many significant questions, 
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such as a few named below, are yet to be answered in order to fully understand the biology 
of this kinase family in mammalian development and human diseases.   
Q1: What is the molecular basis to determine the substrate and/or signaling specificity for 
ICK/MAK/MOK? This information may be stored in their C-terminal non-catalytic 
domains since they share extensive homology in their N-terminal catalytic domains. The 
recent data showing that the C-terminal domain of MAK is essential for its ciliary 
localization and function in regulating ciliary length provided further support to this notion.  
Q2: What are the upstream stimuli or environmental cues that activate ICK/MAK/MOK? 
Are the expression and activity levels of ICK/MAK/MOK regulated during development or 
stress?  
Q3: Do ICK/MAK/MOK have different subsets of physiologic substrates in different 
subcellular compartments and thus regulate distinct biological processes?  
Q4: Is there a functional redundancy between ICK and MAK in testis? More specifically, 
does ICK compensate for the lack of MAK in spermatogenesis in MAK KO mice? Do MAK 
and ICK signal through scythe or different substrates to regulate germ cell development 
during spermatogenesis? 
Q5: Does MOK have an opposite function to that of ICK or MAK in the intestine and testis 
given the existing evidence seem to indicate that ICK and MAK are pro-proliferation and 
MOK is pro-differentiation?  
Q6: How the ICK, MAK and MOK genes are regulated at the transcription level in a specific 
biological context during development and diseases? Currently very little is known on this 
topic. ICK and FBX9 are divergently transcribed from a bi-directional promoter that 
contains functional sites for β-catenin/TCF7L2 and FOXA (Sturgill, Stoddard et al. 2010). 
MAK transcripts can be down-regulated by retinol during spermatogonial proliferation 
phase of spermatogenesis (Wang and Kim 1993). Cdx2, a caudal-related homeobox 
transcription factor, interacts with the MOK promoter and induces expression of MOK 
transcripts (Uesaka and Kageyama 2004).  
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subcellular compartments and thus regulate distinct biological processes?  
Q4: Is there a functional redundancy between ICK and MAK in testis? More specifically, 
does ICK compensate for the lack of MAK in spermatogenesis in MAK KO mice? Do MAK 
and ICK signal through scythe or different substrates to regulate germ cell development 
during spermatogenesis? 
Q5: Does MOK have an opposite function to that of ICK or MAK in the intestine and testis 
given the existing evidence seem to indicate that ICK and MAK are pro-proliferation and 
MOK is pro-differentiation?  
Q6: How the ICK, MAK and MOK genes are regulated at the transcription level in a specific 
biological context during development and diseases? Currently very little is known on this 
topic. ICK and FBX9 are divergently transcribed from a bi-directional promoter that 
contains functional sites for β-catenin/TCF7L2 and FOXA (Sturgill, Stoddard et al. 2010). 
MAK transcripts can be down-regulated by retinol during spermatogonial proliferation 
phase of spermatogenesis (Wang and Kim 1993). Cdx2, a caudal-related homeobox 
transcription factor, interacts with the MOK promoter and induces expression of MOK 
transcripts (Uesaka and Kageyama 2004).  
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1. Introduction 
Signal transduction is defined as the transfer of a signal starting from a primary messenger 
with a ligand that binds to specific receptors on the cell membrane. The signal then reaches 
the effector molecule(s) through a cascade involving various protein kinases and/or protein 
phosphatases as well as other molecules such as adaptor proteins, anchoring proteins, 
amplifier proteins, etc. Although erythrocytes are nucleus-free cells, they use elements of 
cell signal pathways that help them to maintain membrane integrity, ion transport, and 
metabolism. Aging, some “stress” conditions, and various diseases also may generate cell 
signals into erythrocytes (Minetti и Low, 1997; Antonelou et al. 2010; Berzosa et al. 2011; 
Pantaleo et al. 2010). Molecules from both erythrocyte membranes and from cytosol may 
take part in signal transduction. Membrane components involved in signal transduction 
include receptors, heterotrimeric G-proteins, adaptor and anchoring proteins, and some 
proteins of the Ras-superfamily. The еrythrocyte intracellular signaling cascade is divided 
into protein kinases and phosphatases, second messengers and small GTPases, which could 
further be defined as cell surface and intracellular activities (Pasini et al. 2006). In general, 
the mechanisms of signal transduction in erythrocytes can be summarized in the following 
groups: 1) specific mechanisms triggering changes in the activity of erythrocyte enzymes, 2) 
specific mechanisms inducing changes in the activity of transport systems, 3) signal 
transduction related to membrane association/dissociation of cytoskeletal and integral 
proteins, 4) "stressful" conditions may induce activation of specific cellular signals into 
erythrocytes. Phosphorylation of the erythrocyte proteins by protein kinases and 
phosphatases is the key mechanism for controlling erythrocyte functions. 
2. Binding of extracellular ligands to receptors on erythrocytes membrane 
initiates various processes of phosphorylation of erythrocyte proteins 
2.1 Thyroid stimulating hormone 
Thyroid stimulating hormone (TSH) binds to a specific TSH receptor (TSHR) which 





Yang, T., Y. Jiang, et al. (2002). "The identification and subcellular localization of human 
MRK." Biomol Eng 19(1): 1-4. 
Zhang, J., S. Bao, et al. (2005). "Protein phosphatase 5 is required for ATR-mediated 
checkpoint activation." Mol Cell Biol 25(22): 9910-9919. 
Zuo, Z., N. M. Dean, et al. (1998). "Serine/threonine protein phosphatase type 5 acts 
upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth 
arrest." J Biol Chem 273(20): 12250-12258. 
12 
Protein Kinases and Protein Phosphatases  
as Participants in Signal Transduction  
of Erythrocytes 
Ana Maneva1 and Lilia Maneva-Radicheva2 
1Medical University, Pharmaceutical Faculty,  
Department of Chemistry and Biochemistry, Plovdiv, 
2Medical University, Medical Faculty,  
Department of Chemistry and Biochemistry, Sofia,  
Bulgaria 
1. Introduction 
Signal transduction is defined as the transfer of a signal starting from a primary messenger 
with a ligand that binds to specific receptors on the cell membrane. The signal then reaches 
the effector molecule(s) through a cascade involving various protein kinases and/or protein 
phosphatases as well as other molecules such as adaptor proteins, anchoring proteins, 
amplifier proteins, etc. Although erythrocytes are nucleus-free cells, they use elements of 
cell signal pathways that help them to maintain membrane integrity, ion transport, and 
metabolism. Aging, some “stress” conditions, and various diseases also may generate cell 
signals into erythrocytes (Minetti и Low, 1997; Antonelou et al. 2010; Berzosa et al. 2011; 
Pantaleo et al. 2010). Molecules from both erythrocyte membranes and from cytosol may 
take part in signal transduction. Membrane components involved in signal transduction 
include receptors, heterotrimeric G-proteins, adaptor and anchoring proteins, and some 
proteins of the Ras-superfamily. The еrythrocyte intracellular signaling cascade is divided 
into protein kinases and phosphatases, second messengers and small GTPases, which could 
further be defined as cell surface and intracellular activities (Pasini et al. 2006). In general, 
the mechanisms of signal transduction in erythrocytes can be summarized in the following 
groups: 1) specific mechanisms triggering changes in the activity of erythrocyte enzymes, 2) 
specific mechanisms inducing changes in the activity of transport systems, 3) signal 
transduction related to membrane association/dissociation of cytoskeletal and integral 
proteins, 4) "stressful" conditions may induce activation of specific cellular signals into 
erythrocytes. Phosphorylation of the erythrocyte proteins by protein kinases and 
phosphatases is the key mechanism for controlling erythrocyte functions. 
2. Binding of extracellular ligands to receptors on erythrocytes membrane 
initiates various processes of phosphorylation of erythrocyte proteins 
2.1 Thyroid stimulating hormone 
Thyroid stimulating hormone (TSH) binds to a specific TSH receptor (TSHR) which 





reported that TSHR and Na/K-ATPase are localized on the membranes of both erythrocytes 
and erythrocyte ghosts. TSHR responds to TSH treatment by increasing intracellular cAMP 
levels from two to tenfold. The authors suggest a novel cell signalling pathway, potentially 
active in local circulatory control (Balzan et al. 2009).  
2.2 Parathyroid hormone  
Parathyroid hormone (PTH) operates with G-protein dependent receptors and has been 
shown to decrease erythrocyte deformability in a Ca2+-dependent manner (Bogin et al. 
1986). In pseudohypoparathyroidism, PTH resistance results from impairment caused by a 
deficiency of Gsα-signaling cascade due to a metylation defect of the GNAS gene and 
decrease in erythrocyte Gsα activity (Zazo et al. 2011). 
2.3 Insulin  
Insulin stimulates erythrocyte glycolysis, Na+/H+-antiport and Na+/K+-ATPase (Rizvi et 
al.1994), as well as membrane-associated NO-synthase (Bhattacharaya al. 2001). It has been 
shown that insulin uses signaling pathways involving both ζ-PKC and phospatidylinositol 3 
kinase (PI3K), which leads to the activation of Na+/H+-antiports (Sauvage et al. 2000). 
Insulin is also used in the MAPK-signaling cascade of phosphorylation and activation of 
protein NHE1, responsible for Na+/H+ - antiport (Sartori et al. 1999). 
Participation of C-peptide in insulin signaling pathways has also been discussed, including 
involvement of G-protein and Ca-dependent phosphatase. It has been reported that insulin 
restores the activity of Na+/K +-ATPase (De La Tour et al. 1998). The decrease in Na+/K+ 
adenosine triphosphatase (ATPase) in erythrocytes of type 1 diabetes is thought to play a 
role in the development of long-term complication. Infusion of insulin may restore this 
enzyme activity in red cells (Djemli-Shipkolye et al. 2000). 
A reduced erythrocyte insulin receptor binding and tyrosine kinase activity was measured 
in hypertensive subjects with hyperinsulinemia (Corry et al. 2002). Erythrocytes from 
normal individuals showed increased pH and increased sodium influx (NHE1) after insulin 
stimulation. In contrast, insulin had no effect on NHE1 activity of eryhthrocyte from obese 
individuals (Kaloyianni et al. 2001). Insulin activation of insulin receptor kinase in 
erythrocytes is not altered in non-insulin-dependent diabetes and not influenced by 
hyperglycemia (Klein et al. 2000). 
2.4 Insulin-like growth factor I 
Erythrocytes possess receptors for insulin-like growth factor I (IGF-I). Binding to these 
receptors is dependent on cell age (Polychronakos et al. 1983). Acromegalic patients with 
higher plasma IGF-I and insulin levels presented lower IGF-I specific binding and affinity than 
normal adults. Growth hormone (GH)-deficient children showed higher IGF-I binding without 
significant affinity alterations than normal prepubertal children (el-Andere et al. 1995). 
2.5 Leptin 
The specific binding of leptin on erythrocytes is established by Scatchard analysis (Tsuda, 
2006). NHE1 (Na+/H+-exchanger) activity increases in the presence of leptin but significantly 
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less in the obese than in the control group. Since NHE1 activity is associated with insulin 
resistance and hypertension, the activation of this antiport by leptin may represent a link 
between adipose tissue hypertrophy and cardiovascular complication of obesity 
(Konstantinou-Tegou et al. 2001). It is possible to assume that leptin, similarly to insulin, 
might be able to activate NHE1 through MAPK activation (Sartori et al. 1999; Bianchini et al. 
1991). 
2.6 Adrenaline, Noradrenaline and DOPA 
The β-2-adrenergic receptor coupled to the G-protein binds cateholamines and activates 
adenylate cyclase in human erythrocytes (Horga et al. 2000). The functional beta-receptor 
response depends to a large extent on Ca2+ concentrations (Horga et al. 2000). According to 
Muravyov et al. (2010) a crosstalk between adenylyl cyclase signaling pathway and Ca2+ 
regulatory mechanism exists. The potent beta-adrenergic agonist, isoproterenol (2 microM), 
epinephrine (10 microM) and norepinephrine (10 µM) stimulated the cAMP-dependent 
protein kinase in erythrocyte membranes, 38 +/- 7%, 31 +/- 6%, and 30 +/- 6%, respectively 
(Tsukamoto and Sonenberg, 1979). Micromolar concentration of noradrenaline (1 µM) 
increases the 32Р intake in band 2 with 70%, and with 40% in band 3 (Nelson et al. 1979). 
Adrenaline and noradrenaline are both found to stimulate the erythrocyte Na+/H+-antiport 
(Perry et al. 1991; Paajaste and Nikinmar, 1991). Adrenaline stimulates Na+/H+-antiport 
through activation of NHE1 transport system with participation of РКС, since the effect has 
been reported to potentiate in the presence of phorbol ester (PKC activator), and being  
inhibited  from  calphostin (PKC inhibitor), respectively (Bourikas et al. 2003).  
A specific erythrocyte DOPA transport protein was found who is also capable to transports 
choline. Its functions are regulated by insulin (Azoui et al. 1996). 
Several catecholamines (phenylephrine, dobutamine and dopamine) inhibit the Cl-removal-
activated Ca2+ entry into erythrocytes, thus preventing increase of cytosolic Ca2+ activity, 
subsequent cell shrinkage and activation of erythrocyte scramblase. The catecholamines 
thus counteract erythrocyte phosphatidylserine exposure and subsequent clearance of 
erythrocytes from circulating blood (Lang et al. 2005). 
Exposure of RBCs to adrenaline resulted in a concentration-dependent increase in RBC 
filterability and authors supposed that adrenergic agonists may improve passage of 
erythrocytes through microvasculature (Muravyov et al. 2010). Rasmussen et al (1975) 
reported that the same low doses of adrenaline and isoproterenol induce a decrease of 
erythrocyte deformability.   
2.7 Adenosine 
Adenosine binds to the erythrocyte adenosine type1 receptors (A1AR) and adenosine type 2 
receptors (A2AR), (Lu et al. 2004; Zhang et al. 2011). A1ARs are functionally coupled with 
pertussis toxin-sensitive G proteins and inhibit the activity of adenylate cyclase. A1ARs bind 
to erythrocyte membrane cytoskeletal protein 4.1G, which can inhibit A1-receptor action (Lu 
et al. 2004). A1ARs activation can also trigger the release intercellular Ca2+ (Lu et al. 2004). 
Increased adenosine levels promoted sickling, hemolysis and damage to multiple tissues in 





reported that TSHR and Na/K-ATPase are localized on the membranes of both erythrocytes 
and erythrocyte ghosts. TSHR responds to TSH treatment by increasing intracellular cAMP 
levels from two to tenfold. The authors suggest a novel cell signalling pathway, potentially 
active in local circulatory control (Balzan et al. 2009).  
2.2 Parathyroid hormone  
Parathyroid hormone (PTH) operates with G-protein dependent receptors and has been 
shown to decrease erythrocyte deformability in a Ca2+-dependent manner (Bogin et al. 
1986). In pseudohypoparathyroidism, PTH resistance results from impairment caused by a 
deficiency of Gsα-signaling cascade due to a metylation defect of the GNAS gene and 
decrease in erythrocyte Gsα activity (Zazo et al. 2011). 
2.3 Insulin  
Insulin stimulates erythrocyte glycolysis, Na+/H+-antiport and Na+/K+-ATPase (Rizvi et 
al.1994), as well as membrane-associated NO-synthase (Bhattacharaya al. 2001). It has been 
shown that insulin uses signaling pathways involving both ζ-PKC and phospatidylinositol 3 
kinase (PI3K), which leads to the activation of Na+/H+-antiports (Sauvage et al. 2000). 
Insulin is also used in the MAPK-signaling cascade of phosphorylation and activation of 
protein NHE1, responsible for Na+/H+ - antiport (Sartori et al. 1999). 
Participation of C-peptide in insulin signaling pathways has also been discussed, including 
involvement of G-protein and Ca-dependent phosphatase. It has been reported that insulin 
restores the activity of Na+/K +-ATPase (De La Tour et al. 1998). The decrease in Na+/K+ 
adenosine triphosphatase (ATPase) in erythrocytes of type 1 diabetes is thought to play a 
role in the development of long-term complication. Infusion of insulin may restore this 
enzyme activity in red cells (Djemli-Shipkolye et al. 2000). 
A reduced erythrocyte insulin receptor binding and tyrosine kinase activity was measured 
in hypertensive subjects with hyperinsulinemia (Corry et al. 2002). Erythrocytes from 
normal individuals showed increased pH and increased sodium influx (NHE1) after insulin 
stimulation. In contrast, insulin had no effect on NHE1 activity of eryhthrocyte from obese 
individuals (Kaloyianni et al. 2001). Insulin activation of insulin receptor kinase in 
erythrocytes is not altered in non-insulin-dependent diabetes and not influenced by 
hyperglycemia (Klein et al. 2000). 
2.4 Insulin-like growth factor I 
Erythrocytes possess receptors for insulin-like growth factor I (IGF-I). Binding to these 
receptors is dependent on cell age (Polychronakos et al. 1983). Acromegalic patients with 
higher plasma IGF-I and insulin levels presented lower IGF-I specific binding and affinity than 
normal adults. Growth hormone (GH)-deficient children showed higher IGF-I binding without 
significant affinity alterations than normal prepubertal children (el-Andere et al. 1995). 
2.5 Leptin 
The specific binding of leptin on erythrocytes is established by Scatchard analysis (Tsuda, 
2006). NHE1 (Na+/H+-exchanger) activity increases in the presence of leptin but significantly 
 
Protein Kinases and Protein Phosphatases as Participants in Signal Transduction of Erythrocytes 
 
251 
less in the obese than in the control group. Since NHE1 activity is associated with insulin 
resistance and hypertension, the activation of this antiport by leptin may represent a link 
between adipose tissue hypertrophy and cardiovascular complication of obesity 
(Konstantinou-Tegou et al. 2001). It is possible to assume that leptin, similarly to insulin, 
might be able to activate NHE1 through MAPK activation (Sartori et al. 1999; Bianchini et al. 
1991). 
2.6 Adrenaline, Noradrenaline and DOPA 
The β-2-adrenergic receptor coupled to the G-protein binds cateholamines and activates 
adenylate cyclase in human erythrocytes (Horga et al. 2000). The functional beta-receptor 
response depends to a large extent on Ca2+ concentrations (Horga et al. 2000). According to 
Muravyov et al. (2010) a crosstalk between adenylyl cyclase signaling pathway and Ca2+ 
regulatory mechanism exists. The potent beta-adrenergic agonist, isoproterenol (2 microM), 
epinephrine (10 microM) and norepinephrine (10 µM) stimulated the cAMP-dependent 
protein kinase in erythrocyte membranes, 38 +/- 7%, 31 +/- 6%, and 30 +/- 6%, respectively 
(Tsukamoto and Sonenberg, 1979). Micromolar concentration of noradrenaline (1 µM) 
increases the 32Р intake in band 2 with 70%, and with 40% in band 3 (Nelson et al. 1979). 
Adrenaline and noradrenaline are both found to stimulate the erythrocyte Na+/H+-antiport 
(Perry et al. 1991; Paajaste and Nikinmar, 1991). Adrenaline stimulates Na+/H+-antiport 
through activation of NHE1 transport system with participation of РКС, since the effect has 
been reported to potentiate in the presence of phorbol ester (PKC activator), and being  
inhibited  from  calphostin (PKC inhibitor), respectively (Bourikas et al. 2003).  
A specific erythrocyte DOPA transport protein was found who is also capable to transports 
choline. Its functions are regulated by insulin (Azoui et al. 1996). 
Several catecholamines (phenylephrine, dobutamine and dopamine) inhibit the Cl-removal-
activated Ca2+ entry into erythrocytes, thus preventing increase of cytosolic Ca2+ activity, 
subsequent cell shrinkage and activation of erythrocyte scramblase. The catecholamines 
thus counteract erythrocyte phosphatidylserine exposure and subsequent clearance of 
erythrocytes from circulating blood (Lang et al. 2005). 
Exposure of RBCs to adrenaline resulted in a concentration-dependent increase in RBC 
filterability and authors supposed that adrenergic agonists may improve passage of 
erythrocytes through microvasculature (Muravyov et al. 2010). Rasmussen et al (1975) 
reported that the same low doses of adrenaline and isoproterenol induce a decrease of 
erythrocyte deformability.   
2.7 Adenosine 
Adenosine binds to the erythrocyte adenosine type1 receptors (A1AR) and adenosine type 2 
receptors (A2AR), (Lu et al. 2004; Zhang et al. 2011). A1ARs are functionally coupled with 
pertussis toxin-sensitive G proteins and inhibit the activity of adenylate cyclase. A1ARs bind 
to erythrocyte membrane cytoskeletal protein 4.1G, which can inhibit A1-receptor action (Lu 
et al. 2004). A1ARs activation can also trigger the release intercellular Ca2+ (Lu et al. 2004). 
Increased adenosine levels promoted sickling, hemolysis and damage to multiple tissues in 





2.8 Prostaglandins (PG) 
Binding of PGE2 to receptors coupled to the G-protein activates phospholipase C which in 
turn catalizes phospholipide turnover (Minetti et al. 1997) and/or stimulates a Ca2+-dependent 
K+ chanell in human erythrocytes and alters cell volume and filterability (Li et al. 1996). The 
PGE1 receptor coupled to the G-protein activates adenylate cyclase in human erythrocytes and 
increases erythrocyte deformality (Dutta-Roy et al. 1991). Prostacyclin (PGI) binding to human 
erythrocyte receptors stimulate cAMP synthesis and ATP release (Sprague et al. 2008). 
2.9 Thyroid and steroid hormones 
Lipophilic hormones take part in signal transduction also with "non-genomic" effects using 
signals starting from the plasma membrane (Falkenstein et al. 2000). Their role in 
erythrocyte signal transduction pathways and their activities have not been fully explored. 
Similar results have been reported for thyroid hormones (Angel et al.1989; Botta and Farias, 
1985), and for estrogens (Gonçalves et al. 2001). Effect of thyroid hormones is probably 
related to calmodulin-dependent activation of erythrocyte membrane ATPase (Lawrence et 
al. 1993), that is inhibited in the presence of retinoic acid (Smith et al. 1989).  
In vitro beta-estradiol 10-5 M decreased erythrocyte aggregation in blood samples of 
postmenopausal women undergoing hormone therapy, which could prevent high blood 
viscosity and, consequently, cardiovascular events (Gonçalves et al. 2001). 
Results from X-ray diffraction studies revealed that cortisol and estradiol bind into the 
erythrocyte membrane bilayer, and exert opposite effect over Na+/К+-АТPase activity: 
cortisol diminishes its activity by 24%, but estradiol increases it by 18% (Golden et al. 1999). 
Other published in vitro studies showed that aldosterone stimulates Na+/К+-АТPase activity 
in human erythrocyte membranes (Hamlyn and Duffy, 1978). One possible explanation is 
that the incorporation leads to conformational changes and reorganization in the active 
center of the enzyme molecule of Na+/K+-ATPase. In addition to the delayed genomic 
steroid actions, increasing evidence for rapid, nongenomic steroid effects has been 
demonstrated for virtually all groups of steroids, and transmission by so far hypothetical 
specific membrane receptors is very likely. Nongenomic effects on cellular function involve 
conventional second messenger cascades (Falkenstein et al., 2000). Plasma selenium as well 
as plasma and erythrocyte gluthatione peroxidase activity increase with estrogen during the 
menstrual cycle. The mechanism is still unknown (Ha and Smith, 2003). 
2.10 Cytokines 
Biochemical evidence is provided for the presence of endothelin (ET) receptor subtype B in 
syckle and normal red cells. It was found that ET-1, PAF (Platelet Activating Factor), 
RANTES and IL-10 induce a significant increase in red cell density. These data suggest that 
activation of the Gardos channel is functionally coupled to receptors as C-X-C(PAF), C-C 
(RANTES) and ET receptors type B and the cell volume regulation or erythrocyte 
hydratation state might be altered by activation of the Gardos channel by cytokine in vivo 
(Rivera et al. 2002). 
Human red cells bind specifically IL-8 (a neutrophil activating chemokine) with IL-8RA and 
IL-8RB receptors. Red cell absorbtion of IL-8 may function to limit stimulation of leucocytes 
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by IL-8 released into blood (Darbonne et al. 1991). IL-8 released after acute myocardial 
infarction is mainly bound to erythrocytes (de Winter et al. 1997).  
ICAM-4 belongs to the intercellular adhesion molecules and is an erythrocyte membrane 
component. ICAM-4 interacts specifically with platelet alphaIIbeta 3 integrin. RBCs are 
considerated passively entrapped in fibrin polymers during trombosis through ICAM-4 
(Hermand et al. 2003). 
2.11 Thrombin 
It is assumed that thrombin induces a signal that stimulates the formation of cAMP and 
PGE1 via activation of Gs-dependent adenylate cyclase and Ca2+-independent PKC in 
eryhtrocyte progenitors. Signaling pathway is inhibited by amiloride and by PKC inhibitors 
such as GF-109203X, Go 6976 and staurosporine (Haslauer et al. 1998). However, whether or 
not these signals are also valid for mature erythrocytes has not been studied yet. 
2.12 Lactoferrin 
Lactoferrin (Lf) is a metal-binding glycoprotein with antioxidative (Cohen et al., 1992), anti-
inflammatory, immunomodulatory (Legrand et al., 2004), anticancerogenic (Thotathil and 
Jameson, 2007) anti-bacterial (Weinberg, 2007), antiviral (Mistry et al., 2007), antiatherogenic 
(Kajikawa et al. 1994), and antithrombotic properties (Levy-Toledano et al., 1995).  
Our previous studies showed that Lf binding with erythrocyte membrane receptors (Taleva 
et al., 1999) results in stimulation of glycolysis, antioxidative protection (Maneva et al., 2003) 
and activation of Na+/K+-ATPase activity (Maneva et al., 2007). Lf–receptor interaction 
might intervene in short–term effects of regulation, involving processes of changes in 
association, phosphorylation and oxidation of the membrane proteins.  
Lf (10-50 nM) decreased the ATP content from 9 to 57% depending on the concentration 
used. There is a negative correlation found between the concentration of added Lf and 
formed ATP: y = 2.550 - 0.0076.x, r = - 0.993, p <0.001, n = 5 (Figure 1). The reason for the 
decrease of ATP in the presence of Lf could be the processes of phosphorylation and/or ion 
transport activated by Lf. Lf is an activator of protein phosphorylation (Maekawa et al. 2002; 
Curran et al. 2006) and an activator of  ion transport (Sun et al. 1991). Such a decrease in 
ATP content was found by other authors (Assouline-Cohen and Beitner, 1999; Boadu & 
Sager, 2000) due to stimulation of vital processes of erythrocytes.  
Lf could stimulate glycolysis by interfering with phosphorylation processes: 1) There is 
evidence that insulin activates the Na+/H+ - antiport in erythrocytes by PI3K-dependent 
signaling pathway (Sauvage et al. 2000) leading to activation of glycolysis (Madshus, 1988). 
Like insulin, Lf also activates Na+/H+ - antiport (Sun et al. 1991) and stimulates the lactate 
formation (Maneva et al. 2003). Therefore, it could be suggested that Lf uses the same PI3K - 
dependent mechanism for glycolysis activation (Boivin, 1988); 2) Phosphorylation of tyrosin 
residues in band 3 (Boivin, 1988) leads to dissociation of the complex with glycolytic 
enzymes, leading to their activation (Low et al. 1993). Lf could also stimulate the glycolytic 
enzymes by activating Src-kinase-dependent phosphorylation of band 3. There is data 
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by IL-8 released into blood (Darbonne et al. 1991). IL-8 released after acute myocardial 
infarction is mainly bound to erythrocytes (de Winter et al. 1997).  
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enzymes by activating Src-kinase-dependent phosphorylation of band 3. There is data 







Fig. 1. Correlation and regression analysis of the relation between the concentration of Lf 
and content in erythrocyte ATP (unpublished data).  
Sigma-Aldrich test kit has been used in this experiment. The method is based on using a 
reaction from oxidative phosphorylation (OP) in glycolysis where ATP is produced. OP is 
two–stage process involving the enzymes glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), and 3-phosphoglycerate kinase. The output products of OP are 3-
phosphoglycerate, NADH+ and ATP. The test uses GAPDH in reverse direction: a 
conversion of 1,3 bisphosphoglycerate into glyceraldehyde-3-phosphate, where the 
oxidation of NADH+ to NAD+ is directly proportional to the amounts of the ATP produced. 
The results are presented in µmols ATP/g.Hb.  
Several possible mechanisms could be discussed in regard to how Lf binding to the 
receptors on the erythrocyte membrane might lead to Na+/K+-ATРase activation (Maneva 
al. 2007) via changes in levels of phosphorylation of membrane and cytosolic proteins: 1) 
Changes in the levels of phosphorylation of tyrosine residues in erythrocyte membrane 
modulates not only the activities of band 3 (Brunati et al. 2000), but  also the activity of  α–
subunit of Na+/K+-ATРase (Done et al. 2002). α-subunit of Na+/K+-ATРase is 
phosphorylated by tyrosine kinases, as the target of phosphorylation is known to be the 537 
tyrosne residue in the molecule. This phosphorylation is proved to be a prerequisite for the 
participation of Na+/K-ATРase in signal transduction in experiments with renal cells (Done 
et al. 2002). Lf stimulates tyrosine phosphorylation of proteins (Takayama & Mizumachi, 
2001). 2) It is known that Lf activates casein kinase 2 (CK2), and is phosphorylated by the 
latter (Maеkawa et al. 2002). CK2 phosphorylates and activates a wide spectrum of 
erythrocyte membrane proteins associated in multiprotein complexes with  Na+/K+-ATРase 
(Wei and Tao, 1993); 3) Non-receptor tyrosine kinase Src takes part in signal pathway that 
regulates Na-pump activity in other cell types (Haas et al. 2002). Lf is also able to activate 
Src (Takayama and Mizumashi, 2001). 4) Stimulating effect of Lf could be indirect as Lf 
activates Na+/H+ antiport (Sun et al. 1991). By this mechanism erythrocytes are loaded with 
Na+ thus activating Na+/K+-ATРase which exports Na+ out of the erythrocyte cell.  
















y = – 0.026x + 2.589 
R = – 0.955 
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Membrane receptors for polyamines were proved to exist on erythrocyte membranes 
(Moulinoux et al. 1984). After binding with their receptors, polyamines enhance the protein–
protein interactions among the cytoskeletal proteins and membrane lipid bilayer (Bratton, 
1994; Farmer et al. 1985). Polyamine also inhibits transbilayer movement of plasma 
membrane phospholipids in the erythrocyte ghost (Bratton, 1994). 
Polyamines are CK2 protein kinase activators (Leroy et al.1997). It was found that positively 
charged betaine and polyamines inhibit the activity of membrane Na+/K+-АТPase in 
erythrocytes. It has been demonstrated that the effect of polyamines is based on the 
competitive inhibition mechanism (Kanbak et al. 2001). A similar mechanism is most likely 
responsible for the poor ion transport in cancer patients whose tumor cells secrete 
polyamines (Villano et al. 2001). Raised erythrocyte polyamine levels are estimated in 
patients with diabetes type 1 and in non-insulin dependent diabetes mellitus with great 
vessel disease and albuminuria (Seghieri et al. 1997). 
2.14 Caffeine 
Caffeine binds to erythrocytes membrane proteins (Sato et al. 1990) and could induce 
changes in the erythrocyte protein complex’s formation, thus modulating the activity of 
enzymes involved in signal transduction. Caffeine could interfere with the phosphorylation 
processes in erythrocytes as an inhibitor of erythrocyte CK2 (Lecomte et al. 1980), and PI3K 
(Buckley, 1977) as it was reported in other cell types. Methylxanthines are capable for 
inhibition of cyclin-dependent protein kinases found in both cytosol and erythrocyte 
membranes (Biovin, 1988). 
Processes of phosphorylation-dephosphorylation of erythrocyte membrane and plasma 
proteins provide different levels of interaction and participate in maintaining the integrity of 
the erythrocyte membrane. They also exert control over important metabolic processes in 
erythrocytes. The literature data shows that signals in erythrocytes lead to changes in 
phosphorylation and association of integral membrane proteins and other intracellular 
proteins. Cytosolic protein kinases and protein phosphatases were found in erythrocyte 
membrane.  
3. Protein kinases 
3.1 Protein serine/threonine kinases 
3.1.1 сАМР dependent protein kinases 
Type 1 isoform of cAMP dependent protein kinase is localized in the membrane, while type 
2 is located in the cytosol (Dreytuss et al. 1978). cAMP-protein kinases-dependent 
phosphorylation of isoforms of membrane Ca2+-ATPase was found. Isoform 1 is shown to 
be better substrate in comparison to isoforms 2 and 4. Isoform 1 is susceptible to 
degradation by calpain (thiol-dependent protease) (Guerini et al. 2003). 
In all cells, increasing in cAMP are regulated by the activity of phosphodiesterases (PDEs) 
(Sheppard and Tsien, 1975). In erythrocytes, activation of either beta adrenergic receptors 
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(Sprague et al. 2001). Receptor-mediated increases in cAMP are tightly regulated by distinct 
PDEs associated with each signaling pathway, as shown by the finding that selective 
inhibitors of the PDEs localized to each pathway potentiate both increases in cAMP and 
ATP release (Adderley et al. 2010). 
Adenylyl cyclase and cAMP are components of a signal-transduction pathway relating red 
blood cells (RBC) deformation to ATP release from human and rabbit RBCs (Sprague et al. 
2008). Exposure of RBC to catecholamines (epinephrine, phenylephrine, an agonist of α1-
adrenergic receptors, clonidine, an agonist of α2-adrenergic receptors and isoproterenol, an 
agonist of β-adrenergic receptors) led to change in the RBC microrheological properties. 
Forskolin (10 µM), an adenylate cyclase stimulator, increases the RBC deformability (RBCD). A 
somewhat more significant deformability rise appeares after RBC incubation with dibutyril-
AMP. Red blood cell aggregation (RBCA) is significantly decreased under these conditions. 
All drugs having PDE inhibitory activity increase red cell deformability (Muravyov et al. 
2009).  
Ca2+ entry increase is accompanied by red cell aggregation rise, while adenylyl cyclase-
cAMP system stimulation led to red cell deformability increase and its aggregation lowered. 
The crosstalk between two intracellular signaling systems is probably connected with 
phosphodiesterase activity. It was found that all four PDE inhibitors: IBMX, vinpocetine, 
rolipram, pentoxifylline decreased red cell aggregation significantly and, quite the contrary, 
they increased red cell deformability (Muravyov et al. 2010) 
Erythrocytes are oxygen sensors and modulators of vascular tone (Ellsworth et al. 2009). It 
has become evident that erythrocytes participate in the regulation of vascular caliber in the 
microcirculation via release of the potent vasodilator, adenosine triphosphate (ATP). The 
regulated release of ATP from erythrocytes occurs via a defined signaling pathway and 
requires increases in cyclic 3',5'- adenosine monophosphate (cAMP) (Adderley et al. 2010) . 
Heterotrimeric G protein Gi is involved in a signal transduction pathway for ATP release 
from erythrocytes (Olearczyk et al. 2010). Insulin inhibits human erythrocyte cAMP 
accumulation and ATP release. The targets of insulin action are phosphodiesterase 3 and 
phosphoinositide 3-kinase (Hanson et al. 2010). TSH signalling pathway is cAMP-dependent 
and probably it is potentially active in local circulatory control (Balzan et al. 2009). 
3.1.2 cGMP-pependent protein kinases 
Petrov et al. (1994) supposed that human erythrocytes possess membrane and soluble 
guanylate-cyclase activity stimulated by atrial natriuretic peptide III (ANP-III) and that 
activation of Na+/H+ exchange by this peptide is mediated by cGMP (Petrov and Lijnen, 
1996). There are no reported data considering participation of protein kinases and 
phosphatases in the signal pathway.  
3.1.3 Casein kinase 1 and 2 
Membrane proteins of human erythrocytes can be phosphorylated not only by membrane 
casein kinase but also by cytosolic casein kinases, resembling casein kinase 1 and 2 (CK1 and 
CK2), respectively. CK1 and CK2 phosphorylate serine and threonine residues in target 
proteins (Boivin, 1988). CK2 inactivation mediated by phosphatidylinositol-4, 5-bisphosphate, 
a substrate for phospholipase C which catalyzes formation of lipid mediators IP3 and DAG 
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(Chauhan et al. 1993) has been found. It was established that CK2 is inactivated by insulin 
(Sommerson et al. 1987).  
An increased phosphorylation of the membrane proteins, promoted by the okadaic acid 
(strong inhibitor of P-Ser/Thr-protein phosphatase(s)), is accompanied by a release of CK 
from the membrane into the cytosol. Such an intracellular translocation might provide a 
feedback mechanism for the regulation of the CK catalyzed phosphorylation of membrane 
proteins in human erythrocytes (Bordin et al. 1994). 
The membrane mechanical stability of erythrocytes is exclusively regulated by 
phosphorylation of β-spectrin by membrane bound CK1. Increased phosphorylation of β-
spectrin decreased membrane mechanical stability while decreased phosphorylation 
increased membrane mechanical stability (Manno et al. 1995). 
CK2 isolated from erythrocyte membrane and cytosolic fractions exhibited the same subunit 
composition (αα1) and the ability to utilize ATP and GTP as phosphate donors. Both kinases 
were found to catalize the phosphorylation of several erythrocyte membrane cytoskeletal 
proteins (spectrin, ankyrin, adductin, protein 4.1 and protein 4.9). Unlike CK1, CK2 did not 
phosphorylate band 3. Spermine, spermidine, and putrescine stimulated to varying degrees 
the activities of erythrocyte CK2, whereas heparin inhibited the kinase activities (Wei and 
Tao, 1993).  
The phosphorylation sites of calmodulin are important for its ability to activate the human 
erythrocyte Ca2+-ATPase. Phosphorylation of mammalian calmodulin on serine/threonine 
residues by casein kinase 2 decreased its affinity for Ca 2+-ATPase by two fold. In contrast, 
tyrosine phosphorylation of calmodulin by the insulin-receptor kinase did not significantly 
alter calmodulin-stimulated Ca2+-ATPase activity (Sacks et al. 1996). 
The COP9 signalosome (CSN) is a multimeric complex that is conserved from yeast to man 
(Bech-Otschir et al., 2002). Immunoprecipitation and far-western blots reveal that CK2 and 
PKD are associated with CSN. The COP9 signalosome (CSN) purified from human 
erythrocytes possesses kinase activity that phosphorylates proteins such as c-Jun and p53 
with consequence for their ubiquitin (Ub)-dependent degradation. (Uhle et al., 2003)  
3.1.4 MAPK (Mitogen Activated Protein Kinases)  
It is well known that signaling pathways involving MAPKs are associated with control of 
cell growth and proliferation, but erythrocytes are mature highly differentiated cells. There 
are only a few known participants in the MARK-signaling pathways so far. Immunoblot 
with antiMAPK antibody revealed the two erythrocyte forms of MAPK–p44 (ERK1) and p42 
(ERK2). Insulin and okadaic acid (inhibitor of serine/threonine protein phosphatases) 
stimulate MAPK activity. Insulin enhances the erythrocyte Na+/H+-exchanger through 
MAPK activation (Sartori et al. 1999; Bianchini et al. 1991). Membranes of human erythrocytes 
contain several proteins of the Ras superfamily (Ikeda et al. 1988; Damonte et al. 1990). One 
of them, RhoA, was detected in both cytosol and membrane fraction of the erythrocytes. 
Cytosolic Rho bound specifcally to the cytoplasmic surface of the erythrocyte membrane. 
The translocation of Rho to the membrane was absolutely GTP -dependent at low Mg2+ 
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3.2 Protein tyrosine kinases 
Erythrocyte membrane associated tyrosine kinase activity has been established (Zylinska et 
al. 2002), together with surprisingly high levels of phosphorylated tyrosine in erythrocytes 
(Phan-Dinh-Tuy et al. 1983).  
Two tyrosine kinases that are able to phosphorylate band 3 have been found. Involvement 
of the Src-kinases family in regulation of erythrocyte membrane transport has been 
suggested. That family represents an important class of non-receptor protein kinases 
participating in the regulation of cell communications, proliferation, differentiation, 
migration and survival (Minetti et al. 2004). Subsequent two-stage phosphorylation of band-
3 from Syk- and Lyn-tyrosin kinase was found. (Brunati et al. 2000). 
3.3 Ca2+ dependent phosphorylation 
Since mature RBCs lack intracellular calcium stores, elevation in intracellular calcium must 
stem from calcium influx. At low intracellular Ca2+, efflux of potassium and water 
predominates, leading to changes in erythrocyte rheology (Andrews et al. 2002). At higher 
Ca2+ content, activation of kinases and phosphatases was observed (Minetti et al.1996; 
Cohen and Gascard, 1992). Ca2+ ions are involved in regulation of phospholipase C, the 
enzyme generating inositol-1,4,5-triphosphate (InsP3), phosphatidylinositol-3-kinase (PI3K), 
the enzyme metabolizing InsP3 to InsP4 and in the regulation of protein kinase C (Carafoli, 
1994; Carafoli, 2002). 
3.3.1 Protein kinase C (PKC) 
There are four isoforms of PKC established in the erythrocyte: α, ζ, ι and μ (PKD) (Govekar 
and Zingle, 2001). PKС translocates from cytosol to membrane – a process shown to be 
initiated by phorbol esters and diacylglycerols (Cohen and Foley, 1986). PKD and CK2 are 
associated with COP9 signalosome (CSN) (Uhle et al., 2003). 
PKC phosphorylates serine residues in band 3, band 4.1 and band 4.8 (Govekar and Zingle, 
2001). It has been reported that after stimulation with phorbol ester (PMA), РКС-α 
translocates towards the erythrocyte membrane (Govekar and Zingde, 2001), where it 
phosphorylates serine residues in band 2, and 4.1 and band 4.9 which in turn leads to 
thorough rearrangement of the cytoskeleton membrane network (Giraud et al. 1988; 
Ceolotto et al. 1998). РКС phosphorylates membrane Na+/K+-АТPase (Wright et al. 1993) 
and the carboxyl terminus of the plasma membrane Ca2+-ATPase in human erythrocytes 
(Wang et al. 1991; Wright et al.1993; Smallwood et al.1988) and the effect of phosphorylation 
on the activity of the both enzymes depends on the isoenzyme form of protein kinase C.  
The interactions between membrane, peripheral and cytoskeleton proteins are responsible 
for the maintenance of erythrocyte deformability and some of these interactions are 
modulated by PKC activity. Correlation was established between cytoskeleton proteins, 
PKC activity, band 3 phosphorylation degrees and erythrocyte deformability (de Oliveira et 
al. 2008). PKC participates in the processes of phosphorylation of band 3 that regulates its 
activity as a transport protein (Ceolotto et al. 1998). Protein kinase C mediates erythrocyte 
"programmed cell death" following glucose depletion (Klarl et al. 2006). 
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In erythrocytes, lead acetate stimulates the phosphorylation of membrane cytoskeletal 
proteins by a mechanism dependent on protein kinase C. Since levels of calcium or 
diacylglycerols did not increase, it appears that lead may activate the enzyme by a direct 
interaction (Belloni-Olivi et al. 1996). 
Calpain is a Са2+-dependent thiol protease that translocates towards the erythrocytes 
membrane and activates with increase of intracellular calcium concentration (Glasser et al. 
1994). Calmodulin binds proteins as calpain substrates (Wang et al. 1989). It is known that 
calpain causes transition from Са2+-dependent РКС form to Ca2+-independent one, followed 
by decrease in its activity (Saido et al. 1994).  
3.3.2 Calmodulin (CaM)  
The increase in cellular Ca2+ results in reversible formation of Ca2+/CaM complex that binds 
to a number of enzymes modulating their activity (Carafoli, 2002).   
Calmodulin is a ubiquitous protein whose activity is regulated through phosphorylation 
and specific Ca2+-binding (Benaim and Villalobo, 2002). Ca2+-ATPase interacts with the 
carboxy-terminal half of calmodulin, which is the region that contains the majority of the 
phosphorylation sites in calmodulin (Bzdega and Kosk-Kosicka, 1992). СаМ is 
phosphorylated by serine/threonine kinases such as CK2 and PKA (Benaim and Villalobo, 
2002). Phosphorylation of a tyrosine residue in CaM (Tyr99) increases the affinity of its 
binding to the target proteins thus increasing their activity. A similar stimulating effect of 
CaM has been reported for Ca2+-ATPase (Kosk-Kosicka et al. 1990), myosin light chain 
kinase (MLCK), Ca-CaM dependent kinase (CaM kinase II) and Ca-CaM dependent protein 
phosphatase 2B (calcineurin) (Corti et al. 1999). Elevated intracellular Ca2+, in association 
with the Ca2+-binding protein, calmodulin, stimulates erythrocytes phosphofructokinase 
(PFK) activity. This activation involves the detachment of the enzyme from erythrocyte 
membranes, which has been described as an important mechanism of glycolysis regulation 
on these cells (Zancan and Sola-Penna, 2005).  
СаМ is an inhibitor of РІ3Р-kinase (Villalonga et al. 2002), Na+/H+ antiport (Yingst et al. 
1992) and of erythrocyte Na+/K+-ATPase (Yingst at al. 1992). The latter effect could be 
exerted via inducing of signal pathway involving CaM-dependent kinase that activates 
membrane phospholipase A2(PLA2), which in turn inhibits Na-pump (Okafor et al. 1997).  
4. Protein phosphatases 
Erythrocyte phosphatases that dephosphorylate phosphoserine, phosphothreonine and 
phosphotyrosine residues in different proteins were found. Cytoplasmic phosphatases, low-
molecular-weight acid phosphatases, and neutral membrane-associated tyrosine 
phosphatases have been reported (Clari et al. 1987; Graham et al. 1974).  
Protein phosphatases originated from two ancestor genes, one serving as the prototype for 
the phosphotyrosine phosphatases family (the PTP family), and the other for 
phosphoserine/phosphothreonine phosphatases (the PPP and PPM family). The PPP family 
groups the PP1, PP2, PP2B, PP4, PP5, PP6 and PP7 enzymes, whereas PP2C and bacterial 
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Band 3 is a target for tyrosine phosphatases SHР-1 and SHP-2 (Bordin et al. 2002) and PTP1B 
activities (Zipser and Kosower, 1996). Ca2+ promotes erythrocyte band 3 phosphorylation 
via dissociation of phosphotyrosine phosphatase from band 3 (Ziper et al. 2002) 
SHP-2 is an essential soluble protein tyrosine phosphatase (PTP) containing two spectrin 
homologous domains - SH2. SHR-2 domain participates in multiple signaling pathways of 
growth factors (GF) and cytokines, and plays an important role in the release of signals from 
the cell surface to the nucleus. SH2 is the anchor (docking) place where the protein tyrosine 
kinases, e.g. Src family are attracted to and attached to, thus facilitating phosphorylation-
dephosphorylation cycle. SHR-2 is located in the erythrocytes cytosol and it is translocated 
to the erythrocyte membrane when there is increased tyrosine phosphorylation of the 
transmembrane protein band 3, induced by PTP inhibitors such as pervanadate, and  
N-ethylmaleimide. Band 3 is both anchoring protein and substrate for the SHP-2 (Bordin et 
al. 2002). SHР-1 and SHР-2 ensure dephosphorylation of band 3 in different conditions: 
SHР-2 through interaction of its SH2 domain(s) to p-tyr protein is regulated by the band 3 
tyr-phosphorylation level; SHР-1 dephosphorylates tyr-8, tyr-21 and tyr-904 and may be 
involved by simple membrane rearrangement (Bragadin et al. 2007). 
Protein phosphatase-1 α (PP1alpha) is a selective substrate of peroxynitrite activated src family 
kinase frg and tyrosine phosphorylation of PP1alpha correspond to inhibition of its enzyme 
activity. The final effect of peroxynitrite is the ampliphication of tyrosine dependent signaling, 
a finding of general interest in nitrite oxide related pathophysiology (Mallozzi  et al. 2005) 
РТР1В is localized at the erythrocyte membrane associated with band 3. It is activated by 
Mg2+ and inhibited by Mn2+ and vanadate ions (VO3-), (Zipser  and Kosower, 1996). PTP1B, 
unlike the other enzymes examined, was quantitatively conserved during erythrocyte aging 
(Minetti et al. 2004) and erythrocytes may undergo in vivo activation of the Ca2+-dependent 
calpain system that proteolytically regulates PTP1B activity (Ciana et al. 2004). 
The activities of Na+/H+ exchanger and Na-K-2Cl cotransporter in rat erythrocytes are 
regulated by protein phosphatases PP1 and PP2 and stimulated when protein 
dephosphorylation is inhibited (Ivanova et al. 2006). 
5. Control over glycolytic enzymes 
Glycolytic erythrocyte enzymes that form a complex with band 3 are under regulation by 
the processes of phosphorylation and oxidation (Campanella et al. 2005), and pyruvate 
kinase (PK) - by phosphorylation/dephosphorylation (Kiner and Westhead, 1980). Binding 
of phosphofructokinase (PPK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
aldolase to band 3 lead to their reversible inhibition (Low et al. 1993),   which is neutralized 
by tyrosine kinase phosphorylation of band 3 resulting in enzymes activation. (Harrison et 
al. 1991). р72syk and p56/53lyn tyrosine kinases are also involved in band 3 phosphorylation 
(Hubert et al. 2000), and phosphorylation/dephosphorylation cycle is maintained by protein 
phosphatases РТР1В and SHP-2 (Bordin  et al. 2002; Zipser and Kosower, 1996; Minetti et  
al. 2004).  
PK turns to an inactive form after phosphorylation by сАМР-dependent protein kinase, 
though it is unclear why since erythrocytes do not undergo gluconeogenesis. РК is activated 
by erythrocyte protein phosphatases (Kiener and Weathead, 1980).  
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СаМ induces dimerisation of phosphofructokinase (PFK) and physiological levels of 
concentration of intracellular Ca2+ stimulates its catalytic activity (Marinho-Carvalho et al., 
2006). However, results obtained from other authors showed that Ca2+/calmodulin protein 
kinase (CaM-kinase) phosphorylation inhibits phosphofructokinase (PFK) in sheep heart 
(Mahrenholz et al. 1991) 
Ferricyanide activates glycolysis in erythrocytes in two ways. Ferricyanide is the only 
known non-physiological extracellular agent who induces signal transduction leading to 
activation of cytoplasmic protein tyrosin kinase  that phosphorylates enzyme-binding site in 
band 3, which in turn leads to release and activation of glycolytic enzymes GAPDH 
(glyceraldehyde-3-phosphate-dehydrogenase), PPК (phosphofructokinase) and aldolase 
(Low at al. 1990). It is proved that ferricyanide is a stimulator of glycolysis as end acceptor 
of electrons produced in glyceraldehyde-3-phosphate dehydrogenase reaction. Thus, 
ferricyanide is capable of recovering the level of oxidated NAD+ which is important for 
maintaining the rate of glycolysis (Orringer and Roer, 1979). There are experiment-based 
evidence for the existence of erythrocyte e- transport transmembrane chain related to 
transferrin receptor (Orringer and Roer, 1979; Goldenberg et al. 1990), that is known to 
reduce K3Fe(CN)6 and removes protons from inside the cell through the cell membrane 
(Low et al. 1987). Our own experiments showed that K3Fe(CN)6 inhibits 59FeLF binding to 
erythrocytes (Maneva et al. 2003) as most probably Lf and K3Fe(CN)6 compete for one and 
the same electron formed in oxidative phosphorylation in glycolysis; Lf is the physisological 
activator of the signal pathway used by ferricyanide that leads to tyrosine phosphorylation 
of band 3 and consequent glycolysis activation. 
6. Modulation of components of erythrocyte membrane skeleton  
In terms of proteins, the RBC membrane is a complex network of transporters, cytoskeletal 
molecules, and membrane-bound enzymes. The ability of transmembrane receptor proteins 
to change their cytoskeleton associations in response to ligand binding looks like a key 
mechanism for cell signaling through erythrocyte membrane. The erythrocyte membrane 
skeleton has 3 main components: spectrin molecules forming tetramers α2β2, short actin 
oligomers containing 12-15 monomers, and band 4.1. A variety of membrane-associated 
enzymes, including several kinases (protein kinase A, protein kinase C, cdc kinase, casein 
kinase 1) are thought to regulate interactions within the network through induction of 
phosphorylation, methylation, myristoylation, palmytoylation, or farnesylation (Pasini et  
al. 2010). 
Spectrin binding to actin is initiated from aductin and is significantly inhibited in the 
presence of Са2+ and СаМ. СаМ is able to form weak bonds with spectrine and in the 
presence of Са2+ could influence binding of protein 4.1 to actin, and probably spectrin 
phosphorylation as well (Manno et al. 1995).  
Band 4.1 is mainly involved in membrane skeleton organization due to its ability to initiates 
spectrin/actin association. Band 4.1 binds to the membrane in at least two sites: one high 
affinity site localized on glycophorins, and another low-affinity site associated with band 3. 
Phosphorylation of Band 4.1 by РКС was found to modulate its binding to band 3. Most 
probably, this increases the flexibility of the membrane in response to mechanical stress  
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phosphorylation made cells more deformable and more resistant to mechanical stress 
(Danilov and Cohen, 1989). Association of band 4.1 with glycophorin is important for the 
maintenance of cell shape and is regulatated by polyphosphoinositide co-factor. Indeed, 
when a change in erythrocyte shape was found, a change in the phosphoinositide content 
was also found (Danilov et al. 1990). Band 4.1 phosphorylation regulates the assembling of 
spectrin, actin, and band 4.1 as phosphorylation diminish affinity of band 4.1 to spectrin. 
Band 4.1 and band 4.9 could be phosphorylated in different sites by РКС and by сАМР-
dependent protein kinases (Horne et al.1990).  
Cytoskeletal protein band 4.1G binds to the third intercellular loop of the A1 adenosine 
receptor and inhibits receptor action. (Lu et al., 2004)  
7. Modulation of band 3 
The two most important integral proteins in human erythrocyte memranes are glycophorin 
A and band 3. Вand 3 is multifunctional protein whose N- and C-ends are localized on the 
cytoplasmic surface of the membrane and crosses the cell membrane 14 times. The С-
terminal end is 52 kD domain (residues from 360 to 919) of band 3 and is responsible for 
anion transport through the membrane, while 40 kD from N-terminal end of the cytosolic 
domain plays a critical role in the binding of bilayer to spectrin-based skeletal net. 
Cytoplasmic domain of band 3 serves as a center of membrane organization, interacting 
with proteins, such as ankyrin, protein 4.1 and 4.4, hemoglobin, some glycolytic enzymes, 
tyrosine phosphatases, tyrosine kinase p72 (syk), and Na+/K+ - АТРase. There are about 1 
million copies of band 3 per cell and they are presented as dimeric and tetrameric forms. 
Approximately 40-60% of band 3 is associated with spectrin-stabilizing cytoskeleton (van 
den Akker et al. 2010).  
Band 3 (АЕ1) is a member of the family of anion-transportng proteins that maintain Cl-
/HCO3 – exchange. It refers mainly to erythtocytes and plays a role in СО2 transport among 
the tissues and lungs (Saldanha et al. 2007). Erythrocyte PKC phosphorylates serine residues 
in band 3 (Govekar and Zingle, 2001). 
Band 3 modifications normally occur during physiological red blood cell (RBC) senescence 
and some pathological condition in humans (Santos-Silva et al. 1998). Вand 3-tyrosine 
phosphorylation might be induce in “stress” conditions: “oxidative stress”,  inhibition of the 
phosphoprotein phosphatase activity by vanadate or by thiol group blockers (diamide, N-
ethylmaleimide, etc.), protein tyrosine kinase (РТК) activation from hypertonic NaCl 
solution, or by intracellular increase of  Ca2+ levels (Hecht & Zick, 1992). Erythrocyte thiol 
status is an intrinsic regulator of phospho tyrosine residues levels in band 3 by 
oxidation/reduction of band 3–associated phosphotyrosine protein phosphatases (PTP) 
(Zipser et al. 1997). It is considered that the increase in phosphorylation induced by Са2+ 
ions, and including significant inhibition of PTP activity by dissociation of PTPase from 
band 3 may also play an important part in signal transduction pathways in some 
pathophysiological conditions accompanied with increased levels of intracellular Ca2+ 
(Minetti and Low, 1997).  
Abnormal band 3 tyrosine phosphorylation has been observed in a number of red cell 
disorders (Terra et al. 1998). Hyper-phosphorylated band 3 showed a manifest tendency to 
cluster, indicating a change in its interactions with the cytoskeletal network. Irreversible 
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band 3 tyrosine phosphorylation leads to membrane vesiculation in G6PD deficient red 
cells. Syk kinase inhibition largely prevents red cell membrane lysis and vesiculation, 
strongly suggesting a functional role of band 3 tyrosine phosphorylation in the red cell 
membrane destabilization (Pantaleo et al. 2011; Bordin et al. 2005). 
Based on similarity in oligosaccharide components of band 3 and Lf (Ando et al. 1996), a 
competition for binding sites could be assumed (Beppu et al. 2000; Eda et al. 1996) together 
with restructuring of already established complexes. Our experiments revealed that Lf 
activates erythrocyte glycolysis (Maneva et al. 2003). This fact might be explained with some 
conformational changes leading to the release of glycolytic enzymes from their complex 
with band 3. Studies of the same investigators show that Lf, and erythrocyte band 3 occupy 
the same places on monocyte leukemic cell line THP-1 (Eda et al. 1996). Lf could also 
activate tyrosine phosphorylation of band 3 since Lf is already proved to be able to increase 
tyrosine phosphorylation of membrane proteins (Tanata et al. 1998).  
8. Changes in phosphorylation in oxidative stress  
The alteration of red cell thiol status affects the cell phosphotyrosine status and oxidative 
stress involves inhibition of PTP. Erythrocyte thiol alkylation by N-ethylmaleimide results 
in irreversible PTP inhibition and irreversible phosphorylation (Zipser et al. 1997). 
Oxidation of erythrocyte membrane by diamide leads to formation of disulfide bonds and 
following conformational changes in band 3. Most probably those changes lead to the 
opening of cryptic sites that become accessible for the binding of anti-band 3 antibodies 
(Turrini et al. 1994). Macrophages recognize oxidatively damaged autologous erythrocytes, 
and cell surface fibronectin of macrophages enhances the recognition (Beppu et al. 1991). 
Ca2+ signaling including Ca2+ influx, calmodulin activation, and myosin light chain 
phosphorylation are involved in the fibronectin stimulation of the recognition of 
macrophages for oxidized erythrocytes (Beppu et al. 2000). 
Pervanadate, N-ethylmaleimide and diamide strongly increase the two-stage 
phosphorylation of tyrosine residues of band 3 by Syk-kinase and Src-family (probably Lyn-
kinase). An intriguing fact is that there are different mechanisms by which osmotic and 
oxidative stress activate PTK Syk: oxidative stress leads to autophosphorylation, but osmotic 
one-to SH-2 domain phosphorylation. It was demonstrated that the same agents strongly 
enhance interaction between SHP-2 and band 3, which take part simultaneously with the 
translocation of this phosphatase from cytosol to erythrocyte membrane. These events are 
most likely mediated by Src-phosphorylation, since both translocation of SHP-2 and 
phospatase interaction with the erythrocyte membrane are prevented by РР2, a specific Src 
inhibitor. SHP-2 binds to band 3 via its SH2 region(s). Authors suggest that the attraction of 
cytosolic SHP-2 to band 3 preceeds the next dephosphorylation of the transmembrane 
protein (Bordin et al. 2002).  
Peroxynitrite (ONOO.) is a product of the reaction of nitric oxide and superoxide anion. It is 
able to nitrate protein tyrosine. If this modification occurs on phosphotyrosine kinase, 
substrates can down-regulate cell signaling. ONOO. at low concentrations is a stimulator of 
both band 3 tyrosine phosphorylation and erythrocyte glycolysis, but  higher  concentratons 
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substrates can down-regulate cell signaling. ONOO. at low concentrations is a stimulator of 
both band 3 tyrosine phosphorylation and erythrocyte glycolysis, but  higher  concentratons 





nitration of tyrosines in cytosolic domain of band 3, and irreversible inhibition of lactate 
production (Mallozi  et al. 1997). 
Deoxygenation and increase in intracellular Mg2+ content induce phosphorylation of 
tyrosine residues in human erythrocytes (Barbul et al. 1999).  
Increasing in erythrocyte volume is combined with stimulation in the activities of the two 
PTK- р72 (syk) and р56 (lyn) that phosphorylate band 3 (Musch et al. 1999).  
Oxidation of methionine residues in CaM prevents its activating effect on membrane Са2+-
АТPase (Gaop et al. 2001).  
The erythrocyte has a pool of flavonic compounds, which are considered a buffer, 
maintaining the antioxidative activity of the erythrocyte (Fiorani et al., 2003) Quercetin and 
resveratrol (piceatannol) take part in the regulation of the phosphorylation of band 3 in the 
presence of the physiological oxidant peroxinitrite. Quercetin decreases the Syk activity and 
particularly prevents mediated by the free radical peroxynitrite (ONOO.) phosphotyrosine 
phosphatase inhibition. Restraverol (whose anlogue is piceatannol) has another mechanism 
of action – it enables the mediated by peroxynitrite stimulation of tyrosine phosphorylation 
by another phosphotyrosine protein kinase – Lyn (Maccaglia et al., 2003). 
Pleiotropic effects of resveratrol include antioxidant activity and inhibition of 
cyclooxygenase with decrease of PGE(2) formation. In erythrocytes, oxidation and PGE(2) 
activate Ca2+-permeable cation channels. The Ca2+-entry leads to activation of Ca2+-sensitive 
K+channels with subsequent cell shrinkage and cell membrane scrambling with 
phosphatidylserine (PS) exposure at the erythrocyte surface. Cell shrinkage and 
phosphatidylserine exposure are hallmarks of suicidal erythrocyte death or eryptosis. 
Eryptotic cells adhere to the vascular wall, thus compromising microcirculation, and are 
cleared from circulating blood, thus leading to anemia. Resveratrol is a potent inhibitor of 
suicidal erythrocyte death during energy depletion, oxidative stress, and isoosmotic cell 
shrinkage. The nutrient could thus counteract anemia and impairment of microcirculation 
under conditions with excessive eryptosis (Qadri al. 2009). However, in some cases, 
flavonoids have been suggested to work as prooxidants (Kitagawa et al. 2004) 
9. Eryptosis (Apoptosis)  
Two signaling pathways converge to trigger apoptosis: (1) formation of PGE2 leads to 
activation of Ca2+-permeable cation channels; (2) the PLA2 (Phospholipase A 2) mediated 
release of PAF (platelet–activating factor) activates a sphingomielinase, leading to formation 
of ceramide. Increased cytosolic Ca2+ activity and enhanced cermide levels lead to 
membrane scrambling with subsequent PS exposure. Ca2+-activated Ca2+-sensitive K+ 
channels leading to cellular KCl loss and cell shrinkage. Ca2+ stimulates the protease calpain, 
resulting in degradation of cytoskeleton (Foller et al. 2008; Lang et al. 2010). 
Most triggers of eryptosis, except oxidative stress, are effective without activation of caspases. 
The involvement of Fas/caspase 8/caspase 3-dependent signaling in erythrocytes leads to PS 
externalization, a central feature of erythrophagocytosis and erythrocyte biology. The 
oxidatively stressed red cell recapitulated apoptotic events, including translocation of Fas into 
rafts, formation of a Fas-associated complex, and activation of caspases 8 and 3. The ROS 
(Radical Oxygen Species) scavenger N-acetylcysteine inhibits eryptosis (Mandal et al. 2005).  
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Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion 
(Klarl et al. 2006).  
Eryptosis is stimulated in a wide variety of diseases including sepsis, haemolytic uremic 
syndrome, malaria, sickle-cell anemia, beta-thalassemia, glucose-6-phosphate 
dehydrogenase (G6PD)-deficiency, phosphate depletion, iron deficiency, and Wilson's 
disease. Excessive eryptosis is observed in erythrocytes lacking the cGMP-dependent 
protein kinase-1 (cGK1) or cAMP activated protein kinase (AMPK). Moreover, eryptosis is 
elicited by osmotic shock, oxidative stress, and energy depletion, as well as a wide variety of 
endogenous mediators and xenobiotics. Inhibitors of eryptosis include erythropoietin, nitric 
oxide NO, catecholamines, and high concentrations of urea (Lang et al. 2006). 
10. Effect of modulators of phosphorylation on activity of erythrocyte 
glycolysis and sodium pump 
Modulation of cellular signals from other agents is a leading pharmaceutical approach for 
developing a therapeutic strategy for many diseases. Of significant practical importance is to 
address the right questions and to find the appropriate answers in regard to whether certain 
agents would exert synergic or opposite effects over key cellular functions.  
Erythrocyte membranes mediate the relation between ion transport and glycolysis. Na+/K+-
ATPase is not only transport system but also participates in ouabain – initiated signal 
transduction (Haas et al. 2002; Xie and Cai, 2003; Mohammadi et al.2001), and inititated cell 
signals in cardiac myocytes that are independent from changes of intracellular 
concentrations of Na+ and Ca2+ (Liu et al. 2000). It was demonstrated that glyceraldehyde-3-
phosphate-dehydrogenase interacts with cytoplasmic surface of Na+/K+-ATPase, and that 
interaction is shown to be inhibited by ouabain (Fossel and Solomon, 1978). The α-subunit of 
Na+/K+-ATPase and band 3 form a heterodimeric structure (Martin and Sachs,. 1992). 
Similar structural integration allows shared control of both glycolysis and ion transport, and 
possible interference of modulators of ion transport in the control of glycolysis might be 
suggested (Fossel and Solomon, 1978). To verify our hypothesis we studied the effect of the 
same modulators of phosphorylation on both glycolysis (by measuring the amounts of its 
final product lactate) and Na+/K+-ATPase activity.  
10.1 Methods 
10.1.1 Isolation of the erythrocytes 
Heparinized fresh drawn blood from healthy donors was centrifuged at 2,000 ×g for 5 min 
at 4°C and the pellet was resuspended in 4 volumes of phosphate buffered saline (PBS) pH 
7.4. After three washes at 1,800, 1,500, 1,300 xg, the erythrocytes were isolated by density 
separation (Cohen et al., 1976). The erythrocyte fraction was resuspended in PBS pH 7.4 to 
obtain the same concentration as in the fresh blood. Cell concentration was counted in 
Burker’s camera by a Standard KF2 microscope (Carl Zeiss, Jena, Germany). The suspension 
did not contain other cell species. 
10.1.2 Preparation of the erythrocyte membranes 
Five milliliters of packed RBCs were mixed with 15 ml cold PBS (0.144 g/l KH2PO4.7H2O, 
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at 4°C. The supernatant was discarded, and cells were washed with 15 ml cold PBS, 
centrifuged as above, and resuspended in 5 ml of 5 mM Na2HPO4, pH 8.0, for hypotonic cell 
lysis. Lysed cells were centrifuged at 25,000 ×g for 15 min at 4°C, after which the 
supernatant was gently aspirated and discarded. The RBC membrane pellet was repeatedly 
washed (4–5 times) with 5 mM Na2HPO4 until the pellet appeared white (indicating removal 
of Hb), and membranes were used for further experiments. The protein content of 
hemoglobin-free pellets was determined according to Bradford (1976), with human serum 
albumin as a calibrator. Samples were diluted to protein contents of 1.5 g/L. 
10.1.3 Hemoglobin measurement 
The hemoglobin (Hb) concentration of the erythrocyte suspension was determined 
according to Beutler (1975). 
10.1.4 Cell treatment 
The 50 µl erythrocyte suspension (2×107 cells/ml) was incubated 30 min at 25°C. Samples 
were performed in quadruplicates. In order to estimate the effect of cell signal modulators, 
samples were incubated either in the presence or in the absence of the agents.  
10.1.5 Chemicals 
All chemicals were purchased from Sigma-Aldrich Co, St Louis, MO USA. The mentioned 
below concentrations were chosen according the producer’s prescription and data existing 
in the literature about their optimal effect: Go6976 (50 nM) and Go6983 (50 nM) – inhibitors 
of protein serine kinase PKC. Go6976 is an inhibitor of the classic isoforms of PKC and PKD, 
while Go6983 inhibits only the classic isoforms. Both inhibitors were used simultaneously to 
exclude the effect of PKD; Caffeine (20 mM) was used as a phosphodiesterase inhibitor; 
Okadaic acid (20 nM) and Calyculin А (50 nM) as inhibitors of serine/treonine protein 
phosphatases; N-(6-Aminohexyl)-5-chloro-1-naphtalene-sulfonamide (W-7) (30 µM) as a 
calmodulin antagonist. 
10.1.6 Determination of lactate content in erythrocytes 
After centrifugation for 10 min at 2,000 ×g erythrocytes were resuspended in 0.4 ml 10% 
trichloroacetic acid (TCA). For obtaining of total  precipitation the samples were cooled on 
ice 10 min and then centrifuged again at the same conditions. 0.1 ml from the supernatant 
was used further according the prescription of the test kit reagent obtained from “SIGMA 
Diagnostics” (St. Louis, USA). The method was based on the reaction of pyruvate oxidation 
in the presence of NADH and lactate dehydrogenase. To estimate lactate, the reaction was 
carried out with excess NAD+ and the OD of NADH was measured at 340 nm. 
50 µl of erythrocyte suspension (2×107 cells/ml) was incubated for 30 min at 25°C in the 
presence (samples) or absence (control) of the chosen agents. After 10 min of centrifugation 
at 2,000 ×g, erythorcytes were resuspended in 0.4 ml of 10% TCA. For total sedimentation, 
erythrocytes were cooled down for 10 min and the centrifugation step was repeated at the 
same conditions. 0.1 ml from the supernatant was added to a preliminary prepared solution 
of NAD+ in 2.0 ml glycine buffer, 4.0 ml ddH2O and 0.1 ml lactate dehydrogenase. Instead of 
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supernatant, 0.1 ml 10% TCA was added as a blank. After 30 min of incubation at room 
temperature, the extinction was read at OD=340 nm. Results were calculated using a 
standart curve and equation according to kit instruction. Results were presented in μg/ml.  
10.1.7 Erythrocyte membrane ATPase activity 
Here, a method based on enzyme kinetics was used for evaluation of ATPase activity based 
on the amounts of generatated NAD+ in glycolytic reactions. The following reactions were 
explored: 1) conversion of phosphoenolpyruvate (PEP) to pyruvate and ATP by pyruvate 
kinase; 2) interconversion of pyruvate and lactate with concomitant interconversion of 
NADH and NAD+ catalyzed by lactate dehydrogenase (Vásárhelyi et al., 1997).  
Samples (50 µl) with protein concentration 1.5 g/l of erythrocytes membranes were added to 
450 µl of the following solution with final concentration per liter: 100 mmol of NaCl, 20 
mmol of KCl, 2.5 mmol of MgCl2, 0.5 mmol of EGTA, 50 mmol of Tris-HCl, pH 7.4, 1.0 mmol 
of ATP, 1.0 mmol of phosphoenolpyruvate, 0.16 mmol of NADH, 5 kU of pyruvate kinase, 
12 kU of lactate dehydrogenase (all purchased from Sigma). Finally, the tested modulators 
were added in the samples in above mentioned concentrations. After 5 min, 5 µl of 10 
mmol/l ouabain was added to inhibit the ouabain-sensitive ATPase activity. The change in 
absorbance was measured at OD=340 nm by a twin test (i.e., combination of two assays in 
one cuvette); Rate A (i.e., slope of total ATPase activity), 80–280 s; Rate B (i.e., slope of 
ouabain-resistant ATPase activity), 400–600 s. The difference between the two slopes was 
proportional to the Na+/K+-ATPase activity (Vásárhelyi et al. 1997). One unit of ATPase 
activity (1U) equals to one μmol oxidized NADH for 1 min. Calculations are based on the 
fact that NADH solutition with concentration 1 mg/ml has 0.80 extinction at OD=340 nm  
(E340 = 0.80) (Vásárhelyi et al. 1997). 
10.2 Results 
PKC inhibitors (Go6876 and Go6983), protein phosphatase inhibitors (OA and calyculin A), 
caffeine, and W-7 increased reliable lactate formation. Calyculin A  inhibits reliable Na+/K+-
ATPase (Table 1 and 2). From all studied modulators only Go6976 and Go6983, which are 
PKCs inhibitors, stimulated reliably Na+/K+-ATPase, with 194% and 84%, respectively 
(Table 1 and 2; Figure 2 and 3). 
 
Agents ( n = 6) Lactate μmol/g.Hb x ± SD p 
No agents (control) 5.15 ± 0.19 - 
Go6976 8.23 ± 0.63 <0.001 
Go6983 8.21 ± 3.24 <0.05 
Caffeine 8.07 ± 0.65 <0.001 
ОA 7.84 ±  1.45 <0.001 
Calyculin A 7.23 ± 0.37 <0.001 
W-7 11.12 ± 0.30 <0.001 
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supernatant, 0.1 ml 10% TCA was added as a blank. After 30 min of incubation at room 
temperature, the extinction was read at OD=340 nm. Results were calculated using a 
standart curve and equation according to kit instruction. Results were presented in μg/ml.  
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mmol of KCl, 2.5 mmol of MgCl2, 0.5 mmol of EGTA, 50 mmol of Tris-HCl, pH 7.4, 1.0 mmol 
of ATP, 1.0 mmol of phosphoenolpyruvate, 0.16 mmol of NADH, 5 kU of pyruvate kinase, 
12 kU of lactate dehydrogenase (all purchased from Sigma). Finally, the tested modulators 
were added in the samples in above mentioned concentrations. After 5 min, 5 µl of 10 
mmol/l ouabain was added to inhibit the ouabain-sensitive ATPase activity. The change in 
absorbance was measured at OD=340 nm by a twin test (i.e., combination of two assays in 
one cuvette); Rate A (i.e., slope of total ATPase activity), 80–280 s; Rate B (i.e., slope of 
ouabain-resistant ATPase activity), 400–600 s. The difference between the two slopes was 
proportional to the Na+/K+-ATPase activity (Vásárhelyi et al. 1997). One unit of ATPase 
activity (1U) equals to one μmol oxidized NADH for 1 min. Calculations are based on the 
fact that NADH solutition with concentration 1 mg/ml has 0.80 extinction at OD=340 nm  
(E340 = 0.80) (Vásárhelyi et al. 1997). 
10.2 Results 
PKC inhibitors (Go6876 and Go6983), protein phosphatase inhibitors (OA and calyculin A), 
caffeine, and W-7 increased reliable lactate formation. Calyculin A  inhibits reliable Na+/K+-
ATPase (Table 1 and 2). From all studied modulators only Go6976 and Go6983, which are 
PKCs inhibitors, stimulated reliably Na+/K+-ATPase, with 194% and 84%, respectively 
(Table 1 and 2; Figure 2 and 3). 
 
Agents ( n = 6) Lactate μmol/g.Hb x ± SD p 
No agents (control) 5.15 ± 0.19 - 
Go6976 8.23 ± 0.63 <0.001 
Go6983 8.21 ± 3.24 <0.05 
Caffeine 8.07 ± 0.65 <0.001 
ОA 7.84 ±  1.45 <0.001 
Calyculin A 7.23 ± 0.37 <0.001 
W-7 11.12 ± 0.30 <0.001 






10.3.1 Effect of PKC inhibitors 
Four isoforms of PKC in erythrocytes have been found: α, ζ, ι and μ (PKD). Erythrocyte PKC 
phosphorylates serine residues in band 3, band 4.1 and band 4.8 (Govekar and Zingle, 2001). 
Go6976 and Go6983 are used to exclude the involvement of PKD in cell signals. Go6976 
inhibits classical isoforms of PKC and PKD, but Go6983 inhibits classical isoforms only. The 
absence of differences in the effects of Go6976 and Go6983 on the lactate formation (Table 1) 
excludes the involvement of PKD in the control of glycolysis and may indicate involvement 
of classical PKCα as a negative regulator of glycolysis. It was demonstrated that PKC 
translocated from the interior of erythrocytes to the membrane as a result of various stimuli 
(Govekar and Zingle, 2001). 
Go6976 (inhibitor of classic isoforms and PKD), and also PKD "switch-off" inhibitor Go6983, 
reliably activate ATPase activity. This presents PKC as a negative regulator of Na+/K+-
ATPase. The effect of stimulation with Go6976 is almost twice higher than stimulation with 
Go6983 (Table 2 and Fig.3). This probably suggests a specific function of PKD as an inhibitor 
of Na+/K+-ATPase. PKD has a catalytic domain, which shows more similarity to CaM-
dependent kinases than to PKC. PKD efficiently phosphorylated synthetic substrates of 
Ca2+/CaM -dependent kinase II, but does not catalyze phosphorylation of substrates  
 
Agents ( n = 6) Na+/K+ ATPase  [U/g. Protein] p 
No agents (control) 4.44 ±  0.98 - 
Go6976 13.04 + 2.11 <0.001 
Go6983 8.18 + 3.24 <0.05 
Caffeine 5.68 + 1.57 >0.1 
ОA 5.18 ± 0.61 >0.1 
Calyculin A 2.71 ± 0.98 <0.02 
W-7 4.81 + 0.86 >0.1 






















Fig. 2. Effect of modulators of phosphorylation on lactate formation (control=100%). 
 


































Fig. 3. Effect of modulators of phosphorylation on Na+/K+-ATPase (control=100 %) 
typical of PKC (Ron et al., 1999). CaM inhibits the sodium pump in erythrocytes (Okafor et 
al. 1997; Yingst et al. 1992), and because of similarities with the effects of CaM, PKD 
participation in erythrocyte phosphorylation could be assumed, leading to a decrease in 
activity of Na+/K+-ATPase. It is also proven an inhibitory effect of PKD on Na+/H+ - 
antiport in other cell types (Haworth and Sinnet-Smithh, 1999). It could be speculated that 
due to the antiport inhibition by PKD, the activity of Na+/K+-ATPase is being reduced.  
10.3.2 Effect of caffeine 
The mechanisms by which caffeine stimulates erythrocyte glycolysis (Table 1 and Fig.2) may 
include modulation of erythrocyte protein phosphorylation (Boivin, 1988) or changes in the 
conformation of the erythrocyte membrane proteins that facilitate the access of enzymes 
phosphorylating band 3 (Sato et al. 1990). It is known that methylxanthines are able to 
inhibit cyclic nucleotide-dependent protein kinases present in the cytosol and the 
erythrocyte membrane (Boivin, 1988). This inhibition may be due to competition for ATP 
(Boivin, 1988) and may be involved in the regulation of PK, whose active form is the 
dephosphorylated one (Kiener and Weathead, 1980; Garrillo et al., 2000; Nakashima et al., 
1982). Caffeine can exert an indirect effect on lactate formation in erythrocytes through 
stimulation of Na+/K+-ATPase (Gusev et al. 2000), but our results showed that caffeine has 
no reliable effect on the activity of erythrocyte Na+/K+-ATPase (Table 2 and Fig 3). The 
identified differences may be due to the fact that in that study, erythrocytes from Rana 
temporaria were examined (Gusev et al, 2000). 
10.3.3 Effect of protein phosphatases inhibitors 
Okadaic acid (OA) is an inhibitor of serine/treonine phosphatases (Bordin et al. 1993). The 
incentive effect of OA on glycolysis (Table 1 and Fig.2) may be indirect, as a consequence of 
activation of MAPK-dependent way that increases Na+/H+-antiport (Sartori et al. 1999). It is 
known that one of the mechanisms for glycolysis stimulation is the activation of proton 
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growth factors (GF), e.g. TGF and EGF, exert a stimulatory effect on Na+/H+-antiport (NHE-
1) through phosphorylation of identical serine residues in its molecule (Sardet et al. 1991). 
Calyculin A and OA are likely to cause stimulation of glycolysis by using pathways 
involving protein phosphatase type II (PP2), Table 1 and Fig 2. Protein phosphatase type I 
(PP1) is highly sensitive to calyculin A (CalA), but not to OA. Protein phosphatase type II 
(PP2) is highly sensitive to both inhibitors, CalA and OA (Bize et al. 1999). OA has no effect 
on erythrocyte sodium pump (Table 2 and Fig.3), which probably means that phosphatase 
type II (PP2) is not involved in cellular signals engaged with the control of Na+/K+-ATPase, 
but Calyculin A inhibits reliably (with about 40%) the pump activity, which may be due to 
the involvement of PP1 in cell signals leading to activation of Na+/K+-ATPase (Table2 and 
Fig.3).  
10.3.4 Effect of W-7 
As calmodulin antagonist W-7 restores reduced physiological ability of erythrocytes to 
change their shape when loaded with Са2+ (Murakami et al. 1986) and also exerts a 
vasodilator effect (Beresewiz, 1989). The beneficial effect of W-7 on erythrocyte rheology 
may be due to its stimulatory effect on glycolysis and improvement of erythrocyte 
bioenergetics (Table 1 and Fig.2). The stimulatory effect of W-7 on glycolysis may be due to 
blocking the inhibitory effect of calmodulin on Na+/Н+-antiport (Yingst et al. 1992), or to 
decrease in the processes of phosphorylation/dephosphorylation, regulated by 
Са2+calmodulin (Benaim and Villalobo, 2002, Corti et al. 1999). W-7 increases by 8% the 
activity of Na+/K+-ATPase but the effect lacks statistical significance (Table 2 and Fig.3) in 
the absence of Ca2+. There is evidence in the literature for an inhibitory effect of calmodulin 
on erythrocyte Na+/K+-ATPase, which occurs at 2 µM Ca2+ in the incubation medium 
(Yingst et al. 1992). The difference with our results could be explained probably with these  
specific experimental conditions. In our study, no extra ammounts of calcium were added 
into incubation medium. Erythrocytes have about 80 nM intracellular Ca2+ (Astarie et al. 
1992). Perhaps the inhibitory effect of calmodulin (resp. stimulation with W-7) on the 
sodium pump acts as a regulatory mechanism when an increase in intracellular calcium 
content is presented, and primarily affects Ca2+-binding capacity of calmodulin (Astarie et 
al. 1992). 
10.4 Conclusions  
Processes of phosphorylation-dephosphorylation of erythrocyte membrane and plasma 
proteins provide different levels of interaction, and also participate in maintaining the 
integrity of erythrocyte membrane and exerting control over important metabolic processes 
in erythrocytes. Summary of the existing data in literature shows they are more 
comprehensive in terms of the effect of primary messengers that bind to membrane 
receptors on erythrocytes and the consequent biological effects of the ligand-receptor 
interaction. Down-stream signaling pathways, though, where a major role in 
phosphorylation processes is played by protein kinases and protein phosphatases, remain 
less clear. Expansion of our knowledge and better understanding of signal transduction in 
erythrocytes will enable possible control to be exerted over their impact in maintenance of 
vascular tone, procoagulant activity and antioxidant status, erythrocyte aging, senescence, 
eryptosis (apoptosis), and erythrophagocytosis. Our results demonstrate that erythrocytes 
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use different cell signals for regulation of glycolysis and activity of the sodium pump. They 
also reveal that different classes of PKC most likely taking part in regulation of glycolysis and 
Na+/K+-ATPase. Protein phosphatase inhibitors have opposite effects in the control of 
glycolysis and sodium pump, which indicates involvement of different protein phosphatases 
in cellular signal transduction that controls ion transport and cell energetics. Caffeine and W-7 


























Fig. 4. Erythrocytes use different processes of phosphorylation in regulation of glycolysis 
and sodium pump.  
(A). Glycolysis. Go6976 and Go6983 are inhibitors of PKC and stimulators of glycolysis. The 
target for this effect is PKC-α, which is probably a negative regulator of glycolysis. Caffeine 
increases the formation of lactate as: a) an activator of phosphodiesterase and inhibitor of 
c.AMP-dependent phosphorylation processes that keeps pyruvate kinase in dephosphorylated 
active form; b) induces conformational changes or activates phosphorylation of band 3. W-7 as 
a CaM antagonist blocks its inhibitory effect on Na+/H+-antiport, which activates glycolysis. 
Okadaic acid (OA) stimulates glycolysis as an inhibitor of protein phosphatase PP2, which is 
probably a negative regulator of glycolysis, and as a stimulator of MAPK-dependent 
phosphorylation of Na+/H+-antiport. Calyculin A (CalA) activates glycolysis as PP2 inhibitor 
that turns the proteins involved in glycolysis to their active dephosphorylated form. (B) 
Na+/K+-ATPase. PKD is likely a negative regulator of the sodium pump using CaM-
dependent pathway since its specific inhibitor Go6976 significantly increases the activity of 
Na+/K+-ATPase. Cal A inhibits the activity of the pump reliably, which may be due to the 
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The aim of this chapter is to present a review of the main protein kinases involved in the 
signalling pathways between the stimulation of smooth muscle cell and the resulting 
dynamic contraction.   
As in striated muscle cells, contraction in smooth muscle cells (SMC) is primarily triggered 
by intracytosolic Ca2+ ([Ca2+]i) increase. However, by contrast with striated muscle, in SMCs 
[Ca2+]i increase generates contraction by activation of the myosin light chain kinase (MLCK) 
via the formation of the Ca2+-calmodulin-MLCK complex. Activated MLCK phosphorylates 
the 20kDa regulatory light chain (MLC20) of the thick filament. Phosphorylated MLC20 
allows myosin to bind to actin, and this phosphorylation is critical for SMC contraction, 
since its inhibition generally abolishes agonist-dependent contraction, whereas relaxation is 
induced by MLC20 dephosphorylation by myosin light chain phosphatase (MLCP). Hence, 
excitation-contraction coupling in SMCs critically depends on Ca2+-dependent MLCK 
activation and the balance of MLCK/MLCP activity. Moreover, it has been shown that these 
two major enzymes can be modulated by several protein kinases such as protein kinase A 
(PKA), protein kinase C (PKC) and Rho kinase (RhoK). As a consequence, these protein 
kinases indirectly modulate the activity of the thick filament of myosin. Additionally, actin-
myosin interaction can be modulated by proteins associated to the thin filament of actin 
such as caldesmon and calponin, which modulation depends on their phosphorylation by 
several protein kinases. It appears then that in SMCs, the excitation-contraction coupling is 
determined by interacting signalling pathways involving various protein kinases, so that the 
canonical MLCK/MLCP enzymatic balance is embedded in a complex network of protein 
kinases acting both on the thick and thin filaments of the contractile apparatus. The  chapter 
will present the functional structure of the contractile apparatus of SMC, and detail its 
activation by the Ca2+-calmodulin-MLCK complex and down regulation by MLCP, and the 
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The aim of this chapter is to present a review of the main protein kinases involved in the 
signalling pathways between the stimulation of smooth muscle cell and the resulting 
dynamic contraction.   
As in striated muscle cells, contraction in smooth muscle cells (SMC) is primarily triggered 
by intracytosolic Ca2+ ([Ca2+]i) increase. However, by contrast with striated muscle, in SMCs 
[Ca2+]i increase generates contraction by activation of the myosin light chain kinase (MLCK) 
via the formation of the Ca2+-calmodulin-MLCK complex. Activated MLCK phosphorylates 
the 20kDa regulatory light chain (MLC20) of the thick filament. Phosphorylated MLC20 
allows myosin to bind to actin, and this phosphorylation is critical for SMC contraction, 
since its inhibition generally abolishes agonist-dependent contraction, whereas relaxation is 
induced by MLC20 dephosphorylation by myosin light chain phosphatase (MLCP). Hence, 
excitation-contraction coupling in SMCs critically depends on Ca2+-dependent MLCK 
activation and the balance of MLCK/MLCP activity. Moreover, it has been shown that these 
two major enzymes can be modulated by several protein kinases such as protein kinase A 
(PKA), protein kinase C (PKC) and Rho kinase (RhoK). As a consequence, these protein 
kinases indirectly modulate the activity of the thick filament of myosin. Additionally, actin-
myosin interaction can be modulated by proteins associated to the thin filament of actin 
such as caldesmon and calponin, which modulation depends on their phosphorylation by 
several protein kinases. It appears then that in SMCs, the excitation-contraction coupling is 
determined by interacting signalling pathways involving various protein kinases, so that the 
canonical MLCK/MLCP enzymatic balance is embedded in a complex network of protein 
kinases acting both on the thick and thin filaments of the contractile apparatus. The  chapter 
will present the functional structure of the contractile apparatus of SMC, and detail its 
activation by the Ca2+-calmodulin-MLCK complex and down regulation by MLCP, and the 





apparatus to Ca2+. The resultant behaviour of the SMC stimulated by contractile agonists not 
only depends on the structure of the regulatory network that modulates the contractile 
apparatus but also on the dynamics of the reactions. Mathematical modelling of this 
signalling network is of great help to decipher how different protein kinases involved in this 
network participate to the time-dependent behaviour of the contractile system. Several 
theoretical models have been developed in this sense. The chapter will present the general 
principles of these models, their predictions and how they help in understanding the role of 
PK in the time course of the contractile response of SCMs. 
In this chapter, examples are taken from airway smooth muscle cells, though this chapter is 
not limited to this tissue, and describes general mechanisms present in other SMC types. 
2. Ca2+ signalling and the contractile apparatus 
2.1 Ca2+ signalling in airway smooth muscle cells 
In smooth muscle cells, as in heart and skeletal muscle, [Ca2+]i is the primary intracellular 
messenger that generates contraction. Stimulation of smooth muscle cells by contractile 
agonists results in an increase in [Ca2+]i, which in turn activates the contractile apparatus. 
However, the mechanisms by which Ca2+ stimulates the formation of actin-myosin bridges 
critically differ in smooth muscle cells from striated muscle cells (see below). Though Ca2+ 
signalling is not primarily triggered via direct protein kinase activation by contractile agonists, 
several agents that contribute to the Ca2+ signal can be modulated by protein kinases and, on 
the other hand, activation of several protein kinases involved in the modulation of the 
contractile apparatus is Ca2+ sensitive. Hence, this section will present a general overview of 
the mechanisms of Ca2+ signalling in smooth muscle cells, including in airways. 
[Ca2+]i value in basal conditions is maintained around 100 nM, a low value compared to 
extracellular medium, around 1-2 mM, and intracellular organelles like the sarcoplasmic 
reticulum, by active mechanisms of Ca2+ efflux through the plasma membrane and Ca2+ 
pumping into intracellular Ca2+ stores. When cells are stimulated, [Ca2+]i is increased via 
different mechanisms which relative importance depends on smooth muscle cell types 
and/or contractile agonists. Basically, the general mechanisms of [Ca2+]i increase involve 
either intracellular Ca2+ influx or intracellular Ca2+ release from internal Ca2+ stores, or both 
(Sanders, 2001; Somlyo et al., 1994). Voltage-dependent Ca2+ occurs via L-type voltage-
operated Ca2+ channel (VOC). Normal resting membrane potential in airway myocytes is 
around -60 mV (Roux et al., 2006), and is highly dependent on basal K+ conductance. Some 
K+ channels are active at rest, and contribute to the resting K+ conductance and hence 
resting membrane potential. Closure of K+ channels tends to depolarize the plasma 
membrane which in turn induces extracellular Ca2+ influx via VOC. By contrast, additional 
activation of K+ channels tends to hyperpolarize the plasma membrane, to inhibit VOC-
dependent Ca2+ influx and hence to induce relaxation. Voltage-dependent Ca2+ influx and 
subsequent contraction is called the electromechanical coupling. In parallel to voltage-
operated Ca2+ entry, Ca2+ influx can be generated by voltage-independent membrane 
channels. Receptor-operated channels can be opened by direct binding of the agonist on the 
membrane receptor, like P2X purinergic receptors (Mounkaila et al., 2005). Another voltage-
independent source of Ca2+ entry is Ca2+ influx through store-operated Ca2+ channels (SOC). 
These channels are activated by emptying of intracellular Ca2+ stores (Marthan, 2004).  
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The other origin of [Ca2+]i increase is Ca2+ release from intracellular organelles (Sanders, 2001). 
The major one from which Ca2+ is released upon contractile stimulation is the sarcoplasmic 
reticulum (SR). Ca2+ release from the sarcoplasmic reticulum, with internal Ca2+ concentration 
in the millimolar range, occurs via two main types of sarcoplasmic receptors, the inositol-
trisphosphate receptors (InsP3Rs) and the ryanodine receptors (RyRs). InsP3Rs are activated by 
InsP3, which is produced from phosphatidylinositol phosphate by phospholipase C (PLC) 
upon stimulation by contractile agonists (Roux et al., 1998). Activation of contraction via 
primary InsP3 production and InsP3R-operated Ca2+ release, a consequence of enzymatic 
activation of PLC, is called the pharmacomechanical coupling, in opposition with the 
electromechanical coupling described above. RyRs are physiologically activated by an increase 
in Ca2+ concentration on the cytosolic face of the RyR, or by direct mechanical coupling 
between L-type VOC, and it has  been shown that cyclic ADP ribose is a co-agonist of RyR 
(Prakash et al., 1998). RyR activation by Ca2+ self-amplifies [Ca2+]i increase, whatever its initial 
mechanism. This Ca2+-induced Ca2+ release (CICR), however, is not observed in all smooth 
muscle cells. In human bronchial smooth muscle, for example, RyR, though present and 
functional, do not participate in the acetylcholine-induced Ca2+ response (Hyvelin et al., 2000a).  
Basal maintenance of low [Ca2+]i and Ca2+ removal form the cytosol upon and after 
stimulation is due to active mechanisms that either extrude Ca2+ in the extracellular medium 
or uptake Ca2+ into intracellular Ca2+ stores. Ca2+ extrusion is mainly due to the activity of 
the plasma membrane Ca2+ ATPase (PMCA), and the Na+-Ca2+ exchanger (NCX) (Sanders, 
2001).The main mechanisms of Ca2+ uptake from the cytosol are  Ca2+ pumping back into the 
SR by sarcoendoplasmic Ca2+ ATPase (SERCA), Ca2+ uptake into the mitochondria. Also, 
several Ca2+-binding proteins can buffer cytosolic Ca2+ and hence decrease [Ca2+]i (Gunter et 
al., 2000; Roux et al., 2004). 
The Ca2+ signal is not only the overall increase in the cellular Ca2+ pool and subsequent 
[Ca2+]i but also, and most importantly, the pattern of the dynamic change in [Ca2+]i. Indeed, 
the time-dependent variation in the shape of [Ca2+]i is the actual “Ca2+ signal”, since Ca2+ 
binding to signalling protein, e. g., calmodulin, depends on cytosolic Ca2+ concentration. 
Overall [Ca2+]i measurements generally show a transient increase in [Ca2+]i (Ca2+ peak) 
followed by a progressive decay to a steady-state value (Ca2+ plateau) and/or by Ca2+ 
oscillations (Bergner et al., 2002; Hyvelin et al., 2000b; Kajita et al., 1993; Liu et al., 1996). 
Changes in [Ca2+]i are not uniform within the cytosol, and studies have evidenced the role of 
local change in Ca2+ signalling (Prakash et al., 2000). Ca2+ signalling should hence be defined 
as spatiotemporal changes in [Ca2+]i, from which depends the activity of the contractile 
apparatus, and other cell functions. The shape of this Ca2+ signal critically depends on the 
dynamics of Ca2+ fluxes between intra- and extracellular media and also between 
intracellular Ca2+ compartments. The dynamic relationship between the calcium signal and 
MLCK activity and its consequence on force development will be discussed in more detail in 
the section “Theoretical modelling of PK and ASMC contraction”. 
2.2 Smooth muscle contractile apparatus 
2.2.1 Components and general organization 
The contractile apparatus of smooth muscle is basically constituted of thick filaments of 
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channels. Receptor-operated channels can be opened by direct binding of the agonist on the 
membrane receptor, like P2X purinergic receptors (Mounkaila et al., 2005). Another voltage-
independent source of Ca2+ entry is Ca2+ influx through store-operated Ca2+ channels (SOC). 
These channels are activated by emptying of intracellular Ca2+ stores (Marthan, 2004).  
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being about 20/1 to 30/1 (Kuo et al., 2003; Somlyo et al., 1983). These filaments are not 
organized in sarcomeres and do not form well individualized myofibrils. Thick filaments 
are anchored on dense bodies in the cell and dense area on the plasma membrane and actin 
filaments are positioned between thick filaments. Dense bodies and filaments are connected 
by non-contractile intermediate filaments that constitute an intracellular network.  
Thick filaments are 1.5 µm long and 12-14 nm in diameter, and are composed of 
polymerized monomers of myosin. Each monomer of myosin is formed by the association of 
2 identical heavy chains (MHC) complexed to 2 pairs of light chains (MLC). Each of the 2 
heavy chains has a C-terminal extended α-helix twisted to form a single tail and an N-
terminal head. 4 isoforms of MHC have been described in smooth muscle cells, 
corresponding to 4 alternatively-spliced variants derived from the single smooth muscle 
myosin heavy chain gene MYH11, differing in their amino-terminal and carboxy-terminal 
portions (Hong et al., 2011). Polymerized and monomeric myosins are in equilibrium and 
the stimulation of the myocyte increases myosin polymerization. The distal portion of the 
myosin head has the ATPase enzymatic activity required for its motor function, and a 
binding site for actin. A pair of light chains, a 17 kDa one and a 20 kDa one, is complexed 
with each of the head of the myosin heavy chain.  The role of MLC17 is unclear, and it is 
thought to contribute to the stability of the molecule of myosin. Phosphorylation of the so-
called regulatory MLC20 is required for actin-myosin binding, and hence 
phosphorylation/dephosphorylation of MLC20 regulates actin-myosin cross bridge and 
contraction. 2 residues, located in the amino-terminal portion of the protein, threonine 18 
and serine 19, can be phosphorylated by MLCK. The major site of phosphorylation by 
MLCK in intact myocyte is ser19, though thr18 can also be phosphorylated by MLCK. It has 
been shown that Rho kinase can also directly phosphorylate MLC20, but, at least in airway 
smooth muscle, Rho kinase regulates phosphorylated/dephosphorylated MLC20 ratio by 
acting on MLCP (Mbikou et al., 2011). It has been shown that PKC may also phosphorylate 
MLC20 but on different residues, serine 1, serine 2 and threonine 9 (Barany et al., 1996). 
However, it is generally admitted that PKC contributes to smooth muscle contraction 
mainly via MLCP inhibition. 
Smooth muscle thin filaments are formed by a double helix of F-actin complexed with 
tropomyosin, caldesmon and calponin. Globular smooth muscle α-actin molecules assemble 
into filamentous polymers of F-actin, and 2 parallel strands of F-actin rotate on each other to 
form a double helix structure. F-actin filaments are about 1 µm long and 5-7 nmn in 
diameter. As in striated muscle, tropomyosin binds to F-actin in the furrow formed by the 
double helix of actin, and contributes to actin filament stabilization (Shah et al., 2001). In 
contrast with striated muscle, here is no troponin on the thin filament of actin in smooth 
muscle, and other proteins, caldesmon and calponin, are associated with actin. Caldesmon 
and calponin are regulatory proteins that can be phosphorylated by several kinases and 
their phosphorylation modulates the formation of the actin-myosin bridge. Regulation of 
contraction by caldesmon and calponin is detailed below. 
2.2.2 Actin-mysosin bridge cycling 
Basically, muscle contraction is based on cycling attachment and detachment between thick 
filaments of myosin and thin filaments of actin. Interaction between actin and myosin, 
which corresponds to the formation of the actin-myosin crossbridge, is triggered by the 
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head of myosin. As seen above, in smooth muscle, phosphorylation of MLC20 is the key 
event that allows the formation of the actin-myosin bridge, a step required for contraction to 
occur (Harnett et al., 2003; Wingard et al., 2001). MLC20 phosphorylation induces a 
conformational change of the neck of myosin so that the head of myosin can bind to actin. 
This allows the rotation of the head of myosin responsible for the “sliding” of actin and 
myosin filaments. MLC20 phosphorylation also activates the ATPase activity of the myosin 
head, followed by actin and myosin detachment. When MLC20 remains phosphorylated all 
along the crossbridge cycle, crossbridge cycling is rapid, and associated with high ATP 
consumption.  However, sustained contraction can occur even if [Ca2+]i and subsequent 
MLC20 phosphorylation decrease (Mbikou et al., 2006), and this is generally attributed to the 
fact that if dephosphorylation of MLC20 occurs after the attachment of myosin on actin, 
crossbridge cycle goes on but at a slower rate, in particular in the stage where 
dephosphorylated myosin detaches actin. These maintained dephosphorylated crossbridges 
that cycle at a slow rate are termed latch-bridges. 
Hence, 2 types of crossbridges cycling can occur in smooth muscles, a fast, phosphorylated 
one (during which MLC20 remains phosphorylated) and a slow, partially dephosphorylated 
one (during which MLC20 is phosphorylated after actin-myosin attachment), and, 
accordingly, a 4-state model of the contractile apparatus has been proposed, initially by Hai 
and Murphy (Hai et al., 1988a). This model is presented in Figure 1. The first state 
corresponds to unbound actin and unphosphorylated MLC20, the second one to unbound 
actin and phosphorylated MLC20, the third one to actin bond to phosphorylated MLC20, and 
the fourth one to actin bond to dephosphorylated MLC20. Transition between state 1 and 2, 
and 3 and 4, is reversible and depends on MLC20 phosphorylation/dephosphorylation. 
Transition between state 2 and 3 is reversible and corresponds to the phosphorylated 
crossbridge cycling. Rate constant from state 1 to 4 is very slow, and it can be considered 
that transition from state 4 to 1 is almost irreversible. State 1-2-3-4-1 cycling corresponds to 















Fig. 1. 4 state model of smooth muscle contractile apparatus. A, actin; M, unphosphorylated 
myosin; Mp, phosphorylated myosin; AM, unphosphorylated actin-myosin bridge; AMp, 
phosphorylated actin-myosin bridge; MLCK, myosin light chain kinase; MLCK, myosin 
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head of myosin. As seen above, in smooth muscle, phosphorylation of MLC20 is the key 
event that allows the formation of the actin-myosin bridge, a step required for contraction to 
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Fig. 1. 4 state model of smooth muscle contractile apparatus. A, actin; M, unphosphorylated 
myosin; Mp, phosphorylated myosin; AM, unphosphorylated actin-myosin bridge; AMp, 
phosphorylated actin-myosin bridge; MLCK, myosin light chain kinase; MLCK, myosin 





The main enzyme by which MLC20 is phosphorylated is MLCK. Dephosphorylation of 
phosphorylated MLC20 is catalysed by MLCP. Though other enzymes can contribute to 
smooth muscle contraction, muscle contraction critically depends on the balance between 
MLCK and MLCP activity. 
2.3 Modulation of MLC20 phosphorylation: The MLCK/MLCP balance 
2.3.1 MLCK 
MLCK has a ubiquitous distribution and is present in non-muscular cells as well as cardiac, 
skeletal and smooth muscle cells. Several genes encode for distinct isoforms of MLCK. In 
humans, MYLK2 and MYLK3 genes encode for the MLCK isoforms expressed in skeletal 
and cardiac myocytes, respectively, and the smooth muscle isoform is encoded by the 
MYLK1 gene. This gene has 2 initiation sites generating a short isoform corresponding to the 
smooth muscle MLCK and a long isoform corresponding to nonmuscle MLCK. The domain 
structure of smooth muscle mammalian MLCK is shown in Figure 2. MLCK has 2 CaM-
binding domains, one at its aminoterminal portion, composed of 3 DFRxxL motifs, and the 
other at its carboxyterminal portion, before the IgT domain located at the N-terminus. The 
DFrxxL domain is also a binding site to actin, and Ca2+-CaM binding to this domain results 
in weakened actin binding. Some results suggest that Ig1/Ig2 domains bind to actin.  IgT 
domain is a binding site to myosin. The kinase domain is the catalytic portion of MLCK and 
includes a binding site for ATP and for MLC20. The role of the other domains is unknown 
(Hong et al., 2011). Hence, MLCK interacts with myosin on two sites. The catalytic core of 
MLCK interacts with the aminoterminal portion of MLC20, which allows phosphorylation 
MLC20. The IgT domain of MLCK may also interact with myosin at the head-neck junction. 
It is thought that IgT binding to myosin near the MLC20 increases the catalytic activity of 
MLCK. The concentration of MLCK is likely to vary from muscle to muscle, but typical 
values range from 1 to 8 µM, which is low compared with the typical concentration of 
myosin, classically ranging from 50 to 100 µM. 

















Fig. 2. Structural scheme of myosin light chain kinase (MLCK) and its different domains. 
In the absence of calmodulin (AcM) binding, the catalytic site (Kinase) is masked by the N-
terminal CaM binding and IgT domains and hence inactive. Binding of Ca2+-CaM complex 
induces a conformational change and unmasks the kinase domain hence active. 
The major substrate of MLCK in smooth muscle is the smooth muscle myosin, but recent 
results showed that non muscle myosin, which is also expressed in smooth muscle myosin, 
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can be a substrate for MLCK (Yuen et al., 2009). MLCK phosphorylates MLC20 on serine 19 
and, with lower enzymatic activity, on threonine 18 (Deng et al., 2001). MLCK activity is 
essential for airway smooth muscle contraction, as it has been evidenced by 
pharmacological inhibition of MLCK in rat trachea (Mbikou et al., 2006) and knockout mice 
(Zhang et al., 2010).  
The most important regulator of MLCK activity is the Ca2+-CaM complex. MLCK unbound 
to Ca2+-CaM is in an auto-inhibitory state. The IgT domain and the adjacent CaM binding 
domain constitute an auto-inhibitory sequence that masks the catalytic core. Ca2+-CaM 
binding to the auto-inhibitory site induces a conformational change. This displacement of 
the auto-inhibitory sequence unmasks the catalytic core and thereby reveals the enzymatic 
activity of MLCK. On the other hand, phosphorylation of MLCK on serine 512 by several 
kinases such as protein kinase A in the C-terminal CaM binding domain decreases MLCK 
affinity for the Ca2+CaM complex, thereby inactivating MLCK even in the presence of Ca2+, a 
mechanism responsible for MLCK desensitization (Stull et al., 1993). CaM is a rather small 
protein (16700 Da) consisting of a single polypeptidic chain of 148 to 149 aminoacids. 3 
distinct domains can be identified: an N-terminal domain, a central helix domain, and a C-
terminal domain. Both amino- and carboxy-terminal domain possesses 2 binding sites for 
Ca2+. The 4 sites have a high affinity for Ca2+, though the affinity of the C-terminal sites is 
higher. These sites have an EF-hand structure. Ca2+ binding induces a conformational 
change of the F-helix of the EF-hand motif. In this conformation CaM binds to several 
proteins and modulates their activity. Amongst almost 40 different proteins that have been 
shown to be regulated by CaM, the most important in smooth muscle are MLCK and CaM-
kinase II. 
2.3.2 MLCP 
MLCP is a holoenzyme composed of three subunits: the 38 kDa phosphatase catalytic 
subunit PP1cδ, the 110 kDa regulatory subunit MYPT1, and a 20 kDa noncatalytic subunit, 
M-20, which role remains unclear (Hartshorne et al., 1999; Hartshorne et al., 1998). PP1cδ is a 
serine/threonine phosphatase that dephosphorylates MLC20 on serine 19 and threonine 18. 
Disruption of the quaternary structure of MLCP, either by dissociation of the regulatory 
subunit MYPT1 to PP1c or by disruption of the interactions between the three subunits, 
decreases MLCP activity toward MLC20 dephosphorylation.  
PP1c alone is capable of dephosphorylating the MLC20, but its activity is potentiated when 
complexed to MYPT1. Indeed, MYPT1s targets PP1c to its substrate, MLC20, and confers 
substrate specificity to the phosphatase. A recent study by crystallography has revealed a 
basic structure which potentiates the catalytic activity of the holoenzyme (Terrak et al., 2004). 
Structurally, MYPT1 subunit possesses a C-terminal leucine-zipper domain and a binding 
site of protein kinase G. Four N-terminal amino acids, KVKF, give a strong affinity for PP1c. 
MYPT1 also has six repeated domains of ankyrin, which serve as anchoring sites for protein-
protein interactions. Several kinases are able to phosphorylate MYPT1 at various sites: Rho 
kinase, MYPT kinase (also known as Zip-like kinase), integrin-like kinase, myotonic 
dystrophy kinase (DMPK). PKC also has been shown to phosphorylate ankyrin repeated 
domains and inhibit the interaction between MYPT1 and PP1c (Toph et al., 2000). In addition 
to this negative regulation of MLCP, MYPT1 phosphorylation is also associated with an 
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Fig. 2. Structural scheme of myosin light chain kinase (MLCK) and its different domains. 
In the absence of calmodulin (AcM) binding, the catalytic site (Kinase) is masked by the N-
terminal CaM binding and IgT domains and hence inactive. Binding of Ca2+-CaM complex 
induces a conformational change and unmasks the kinase domain hence active. 
The major substrate of MLCK in smooth muscle is the smooth muscle myosin, but recent 
results showed that non muscle myosin, which is also expressed in smooth muscle myosin, 
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can be a substrate for MLCK (Yuen et al., 2009). MLCK phosphorylates MLC20 on serine 19 
and, with lower enzymatic activity, on threonine 18 (Deng et al., 2001). MLCK activity is 
essential for airway smooth muscle contraction, as it has been evidenced by 
pharmacological inhibition of MLCK in rat trachea (Mbikou et al., 2006) and knockout mice 
(Zhang et al., 2010).  
The most important regulator of MLCK activity is the Ca2+-CaM complex. MLCK unbound 
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binding to the auto-inhibitory site induces a conformational change. This displacement of 
the auto-inhibitory sequence unmasks the catalytic core and thereby reveals the enzymatic 
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kinases such as protein kinase A in the C-terminal CaM binding domain decreases MLCK 
affinity for the Ca2+CaM complex, thereby inactivating MLCK even in the presence of Ca2+, a 
mechanism responsible for MLCK desensitization (Stull et al., 1993). CaM is a rather small 
protein (16700 Da) consisting of a single polypeptidic chain of 148 to 149 aminoacids. 3 
distinct domains can be identified: an N-terminal domain, a central helix domain, and a C-
terminal domain. Both amino- and carboxy-terminal domain possesses 2 binding sites for 
Ca2+. The 4 sites have a high affinity for Ca2+, though the affinity of the C-terminal sites is 
higher. These sites have an EF-hand structure. Ca2+ binding induces a conformational 
change of the F-helix of the EF-hand motif. In this conformation CaM binds to several 
proteins and modulates their activity. Amongst almost 40 different proteins that have been 
shown to be regulated by CaM, the most important in smooth muscle are MLCK and CaM-
kinase II. 
2.3.2 MLCP 
MLCP is a holoenzyme composed of three subunits: the 38 kDa phosphatase catalytic 
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M-20, which role remains unclear (Hartshorne et al., 1999; Hartshorne et al., 1998). PP1cδ is a 
serine/threonine phosphatase that dephosphorylates MLC20 on serine 19 and threonine 18. 
Disruption of the quaternary structure of MLCP, either by dissociation of the regulatory 
subunit MYPT1 to PP1c or by disruption of the interactions between the three subunits, 
decreases MLCP activity toward MLC20 dephosphorylation.  
PP1c alone is capable of dephosphorylating the MLC20, but its activity is potentiated when 
complexed to MYPT1. Indeed, MYPT1s targets PP1c to its substrate, MLC20, and confers 
substrate specificity to the phosphatase. A recent study by crystallography has revealed a 
basic structure which potentiates the catalytic activity of the holoenzyme (Terrak et al., 2004). 
Structurally, MYPT1 subunit possesses a C-terminal leucine-zipper domain and a binding 
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protein interactions. Several kinases are able to phosphorylate MYPT1 at various sites: Rho 
kinase, MYPT kinase (also known as Zip-like kinase), integrin-like kinase, myotonic 
dystrophy kinase (DMPK). PKC also has been shown to phosphorylate ankyrin repeated 
domains and inhibit the interaction between MYPT1 and PP1c (Toph et al., 2000). In addition 
to this negative regulation of MLCP, MYPT1 phosphorylation is also associated with an 





nucleotides such as PKA and PKG are able to phosphorylate MYPT1 on serine 692, 695 and 
852. The S695 and S852 residues are adjacent to two residues, T696 and T853, that are 
phosphorylation sites of MYPT1 by RhoK. Phosphorylation at S695 by PKG or PKA 
prevents RhoK phosphorylation at S696 and vice versa (Wooldridge et al., 2004), and it is 
supposed that phosphorylation at S852 has a similar effect on T853 phosphorylation. Thus 
the phosphorylation of MYPT1 by PKA and PKG protein antagonizes the inhibition of 
MLCP induced by RhoK (Grassie et al., 2011). 
CPI-17 is another regulation pathway of MLCP activity (Ito et al., 2004). CPI-17 is a 17 kDa 
protein composed of 147 aminoacids that can inhibit the activity of the MLCP holoenzyme 
as well as that of isolated PP1c. Phosphorylation of CPI-17 at threonine 38 enhances its 
inhibitory potency about 1000 fold. The proposed mechanism is that CPI-17 binds at the 
PP1c active site, resulting in formation of a complex of MYPT1/PP1C/CPI-17 (Eto et al., 
2004). The major kinase responsible for in vivo CPI-17 phosphorylation is PKC, especially 
PKCα and PKCδ. In vitro studies have shown that other kinases can phosphorylate CPI-17 at 
T38, including Rho kinase, protein kinase N (PKN), MYPT-kinase, integrin-like kinase and 






















Fig. 3. Regulation of MLCP activity by protein kinases. DAP kinase, death-associated 
protein kinase;; DMPK, myotonic dystrophy protein kinase; ILK, integrin-linked kinase; 
MLCP, myosin light chain phosphatase; MYPT1, myosin phosphatase target subunit 1 of 
MLCP; M20, 20 kDa non-catalytic subunit of MLCP; PAK, p21-activated protein kinase; 
PKA, protein kianse A; PKC, protein kinase C; PKG, protein kinase G; PKN, protein kinase 
N; PLA2, phospholipase A2; PP1c, catalytic subunit of type1 protein phosphatase; RhoK, 
Rhokinase; ZipK; zipper-interacting protein kinase (adapted from (Hirano et al., 2003)). 
2.4 Thin filament-associated regulation of AM bridge cycling 
2.4.1 Caldesmon 
Caldesmon is a small protein of 87 kDa associated with the thin filaments of actin and 
involved in the regulation of smooth muscle contraction. Structurally, caldesmon possesses 
4 distinct domains and can bind to actin, tropomyosin, myosin and calmodulin.  The fourth 
domain located at the C-terminus is the most important since it is the binding domain to 
actin, to myosin and to Ca2+-binding proteins. Caldesmon interacts stoichiometrically with 
 
Role of Protein Kinase Network in Excitation-Contraction Coupling in Smooth Muscle Cell 
 
295 
tropomyosin to consolidate the actin filaments (Gusev, 2001), and contributes to the 
sensitivity of the myofilament to Ca2+. In the absence of Ca2+, the fourth domain interacts 
closely with actin and inhibits the ATPase activity. [Ca2+]i increase induces a conformational 
change of the actin-tropomyosin-caldesmon complex, allowing the ATPase activity of 
myosin. In addition, it allows an interaction between the thin and thick filaments as it is able 
to bind to both actin and myosin and this property seems to be involved in the sustained 
phase of the contractile response (Marston et al., 1991). In vitro studies have shown that 
caldesmon can be a substrate for several kinases (Kordowska et al., 2006). 
2.4.2 Calponin 
Calponin is a molecule of approximately 34 kDa related to the skeletal muscle troponin T. 
Calponin is present in smooth muscle at a concentration almost equivalent to that of 
tropomyosin. Calponin binding to F-actin disrupts actin-myosin interaction and hence 
negatively regulates the contraction of smooth muscle. Calponin inhibits the sliding of actin 
filament on myosin and the ATPase activity of myosin. The inhibitory effect of calponin is 
suppressed by high [Ca2+]i values, but only in the presence of calmodulin. Phosphorylation 
and dephosphorylation of calponin plays a key role in the regulation of smooth muscle 
contraction. Indeed, the inhibitory effect of calponin is abolished when calponin is 
phosphorylated by CaM kinase II or PKC, and is restored when calponin is 
dephosphorylated by phosphatase 2A (Winder et al., 1998; Winder et al., 1990). Based on 
these properties, 3 physiological roles have been identified for calponin: (1) maintenance of 
relaxation at rest when [Ca2+]i is low; (2) Ca2+-dependent contribution, involving 
calmodulin, to contraction when [Ca2+]i is increased and, (3) Ca2+-independent contribution 
to contraction via PKC-dependent phosphorylation. 
3. Role of protein kinases in the modulation of excitation-contraction 
coupling 
3.1 General overview 
3.1.1 Modulation of Ca2+ signalling 
Though protein kinases modulate smooth muscle contraction by acting mainly downstream 
of the Ca2+ signal, some of them have been shown to act upstream of the Ca2+ signal and 
regulate the activity of structures involved in Ca2+ signal encoding. It has been shown by in 
vitro studies that PKA can phosphorylate InsP3 receptors on serine 1755 and serine 1589 
(Ferris et al., 1991a). Studies using purified receptor protein reconstituted in liposomes have 
also evidenced that PKC and CaM kinase II can phosphorylate InsP3 receptors (Ferris et al., 
1991b). Ryanodine receptors also can be phosphorylated by PKA, PKC and CaM kinase II 
(Coronado et al., 1994). These phosphorylations may play an important role in smooth 
muscle physiology since Ca2+ release from SR plays a critical role in Ca2+ homeodynamics in 
airway myocyte (Ay et al., 2004; Roux et al., 2004). Indeed, contractile agonists such as 
acetylcholine act via InsP3 production but also activate PKC (Mbikou et al., 2006). On the 
other hand, PKA stimulation is a important pathway involved in bronchorelaxation since β2-
adrenergic stimulation, a major pharmacological treatment of asthma, acts mainly via Gs 
protein stimulation, adenylate cyclase activation, cAMP production and PKA activation 
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tropomyosin to consolidate the actin filaments (Gusev, 2001), and contributes to the 
sensitivity of the myofilament to Ca2+. In the absence of Ca2+, the fourth domain interacts 
closely with actin and inhibits the ATPase activity. [Ca2+]i increase induces a conformational 
change of the actin-tropomyosin-caldesmon complex, allowing the ATPase activity of 
myosin. In addition, it allows an interaction between the thin and thick filaments as it is able 
to bind to both actin and myosin and this property seems to be involved in the sustained 
phase of the contractile response (Marston et al., 1991). In vitro studies have shown that 
caldesmon can be a substrate for several kinases (Kordowska et al., 2006). 
2.4.2 Calponin 
Calponin is a molecule of approximately 34 kDa related to the skeletal muscle troponin T. 
Calponin is present in smooth muscle at a concentration almost equivalent to that of 
tropomyosin. Calponin binding to F-actin disrupts actin-myosin interaction and hence 
negatively regulates the contraction of smooth muscle. Calponin inhibits the sliding of actin 
filament on myosin and the ATPase activity of myosin. The inhibitory effect of calponin is 
suppressed by high [Ca2+]i values, but only in the presence of calmodulin. Phosphorylation 
and dephosphorylation of calponin plays a key role in the regulation of smooth muscle 
contraction. Indeed, the inhibitory effect of calponin is abolished when calponin is 
phosphorylated by CaM kinase II or PKC, and is restored when calponin is 
dephosphorylated by phosphatase 2A (Winder et al., 1998; Winder et al., 1990). Based on 
these properties, 3 physiological roles have been identified for calponin: (1) maintenance of 
relaxation at rest when [Ca2+]i is low; (2) Ca2+-dependent contribution, involving 
calmodulin, to contraction when [Ca2+]i is increased and, (3) Ca2+-independent contribution 
to contraction via PKC-dependent phosphorylation. 
3. Role of protein kinases in the modulation of excitation-contraction 
coupling 
3.1 General overview 
3.1.1 Modulation of Ca2+ signalling 
Though protein kinases modulate smooth muscle contraction by acting mainly downstream 
of the Ca2+ signal, some of them have been shown to act upstream of the Ca2+ signal and 
regulate the activity of structures involved in Ca2+ signal encoding. It has been shown by in 
vitro studies that PKA can phosphorylate InsP3 receptors on serine 1755 and serine 1589 
(Ferris et al., 1991a). Studies using purified receptor protein reconstituted in liposomes have 
also evidenced that PKC and CaM kinase II can phosphorylate InsP3 receptors (Ferris et al., 
1991b). Ryanodine receptors also can be phosphorylated by PKA, PKC and CaM kinase II 
(Coronado et al., 1994). These phosphorylations may play an important role in smooth 
muscle physiology since Ca2+ release from SR plays a critical role in Ca2+ homeodynamics in 
airway myocyte (Ay et al., 2004; Roux et al., 2004). Indeed, contractile agonists such as 
acetylcholine act via InsP3 production but also activate PKC (Mbikou et al., 2006). On the 
other hand, PKA stimulation is a important pathway involved in bronchorelaxation since β2-
adrenergic stimulation, a major pharmacological treatment of asthma, acts mainly via Gs 
protein stimulation, adenylate cyclase activation, cAMP production and PKA activation 





relaxation via PKA activation (Mounkaila et al., 2005). Protein kinase may also modulate 
Ca2+ homeostasis by acting on voltage-dependent Ca2+ entry. As explained above, K+ 
channels critically contribute to the maintenance of myocyte membrane voltage, and it has 
been shown in vascular smooth muscle that PKA and PKC can phosphorylate several 
voltage-dependent K+ channels, Ca2+-activated K+ channels and ATP-dependent K+ 
channels, thus regulating the electromechanical coupling (Ko et al., 2008).  Phosphorylation 
by PKA activates these K+ channels and hence tends to hyperpolarize the plasma membrane 
and limit extracellular Ca2+ entry, whereas phosphorylation by PKC has an opposite effect. 
The effective contribution of these mechanisms in airway in unclear, since it has been shown 
that in airways activation of Ca2+-activated K+ channels does not seem to have a significant 
effect on β-adrenergic relaxation (Corompt et al., 1998). 
3.1.2 Modulation of the  Ca2+ sensitivity of the contractile apparatus 
The signalling pathways capable of modulating the contraction of a given Ca2+ signal 
constitute the modulation of the sensitivity of the contractile apparatus to Ca2+. As detailed 
previously, the importance of contraction depends on the balance between MLCK and 
MLCP activity, which is under control of several signalling pathways. In parallel with the 
canonical MLCK-dependent MLC20 phosphorylation, in several smooth muscles, MLC can 
be directly phosphorylated by Ca2+-independent kinases like ZIP kinases and Integrin-
linked kinase (ILK), which can also inhibit MLCP (Deng et al., 2002; Huang et al., 2006; 
Murthy, 2006; Niiro et al., 2001). Rho kinase, activated by small GTPase (Rho), which seems 
to be activated both by Ca2+-dependent and Ca2+-independent pathways, can phosphorylate 
directly MLC and, by inhibition of MLCP, indirectly increase MLC phosphorylation and hence 
regulate smooth muscle contraction (Bai et al., 2006; Murthy, 2006; Schaafsma et al., 2006). Also, 
contractile agonists may, in parallel to MLCK activation, inhibit MLCP activity. PKC can 
inhibit MLCP, and hence modulate contraction (Bai et al., 2006). By contrast, relaxant agonists, 
such as β2-agonists in airways, may act via MLCP activation and/or MLCK inhibition (Janssen 
et al., 2004; Johnson, 1998). So, in addition with the Ca2+-calmodulin-MLCK pathway, other 
Ca2+-dependent and independent enzymatic pathways regulate the contractile apparatus in 
smooth muscles, which status depends on the balance between MLCP/MLCK 
phosphorylation and dephosphorylation. Additionally, smooth muscle contraction can be 
modulated independently from MLC20 phosphorylation via caldesmon and calponin. The 
major kinases involved in smooth muscle contraction are listed below. 
3.2 RhoK 
Rho-associated kinase (Rho-kinase), originally identified as an effector of the small GTPase 
Rho, has been shown to play a major role in many processes including cell migration, 
neuronal polarisation, cytokinesis and cell contraction. It is a serine/threonine kinase 
structurally related to myotonic dystrophy kinase as there is 72% homology in the kinase 
domains. Different studies support the idea that Rho-kinase exists as a dimer resulting from 
parallel association through the coil-coil domain (Shimizu et al., 2003). There are two Rho- 
kinase members, Rho-kinase I/ROKβ/p160ROCK and Rho-kinase II /ROKα/Rho kinase, 
which share 65% sequence identity and 95% sequence similarity at the amino acid level 
(Riento et al., 2003b). The kinase domain is highly conserved between these two proteins 
(83% identical), suggesting that they may have similar substrate specificity. The consensus 
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phosphorylation sequence for Rho-kinase is R/KXS/T or R/KXXS/T (X is any amino acid). 
The Rho-kinase protein is composed of three domains: a N-terminal kinase domain, a 
central coiled-coil domain containing a Rho binding site (RhoBD), and a C-terminal 
pleckstrin homology-like domain (PH-like domain) containing a Cys-rich region similar to 
the C1 domain of protein kinase C. The C-terminal region including the RhoBD plus the PH 
domain has been shown to directly interact with the kinase domain to inhibit its activity 
(Amano et al., 1999). The interaction between Rho•GTP and the RhoBD releases this 
autoinhibition and thus activates the kinase (Ishizaki et al., 1996). In addition to Rho other 
small as GTPases such Rnd3/RhoE, Gem and Rad can bind Rho-kinase outside of the Rho-
binding region and inhibit its function (Komander et al., 2008; Riento et al., 2003a). Arachidonic 
acid has been also shown to activate Rho-kinase via its PH domain (Araki et al., 2001). 
Although both Rho-kinase I and Rho-kinase II proteins are ubiquitously expressed in most 
tissues, higher levels of Rho-kinase II are found in brain and muscles whereas higher levels of 
Rho-kinase I are found in non-neuronal tissues such as liver, lung and testis (Leung et al., 1996; 
Nakagawa et al., 1996). Functional differences have been reported between Rho-kinase I and 
Rho-kinase II. For instance Rho-kinase I seems to be essential for the formation of stress fibres, 
whereas Rho-kinase II seems important for phagocytosis and cell contraction, both being 
dependent on MLC phosphorylation (Wang et al., 2009; Yoneda et al., 2005). Binding tests 
revealed that RhoE preferentially binds Rho-kinase I, but not Rho-kinase II, whereas MYPT1 
binds only Rho-kinase II (Komander et al., 2008; Wang et al., 2009). 
There has been a great deal of interest in the involvement of the Rho/ROCK signalling 
pathway in excitation–contraction coupling (Iizuka et al., 1999; Mbikou et al., 2011; Yoshii et 
al., 1999). Activation of the Rho/Rho-kinase pathways is likely due to the stimulation of the 
G-coupled protein receptor.  Stimulation of M3 muscarinic receptors agonist for instance 
activates the Gq, G12 and G13 α-subunits which cause the cascade activation of GEFs, RhoA 
and Rho-kinase leading to Ca2+ sensitization (Hirano et al., 2004; Somlyo et al., 2003). It is 
well-known that Rho/Rho-Kinase signalling modulates Ca2+ sensitivity of the smooth 
muscle likely either by inhibition of the MLCP activity or by direct phosphorylation of the 
MLC20. Precisely, Rho-kinase has been shown to phosphorylate the MYPT1 subunit of the 
MLCP at two inhibitory sites, Thr696 and Thr853, by that causing the dissociation between 
the MLCP and MLC20 (Feng et al., 1999; Kawano et al., 1999; Kimura et al., 1996; Velasco et al., 
2002). Phosphorylation of MYPT1 by Rho-kinase alters the MYPT1-PP1c interaction, which 
decreases MLCP activity toward MLC20. Rho-kinase is also able to directly phosphorylate 
Ser19 and Thr18 in non-muscle cells (Ueda et al., 2002), but the direct contribution of Rho-
kinase to phospho-MLC20 levels in vivo is not yet proven. Moreover, Rho kinase exerts an 
inhibitory activity toward PP1c subunit of MLCP upon the phosphorylation of the latter (Eto 
et al., 1995; Eto et al., 1997). Taken together, the mechanisms triggered by Rho-kinase activity 
enhance the level of phosphorylated MLC20 and, consequently, myosin ATPase activity and 
therefore contraction. In vitro tests have shown that Rho-kinase is also able to phosphorylate 
CPI17 (MLCP inhibitor protein), thus inducing the inhibition of MLCP and thereby raising 
the level of phosphor MLC20 (Amano et al., 2010). 
3.3 PKC 
The protein kinase C (PKC) family is the largest serine/threonine-specific kinase family 
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3.3 PKC 
The protein kinase C (PKC) family is the largest serine/threonine-specific kinase family 





and function (Nishizuka, 1995). Depending on their cofactor requirements, the homologous 
group of PKC can be divided into three groups as follows: the group of conventional (c)PKC 
isoforms (α, βI, βII and γ), that require Ca2+ and diacylglycerol (DAG) to become activated; 
the group of novel (n)PKC isoforms (δ, ε, ζ, θ and μ) that require only DAG; and group of  
the atypical (a)PKC isoforms, namely ζ, ι and λ (the mouse homologue of human PKCι), that 
require neither Ca2+ nor DAG. The general structure of a PKC molecule consists of a 
catalytic domain in N-terminal and a regulatory pseudosubstrate in C-terminal, both 
framing 3 distinct sites able to bind specifically ATP, Ca2+ or phosphatidyl serine. The 
pseudosubstrate region is a small sequence of amino acids that binds the substrate-binding 
cavity in the catalytic domain, thus keeping the enzyme inactive. The activity of PKC is 
controlled by its compartmentalization within the cell. All PKC family members possess a 
phosphatidylserine binding domain for membrane interaction. The expression and 
distribution of PKC isoforms is tissue- and species–specific. Some isoforms (e.g. PKCα) are 
ubiquitously expressed in tissues whereas others seem to be restricted to certain tissues 
(Webb et al., 2000). In ASM, the protein and mRNA expression of PKC isoforms differs 
depending on the specie. In human trachealis for instance, there is expression of the 
conventional α, βI, and βII PKC isoforms as well as novel  (δ, ε, ζ, θ) and atypical (ζ) (Webb et 
al., 1997) while canine trachealis does not express the α isoform and bovine ASM expresses 
the θ-PKC variants (Webb et al., 2000). 
It is well known that the stimulation of a Gq protein-coupled receptor, for instance by 
cholinergic agonist, induces the elevation of the cytosolic Ca2+ concentration and the 
production of DAG by phospholipase C. Both Ca2+ and DAG bind to the C2 and C1 domain, 
respectively, and recruit PKC to the membrane (Bell et al., 1991; Huang, 1989). This 
interaction with the membrane results in release of the pseudosubstrate from the catalytic 
site and activation of the enzyme(Lester et al., 1990).  
PKC may modulate the sensitivity of the contractile apparatus to Ca2+, since it can inhibit 
MLCP activity. However, the effectiveness of PKC contribution to airway contraction 
remains controversial. PKC has been shown to be involved in force maintenance in human 
airways (Rossetti et al., 1995).  However, other studies do not implicate PKC in agonist-
induced Ca2+ sensitization and point to other effectors such as the small GTP-binding 
protein p21rho  (Akopov et al., 1998; Itoh et al., 1994; Otto et al., 1996; Yoshii et al., 1999). Our 
recent studies have shown that PKC contributes to the sustained phase, but not to the initial 
phase, of cholinergic-induced contraction in rat airways (Mbikou et al., 2006). 
3.4 PKA 
Cyclic-AMP-dependent protein kinase (PKA) is an ubiquitous mammalian enzyme which 
catalyzes Ser/Thr phosphorylation in protein substrates that in turn control a wide range of 
cellular functions including gene regulation, cell cycle, metabolism and cell death (Shabb, 
2001). This tetrameric holoenzyme comprises two catalytic (C) subunits that possess kinase 
activity and two inhibitory regulatory (R) subunits, each including two tandem cAMP 
binding domains, i.e. CBD-A and CBD-B (Johnson et al., 2001). cAMP is the essential second 
messenger that activates PKA (Berman et al., 2005; McNicholl et al.). In the absence of cAMP, 
the R-subunit and the C-subunit create a complex that blocks substrate access and thus 
prevents the kinase activity. cAMP binding to the R-subunits releases these inhibitory 
interactions and unleashes the C-subunit, allowing substrate phosphorylation. There are 
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three isoforms of C (Cα, Cβ, and Cγ) and two major isoforms of R (RI and RII) that are 
further distinguished into subforms (α and β) (Zhao et al., 1998). The physiological 
importance of these isozyme variations is not fully understood, but anchoring proteins 
(AKAPs) for RII give it a unique cellular distribution (Scott et al., 1994) RI and RII show 
sequence homology in their cAMP-binding and pseudosubstrate domains but differ 
extensively in their dimerization domains as well as in the sequence connecting the 
dimerization and pseudosubstrate domains. All known R-subunit isoforms share a common 
organization that consists of a dimerization domain at the NH2 terminus followed by an 
autoinhibitor site and two-tandem cAMP-binding domains noted CBD-A and B (Taylor et 
al., 2005). While the portion of the R subunit COOH-terminal to the inhibition site is 
responsible for high affinity binding of the C-subunit and cAMP, the remaining NH2 
terminus serves as an adaptor for binding to kinase anchoring proteins (Scott et al., 1994) 
and is responsible for in vivo subcellular localization and targeting of PKA. 
The ordered sequential mechanism of PKA activation is described as follows: cAMP binds 
first to CBD-B, making site CBD-A accessible to a second molecule of cAMP, which in turn 
causes the release of the active C-subunit (Kim et al., 2007; Su et al., 1995). In other words 
CBD-B functions as a gatekeeper for CBD-A, whereas the latter acts as the central controlling 
unit of the PKA system and provides the primary interfaces with the C-subunit (McNicholl 
et al.). The structures of the R-subunit in its active and inhibited states have also 
demonstrated that although CBD-A and CBD-B play clearly distinct roles in the activation of 
PKA, they both share similar allosteric features.  
PKA activation is closely dependent on the cytosolic cAMP level which is itself regulated by 
G proteins via an enzyme named adenylate cyclase. Stimulation of GPCRs, by muscarinic 
receptor agonist for instance, can rise up or drop off AMPC production depending on the 
type of GPCRs. Indeed, GPCRs that activate the Gαi subunits inhibit cAMP production 
whereas GPCRs that activate the Gαs subunits activate cAMP production through this 
specific sequence: 1) activated Gαs subunit interacts with the adenylate cyclase 2)  adenylate 
cyclase quickly converts ATP into cAMP, 3) AMPc molecule activate the PKA. Activation of 
PKA is involved in airway smooth muscle relaxation (Zhou et al., 1992), which may involve 
phosphorylation of a number of effector proteins that cause either reduction of [Ca2+]i 
and/or reduction of MLCK sensitivity to Ca2+-calmodulin (de Lanerolle et al., 1991). 
 Studies have demonstrated that cAMP-dependent signaling pathway activation prevents or 
reverses the ASM contraction indirectly, via the inhibition of InsP3 receptor (InsP3R) of the 
sarcoplasmic reticulum, reducing the [Ca2+]i. The InsP3R are responsible for mobilizing Ca2+ 
from sarcoplasmic reticulum in response to agonist binding. PKA has been shown to 
mediate the phosphorylation of the InsP3R which consequently reduces the ability of 
Inositol(l,4,5)triphosphate to release Ca2+ from membrane vesicles (Schramm et al., 1995). 
The mechanism by which PKA-induced phosphorylation decreases insP3-induced Ca2+ 
release has not been determined, but known consequences of receptor/channel 
phosphorylation include altered agonist affinity as well as altered function. 
3.5 CaMkinase II 
Calcium-calmodulin-dependent protein kinase II (CaMKII) is an oligomeric 
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the calcium-calmodulin complex similarly to the MLCK. Increases in the cytosolic Ca2+ 
concentration following the stimulation modulate the function of many intracellular 
proteins (Zhou et al., 1994). One of the most important intracellular acceptors of the Ca2+ 
signal is calmodulin (CaM), which exerts a modulating influence on the function of 
Ca2+/CaM-dependent protein kinases. Among them, the CaMKII shows a broad substrate 
specificity and has been thought to be a multifunctional protein kinase (Cohen et al., 1992; 
Colbran et al., 1989a; Colbran et al., 1989b). Four genes encode related but distinct isoforms 
of CaM kinase II (α, β, γ, and δ). It was originally isolated from brain tissues (Fukunaga et 
al., 1982) (Goldenring et al., 1983; Kuret et al., 1984) and preparations of CaM kinase II 
purified from rat forebrain consist of the α (50 kDa) and β (60 kDa) subunits whose cDNAs 
have been cloned and sequenced (Kolb et al., 1998). Non neuronal tissues express mostly the 
isoform γ, and δ but in such a low level that it makes difficult the purification of  the 
enzyme; so most biochemical and physical data on the enzyme have been established with 
CaMkinase II-α and -β/β’ from mammalian brain.  In smooth muscle, CaM kinase II was 
first isolated as caldesmon kinase (Ikebe et al., 1990b) with a molecular mass of the major 
subunit of 56 kDa. Isolated smooth-muscle CaM kinase II has enzymological properties 
similar to that of brain; however, smooth-muscle CaMKII is a tetramer according to its 
native molecular mass rather than a decamer or octamer as are the brain enzymes (Zhou et 
al., 1994). 
The CaMKII subunits are thought to assemble to holoenzyme through their C-terminal 
association domains (Fahrmann et al., 1998). The linear structure of the CaMKII core consists 
of a catalytic/autoregulatory domain (A) containing a variable region V1, a conserved linker 
(B), and an association domain that contains two highly conserved sequences  (C and D) as 
well as multiple variable regions (V2-V4). Function of each variable region has been 
identified as follows: V1 contains insert implicated in SR-membrane targeting; V2 possesses 
a functional nuclear localization signal, as well as a site of autophosphorylation; Insert X 
within V3 is rich in proline residues and conforms to a SH3-binding sequence. The variable 
regions are diversely expressed in the different subunits. For instance the α and δG isoforms 
are the smallest catalytically competent CaMKII products because they contain the A–D core 
sequences, but no inserts (Hudmon et al., 2002). The most prominent proteins 
phosphorylated by the Type II CaM kinase are its own subunits (Bennett et al., 1983; 
Kennedy et al., 1983; Miller et al., 1985; Miller et al., 1986). Some studies suggest that kinase 
activity decrease after autophosphorylation (Kuret et al., 1984; LeVine et al., 1985; Yamauchi 
et al., 1985) while others suggest that it increases (Shields et al., 1984) or becomes 
autonomous (Saitoh et al., 1985). Despite these discrepancies, the most accepted theory is 
that the autophosphorylation allows for the activation of the catalytic domain (Hanley et al., 
1987). The Ca2+-CaM complex interacts with and promotes autophosphorylation of each 
subunit of the CaMKII. 
The implication of the CAMKII in the artery smooth muscle reactivity has been extensively 
investigated whereas little is known regarding its role in the airways smooth muscle. In 
contracted cultured ASM cells from bovine, studies demonstrated that CaMKII is 
responsible for the phosphorylation of the MLCK (Stull et al., 1993). Biochemistry data 
showed that MLCK is phosphorylated by CaMKII (Hashimoto et al., 1990; Ikebe et al., 1990a) 
at a specific serine near the calmodulin-binding domain; and this phosphorylation brings 
about the reduction of the affinity of MLCK for the Ca2+•CaM complex (Stull et al., 1990). In 
another hand the phosphorylation of MLCK by CaMKII have been shown to decrease the 
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Ca2+ sensitivity of MLC20 phosphorylation (Tansey et al., 1994; Tansey et al., 1992). Taken 
together, these findings would suggest that the net effect of the CaMKII is the relaxation of 
the ASM. However, enzymatic tests revealed two key elements which exclude this 
hypothesis: 1) the rate of phosphorylation of MLCK likely by the CaMKII is first of all 
slower than the rates of increase in cytosolic Ca2+ concentrations, 2) and also slower than the 
rate of phosphorylation of the MLC in intact tracheal smooth muscle cells in culture (Tansey 
et al., 1994). Therefore, the CaMKII activity is thought not to affect significantly the reactivity 
of the bovine ASM. Moreover, other studies showed that the CAMKII do not play a role in 
the profile of the contractile response upon stimulation in intact ASM from rat or cow (Liu et 
al., 2005; Mbikou et al., 2011; Sakurada et al., 2003). 
3.6 PI3K 
The phosphatidy inositol 3-kinases (PI3K) superfamily draws together all the enzymes 
capable of phosphorylating specifically the hydroxyl group of a membrane phospholipid 
called phosphatidyl inositol (PtdIns). Cloning approaches revealed the existence of eight 
distinct PI3K genes expressing eight isoforms in human and mouse genomes. Based on their 
domain structure, lipid substrate specificity and associated regulatory subunits, these 
isoforms have been divided into three main classes as follows: class I including p110α, 
p110β, p110δ and p110γ; class II including PI3K-C2α, PI3K-C2β and PI3K-C2γ, and the class 
III consisting of the sole enzyme Vps34. The PI3K phosphorylates the PtdIns into four 
possible products, PtdIns(3)phosphate, PtdIns(3,4)biphosphate, PtdIns(3,5) biphosphate and 
PtdIns(3,4,5)triphosphate, which are involved in a wide range of cellular functions, 
including cell growth, proliferation, motility, differentiation, survival and intracellular 
trafficking (Fry, 2001; Fry, 1994; Katso et al., 2001; Rameh et al., 1999). 
Purified PI3K is a heterodimer of 85 and 110 kDa subunits (Carpenter et al., 1990; Fry et al., 
1992; Morgan et al., 1990; Shibasaki et al., 1991). Analysis of the primary sequence of p85 
reveals a multidomain protein which contains a number of non-catalytic domains, a Src 
homology region 3(SH3), and a region with significant sequence similarity to the product of 
the breakpoint cluster region gene BCR (Otsu et al., 1991). In vascular smooth muscle, PI3K 
appears to play a role in the regulation of contraction as experiments showed that the 
specific isoform PI3K-C2α is necessary for Rho/RhoKinase-dependent MLCP inhibition and 
consequently for the MLC20 phosphorylation and the contraction (Yoshioka et al., 2007). 
However, in the ASM, the PI3K does not regulate the agonist-induced contractile response 
(Mbikou et al., 2006). 
4. Theoretical modelling of PK and ASMC contraction 
4.1 Interest and general priniples 
Since the contractile pattern of SMC in response to contractile agonists not only depends on 
the structure of the regulatory network that modulates the contractile apparatus but also on 
the dynamics of the reactions, understanding of the mechanisms underlying this contractile 
profile is quite impossible by a non-mathematical intuitive approach. In the following 
sections, we will present the concepts of our recent mathematical modelling of isometric 
contraction and force development in airway smooth muscle cells based on the 4-state latch 
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MLCP regulatory pathways (Fajmut et al., 2008; Fajmut et al., 2005a; Fajmut et al., 2005b; 
Fajmut et al., 2005c; Mbikou et al., 2011; Mbikou et al., 2006). 
The latch state was first described by the mathematical model by Hai and Murphy in 1988 
(Hai et al., 1988a). They introduced the model of isometric contraction based on the 4-state 
kinetic scheme of actomyosin crossbridges, in which to actin bound and unbound to myosin 
(phosphorylated and dephosphorylated) represent four different states. Even nowadays, 
that model represents the reference in modelling of smooth muscle contraction.  
Huxley (Huxley, 1957) pioneered the modelling of smooth muscle contraction. His model 
from 1957 was based on the sliding filament theory. Until the occurrence of Hai and 
Murphy's model in 1988 (Hai et al., 1988b), relatively small number of models of smooth 
muscle contraction was developed compared to striated muscles. In 1986 Gestrelius and 
Börgström (Gestrelius et al., 1986) introduced new concepts in modelling. They first 
considered viscoelastic properties of the filaments and the cytoskeleton. The later model and 
Huxley's model enabled the study of nonisometric contraction and took into account mostly 
the dynamics and mechanics of the filaments and myosin crossbridges. Although the 
original Hai and Murphy's model (Hai et al., 1988a) enabled only the prediction of isometric 
force its advantage was in considering the regulatory mechanisms that drive smooth muscle 
contraction. Several authors have later upgraded it to enable the prediction of nonisometric 
contraction. In 1997 Yu et al. (Yu et al., 1997) expanded it to simulate the nonisometric 
contractions of smooth muscles, added length dynamics and assumed length-dependent 
bonding and unbonding rates to be distributed according to the Gaussian distribution. In 
1999 Fredberg et al. (Fredberg et al., 1999) and Mijailovich et al. (Mijailovich et al., 2000) 
integrated the latch regulation scheme of Hai and Murphy with Huxley’s sliding filament 
model of muscle contraction for the studies of the effects of length fluctuations on the 
dynamically evolving cross-bridge distributions, simulating those that occur in airway 
smooth muscle during breathing. The later model has been recently upgraded by simple 
description of Ca2+-dependent regulation of MLCK activity (Bates et al., 2009; Wang et al., 
2008). Our approach in the modelling of smooth muscle contraction is to upgrade the 4-state 
kinetic description of Hai and Murphy (Hai et al., 1988a) with the signalling pathways that 
regulate the MLC phosphorylation and dephosphorylation. This was for a long time the 
missing part in the modelling of smooth muscle contraction. 
Development of force in smooth muscles is achieved by interactions between myosin cross-
bridges and actin filaments. To describe theses interactions Hai and Murphy proposed a 
kinetic scheme shown in Figure 1 (Hai et al., 1988a). The scheme was later upgraded by 
Rembold and Murphy (Rembold et al., 1990) with the consideration of the attachment of 
dephosphorylated myosin to actin with a very slow rate. Many authors ignore this 
interaction, since the rate of attachment of dephosphorylated myosin is 150-fold lower than 
that of phosphorylated myosin (0.002 s-1 and 0.3 s-1, respectively) (Trybus, 1996). In our 
studies we consider it in the modelling (Fajmut et al., 2008; Fajmut et al., 2005a; Mbikou et al., 
2011; Mbikou et al., 2006).   
The four different states of the myosin cross-bridges are presented in Figure 1. : A+M - 
detached, dephosphorylated, A+MP - detached, phosphorylated, AMP - attached, 
phosphorylated, and AM - attached, dephosphorylated, the last one termed also a latch 
bridge. The corresponding reaction velocities of phosphorylation/dephosphorylation and 
attachment/detachment of myosin cross bridges, the relevant variables of mathematical 
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modelling, are indicated together with sites of action of enzymes MLCK and MLCP 
responsible for phosphorylation and dephosphorylation of MLCs, respectively. In the 
model, the magnitude of stress in smooth muscles is proportional to the concentration of 
myosin cross-bridges associated with actin filaments (AMP and AM), whereby myosin 
cross-bridges in the state AMP generate stress and cross-bridges in the state AM maintain 
stress in smooth muscles. v are either the velocities of  crossbridge attachment/detachment 
or the velocities of phosphorylation/ dephosphorylation, which are regulated by MLCK and 
MLCP. 
Hai and Murphy's model considered a very simple semi-theoretical description of the Ca2+-
dependent MLCK activation, and thus first coupled Ca2+ signalling pathway with the 
contraction. In this chapter we will present an upgrade from that model in the sense of 
purely theoretical and more detailed description of Ca2+-dependent MLCK activation and 
functioning as well as MLCP regulation of force development. Our new concepts will be 
compared with the old ones. As a basic model scheme, we take the four-state model, in 
which we incorporate explicitly the description of both enzymatic reactions. The activity of 
MLCK is under the influence of transmitting Ca2+ signal and, hence, Ca2+ directly affects the 
force development. On the other hand, the action of MLCP is considered either independent 
of other signalling pathways or being under influence of Rho-kinase (RhoK), which 
phosphorylates MLCP and regulates its activity and catalytic properties. 
4.2 Modelling of MLCK activity 
According to the generally accepted view, MLCK is activated by the Ca2+-CaM complex 
(Kamm et al., 2001). In general, an increase in [Ca2+]i is considered to initiate the binding of 
four Ca2+ ions to CaM, which is finally followed by association of complex Ca4CaM with 
MLCK (Dabrowska et al., 1982; Smith et al., 2000). In this chapter we will present three 
different approaches to deal with interactions between Ca2+, CaM and MLCK: a three-state 
model proposed by Kato et al. in 1984 (Kato et al., 1984), our eight-state model proposed by 
Fajmut et al. in 2005 (Fajmut et al., 2005b) and a semi-theoretical approach proposed by 
Rembold and Murphy in 1990 (Rembold et al., 1990). The kinetic scheme of a three-state 






Fig. 4. The three-state kinetic scheme of MLCK activation proposed by Kato et al. (Kato et 
al., 1984). 
It assumes four independent and equivalent Ca2+ binding sites on CaM and considers a 
minimum number of possible states for CaM in the activation of MLCK. According to the 
kinetic scheme, MLCK is activated in two steps. The first step assumes simultaneous 
binding of four Ca2+ ions to CaM. In the second step, the intermediate complex of CaM with 
four Ca2+ ions bound (Ca4CaM) is associated with MLCK. The final product Ca4CaM-MLCK 
represents the active form of MLCK in the sense that it is able to phosphorylate MLCs. It 
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older and simplified view on the interactions between Ca2+, CaM and MLCK. Newer 
experimental studies show that not only Ca4CaM complex but also Ca2CaM complexes and 
Ca2+-free CaM interact with MLCK (Bayley et al., 1996; Johnson et al., 1996). It has been also 
shown that CaM and MLCK can interact without the presence of Ca2+ (Wilson et al., 2002) 
and that the velocity of Ca2+ binding to CaM is different with respect to N and C terminals 





















Fig. 5. The eight-state kinetic scheme of MLCK activation proposed by Fajmut et al. 
(Fajmut et al., 2005a). 
On the basis of these experimental findings we proposed more detailed and profound 
kinetic model of MLCK activation that considers either six (Fajmut et al., 2005c) or eight 
(Fajmut et al., 2005a) different states of CaM with respect to binding sites for Ca2+ on C and 
N terminals and a binding site for MLCK. The corresponding eight-state kinetic scheme is 
presented in Figure 5.  
Binding reactions and reaction components involved can easily be recognised from the 
scheme. The complex Ca4CaMMLCK represents the active form of MLCK and can be 
applied in the 4-state kinetic scheme of force development as indicated in Figure 1. 
In contrast to theoretical models of MLCK activation described here, a semi-theoretical 
approach was proposed by Hai and Murphy (Hai et al., 1988a). This approach was based on 
the expression fitted to the experimentally determined dependence of MLC phosphorylation 
on [Ca2+]i. The corresponding expression was built into the mathematical model of force 
development proposed by them (Hai et al., 1988a). The predictions of all abovementioned 
models for the steady state relative amount of the active MLCK (A), i.e., the ratio between 
Ca4CaMMLCK and total MLCK versus [Ca2+]i, are presented in Figure 6.  
From the comparison of the model results (lines on the left panel) with the measurements 
(open circles) (Geguchadze et al., 2004) in Figure 6 one can conclude that predictions of the 
eight-state model (Fajmut et al., 2005a) (full line), most properly describes the process of 
MLCK activation. The other two models give either too sensitive (dotted line) (Rembold et 
al., 1990) or too insensitive (dashed line) (Kato et al., 1984) responses to [Ca2+] and they also  
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Fig. 6. Model prediction of MLCK activation.  Left panel: Relative amount of the active 
MLCK (A) in dependence on [Ca2+] according to: semi-theoretical approach by Rembold and 
Murphy (Rembold et al., 1990) (dotted line); eight-state model by Fajmut et al. (Fajmut et al., 
2005a) (full line); three-state model by Kato et al. (Kato et al., 1984) (dashed line). 
Experimental results of Geguchadze et al. (Geguchadze et al., 2004) (open circles). Right 
panel: The corresponding steady state force dependencies on [Ca2+] according to: Rembold 
and Murphy (Rembold et al., 1990) (curve 1); Fajmut et al. (Fajmut et al., 2005a) (curve 2); 
Kato et al. (Kato et al., 1984) (curve 3).  
do not have strong support by other experimental evidence (Gallagher et al., 1993; 
Geguchadze et al., 2004). The corresponding steady state force dependency on [Ca2+] (right 
panel) shows similar behaviour. Rembold and Murphy's model gives sensitive and Kato's 
model gives insensitive response to [Ca2+] and again don't have a strong support by 
experiments (Sieck et al., 1998). These findings speak in favour of the necessity for more 
complex description of interactions between Ca2+, CaM and MLCK in Ca2+-signal 
transduction pathway. Another important property, which has not been implicated in this 
steady state analysis, is time dependency. In the past the interactions between Ca2+, CaM 
and MLCK were considered as very fast (Kasturi et al., 1993; Torok et al., 1994) and thus 
modelled as being in the steady state. The reason for that were the results obtained in in 
vitro experiments, which exhibited very fast kinetics between Ca2+, CaM and MLCK. 
However, experiments from 2001 performed by Wilson et al. (Wilson et al., 2002) revealed 
that this might not be the case in vivo. Their experiments showed that at low [Ca2+]i  MLCK 
is present in complexes with Ca2+-free CaM as well as with Ca2CaM, in which Ca2+ is bound 
to the C-terminal of CaM (Wilson et al., 2002). It has been suggested that this is a 
consequence of the increased affinity of CaM for Ca2+ by the presence of MLCK in the 
complex (Wilson et al., 2002). In accordance with these findings the Ca2+-CaM activation of 
MLCK appears at sufficiently high Ca2+ levels, when in addition to the C-terminal binding 
sites, the N-terminal binding sites for Ca2+ on CaM are saturated. However, the transition 
from CaM-MLCK and Ca2CaMMLCK complexes is much slower compared to the transition 
from Ca2+- and MLCK- free CaM state. Our model simulations show for typical 
physiological total amounts of CaM and MLCK (10 µM and 2 µM, respectively) in smooth 
muscle cells that for [Ca2+]i = 0.3 µM approximately one third of MLCK is in complexes with 
Ca2CaM, one third is Ca2+-CaM-free and one third is in active form. Moreover, the half 
saturation time for achieving the final active MLCK form for [Ca2+]i = 0.1 µM is 1.5 s and for 
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saturation time for achieving the final active MLCK form for [Ca2+]i = 0.1 µM is 1.5 s and for 





activation/deactivation of MLCK are not as fast as proposed by earlier models (Kato et al., 
1984) and some in vitro experiments on isolated CaM and MLCK (Kasturi et al., 1993; Torok 
et al., 1994). Moreover, the half-saturation time of MLCK activation/deactivation is of the 
same order of magnitude as the typical periods of oscillatory Ca2+ signals in smooth muscle 
cells (Mbikou et al., 2006; Perez et al., 2005), thus the processes of MLCK activation 
significantly contribute to decoding of oscillatory Ca2+ signal into a rather steady developed 
force already at the cellular level (Fajmut et al., 2008; Fajmut et al., 2005b; Mbikou et al., 2011; 
Mbikou et al., 2006) and add a small delay in force development after [Ca2+]i increase.  
4.3 Modelling of the MLCK/MLP balance and Ca2+-contraction coupling 
In our models (Fajmut et al., 2008; Fajmut et al., 2005b; Mbikou et al., 2011; Mbikou et al., 
2006) we showed that the transduction of the Ca2+ signal from its appearance in the cytosol 
as a time-dependent variation of concentration to the development of force in smooth 
muscle cells is decoded mainly by the interactions between Ca2+, CaM and MLCK, and is 
further translated to force by the balance between the phosphorylation and 
dephosphorylation of MLC, whereby both processes are regulated by MLCK and MLCP, 
respectively. The abundance of actomyosin crossbridges either phosphorylated or in the 
latch state is reflected in the magnitude of developed force. Our model results point out that 
a complete description of MLCK activation by Ca2+-CaM is necessary for the relevant 
prediction of Ca2+-contraction coupling and that 4-state latch bridge model upgraded with 
Ca2+-CaM-dependent MLCK activation well describes the fast phase (first few minutes) of 
force development in the isometric contraction of rat tracheal rings (Fajmut et al., 2008; 
Mbikou et al., 2011; Mbikou et al., 2006). 
Essentially, the last and the most elaborated version of the model describing Ca2+-
contraction coupling consists of three parts (Mbikou et al., 2011). The first one describes the 
activation of MLCK by Ca2+-CaM complexes, considers binding of MLCK to Ca2+-free CaM 
as well as to various Ca2+-CaM complexes, predicts the concentration of the active form of 
MLCK, i.e. the complex Ca4CaMMLCK, in dependence of [Ca2+]i. The kinetic scheme of 
these interactions is presented in Figure 5. 
The second part describes the regulation of MLCP activity and represents an essential 
upgrade from the original description of Hai and Murphy (Hai et al., 1988a), in which 
dephosphorylation velocity was taken as a linear function of AMP and MP. In our first 
models (Fajmut et al., 2008; Fajmut et al., 2005b; Mbikou et al., 2006) we treated 
dephosphorylation process with two parallel enzymatic reactions of Michaelis-Menten type 
with AMP and MP as the substrates for MLCP and with MLCPMP and MLCPAMP as the 
intermediate complexes. All these models considered constant total amount of the enzyme 
and one Ca2+ independent catalytic activity of MLCP. In accordance with recent 
experimental results indicating that the activity of MLCP is under the influence of Rho-
Kinase (RhoK) (Somlyo et al., 2000), we modelled RhoK-dependent MLCP regulation 
(Mbikou et al., 2011). RhoK phosphorylates MLCP and thus modifies its enzymatic 
properties. It decreases the rate constant of enzyme-substrate breakdown (kcat) and increases 
the Michaelis constant (KM) (Feng et al., 1999; Ichikawa et al., 1996; Lukas, 2004). The 
mechanisms by which RhoK is itself activated have not yet been fully determined. However, 
according to our present experimental results, RhoK is likely to be activated by the Ca2+ 
signal (Mbikou et al., 2011). Thus, we consider the transition of RhoK from inactive state into 
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active state to be Ca2+-dependent. On these statements, RhoK activity has been modelled 
according to the kinetic scheme, represented in Figure 7 (Mbikou et al., 2011).  
 
Fig. 7. Kinetic scheme of RhoK dependent MLCP phosphorylation and partial inhibition 
proposed by Mbikou et al. (Mbikou et al., 2011). RhoKi, inactive RhoK; RhoK*, active 
Rhok. MLCPi, inactive MLCP; MLCP*, active MLCP. 
RhoK can be either in an inactive (RhoKi) or active (RhoK*) state. k+RK and k-RK are the 
corresponding on- and off- rate constants. k+RK depends on the Ca2+ response, that is the 
[Ca2+]i above baseline. Modelling of MLCP phosphorylation by RhoK* is based on the 
steady-state Michaelis-Menten enzyme kinetics, whereby MLCP*RhoK* is the intermediate 
complex and kcatP is the rate constant for the breakdown of this intermediate complex into 
product, i.e. MLCPi. k+P and k-P are the corresponding overall rate constants for MLCP 
phosphorylation and dephosphorylation, respectively. The values of the rate constant of 
MLCP-substrate breakdown (kcat) and the Michaelis constant of MLCP (KM) depend on the 
net effective form of MLCP, which is dependent on the fraction of unphosphorylated and 
inhibited MLCP ([MLCP]*/[MLCP]i). 
The third part of the modelling represents the well-known 4-state actomyosin latch bridge 
model (Hai et al., 1988a). Links between all three parts of the model are the active form of 
MLCK and the net effective form of MLCP, which both modulate the rate of MLC 
phosphorylation and dephosphorylation.  
In our experimental and theoretical study (Mbikou et al., 2006), the version of the model 
without RhoK-dependent regulation of MLCP was first developed and analysed. The model 
was applied to the studies of the effect of different calcium signals to the amplitude and the 
velocity of force developed in airway smooth muscles. It was shown that the velocity and 
magnitude of the force that develops in several seconds after cholinergic stimulation are 
determined by the following signal parameters: the amplitude and the frequency of the 
oscillating Ca2+ signal as well as the plateau - but not the peak - in the biphasic Ca2+ signal, 
which comprises a peak followed by a decline to a plateau phase (Mbikou et al., 2006). On 
the other hand, the increased frequency of oscillating Ca2+ signal is translated into the 
increase of force magnitude (Fajmut et al., 2008; Mbikou et al., 2006). One main physiological 
implication of that model (Mbikou et al., 2006) was the prediction of the temporal delay of 
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active state to be Ca2+-dependent. On these statements, RhoK activity has been modelled 
according to the kinetic scheme, represented in Figure 7 (Mbikou et al., 2011).  
 
Fig. 7. Kinetic scheme of RhoK dependent MLCP phosphorylation and partial inhibition 
proposed by Mbikou et al. (Mbikou et al., 2011). RhoKi, inactive RhoK; RhoK*, active 
Rhok. MLCPi, inactive MLCP; MLCP*, active MLCP. 
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increase of force magnitude (Fajmut et al., 2008; Mbikou et al., 2006). One main physiological 
implication of that model (Mbikou et al., 2006) was the prediction of the temporal delay of 





dependent relative MLC phosphorylation (p) (full line) and relative MLCK activity (A) 
(dotted line) after biphasic [Ca2+]i with a peak and a plateau with the characteristic values 
(peak: 0.6 µM, plateau: 0.2 µM, baseline: 0.15 µM) as well as the time dependent relative 
force development (F) as predicted by the model (Mbikou et al., 2006) (right panel). 
 
Fig. 8. Predicted MLCK activity and MLC20 phosphorylation. Left panel: Time dependent 
relative MLC phosphorylation (p) (full line) and relative MLCK activity (A) (dotted line) after 
biphasic [Ca2+]i with a peak and plateau as predicted by the model (Mbikou et al., 2006). Right 
panel: Time dependent relative force development (F) as predicted by the model (Mbikou et al., 
2006). F is defined relatively to the force obtained at supramaximal steady [Ca2+]i.   
This time-delay originates also from the process of MLCK activation/inactivation. Namely, 
the process of Ca2+-CaM-dependent MLCK activation contributes significantly to the time 
delay, in contrast with other studies (Kasturi et al., 1993; Torok et al., 1994), hypothesizing 
that the process of MLCK activation is extremely fast and is not likely to contribute more 
than a few milliseconds to the overall delay in force development (Sieck et al., 1998). Slow 
force generation in our model is also a consequence of the slow-rate of MLCK 
activation/inactivation kinetics. Additionally, the kinetics of formation of actomyosin cross 
bridges explains the delay between MLC phosphorylation and force development, and the 
Hill-shaped time course of isometric contraction. 
In another purely theoretical study (Fajmut et al., 2008) we confirmed that upon biphasic 
Ca2+-signal transduction through the system, MLCK controls amplitude more than duration, 
whereas MLCP tends to control both. These general characteristic regulatory properties of 
kinases and phosphatases were previously described by Heinrich et al. and Hornberg et al. 
(Heinrich et al., 2002; Hornberg et al., 2005) in other signalling processes. 
In our most recent work (Mbikou et al., 2011), the model was applied to the studies of RhoK 
contribution to the early phase of the Ca2+-contraction coupling in airway smooth muscle. 
For this purpose, the simulation of RhoK inhibitor Y27632 was simulated by the model. 
Theoretical results of early stress development agreed with experimental results, which 
showed an evident drop in the stress development after RhoK inhibition in the early phase 
of contraction, whereby the shape and the characteristic time of stress development did not 
change significantly. The model further predicted that maximal RhoK activation and 
subsequent MLCP inactivation occur in less than 10 s, i.e., before the short time maximal 
contraction is achieved (Mbikou et al., 2011). 
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An essential property of our models coupling Ca2+ and contraction is the explicit 
consideration of MLC phosphorylation and dephosphorylation steps described by 
Michaelis-Menten kinetics. This permits simulations of the effects that variations in  
enzyme contents and their catalytic properties exert on their velocities of 
phosphorylation/dephosphorylation, signal transduction and development of force. In this 
sense our models provide an upgrade with respect to the original Hai and Murphy's model 
as well as other models describing smooth muscle contraction. 
4.4 Modelling of thin filament-associated regulation of contraction 
An additional upgrade to the original Hai and Murphy's model has been proposed by Hai 
and Kim in 2005 (Fajmut et al., 2005c) to address some experimental data that could not be 
explained by the four-state model. Because in phorbol ester-induced force development 
constant myosin phosphorylation could not be explained by the original 4-state model, the 
authors proposed and postulated a thin-filament-regulated latch-bridge model that includes 
two latch-bridge 4-state cycles, one of which is identical to the original Hai and Murphy's 
model, and the other one is the ultraslow 4-state cycle with lower cross-bridge cycling rates 
(Hai et al., 2005). The model is able to fit phorbol ester-induced contractions at constant 
myosin phosphorylation. This was achieved by shifting cross bridges from the regular to the 
ultraslow cross-bridge cycle. It was also proposed that PKC activation leads to the thin-
filament-based inhibition of actomyosin ATPase activity in ultraslow cycle, however, 
authors did not specify the target, the signalling pathway and the mechanism of this 
regulation. They hypothesized about calponin and caldesmon – the thin-filament-based 
regulatory proteins – being the candidates for the inhibition of actomyosin ATPase activity 
caused by PKC, because both proteins can exist in the unphosphorylated and 
phosphorylated form (Gerthoffer et al., 1994).  
In the early 1990s it was believed that the actin bound proteins, calponin and caldesmon, 
have large modulatory role in the latch state, however, in the late 1990s, the discovery of the 
significant regulatory role of myosin light chain phosphatase in smooth muscle contraction 
draw attention away from the thin-filament-based regulatory proteins (Paul, 2009). There is 
evidence that regulation of the response to a given [Ca2+]i, that is, regulation of the ‘Ca2+ 
sensitivity’ via modulating phosphatase activity, is as important as regulation of [Ca2+]i in 
the control of contractility (Paul, 2009). PKC-mediated phosphorylation of CPI-17 has been 
postulated as a mechanism of PKC-mediated inhibition of MLCP (Hirano et al., 2003). 
However, according to Hai and Kim (Hai et al., 2005) this mechanism can potentially explain 
only the initial increase in the MLC phosphorylation but not the continued force 
development after myosin phosphorylation has already reached steady state.  
In our experimental studies (Mbikou et al., 2011; Mbikou et al., 2006) we also observed the 
biphasic force development similar to that observed by phorbol ester-induced contraction 
(Hai et al., 2005). The analysis of the time course of isometric contraction and MLC 
phosphorylation showed that the contractile response of rat tracheal rings to cholinergic 
stimulation developed in two distinct phases (Mbikou et al., 2006). The first, short-time 
contractile response, which represents 70 % of the total contraction, was associated with a 
fast [Ca2+]i peak followed by a plateau with, in some cases, with superimposed [Ca2+]i 
oscillations, in correlation with fast and transient MLC phosphorylation, and Hill-shaped 
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biphasic [Ca2+]i with a peak and plateau as predicted by the model (Mbikou et al., 2006). Right 
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2006). F is defined relatively to the force obtained at supramaximal steady [Ca2+]i.   
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Hill-shaped time course of isometric contraction. 
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Ca2+-signal transduction through the system, MLCK controls amplitude more than duration, 
whereas MLCP tends to control both. These general characteristic regulatory properties of 
kinases and phosphatases were previously described by Heinrich et al. and Hornberg et al. 
(Heinrich et al., 2002; Hornberg et al., 2005) in other signalling processes. 
In our most recent work (Mbikou et al., 2011), the model was applied to the studies of RhoK 
contribution to the early phase of the Ca2+-contraction coupling in airway smooth muscle. 
For this purpose, the simulation of RhoK inhibitor Y27632 was simulated by the model. 
Theoretical results of early stress development agreed with experimental results, which 
showed an evident drop in the stress development after RhoK inhibition in the early phase 
of contraction, whereby the shape and the characteristic time of stress development did not 
change significantly. The model further predicted that maximal RhoK activation and 
subsequent MLCP inactivation occur in less than 10 s, i.e., before the short time maximal 
contraction is achieved (Mbikou et al., 2011). 
 
Role of Protein Kinase Network in Excitation-Contraction Coupling in Smooth Muscle Cell 
 
309 
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biphasic force development similar to that observed by phorbol ester-induced contraction 
(Hai et al., 2005). The analysis of the time course of isometric contraction and MLC 
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contractile response, which represents 70 % of the total contraction, was associated with a 
fast [Ca2+]i peak followed by a plateau with, in some cases, with superimposed [Ca2+]i 
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Figure 8. The first fast phase was then followed by the second slow phase in which progressive 
increase of force reached plateau after 30 minutes (Mbikou et al., 2006). Our model (Mbikou et 
al., 2006) of force development generated by Ca2+-dependent MLCK activation properly 
predicted the short-time contractile response. Simulations with the existing model showed that 
the long-time contractile response might be explained either by a long-term increase in 
oscillation frequency or [Ca2+]i plateau. However, recordings of [Ca2+]i responses to cholinergic 
stimulation for several minutes did not support such a hypothesis (Perez et al., 2005). A 
possible explanation was, in parallel with the activation of MLCK, the inactivation of MLCP, 
which may be due to the action of PKC or RhoK (Mizuno et al., 2008). For RhoK we have 
recently shown that it is implicated only in the fast phase of force development (Mbikou et al., 
2011). However, incorporation of progressive slow inactivation of MLCP in our modelling 
predicts a time course of isometric contraction similar to the experimental one, and explains 
the second increase in MLC phosphorylation and a slow phase in force development (Mbikou 
et al., 2006). But, it does not explain a decrease in MLC20 phosphorylation associated with 
maximal force observed after 30 minutes (Mbikou et al., 2006).  
5. Conclusion 
In airway smooth muscle as in other smooth muscles, actin-myosin cross bridge cycling 
critically depends on the phosphorylation of MLC20 and hence on MLCK/MLCP balance. 
MLCK, which activity is modulated by the Ca2+ signal through the formation of the Ca2+-
calmodulin-MLCK complex, is the most important kinase in airway myocyte contraction and 
the contractile properties of airway smooth muscle cells are lost when MLCK is inactivated or 
deleted. However, though activation of MLCK is indispensable, contraction of airway smooth 
muscle, both in its amplitude and time-course, is modulated by a network of kinases that can 
act upstream the Ca2+ signal, modulating the Ca2+ signal itself, or downstream, modulating the 
sensitivity of the contractile apparatus to Ca2+. The main targets of the protein kinases acting 
on the decoding of the Ca2+ signal are MLCP and MLCK, though direct MLC20 
phosphorylation, in parallel to MLCK, may be possible. Indeed, MLCP and MLCK have 
several sites of phosphorylation and their enzymatic activity depends on whether these sites 
are phosphorylated or not. These phosphorylations may up- or downregulate MLCP and 
MLCK activity. Stimulation of airways by contractile agonists such as acetylcholine activates 
kinases such as Rho kinase and PKC that inhibit MLCP activity and hence increase the 
sensitivity of the contractile apparatus to Ca2+. By contrast, β2-adrenergic stimulation, a major 
relaxant pathway, activates PKA which inhibits MLCK and favours MLCP activity. 
Additionally, contraction may be modulated by phosphorylation of caldesmon and calponin, 
proteins associated with the thin filament of actin. The MLCK/MLCP balance is hence 
embedded in a network of protein kinases. The resultant contractile behaviour of the SMC 
depends on the dynamics of the reaction of this regulatory network, and mathematical 
modelling is essential to decipher how the different protein kinases determine the time-
dependent variation of the contractile status of the airway smooth muscle cell. 
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One of the major functions of the kidneys is to maintain the volume and composition of the 
body fluids constant despite wide variation in the daily intake of water and solutes. To 
accomplish this task, the activities of a number of transport proteins along the nephron are 
tightly regulated.  
The nephron is the functional unit of the kidneys. Each human kidney contains approximately 
1.2 millions of nephrons. At the beginning of each nephron, in the glomerulus, the blood is 
filtered: cells and most proteins are retained, whereas water and small solutes pass from the 
glomerular capillaries to the Bowman’s capsule. As the glomerular filtrate leaves Bowman’s 
capsule and enters the renal tubule, it flows sequentially through the proximal tubule, the 
loop of Henle, the distal tubule, and the collecting duct. Along this course, greater part of 
the glomerular filtrate is transported across and between the tubule cells and reenters the 
blood (reabsorption), whereas some is secreted from the blood into the luminal fluid 
(secretion). The formation of urine involves the sum of these three major processes: 
ultrafiltration of plasma by the glomerulus, reabsorption of water and solutes from the 
ultrafiltrate, and secretion of solutes into the tubular fluid. Although 180 liters of plasma is 
filtered by the human glomeruli each day, less than 1% of water, sodium chloride and 
variable amounts of other solutes are excreted in the urine. By the processes of reabsorption 
and secretion the renal tubule modulates the volume and composition of the urine. 
Consequently, the tubules precisely control the volume, composition, and pH of the body 
fluids.  
The renal proximal tubule is responsible for reabsorption of the majority of the filtered 
sodium, bicarbonate, chloride and water. Na+/H+ exchange is the predominant mechanism 
for absorption of Na+ and secretion of H+ across the apical membrane of proximal tubule 
cells (Alpern, 1990). Apical membrane Na+/H+ exchange also has a major role in mediating 
chloride reabsorption in the proximal tubule through its combined activity with a Cl-/base 
exchanger and by creating an increase in luminal chloride concentration that favors the 
diffusion of the anion from the tubular lumen to the blood (Warnock and Yee, 1981; 
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the major topic of this chapter; therefore the properties of the NHE family will be briefly 
discussed bellow. 
 
Fig. 1. Schematic illustration of the nephron depicting the most important transport 
mechanisms involved with NaCl reabsorption in proximal tubule. The inset shows Na+/K+-
ATPase, Na+/H+ exchanger and Cl-/Base exchanger localization in proximal tubule. BL = 
basolateral; AP = apical. 
The mammalian Na+/H+ exchanger (NHE) gene family (SLC9) consists of secondary active 
transporters that mediate the electroneutral exchange of intracellular protons for 
extracellular sodium (Aronson, 1985). The transport activity of this protein is crucial to 
regulation of intracellular pH and cellular volume. In polarized epithelia, Na+/H+ 
exchangers are also involved in transepithelial NaHCO3 and NaCl transport.  
All members of the NHE family share a common structural feature. They consist of two 
major portions, an N-terminal transmembrane domain and a large cytoplasmic C-terminal 
domain. The N-terminal portion of all known isoforms is predicted to span the plasma 
membrane twelve times. This domain is responsible for the Na+/H+ exchange transport 
function (Pouyssegur, 1994). The C-terminal portion is mainly hydrophilic and it is the 
portion through which the activity of the exchanger is regulated.  
Thus far, five sodium proton exchangers (NHE1, NHE2, NHE3, NHE4 and NHE8) have 
been identified in plasma membrane of renal tubular cells (Biemesderfer et al., 1992; 
Biemesderfer et al., 1993a; Amemiya et al., 1995; Chambrey et al., 1997; Chambrey et al., 
1998). Of these, NHE3, the most abundant NHE isoform in renal tissue, is confined to the 
apical membrane of proximal tubule and thin and thick ascending limb. Several lines of 
evidence strongly support the conclusion that NHE3 is the principal NHE isoform 
responsible for apical membrane Na+/H+ exchange in the proximal tubule. First, studies  
 





Fig. 2. Secondary structure of sodium/proton exchangers (NHE). All NHE isoforms have a 
membrane topology of 10-12 transmembrane segments. The carboxy-terminal region at the 
cytoplasmic site of NHE3 has consensus phosphorylation sites for PKA. 
using isoform-specific antibodies have demonstrated that NHE3 is expressed on the brush 
border membrane of proximal tubule cells (Biemesderfer et al., 1993b; Biemesderfer et al., 
1997). Second, the pattern of sensitivity to different inhibitors of Na+/H+ exchange in renal 
brush border vesicles and of bicarbonate absorption in microperfused proximal tubules is 
most consistent with the properties of NHE3 among the known NHE isoforms (Vallon et al., 
2000). Third, micropuncture analysis on NHE3 knockout mice revealed a remarkable 
reduction of fluid and bicarbonate reabsorption in renal proximal tubule further supporting 
the concept that NHE3 is the isoform that accounts for most Na+/H+ exchange in this 
nephron segment (Lorenz et al., 1999; Wang et al., 1999). Indeed, mice lacking NHE3 display 
hypotension and had a mild hyperchloremic metabolic acidosis (Schultheis et al., 1998). 
Despite the reduced salt reabsortive capacity in the renal proximal tubule, the NHE3 
deficient mice grows well when fed a normal sodium diet, mostly due to reduced 
glomerular filtration rate and increased sodium and bicarbonate reabsorption in the distal 
nephron. However, if these animals are subjected to dietary salt restriction the adaptative 
mechanisms are not sufficient to fully compensate for the large defect on proximal 
reabsorption and they may die from hypovolemic shock (Ledoussal et al., 2001).  
Given the important role of NHE3 in mediating NaHCO3 and NaCl reabsorption in the 
proximal tubule, this transporter is subject to acute and chronic regulation in response to a 
variety of conditions and humoral factors affecting acid-base or salt balance. In this chapter 
we will focus on the regulation of NHE3 by protein kinase A and the implications of this 
regulatory mechanism on renal function under physiological and pathophysiological 
conditions. 
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2. Regulation of NHE3 activity by hormones that activate cAMP-dependent 
protein kinase A (PKA) in renal proximal tubule  
The signal transduction cascade mediating the acute effect of NHE3 agonists and 
antagonists involves multiple pathways. One of the best studied regulatory mechanisms 
affecting NHE3 activity is the inhibition resulting from protein kinase A (PKA) activation. 
Hormones activating cAMP-dependent PKA have been shown to reduce sodium and 
bicarbonate reabsorption in renal proximal tubule by inhibiting NHE3 transport activity. 
Table 1 presents a summary of hormones and molecular mechanisms associated with 
inhibition of NHE3 by PKA. These hormones act via G-protein coupled receptors (GPCR) 
expressed in the apical membrane of the renal proximal tubule (Felder et al., 1984; Muff et 
al., 1992; Marks et al., 2003; Schlatter et al., 2007; Crajoinas et al., 2011) . GPCR signal 
transduction occurs through coupling to heterotrimeric G proteins on the intracellular side 
of the membrane. Heterotrimeric G proteins contain three subunits referred as Gα, G, and 
Gγ. Upon ligand binding, the GPCR undergoes a conformational change that promotes the 
exchange of bound guanosine diphosphate (GDP) from the Gα subunit for guanosine 
triphosphate (GTP). The G protein Gα subunit bound to GTP can then dissociate from the 
Gγ dimer and initiate the intracellular signaling cascade that leads to cAMP dependent 
PKA activation that further elicits NHE3 inhibition (Fig. 3). 
 
Fig. 3. Downstream effect of a receptor coupled to adenylyl cyclase. The ligand (L) binds to 
its receptor coupled to protein G (S) and adenylyl cyclise (AC) is activated. The activated 
enzyme converts ATP to cAMP, which activates protein kinase A (PKA) which, in turn, is 
ready to phosphorylate NHE3 at the specific PKA consensus sites. 
2.1 Parathyroid hormone 
The kidney is a principal target organ for the action of the parathyroid hormone (PTH). PTH 
is primarily involved in modulation of serum calcium and phosphate homeostasis but also 
acts on the proximal tubule, the thick ascending limb, and the distal convoluted tubule to 
alter urinary electrolyte and fluid excretion. The inhibitory effect of PTH on renal proximal  
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Hormone/Condition Associated Mechanism References 
Parathyroid hormone  of NHE3 affinity for protons due 
to phosphorylation of the 
exchanger 
 of NHE3 maximum velocity due 
to a decrement of the number of 
NHE3 molecules at the plasma 
membrane 
 of NHE3 promoter activity, NHE3 
mRNA and protein abundance 
(Fan et al., 1999; Collazo et 
al., 2000; Zhang et al., 1999; 
Girardi et al., 2000; Bezerra 
et al., 2008) 
Dopamine  NHE3-mediated Na+/H+ 
exchange due to increased 
endocytosis caused by increased 
PKA-mediated NHE3 
phosphorylation 
(Gomes & Soares-da-Silva, 
2004; Hu et al., 2001; Bacic et 
al., 2003) 
Glucagon-like peptide 1  NHE3 activity due to increased 
NHE3 phosphorylation 
(Crajoinas et al., 2011; 
Carraro-Lacroix et al., 2009) 
Glucagon Acutely -  NHE via a PKA-
dependent pathway 
Chronically -  NHE3 mRNA and 
protein expression at the plasma 
membrane 
(Amemiya et al., 2002) 
Guanylins  NHE3-mediated Na+/H+ due to 
increased levels of NHE3 PKA-
dependent phosphorylation and 
reduction of the exchanger at the 
plasma membrane 
(Amorim et al., 2006; Lessa 
LM, Girardi AC, and Malnic 
G, unpublished 
observations) 







 NHE3-mediated Na+/H+ due to 
higher NHE3 phosphorylation on 
serine 552, redistribution from 
microvilli to the intermicrovillar 
region together with its regulatory 
partner dipeptidyl peptidase IV 
 NHE3-mediated Na+/H+ due to 
higher NHE3 phosphorylation on 
serine 552, redistribution of the 
transporter to the intermicrovillar 
region 






(Magyar et al., 2000; Panico 
et al., 2009; Crajoinas et al., 
2010) 
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Hormone/Condition Associated Mechanism References 
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to phosphorylation of the 
exchanger 
 of NHE3 maximum velocity due 
to a decrement of the number of 
NHE3 molecules at the plasma 
membrane 
 of NHE3 promoter activity, NHE3 
mRNA and protein abundance 
(Fan et al., 1999; Collazo et 
al., 2000; Zhang et al., 1999; 
Girardi et al., 2000; Bezerra 
et al., 2008) 
Dopamine  NHE3-mediated Na+/H+ 
exchange due to increased 
endocytosis caused by increased 
PKA-mediated NHE3 
phosphorylation 
(Gomes & Soares-da-Silva, 
2004; Hu et al., 2001; Bacic et 
al., 2003) 
Glucagon-like peptide 1  NHE3 activity due to increased 
NHE3 phosphorylation 
(Crajoinas et al., 2011; 
Carraro-Lacroix et al., 2009) 
Glucagon Acutely -  NHE via a PKA-
dependent pathway 
Chronically -  NHE3 mRNA and 
protein expression at the plasma 
membrane 
(Amemiya et al., 2002) 
Guanylins  NHE3-mediated Na+/H+ due to 
increased levels of NHE3 PKA-
dependent phosphorylation and 
reduction of the exchanger at the 
plasma membrane 
(Amorim et al., 2006; Lessa 
LM, Girardi AC, and Malnic 
G, unpublished 
observations) 
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tubule NHE3 activity has been consistently reported by several laboratories on both in vivo 
(Bank and Aynediian, 1976; Girardi et al., 2000) and in vitro studies (Pollock et al., 1986; 
Mrkic et al., 1992; Mrkic et al., 1993). Experiments performed in vitro and ex vivo provide 
evidence that the acute inhibition of NHE3 by PTH is mediated by molecular mechanisms 
the include reduction of the transporter’s apparent affinity for protons in consequence of the 
direct phosphorylation of the exchanger followed by reduction of its maximum velocity due 
to a decrement of the number of NHE3 molecules expressed at the plasma membrane (Fan 
et al., 1999; Collazo et al., 2000). Consistent with a decrease of NHE3 surface expression in 
response to PTH, studies carried out by the McDonough laboratory have shown that 
reduction of NHE3 activity in response to acute treatment with this hormone is a 
consequence of NHE3 redistribution from the apical microvilli to the base of the 
intermicrovillar region of the proximal tubule brush border (Zhang et al., 1999).  
The chronic effect of PTH on NHE3 regulation has also been evaluated (Girardi et al., 2000; 
Bezerra et al., 2008). Long term inhibition of NHE3 by PTH is associated with a reduction on 
NHE3 protein and mRNA levels. PTH also provokes a mild inhibitory effect on NHE3 
promoter that seems to be PKA-dependent (Bezerra et al., 2008). 
2.2 Dopamine 
The intrarenal dopamine natriuretic system is critical for mammalian sodium homeostasis. 
Numerous studies have demonstrated that dopamine remarkably increases urinary sodium 
excretion mainly by inhibiting tubular sodium reabsorption. The inhibitory effect of 
dopamine on NHE3 transport activity is mediated mainly via the dopamine D1 receptor and 
stimulation of adenylyl cyclase/PKA system and phospholipase C/PKC (Gomes and 
Soares-da-Silva, 2004). The underlying molecular mechanisms by which dopamine 
decreases NHE3-mediated Na+/H+ exchange in renal proximal tubule involves increased 
endocytosis and is associated with increased PKA-mediated NHE3 phosphorylation (Hu et 
al., 2001; Bacic et al., 2003). 
2.3 Glucagon-like peptide-1 
Glucagon-like peptide-1 (GLP-1) is produced by posttranslational modification of the 
proglucagon gene product in the intestinal L-cells, predominantly localized in the colon and 
ileum (Holst, 1997; Drucker, 2005). This incretin hormone plays an important role on the 
maintenance of systemic glucose homeostasis by stimulating insulin secretion and 
improving insulin sensitivity (Drucker, 2005). Numerous reports in the literature have 
demonstrated that GLP-1 also exerts renoprotective actions. In this regard, continuous 
administration of GLP-1 induces diuresis and natriuresis in both humans (Gutzwiller et al., 
2004; Gutzwiller et al., 2006) and experimental animal models (Moreno et al., 2002; Yu et al., 
2003).  
The molecular mechanisms underlying the renal actions of GLP-1 seems to involve increases 
of GFR and RPF and decrease of NHE3-mediated Na+/H+ exchange in the renal proximal 
tubule (Carraro-Lacroix et al., 2009). Recent studies by our group have demonstrated that 
binding of GLP-and/or the GLP-1R agonist exendin-4 to its receptor in the renal proximal 
tubule activates the cAMP/PKA signaling pathway, leading, in turn, to phosphorylation of 
the PKA consensus sites located at the C-terminal region of the exchanger (Carraro-Lacroix 
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et al., 2009; Crajoinas et al., 2011). Increased NHE3 phosphorylation levels induced by GLP-1 
was not accompanied by a decrease of NHE3 expression at the microvillar microdomain of 
the brush border, suggesting that the mechanism by which GLP-1 inhibits NHE3 activity 
does not involve subcellular redistribution of the exchanger between the subcompartiments 
of the renal proximal tubule brush border.  
2.4 Glucagon 
Glucagon is a 29-amino-acid pancreatic peptide produced by the α-cells present at the 
periphery of the islets of Langerhans (Baum et al., 1962) and its major function is the 
maintenance of plasma glucose homeostasis between meals and during fasting. Glucagon 
binding to its receptor primarily activates adenylyl cyclase and increases cAMP (Pohl et al., 
1971; Rodbell et al., 1971). The tissue distribution of the glucagon receptor is broad, with 
higher levels of expression in liver and kidney (Svoboda et al., 1993; Dunphy et al., 1998). 
In the kidney, glucagon affects renal glomerular filtration, renal blood flow, and decreases 
renal tubular sodium reabsorption (Pullman et al., 1967). Part of the acute natriuretic action of 
glucagon are mediated by inhibition of NHE3 in the renal proximal tubule via a cAMP/PKA-
dependent pathway. Interestingly, in vitro studies using OKP cells have shown that glucagon 
acutely inihibits and chronically stimulates NHE3 activity (Amemiya et al., 2002).  
2.5 Guanylins 
The guanylin and uroguanylin are endogenous ligants of the Escherichia coli heat-stable 
enterotoxin (STa) receptor, guanylate cyclase C (Currie et al., 1992; Fonteles et al., 1998) and 
are known to be involved in a control system that regulates salt balance in response to oral 
salt intake. Both guanylin and uroguanylin are synthesized in the intestine and in the kidney 
and have already been identified in several animal species, including as mammals, fishes 
and birds (Forte, 2004).  
The renal effects of uroguanylin are much more pronounced than the ones produced by 
guanylin and include natriuresis, kaliuresis, diuresis and increased excretion of cGMP (Forte 
et al., 1996; Greenberg et al., 1997; Fonteles et al., 1998). In the renal proximal tubule, 
uroguanylin significantly inhibits NHE3 transport function (Amorim et al., 2006). Ongoing 
studies by the Malnic laboratory have demonstrated that the mechanism by which 
uroguanyn inhibits NHE3 involves increased levels of NHE3 phosphorylation followed by 
retrieval of the exchanger from the plasma membrane (unpublished observations, Lessa LM, 
Girardi AC, and Malnic G) ). The mechanism by which NHE3 is phosphorylated by PKA in 
response to coupling of uroguanylin to its receptor in the renal proximal tubule possibly 
involves a crosstalk mechanism between cGMP and cAMP pathways.  
3. The Na+/H+ exchanger regulatory factor NHERF 
Although a large number of hormones reported to affect NHE3 share the same signal 
pathways, the molecular mechanisms by which they regulate NHE3 may differ greatly among 
them. The identification of regulatory proteins that interact with NHE3 has unraveled some 
aspects of the molecular mechanisms underlying this transporter regulation.  
The first NHE3 regulatory factor was isolated and characterized byWeinman and Shenolikar 
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demonstrated that the presence of this cofactor was essential for PKA-mediated inhibition of 
NHE3. This protein was cloned and termed NHERF-1 (Na/H exchanger regulatory factor). 
Subsequently, in an attempt to identify proteins that interact with NHE3, Yun and 
coworkers used the C-terminus of NHE3 as a bait in a yeast two-hybrid screen and isolated 
E3KARP (exchanger-3 kinase A regulatory protein, or NHERF-2) . NHERF-1 and NHERF-2 
are highly homologous proteins (52% sequence identity for the human orthologs) (Yun et 
al., 1997). Physical association of NHERF-1 and NHERF-2 with NHE3 has been 
demonstrated by binding assays using fusion proteins or by co-precipitation experiments 
using transfected cells overexpressing NHE3.  
NHERF-1 and NHERF-2 are both members of a family of proteins that contain two tandem 
PDZ domains (that are conserved modules that mediate protein-protein interaction) and a 
C-terminal ezrin-radixin-moesin (ERM) binding domain which anchors the proteins to the 
actin cytoskeleton through ezrin. Lamprecht and Yun have proposed a model whereby the 
complex NHERF/ezrin acts as a functional AKAP (A kinase anchoring protein) for NHE3, 
serving as a structural link between not only NHE3 and the cytoskeleton but also between 
NHE3 and PKA, since ezrin is capable of binding the RII regulatory subunit of PKA 
(Dransfield et al., 1997; Lamprecht et al., 1998). The current model suggests that NHERF-1 is 
required for cAMP-dependent regulation of NHE3 and acts as an adapter to link NHE3 to 
ezrin, which then serves as a PKA anchoring protein. Upon activation of PKA by hormones 
and/or factors that increase intracellular cAMP, PKA phosphorylates serine residues in the 
C-terminal hydrophilic domain of NHE3 (Fig. 4). Biochemical experiments with brush 
border vesicles isolated from NHERF-1 knockout mice corroborate with this model 
(Weinman et al., 2003). These studies showed that NHERF-1 is crucial for PKA-mediated 
phosphorylation and inhibition of NHE3 transport activity. Moreover, NHE3 expression 
was not affected in these animals, showing that NHERF-1 plays an essential role on NHE3 
modulation but it is not required for expression or apical targeting of the transporter in the 
proximal tubule (Weinman et al., 2003).  
 
 
Fig. 4. Model of NHERF requirement for PKA-mediated NHE3 inhibition. NHERF facilitates 
cAMP-dependent regulation of NHE3 by interacting with the cytoskeleton to target PKA to 
phosphorylation sites within the cytoplasmic domain of NHE3. 
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To date, four members of the NHERF family of PDZ domain proteins have been described. 
These proteins bind to a variety of membrane transporters regulating their cell surface 
expression, protein interactions as well as the formation of signaling complexes.  
4. NHE3 phosphorylation at the PKA consensus sites  
Moe and coworkers were the first to demonstrate that the cytoplasmic domain of NHE3 is a 
substrate for PKA in vitro (Moe et al., 1995). There are multiple putative consensus motifs 
for PKA on the NHE3 C-terminal region. Three of these sites (S552, S605 and S634) are 
highly conserved among species. Based on that, transfection studies using truncation of the 
NHE3 C-terminal domain and site direct mutagenesis of the above mentioned serine 
residues were carried out to evaluate whether PKA directly phosphorylates one or more of 
these consensus sites in vivo (Cabado et al., 1996; Kurashima et al., 1997; Zhao et al., 1999). 
Kurashima and coworkers have shown that both serines 605 and 634 are important for PKA-
mediated inhibition of NHE3, although only serine 605 is phosphorylated in vivo 
(Kurashima et al., 1997). The studies by Zhao and colleagues confirmed that 
phosphorylation of serine 605 is increased by cAMP/PKA. These investigators also found 
that PKA directly phosphorylates serine 552 and that both 552 and 605 residues appear to be 
critical for inhibition of NHE3 by PKA (Zhao et al., 1999).  
Years later, the Aronson laboratory generated phosphospecific antibodies directed to the 
PKA consensus sites S552 and S605 of rat NHE3 (Kocinsky et al., 2005). These reagents are of 
great value, since they have enable investigators to evaluate the phosphorylation state of 
these two residues in endogenous NHE3 under basal conditions, under a variety of 
physiological and pharmacological maneuvers and in disease states. Indeed, increments in 
the phosphorylation status of NHE3 at serines 552 and 605 have been shown to occur in 
response to dopamine (Kocinsky et al., 2005), PTH (Kocinsky et al., 2007), and GLP-1 
(Crajoinas et al., 2011). 
 Studies by Kocinsky and colleagues have also demonstrated that serine 552 is 
phosphorylated to a much greater extent than serine 605 in baseline in vivo. Moreover, these 
investigators found that when NHE3 is phosphorylated at serine 552, it mainly resides at the 
intermicrovillar domain of the brush border (Kocinsky et al., 2005). This observation is 
consistent with a decrease on NHE3-mediated Na+/H+ exchange in the renal proximal 
tubule, since within the intermicrovillar subcompartment of the brush border, this 
transporter must have very limited assess to the tubular fluid.  
The precise mechanism by which NHE3 phosphorylation leads to NHE3 inhibition remains 
obscure. Although phosphorylation of NHE3 at the 552 and 605 residues are necessary for the 
PKA-dependent inhibitory effect, phosphorylation of NHE3 at these PKA consensus sites 
precedes transport inhibition (Kocinsky et al., 2007) indicating that phosphorylation per se is 
not sufficient to inhibit NHE3 activity. The current body of data suggests that PKA 
phosphorylation may ultimately result in inhibition of NHE3 by modulating NHE3 subcellular 
trafficking, interaction with regulatory proteins, or localization within the plasma membrane.  
5. Pathophysiological Implications of NHE3 Phosphorylation by Protein 
Kinase A 
As mentioned above, NHE3 is phosphorylated on serine 552 under basal conditions by the 
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phosphorylation is often affected as part of acute NHE3 regulation. Interestingly, baseline 
levels of NHE3 phosphorylation at this residue may also be associated with chronic 
regulation of NHE3 activity.  
5.1 High Salt Diet 
During high salt diet the kidneys increase sodium and volume excretion to match intake. 
IYang and colleagues have demonstrated that three weeks of high salt diet (4%) doubled the 
levels of NHE3 phosphorylation at the serine 552 (Yang et al., 2008), possibly contributing to 
the natriuretic effect triggered by high sodium load. 
5.2 Hypertension 
Mice lacking Na+/H+ exchanger NHE3 are hypotensive and hypovolemic, underscoring the 
importance of the transporter on blood pressure control.  
We have recently assessed in vivo NHE3 transport activity and defined the mechanisms 
underlying NHE3 regulation before and after development of hypertension in 
spontaneously hypertensive rats (SHR). By means of in vivo stationary microperfusion, we 
found that NHE3-mediated bicarbonate reabsorption is higher in the proximal tubule of 5-
week-old pre-hypertensive spontaneously hypertensive rat (SHR) and lower in 14-week-old 
SHR compared to age-matched normotensive rats (Wistar Kyoto, WKY). Higher NHE3 
activity in young pre-hypertensive SHR is associated with lower phosphorylation levels 
(serine 552) and increased NHE3 expression at the microvillar brush border. During the 
hypertensive stage, NHE3 was found to be mainly confined to the intermicrovillar region 
and the relative abundance of NHE3 phosphorylated on serine 552 is increased compared to 
normotensive animals (Fig. 5) (Crajoinas et al., 2010).  
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reabsorption in the proximal tubule, might be upregulated in heart failure. To test this 
hypothesis, we employed both stationary in vivo microperfusion and pH-dependent 
sodium uptake to verify whether NHE3 activity would be altered in the proximal tubule of 
an experimental model of heart failure (Antonio et al., 2009). Our data demonstrated that 
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tubule which may contribute to extracellular volume expansion and edema. In addition to 
increased renal cortical NHE3 expression at both protein and mRNA levels, we have also 
observed that the levels of NHE3 phosphorylation at serine 552 in renal cortical membranes 
of heart failure rats are lower than in Sham animals. Thus, the molecular mechanisms 
mediating enhanced sodium reabsorption in the renal proximal tubule of heart failure rats 
also involves posttranslational covalent modification of NHE3 (Fig. 5) (Inoue et al., 2012). 
6. Conclusion  
PKA activation plays an important role in inhibiting the activity NHE3, the major apical 
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inhibition may be involved in NHE3 stimulation, as suggested by the studies carried out in 
young hypertensive and in heart failure animals. The elucidation of the mechanisms by 
which phosphorylation of NHE3 at the PKA consensus sites leads to inhibition of NHE3-
mediated Na+/H+ exchange in the renal proximal tubule may also unravel important 
molecular underpinnings that lead to the development and/or progression of primary 
kidney diseases and other conditions that affect the kidneys. 
                                   A)                                                                B) 
 
Fig. 5. NHE3 activity negatively correlates with the levels of endogenous phosphorylation of 
the PKA consensus site, serine 552, located at the C-terminus region of the exchanger 
Adapted from (Crajoinas et al., 2010; Inoue et al., 2012). (A) Stationary microperfusion was 
employed to measure NHE3-mediated bicarbonate reabsorption (JHCO3- ) in the proximal 
tubules of 5-week-old Wistar Kyoto rats (Y-WKY, n = 5 rats, 12 tubules), 5-week old SHR (Y-
SHR, n = 5 rats, 12 tubules, and heart failure rats (HF, n = 5 rats, 15 tubules). Data are 
expressed as means ± SE. *P < 0.05 vs. Y-WKY. (B) Top: Representative immunoblot of 
phosphorylated and total NHE3 expression in renal cortical membranes isolated from Y-
WKY, Y-SHR or HF rats. Equivalent samples (15 µg of protein for NHE3 and 5 µg for PS552-
NHE3 and actin) of renal cortical membranes were prepared for immunoblot analysis. The 
membranes were incubated with monoclonal antibodies against phosphorylated NHE3 at 
serine 552 (PS552-NHE3 (1:1,000)), total NHE3 (1:1,000) or anti-actin (1:50,000). Bottom: Left - 
Graphical representation of the phosphorylation ratio of NHE3 at Serine 552 to total NHE3 
in renal cortical membranes (PS552-NHE3/NHE3). Values are means ± SE. n = 3/group, **P 
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1. Introduction 
Cyclic GMP-dependent protein kinase (PKG) was discovered in 1970 in lobster muscle (Kuo 
& Greengard, 1970). It is a serine/threonine protein kinase specifically activated by cyclic 
guanosine monophosphate (cGMP). PKG is a ubiquitous intracellular second messenger 
mediating the biological effects of cGMP elevating agents including nitric oxide (NO), 
natriuretic peptides, and guanylin (an intestinal peptide involved in intestinal fluid 
regulation). It is now well recognized that PKG plays a central role in a broad range of 
physiological processes, such as contractility and proliferation of smooth muscle and cardiac 
myocytes, platelet aggregation, synaptic plasticity and learning, behavior, intestinal chloride 
reabsorption, renin secretion, and endochondral ossification (Francis et al., 2010; Hofmann 
et al., 2009; Lincoln et al., 2001; Lohmann & Walter, 2005). This chapter will focus on the role 
of PKG in the regulation of cardiovascular functions under physiological and 
pathophysiological conditions.  
2. PKG structure and tissue distribution  
In mammalian cells PKG exists as two types, PKG-I and PKG-II, respectively. They are 
encoded by two separated genes prkg1 and prkg2. The human prkg1 gene is located on 
chromosome 10 at p11.2 - q11.2 and has 15 exons. The NH2 terminus (the first 100 residues) 
of PKG I is encoded by two alternative exons that produce the isoforms PKG Iα and PKG Iβ. 
The human prkg2 gene is located on chromosome 4 at q13.1 - q21.1 and has 19 exons. PKG-I 
and PKG-II is composed of two identical subunits of the homodimer about 75-80 kDa and 
84-86 kDa, respectively and shares common structural features. Each subunit of the enzyme 
consists of a regulatory domain and a catalytic domain. The regulatory domain is composed 
of an N-terminal domain and a cGMP binding domain. The N-terminal domain mediates 
homodimerization, suppression of the kinase activity in the absence of cGMP, and 
interactions with other proteins including protein substrates. The cGMP binding domain 
contains a high and a low cGMP affinity binding sites. The two cGMP-binding sites interact 
allosterically. Binding of cGMP releases the inhibition of the catalytic center by the N-
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contains a high and a low cGMP affinity binding sites. The two cGMP-binding sites interact 
allosterically. Binding of cGMP releases the inhibition of the catalytic center by the N-





proteins. The catalytic domain contains a MgATP and a target protein-binding site, which 
catalyze the phosphate transfer from ATP to the hydroxyl group of a serine/threonine side 
chain of the target protein. When stimulated with cGMP, the phosphotransferase activity 
increases by 3- to 10-fold (Francis et al., 2010; Hofmann et al., 2009).  
PKG-I is predominantly localized in the cytoplasm (except in the platelets where it is with 
the membrane). PKG-II is anchored to the plasma membrane by N-terminal myristoylation. 
In general, PKG-I and PKG-II are expressed in different cell types. PKG-I exists at high 
concentrations in all types of smooth muscle cells (~0.1µM) including vascular smooth 
muscle cells and at lower levels in vascular endothelium and cardiomyocytes. The enzyme 
has also been detected in other cell types such as fibroblasts, certain types of renal cells and 
leukocytes, and in specific regions of the nervous system. Platelets express predominantly 
PKG Iβ while both PKG Iα and PKG Iβ isoforms are present in smooth muscle, including 
uterus, blood vessels, intestines, and trachea. PKG-II is expressed in several brain nuclei, 
intestinal mucosa, kidney, chondrocytes and the lung but not in cardiac and vascular 
myocytes (Francis et al., 2010; Hofmann et al., 2009). 
Existing research results show that PKG-I is the major type of the enzymes in the 
cardiovascular system involved in the regulation of vascular tone, regulation of vascular 
smooth muscle cells and myocardial cells proliferation and phenotypic modulation, and 
inhibiting platelet aggregation. Both PKG-Iα and PKG-Iβ can be specially activated by 
cGMP, with the former is about 10 times more sensitive to cGMP than the latter. PKG can 
also be activated by cAMP, although more than 100 times less potent than cGMP. The main 
role of PKG-II is phosphorylation in the intestinal mucosa of cystic fibrosis transmembrane 
conductance regulator, regulation of intestinal chloride ion/fluid secretion, inhibition of 
renin secretion in the kidney, and the regulation of bone tissue and bone endochondral bone 
growth (Francis et al., 2010; Hofmann et al., 2009; Lincoln et al., 2001; Lohmann & Walter, 
2005). 
3. PKG function in the cardiovascular system  
3.1 Blood vessels 
3.1.1 Vasodilatation 
PKG is involved in vasodilatation caused by cGMP elevating agents including endothelium-
derived NO, ANP, CNP, and exogenous nitrovasodilators (Gao, 2010; Hofmann et al., 2009). 
In certain vessel types such as ovine perinatal pulmonary artery and vein (Dhanakoti et al., 
2000; Gao et al., 1999) as well as porcine coronary artery and vein (Qin et al., 2007; Qi et al., 
2007) relaxation caused by nitrovasodilators is primarily mediated by PKG. Studies show 
that the expression and activity of PKG can be modulated by physiological variables such as 
oxygenation (Gao et al., 2003).  
Activation of calcium activated potassium (BK) channels has been implicated as a 
mechanism for PKG-mediated relaxation of vascular smooth muscle in a number of vessel 
types including cerebral artery (Robertson et al., 1993), coronary artery (White et al., 2000), 
and pulmonary artery (Barman et al., 2003), which leads to increased membrane polarization 
and thus decreased Ca2+ influx and vasodilatation. PKG may stimulate BK channels by 
direct phosphorylation of the α-subunit at serine 1072 (Fukao et al., 1999) or through 
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activation of protein phosphatase 2A (Zhou et al., 1996). In ovine basilar arterial smooth 
muscle cells PKG has been shown to play a larger role in the regulation of BK activity in 
fetal than in adult myocytes, indicating a developmental changes in the role of PKG (Lin et 
al., 2005). 
PKG may also modulate Ca2+ release from the inositol-trisphosphate receptor (IP3R) of the 
sarcoplasmic/endoplasmic reticulum (SERCA) through phosphorylation of IP3R-associated 
cGMP kinase substrate (IRAG), a 125-kDa protein that resides in the SERCA membrane 
in a trimeric complex with PKG Iβ and IP3R. In aortic smooth muscle cells of mice 
expressing a mutated IRAG protein that does not interact with the IP3R the inhibition of 
cGMP on hormone-induced increases in [Ca2+]i and contractility are blunted (Geiselhöringer 
et al., 2004). NO-, ANP-, and cGMP-dependent relaxation of aortic vessels is also attenuated 
in IRAG-knockout mice (Desch et al., 2010). 
Increasing evidence has pointed to Ca2+ desensitization through interference with RhoA and 
Rho kinase (ROK) signaling as a key mechanism for PKG-mediated vasodilatation (A.P. 
Somlyo & A.V. Somlyo, 2003). PKG may phosphorylate RhoA at Ser188, resulting in 
increased extraction of Rho A from cell membranes and thus reduced activation of this small 
GTPase protein and attenuated vasocontractility (Loirand et al., 2006). PKG may suppress 
the inhibitory effect of ROK on myosin light chain phosphatase (MLCP) by phosphorylation 
of the regulatory subunit of MLCP, myosin phosphatase targeting subunit (MYPT1), at 
Ser695 and Ser852, which leads to decreased phosphorylation of MYPT1 at Thr696 and 
Thr853 by ROK, increased activity of MLCP, decreased phosphorylation of myosin light 
chain (MLC), and diminished vasoreactivity (Wooldridge et al., 2004; Gao et al., 2007 
&2008). The effect of PKG on MLCP requires its binding to the leucine zipper domain in the 
C-terminal of MYPT1. The expression of the leucine zipper domain in MYPT1 is modulated 
by various physiological and pathophyiological conditions (Chen et al., 2006; Dou et al., 
2010; Payne et al., 2006), which may alter the action of PKG on MLCP. Studies also show 
that PKG/MYPT1 signaling plays a greater role in mediating relaxation of proximal arteries 
induced by NO than that of distal arteries in coronary vasculature (Ying et al., 2011). 
A number of PKG substrates not mentioned above may also be targeted by PKG and 
involved in PKG-mediated vasodilatation, such as phosphodiesterase 5 (PDE5), 
phospholamban, and RGS (regulator of G-protein signaling) proteins (Schlossmann & 
Desch, 2009). It is worth noting that cGMP may affect vasodilatation by PKG-dependent and 
independent mechanism. Global PKG-knockout causes only a slight hypertension in young 
mice whereas in the adult the basal blood pressure of the PKG-knockout mice is not 
different from the control (Pfeifer et al. 1998), indicating other mechanisms may take place 
to compensate the lose of PKG in maintaining a normal blood pressure. 
3.1.2 Phenotype modulation and antiproliferation action  
Vascular smooth muscle cells (VSMCs) exist in either a differentiated, contractile or a 
dedifferentiated, synthetic phenotype. A normal PKG activity appears critical to maintain 
vascular smooth muscle cells in a contractile and differentiated state. Repetitively passaged 
VSMCs of the rat aorta do not express PKG and exist in the synthetic phenotype. Transfection 
of PKG Iα cDNA induces a morphologic change of VSMCs consistent with the contractile 
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vascular smooth muscle cells in a contractile and differentiated state. Repetitively passaged 
VSMCs of the rat aorta do not express PKG and exist in the synthetic phenotype. Transfection 
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Myocardin is a smooth muscle and cardiac muscle-specific transcriptional coactivator of 
serum response factor (SRF) while E26-like protein-1 (Elk-1) is a SRF/myocardin transcription 
antagonist. PKG-I has been shown to decrease Elk-1 activity by sumo modification of Elk-1, 
thereby increasing myocardin-SRF activity on SMC-specific gene expression and keeping 
the cells in a contractile phenotype (Choi et al., 2010). In VSMCs of ovine fetal pulmonary 
veins hypoxia-induced reduction in PKG protein expression is closely correlated with the 
repressed expression of VSMC phenotype markers, along with a reduced expression of 
myocardin and increased expression of Elk-1. It is postulated that the increased expression 
of Elk-1 resulting from the downregulation of PKG under hypoxia displaces myocardin 
from SRF and thereby leads to suppression of SMC marker genes and activation of 
expressions of genes related with the synthetic phenotype (Zhou et al., 2007 & 2009). The 
PKG-dependent modulation of phenotypes of VSMCs appears to need the cysteine-rich LIM-
only protein CRP4 to act as a scaffolding protein that promotes cooperation between SRF and 
other transcription factors and cofactors since PKG stimulation of the SM-α-actin promoter is 
suppressed when CRP4 is deficient in PKG binding (Zhang et al., 2007).  
PKG has been reported to exert anti- and pro-atherogenic effects in vascular smooth muscle. 
In coronary and cerebral arterial smooth muscle cells (El-Mowafy et al., 2008; Luo et al., 
2011) the proliferation induced by vascular mitogens was inhibited by the cGMP elevating 
agent or PKG I transfection. However, 8-Br-cGMP stimulated proliferation of aortic SMCs 
from the wide-type mice but not from PKG I-deficient mice (Wolfsgruber et al., 2003). The 
contradictory effects may have in part resulted from differences in PKG activation levels 
(i.e., basal activation vs. hyperactivation). For instance, PKG at low activation levels 
prevents apoptosis whereas high-level activation causes apoptosis of aortic SMCs of the 
mice (Wong & Fiscus, 2010). 
3.2 Heart 
3.2.1 Cardiac contractility 
A critical role for PKG in the negative inotropic effect caused by NO and cGMP has been 
demonstrated in myocardial preparations from PKG I-deficient juvenile mice, from the 
cardiomyocyte-specific knockout adult mice (Wegener et al., 2002), and in rat ventricular 
myocytes with the PKG inhibitor (Layland et al., 2002). The Ca2+ current of rat ventricular 
cells is inhibited by cGMP and a catalytically active fragment of PKG (Mery et al., 1991). In 
murine cardiac myocytes overexpressing PKG I the basal and stimulated activities of L-type 
Ca2+ channels are inhibited by NO and the cGMP analog (Schroder et al. 2003). Hence, PKG 
may exert its negative inotropic effect action by reducing [Ca2+] i through inhibiting the 
activity of Ca2+ channels. Recent studies suggest that PKG I-mediated inhibition of L-type 
Ca2+ channels of cardiac myocytes may result from the phosphorylation of Cav 1.2 α1c and β2 
subunits (Yang et al., 2007).  
PKG may also reduce [Ca2+]i of cardiomyocytes through phosphorylation of phospholamban, 
which leads to an increased activity of the sarcoplasmic reticulum Ca2+-ATPase (SERCA) 
and thereby an increased Ca2+ uptake from the cytosol. Indeed, phospholamban of the 
rabbit cardiac myocytes is phosphorylated by cGMP in a manner sensitive to the inhibition 
of PKG. Moreover, the inhibitory effect of contractility of the cardiac myocytes caused by 
cGMP is prevented by the inhibition of PKG or SERCA (Zhang et al., 2005). C-type natriuretic 
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peptide and the cGMP analog have been found to cause positive inotropic and lusitropic 
responses of murine hearts, which are associated with an increased phosphorylation of 
phospholamban (Wollert et al., 2003). These observations are in vary with those obtained in 
studies by Zhang et al. discussed above. The underlying reasons for the different inotropic 
effects remain to be determined (Wollert et al., 2003).  
In intact cardiomyocytes of the rat, the negative inotropic and relaxant effects of DEA/NO, 
an NO donor, occur without significant changes in the amplitude or kinetics of the 
intracellular Ca2+ transient. The effect is diminished in the presence of the inhibitor of 
soluble guanylyl cyclase (sGC) or PKG, indicating a PKG-dependent Ca2+ desensitization of 
the myofilaments. Meanwhile, hearts treated with DEA/NO showed a significant increase 
in troponin I phosphorylation (Layland et al., 2002). The PKG may reduce the Ca2+ 
sensitivity of cardiac myofilaments through phosphorylation of cardiac troponin I (cTnI) at 
the same sites (Ser23/24) as those phosphorylated by PKA (Layland et al., 2005). Studies 
suggest that cardiac Troponin T may serve as an anchoring protein for PKG to facilitate 
preferential and rapid cTnI phosphorylation (Yuasa et al., 1999). 
3.2.2 Antihypertrophy 
An increased left ventricular mass has been recognized as an independent risk factor that 
correlates closely with cardiovascular risk and has strong prognostic implications. In the mice 
administration of sildenafil, which elevates cGMP level by inhibiting PDE5, suppresses the 
development of cardiac hypertrophy caused by chronic pressure overload and can even 
reverse pre-established cardiac enlargement. These effects are associated with an increased 
activity of PKG I (Takimoto et al. 2005). Mice with myocyte-specific PDE5 gene overexpression 
develop more severe cardiac hypertrophy and PKG activation is inhibited as compared to 
controls in response to pressure overload. Under such a cardiomyopathic state, the 
suppression of PDE5 expression/activity in myocytes enhanced PKG activity and reversed all 
previously amplified maladaptive responses (Zhang et al., 2010). In contrast to many studies 
which indicate an antihypertrophic role for PKG, Lukowski et al. have found that total PKG I-
knockout and myocyte-specific rescue of PKG expression (in the context of global gene 
silencing) did not affect isoproterenol and stress-induced development of cardiac hypertrophy 
in mice (Lukowski et al., 2010). It is suspected that the lack of differences between controls and 
PKG I-deficient mice may be in part due to that PKG I-targeted cascades have not been 
activated under the experimental conditions (Kass & Takimoto, 2010). 
RGSs are GTPase-accelerating proteins that promote GTP hydrolysis by the alpha subunit of 
heterotrimeric G proteins, thereby accelerating signal termination in response to GPCR 
stimulation (Schlossmann & Desch, 2009). Among more than 30 RGS proteins, RGS4 is 
richly expressed in murine coronary myocytes. In cultured cardiac myocytes, atrial 
natriuretic peptide stimulated PKG-dependent phosphorylation of RGS4 and association of 
RGS4 with the alpha subunit of Gq protein. Mice lacking guanylyl cyclase-A (GC-A), a 
natriuretic peptide receptor, have pressure-independent cardiac hypertrophy, reduced 
expression and phosphorylation of RGS4 in the hearts compared with wild-type mice. The 
RGS4 overexpression in GC-A-KO mice reduced cardiac hypertrophy and suppressed the 
augmented cardiac expressions of hypertrophy-related genes. These results suggest that 
GC-A activation may counteract cardiac hypertrophy via RGS4 in a PKG-dependent 
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involved in β-adrenergic but not angiotensin II (Ang II)–induced (Gs vs. Gaq mediated) 
cardiomyocyte hypertrophy. ANP attenuated Ang II-stimulated Ca2+ currents of 
cardiomycytes but had no effect on isoproterenol stimulation. The effect of ANP on Ang II 
stimulation was eliminated in cardiomyocytes of mice deficient in GC-A, in PKG I, or in 
RGS2. Furthermore, cardiac hypertrophy induced by Ang II but not by β- adrenoreceptor 
was exacerbated in mice with cardiomyocyte-restricted GC-A deletion (Klaiber et al., 2010). 
Multiple subclasses of transient receptor potential (TRP) channels are expressed in the heart. 
These channels, especially the TRPC subclass, have been implicated being involved in the 
regulation of the cardiac hypertrophic response, most likely coordinating signaling within 
local domains or through direct interaction with Ca2+-dependent regulatory proteins. 
Overexpression of TRPC6 in mice lacking GC-A exacerbated cardiac hypertrophy while the 
blockade of TRPC channels attenuated the cardiac hypertrophy. ANP inhibited agonist-
evoked Ca2+ influx of murine cardiomyocytes. The inhibitory effects of ANP were abolished 
by PKG inhibitors or by substituting an alanine for threonine 69 in TRPC6, suggesting that 
PKG-dependent phosphorylation of TRPC6 at threonine 69 is a critical target of 
antihypertrophic effects elicited by ANP (Kinoshita et al., 2010) 
3.2.3 Cardioprotective action against ischemia-reperfusion injury 
In isolated murine heart and cardiomyocytes elevation of cGMP by the activators of soluble 
or particulate guanylyl cyclase, by the inhibitor of PDE5, or by the cGMP analog elicits potent 
protection against myocardial ischemia-reperfusion injury and reduces cardiomyocyte 
necrosis and apoptosis. These effects are accompanied by an increased PKG activity and 
attenuated by PKG inhibitors or by selective knockdown of PKG in cardiomyocytes (Das, 2008 
et al.; Gorbe et al., 2010). It is generally recognized that ischemia/reperfusion injury arises 
primarily from the opening of the mitochondrial permeability transition pore (mPTP) in the 
first minutes of reperfusion. cGMP-PKG signaling may prevent opening of mPTP via 
activation of the mitochondrial KATP channels, direct phosphorylation of an unknown 
protein on the mitochondrial outer membrane, and upregulation of the antiapoptotic 
protein Bcl-2 (Costa et al.,2008; Deschepper, 2010). Glycogen synthase kinase 3β (GSK-3β) 
plays a central role in transferring cardio protective signals downstream to target(s) that act 
at or in proximity to the mPTP. Phosphorylation and inhibition of GSK-3β has also been 
demonstrated being involved in PKG-mediated cardioprotective action (Das et al., 2008; 
Juhaszova et al., 2009; Xi et al., 2010). 
3.3 eNOS activity and endothelial permeability 
PKG I has been detected within a range of 0.15 to 0.5 µg/mg cellular protein in adult artery 
and vein endothelial cells (ECs) and in microvascular ECs (Diwan et al., 1994; Draijer et al., 
1995; MacMillan-Crow et al., 1994). There are only limited studies on the role of PKG in the 
regulation of endothelial function, which is related to eNOS activity and endothelial 
permeability (Butt et al., 2000; Draijer et al., 1995; Moldobaeva et al., 2006; Rentsendorj et al., 
2008). Studies using recombinant human eNOS suggest that the enzyme can be 
phosphorylated at Ser1177, Ser633, Thr495 and activated by PKG II in a manner independent of 
Ca2+ and calmodulin (Butt et al., 2000). Cyclic GMP analog inhibits an increase in [Ca2+]i and 
endothelial permeability caused by thrombin in cultured ECs expressing PKG I but not 
those lacking PKG expressing (Draijer et al., 1995). In human pulmonary artery endothelial 
cells infected with adenovirus encoding PKG Iβ the cGMP analog prevents the increase in 
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endothelial permeability caused by H2O2. The barrier protection effect was not affected by 
inhibition of the expression of VASP, a PKG substrate (Moldobaeva et al., 2006; Rentsendorj 
et al., 2008). 
3.4 Anti-platelet aggregation action 
Substantial evidence supports a critical role for PKG in mediating the anti-platelet 
aggregation action caused by cGMP elevating agents such as endothelium-derived NO 
(EDNO) and exogenous nitrovasodilators (Walter & Gambaryan, 2009; Dangel et al., 2010). 
PKG Iβ is the predominate isoform of the enzyme in platelets. The concentration of PKG Iβ 
in human platelets is 3.65μM, which is higher than that of any other cell type examined 
(Antl et al., 2007; Eigenthaler et al., 1992). In PKG-deficient murine platelets the inhibition of 
the cGMP analog on granule secretion, aggregation and adhesion is severely affected 
(Massberg et al. 1999; Schinner et al., 2011). The effect of PKG may be in part mediated by 
IRAG. IRAG is abundantly expressed in platelets and constitutively formed in a 
macrocomplex with PKGIβ and the InsP3R. PKGIβ phosphorylates IRAG at Ser664 and 
Ser677 in intact platelets, resulting in attenuated release of Ca2+ from the sarcoplasmic 
reticulum evoked by IP3. Targeted deletion of the IRAG-InsP3RI interaction in IRAGΔ12/Δ12 
mutant mice causes a loss of NO/cGMP-dependent inhibition of [Ca2+]i increase and platelet 
aggregation. The preventive effect of NO on arterial thrombosis in the injured carotid artery 
was observed in wide-type platelets but not in IRAGΔ12/Δ12 mutants (Antl et al. 2007). 
Vasodilator-stimulated phosphoprotein (VASP) belongs to the Ena-VASP protein family. It is 
associated with filamentous actin formation and may play a widespread role in cell adhesion 
and motility. In VASP-deficient mice, the inhibitory effect of NO on platelet adhesion is 
impaired. Under physiologic conditions, platelet adhesion to endothelial cells was enhanced in 
VASP null mutants. Under pathophyiological conditions, the loss of VASP augments platelet 
adhesion to the postischemic intestinal microvasculature, to the atherosclerotic endothelium of 
ApoE-deficient mice, and to the subendothelial matrix of blood vessels (Massberg et al. 2004). 
In VASP-deficient mice, although cGMP-mediated inhibition of platelet aggregation is 
impaired, cGMP-dependent inhibition of agonist-induced increases in cytosolic calcium 
concentrations and granule secretion is preserved (Aszódi et al., 1999). 
Although it is a currently prevailing concept that PKG signaling inhibits platelet function, 
some studies show that activation of NO-cGMP-PKG pathway promotes platelet aggregation 
(Blackmore, 2011; Li et al., 2003; Zhang et al., 2011). In PKG knockout mice platelet responses 
to von Willebrand factor (vWF) or low doses of thrombin are impaired and bleeding time is 
prolonged. Human platelet aggregation induced by these agents is also diminished by PKG 
inhibitors but enhanced by cGMP (Li et al., 2003). A defect in platelet aggregation in response 
to low doses of collagen or thrombin also occurs in platelet-specific sGC-deficient mice (Zhang 
et al., 2011). It appears that cGMP at low concentrations promotes while at higher 
concentrations inhibits platelet aggregation (Blackmore et al., 2011; Li et al., 2003).  
4. PKG and cardiovascular diseases 
4.1 Hypertension  
Global deletion of eNOS (Huang et al., 1995), sGC (Friebe et al., 2007), or PKG I (Pfeifer et al. 
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(Blackmore, 2011; Li et al., 2003; Zhang et al., 2011). In PKG knockout mice platelet responses 
to von Willebrand factor (vWF) or low doses of thrombin are impaired and bleeding time is 
prolonged. Human platelet aggregation induced by these agents is also diminished by PKG 
inhibitors but enhanced by cGMP (Li et al., 2003). A defect in platelet aggregation in response 
to low doses of collagen or thrombin also occurs in platelet-specific sGC-deficient mice (Zhang 
et al., 2011). It appears that cGMP at low concentrations promotes while at higher 
concentrations inhibits platelet aggregation (Blackmore et al., 2011; Li et al., 2003).  
4. PKG and cardiovascular diseases 
4.1 Hypertension  
Global deletion of eNOS (Huang et al., 1995), sGC (Friebe et al., 2007), or PKG I (Pfeifer et al. 





at age of 8-week. Those lived to adulthood showed no significant difference in blood 
pressure from the wild type animals, indicating compensatory mechanisms are functioning 
(Pfeifer et al. 1998). Loss of PKG I abolishes NO- and cGMP-dependent relaxations of 
smooth muscle (Pfeifer et al. 1998). In mice with a selective mutation in the N-terminal 
protein interaction domain of PKG Iα also results in reduced vasodilator response to EDNO 
and cGMP and increased systemic blood pressure, suggesting that the hypertension results 
from a diminished response of blood vessels to cGMP (Michael et al., 2008). Vascular 
reconstitution of PKG Iα or PKG Iβ in PKG I-deficient mice restores the diminished 
vasodilatation to NO and cGMP and normalizes the elevated blood pressure, (Weber et al., 
2007). In spontaneously hypertensive rats (SHR) cardiomyocytes PKG-I expression is 
decreased, making the NO/cGMP-dependent regulation on calcium transient in 
cardiomyocytes weakened, and promoting cardiac hypertrophy (Mazzetti et al., 2001). 
Abnormality in the renin-angiotensin-aldosterone system is an important etiologic event in 
the development of hypertension. Renal renin mRNA levels under stimulatory (low-salt diet 
plus ramipril) and inhibitory (high-salt diet) conditions were elevated in PKG II deficient 
mice. The deletion of PKG II abolishes the attenuation of forskolin-stimulated renin 
secretion caused by 8-Br-cGMP in cultured renal juxtaglomerular cells. Activation of PKG 
by 8-Br-cGMP decreased renin secretion from the isolated perfused rat kidney of the wild-
type mice but not that of PKG II-/- mice. These findings suggest that PKG II exerts an 
inhibitory effect on renin secretion (Wagner et al., 1998). Mice deficient in PKG II display no 
elevated blood pressure, suggesting that PKG II is not critically involved in the regulation of 
overall systemic blood pressure (Hofmann et al., 2009). 
4.2 Atherosclerosis  
In an animal model of late-stage atherosclerosis obtained by feeding 8-week-old rabbits with 
hypercholesterol diet for 50 weeks the protein levels of sGC and PKG I of the aorta were 
reduced. These changes were most prominent in the neointimal layer. Phosphorylation of 
VASP at Ser239, a specific indicator of PKG activity, was also reduced. The preferential 
down-regulation of cGMP/PKG signaling in neointima suggests a direct connection of these 
changes to neointimal proliferation and vascular dysfunction occurred in atherosclerosis 
(Melichar et al., 2004). It seems that the decreased PKG expression occurred only at late-
stage atherosclerosis, as the protein level of PKG was unaltered in Watanabe heritable 
hyperlipidemic rabbits of three month old (Warnholtz et al., 2002). Thrombospondin-1 and 
osteopontin are extracellular matrix (ECM) proteins involved in the development of 
atherosclerosis. PKG may exert its anti- atherosclerotic effect in part through these two ECM 
proteins, since their expression could be marked reduced by PKG I (Dey et al., 1998). 
Interestingly, postnatal ablation of PKG I selectively in the VSMCs of mice reduced 
atherosclerotic lesion area, which would suggest that smooth muscle PKG I promotes 
atherogenesis (Wolfsgruber et al., 2003). 
4.3 Diabetic vascular disease  
High glucose exposure has been found to reduce the protein and mRNA levels of PKG I as 
well as PKG I activity in cultured rat VSMCs. PKG I protein levels were decreased in 
femoral arteries from diabetic mice. Glucose-mediated decrease in PKG I levels was 
inhibited by the superoxide scavenger or NAD(P)H oxidase inhibitors. High glucose 
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exposure increased the protein levels and phosphorylated levels of p47phox (an NADPH 
oxidase subunit) in VSMCs, associated with increased superoxide production. The 
suppressed PKG expression and increased superoxide production were prevented by 
transfection of cells with siRNA-p47phox, suggesting that NADPH oxidase-derived 
superoxide may mediate the high glucose-induced downregulation of PKG occurred in 
diabetic blood vessels (Liu et al., 2007). Studies also show that activation of PKG by 
expression of constitutively active PKG suppressed high glucose-induced VSMC 
proliferation and inhibited first gap phase (G1) to synthesis phase (S) phase progression of 
the cell cycle. These changes were accompanied with reduced glucose-induced cyclin E 
expression and cyclin E-cyclin-dependent kinase 2 activity as well as inhibition of glucose-
induced phosphorylation of retinoblastoma protein (Rb) and p27 degradation. It suggests 
that PKG may inhibit VSMC proliferation through attenuation of cyclin E expression and 
increase in p27 protein stability, which leads to decreased CDK 2 activity and reduced Rb 
phosphorylation, thereby resulting in cell cycle arrest and cell growth inhibition (Wang & 
Li, 2009). Increased activity of transforming growth factor-β (TGF-β) is implicated in the 
development of diabetic macrovascular fibroproliferative remodeling. High glucose was 
found to stimulate the expression of thrombospondin1 (TSP1), a major activator of 
transforming growth factor-β (TGF-β), and to stimulate TGF-β activation in primary murine 
aortic SMCs. These effects were inhibited by overexpression of constitutively active PKG. 
Since PKG is downregulated in diabetic vasculature, it is likely that the downregulation of 
PKG action may relieve its suppression on TSP1 expression and TGF-β activity, thereby 
leading to augmented vascular remodeling in diabetes (Wang et al., 2010). 
4.4 Pulmonary arterial hypertension 
PKG expression and/or activity are/is reduced in animal models of pulmonary arterial 
hypertension (PAH) induced by ligation of the ductus arteriosus of fetal lambs (Resnik et al., 
2006) and in caveolin-1 (Cav-1) knockout mice (Zhao et al., 2009). Cav-1, a 21-kDa integral 
membrane protein, is an intracellular physiological inhibitor of eNOS activity. Mice 
deficient in Cav-1 led to chronic eNOS activation and PAH. Activation of eNOS in Cav-1-/- 
lungs resulted in an impaired PKG activity through tyrosine nitration, probably at Tyr345 or 
Tyr549 of the catalytic domain of human PKG Iα. The PAH phenotype in Cav-1-/- lungs 
could be rescued by overexpression of PKG 1α. The treatment of these mice with either a 
superoxide scavenger or an eNOS inhibitor reverses their pulmonary vascular pathology 
and PAH phenotype, suggesting that an increased peroxynitrite formed from chronic 
overproduction of NO and superoxide may result in tyrosine nitration and loss of activity of 
PKG. Clinically, lung tissues from patients with idiopathic PAH have been found to display 
reduced Cav-1 expression, increased eNOS activation, and PKG nitration (Zhao et al., 2009). 
In ovine fetal pulmonary veins hypoxic exposure also causes peroxynitrite-mediated PKG 
nitration, reduced PKG activity, and suppressed dilator response to 8-Br-cGMP (Negash et 
al., 2007). 
An upregulated ROK activity is implicated in a number of cardiovascular diseases including 
PAH (Satoh et al., 2011). ROK augments vasoconstriction primarily by inhibiting MLCP 
activity through phosphorylation of the regulatory subunit MYPT1 at Thr696 and Thr853, 
which leads to increased Ca2+-sensitization of smooth muscle. The effect of ROK can be 
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and Ser852. Pulmonary arteries from fetuses exposed to chronic intrauterine hypoxia (CH) 
displayed thickening vessel walls and diminished relaxant response to 8-Br-cGMP, two 
important characteristics of newborn PAH (Bixby et al., 2007; Gao et al., 2007). Rp-8-Br-PET-
cGMPS, a specific PKG inhibitor, attenuated relaxation to 8-Br-cGMP in control vessels to a 
greater extent than in CH vessels while Y-27632, a ROCK inhibitor, potentiated 8-Br-cGMP-
induced relaxation of CH vessels and had only a minor effect in control vessels. The specific 
activity of PKG was decreased while ROK activity was increased in CH vessels as compared 
with the controls. The phosphorylation of MYPT1 at Thr696 and Thr853 was inhibited by 8-
Br-cGMP to a lesser extent in CH vessels than in controls. The difference was eliminated by 
Y-27632. These data indicate that the attenuated PKG-mediated relaxation in pulmonary 
arteries exposed to chronic hypoxia in utero is due to inhibition of PKG activity and due to 
enhanced ROCK activity. Increased ROCK activity may inhibit PKG action through 
increased phosphorylation of MYPT1 at Thr696 and Thr853 (Gao et al., 2007). In contrast to 
pulmonary arteries, relaxation of pulmonary veins of fetuses exposed to (CH) displayed no 
changes in the thickness of vessel walls and relaxant response to 8-Br-cGMP. In these veins 
phosphorylation of MYPT1 at Thr696 by ROK and at Ser695 by PKG was diminished as 
compared with control veins, suggesting that CH attenuates both PKG action and ROK 
action on MYPT1, resulting in an unaltered response to cGMP (Gao et al., 2008).  
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily. Mutations in 
the BMP type II receptor (BMPR-II) are responsible for the majority of cases of heritable 
PAH. Dysfunction in BMP signaling is implicated in idiopathic PAH and in a number of 
experimental models of PAH (Toshner et al., 2010). Studies found that PKG I may regulate 
the activation of BMP receptor and receptor-regulated Smad, a key mediator for BMP 
signaling, at the plasma membrane and regulate the expression of BMP target genes in the 
nucleus. These mechanisms may enable PKG I to compensate for the aberrant cellular 
responses to BMP caused by mutations in BMPRII found in PAH patients. Indeed, the 
overexpression of PKG I restores normal BMP responsiveness in cells expressing signaling 
deficient PAH mutant receptors such as the mutant BMPRII-Q657ins16 (Schwappacher et 
al., 2009; Thomson et al., 2000).  
4.5 Nitrate tolerance  
Nitroglycerine (NTG) is a widely used vasodilator in the treatment of angina pectoris and 
acute heart failure. It is converted inside the cell to NO or an NO-related intermediate and 
causes vasodilatation in a cGMP-dependent fashion. The effectiveness of NTG is often 
diminished when it is continuously used for a period of time, termed nitrate tolerance. The 
underlying mechanisms include an increased production of reactive oxygen species (ROS), 
impairment of biotransformation of NTG by aldehyde dehydrogenase, desensitization of 
sGC, upregulation of phosphodiesterases, and downregulation PKG activity (Münzel et al., 
2005). In human arteries and veins, nitrate tolerance is associated with decreased PKG 
activity (Schulz et al., 2002). In the arteries of rats and rabbits, nitrate tolerance induced by 
low-dose NTG is associated with decreased PKG activity, while the tolerance induced by 
high-dose NTG is associated with decreased PKG protein level and activity (Mülsch et al., 
2001). In porcine coronary arteries nitrate tolerance induced by NTG at low concentrations is 
prevented by the scavenger of ROS. However the tolerance induced by NTG at higher 
concentrations is not affected by the scavenger of ROS and shows cross-tolerance to the NO 
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donor and 8-Br-cGMP. Meanwhile, the protein and mRNA levels of PKG are reduced. It 
seems that the tolerance induced by NTG at higher concentrations may be due to 
suppression of PKG expression resulting from sustained activation of the enzyme (Dou et 
al., 2008). A diminished expression and activity of PKG was also observed in pulmonary 
veins of newborn lambs after prolonged exposure to the NO donor (Gao et al., 2004). 
Activation of MLCP is a key mechanism for vasodilatation induced by nitrovasodilators 
such as NTG and NO. MLCP is a heterotrimer, composed of a catalytic subunit PP1cδ, a 
regulatory subunit MYPT1, and a subunit with unknown function. The regulatory subunit 
MYPT1 exists as isoform either with or without leucine zipper domain in its C-terminal 
[MYPT1 (LZ+) and MYPT1 (LZ−), respectively]. The presence of leucine zipper is necessary 
for PKG binding to MYPT1 and for PKG-mediated stimulatory effect on MLCP. Studies 
consistently demonstrate that the expression of MYPT1 (LZ+) determines the sensitivity to 
cGMP-mediated vasodilatation (Lee et al., 2007; A.P. Somlyo & A.V. Somlyo, 2003). Nitrate 
tolerance induced under in vitro conditions in porcine coronary arteries and induced under 
in vivo preparations in murine aorta show a decreased protein levels of MYPT1 (LZ+) but 
not of PP1cδ. The decrease in the MYPT1 (LZ+) protein level of coronary artery can also be 
induced by the NO donor and 8-Br-cGMP in a manner sensitive to the inhibitors of sGC and 
PKG, respectively. The tolerance to NTG in porcine coronary artery and mouse aorta is 
ameliorated by proteasome inhibitors. Therefore a downregulation of MYPT1 (LZ+) caused 
by increased proteasome-dependent degradation may contribute to development of nitrate 
tolerance (Dou et al., 2010). 
5. Conclusion 
Overwhelming evidence, obtained by genetic manipulation and pharmacological tools, 
under both in vivo and in vitro conditions, suggests that PKG is the primary enzyme in 
mediating vasodilatation, antiproliferation of vascular smooth muscle, and anti-platelet 
aggregation action induced by endogenous and exogenous nitrovasodilators via cGMP 
elevation (Francis et al., 2010; Gao, 2010; Hofmann et al., 2009; Walter & Gambaryan, 2009). 
Studies also support a barrier protection effect in the vascular endothelium (Moldobaeva et 
al., 2006; Rentsendorj et al., 2008). Increasing evidence also suggests that PKG exerts 
negative inotropic and antihypertrophic actions in the heart (Takimoto et al. 2005; Yang et 
al., 2007; Zhang et al., 2010) as well as a cardioprotective action against ischemia-reperfusion 
injury (Das et al., 2008; Juhaszova et al., 2009; Xi et al., 2010). Despite substantial progress 
has been made in elucidating the role of PKG in the regulation of cardiovascular functions 
there are many aspects remain to be explored. For instance, the developing and ageing 
aspects for the role of PKG, the gender difference, and the heterogeneity in the role of PKG 
in different vasculatures. Also, the roles of many PKG substrates in the regulation of 
cardiovascular activities remain to be defined (Schlossmann & Desch, 2009).  
Dysfunction in NO-cGMP signaling is a common initiator and independent predictor of 
cardiovascular events (Vanhoutte et al., 2009). An impaired PKG action has been implicated 
in various cardiovascular disorders such as hypertension, atherosclerosis, diabetic vascular 
disease, pulmonary arterial hypertension, and nitrate tolerance (Francis et al., 2010; Gao, 
2010; Hofmann et al., 2009). Cardiovascular alterations are a long-term process comprising 
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the dissection of the role of PKG rather challenging. However, a better understanding of its 
role and the underlying mechanism will be of great therapeutic significance.  
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1. Introduction  
c-Src belongs to the SRC Family of non receptor tyrosine kinases (SFKs), which includes at 
least ten members (Lyn, Fyn, Lck, Hck, Fgr, Blk, Yrk, Gfr, Yes and c-Src) sharing high 
homology in their domain structure  (Brown & Cooper, 1996).  
Due to its proto-oncogene nature, c-Src is the SFK most frequently associated with 
malignancy (Yeatman, 2004). Over 100 years ago, Peyton Rous observed that injection of 
cell-free extracts from tumours grown in chickens caused the development of the same type 
of tumour in host animals.  This observation prompted the hypothesis that a filterable agent 
was the cause of the tumour (Rous, 1911a, 1911b). In support of this notion, in 1955 Rubin 
showed that the Rous’filterable agent was a virus, called Rous Sarcoma Virus (RSV), which 
was found to play a direct role in inducing cell malignancy (Rubin, 1955). In the ‘60s and 
‘70s, the tools of modern molecular biology provided the genetic definition of v-Src, a viral 
oncogene included within the RSV genome. v-Src was observed not to be required for virus 
replication but to be the causative agent of cancer (Martin, 1970; Duesberg & Vogt, 1970). 
Shortly thereafter, it was shown that v-Src had a counterpart in eukaryotic cells, named c-Src 
(Takeda and Hanafusa, 1983). c-Src is involved in many physiological functions of the cells. 
It carries a regulatory domain lacking in v-Src (Fig. 1), therefore, its activity is under tight 
molecular control. c-Src was the first of several proto-oncogenes discovered in the vertebrate 
genome and, in 1989, this discovery earned Bishop and Varmus the Nobel Prize in 
Physiology or Medicine, for the description of “the cellular origin of retroviral oncogenes”.  
In 1977, Brugge and Erikson immunoprecipitated a 60-kDa phosphoprotein from RSV-
transformed fibroblasts. The protein was called pp60v-src, but it is now usually referred as v-
Src. Both v- and c-Src have tyrosine kinase activity (Collett et al, 1978; Oppermann et al, 
1979).  c-Src also autophosphorylates itself at tyrosine residues (Hunter & Sefton, 1980), and 
is the prototype of a large family of kinases that we now know are involved in the 
regulation of cell growth and differentiation. 
v-Src lacks the C-terminal domain that in c-Src has a negative regulatory role on its tyrosine 
kinase activity. Consequently, v-Src shows constitutive activity and transforming ability 
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Fig. 1. Structure and activation of Src proteins 
A) Comparison of protein structure of viral (v-)Src, chicken and human cellular (c-)Src, with 
indication of Src homology (SH) and membrane-binding (M), unique (U), linker (L) and  
regulatory (R) domains. (B) Representation of inactive (left) and active (right) conformation 
of chicken c-Src. 
Aberrant activation of c-Src results in a wide variety of cellular phenotypic changes, including 
morphological transformation and acquisition of anchorage and growth-factor independence, 
that are implicated in the development, maintenance, progression, and metastatic spread of 
several human cancers, such as prostate, lung, breast, and colorectal carcinomas (Irby & 
Yeatman, 2000). Indeed, a number of human malignancies display increased c-Src expression 
and activation, confirming its involvement in oncogenesis (Alvarez et al, 2006). 
c-Src is ubiquitous and physiologically expressed at high levels in a variety of cell types, 
including neurons and platelets (Brown & Cooper, 1996). Nonetheless, the very first mouse 
model of c-Src deficiency (Soriano, 1991) showed an unexpected prominent bone phenotype 
characterized by increased bone mass and lack of bone resorption, unveiling a previously 
unrecognized role of c-Src in bone cells (Boyce et al, 1992; Marzia et al, 2000).  
In this review, we will describe the structure and function of c-Src and will highlight its 
crucial physiological and pathogenetic role in bone metabolism.    
2. c-Src structure, activation and function 
2.1 c-Src structure 
c-Src shares with the other SFK members a conserved domain structure consisting of four 
consecutive Src Homology (SH) domains (Fig. 1A). The N-terminal segment includes the 
SH4 domain, as well as an “unique” domain of 50-70 residues that display the greatest 
divergence among the family members (Koegl et al., 1994 ; Resh, 1999). The SH3, SH2 and 
SH1 (catalytic) domains follow in order in the polypeptide chain. There is also a short, C-
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terminal “tail” which includes a hallmark of Src kinases, that is an autoinhibitory 
phosphorylation site [Tyrosine (Tyr) 527 in chicken, Tyr 530 in human] (Cooper & King, 
1986).  This tail is not present in the v-Src isoform (Fig.1A). 
The SH4 domain is a 15-amino acid sequence whose myristoylation allows binding of SFK 
members to the inner surface of the plasma membrane. The unique domain has been 
proposed to be important for mediating interactions with receptors or proteins that are 
specific for each family member. Serine and threonine phosphorylation sites have also been 
identified in the unique domains of c-Src and Lck (Winkler et al, 1993).  
SH3 and SH2 are protein-binding domains widely present in other molecules, such as lipid 
kinases, protein and lipid phosphatases, cytoskeletal proteins, adaptor molecules and 
transcription factors (Mayer & Baltimore, 1993). The SH3 domain consists of small, -barrel 
modules and is important for intra- as well as inter-molecular interactions, regulating  c-Src 
catalytic activity, localization and recruitment of substrates. Proline-rich sequences in target 
molecules mediate the interactions with SH3 (Ren et al, 1993). The other domain regulating 
c-Src interaction with proteins is SH2, which preferentially binds to polypeptide segments 
containing a phosphotyrosine (Mayer et al, 1991; Pawson, 1995). 
The catalytic domain (SH1) is the most conserved domain in all tyrosine kinases. It contains 
an ATP-binding pocket and the tyrosine-specific protein kinase activity. As it will be 
described in the next paragraph, the first step of c-Src activation is the autophosphorylation 
of Tyr416 (in chicken, Tyr419 in human), while phosphorylation of Tyr527 by c-Src kinase 
(CSK) and CSK homologous kinase (CHK) results in its inhibition (Kmiecik & Shalloway, 
1987; Cartwright et al, 1987; Piwnica-Worms et al, 1987; Okada & Nakagawa, 1989). 
2.2 c-Src activation 
c-Src is normally maintained in an inactive or “closed” conformation, where the SH2 
domain is engaged with the phosphorylated Tyr527, the SH3 domain binds the SH2-kinase 
linker sequence and the Tyr416 is dephosphorylated. Dephosphorylation of Tyr527 disrupts 
its intramolecular interaction with the SH2 domain and this open conformational state 
allows autophosphorylation of Tyr416, resulting in c-Src activation (Fig. 1B) (Yamaguchi & 
Hendrickson, 1996).  
Phosphorylation of Tyr527 can be removed by several protein phosphatases that function as 
activators of c-Src, such as protein tyrosine phosphatase-α (PTPα) (Zheng et al, 1992), PTP1, 
SH2-containing phosphatase 1 (SHP1) and SHP2 (Jung & Kim, 2002). The most direct 
evidence for a role of c-Src activation in cancer among these phosphatases is for PTP1B, 
which is present at high levels in breast cancer cell lines (Jung & Kim, 2002).  In addition, the 
direct binding of focal-adhesion kinase (FAK) (Schaller et al, 1994) or its molecular partner 
CRK-associated substrate (CAS, also known as p130CAS) to the SH2 and the SH3 domains 
of c-Src also results in the open, active configuration of c-Src, since the intramolecular 
interactions that maintain the closed configuration are displaced (Thomas et al, 1998).  
2.3 c-Src functions 
c-Src plays a key role in regulating the assembly and disassembly of cell-cell (adherens 
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junctions are maintained by homotypic interactions between E-cadherin molecules present 
on neighboring cells, and loss of E-cadherin is a key event in the epithelial-to-mesenchymal 
transition of cancer cells. It has been shown that increased c-Src signalling correlates with 
decreased E-cadherin expression and decreased cell-cell adhesion (Irby and Yeatman, 2002; 
Nam et al, 2002). Moreover, constitutively active c-Src can phosphorylate the cadherins, 
resulting in loss of the cadherin–catenin complex function, thereby promoting cell 














Fig. 2. c-Src involvement in cell adhesion signals. 
Molecular interactions among c-Src and the components of both adherens junction and focal 
adhesion structure. 
At the cell periphery, activated c-Src forms complexes with FAK, which in turn interacts 
with a multitude of substrates, including CAS, paxillin, and p190RhoGAP, that play critical 
roles in promoting actin remodelling and cell migration (Fig. 2) (Guarino, 2010; Playford & 
Schaller, 2004). In cancer, deregulated focal adhesion signalling has been implicated in 
increased invasion and metastasis, and decreased patient survival (McLean et al, 2005). c-Src 
can also be activated downstream of tyrosine kinase growth factor receptors, such as 
epidermal growth factor (EGF) (Tice et al, 1999), platelet-derived growth factor (PDGF) (De 
Mali et al, 1999; Bowman et al, 2001), insulin-like growth factor (IGF)-1 (Arbet-Engels et al, 
1999), fibroblast growth factor (FGF) (Landgren et al, 1995), colony-stimulating factor (CSF)-
1 (Courtneidge et al, 1993) and hepatocyte growth factor (HGF) receptors (Mao et al, 1997) 
(Fig.  3). Ligand binding to receptor tyrosine kinases leads to receptor dimerization, kinase 
activation, and autophosphorylation of tyrosine residues. These phosphorylated tyrosines then 
serve as docking sites for the SH2 domains of several signalling molecules, including c-Src 
(van der Geer et al, 1994). For instance, the EGF receptor can bind to c-Src and phosphorylate 
tyrosine sites on its C-terminal loop. Conversely, c-Src can directly bind to the EGF receptor 
and phosphorylate the Y845 residue, resulting in increased Ras/ERK/MAPK activity and 
enhanced cell mitogenesis and transformation (Biscardi et al, 2000).  
c-Src has also been implicated in signalling activated by integrins and G-protein coupled 
receptors (GPCRs). Indeed, clustering of integrins can lead to downstream signalling 
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pathways inducing activation of c-Src, FAK, Abl, and Syk (Miyamoto et al, 1995, Schlaepfer 
& Hunter, 1998). There is an increasing body of evidence for synergy between receptor 
tyrosine kinases and integrins, demonstrated by an increase in MAPK activation in response 
to various growth factors if integrins are preclustered (Miyamoto et al, 1996). The crosstalk 
between these pathways could be mediated by a common signalling molecule, including c-
Src. A FAK-independent signalling pathway from integrins has also been described, in 
which caveolins act as adaptors, linking integrins and c-Src family kinases. Indeed, Wei et al. 
(1999) showed that caveolin is important for the association between β1 integrin and c-Src, 
and disruption of this interaction affected focal adhesions. On the other hand, c-Src can 
suppress the integrins attached to the extracellular matrix via phosphorylation of integrin 
subunits (Sakai et al, 2001; Datta et al, 2002). c-Src can also interrupt Rho-A function, which 
has an important role in actin filament assembly and stabilization of focal adhesions (Arthur 
& Burridge, 2001). c-Src activates FAK, Ras and phosphatidylinositol phosphate kinase, 
































Genes involved in Proliferation/Tumorigenesis
Fig. 3. c-Src-activating signals. 
Extracellular signals involving Receptor Tyrosine Kinases (RTK), or G-Protein Coupled 
Receptors (GPCR) or integrins are shown to activate c-Src and its downstream pathways. 
The localization of c-Src at the membrane–cytoskeletal interface in focal adhesions, 
lamellipodia and filopodia seems to be regulated by the small G-proteins RhoA, Rac1 and 
CdC42 (Timpson et al, 2001). The Cbl ubiquitin ligase has been shown to be important in 
suppressing v-Src transformation through ubiquitin-dependent protein degradation (Kim et 
al, 2004). Recent evidence indicates that the ubiquitin–proteasome pathway is deregulated in 
cancer cells, which might allow c-Src activation (Kamei et al, 2000).  
Finally, there is also evidence that c-Src is activated through nitric-oxide signalling (Akhand 
et al, 1999) in mechanisms mainly implicated in cellular adhesion and motility (Gianni et al, 
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3. c-Src in the bone metabolism 
Understanding the physiological role of SFKs has been aided by the advent of gene 
targeting and embryonic stem cell technology in the mouse. Targeted disruptions of all 
known mammalian SFK genes have been obtained in mice, with their phenotypes ranging 
from no overt defects to very distinct abnormalities in specific cell types and tissues. As 
stated above, the first SFK member to be disrupted was c-Src (Soriano et al, 1991). Although 
c-Src is ubiquitously expressed, mice lacking the src gene presented with overt alterations 
only in the bone tissue, suggesting a crucial role of this tyrosine kinase in the bone 
microenvironment that cannot be replaced by other SFK members, as probably occurs in the 
rest of the body. 
The main phenotype associated with c-Src deletion is osteopetrosis, a bone remodelling 
disease in which excess of bone accumulates as a result of defective osteoclast bone 
resorption (Soriano et al, 1991). This mutation manifests itself by the failure of incisors to 
erupt, and the mutants have a much reduced survival rate after weaning. However, animals 
maintained on a soft food diet have been found to survive for at least a year and, on rare 
occasions, can breed, although some alterations in reproduction have been documented 
(Roby et al, 2005). In contrast with a general concept of c-Src involvement in cell 
proliferation, a detailed analysis of the bone phenotype of c-Src knock-out (KO) mice 
revealed the crucial role of the tyrosine kinase in regulating osteoclast activity, rather than 
formation and proliferation (Soriano et al, 1991). As discussed in more detail below, 
substantial evidence has been already provided in identifying c-Src as a key player in the 
correct cytoskeletal rearrangement necessary for bone resorption. Further studies pointed 
out the role of c-Src in bone metabolism, thus showing that the deletion of Src expression 
also enhances the differentiation and the function of osteoblasts, the cells of the bone tissue 
having osteogenic function, with a consequent further increase of bone mass (Marzia et al, 
2000). Therefore, in this section we will introduce the bone cells and discuss in detail the 
multiple roles that c-Src exerts in the bone microenvironment.  
3.1 c-Src regulation of osteoclast behaviour 
Osteoclasts are multinucleated cells, originating from the myeloid tissue from which the 
mononuclear osteoclast progenitors arise and fuse into polykaria when their maturation is 
completed (Baron & Horne, 2005). They are terminally differentiated cells that resorb the 
mineralized matrix during physiological and pathological bone turnover by a peculiar 
extracellular mechanism involving specific domains of the plasma membrane. Indeed, 
during the bone resorbing process, the osteoclast is markedly polarized, in order to create 
three morphologically distinct areas of the plasma membrane: the basolateral membrane, 
which is not in contact with the bone; the tight sealing zone, which is closely apposed to the 
bone surface; and the ruffled border, a highly convoluted membrane that faces the resorbing 
surface (Baron & Horne, 2005).  
The characterization of the phenotype of the c-Src KO mouse revealed that the most critical 
role of c-Src is related to osteoclast function rather than differentiation, since the number of 
osteoclasts in bones of c-Src KO mice is more than twice that in normal mice (Boyce et al, 
1992). While osteoclasts also express other c-Src family kinases (Lowell et al, 1996), the 
deletion of any one of the genes encoding Fyn, Yes, Hck, and Fgr fails to produce 
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osteopetrosis (Stein et al, 1994). Moreover, re-expression of c-Src in c-Src KO osteoclasts 
restores in vitro the bone-resorbing activity (Miyazaki et al, 2004), implying that c-Src 
performs some specific functions in osteoclasts that cannot be compensated by these other 
SFKs. A possible exception is Hck, since its expression is upregulated in c-Src KO osteoclasts 
and c-Src KO/Hck KO double-mutant mice are significantly more osteopetrotic than the c-
Src KO animals (Lowell et al, 1996). At the cellular level, c-Src KO osteoclasts present with a 
critical feature, that is the absence of the ruffled border (Boyce et al, 1992), suggesting a c-Src 
contribution to the regulation of exocytic and/or endocytic vesicle trafficking, as well as to 
the attachment and motility mediated by the adhesion structures.  
Osteoclastic bone resorption involves a series of regulatory phases: migration of osteoclasts 
to the resorption site, their attachment to the calcified tissue and development of the ruffled 
border and the clear zone, followed by the secretion of acids and lysosomal enzymes into 
the space beneath the ruffled border (reviewed in Peruzzi & Teti, 2011). The formation of the 
sealing zone is essential for the osteoclastic bone resorption, since it forms a diffusion barrier 
and permits the directional secretion of lysosomal enzymes into the space beneath the 
ruffled border. In the ruffled border membrane, the vacuolar-type proton ATPase mediates 
the transport of protons into the resorption lacunae. Lysosomal enzymes of osteoclasts, such 
as cathepsin K, and metalloproteinase-9 are also secreted through this membrane and 
degrade the organic matrix of bone. To organize these highly polarized cellular structures, 
osteoclasts must adhere to the bone surface as the initial and essential phase for their 
activity (Coxon & Taylor, 2008), which involves the interaction of integrins with the 
extracellular matrix proteins within the bone. Among several integrins, osteoclasts express 
very high levels of αVβ3 integrin, and lower levels of the collagen/laminin receptor α2β1 
and the vitronectin/fibronectin receptor αVβ1 (Nakamura et al, 2007; Horton, 1997; Horton 
& Rodan, 1996).  
Like all members of the αV integrin family, the αVβ3 receptor recognizes the RGD (Arg-Gly-
Asp) adhesion motif present in several matrix proteins such as vitronectin, bone sialoprotein 
II and osteopontin (Rupp & Little, 2001; Wilder, 2002; Horton, 1997). This interaction 
induces an integrin conformational change leading to the so-called outside-in signalling, 
which in turn triggers a number of intracellular events, including changes in cytosolic 
calcium, protein tyrosine phosphorylation and cytoskeletal remodelling (Duong & Rodan, 
2000; Teitelbaum, 2007; Faccio et al, 2003). The engagement of the matrix by the αVβ3 
integrin in osteoclasts and osteoclast precursors activates the non-receptor tyrosine kinase 
Pyk2, a member of the FAK family, by a mechanism that involves an increase in cytosolic 
Ca2+ and the binding of Pyk2 to the cytoplasmic domain of the β subunit (Fig.4) (Faccio et al, 
2003; Duong & Rodan, 2000).  
Both the capacity of c-Src to bind the αVβ3 integrin and the subsequent activation of the 
kinase are mediated by Pyk2, which mobilizes c-Src to the integrin. αVβ3 integrin 
occupancy induces phosphorylation of Pyk2, which then binds the SH2 domain of c-Src. The 
proposed association between phosphorylated Pyk2 and c-Src would prevent c-Src-Y527 
inactivating phosphorylation, thus relieving auto-inhibition of kinase function.  
The signalling downstream of c-Src activation involves tyrosine phosphorylation of a 
distinct set of proteins, including Pyk2 itself, Cbl, PI3K, paxillin, cortactin, vinculin, talin, 
tensin, and p130Cas, which are present in the osteoclast adhesion structures, called 
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Fig. 4. c-Src involvement in osteoclast function. 
Among several pathways regulating osteoclast activity, the cartoon shows c-Src activation 
and downstream effect depending on receptor signals. 
Podosomes, which serve as attachment structures in osteoclasts and other highly motile 
cells, are more transient and dynamic than focal adhesion plaques (Destaing et al, 2003). As 
originally described (Marchisio et al, 1984; Marchisio et al, 1987), podosomes are small 
punctate structures with an F-actin-rich core surrounded by a ring of integrins and certain 
focal adhesion-associated proteins (e.g., paxillin, talin and vinculin). Cortactin, gelsolin, the 
actin-regulatory proteins Neuronal Wiskott–Aldrich Syndrome Protein (N-WASP), and 
Arp2/3 have also been identified in the podosome core (Linder & Aepfelbacher, 2003; 
Buccione et al, 2004). In osteoclasts, Src, Cbl, Pyk2, and various actin-associated proteins, 
including dynamin and filamin, are also associated with podosomes, whose rapid turnover 
(within minutes) is probably essential for the high mobility of the cells in which they occur 
(Fig. 4) (Destaing et al, 2003). 
Among the substrates of c-Src activity involved in the mechanisms of bone resorption, Cbl 
plays a key role in promoting turnover or disassembly of podosomes (Sanjay et al, 2001). 
Indeed, c-Src, in association with Pyk2, recruits Cbl through its SH3 domain and promotes 
its activation by phosphorylation. Once activated, Cbl recruits PI3K and dynamin to the 
adhesion complex.  
Since Cbl is an ubiquitin E3 ligase, it has been described to drive the negative feedback that 
has the potential to promote proteasomal degradation of the integrin-associated Pyk2/c-
Src/Cbl complex (Fig. 4) (Yokouchi et al, 2001). Thus, Cbl is crucial in the integrin-mediated 
“inside-out” signalling, playing a key role in podosome detachment and subsequent 
disassembly. In this way, the c-Src/Pyk2/Cbl complex forms the basis for the cyclic 
attachment–detachment of single adhesion sites at the leading edge of lamellipodia in motile 
cells, and thereby participates in the assembly–disassembly of individual podosomes, 
ensuring cell adhesion while still allowing cell motility (Sanjay et al, 2001). 
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In the integrin-mediated outside-in signalling, also the non-receptor tyrosine kinase Syk 
plays a pivotal role in osteoclast activity, since it associates with the β3 integrin subunit 
domain in a region close to the c-Src binding site and is activated by c-Src itself, a key event 
in organizing the cytoskeleton (Zou W et al., 2007). Recently, it has been shown that c-Src 
and Syk are also involved in the signal downstream the immunoreceptor tyrosine-based 
activation motif (ITAM)-bearing co-receptors, DAP12 and FcRγ (Fig.4). DAP12 and FcRγ are 
associated with the immunoreceptors OSCAR/PIR-A and TREM2/SIRPβ1, respectively, 
recently identified on the osteoclast surface (Mócsai et al, 2004). The c-Src-mediated 
phosphorylation of Syk kinase leads to activation of a number of cytoskeleton-regulating 
proteins, including the Vav family of guanine nucleotide exchange factor (GEFs). These 
proteins convert Rho GTPases from their inactive GDP to their active GTP conformation. 
Among these proteins, Vav3 is expressed in osteoclasts (Faccio et al, 2005), where it is 
triggered upon matrix-induced Syk activation and regulates RhoGTPase-dependent effect 
on actin cytoskeleton (Zou et al, 2007). In this context, the small GTPases Rac and Rho exert 
distinctive effects on osteoclasts. Indeed, Rac stimulation in osteoclast precursors prompts 
the appearance of lamellipodia, thus forming the migratory front of the cell, while RhoA 
stimulates actin filament formation which, in osteoclasts, allow organization of the sealing 
zone (Fig.4) (Fukuda et al, 2005). 
The integrin-activated c-Src signalling also functions in other processes necessary for normal 
osteoclast function, among which adenosine triphosphate (ATP)-dependent events, 
especially those involved in cell motility, proton secretion, and the maintenance of 
electrochemical homeostasis (Baron, 1993). Indeed, c-Src promotes the maintenance of 
energy stores in osteoclasts by phosphorylating cytochrome c oxidase within the 
mitochondria (Miyazaki et al, 2003), which are very abundant in osteoclasts, consistent with 
the energy requirements of their activity (Miyazaki et al, 2006). 
3.2 c-Src regulation of osteoblast differentiation 
Osteoblasts are mononucleated cells of mesenchymal origin that synthesize and mineralize 
the bone matrix during bone accrual and remodelling events. Bone formation involves 
osteoblast maturation that requires a spectrum of signalling proteins including morphogens, 
hormones, growth factors, cytokines, matrix proteins, transcription factors, and their co-
regulatory proteins. They act coordinately to support the temporal expression (i.e., 
sequential activation, suppression, and modulation) of other genes that represent the 
phenotypic and functional properties of osteoblasts during the differentiation process from 
osteoblast precursors (Jiang et al, 2002). Pre-osteoblasts are also responsible of the 
production of cytokines regulating osteoclastogenesis, that is receptor activator of nuclear 
factor kappa B ligand (RANKL), osteoprotegerin (OPG) and CSF-1, thereby coupling 
osteoblast and osteoclast function. Given the osteoblast-mediated regulation of osteoclast 
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Fig. 4. c-Src involvement in osteoclast function. 
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performed a detailed molecular analysis of the c-Src null osteoblasts (Marzia et al, 2000). 
This study clearly demonstrated that a decreased c-Src activity is responsible of enhanced 
osteoblast differentiation and in vivo bone formation, thereby highlighting the role of c-Src in 
maintaining osteoblasts in a poorly differentiated status.  
Bone formation requires transcriptional mechanisms for sequential induction and repression 
of genes that support progressive osteoblast phenotype development. The Runx transcription 
factors and their co-regulators control cell differentiation and lineage commitment 
(Westendorf & Hiebert, 1999) by influencing the functional architecture of target gene 
promoters (Stein et al, 2000). Runx proteins are directed to subnuclear domains through the C-
terminal nuclear matrix-targeting signal (NMTS) and interact with the DNA through the N-
terminal runt homology domain (Zaidi et al, 2001). The Runx2 family member is essential for 
osteoblast maturation in vivo and its alteration is associated with the cleidocranial dysplasia 
(Komori et al, 1997). Runx2 is a target of several extracellular signals that regulate skeletal 
formation and homeostasis. The C-terminus of Runx2, which includes the NMTS, interacts 
with proteins involved in the transforming growth factor bone morphogenetic proteins 
(TGF/BMPs) (i.e., Smads), the transducin-like enhancer (TLE)/groucho and the c-Src/Yes 
tyrosine kinase (e.g., the Yes-associated protein, YAP) signalling pathways (Hanai et al, 1999; 
Yagi et al, 1999). Indeed, in response to c-Src/Yes signalling, YAP is phosphorylated and 
recruited by Runx2 to subnuclear sites of Runx2 target genes, resulting in their repression 
(Fig.5). Thus, c-Src controls osteoblast differentiation by regulation of Runx2–YAP interaction. 
Another mechanism by which c-Src regulates osteoblast differentiation involves estrogens, 
which are known to control a variety of tissues, including the bone (Hall et al, 2001). Indeed, 
estrogen deficiency leads to accelerated bone loss which is the primary cause of 
postmenopausal osteoporosis (Manolagas et al, 2002). The estrogen receptors (ERs) belong 
to the nuclear receptor superfamily, acting as ligand-inducible transcription factors (Hall et 
al, 2001).  
Indeed, ER expression is regulated by a c-Src/PKC-dependent mechanism involving 
osteoblast differentiation, with an increased responsiveness to estrogens in mature 
osteoblasts (Fig.5) (Longo et al., 2004). Estrogens are also responsible for an anti-apoptotic 
effect on osteoblasts, which is due to a rapid and sequential phosphorylation of the c-Src, 
Shc and ERK1/2 kinases. The c-Src/Shc/ERK signalling cascade rapidly phosphorylates the 
transcription factors Elk1, CREB and C/EBP with a mechanism that is retained when the 
receptor is localized outside the nucleus (Kousteni et al, 2003).  
Beside the estrogen-mediated effect, other extracellular stimuli, such as mitogens and 
changes in the mechanical stress, are responsible of c-Src activation and of the downstream 
cascade involving the MAPK signalling. In this circumstance, the transcriptional target is the 
AP-1 complex, a heterodimer composed of members of the c-Fos, c-Jun, and activating 
transcription factor (ATF) families (Hess et al, 2004), which is an important regulator of bone 
development and homeostasis (Wagner & Eferl, 2005). 
Of special interest in the regulation of c-Src activation and activity is the role of caveolae. 
They are small bulb-shaped invaginations located close to the cell surface representing 
specialized domains of the plasma membrane (Severs, 1988). Caveolin, a 21–24-kDa integral 
membrane protein, is a major structural and regulatory component of caveolae membranes 
(Rothberg et al., 1992). Several data suggest that caveolin may act as a scaffolding protein  
 

































Fig. 5. c-Src involvement in osteoblast differentiation.  
TGFβ/BMP signals, mechanical stress, mitogens and estrogen modulate c-Src activity and 
osteoblast differentiation. 
within caveolae membranes, since both the N-terminal and C-terminal domains of caveolin 
face the cytoplasm (Dupree et al., 1993). Caveolin interacts with cytoplasmic signalling 
molecules including trimeric G proteins, Src family tyrosine kinases, and Ras-related 
GTPases. Thus, caveolin may serve as an oligomeric docking site for organizing and 
concentrating inactive signalling molecules within the caveolae membranes (Sargiacomo et 
al, 1995). Modification and/or inactivation of caveolin may be a common feature of the 
transformed phenotype. Caveolin can be phosphorylated by c-Src at Tyr14, an event that 
induces caveolar internalization by reorganizing the actin cytoskeleton (mediated by 
dynamin and PKC) (Mayor & Pagano, 2007). 
On the other hand, caveolin has a role in regulating c-Src activation, since its interaction 
with c-Src, as well as with the other components of the SFKs, leads to the inhibition of auto-
phosphorylation of these kinases, thus holding these molecules in the inactive conformation 
(Li et al, 1996).  
Recently, we demonstrated that in osteoblasts c-Src regulates interleukin (IL)-6 and insulin-like 
growth factor binding protein (IGFBP)-5 expression (Peruzzi et al, 2012). More in details, c-Src 
controls IL-6 expression acting on STAT3, which is a downstream component of the IL-6 
pathway and a transcription factor for IL-6 itself. At the same time, IL-6 stimulates the 
expression of IGFBP5 which, in turn, acts in an autocrine manner on osteoblasts inducing the 
c-Src activating-phosphorylation and inhibiting further osteoblast differentiation. On the other 
hand, in mature osteoblasts c-Src is barely expressed and therefore this loop is inactive, 
although IGFBP5 is still expressed under the control of Runx2. In this context, IGFBP5 has 
been observed to enhance osteoclast formation and bone resorption, thus unveiling its new 
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4. c-Src in cancer-related bone diseases 
When deregulated, c-Src has the potential to participate in cancer pathogenesis and 
progression (Rucci et al, 2008). High levels of c-Src activity are found in numerous epithelial 
cancers, including colon and breast carcinomas (reviewed in Tsygankov & Shore, 2004), and 
a correlation between c-Src activity and the degree of tumour malignancy has been 
described (Aligayer et al, 2002). Among several mechanisms proposed for increased c-Src 
activity in cancer, mutations resulting in constitutive activation of the kinase domain of the 
protein have been found in a subset of human cancers (Irby et al, 1999). However, it is 
thought that rather than being a transforming agent on its own, c-Src is a pivotal regulator 
of a number of signalling cascades associated with tumour development and progression, 
including the JAK/STAT pathway (Silva, 2004) and the EGFR family member pathways 
(Biscardi et al, 2000). Indeed, increased c-Src activity upregulates these signals, leading to 
increased cell growth, migration and invasion. 
Because of the central role of c-Src in both bone metabolism and tumourigenesis, c-Src 
signalling may be of particular importance in patients with cancer-related bone diseases. 
Therefore, in this section the role of c-Src in bone malignancies such as osteosarcoma and 
bone metastases will be elucidated. 
Osteosarcoma is the most common and most often fatal primary malignant bone tumour, 
especially affecting children, adolescents and young adults (Raymond et al, 2002). It is a 
highly aggressive tumour that metastasizes primarily to the lung, with a consequent very 
poor prognosis (Shanley & Mulligan, 1991). Osteosarcoma arises from primitive 
transformed cells that exhibit osteoblastic features and produce malignant osteoid (Kansara 
& Thomas, 2007). Among the factors involved in the progression of this pathology, c-Src has 
been described as a mediator of tumour cell invasive features. Caveolin-1 downregulation 
has been proposed to function as a permissive mechanism by which c-Src signalling is 
activated, enabling osteosarcoma cells to become metastatic and invade the neighboring 
tissues (Cantiani et al, 2007). 
Bone represents the principal site of relapse of many cancers, especially prostate and breast 
carcinomas. In the latter, skeletal metastases are osteolytic in nature, with a resulting bone 
destruction mediated by an exaggerated osteoclast activity. Tumour cells colonizing the 
bone produce factors that stimulate osteoclast formation, with a consequent increase of bone 
resorption. This leads to the release of growth factors normally stored in the bone matrix, 
which in turn stimulate tumour cell proliferation and survival. This mutual enhancement of 
tumour cell and osteoclast activities is termed “vicious cycle”, which progressively increases 
both bone destruction and tumour burder (Weilbaecher et al, 2011). c-Src plays a role in the 
context of bone metastases. In fact, MDA-MB-231 breast cancer cells overexpressing a kinase 
dead dominant negative c-Src were found to form far less osteolytic metastases in 
immunocompromised mice than their wild-type counterpart (Myuoi et al, 2003; Rucci et al, 
2006). Recent data demonstrate that c-Src is crucial for breast cancer cell growth in the bone 
marrow since it mediates AKT regulation and tumour cell survival in response to 
chemokine (C-X-C motif) ligand 12 CXCL12, thus confering resistance to the pro-apoptotic 
member of the tumour necrosis factor family, TRAIL (Zhang et al, 2009).  
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5. c-Src as pharmacological target in bone metastases 
Several compounds have been tested in pre-clinical studies in vitro and in vivo to inhibit  
c-Src activity and reduce the incidence of metastases. In an model of experimentally 
induced breast cancer metastases, the pyrrolo-[2,3-d]pyrimidine c-Src inhibitor, 
CGP76030, proved effective at inhibiting the incidence of relapse in bone and visceral 
organs, thus improving mice survival. CGP76030 was observed to have potent anti-
osteoclastic and anti-tumoral effects (Recchia et al, 2004; Rucci et al, 2006), explaining its 
in vivo effects on both fronts. 
The efficacy of c-Src inhibitors in the treatment of breast cancer-induced bone metastases 
was strengthened by recent data showing that c-Src is a key signalling molecule for the 
growth of antiestrogen-resistant tumour cells. Indeed, it has been demonstrated that the 
expression of a constitutively active c-Src attenuated the sensitivity of MCF7 breast cancer 
cells to tamoxifen (Morgan et al, 2009). In the same cell line the synergistic interaction 
between ER, EGF receptor and c-Src enhanced tumour cell responsiveness to mitogenic 
stimuli, allowing their survival also in the presence of tamoxifen (Yue et al, 2007). 
Another compound employed in preclinical studies is Dasatinib, a potent inhibitor of SFKs, 
which proved effective at inhibiting breast cancer cell growth, with a synergic effect when 
used in combination with chemotherapeutics (Nautiyal et al, 2009), while in  
mice inoculated with a triple-negative (for ER, progesterone receptor and Her2/neu 
expression) breast cancer cell line it prevented the formation of osteolytic metastases (Zhang 
et al, 2009). 
Based on this body of evidence, clinical studies have recently been started using sarcatinib, 
which is a dual c-Src/Abl inhibitor. In a phase I study performed on patients with solid 
tumours, sarcatinib decreased the levels of bone resorption markers (Baselga et al, 2010). 
Sarcatinib is currently being tested in phase II clinical studies in patients with breast cancer 
bone metastases. Another dual c-Src/Abl inhibitor in clinical development with similar 
properties is Bosutinib. 
6. Conclusions 
c-Src is a non receptor tyrosine kinase ubiquitously expressed and involved in the regulation 
of many cellular functions, such as adhesion, growth, migration and survival. Indeed, its 
activity increases in response to several signals, especially downstream of growth factor and 
cytokine receptors, integrin receptors and G-coupled receptors. The proto-oncogene nature 
of c-Src is also well known, so that its aberrant activation is involved in the development 
and progression of many human cancers.  
c-Src plays an unique role in bone metabolism, regulating the activity of both the bone-
resorbing osteoclasts and the bone-forming osteoblasts. The interest on c-Src within the bone 
metabolism derived from the pioneer work of Soriano et al. (1991), who demonstrated that, 
despite the ubiquitous expression of c-Src, knock-out mice showed only a bone phenotype. 
This molecule is currently thought to be a suitable pharmacological target for bone 
metastases. Clinical studies are currently in progress to establish the efficacy of c-Src 
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1. Introduction 
The Extracellular signal-related kinase (ERK) Mitogen-activated protein kinase (MAPK) 
pathway is a signaling cascade that is activated by various extracellular stimuli including 
fibroblast growth factors. The ERK MAPK pathway has recently been shown to play critical 
roles in skeletal development. A number of human skeletal syndromes have been shown to 
result from mutations in this pathway. These include Noonan, Costello, and cardio-facio-
cutaneous syndromes (Aoki et al., 2005; Pandit et al., 2007; Rodriguez-Viciana et al., 2006). In 
addition, activating mutations in FGFR2 cause craniosynostosis syndromes such as Apert and 
Crouzon syndromes, while activating mutations in fibroblast growth factor receptor 3 (FGFR3) 
are responsible for the most common forms of human dwarfism, achondroplasia, 
thanatophoric dysplasia, and hypochondroplasia (Bellus et al., 1995; Jabs et al., 1994; Rousseau 
et al., 1994, 1995; Rutland et al., 1995; Shiang et al., 1994; Wilcox et al., 1998; Wilkie et al., 1995).  
Although a number of in vitro experiments indicated profound effects of the ERK MAPK 
pathway on chondrocyte and osteoblast phenotype, sometimes conflicting results were 
reported presumably due to variable culture conditions (Bobick & Kulyk, 2008; Schindeler & 
Little, 2006), and the roles of the ERK MAPK pathway in vivo remained elusive. Therefore, 
to examine the role of ERK MAPK in skeletal development, we used both gain-of-function 
and loss-of-function approaches to activate or inactivate the ERK MAPK pathway in skeletal 
tissues of genetically engineered mice. We used the Cre-loxP system to inactivate ERK1 and 
ERK2 in skeletal tissues (Logan et al., 2002; Matsushita et al., 2009a). By using the Prx1-Cre 
transgene, mice lacking ERK1 and ERK2 in the limb and head mesenchyme were created. 
We also generated a loss of function model in chondrocytes by using the Col2a1-Cre 
transgene (Matsushita et al., 2009a; Ovchinnikov et al., 2000). To induce postnatal 
inactivation of ERK1 and ERK2 in chondrocytes, we used the Col2a1-CreER transgene to 
express a tamoxifen-inducible form of Cre recombinase (Nakamura et al., 2006; Sebastian et 
al., 2011). For gain-of-function experiments, we generated Prx1-MEK1 transgenic mice that 
express a constitutively active mutant of MEK1 in undifferentiated mesenchymal cells under 
the control of a Prx1 promoter (Matsushita et al., 2009a). We also generated Col2a1-MEK1 
transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes under 
the control of the regulatory sequences of Col2a1 (Murakami et al., 2004). In this review, we 
will summarize the roles of the ERK MAPK pathway in skeletal development based on our 





Zheng, XM., Wang, Y. & Pallen, CJ. (1992). Cell transformation and activation of pp60c-src 
by overexpression of a protein tyrosine phosphatase. Nature, Vol.359, No.6393, 
(September 1992), pp. 336–339, ISSN 0028-0836  
Zou, W., Kitaura, H., Reeve, J., Long, F., Tybulewicz, VL., Shattil, SJ., Ginsberg, MH., Ross, 
FP. & Teitelbaum, SL. (2007). Syk, c-Src, the alphavbeta3 integrin, and ITAM 
immunoreceptors, in concert, regulate osteoclastic bone resorption. The Journal of 
cell biology, Vol.176, No.6, (March 2007), pp. 877-888, ISSN 0021-9525 
17 
The ERK MAPK Pathway  
in Bone and Cartilage Formation 
Takehiko Matsushita and Shunichi Murakami 
Department of Orthopaedics, Case Western Reserve University, 
USA 
1. Introduction 
The Extracellular signal-related kinase (ERK) Mitogen-activated protein kinase (MAPK) 
pathway is a signaling cascade that is activated by various extracellular stimuli including 
fibroblast growth factors. The ERK MAPK pathway has recently been shown to play critical 
roles in skeletal development. A number of human skeletal syndromes have been shown to 
result from mutations in this pathway. These include Noonan, Costello, and cardio-facio-
cutaneous syndromes (Aoki et al., 2005; Pandit et al., 2007; Rodriguez-Viciana et al., 2006). In 
addition, activating mutations in FGFR2 cause craniosynostosis syndromes such as Apert and 
Crouzon syndromes, while activating mutations in fibroblast growth factor receptor 3 (FGFR3) 
are responsible for the most common forms of human dwarfism, achondroplasia, 
thanatophoric dysplasia, and hypochondroplasia (Bellus et al., 1995; Jabs et al., 1994; Rousseau 
et al., 1994, 1995; Rutland et al., 1995; Shiang et al., 1994; Wilcox et al., 1998; Wilkie et al., 1995).  
Although a number of in vitro experiments indicated profound effects of the ERK MAPK 
pathway on chondrocyte and osteoblast phenotype, sometimes conflicting results were 
reported presumably due to variable culture conditions (Bobick & Kulyk, 2008; Schindeler & 
Little, 2006), and the roles of the ERK MAPK pathway in vivo remained elusive. Therefore, 
to examine the role of ERK MAPK in skeletal development, we used both gain-of-function 
and loss-of-function approaches to activate or inactivate the ERK MAPK pathway in skeletal 
tissues of genetically engineered mice. We used the Cre-loxP system to inactivate ERK1 and 
ERK2 in skeletal tissues (Logan et al., 2002; Matsushita et al., 2009a). By using the Prx1-Cre 
transgene, mice lacking ERK1 and ERK2 in the limb and head mesenchyme were created. 
We also generated a loss of function model in chondrocytes by using the Col2a1-Cre 
transgene (Matsushita et al., 2009a; Ovchinnikov et al., 2000). To induce postnatal 
inactivation of ERK1 and ERK2 in chondrocytes, we used the Col2a1-CreER transgene to 
express a tamoxifen-inducible form of Cre recombinase (Nakamura et al., 2006; Sebastian et 
al., 2011). For gain-of-function experiments, we generated Prx1-MEK1 transgenic mice that 
express a constitutively active mutant of MEK1 in undifferentiated mesenchymal cells under 
the control of a Prx1 promoter (Matsushita et al., 2009a). We also generated Col2a1-MEK1 
transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes under 
the control of the regulatory sequences of Col2a1 (Murakami et al., 2004). In this review, we 
will summarize the roles of the ERK MAPK pathway in skeletal development based on our 





2. Skeletal development and ossification processes 
Bone formation takes place in two major ossification processes, endochondral ossification 
and intramembranous ossification (Colnot, 2005; Hunziker, 1994; Opperman, 2000; Shapiro 
et al., 2005). Both chondrocytes and osteoblasts arise from common undifferentiated 
mesenchymal progenitor cells. In endochondral ossification, the skeletal element is formed 
as a cartilaginous template that is subsequently replaced by bone. Undifferentiated 
mesenchymal cells first aggregate to form mesenchymal condensation and differentiate into 
chondrocytes. Chondrocytes proliferate in columnar stacks to form the growth plate, then 
exit the cell cycle, and differentiate into hypertrophic chondrocytes. The cartilaginous matrix 
of hypertrophic chondrocytes is calcified and subsequently invaded by blood vessels. 
Hypertrophic chondrocytes are removed by apoptotic cell death, and the cartilaginous 
matrix is resorbed by chondroclasts/osteoclasts and replaced by trabecular bone. 
Chondroclast/osteoclast formation is supported by receptor activator of nuclear factor-
kappa B ligand (RANKL) secreted from osteoblasts and bone marrow stromal cells (Kim et 
al., 2000; Yasuda et al., 1998). In intramembranous ossification, mesenchymal cells directly 
differentiate into bone-forming osteoblasts; cortical bone is formed by osteoblasts that arise 
from the osteochondro progenitor cells in the perichondrium. The entire process of 
endochondral ossification and intramembranous ossification is under the control of various 
hormones and growth factors. These include systemic factors such as growth hormone, 
estrogen, and glucocorticoids; and local factors such as Indian hedgehog (Ihh), parathyroid 
hormone-related peptide (PTHrP), fibroblast growth factors (FGF), transforming growth 
factor- (TGF-), and bone morphogenetic proteins (BMP) (DeLise et al., 2000; van der 
Eerden et al., 2003). 
3. The ERK MAPK pathway and human syndromes 
3.1 The ERK MAPK pathway 
The ERK MAPK pathway (Fig. 1), which is activated by various stimuli in eukaryotic cells, 
transduces extracellular signals into cells and coordinates cellular responses. The MAPK 
pathways are generally organized into three kinase modules: MAPKK kinase (MAPKKK), 
MAPK kinase (MAPKK), and MAPK. MAPKKK phosphorylates and activates MAPKK, 
which in turn phosphorylates and activates MAPK. A diverse array of growth factors and 
cytokines transduce their signals through the activation of the small G protein Ras, which 
leads to the activation of the Raf members of MAPKKK, and then to the activation of 
MAPKK, MEK1 and MEK2. MEK1 and MEK2 then phosphorylate and activate MAPK, 
ERK1 and ERK2. ERK1 and ERK2 then phosphorylate various cytoplasmic and nuclear 
target proteins, ranging from cytoplasmic adaptor proteins and transcription factors to 
kinases including RSK (Cargnello & Roux, 2011; Roux & Blenis, 2004). The ERK MAPK 
pathway has been shown to mediate the intracellular signaling induced by a variety of 
growth factors such as FGFs, BMPs, and TGFs (Jun et al., 2010; Mu et al., 2011; Murakami et 
al., 2000; Osyczka & Leboy, 2005; Qureshi et al., 2005; Tuli et al., 2003).  
3.2 Human syndromes caused by mutations in the MAPK pathway 
Recently, a number of human mutations have been identified in the molecules in the MAPK 
cascade (Fig. 1). Missense activating mutations in KRAS, BRAF, MEK1, and MEK2 have 
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been identified in Cardio-facio-cutaneous syndrome (Rodriguez-Viciana et al., 2006). KRAS 
mutations have been also identified in Noonan syndrome (Schubbert et al., 2006). HRAS 
mutations cause Costello syndrome (Aoki et al., 2005), and loss-of-function mutations in 
RSK2 cause Coffin-Lowry syndrome (Trivier et al., 1996). In addition, haploinsufficient 
expression of ERK2 has been associated with DiGeorge syndrome (Newbern et al., 2008). All 
of these syndromes present with various skeletal manifestations, including short stature and 
craniofacial and limb abnormalities, underscoring the importance of the MAPK pathway in 
human skeletal development (Hanauer & Young, 2002; Hennekam, 2003; Noonan, 2006; 
Reynolds et al., 1986; van der Burgt, 2007).  
 
Fig. 1. The ERK MAPK pathway and human skeletal syndromes 
4. Genetic manipulation of molecules in the ERK MAPK pathway in mice 
To examine the role of the MAPK pathway, various mutant mice have been generated. 
Inactivation of Rsk2, a downstream kinase of the MAPK pathway, caused a widening of 
cranial sutures at birth, similar to the delayed closure of fontanelles in patients with Coffin-
Lowry syndrome (David et al., 2005; Yang et al., 2004). These observations indicate that Rsk2 
plays a critical role in osteoblast differentiation. In contrast to Rsk2-null mice, the 
inactivation of ERK, MEK, and Raf family members has provided little information 
regarding skeletal development. ERK1-null mice are viable and fertile and develop normally 
without obvious skeletal abnormalities, suggesting that ERK1 is dispensable for skeletal 
development (Pages et al., 1999; Selcher et al., 2001). In remarkable contrast, ERK2-null mice 
show early embryonic lethality at E6.5, precluding the analysis of skeletal development 
(Saba-El-Leil et al., 2003; Yao et al., 2003). Mek1-null embryos die at E10.5 due to placental 
defects, while Mek2-null mice develop normally without any obvious abnormalities 
(Belanger et al., 2003; Giroux et al., 1999). Araf-null mice show neurological and 
gastrointestinal defects, but do not show an obvious skeletal phenotype (Pritchard et al., 
1996). Braf-deficient embryos die at midgestation due to vascular defects, precluding the 
analysis of skeletal development (Wojnowski et al., 1997). Craf-null mice show placental 
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CD1 background, two-thirds of embryos reach term and die soon after birth. These 
surviving embryos show a mild delay in ossification; however, it is not clear whether the 
observed skeletal phenotype is primarily caused by Craf deficiency in the skeletal tissues 
(Wojnowski et al., 1998). Furthermore, mice with chondrocytes deficient in both Araf and 
Braf showed normal endochondral bone development (Provot et al., 2008). These 
observations suggest that members of the ERK, MEK, and Raf family are functionally 
redundant, while some of the tissue-specific functions are not fully compensated by other 
family members. To circumvent early embryonic lethality caused by the systemic 
inactivation of the target gene, tissue-specific inactivation would be essential. Furthermore, 
the inactivation of multiple family members may be necessary to uncover the roles of ERK, 
MEK, and Raf family members in skeletal development.  
5. Inactivation of ERK1 and ERK2 in undifferentiated mesenchymal cells 
disrupts bone formation and induces ectopic cartilage formation 
Since early embryonic lethality hampered researchers from analyzing the role of the ERK 
MAPK pathway in skeletal development in vivo as described above, we used the Cre-loxP 
system to inactivate ERK1 and ERK2 in skeletal tissues. We used Prx1-Cre transgenic mice 
that express Cre recombinase under the control of the 2.4 kb Prx1 promoter (Logan et al., 
2002) to inactivate ERK1 and ERK2 in the limb and head mesenchyme (Matsushita et al., 
2009a). The Prx1 promoter has been shown to direct transgene expression in 
undifferentiated mesenchyme in the developing limb buds and head mesenchyme. The 
transgene expression is detectable as early as E10.5, and the transgene expression is confined 
to the periosteum of the long bones and tendons of the limbs at E15.5 (Logan et al., 2002). 
We analyzed ERK1-null mice and ERK2flox/flox; Prx1-Cre mice, and these mice did not show 
obvious skeletal abnormalities. Therefore, we further inactivated ERK2 in the ERK1-null 
background to totally inactivate ERK1 and ERK2 in the head and limb mesenchyme of 
mouse embryos using the Prx1-Cre transgene (Matsushita et al., 2009a). 
5.1 Inactivation of ERK1 and ERK2 in mesenchymal cells disrupts osteoblast 
differentiation 
Skeletal preparation of ERK1 -/-; ERK2 flox/flox; Prx1-Cre mutants revealed severe limb 
deformities as well as calvaria defects characterized by delayed closure of the cranial sutures 
(Fig. 2). Histological analysis of the long bones showed disruption of bone formation. These 
findings indicate that ERK1 and ERK2 play an essential role in bone formation. In situ 
hybridization analysis indicated that master osteogenic transcription factors Runx2, Osterix, 
and Atf4 were expressed at normal levels, while expression of Osteocalcin, a marker of 
mature osteoblasts, was strongly decreased in ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice. These 
observations suggest that osteoblast differentiation was blocked after Runx2, Osterix, and 
Atf4 expression and before Osteocalcin expression. The impaired bone formation was 
associated with decreased beta-catenin protein levels in the periosteum, suggesting 
decreased Wnt signaling. We also found that other transcriptional regulators such as Krox20, 
Fra1, Fra2, cFos, and Cbfb were downregulated in ERK1 -/-; ERK2 flox/flox; Prx1-Cre embryos. 
While the regulatory mechanisms of osteoblast differentiation require further investigation, 
ERK1 and ERK2 are likely to control skeletal development and osteoblast differentiation 
through multiple downstream molecules. Consistent with our observation, Ge et al. reported 
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that transgenic mice that express dominant negative MEK1 under an Osteocalcin promoter 
showed delayed bone formation and reduced mineralization of calvaria, while mice that 
express a constitutively active MEK1 under the Osteocalcin promoter showed accelerated bone 
formation (Ge et al., 2007). These observations also indicated a critical role of ERK1 and ERK2 
in osteoblast differentiation. In vitro studies have also suggested that the ERK MAPK pathway 
regulates osteoblast differentiation through phosphorylation and acetylation of Runx2 (Ge et 
al., 2007; Park et al., 2010; Xiao et al., 2000, 2002). The importance of the ERK MAPK pathway 
in osteoblast differentiation in head mesenchyme was also demonstrated by Shukla et al., who 
showed that craniosynostosis in a mouse model of Apert syndrome that carries a mutation in 
Fgfr2 was prevented by the treatment of MEK1/2 inhibitor (Shukla et al., 2007). These 
observations further link the activation of the ERK MAPK pathway to the pathogenesis of 
craniosynostosis syndromes caused by activating mutations in FGFR2.  
 
Fig. 2. (A) Skeletal preparation after alizarin red and alcian blue staining at postnatal day 1. 
(B) Skeletal preparation after alizarin red and alcian blue staining at postnatal day 5. 
5.2 Inactivation of ERK1 and ERK2 disrupts osteocyte differentiation 
Osteoblasts undergo sequential steps of differentiation and subsequently become embedded 
in bone matrix as osteocytes. Osteocytes function as a mechanosensor in the bone and 
secrete dentin matrix protein 1 (Dmp1) and FGF23 to regulate phosphate homeostasis 
(Dallas & Bonewald, 2010; Feng et al., 2006; Tatsumi et al., 2007; Xiao and Quarles, 2010). 
Although ERK1-/-; ERK2flox/flox; Prx1-Cre mice showed a remarkable impairment of bone 
formation, bone-like architecture was observed in the diaphyses of long bones, and 
osteocyte-like cells were found within the bone-like matrix. Our real-time PCR and 
immunohistochemical analysis indicated a strong decrease in Dmp1 expression in the 
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microscopic analysis revealed that osteocytes in ERK1-/-; ERK2flox/flox; Prx1-Cre mice lack 
dendritic processes, indicating that ERK1 and ERK2 inactivation disrupts the formation of 
osteocyte-lacunar-canalicular system (Kyono et al., 2011). These observations indicate that 
ERK signaling is essential for Dmp1 expression and osteocyte differentiation.  
5.3 Inactivation of ERK1 and ERK2 in mesenchyme causes ectopic cartilage formation  
While inactivation of ERK1 and ERK2 inhibited osteoblast differentiation and bone 
formation, we found ectopic cartilage formation in the perichondrium of ERK1 -/-; ERK2 
flox/flox; Prx1-Cre mice (Fig. 3). The ectopic cartilage expressed Sox9, a transcription factor for 
chondrocyte differentiation, and Col2a1, the gene for type II collagen (Matsushita et al., 
2009a). These findings suggest that inactivation of ERK1 and ERK2 in mesenchyme inhibited 
osteoblast differentiation and promoted chondrocyte differentiation. Ectopic cartilage 
formation has been also reported in the perichondrium of Osterix-null mice (Nakashima et 
al., 2002) and in the perichondrium of mice in which beta-catenin was disrupted in 
mesenchymal cells (Day et al., 2005; Hill et al., 2005). While normal Osterix expression was 
observed in ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice, beta-catenin protein levels were decreased 
in the perichondrium of ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice. These observations suggest a 
role for decreased beta-catenin in the ectopic cartilage formation in the perichondrium. 
 
Fig. 3. Hematoxylin, eosin and alcian blue staining of femur of newborn mice. Arrows 
indicate ectopic cartilage formation in the perichondrium of ERK1-/-;ERK2flox/flox;Prx1-Cre 
mice. 
6. Constitutive activation of MEK1 in undifferentiated mesenchymal cells 
leads to increased bone formation and inhibition of cartilage formation 
As a complementary experiment, we generated Prx1-MEK1 transgenic mice that express a 
constitutively active mutant of MEK1 in undifferentiated limb and cranial mesenchyme 
(Matsushita et al., 2009a). Prx1-MEK1 mice showed a marked increase in cortical bone 
formation, fusion of long bones as well as carpal and tarsal bones, and an accelerated 
closure of cranial sutures, mimicking the phenotype of human craniosynostosis syndromes 
caused by activating mutations in FGFR2. The increase in bone formation was associated 
with increased expression of osteoblast markers, such as Runx2, Osterix, Bsp, and Osteocalcin. 
In contrast, cartilage formation was inhibited in Prx1-MEK1 transgenic mice. There was a 
clear delay in the formation of cartilage anlagen as well as a decrease in anlagen size. In 
 





Table 1. Genetically engineered mouse models with increased or decreased ERK MAPK 
signaling in skeletal cells. CA MEK1/Prx1, Transgenic mice that express a constitutively 
active mutant of MEK1 under the control of a Prx1 promoter. CA MEK1/Col2a1, Transgenic 
mice that express a constitutively active mutant of MEK1 under the control of a Col2a1 
promoter. DN MEK1/Osteocalcin, Transgenic mice that express a dominant-negative 
mutant of MEK1 under the control of an Osteocalcin promoter. CA MEK1/Osteocalcin, 
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signaling in skeletal cells. CA MEK1/Prx1, Transgenic mice that express a constitutively 
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addition, expression of Col2a1 was reduced in the cartilage primordia. These observations 
are consistent with the phenotypes of ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice, in which the lack 
of ERK1 and ERK2 disrupts bone formation and induces ectopic cartilage formation. These 
observations are also consistent with the in vitro studies showing inhibitory effects of the 
ERK MAPK pathway on chondrogenesis. The ERK MAPK inhibitors U0126 and PD98059 
increased the expression of Col2a1 and aggrecan in embryonic limb mesenchyme, and 
transfection of limb mesenchyme with constitutively active mutant of MEK decreased the 
activity of a Sox9-responsive Col2a1 enhancer reporter gene (Bobick & Kulyk, 2004). 
Collectively, these observations indicate that ERK MAPK signaling plays an important role 
in the lineage specification of mesenchymal cells.  
7. Inactivation of ERK1 and ERK2 in chondrocytes causes severe 
chondrodysplasia and enhances bone growth 
Type II collagen is the most abundant collagen in cartilage. Col2a1, the gene encoding the 
proalpha1(II) collagen chain, is a principal marker of chondrocyte differentiation. We created a 
loss of function model of ERK1 and ERK2 in chondrocytes by using the Col2a1-Cre transgenic 
mice that express Cre recombinase under the regulatory sequences of Col2a1 (Matsushita et al., 
2009a; Ovchinnikov et al., 2000). ERK1 -/-; ERK2 flox/flox; Col2a1-Cre mutant mice died 
immediately after birth, likely secondary to respiratory insufficiency caused by rib cage 
deformity (Matsushita et al., 2009a). To circumvent the perinatal lethality, we also used the 
Col2a1-CreER transgene to express a tamoxifen-inducible form of Cre recombinase and 
examined the role of ERK1 and ERK2 in chondrocytes during postnatal growth (Nakamura et 
al., 2006; Sebastian et al., 2011). For the gain-of-function experiments, we generated Col2a1-
MEK1 transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes 
under the control of the regulatory sequences of Col2a1 (Murakami et al., 2004). 
7.1 ERK1 and ERK2 are essential for proper organization of epiphyseal cartilage 
A strong skeletal phenotype was observed in ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos. We 
observed severe kyphotic deformities of the spine. Histological analysis of ERK1 -/-; ERK2 
flox/flox; Col2a1-Cre embryos at embryonic day 16.5 showed an absence of primary ossification 
centers in the axial skeleton and a widening of the zone of hypertrophic chondrocytes in the 
long bones (Fig. 4). In addition, disorganization of the epiphyseal cartilage with lack of 
columnar growth structures was observed in ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos at 
embryonic day 18.5. These findings indicate that ERK1 and ERK2 are essential for the 
proper organization of the epiphyseal cartilage. 
 
Fig. 4. Hematoxylin, eosin and alcian blue staining of the tibia showed delayed formation of 
primary ossification center in ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos at embryonic day 16.5. 
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7.2 ERK1 and ERK2 inhibit hypertrophic chondrocyte differentiation 
Both ERK1 -/-; ERK2 flox/flox; Prx1-Cre and ERK1 -/-; ERK2 flox/flox; Col2a1-Cre mice showed a 
remarkable expansion of the zone of hypertrophic chondrocytes. In both animal models, 
chondrocytes that were closer to the articular surface expressed hypertrophic chondrocyte 
marker Col10a1, suggesting premature chondrocyte hypertrophy. These observations are 
consistent with the growth plate phenotype of Col2a1-MEK1 transgenic mice that express a 
constitutively active MEK1 mutant in chondrocytes (Murakami et al., 2004). The growth 
plate of Col2a1-MEK1 transgenic mice was characterized by smaller than normal 
hypertrophic chondrocytes and narrower zone of hypertrophic chondrocytes. BrdU labeling 
of proliferating chondrocytes and subsequent identification of BrdU-labeled hypertrophic 
chondrocytes indicated reduced rate of chondrocyte hypertrophy in Col2a1-MEK1 mice. 
Collectively, these observations indicate that ERK MAPK signaling inhibits hypertrophic 
chondrocyte differentiation.  
The pronounced expansion of the zone of hypertrophic chondrocytes in ERK1 -/-; ERK2 flox/flox; 
Prx1-Cre mice was also characterized by an increase in terminally differentiated 
hypertrophic chondrocytes expressing Vegf, Mmp13, and Osteopontin, suggesting impaired 
removal of terminally differentiated hypertrophic chondrocytes. We also observed a 
decrease in TRAP-positive osteoclasts in association with reduced expression of receptor 
activator of nuclear factor-kappa B ligand (RANKL). Therefore, decreased osteoclastogenesis 
may also account for the expansion of the zone of hypertrophic chondrocytes.  
7.3 ERK1 and ERK2 inhibit growth of cartilaginous skeletal element 
A number of genetic studies have indicated the growth inhibitory role of FGFR3 signaling. 
Mice with activating mutations in Fgfr3 show a dwarf phenotype similar to the human 
syndromes of achondroplasia and thanatophoric dysplasia (Chen et al., 1999; Iwata et al., 
2000, 2001; Li et al., 1999; Naski et al., 1998; Wang et al., 1999). In contrast, Fgfr3-null mice 
show a skeletal overgrowth (Colvin et al., 1996; Deng et al., 1996). Our observations in 
genetically engineered mouse models have provided evidence indicating that the ERK 
MAPK pathway is a critical downstream effector of Fgfr3 signaling. We have shown that 
Col2a1-MEK1 transgenic mice that express a constitutively active MEK1 mutant in 
chondrocytes show an achondroplasia-like dwarf phenotype (Murakami et al., 2004). We 
have also shown that ERK1 and ERK2 inactivation in chondrocytes promotes bone growth. 
We found increased length of the proximal long bones, specifically the humerus and femur, 
of ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos (Sebastian et al., 2011). These embryos also 
showed an increase in the width of epiphyses in the humerus and femur. Histological 
analysis of the vertebrae also showed an overgrowth of cartilage in the vertebral body. 
These observations indicate that ERK1 and ERK2 negatively regulate the growth of 
cartilaginous skeletal elements.  
8. Postnatal ERK1 and ERK2 inactivation delays synchondrosis closure and 
enlarges the spinal canal  
Our studies have indicated that FGFR3 and the MAPK pathway are important regulators of 
synchondrosis closure. In bones such as the vertebrae, sternum, pelvis, and bones in the 
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ossification centers and contributes to the bone growth. During postnatal skeletal 
development, the width of synchondroses reduces with age. Ossification centers eventually 
unite when synchondroses close. Histologically, a synchondrosis consists of two opposed 
growth plates with a common zone of resting chondrocytes (Fig. 5A). We have found 
premature synchondrosis closure in the vertebrae and cranial base of human samples of 
achondroplasia and thanatophoric dysplasia (Matsushita et al., 2009b). In addition, we have 
also observed premature synchondrosis closure in a mouse model of achondroplasia and 
Col2a1-MEK1 transgenic mice that express a constitutively active MEK1 mutant in 
chondrocytes (Fig. 5B). Because growth at the synchondrosis determines the final dimension 
and shape of the endochondral skeletons, premature synchondrosis closure should play a 
critical role in the development of spinal canal stenosis that is frequently seen in patients with 
achondroplasia. 
Since increased Fgfr3 and MEK1 signaling accelerates synchondrosis closure, we 
hypothesized that ERK1 and ERK2 inactivation delays synchondrosis closure and enlarges 
the spinal canal. To test this hypothesis, we inactivated ERK2 in chondrocytes of ERK1-null 
 
Fig. 5. (A) Spheno-occipital synchondrosis of a 4-day-old wild type mouse. HZ; 
hypertrophic zone. PZ; proliferation zone. RZ; resting zone. (B) Thoracic spine of wild type 
and Col2a1-MEK1 transgenic mice at postnatal day 4. Arrows indicate prematurely closing 
synchondroses. Wt; wild type. 
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mice using the Col2a1-CreER transgene (Sebastian et al., 2011). Tamoxifen injection into ERK1 -/-; 
ERK2 flox/flox; Col2a1-CreER mice resulted in 60% inhibition of ERK2 expression in the epiphyseal 
cartilage. Although these mice did not show an increased growth of the long bones 
presumably due to incomplete ERK2 inactivation, we observed a significant delay in 
synchondrosis closure of the vertebrae and an increase in the cross-sectional area of vertebral 
foramen. The delayed synchondrosis closure was associated with a decreased expression of 
the endothelial marker CD31 surrounding the synchondroses, suggesting that ERK1 and ERK2 
inactivation in chondrocytes causes reduced vascular invasion. These observations indicate the 
potential of ERK1 and ERK2 as therapeutic targets for spinal canal stenosis in achondroplasia.  
9. Conclusion 
By creating and analyzing gain-of-function and loss-of-function mouse models, we have 
identified multiple roles of the ERK MAPK pathway at successive steps of skeletal 
development. In undifferentiated mesenchymal cells, ERK1 and ERK2 inactivation causes a 
block in osteoblast differentiation and induces ectopic cartilage formation. In contrast, 
increased MEK1 signaling promotes bone formation and inhibits cartilage formation. These 
observations indicate that ERK MAPK signaling plays a critical role in the lineage specification 
of mesenchymal cells (Fig. 6). ERK MAPK signaling also inhibits hypertrophic chondrocyte 
differentiation and bone growth. Furthermore, ERK MAPK signaling regulates the timing of 
growth plate and synchondrosis closure, the very last step of endochondral ossification. A 
better understanding of the roles of the ERK MAPK pathway in skeletal tissues will lead to 
new insights in skeletal development and the treatment of various skeletal disorders.  
 
Fig. 6. Proposed model of the role of ERK1 and ERK2 in the regulation of osteoblast and 
chondrocyte differentiation. 
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1. Introduction 
Intense research on pancreatic islet function is fuelled by its link to the disease diabetes 
mellitus. Diabetes is a chronic disease that is characterised by inappropriate regulation of 
blood glucose levels. This dysregulation of blood glucose homeostasis occurs when the 
pancreas produces insufficient amounts of the hormone, insulin, or when insulin sensitive 
organs lose sensitivity to insulin (insulin resistance). Increasingly there is evidence to support 
the idea that abnormal release of another pancreatic hormone, glucagon, may be involved in 
the dysregulation of blood glucose homeostasis.  
There are two types of diabetes. Type 1 diabetes is characterised by the failure of the pancreas 
to produce insulin. In most cases, type 1 diabetes is caused by autoimmune destruction of the 
pancreatic β cells that produce insulin and release the hormone in response to changes in 
blood glucose levels. Type 2 diabetes is characterised by relative insulin insufficiency and 
insulin resistance. This is the more common form of diabetes, comprising of 90 % of people 
with diabetes worldwide. The prominence of this form of diabetes is associated with lifestyle 
choices: the obesity epidemic has led to an increase in the incidence of diseases associated 
with metabolic imbalance such as diabetes. Energy homeostasis and obesity are intimately 
linked. Between 45-80 % of our energy intake is in the form of carbohydrates (1;2), which are 
converted to glucose and transported in the blood stream (3). Thus, there has been much 
interest in the mechanisms that regulate glucose homeostasis, particularly those involving the 
endocrine pancreas. The pancreatic hormones glucagon and insulin, produced and released 
in the pancreatice α and β cells, repectively, are involved in maintaining blood glucose 
homeostasis. 
Uncontrolled diabetes leads to hyperglycaemia and can lead to a number of diabetes related 
complications over time, such as increased risk of cardiovascular disease, diabetic 
retinopathy, kidney failure, and diabetic neuropathy. Current figures published by the World 
Health Organisation (WHO) indicate that 346 million people worldwide have diabetes. It is 
estimated that 5 % of all deaths worldwide each year are as a consequence of diabetes and its 
associated complications, with more than 80 % of these deaths occuring in low- and middle- 
income countries (WHO figures). It is projected that the number of diabetes related deaths 
will double between 2005 and 2030 (WHO figures), making diabetes a major burden on 
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linked. Between 45-80 % of our energy intake is in the form of carbohydrates (1;2), which are 
converted to glucose and transported in the blood stream (3). Thus, there has been much 
interest in the mechanisms that regulate glucose homeostasis, particularly those involving the 
endocrine pancreas. The pancreatic hormones glucagon and insulin, produced and released 
in the pancreatice α and β cells, repectively, are involved in maintaining blood glucose 
homeostasis. 
Uncontrolled diabetes leads to hyperglycaemia and can lead to a number of diabetes related 
complications over time, such as increased risk of cardiovascular disease, diabetic 
retinopathy, kidney failure, and diabetic neuropathy. Current figures published by the World 
Health Organisation (WHO) indicate that 346 million people worldwide have diabetes. It is 
estimated that 5 % of all deaths worldwide each year are as a consequence of diabetes and its 
associated complications, with more than 80 % of these deaths occuring in low- and middle- 
income countries (WHO figures). It is projected that the number of diabetes related deaths 
will double between 2005 and 2030 (WHO figures), making diabetes a major burden on 
society and the health system. There is currently no cure for diabetes. 
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2. The pancreatic endocrine compartment 
Blood glucose homeostasis is regulated by the pancreatic hormones, glucagon and insulin, 
which are secreted from the pancreatic islets of Langerhans. There are approximately one 
million islets in the adult human pancreas; this equates to about 2 % of total pancreatic 
mass. Pancreatic islets of Langerhans consist of four different cell types: glucagon producing 
α cells, insulin producing β cells, somatostatin producing δ cells and pancreatic polypeptide 
producing PP cells. The hormones insulin and glucagon are the principal islet hormones 
regulating blood glucose levels. Insulin is characteristic of the fed state and is released in 
response to hyperglycaemia. Glucagon is characteristic of the fasted state and is released in 
response to hypoglycaemia. Multiple other factors, including neural factors, regulate hormone 
release. The regulation of hormone release occurs at the level of the single hormone producing 
cell, the islet of Langerhans, the pancreas and the whole organism (Fig. 1). 
Each islet of Langerhans is composed of about 2000 cells; typically, 60 % of these cells are 
insulin producing β cells. Insulin ensures that glucose is taken up and stored by peripheral 
tissues (4). Insulin secretion from islet β cells is regulated by nutrient availability,  
 
Fig. 1. Insulin and glucagon release are regulated by nutrient availability, and a range of 
other factors. Glucose entry in pancreatic α and β cells leads to increased ATP production, 
which in turn leads to closure of K-ATP (KATP) channels and membrane depolarisation. In 
the β cell this leads to opening of L-type voltage-gated calcium channels (L-Ca2+) and 
subsequent release of insulin via the triggering pathway. Glucose metabolism augment the 
calcium signal to enhance insulin secretion through the amplification pathways (dashed 
line). The incretin, glucagon-like peptide 1 (GLP-1), which is secreted from L-cells in the gut, 
can enhance insulin secretion from pancreatic β cells. In the α cells the presence of voltage 
gated sodium (Nav) and potassium (Kv) channels keep voltage-gated calcium (Cav) channels 
closed, and leads to inhibition of glucagon release when extracellular glucose concentrations 
are high. Insulin and other factors secreted by the pancreatic β cell, e.g. zinc ions and 
gamma aminobutyric acid (GABA), somatostatin (secreted by pancreatic δ cells), and 
catecholamines all play a part in the regulation of glucagon release (42;220-224). 
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neurotransmitters, and hormones. β cells are electrically excitable and transduce variations in 
circulating glucose concentrations into secretory signals through changes in their own 
metabolic state. β cells are equipped with a high capacity glucose transporter (5-7) and the 
high Km type IV hexokinase (or glucokinase) (8;9). Thus, glucose phosphorylation is a rate 
limiting step in glucose metabolism in the β cell and glucokinase is generally known as the β 
cell glucose sensor (10). However, other steps in the lower glycolytic pathway are also 
important in regulating glucose metabolism (11-13; reviewed in 14). Ultimately, the resultant 
increase in cellular ATP leads to changes in the activity of the KATP and L-type voltage gated 
Ca2+ channels, influx of calcium into the cell and, subsequently, insulin secretion (15-19; Fig. 1). 
2.1 Insulin release from the islet β cell 
Glucose stimulated insulin secretion from islets of Langerhans is biphasic (20), with a rapid 
first phase and more sustained second phase. The first phase is activated by the triggering 
pathway- KATP channel closure following increased glucose influx into pancreatic β cells, as 
described above. The second phase involves the activation of amplification pathways, also 
called KATP channel independent mechanisms (18;21), whereby the increase in intracellular 
calcium concentrations following KATP channel closure leads to changes in the sensitivity of 
the secretory machinery (18;22). Protein kinase A and C (21), AMP activated protein kinase 
(AMPK; (23-27), and insulin sensitive protein kinases such as protein kinase B and p70S6 
kinase (28-33), are involved in regulating the amplifying pathways. The phosphoinositide 3 
kinases (PI3Ks) are also thought to be important in the regulation of insulin secretion and 
synthesis (34-40). The roles of some of these protein kinases will be discussed in section 3.  
2.2 Glucagon release from the islet α cell 
Glucagon is released from pancreatic α cells in response to low blood glucose concentration, 
amongst other stimuli, to maintain blood glucose levels in the fasted state (Fig. 1). Elevated 
glucose concentrations (> 3.5 mM) normally suppress the release of glucagon from 
pancreatic α cells and dysregulation of this process is a feature of both types 1 and 2 
diabetes (41;42). The lack of a counter regulatory response leads to potential danger from 
episodes of hypoglycaemia and is a limiting factor for good glycaemic management in 
diabetes (43).  
Many of the proteins that are involved in glucose sensing in the β cell, such as glucokinase 
(44), are also present in the α cell and glucose is able to raise intracellular ATP 
concentrations in the α cells (45). Both intrinsic (45;46) and extrinsic (42;47;48) mechanisms 
for the regulation of glucagon secretion have been proposed. Recent evidence suggest that 
two fuel sensitive protein kinase, PAS-domain containing protein kinase (PASK) and 
AMPK, may be involved in the regulation of glucagon release and may have a role in the 
pathophysiology of type 2 diabetes (49; see section 3.1 and 3.2).  
3. Glucose sensing and hormone production/release  
A number of protein kinases are known to play crucial roles in the regulation of islet α and β 
cell function. These protein kinases represent potential drug targets for the treatment of type 
2 diabetes, as glucose sensitivity and secretory capacity of the pancreatic islets may be 
improved (or restored) through the manipulation of the action of these proteins.  
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neurotransmitters, and hormones. β cells are electrically excitable and transduce variations in 
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3.1 AMP activated protein kinase (AMPK) 
AMPK is an evolutionarily conserved fuel-sensitive protein kinase that plays a role in 
glucose homeostasis (23-25;50-53). It is a target of the glucose-lowering drugs, metformin 
and thiazolidinediones, which act to improve insulin sensitivity in insulin-sensitive tissues 
such as muscle and liver (54). However, the long term effects of these drugs on β cell 
survival and function are less clear (53). 
AMPK is a heterotrimeric protein consisting of an α catalytic subunit (two isoforms, α1 and 
2), a β (two isoforms, β1 and 2) scaffold subunit, and a gamma (three isoforms, gamma 1, 2, 
3) regulatory subunit (55;56). It is activated by increased intracellular AMP concentrations, 
i.e. at times of fuel deprivation. Salt and colleagues (23) showed that both AMPK catalytic 
subunits are present in the clonal rat pancreatic β cell line, INS-1 (57), and that AMPK 
activity is regulated by extracellular glucose concentrations in this cell type (23). Moreover, 
they demonstrated that insulin secretion and AMPK activity were inversely related (23). 
AICA riboside (5-aminoimidazole-4-carboxamide riboside; AICAR) (23;25), an activator of 
AMPK, and metformin (58), inhibited glucose stimulated insulin secretion in both clonal β 
cell lines and primary rat islets. Similarly, overexpression of a constitutively active form of 
AMPK in clonal β cells (25) and primary islets (59) led to impaired β cell function, due in 
part to the inhibition of secretory granule transport to the cell surface (27). In contrast, 
overexpression of a dominant negative form of AMPK led to increased insulin secretion at 
non-premissive glucose concentrations (25) without affecting release at elevated glucose 
concentrations (60).  
In support of the above findings, it was recently demonstrated that transgenic mice over-
expressing constitutively active AMPK specifically in pancreatic β cells were glucose 
intolerant and displayed defective insulin secretion (26). Mice in which expression of both 
AMPK catalytic subunits was ablated selectively in pancreatic β cells displayed defective 
glucose homeostasis due to defective insulin secretion in response to hyperglycaemia in vivo 
(26). Ablation of the expression of AMPK catalytic subunits in the β cell was protective 
against the deleterious effects of exposure to a high fat diet on insulin secretion (26). 
Aside from insulin secretion, data from work in clonal cell lines indicate that AMPK may 
also be involved in the regulation of insulin gene expression in response to changing glucose 
concentrations (24;25). Thus, inhibition of the AMPK α2 catalytic subunit (24), which 
displays substantial nuclear localisation (24;57), led to increased insulin gene expression, 
while inhibition of the AMPK α1 catalytic subunit, which is predominantly cytosolic (57), 
had no effect on insulin gene expression (24). 
Recently, Leclerc and colleagues showed that AMPK activity is modulated by glucose in a 
mouse clonal α cell line, αTC1-9 cells (61). Overexpression of constitutively active AMPK in 
αTC1-9 cells and specifically in pancreatic α cells in primary mouse islets of Langerhans led 
to activation of glucagon release at inhibitory glucose concentrations (61). Activation of 
AMPK with metformin, phenformin (62) and a selective activator of AMPK, A-769662 (63-
65), in αTC1-9 cells led to increased AMPK activity and stimulated glucagon secretion at 
both permissive and non-permissive glucose concentrations (61). In contrast, overexpression 
of dominant negative AMPK and/or the AMPK inhibitor, compound C (66), inhibited 
glucagon release (61).  
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Thus, AMPK is involved in the regulation of both the release and biosynthesis of insulin in 
pancreatic β cells, and glucagon release from pancreatic α cells, in response to glucose 
challenge. Drugs that specifically inhibit AMPK activity in the pancreatic islet are likely to 
be useful in the treatment of diabetes by performing the dual role of increasing insulin 
secretion and inhibiting glucagon secretion. 
3.2 PAS domain containing protein kinase (PASK) 
Whilst homologous genes are common in prokaryotes, there is only one known mammalian 
PASK (67;68). The enzyme has one well-defined ligand-binding domain with potential for 
drug-targeting (67). We (49;69) and others (70;71) have shown that PASK is important for 
energy-sensing and maintenance of normal cellular energy balance in mammalian systems. 
Thus, PASK/Pask is expressed in human and rodent pancreatic islets of Langerhans and its 
expression is regulated by glucose (49;69;71). PASK is expressed in both α and β cells in 
human pancreatic islets (49). Importantly, PASK expression is lower in the β cells of patients 
with type 2 diabetes in comparison to β cells of non-diabetic individuals (49). Very recently, 
an activating mutation in PASK was identified which is associated with non-autoimmune 
early-onset diabetes in humans (72). However, this mutant did not fully co-segregate with 
the disease and appears to serve as a modifier for a separate disease-causing mutation in 
another gene. Thus, the mutated PASK (G1117E) has ~25 % higher activity than wild-type 
PASK and overexpression of this kinase variant led to a left-shift in the glucose response in 
mouse pancreatic islets. As a result, glucose-stimulated insulin secretion and insulin gene 
expression were increased at normally non-permissive (3 mM) glucose concentrations (72). 
Pask activity is regulated by glucose and the enzyme is involved in the regulation of 
glucose-induced preproinsulin and pancreatic duodenum homeobox-1 (PDX-1) gene 
expression in the mouse pancreatic β cell line, MIN6 (69;71). Recently, PASK was implicated 
in the regulation of lipogenic gene expression (70) and might, therefore, influence glucose 
signaling through lipid intermediates as proposed for glucose-induced insulin secretion 
(73). Pask null (Pask-/-) mice (74) have normal glucose tolerance (49;70;74) and lower plasma 
insulin content than control littermates (49;70), but increased insulin sensitivity in peripheral 
tissues (70). 
Glucose-stimulated insulin secretion from Pask-/- islets was variously shown to be not 
different (74) or lower (70) vs control islets. However, the lack of corresponding total islet 
insulin measurements in these studies made it difficult to evaluate islet secretory capacity 
(70). In our hands, Pask-/- islets were able to release insulin in response to glucose (49) but 
islet insulin content (49) and, thus, the amount of insulin released, was lower, in agreement 
with (70). Our data also indicate that the total pancreatic insulin content in Pask-/- is lower 
than control mice (49).  
Pask-/- mice, when maintained on a high fat diet (HFD), develop glucose intolerance (70). 
Furthermore, inhibition of insulin gene expression by palmitate was reversed by PASK over-
expression in MIN6 β cells (71), suggesting a role for PASK in protection against lipotoxicity. 
Thus, PASK appears to exert a protective effect in mature β cells and aberrant PASK 
expression and function may play a role in the development of diabetes.  
Our recent data (49) indicate that PASK may regulate glucagon secretion in rodent and 
human pancreatic α cells. Eight-week old Pask-/- mice displayed higher plasma glucose after 
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16 h of fasting than wild-type littermate controls, but normal glucose tolerance after 
intraperitoneal glucose injection. After fasting, plasma glucagon was higher in Pask-/- mice 
than littermate controls. This increased glucagon concentration may account for the 
increased levels of blood glucose after the 16 h fast. This is physiologically relevant as long-
term elevated plasma glucagon and glucose is a feature of type 2 diabetes (75). 
The regulation of glucagon secretion by glucose was also impaired in Pask-/- islets (49). 
Interestingly, we observed a slight inhibitory effect of glucose on glucagon secretion, 
suggesting either a cell autonomous role for PASK in the α cell and/or reflecting altered 
secretion of regulatory factors from neighbouring β cells, e.g. insulin (49). Forced changes in 
PASK content affected the regulation of glucagon secretion by glucose in αTC1-9 cells (a 
mouse clonal α cell line) and human islets (49). RNAi-mediated silencing of Pask expression 
in αTC1-9 cells led to constitutive release of glucagon (49), while over-expression of PASK in 
αTC1-9 cells or in human islets led to inhibition of glucagon secretion, suggesting that PASK 
may be involved in glucose-sensing in pancreatic α cells (49). Inhibition of glucagon 
secretion by insulin was not affected in Pask silenced αTC1-9 cells indicating that the insulin 
signalling pathway was intact (49). Interestingly, there was still an apparent effect of glucose 
on glucagon secretion in human islets over-expressing PASK, possibly due to insulin release 
from β cells. Thus, the dysregulation of glucagon secretion in Pask-/- islets may be due, in 
part, to the decrease in insulin secretion.  
To identify the mechanism(s) through which PASK may regulate glucagon secretion, we 
measured the expression of a number of potential target genes in Pask-/- islets (49) and αTC1-
9 cells (49). The expression of both the insulin and Pdx-1 genes was impaired in Pask-/- islets 
(49;69;71). Thus, the decrease in insulin release may be due to decreased insulin synthesis 
and/or islet number in Pask-/- pancreata (49). Preproglucagon gene expression was 
increased, although total glucagon protein content was unaltered (49), consistent with the 
relatively slow turnover of mature glucagon. AMPKα2, but not AMPKα1, gene expression 
was increased by loss of Pask expression (49). This is an interesting observation since AMPK 
activity is glucose-responsive in pancreatic α and β cells (24;61) and regulates insulin (25;27) 
and glucagon (61) release.  
Interestingly, we also observed that E13.5 rat pancreatic epithelial explants (76) in which 
PASK gene expression was silenced also display similar gene expression changes following 
culture to allow the development of endocrine cells (49) indicating that loss of PASK gene 
expression may have effects on pancreatic development that lead to the dysregulation of 
glucagon release. These data, and those from pancreatic β cells (69;71;72), suggest that 
changes in PASK activity may be important for appropriate glucose signalling in both α and 
β cells.  
3.3 Protein kinase A (PKA) 
Glucose administered via the gastointestinal tract leads to a greater induction of glucose-
stimulated insulin secretion than a comparable intravenous adminstration of glucose (77;78) 
due to stimulation of the release of the incretin hormones, glucagon-like peptide 1 (GLP-1) 
and gastric inhibitory peptide (GIP), from intestinal L- and K-cells respectively (79;80). 
Potentiation of glucose stimulated insulin secretion only occurs at permissive glucose 
concentrations (81), making the use of incretins attractive in the treatment of diabetes (80). 
Both hormones potentiate glucose stimulated insulin secretion (82) via binding to their 
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cognate G-protein coupled receptors on pancreatic β cells, activating adenylyl cyclase and 
thereby increasing cytosolic cyclic AMP (cAMP) levels (83-85). cAMP regulates insulin 
secretion, in part, by inducing the phosphorylation of proteins involved in the secretory 
process by PKA (86-88). For example, there is evidence that PKA activation is involved in 
controlling vesicle exocytosis by regulating Munc 13-1 function (89;90). 
3.4 Protein Kinase C (PKC) 
There is evidence both for and against the involvement of PKC in stimulus secretion 
coupling in the β cell (reviewed in (91;92). Early studies using pharmacological modulation 
of PKC activity in β cells gave contradictory results (91;92). Conventional PKCs are recruited 
to the plasma membrane by calcium-dependent binding of the C2 domain to the 
phospholipids, which is potentiated by the binding of diacyglycerol to the C1 domains (93). 
Conventional, novel and atypical PKCs are found in pancreatic islet cells (94-97), and PKC 
activity is present in primary pancreatic islets (98) and clonal β cell lines (99;100). It was 
proposed that the increase in cytosolic calcium concentrations, following exposure of 
pancreatic β cells to high glucose concentrations, leads to increased diacyglycerol (DAG) 
production which leads to the activation of PKC, and the translocation of PKC to the plasma 
membrane leading to potentiation of insulin release (92;101). DAG is produced by activated 
phospholipase C (PLC) from phosphatidyl-4,5-bisphosphate, and PLC activity in pancreatic 
β cells has been shown to occur in a dose-dependent manner in parallel to physiologically 
relevant increases in glucose that lead to insulin secretion (102-104).  
The use of PKC isoform and green fluorescent protein chimeras, coupled with the use of 
total internal reflection fluorescence (TIRF) microscopy, demonstrated that elevated glucose 
concentrations led to complex oscillatory translocation of the conventional PKC, PKCβ2, to 
the plasma membrane, in primary β cells and clonal β cell lines, in response to the formation 
of calcium microdomains following transient depolarisation of the plasma membrane (101). 
Moreover, PKCβ2 was shown to migrate to the surface of secretory vesicles, suggesting that 
the process of vesicle fusion may be regulated locally (101) by this kinase.  
3.5 Phosphoinositide 3 Kinases (PI3Ks) 
The autocrine feedback action of insulin on pancreatic β cell function is a subject of much 
debate. β cells secrete insulin at basal glucose concentrations and increase the level of 
secretion in response to a glucose challenge. Thus, much of the discussion has been on 
whether the insulin signalling pathway in β cells is desensitised as these cells are constantly 
exposed to the hormone. Recent studies, using approaches that circumvent some of the 
confounding factors in earlier studies, have provided evidence that insulin acts as a positive 
regulator of its own secretion and synthesis in pancreatic β cells, and of β cell mass and 
survival (30;32;34-36;38;39;105-130). Activation of the insulin and insulin-like growth factor 1 
(IGF-1) receptor (IGF-1R), through insulin and/or IGF-1 binding to these receptors, leads to 
activation of downstream signalling cascades including, those involving the PI3Ks 
(35;36;110;111;116;126;130), resulting in the moderation of β cell function. There are three 
classes of mammalian PI3Ks, class I-III (131). Class Ia and II PI3Ks have been reported to be 
activated by insulin and will be reviewed in the following subsections. The class I PI3Ks 
generate phosphatidyl 3,4,5-trisphosphate (132), while the class II PI3Ks generate 
phosphatidyl 3-phosphate (PI3P) in vivo (133;134), both of which interact with distinct 
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classes of mammalian PI3Ks, class I-III (131). Class Ia and II PI3Ks have been reported to be 
activated by insulin and will be reviewed in the following subsections. The class I PI3Ks 
generate phosphatidyl 3,4,5-trisphosphate (132), while the class II PI3Ks generate 
phosphatidyl 3-phosphate (PI3P) in vivo (133;134), both of which interact with distinct 
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molecules. Therefore, the activation of class I and II PI3Ks result in the activation of distinct 
signaling cascades. 
3.5.1 PI3Ks and insulin gene expression 
There is evidence in the literature suggesting that insulin regulates the expression of its own 
gene via activation of Class Ia PI3K (PI3K-1a) (35;36). Of a number of transcription factors 
that regulate the expression of the insulin gene, the action of the transcription factors 
pancreatic duodenal homeobox-1 (PDX-1) (110;135-141) and FoxO-1 (142) are thought to be 
regulated by insulin in a PI3K-1a dependent manner. 
Insulin gene expression is upregulated in response to increasing glucose concentrations in a 
PI3K-1a-dependent manner (30;35;36;110). The increase in insulin gene expression in 
response to elevated glucose concentrations is due, at least in part, to the the activation of 
PI3K-1a by secreted insulin (35;36;107;143;144). Thus, PDX-1 translocates from the cytosol to 
the nucleus in response to an increase in circulating glucose concentrations (110;144;145) and 
binds to a region upstream of the insulin gene called the A3 box (139). This binding is 
upregulated as glucose concentrations are increased in the near physiological range 
(140;141), and in response to insulin (146), to activate insulin gene expression. The 
expression of the PDX-1 gene itself is regulated by insulin (147), further implicating insulin 
and PI3K-1a in the feed-forward regulation of insulin gene expression.  
Activation of PI3K-1a by insulin also leads to enhanced expressionof glucose/insulin-
responsive genes through the removal of transcriptional repressors. For example, the 
transcription factor, FoxO1, is phosphorylated at Ser-256 in response to activation of PI3Ks 
and PKB by insulin (142;148), translocates from the nucleus to the cytosol (149;150) and is 
degraded (151). The degradation of FoxO1 leads to enhanced expression of glucose/insulin-
responsive genes (152) such as the L-type pyruvate kinase (36), insulin 2 (Ins2) and Pdx-1 
genes in pancreatic β cells (142).  
3.5.2 PI3Ks and insulin secretion 
Data is available in the published literature suggesting that insulin has an inhibitory, 
activatory or no role in the regulation of its own secretion (153-160). Whilst most studies 
have focussed on the action of the class I PI3Ks on insulin secretion, recent data implicated 
the class II PI3K, PI3K-C2α, in the regulation of insulin secretion (126;130).  
PI3K-C2α gene expression was shown to be down-regulated in islets of Langerhans of 
patients with type 2 diabetes (130). Leibiger and colleagues showed that PI3K-C2α is able 
to enhance glucose-stimulated insulin release in a feed-forward (126) mechanism, in 
response to stimuli from insulin itself, via the activation of PKB by PI3P. Subsequently, it 
was shown that PI3K-C2α may have a role in the late stages of insulin granule release 
through its action on the synaptosomal-associated protein of 25 kDA (SNAP25), which is 
independent of nutrient control (130). Insulin granules dock at the plasma mebrane via 
the interaction of SNAP25 within a protein complex (161-163), with granule fusion and 
insulin release occuring post proteolysis of SNAP25 (164). PI3K-C2α was shown to 
regulate the degradation rate of SNAP2, thereby controlling insulin granule fusion with 
the plasma membrane (130). 
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3.6 Homeodomain interacting protein kinase 2 (HIPK2) 
Homeodomain interacting protein kinase 2 (HIPK2) belongs to the family of homeodomain 
interacting protein kinases, which was originally identified as binding partners of the 
homeodomain protein neurokinin-3 (NK-3) (165). Studies have shown that members of the 
HIPK family interact with, phosphorylate and modulate the function of other homeodomain 
containing proteins and transcription factors (166-170), indicating that the HIPKs may have 
an important role in the control of transcription. Recently it was shown that HIPK2 is 
expressed in the developing pancreatic epithelium from E12 to E15 and that its expression is 
confined preferentially to pancreatic endocrine cells later in development (171). 
Phosphorylation of the transcription factor, PDX-1, in the C-terminus by HIPK2, possibly at 
Ser-214 (172), was reported to increase the stability and transcriptional activity of PDX-1 
(171). Our own data indicate that HIPK2 posphorylates PDX-1 at Ser-269 in the C-terminal 
portion of PDX-1 in pancreatic β cells in vivo and that phosphorylation at this site leads to 
nuclear exclusion of PDX-1 and a decrease in PDX-1 target gene expression (172). As PDX-1 
has been shown to directly bind to and regulate the promoter activity of various β cell 
genes, e.g. insulin (110;135;140;144-146), glucose transporter 2 (GLUT2;173), glucokinase 
(GCK)(174;175), and islet amyloid polypeptide (176;177), HIPK2 represents an important 
regulator of β cell gene expression during development and in adult β cells. 
4. β cell survival, growth and proliferation 
Maintenance of an adequate functional β cell mass is a potential therapeutic target for 
diabetes. In this section we will look at the evidence that indicate protein kinases such as 
AMPK, Serine/threonine protein kinase 11 (STK11/LKB1), mammalian target of rapamycin 
(mTOR), and protein kinases in the Wnt signalling pathway may be involved in the 
regulation of β cell proliferation. 
4.1 AMPK and LKB1 
In section 3.1, we discussed the role of AMPK in the regulation of pancreatic β cell function. 
Recent data indicate that AMPK may also have a role in the maintenance of adequate β cell 
mass. Activation of AMPK has been shown to lead to decreased β cell viability (178;179), 
potentially through its action on the cell cycle regulator, p53 (180). Mice in which the 
expression of both AMPK catalytic subunits was ablated selectively in pancreatic β cells 
have normal β cell mass but smaller β cells and pancreatic islets (26). Islets of Langerhans in 
which the expression of both AMPK catalytic subunits was ablated did not display apparent 
differences in the ratio of α to β cells or in islet architecture. β cell proliferation was 
enhanced in islets from mice in which the expression of both AMPK catalytic subunits was 
ablated selectively in pancreatic β cells (26). In contrast, islets of Langerhans from mice in 
which the expression of an AMPK upstream kinase liver kinase B1 (LKB1) was ablated, had 
increased islet and β cell size (181) and altered islet architecture (181-184). Thus, the number 
of large islets, which may account for as much as 50 % of the total pancreatic β cell mass in 
normal pancreata (185), was increased in pancreata from mice in which LKB1 expression 
was selectively ablated in the β cell (181). These data indicate that AMPK and LKB1 play 
distinct roles in the control of islet development and cell proliferation and may impact on 
the development of pharmacological reagents targetting these pathways for the treatment of 
diabetes. In particular, inhibition of LKB1, or its downstream targets, may be a means by 
which β cell mass may be increased for the treatment of diabetes. 
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molecules. Therefore, the activation of class I and II PI3Ks result in the activation of distinct 
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response to stimuli from insulin itself, via the activation of PKB by PI3P. Subsequently, it 
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interacting protein kinases, which was originally identified as binding partners of the 
homeodomain protein neurokinin-3 (NK-3) (165). Studies have shown that members of the 
HIPK family interact with, phosphorylate and modulate the function of other homeodomain 
containing proteins and transcription factors (166-170), indicating that the HIPKs may have 
an important role in the control of transcription. Recently it was shown that HIPK2 is 
expressed in the developing pancreatic epithelium from E12 to E15 and that its expression is 
confined preferentially to pancreatic endocrine cells later in development (171). 
Phosphorylation of the transcription factor, PDX-1, in the C-terminus by HIPK2, possibly at 
Ser-214 (172), was reported to increase the stability and transcriptional activity of PDX-1 
(171). Our own data indicate that HIPK2 posphorylates PDX-1 at Ser-269 in the C-terminal 
portion of PDX-1 in pancreatic β cells in vivo and that phosphorylation at this site leads to 
nuclear exclusion of PDX-1 and a decrease in PDX-1 target gene expression (172). As PDX-1 
has been shown to directly bind to and regulate the promoter activity of various β cell 
genes, e.g. insulin (110;135;140;144-146), glucose transporter 2 (GLUT2;173), glucokinase 
(GCK)(174;175), and islet amyloid polypeptide (176;177), HIPK2 represents an important 
regulator of β cell gene expression during development and in adult β cells. 
4. β cell survival, growth and proliferation 
Maintenance of an adequate functional β cell mass is a potential therapeutic target for 
diabetes. In this section we will look at the evidence that indicate protein kinases such as 
AMPK, Serine/threonine protein kinase 11 (STK11/LKB1), mammalian target of rapamycin 
(mTOR), and protein kinases in the Wnt signalling pathway may be involved in the 
regulation of β cell proliferation. 
4.1 AMPK and LKB1 
In section 3.1, we discussed the role of AMPK in the regulation of pancreatic β cell function. 
Recent data indicate that AMPK may also have a role in the maintenance of adequate β cell 
mass. Activation of AMPK has been shown to lead to decreased β cell viability (178;179), 
potentially through its action on the cell cycle regulator, p53 (180). Mice in which the 
expression of both AMPK catalytic subunits was ablated selectively in pancreatic β cells 
have normal β cell mass but smaller β cells and pancreatic islets (26). Islets of Langerhans in 
which the expression of both AMPK catalytic subunits was ablated did not display apparent 
differences in the ratio of α to β cells or in islet architecture. β cell proliferation was 
enhanced in islets from mice in which the expression of both AMPK catalytic subunits was 
ablated selectively in pancreatic β cells (26). In contrast, islets of Langerhans from mice in 
which the expression of an AMPK upstream kinase liver kinase B1 (LKB1) was ablated, had 
increased islet and β cell size (181) and altered islet architecture (181-184). Thus, the number 
of large islets, which may account for as much as 50 % of the total pancreatic β cell mass in 
normal pancreata (185), was increased in pancreata from mice in which LKB1 expression 
was selectively ablated in the β cell (181). These data indicate that AMPK and LKB1 play 
distinct roles in the control of islet development and cell proliferation and may impact on 
the development of pharmacological reagents targetting these pathways for the treatment of 
diabetes. In particular, inhibition of LKB1, or its downstream targets, may be a means by 
which β cell mass may be increased for the treatment of diabetes. 
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4.2 mTOR 
Activation of the PI3K-PKB pathway by growth factors such as insulin and IGF-1, and 
subsequent activation of mammalian target of rapamycin (mTOR), is involved in β cell 
compensation in animals with genetic or high-fat diet induced insulin resistance (122;186). 
mTOR is an important nutrient sensor that plays a central role in the regulation of cellular 
metabolism, growth, proliferation and apoptosis (187-190). Signalling by (mTOR) to 
eukaryotic initiation factor 4-binding protein-1 (4E-BP1) and ribosomal S6 kinase (S6K) was 
enhanced in islets of Langerhans from mice in which LKB1 expression was specifically 
ablated in the β cell (181). Likewise, there is evidence for crosstalk between mTOR and 
AMPK as a regulatory pathway that couples cellular fuel availability to β cell apoptosis 
(58;59;191). S6K1 knockout mice are glucose intolerant, despite increased insulin sensitivity, 
which is associated with depletion of pancreatic insulin content, hypoinsulinaemia and 
reduced β cell mass (192;193), indicating that S6K1 is required for β cell growth and 
function. In addition, crosstalk between the mTOR and JNK pathways (194) is thought to 
regulate β cell survival through action on FoxO1 (195;196), whereby activation of FoxO1 in β 
cells protects the cells from oxidative stress by reducing cellular metabolic activity and 
energy-consuming processes, e.g. proliferation, and cell-specific function, e.g. insulin 
secretion (195;196). 
4.3 Wnt signalling 
The Wnt proteins are a family of cysteine-rich glycoproteins involved in intracellular 
signalling during vertebrate development. Activation of Wnt signalling leads to the 
expression of genes that are involved in promoting stem cell fate and inhibiting cell 
differentiation (197). One of the prominent biological phenomena controlled by Wnt 
signaling is the expansion of cells with predefined fates (198;199). It has previously been 
shown to be involved in the regulation of pancreatic development at all stages during 
organogenesis from specification to maintenance of normal function (200-206;206-211). Thus, 
tight temporal regulation of the Wnt signalling pathway is required for normal 
development.  
Activation of the Wnt signalling pathway was shown to upregulate β cell proliferation in 
mouse islets (208;212;213) with upregulation of cell cycle genes that have been shown to 
regulate β cell proliferation (214) such as cyclin D1 and D2, and cyclin-dependent kinase 4 
(CDK4) (208;213). The Wnt signalling pathway was also shown to be involved in the 
neogenesis of human β cells in vitro (215).  
It was recently demonstrated that the incretin, GLP-1, induced β cell proliferation via 
activation of the Wnt signaling pathway (216). GLP-1 has previously been shown to increase 
β cell proliferation and survival (217-219). Liu and colleagues showed that Wnt signaling 
can be activated by downstream events from GLP-1 receptor activation in a Protein kinase B 
(PKB) and PKA-dependent manner (216).  
5. Prospects for the development of treatment  
Type 2 diabetes is fast becoming a major global problem and understanding the signalling 
molecules that regulate the maintenance of glucose homeostasis, particularly those that 
regulate pancreatic islet function, could lead to better therapeutic intervention for the 
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disease. Increasing functional β cell mass is a particularly promising strategy: although islet 
transplantation is an effective means to restore glucose homeostasis, the lack of 
transplantable material makes this a non-viable treatment module for the masses. Thus, 
strategies that can lead to the generation and proliferation of β cells in vivo and/or in vitro 
may be important for the treatment of the disease. 
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1. Introduction 
The Raf protein kinases are members of the mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway, which links the 
activation of cell surface receptors to intracellular cytoplasmic and nuclear molecular 
targets. Raf kinases relay signals from growth factor receptor-coupled GTPases of the Ras 
family to the MAPK/ERK kinase (MEK). This pathway is very important in developmental 
processes, cell survival and proliferation (Zebisch & Troppmair, 2006). Three different Raf 
isoenzymes exist in mammals: C-Raf, B-Raf and A-Raf. They originate from 3 independent 
genes (for review, see Matallanas et al., 2011). The Raf genes are protooncogenes; they are 
the cellular counterparts of the v-Raf oncogene, originally discovered in murine sarcoma cell 
lines (Rapp et al. 1988). The Raf genes are ubiquitously present in different tissues, showing 
a relatively segregated expression pattern: B-Raf gene is expressed mainly in the brain and 
testes, C-Raf gene is ubiquitous, although the degree of expression is uneven, A-Raf gene is 
expressed in gonads, kidney, spleen and bone mainly, as detected in mice (Storm et al., 1990). 
Accordingly, the Raf proteins are present in three isoforms: the A-Raf, B-Raf and C-Raf are 
protein kinase isozymes, showing similar molecular structure (Zebisch & Troppmair, 2006). 
The Raf proteins consist of three conserved regions (CR1, CR2, CR3), which display different 
functions: CR1 contains the Ras-binding region, which is responsible for the interaction with 
Ras and membrane phopholipids; CR2 contains phosphorylation site and CR3 is the kinase 
region of the molecule (Heidecker et al., 1991; Zebisch and Troppmair, 2006). The inactive Raf 
molecule is in a closed conformation: the N-terminal and C-terminal regions are above each 
other (Matallanas et al., 2011). When this molecule opens, activation and dimerization can 
happen (Heidecker et al., 1991; Matallanas et al., 2011; Zebisch & Troppmair, 2006). 
Activation-inactivation are regulated by phosphorylation-dephosphorylation of the molecule 
(Matallanas et al., 2011). Activation also needs the recruitment of Raf to the cell membrane 
(Leevers et al., 1994). Many details of the Raf kinase activation steps have been described in 
the last twenty years (for review, see Matallanas et al., 2011). The regulation of Raf signaling 
by intracellular proteins is complicated: (1) because of the membrane recruitment of Raf 
during activation, scaffolding proteins exert regulatory role on the Ras-Raf-MEK pathway 
(Matallanas et al., 2011). (2) Recently discovered Raf kinase inhibitor protein (RKIP) 
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negatively modulates Raf kinase, being important mainly in cancer cells (Klysik et al., 2008; 
Matallanas et al., 2011). Over the years, B-Raf has been increasingly associated with cancer 
development (Niault & Baccarini, 2010). Mutations of B-Raf proved to be important in 
malignant melanoma, thyroid carcinomas and colorectal tumors (Niault & Baccarini, 2010). 
This underlines the utmost importance of B-Raf in mitogenic signal transduction. 
Experimental data suggest, that Raf kinases are activated by growth factor- and cytokine 
receptors. Platelet-derived growth factor (PDGF; Morrison et al., 1989), epidermal growth 
factor (EGF; App et al., 1991), nerve growth factor (NGF; Oshima et al., 1991), insulin 
(Blackshear et al., 1990), interleukins (Carrol et al., 1990), neuronal angiotensin receptor 
(Yang et al., 1997) and vascular endothelial growth factor (VEGF; Lu et al., 2011) act through 
the Raf-MEK signaling pathway. Raf mediated signals are able to move in the cytoplasm; 
the Golgi-apparatus, the mitochondria and the cell nucleus are targets of Raf-mediated 
phosphorylation signals (Matallanas et al., 2011; Zebisch & Troppmair, 2006). The question 
arises, if these organelles contain Raf kinase, or Raf kinase translocates to them during the 
signalling process (Mor & Philips, 2006). 
Immunohistochemical studies have revealed that B-raf and C-Raf are widely distributed in 
central nervous system (CNS) areas including the hippocampus, neocortex and spinal cord 
(Mihály et al. 1991, 1993; Mihály & Rapp 1993). They are present not only in neurons but 
also in astrocytes (Mihály & Rapp 1994). Although most CNS neurons express Raf 
immunoreactivity, the possibility remains that Raf expression varies according to the type of 
growth factor receptor that a neuron expresses (Mihály & Endrész, 2000). Our 
ultrastructural immunohistochemical studies proved that Raf protein-like immunoreactivity 
was localized primarily in postsynaptic densities, dendritic spines, dendrites and soma of 
the neurons (Mihály et al., 1991). On the basis of these observations the possibility arose, 
that Raf kinases participated in some receptor-mediated postsynaptic phenomena which 
might initiate long-term changes in postsynaptic neurons (Mihály et al., 1990). The present 
review collects the relevant localization data of Raf protein kinases in CNS structures. The 
localization of the Raf proteins will be discussed in light of some plasticity experiments 
(Mihály et al., 1990; 1991; 1996).  
2. Detection of Raf protein kinases in the brain with Western blotting 
The first literature data about the presence of Raf protein kinase in the mammalian brain are 
those of Mihály et al. (1991). In these studies we used the polyclonal v-Raf antiserum which 
was produced in the laboratory of Dr. Ulf Rapp. The serum was raised in rabbit, against a 
large (30 kDa) C-terminal Raf protein, expressed in E. coli, by inserting the v-Raf oncogene 
into the bacterial DNA (Kolch et al., 1988). Adult Wistar rats were deeply anesthetized with 
halothane, decapitated and the brains were homogenized, lysed and immunprecipitated. 
The precipitates were subjected to gel electrophoresis, then proteins were transferred to 
nitrocellulose membranes and incubated with the polyclonal v-Raf antiserum (Mihály et al., 
1991). One conspicuous 95 kDa protein band was detected with this method (Mihály et al., 
1991). The same antibody was used on isolated subcellular fractions of the rat brain, where 
the cytosolic- and microsome fractions displayed positive signals, again at 95 kDa (Mihály et 
al., 1996). Efforts aiming the detection of C-Raf and B-Raf separately, were also successful 
(Morice et al., 1999): Western blotting revealed the presence of C-Raf and B-Raf proteins in 
different areas of the rat brain (Morice et al., 1999). Immunoblotting of guinea pig brain 
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homogenates also resulted in positive signals at 95 kDa with the aforementioned polyclonal 
anti-v-Raf serum (Mihály & Endrész, 2000). Several years later, using specific, polyclonal B-
raf antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), we detected the 95 kDa 
protein again in rat brain homogenates (Mihály et al., 2007). Therefore, we conclude, that 
brain B-Raf kinase is ubiquitous and detectable through Western blotting in the rodent 
brain, as a 95 kDa protein (Fig. 1). 
 
Fig. 1. Rat brain Western blots made with v-Raf-specific (a) and B-raf-specific (b) polyclonal 
antibodies. Molecular weight markers are on the left side (Mr, kDa; M). Fig. 1a: lane 1 
represents the cytosolic fraction, lane 2 the microsome fraction (Mihály et al., 1996). Fig. 1b: 
„Ctx” represents the signal obtained from brain cortex homogenate; „Bst” represents the 
signal obtained from brain stem homogentes (Mihály et al., 2007). The two antibodies detect 
one 95 kDa protein, indicating the presence of B-raf kinase in the rat brain. 
3. Light microscopic localization of Raf proteins in the central nervous 
system (CNS) 
Light microscopic immunohistochemistry of brain areas from laboratory rats, laboratory 
guinea pigs and domestic cats have been performed with help of the polyclonal v-Raf 
antibodies (Mihály et al., 1991), polyclonal B-raf antibodies (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), monoclonal B-Raf antibodies (produced against the last 12 amino 
acids of the C-terminal region of B-Raf) and polyclonal C-Raf antibodies (anti-SP 63 serum). 
The polyclonal anti-v-Raf-, anti-SP 63- and monoclonal anti-B-Raf antibodies were prepared 
in the laboratories of Dr. Ulf Rapp (National Cancer Institute, Frederick Cancer Research 
and Development Center, Frederick, MD, USA; see descriptions of the antibodies in Mihály 
et al., 1993; 1996). Two human hippocampi were investigated, too. The human brain samples 
were obtained from autopsy in the Department of Pathology, Szeged University. The 
autopsy was performed 16 h after death. The hippocampal tissue was kept in fixative 
solution (4% paraformaldehyde in 0.1 M phosphate buffer) for 12 days, then transverse 
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guinea pigs and cats were deeply anesthetized and perfused through the heart with fixative 
solution (4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4). The brains were 
sectioned with freezing microtome, cryostat and vibratome. The tissue sections were 
immunostained as glass-mounted- or free-floating sections. Immunofluorescence was 
performed on cryostat sections, mounted on glass slides. The slides were incubated with 
primary antibodies (anti-Raf serum), then with secondary antibodies conjugated with 
fluorescein isothiocyanate (FITC). In peroxidase-based techniques, free-floating sections 
were used, incubated with the primary antibody, then treated according to the avidin-biotin 
method, using the Vectastain ABC kits (Vector, Burlingame, CA, USA). Independent from 
the antibody and method used, the staining pattern of the different brain areas was 
consistent, showing neuronal and glial localization of Raf kinases. The differences between 
B-Raf and C-Raf localizations are indicated in the text. No differences were detected in the 
staining pattern comparing the different species (rat, cat, guinea pig, human). The 
descriptions below refer to the results obtained with polyclonal v-Raf antibodies, if not 
indicated otherwise. Staining obtained with v-Raf antibodies will be referred to as B-Raf-like 
staining, staining with anti-SP 63 will be described as C-Raf-like immunoreactivity. Controls 
of the immunohistochemical procedure included absorption controls performed with the 
recombinant v-Raf protein and the SP 63 peptide. One mg of the protein and 10 mg of the 
peptide were reconstituted in 1 ml of deionized water, mixed with the undiluted antibody 
(0.01 ml), and kept at room temperature overnight with slow agitation. The mixture was 
diluted to working concentration (1:500), centrifuged at 70,000xg for 20 min, and used for 
the immunohistochemical procedure (Mihály et al., 1993). No immunostaining was seen 
after the procedure (Mihály et al., 1993). Other controls included incubations without the 
primary anti-Raf sera: in these experiments the primary antibody was omitted, and the 
sections were incubated in normal horse serum, diluted to 1:100, and secondary antibodies 
as usual. In these sections, no specific immunostaining was detected (Fig. 6e). 
3.1 Localization of B-Raf in the spinal cord and brain stem 
Neuronal and glial localization of Raf-protein-like immunoreactivity (RPI) was encountered 
in the spinal cord of the laboratory rat and guinea pig (Mihály & Rapp, 1993; 1994). Neurons 
in laminae I, V, VI and IX displayed strong cytoplasmic staining. Glial cells in the white 
matter and grey substance were stained, too (Fig. 7). Axonal staining (e.g.: in the dorsal 
horn, where afferent axons terminate in large numbers) was not observed (Mihály et al., 
1996). Different levels of the brain stem displayed similar staining pattern: cytoplasmic 
staining in large- and medium-sized nerve cells. The motor neurons of the cranial nerve 
nuclei were strongly stained. Scattered RPI was detected in sensory nuclei, such as the 
superior and medial vestibular nuclei and the ventral cochlear nucleus. The raphe nuclei of 
the pons and medulla also contained RPI (Mihály & Endrész, 2000; Mihály et al., 2007). 
Large neurons of the reticular formation and the inferior olive were containing strong RPI 
(Fig. 3). The neurons of the mesencephalic trigeminal nucleus were strongly stained (Mihály 
et al., 2007). On the other hand, the spinal trigeminal nucleus displayed only faint staining 
(except lamina I neurons, which were strongly stained; Mihály et al., 2007). The red nucleus 
displayed strong staining, whilst the substantia nigra cells contained less RPI (Fig. 3). The 
immunostaining was always localized in cell bodies, no axonal staining was observed in any 
of the brain stem areas. Detailed examination of the brain stem of the rat and the guinea pig 
did not reveal any species differences (Mihály & Endrész, 2000; Mihály et al., 2007). 
Raf Serine/Threonine Protein Kinases:  




Fig. 2. B-Raf immunoreactivity in the spinal cord of the rat. The RPI is localized in cell 
bodies and proximal dendrites. No axonal staining is visible. Bar: 0.5 mm. Rexed laminae 
are indicated with roman numerals (a). Strong staing of lamina I neurons in the dorsal horn 
is conspicuous. Bar: 10 μm (b). Large motor neurons of lamina IX are labelled strongly, too. 
Bar: 10 μm (c). Immunolabeling was obtained with polyclonal anti-v-Raf serum.  
3.2 Localization of B-Raf and C-Raf proteins in the cerebellum 
The C-Raf and B-Raf proteins were detected in the vermis of the guinea pig cerebellum, 
using polyclonal anti-SP 63 (anti-C-Raf), and polyclonal anti-v-Raf (Mihály et al., 1993) 
antibodies. The B-Raf-like staining was very strong in neuronal cell bodies and glia-like 
cells. The staining was localized in neuronal cell bodies and dendrites. Dendritic staining 
was conspicuous in Purkinje cells, mainly in primary and secondary, large dendrites. Cell 
bodies of Purkinje cells were stained, too. Strong RPI was seen in the granular layer, where 
cell bodies of the granule cells and Golgi cells were immunoreactive. Small groups of glia 
cells stained in the white matter, and strong RPI was detected in the neurons of the fastigial 
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Fig. 3. Representative cross sections of the rat brain stem (Swanson, 1992), showing the 
cellular distrubution of Raf-protein-like immunoreactivity. Large dots represent strongly 
stained neurons, small dots represent medium or faint staining. Triangles represent large 
nerve cells with outstanding RPI. The upper mesencephalon (a), the upper pons (b), the 
lower pons (c) and the lower medulla (d) are represented (Mihály et al., 2007). 
Abbreviations: 5: mesencephalic nucleus of trigeminal nerve; m5: motor nucleus of 
trigeminal nerve; s5: principal sensory nucleus of trigeminal nerve; r5: radix of trigeminal 
nerve; s5po: spinal trigeminal nucleus pars oralis; s5pc: spinal trigeminal nucelus pars 
caudalis; ts5: spinal trigeminal tract; 6: abducens nucleus; 7: facial motor nucleus; g: genu of 
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The C-Raf staining was pale, displaying Purkinje cells and their large (primary and 
secondary) dendrites. Other neuronal elements (e.g.: granule cells, basket cells, Golgi cells) 
did not stain. C-Raf-like staining was seen in the nerve cells of the fastigial nucleus, and 
faint labeling was detected in some glia-like cells in white matter (Fig. 5). 
3.3 Localization of B-Raf and C-Raf proteins in the cerebral cortex 
RPI has been detected with polyclonal anti-v-Raf antibody and polyclonal anti-SP 63 
antiserum. The latter is specific for C-Raf (Schultz et al., 1985; 1988; Morice et al., 1999). The 
RPI was detected in the neocortex (Fig. 6), cingular, pyriform, perirhinal, entorhinal areas 
and in the hippocampus (Mihály et al., 1993). RPI was localized in neurons and glia-like 
cells. No attempt was made to identify the cell types with double immunostainings. 
However, on the basis of the shape of the RPI-containing cells, we state that pyramidal and 
non-pyramidal cells of the Ammon’s horn, granule cells of the dentate fascia and multipolar 
cells of the hilum of the dentate fascia were strongly stained (Mihály et al., 1993). Similar 
localizations were detected with the two antibodies, although C-Raf-like staining was faint 
compared to the B-Raf-like immunoreactivity. The intensity differences of the staining 
obtained with serial dilutions of the antibodies indicated that the cytoplasmic concentration 
of B-Raf kinase was much higher than that of the C-Raf in every region of the cerebral 
cortex. Detailed analysis of C-Raf-like staining and localization was not performed (Mihály 
et al., 1993). The brains of three domestic cats were also studied, using vibratome sections of 
the motor neocortex (sigmoid gyrus). Similarly to rats and guinea pigs, RPI has been 
detected in neuronal and glial cells bodies. Layer V pyramidal cells were stained in their cell 
bodies and proximal, large dendrites (Fig. 6). Scattered, small, glia-like cells were labeled, 
too. The human hippocampus displayed faint immunostaining with the B-Raf antiserum. 
Neuronal cell bodies were stained, which were similar to pyramidal cells, located in the 
stratum pyramidale of CA1 (Fig. 6). 
3.4 Localization of Raf proteins in glia cells 
B-Raf immunostaining was observed in small, glia-like cells, measuring 8-12 μm, in the 
cerebral cortex (gray and white matter), cerebellum (mentioned above), brain stem and 
spinal cord. Glial cells in the grey substance and in the whitte matter were regularly seen 
(Fig. 4; Fig. 7). Marginal astrocytes contained RPI in the spinal cord. Radial glia processes 
were stained in the cerebellar cortex (Fig. 4). No double immunolabelling was attempted in 
order to identify the cells. RPI was localized in the cytoplasm of the cell body and the 
processes (Fig. 7). No systematic study was made for the exploration of RPI in other glial cell 
types (oligodendroglia, microglia). 
4. Electron microscopic localization of RPI in neurons 
Ultrastructural immunohistochemistry was performed on vibratome sections of rat and cat 
cerebral cortex, using peroxidase-based preembedding methods (Mihály et al., 1991; Mihály 
& Rapp, 1994). These reports were the first in the literature, describing the electron 
microscopic localization of Raf kinases in the brain (Mihály et al., 1991; Mihály & Rapp, 
1994). Comparison of the Raf kinase localization in a rodent and a carnivore, did not reveal 






Fig. 3. Representative cross sections of the rat brain stem (Swanson, 1992), showing the 
cellular distrubution of Raf-protein-like immunoreactivity. Large dots represent strongly 
stained neurons, small dots represent medium or faint staining. Triangles represent large 
nerve cells with outstanding RPI. The upper mesencephalon (a), the upper pons (b), the 
lower pons (c) and the lower medulla (d) are represented (Mihály et al., 2007). 
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Fig. 4. Cerebellar immunostaining with polyclonal v-Raf serum in the guinea pig. Fig. 4a: 
Immunostaining depicts the layers of the cerebellar cortex: (1) white matter; (2) granular layer; (3) 
molecular layer; arrowheads: Purkinje cell layer; bar: 0.5 mm. Fig. 4b: the Purkinje cell RPI was 
detected not only in cell bodies, but also in dendrites (Fig. 4g). Arrowheads: radial glia processes; 
arrows: small neurons in the molecular layer (mol). Bar: 50 μm in Fig. 4b; 5 μm in Fig. 4g. The RPI 
in granule cells (Fig. 4c), Golgi cells (Fig. 4d), Purkinje cells (Fig. 4e) and outer stellate cells (Fig. 
4f) are pointed by arrows. Bar as in Fig. 4g. Fig. 4h: the B-Raf staining of the neurons of the 
fastigial nucleus (arrow). Bar: 10 μm. Fig. 4i: white matter RPI apparently localized in glia cells 
(arrow). Arrowheads point to white matter axons containing RPI. Bar: 50 μm. 
Raf Serine/Threonine Protein Kinases:  




Fig. 5. Cerebellar immunostaining with anti-C-Raf serum in the guinea pig. Fig. 5a shows the 
overall weak staining (arrowheads: Purkinje cell layer; 1,2,3: as in Fig. 4a; bar: 0.5 mm). Fig. 5b: 
Purkinje cells contain C-Raf, which is localized in cell bodies and dendrites (arrowheads). Arrow 
points to outer stellate cell, which displays weak staining. Bar: 50 μm. Fig. 5c: Purkinje cell (P) 
staining with high magnification. Arrows point to dendrites (n: unstained granule cells; bar: 50 
μm). Fig. 5d: neurons of the fastigial nucleus (arrows) containing C-Raf. Fig. 5e: white matter 
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Fig. 6. B-Raf localization in the cat neocortex (a, b), rat neocortex (c) and human hippocampus 
(d, e). Bars: 50 μm. Roman numerals show neocortex layers. Arrowheads point to large nerve 
cells with immunostaining. Thin arrows in (b), (c) and (d) point to immunostained apical 
dendrites. Thick arrows in (d) and (e) point to red blood cells remaining in capillaries. Fig. 6e: 
control section was incubated in normal horse serum, the anti-B-Raf serum was omitted.  
Neurons contain strong Raf kinase immunoreactivity in the cytoplasm of the cell body and 
dendrites (Figs 8-11). Not every neuron did stain: in the granule cell layer of the dentate 
fascia, cca. 20% of the granule cells remained unstained. This feature was visible already 
under the light microsocope, and was applicable to other cortical areas, as well (Mihály et al., 
1993). As to the staining of the dendrites, very strong RPI was seen in dendritic spines (Figs 8-
9; Fig. 11). The Raf-kinase-like staining was strong in postsynaptic densities, and in spine 
apparatuses (Fig. 9; Fig. 11; Mihály et al., 1991). Not only the spine apparatuses, but also 
dendritic subsynaptic cisternae contained RPI (Fig. 10d). In these membrane cisternal 
organelles the immunprecipitate was localized between the membrane cisternae; the cavity of 
the cisternae did not contain RPI (Fig. 11). We did not observe immunostained axon terminals 
in the tissues studied so far. None of the synapsing axons terminating on dendrites, dendritic 
spines or neuron somas did contain Raf-kinase-like immunostaining (see Figs 8-11). There are 
no comprehensive electron microscopic data about the ultrastructural localization of C-Raf, 
so this issue requires and deserves further, extensive experimentation. 
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Fig. 7. Glial B-Raf kinase localization in rat spinal cord (a) and rat hippocampus (b). Fig. 7a 
displays RPI in astroglia-like cells of the white matter (bar: 10 μm). Fig. 7b shows the 
ultrastructural localization of B-Raf immunoreactivity in the cytoplasm of astrocyte-like cell 
of the rat hippocampus (solid arrows point to the contours of the astrocyte; empty arrow 
point to a synapse in the vicinity of the astrocyte; bar: 5 μm). 
4.1 Electron microscopic localization of RPI in astrocytes 
We observed several immunostained astrocytes in the cerebral cortex of rats (Fig. 7) and cats 
(Mihály & Rapp, 1994). The cytoplasmic staining of the cell body was conspicuous: very 
often in the vicinity of bundles of intermediate GFAP filaments (Mihály & Rapp, 1994). RPI 
was also observed in perivascular glial processes, and glial processes in the neuropil, around 
synapses (Mihály & Rapp, 1994). The RPI containing astrocytes were detected in the white 
matter, too – similarly to light microscopy observations. No RPI containing oligodendroglia 
cells were observed – in some sections we have seen RPI containing astrocytes together with 
unstained oligodendroglial cells (Mihály & Rapp, 1994). However, no systematic studies 
were performed to prove or disprove the lack of Raf proteins in oligodendroglia cells. The 
endothelial cells and pericytes were not labelled with any of the antibodies. 
5. Comparison of B-Raf and C-Raf brain immunolocalization patterns 
The localization of the two isozymes did not show substantial differences. The main 
observation in this respect was, that C-Raf kinase was expressed only in a few neurons and 
glia cells – compared to the expression of B-Raf. The staining was also weaker in most of the 
experiments. The C-Raf staining was specific, because the absorption controls did not show 
immunostaining (Mihály et al., 1993). The C-Raf was detected in the cerebellum and the 
cerebral cortex: these structures are compared in Table 1. B-Raf antibodies stained several 
neurons, irrespective of the size and type. However, staining was stronger in large cells 
(Figs 2-4). The B-Raf was also localized in astrocytes, as strong cytoplasmic staining. Under 
the electron microscope, the neuronal immunostaining was cytoplasmic, and exceptionally 
strong in dendritic spines, spine apparatuses and postsynaptic densities. Axon terminals did 
not stain. The C-Raf was localized in large neurons and their proximal dendritic branches. A 
few glia-like cells also displayed faint C-Raf-like staining (Fig. 5). We did not perform 
systematic electron microscopic studies for the localization of C-Raf kinase: only one series 
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in the tissues studied so far. None of the synapsing axons terminating on dendrites, dendritic 
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no comprehensive electron microscopic data about the ultrastructural localization of C-Raf, 
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Fig. 7. Glial B-Raf kinase localization in rat spinal cord (a) and rat hippocampus (b). Fig. 7a 
displays RPI in astroglia-like cells of the white matter (bar: 10 μm). Fig. 7b shows the 
ultrastructural localization of B-Raf immunoreactivity in the cytoplasm of astrocyte-like cell 
of the rat hippocampus (solid arrows point to the contours of the astrocyte; empty arrow 
point to a synapse in the vicinity of the astrocyte; bar: 5 μm). 
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neurons, irrespective of the size and type. However, staining was stronger in large cells 
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in guinea pig hippocampal slices (Mihály et al., 1991). In this electron microscopic study we 
observed neuronal and dendritic localization of C-Raf, thus corroborating the light 
microscopy findings (Mihály et al., 1991). 
 
Isozymes  Neuronal localization Glial localization Other (e.g.: endothelium) 
B-Raf ++++ ++++ None 
C-Raf + + None  
Table 1. Comparison of B-Raf and C-Raf localization and expression in the cerebellum and 
cerebral cortex of the rat and the guinea pig. The staining intensities are characterized by (+) 
symbols; (++++) means strong immunostaining; (+) means weak, but consistent staining. 
 
Fig. 8. B-Raf immunostaining in the rat cerebral cortex. Dendrites (stars) are labeled, axons 
(A) do not stain. The immunostaining of the dendritic spines (arrows) is extremely strong. 
My: myelinated axon. Bar: 1 μm. 
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Fig. 9. a-d. Immunohistochemical localization of B-raf kinase in the hippocampus of the rat. 





in guinea pig hippocampal slices (Mihály et al., 1991). In this electron microscopic study we 
observed neuronal and dendritic localization of C-Raf, thus corroborating the light 
microscopy findings (Mihály et al., 1991). 
 
Isozymes  Neuronal localization Glial localization Other (e.g.: endothelium) 
B-Raf ++++ ++++ None 
C-Raf + + None  
Table 1. Comparison of B-Raf and C-Raf localization and expression in the cerebellum and 
cerebral cortex of the rat and the guinea pig. The staining intensities are characterized by (+) 
symbols; (++++) means strong immunostaining; (+) means weak, but consistent staining. 
 
Fig. 8. B-Raf immunostaining in the rat cerebral cortex. Dendrites (stars) are labeled, axons 
(A) do not stain. The immunostaining of the dendritic spines (arrows) is extremely strong. 
My: myelinated axon. Bar: 1 μm. 
Raf Serine/Threonine Protein Kinases:  




Fig. 9. a-d. Immunohistochemical localization of B-raf kinase in the hippocampus of the rat. 





arrows point to postsynaptic densities (thin arrow shows multivesicular body); arrowhead 
points to neck of spine, asterisk is in dendritic stem (A1, A2 are axon terminals); bar: 1 μm. 
In (b) dendrite (asterisk) is seen from which spine originates (arrowhead); A1-A5 are 
presynaptic axons; bar: 1 μm. In (c) mossy fiber terminal is unstained (M: mitochondria, 
black arrows point to dense core vesicles), postsynaptic dendrite (spine) is strongly 
immunoreactive (white arrows point to postsynaptic densities); bar: 1 μm. In (d) unstained 
axons (AX, A) synapsing with strongly stained small dendrite (asterisk); bar: 1 μm. 
 
Fig. 10. a-d. Ultrastructural localization of RPI in the CA3 sector of the rat hippocampus. Fig. 
9a displays the light microscopic appearance of the stratum pyramidale and stratum 
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lucidum after staining with polyclonal v-Raf antibodies. Cell bodies and apical dendrites are 
immunostained; mossy fibers do not stain (bar: 100 μm). Fig. 9b and c show two unstained 
mossy fiber ending (MF) synapsing with RPI containing dendrites (arrow and D). My: 
myelinated axon (unstained). Bars: 1 μm. Fig. 9d: large dendrite (D) containing RPI and 
immunostained subsynaptic cisternae (arrowhead). Synapsing axon (A) is unstained. En: 
unstained endothelial cell, bar: 1 μm. 
 
Fig. 11. Typical spine apparatus localization of B-Raf kinase in the rat cerebral cortex. The 
dendritic spine is pointed by the large solid arrow. The membranes of the spine apparatus 
are pointed by arrowheads. The postsynaptic density (empty arrows) is containing RPI, too. 
A: axon terminal; D: dendrite, containg RPI. Bar: 0.1 μm. 
6. Discussion of the immunohistochemical findings 
6.1 Neuronal B-Raf kinases 
The immunolocalization of Raf kinases shows consistent patterns in different mammalian 
species (rat, guinea pig, cat and human). The main Raf molecule of the brain is certainly the 
B-Raf isozyme. The 95 kDa protein was detected in rat and guinea pig (Mihály et al., 1991; 
1996; 2007; Mihály & Endrész, 2000). This observation conforms the literature data which 
give the same molecular weight in other experiments (Stephens et al., 1992; Dwivedi et al., 
2006). Based on the specificity of the polyclonal v-Raf serum we refer to the immunostaining 
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unstained endothelial cell, bar: 1 μm. 
 
Fig. 11. Typical spine apparatus localization of B-Raf kinase in the rat cerebral cortex. The 
dendritic spine is pointed by the large solid arrow. The membranes of the spine apparatus 
are pointed by arrowheads. The postsynaptic density (empty arrows) is containing RPI, too. 
A: axon terminal; D: dendrite, containg RPI. Bar: 0.1 μm. 
6. Discussion of the immunohistochemical findings 
6.1 Neuronal B-Raf kinases 
The immunolocalization of Raf kinases shows consistent patterns in different mammalian 
species (rat, guinea pig, cat and human). The main Raf molecule of the brain is certainly the 
B-Raf isozyme. The 95 kDa protein was detected in rat and guinea pig (Mihály et al., 1991; 
1996; 2007; Mihály & Endrész, 2000). This observation conforms the literature data which 
give the same molecular weight in other experiments (Stephens et al., 1992; Dwivedi et al., 
2006). Based on the specificity of the polyclonal v-Raf serum we refer to the immunostaining 





repeated Western blot experiments, which gave very consistent results: the polyclonal v-Raf 
serum and the B-Raf antibodies resulted in the same 95 kDa band in brain homogenates 
(Mihály et al., 1991; 2007; Mihály & Endrész, 2000). We did not perform immunoblotting 
with the C-Raf antibody because the polyclonal anti-SP 63 serum was thoroughly 
investigated (Schultz et al., 1985; 1988; Morice et al., 1999). The synthetic SP 63 peptide is the 
C-terminal part of the C-Raf protein (Schultz et al., 1985; 1988). This 12 amino acids peptide 
was used for immunization in rabbits (Schultz et al., 1985; 1988). The polyclonal serum was 
affinity purified, tested with immunoprecipitation and was found to be specific for the 
murine and human C-Raf terminal sequences in cell cultures and in tissue sections (Schultz 
et al., 1985; 1988; Mihály et al., 1993). This immunostaining is therefore referred to as the 
immunolocalization of C-Raf kinase. Neuronal B-Raf and C-Raf localization at the light 
microscopic level was found to be very similar in other experiments, years later (Morice et 
al., 1999). We think therefore, that our descriptions concerning the brain localization of Raf 
kinases are the first in the literature, and give a precise picture of neuronal B-Raf kinases 
(Mihály et al., 1991; 1993). 
The main features of neuronal B-Raf kinase localization are as follows: 
1. Cytoplasmic localization in the cell body was a general feature. This reflects the 
existence of a standard pool of the B-Raf kinase in the neuron. In case of growth factor 
signals, this cytoplasmic kinase pool can be mobilized quickly, in form of recruitment to 
the cell membranes or to the nucleus, if necessary.  
2. Localization in dendrites was another characteristic feature of neuronal B-Raf. Dendritic 
staining was extremely strong in dendritic spines and in postsynaptic densities, 
meaning that a certain amount of B-Raf was already attached to the membrane, in 
proximity of the synaptic receptors. This localization suggested a very effective signal 
transduction process, mediated by the B-Raf. 
6.2 Neuronal signal transduction with B-Raf: experimental proofs 
The first observations pointing to the possible significance of Raf kinases in learning and 
memory were those of Mihály et al., (1990). In these experiments long term potentiation 
(LTP) was induced in rats, then the animals were subjected to immunohistochemical 
detection of Raf kinase with the polyclonal v-Raf antibodies (Mihály et al., 1990). The RPI 
was investigated in the granule cell layer of the dentate gyrus, by counting the 
immunoreactive neuronal cell bodies (Mihály et al., 1990). The number of RPI-containing 
cell bodies increased significantly in successfully potentiated animals (Mihály et al., 1990). 
This observation has been discussed either as the post-LTP increase of Raf kinase expression 
in dentate granule cells; or as the translocation of the Raf kinase from the distal dendrites to 
the cell body, following LTP (Mihály et al., 1990). We were not able to decide between these 
two possibilities in these in vivo experiments (Mihály et al., 1990). Years later, with help of 
in situ hybridization, it turned out that 24 h following LTP, the B-Raf expression in the 
dentate gyrus increased significantly (Thomas et al., 1994). Recently, experiments on B-Raf 
knockout mice proved, that the B-Raf is absolutely necessary for learning and memory 
consolidation (Chen et al., 2006; Valluet et al., 2010). However, the detailed mechanisms of 
the participation of B-Raf in LTP are unknown. 
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6.3 The possible intracellular translocation of B-Raf in neurons 
Since the early immunohistochemical experiments on LTP (Mihály et al., 1990), the 
possibility of intracellular Raf translocation was an important issue, because the translocation 
could be one intracellular mechanism for signal transduction. The translocation was observed 
in vitro (Leevers et al., 1994) and in vivo (Oláh et al., 1991) in different experimental 
conditions. The recruitment to the cell membrane is considered to be a necessary step of Raf 
activation (Matallanas et al., 2011). However, the translocation to the cell nucleus is difficult 
to explain, although the experimental facts seem to be firm (Oláh et al., 1991). Another, 
translocation-like phenomenon was observed in sensory ganglion cells (Mihály et al., 1996). 
Primary sensory neurons contain B-Raf in their cell body, in form of homogeneous 
immunoreactivity (Mihály et al., 1996). Two-eight days after the transection of the peripheral 
nerve, this cytoplasmic staining pattern displays translocation towards the periphery, and at 
8 days, most of the RPI was localized beneath the cell membrane of the sensory ganglion 
cells (Mihály et al., 1996). The significance of this phenomenon is not known, possibly it is 
connected to the process of chromatolysis (Mihály et al., 1996). The phenomenon of the 
translocation has been proved in cell cultures (see Mor & Philips, 2006), but not in vivo, in 
plasticity or pathological conditions. Further experiments are needed for the understanding 
of the possible in vivo translocation processes. 
6.4 Possible functions of C-Raf in the neuron  
Although C-Raf was found to be ubiquitous (Storm et al., 1990; Matallanas et al., 2011), not 
every neuron displayed immunoreactivity in our studies. These findings are in conform 
with other immunohistochemical studies (Morice et al., 1999). On the other hand, it seems, 
that C-Raf expression can be induced by some (yet unknown) conditions. Hippocampal 
slices maintained in vitro do not express C-Raf at the beginning of the in vitro incubation. 
Incubation of the slice for 2-4 h in oxygenized environment induced the appearance of the 
C-Raf staining in the nerve cells (Mihály et al., 1991). Upregulation of C-Raf was observed in 
Alzheimer-brains, too (Mei et al., 2006). In vitro grown neurons were protected by C-Raf 
inhibitors against the toxicity of amyloid peptides (Echeverria et al., 2008). It seems 
therefore, that the upregulation of C-Raf in the cell causes cell damage and death: it can 
happen through the activation of apoptosis signals (Echeverria et al., 2008). No data exist 
about the causes of C-Raf upregulation: excess excitatory amino acids (excitotoxic effects), 
hypoxic conditions, and ageing may operate through unknown signaling pathways in brain 
cells. 
7. Conclusions 
Raf protein kinases are widespread in the mammalian brain and spinal cord. Raf protein 
kinases are activated by several cytokines and growth factors through their membrane 
receptors. We investigated the immunohistochemical localization of B-Raf kinase and C-Raf 
kinase in neurons and glial cells. The B-Raf kinase is localized in the cell body, in dendrites, 
dendritic spines, spine apparatuses, subsynaptic cisternae and postsynaptic densities. The 
localization does not depend on neuronal type, but the intensity of the immunostaining is 
greater in large neurons. Neuronal B-Raf was not found in presynaptic axons, suggesting, 
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similarities of the presence and localization of B-Raf in three mammalian orders (rodents, 
carnivores and hominids) suggest that this protein kinase has an important, and 
phylogenetically conserved function in normal, adult neurons. Data are available that 
learning and memory consolidation are processes in which B-Raf participates importantly. 
The C-Raf kinase has a similar CNS localization, but the amount of C-Raf in the cells is 
generally lower, than that of B-Raf. On the other hand, results from different experiments 
suggest, that the neuron adapts and alters the C-Raf expression, and thus regulates the 
amount of C-Raf present in the cytoplasm and in the membrane compartments. Therefore, 
we can state, that the regulation of the two isozymes (B-Raf and C-Raf) are different 
(although the downstream cellular events are similar):  
1. CNS cells have a constant cytoplasmic pool of B-Raf, which translocates to different 
neighbouring organelles, in order to participate in signaling. The short-term regulation 
of B-Raf depends on membrane receptor stimulation. 
2. CNS cells have another signaling molecule, the C-Raf, which displays low cytoplasmic 
concentration in normal neurons. However, the amount of cytoplasmic C-Raf is 
probably regulated by gene expression, the mechanisms of which are largely unknown. 
Therefore, C-Raf can be regulated twice: first by gene expression (upstream), second by 
membrane receptor activation (downstream). The significance and effects of this double 
regulation in the brain is not known: the effects probably manifest on the system level 
(e.g.: as alterations of the viability of neuronal networks). 
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1. Introduction 
Neural plasticity is characterized by the lasting modulation of synaptic strength which alters 
the central nervous system’s (CNS) capacity to encode and store information. Changes in 
synaptic plasticity have implications for brain-dependent learning and memory as well as a 
number of other forms of CNS information processing, including alterations in spinal cord 
function (reviewed in Patterson & Grau, 2001). As protein kinases have been shown to 
greatly affect neurotransmitter receptor dynamics, their role in synaptic plasticity is 
essential. A large body of work has highlighted the link between group I metabotropic 
glutamate receptor (mGluR) activation, subsequent protein kinase activation, and synaptic 
plasticity (Gereau & Heinemann, 1998; Sheng et al., 2002; Gallagher et al., 2004). Upon 
glutamate binding to mGluRs, a G-protein coupled to the receptor sets off an intracellular 
cascade, activating phospholipase C (PLC), diacyl glycerol (DAG), and ultimately protein 
kinases. Once activated, protein kinases can then exert a modulatory effect on both 
excitatory and inhibitory receptors that ultimately affects synaptic strength. In this way, 
mGluRs and protein kinases both play critical roles in a number of forms of neural 
plasticity, including those that are thought to underlie learning and memory (Bortolotto & 
Collingridge, 1993; Wang, et al. 2004). What many in neuroscience have overlooked is the 
fact that, just like in the brain, the spinal cord also exhibits the capacity for an amazing 
amount of plasticity, including simple forms of learning and memory that are relevant to 
pain, motor learning, and recovery of function after spinal cord damage (Woolf & Salter, 
2000; Grau et al., 2006; Raineteau & Schwab, 2001). And, just as in the brain, spinal plasticity 
has been shown across a number of preparations to be mediated by mGluR/protein kinase 
signaling (Giles et al., 2007; Ferguson et al., 2008a).  
This chapter will detail the specific role of protein kinase C (PKC) as an intermediary 
between initial mGluR activity and long-term changes in synaptic strength, and how this 
critical interaction affects a number of spinal processes. We will highlight how PKC and its 
isoforms provide a critical link between initial glutamatergic input and the alterations in 
receptor phosphorylation and trafficking that lead to spinal plasticity. We will first look at 
the role of mGluR/PKC signaling in the dorsal horn of the spinal cord, and the implications 
of this process on pain. We will then explore how the mGluR/PKC pathway also exerts 
modulatory control over the changes in plasticity (or metaplasticity) in the spinal cord, as 
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1. Introduction 
Neural plasticity is characterized by the lasting modulation of synaptic strength which alters 
the central nervous system’s (CNS) capacity to encode and store information. Changes in 
synaptic plasticity have implications for brain-dependent learning and memory as well as a 
number of other forms of CNS information processing, including alterations in spinal cord 
function (reviewed in Patterson & Grau, 2001). As protein kinases have been shown to 
greatly affect neurotransmitter receptor dynamics, their role in synaptic plasticity is 
essential. A large body of work has highlighted the link between group I metabotropic 
glutamate receptor (mGluR) activation, subsequent protein kinase activation, and synaptic 
plasticity (Gereau & Heinemann, 1998; Sheng et al., 2002; Gallagher et al., 2004). Upon 
glutamate binding to mGluRs, a G-protein coupled to the receptor sets off an intracellular 
cascade, activating phospholipase C (PLC), diacyl glycerol (DAG), and ultimately protein 
kinases. Once activated, protein kinases can then exert a modulatory effect on both 
excitatory and inhibitory receptors that ultimately affects synaptic strength. In this way, 
mGluRs and protein kinases both play critical roles in a number of forms of neural 
plasticity, including those that are thought to underlie learning and memory (Bortolotto & 
Collingridge, 1993; Wang, et al. 2004). What many in neuroscience have overlooked is the 
fact that, just like in the brain, the spinal cord also exhibits the capacity for an amazing 
amount of plasticity, including simple forms of learning and memory that are relevant to 
pain, motor learning, and recovery of function after spinal cord damage (Woolf & Salter, 
2000; Grau et al., 2006; Raineteau & Schwab, 2001). And, just as in the brain, spinal plasticity 
has been shown across a number of preparations to be mediated by mGluR/protein kinase 
signaling (Giles et al., 2007; Ferguson et al., 2008a).  
This chapter will detail the specific role of protein kinase C (PKC) as an intermediary 
between initial mGluR activity and long-term changes in synaptic strength, and how this 
critical interaction affects a number of spinal processes. We will highlight how PKC and its 
isoforms provide a critical link between initial glutamatergic input and the alterations in 
receptor phosphorylation and trafficking that lead to spinal plasticity. We will first look at 
the role of mGluR/PKC signaling in the dorsal horn of the spinal cord, and the implications 
of this process on pain. We will then explore how the mGluR/PKC pathway also exerts 
modulatory control over the changes in plasticity (or metaplasticity) in the spinal cord, as 
evidenced in a spinal cord learning preparation. In addition, we will consider how the 
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reorganization and reclamation of appropriate function after spinal cord injury is affected in 
large part by various forms of mGluR-mediated, protein kinase-dependent plasticity. 
Finally, we will investigate the neurobiological consequences and possible therapeutic 
potential to be found in altering protein kinase activity. 
2. Nociceptive plasticity: mGluRs, protein kinase C, and pain 
mGluR-mediated activation of protein kinases can modulate synaptic strength, by altering 
presynaptic and postsynaptic signaling. While these forms of synaptic plasticity have been 
suggested to underlie learning and memory in the hippocampus, similar mechanisms at 
work in the dorsal horn of the spinal cord produce a decidedly different form of learning 
that contributes to neuropathic pain. As the dorsal horn is the locus for the integration of 
incoming sensory information, sensitization of these neurons and their synaptic targets can 
have a dramatic behavioral effect (Mendell, 1966; Woolf, 1983). If a strong nociceptive signal 
is relayed from the periphery to the superficial dorsal horn, neurons in this area become 
sensitized, in a fashion that is mechanistically very similar to long-term potentiation (LTP), 
an electrophysiological mechanism believed to underlie learning and memory in the 
hippocampus (Sandkuhler & Liu, 1998; Bliss & Collingridge, 1993). This effect has been 
termed central sensitization (Woolf, 1983). As in any form of potentiation, subsequent input 
following sensitization can elicit a response even if it is much weaker than the initial input. 
That is, even those stimuli that would not normally be considered painful may now have the 
capacity to elicit a nociceptive response (allodynia). Likewise, normally painful stimuli can 
now induce a much more robust nociceptive response (hyperalgesia). These phenomena are 
conserved across species, and this makes sense from an evolutionary standpoint. To be 
rapidly sensitized to a painful stimulus is indeed adaptive, in that an organism will ‘learn’ 
to avoid this stimulus. Although this type of plasticity is essential for self-preservation, it 
can be problematic if dysregulated. Neural insult, whether it be an injury to the peripheral 
nervous system (e.g., nerve damage) or central nervous system (e.g., spinal cord injury), can 
produce an unregulated barrage of nociceptive input that may have no external initiator. 
This can produce a persistent pain response, and lasting nociceptive plasticity, that is 
generated wholly within the organism (neuropathic pain) (Kim & Chung, 1992; Christensen 
& Hulsebosch; Willis & Coggeshall, 1991; Willis & Westlund, 1997; Lindsey et al., 2000). A 
number of studies have outlined an important role for spinal protein kinase C (PKC) in 
mediating persistent pain states, including hyperalgesia, allodynia, and neuropathic pain 
(Coderre, 1992; Sun et al., 2004; Hua et al. 1999). As a major activator of PKC, group I 
mGluRs have been implicated as a driver of nociceptive plasticity (Yashpal et al., 2001; 
Fisher & Coderre, 1996; Adwanikar et al., 2004).  
mGluRs activate PKC in two ways: both directly, through the G-coupled protein-PLC-DAG 
pathway, as well as indirectly by freeing intracellular Ca++ via activation of 
phosphoinositide-3 kinase (PI3K) pathway. In vitro work has shed light on how PKC works 
to sensitize spinal neurons and elicit persistent nociceptive behavior. PKC appears to have 
the capacity to induce sensitization through both presynaptic and postsynaptic effects. 
Presynaptically, PKC has been shown to phosphorylate voltage-gated calcium channels, 
thus increasing intracellular calcium and promoting neurotransmitter release (Yang et al., 
2005). Postsynaptically, PKC can facilitate excitatory tone through actions on ionotropic 
glutamate receptors (Lu et al., 1999; Li et al., 1999). Following post-synaptic binding of 
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glutamate to mGluRs, and subsequent PKC activation, PKC then phosphorylates NMDA 
receptors, increasing their open probability (Liao et al., 2001). Further, PKC has been shown 
to induce the rapid exocytosis of AMPA receptors (Li et al., 1999). Taken together, these 
excitatory effects have been suggested to play a critical role in sensitizing dorsal horn 
neurons (Ji et al., 2003).  
In the brain, however, mGluR activation can have contradictory effects. For example, in 
hippocampal culture, mGluR activation has been shown to cause internalization of AMPA 
receptors leading to long-term depression (LTD) of postsynaptic potentials rather than 
sensitization (Huber et al., 2000; Oliet et al., 1997; Moult et al., 2002). This effect has been 
shown to depend on activation of the immediate early gene Arc/Arg 3.1 (Waung et al., 
2008) as well as PKC (Camodeca et al., 1999; Oliet et al., 1997). On the other hand, mGluR-
induced activation of PKC has also been implicated in LTP (Jia et al., 1998; Balschun et al., 
1999; Aiba, et al., 1994; Conquet et al., 1994; Bortolotto, et al., 1994; Anwyl et al., 2009). This 
confusion about the bi-directional role of mGluRs and downstream PKC in hippocampal-
dependent synaptic plasticity has been reviewed elsewhere (Bortolotto et al., 1999; Malenka 
& Bear, 2004) and the role of mGluRs in LTP and LTD remains a topic of ongoing research in 
the hippocampal plasticity literature (Mockett et al., 2011). It is clear that much more work is 
required to reconcile the hippocampal literature with the spinal plasticity literature 
regarding mGluR-PKC activation.  
Tests of the necessity of mGluRs and PKC in vivo have confirmed the critical role of this 
pathway in spinally-mediated nociceptive plasticity. In order to study persistent 
inflammation, researchers will often give a subcutaneous injection of a noxious substance to 
the periphery, and then assess the effect this treatment has on the activity of dorsal horn 
neurons within nociceptive fields (Harris & Ryall, 1988; LaMotte et al., 1992). To investigate 
the specific role of mGluRs on this type of nociceptive plasticity, Young et al. (1995) gave an 
injection of the noxious substance algogen (mustard oil) to the hindpaws of rats, a substance 
known to evoke sustained activity in neurons of the dorsal horn. This treatment was 
followed by microinjections of the mGluR antagonist CHPG directly into the dorsal horn. 
They found that blocking mGluR activity with CHPG strongly inhibited mustard oil-evoked 
activity in these nociceptive areas. Beyond the necessity for mGluRs in sustained nociceptive 
activity, they also demonstrated the sufficiency for an mGluR agonist (ACPD) to produce 
sustained activity in these neurons (Young et al., 1995). Interestingly, Munro et al. found 
that treatment with a PKC inhibitor (chelerythrine or GF109203X) was able to inhibit both 
mustard oil- and ACPD-evoked activity (Munro et al. 1994). Together, these findings 
provide a strong case for mGluR/PKC signaling in mediating at least one form of long-term 
nociceptive plasticity. In 2001, Yashpal and colleagues demonstrated a further role for 
mGluR/PKC interaction in chronic neuropathic pain. Following a chronic constriction of the 
sciatic nerve (known to produce long-term nociceptive activity in the dorsal horn), they 
found that membrane localization of PKC was increased. Behaviorally, such an injury 
manifests as a chronic and robust hypersensitivity to both touch (mechanical allodynia) and 
temperature (thermal hyperalgesia). But, if an mGluR inhibitor was given prior to and after 
the injury, they found a decrease in the membrane-bound PKC expression, as well as a 
decrease in the subjects’ injury-induced mechanical and thermal hypersensitivity. 
Based on the mechanistic similarities, many researchers have drawn the distinct parallels 
between learning/memory and pain (Sandkuhler, 2000; Ji et al., 2003; Latremoliere and 
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Woolf, 2009). It is perhaps not surprising then that recent breakthroughs in our 
understanding of long-term memory storage in the brain continue to shed light on persistent 
pain syndromes that are mediated by the spinal cord. The protein kinase PKM (an isoform 
of PKC) is unique in that, unlike most enzymes, it can remain active for extremely long 
periods of time. This persistence is possibly due to the fact that activated PKMζ inhibits the 
protein PIN1, an inhibitor of PKMζ mRNA translation. Thus, by blocking the action of its 
regulator, PKMζ effectively creates a positive feedback loop, perpetuating PKMζ activity 
(Sacktor, 2011). Once PKMζ becomes active, it can promote trafficking of the major fast 
excitatory ionotropic glutamate receptor (AMPAR) to post-synaptic membranes, which in 
turn aids in potentiating the synapse (Sacktor, 2008; Migues et al., 2010; Malinow & 
Malenka, 2002). Further, PKMζ has been shown to also inhibit the internalization of these 
trafficked AMPARs (Yao et al., 2008). In this way, synaptic strength is not only induced, but 
also maintained. This finding has led many to investigate PKMζ has a critical component in 
long-term memory. Researchers have found that inhibiting PKMζ produces profound 
behavioral effects. A number of recent studies have shown that treatment with a PKMζ 
inhibitor effectively eliminates long-term memories from a number of learning paradigms 
(Pastalkova et al., 2006; Shema et al. 2007; Parsons & Davis, 2011; Madronal et al., 2010). 
While these findings provide compelling evidence for the necessity for PKMζ in long-term 
memory, erasing long-term memories may not be a likely sought-after therapy. But consider 
the problem of chronic pain. As we have discussed, long-term neuropathic pain bears a 
striking mechanistic resemblance to memory, yet it is often regarded to be biologically 
dysfunctional. Therefore, inhibiting PKMζ may prove to be a very attractive therapeutic tool 
in overcoming persistent neuropathic pain. Asiedu and colleagues have recently shown this 
idea to be entirely possible. They initially primed rat subjects with a peripheral intraplantar 
injection of the inflammatory cytokine IL-6 or vehicle to the hindpaw. This treatment has 
previously been shown to induce allodynia for up to 3 days after injection (Asiedu et al., 
2011). They then injected the mGluR agonist DHPG intrathecally to the spinal cord 6 days 
after initial peripheral injection, and found that DHPG injection produced a markedly 
enhanced nociceptive response in those subjects that had been primed days earlier with IL-
6. This finding suggested that the maintenance of peripheral nociceptive sensitization was 
mediated centrally in the spinal cord and led them to investigate the possibility that PKMζ 
might mediate the storage of this nociceptive ‘memory’. They found that intrathecal 
administration of the PKMζ inhibitor ZIP attenuated the capacity for DHPG to evoke the 
expression of nociceptive behavior. This lends support for the argument that, as in learning 
and memory in the brain, this persistent nociceptive sensitization reflects an LTP-like 
mechanism. Given that PKMζ has been shown to maintain LTP by inhibiting the 
internalization of AMPARs, and this effect can be disrupted by the peptide pep2m (Yao et 
al. 2008), Asiedu and colleagues hypothesized that this same mechanism is involved in the 
maintenance of nociceptive hypersensitivity. To test this, they gave an intrathecal injection 
of pep2m, and found that this treatment also blocked the DHPG evoked expression of 
sensitization (Asiedu et al., 2011). Together these findings suggest that the maintenance of 
nociception involves a PKMζ-dependent process within the spinal cord, and lends 
confirmatory evidence that the maintenance of LTP, memory, and nociception may be 
mediated by a common mechanism. In the future, PKMζ inhibition could hold very 
promising therapeutic potential for those suffering from chronic pain.  
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3. Learning in the spinal cord: Metaplasticity is PKC-dependent 
The spinal cord supports a number of other forms of plasticity beyond just nociception. 
Throughout development, ventral motor neurons undergo a great amount of plasticity, as 
complex motor skills and locomotion are honed. Although the spinal cord was once 
believed to be fairly hard-wired after development, we now understand that the capacity for 
ongoing plasticity in spinal motor neurons persists throughout life (Edgerton et al. 2001; 
Courtine et al. 2008; De Leon et al. 2001; Wolpaw, 2007; Grau et al., 2006). This is evident in 
the spinal cord injury literature from the previous decade, where researchers have 
demonstrated the ability for spinal cord injured-subjects to regain locomotor function 
through the use of behavioral training, often in combination with pharmacological agents 
that facilitate plasticity (Wernig et al., 2000; Rossignol, 2007; Edgerton & Harkema, 2011). 
Promoting this kind of adaptive, use-dependent spinal plasticity is essential in order to 
realize functional recovery after injury.  
Despite advances in our awareness of the spinal cord’s capacity for plasticity, the 
underlying mechanisms dictating use-dependent spinal cord plasticity still require 
investigation. In order to better understand the unique role of the spinal cord in neural 
plasticity, outside of any supraspinal input, researchers have developed an in vivo, 
behavioral method for measuring plasticity in the isolated spinal cord. Building upon earlier 
work from Chopin and Buerger, Grau and colleagues demonstrated that following a 
complete spinal transection, spinal neurons below the lesion were able to support a simple 
form of instrumental (response-outcome) learning (Buerger and Fennesey, 1970; Chopin & 
Buerger, 1976; Grau et al., 1998). In this preparation, transected rats receive an electrical 
shock to the tibilias anterior muscle of their hindlimb whenever that limb is in an unflexed 
position (see Figure 1A). This stimulation causes a flexion of the hindlimb, at which point 
the stimulation is terminated. When the limb again falls to a resting, unflexed position, 
another shock is delivered.  
Without input from the brain, spinalized subjects will learn to keep the hindlimb flexed in 
order to reduce exposure to the stimulation (Fig 1C). This form of spinal learning can also be 
inhibited: if subjects are given electrical stimulation that is not contingent upon limb 
position (intermittent stimulation), they will later fail to learn to keep their hindlimb flexed 
when tested with response-contingent stimulation (controllable stimulation; Figure 1B; Crown 
et al., 2002). Although these subjects are not learning the target response, they are still 
exhibiting a form of plasticity. Essentially, they have learned from the exposure to 
intermittent stimulation, that their limb position is not related to stimulation exposure, and 
thus fail even when later tested with controllable stimulation. This phenomenon has been 
considered analogous to the phenomenon of learned helplessness (Grau et al., 1998; Seligman 
& Maier, 1967). In contrast to the maladaptive effects of intermittent stimulation, training 
with controllable stimulation can enhance future learning (Grau et al., 1998). Subjects that 
have previously learned this instrumental task can be tested in the future with a more 
difficult response criterion (one that untrained subjects would not be able to exhibit), and 
this prior training facilitates learning. While both the learning deficit and the facilitation of 
learning are forms of plasticity, they are something more. Both of these phenomena affect 
lasting change in plasticity: a lasting alteration in the threshold at which learning occurs, 
either shifting the threshold up (in the case of intermittent stimulation inducing a future 
learning deficit) or down (in the instance of instrumental training facilitating future 
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Woolf, 2009). It is perhaps not surprising then that recent breakthroughs in our 
understanding of long-term memory storage in the brain continue to shed light on persistent 
pain syndromes that are mediated by the spinal cord. The protein kinase PKM (an isoform 
of PKC) is unique in that, unlike most enzymes, it can remain active for extremely long 
periods of time. This persistence is possibly due to the fact that activated PKMζ inhibits the 
protein PIN1, an inhibitor of PKMζ mRNA translation. Thus, by blocking the action of its 
regulator, PKMζ effectively creates a positive feedback loop, perpetuating PKMζ activity 
(Sacktor, 2011). Once PKMζ becomes active, it can promote trafficking of the major fast 
excitatory ionotropic glutamate receptor (AMPAR) to post-synaptic membranes, which in 
turn aids in potentiating the synapse (Sacktor, 2008; Migues et al., 2010; Malinow & 
Malenka, 2002). Further, PKMζ has been shown to also inhibit the internalization of these 
trafficked AMPARs (Yao et al., 2008). In this way, synaptic strength is not only induced, but 
also maintained. This finding has led many to investigate PKMζ has a critical component in 
long-term memory. Researchers have found that inhibiting PKMζ produces profound 
behavioral effects. A number of recent studies have shown that treatment with a PKMζ 
inhibitor effectively eliminates long-term memories from a number of learning paradigms 
(Pastalkova et al., 2006; Shema et al. 2007; Parsons & Davis, 2011; Madronal et al., 2010). 
While these findings provide compelling evidence for the necessity for PKMζ in long-term 
memory, erasing long-term memories may not be a likely sought-after therapy. But consider 
the problem of chronic pain. As we have discussed, long-term neuropathic pain bears a 
striking mechanistic resemblance to memory, yet it is often regarded to be biologically 
dysfunctional. Therefore, inhibiting PKMζ may prove to be a very attractive therapeutic tool 
in overcoming persistent neuropathic pain. Asiedu and colleagues have recently shown this 
idea to be entirely possible. They initially primed rat subjects with a peripheral intraplantar 
injection of the inflammatory cytokine IL-6 or vehicle to the hindpaw. This treatment has 
previously been shown to induce allodynia for up to 3 days after injection (Asiedu et al., 
2011). They then injected the mGluR agonist DHPG intrathecally to the spinal cord 6 days 
after initial peripheral injection, and found that DHPG injection produced a markedly 
enhanced nociceptive response in those subjects that had been primed days earlier with IL-
6. This finding suggested that the maintenance of peripheral nociceptive sensitization was 
mediated centrally in the spinal cord and led them to investigate the possibility that PKMζ 
might mediate the storage of this nociceptive ‘memory’. They found that intrathecal 
administration of the PKMζ inhibitor ZIP attenuated the capacity for DHPG to evoke the 
expression of nociceptive behavior. This lends support for the argument that, as in learning 
and memory in the brain, this persistent nociceptive sensitization reflects an LTP-like 
mechanism. Given that PKMζ has been shown to maintain LTP by inhibiting the 
internalization of AMPARs, and this effect can be disrupted by the peptide pep2m (Yao et 
al. 2008), Asiedu and colleagues hypothesized that this same mechanism is involved in the 
maintenance of nociceptive hypersensitivity. To test this, they gave an intrathecal injection 
of pep2m, and found that this treatment also blocked the DHPG evoked expression of 
sensitization (Asiedu et al., 2011). Together these findings suggest that the maintenance of 
nociception involves a PKMζ-dependent process within the spinal cord, and lends 
confirmatory evidence that the maintenance of LTP, memory, and nociception may be 
mediated by a common mechanism. In the future, PKMζ inhibition could hold very 
promising therapeutic potential for those suffering from chronic pain.  
 
Protein Kinases in Spinal Plasticity: A Role for Metabotropic Glutamate Receptors 447 
3. Learning in the spinal cord: Metaplasticity is PKC-dependent 
The spinal cord supports a number of other forms of plasticity beyond just nociception. 
Throughout development, ventral motor neurons undergo a great amount of plasticity, as 
complex motor skills and locomotion are honed. Although the spinal cord was once 
believed to be fairly hard-wired after development, we now understand that the capacity for 
ongoing plasticity in spinal motor neurons persists throughout life (Edgerton et al. 2001; 
Courtine et al. 2008; De Leon et al. 2001; Wolpaw, 2007; Grau et al., 2006). This is evident in 
the spinal cord injury literature from the previous decade, where researchers have 
demonstrated the ability for spinal cord injured-subjects to regain locomotor function 
through the use of behavioral training, often in combination with pharmacological agents 
that facilitate plasticity (Wernig et al., 2000; Rossignol, 2007; Edgerton & Harkema, 2011). 
Promoting this kind of adaptive, use-dependent spinal plasticity is essential in order to 
realize functional recovery after injury.  
Despite advances in our awareness of the spinal cord’s capacity for plasticity, the 
underlying mechanisms dictating use-dependent spinal cord plasticity still require 
investigation. In order to better understand the unique role of the spinal cord in neural 
plasticity, outside of any supraspinal input, researchers have developed an in vivo, 
behavioral method for measuring plasticity in the isolated spinal cord. Building upon earlier 
work from Chopin and Buerger, Grau and colleagues demonstrated that following a 
complete spinal transection, spinal neurons below the lesion were able to support a simple 
form of instrumental (response-outcome) learning (Buerger and Fennesey, 1970; Chopin & 
Buerger, 1976; Grau et al., 1998). In this preparation, transected rats receive an electrical 
shock to the tibilias anterior muscle of their hindlimb whenever that limb is in an unflexed 
position (see Figure 1A). This stimulation causes a flexion of the hindlimb, at which point 
the stimulation is terminated. When the limb again falls to a resting, unflexed position, 
another shock is delivered.  
Without input from the brain, spinalized subjects will learn to keep the hindlimb flexed in 
order to reduce exposure to the stimulation (Fig 1C). This form of spinal learning can also be 
inhibited: if subjects are given electrical stimulation that is not contingent upon limb 
position (intermittent stimulation), they will later fail to learn to keep their hindlimb flexed 
when tested with response-contingent stimulation (controllable stimulation; Figure 1B; Crown 
et al., 2002). Although these subjects are not learning the target response, they are still 
exhibiting a form of plasticity. Essentially, they have learned from the exposure to 
intermittent stimulation, that their limb position is not related to stimulation exposure, and 
thus fail even when later tested with controllable stimulation. This phenomenon has been 
considered analogous to the phenomenon of learned helplessness (Grau et al., 1998; Seligman 
& Maier, 1967). In contrast to the maladaptive effects of intermittent stimulation, training 
with controllable stimulation can enhance future learning (Grau et al., 1998). Subjects that 
have previously learned this instrumental task can be tested in the future with a more 
difficult response criterion (one that untrained subjects would not be able to exhibit), and 
this prior training facilitates learning. While both the learning deficit and the facilitation of 
learning are forms of plasticity, they are something more. Both of these phenomena affect 
lasting change in plasticity: a lasting alteration in the threshold at which learning occurs, 
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learning). In essence, these experience-dependent spinal changes represent a plasticity of 
plasticity. Abraham and Bear (1996) first described this type of plasticity of plasticity, 
characterizing it as “a higher-order form of synaptic plasticity” that they termed 
metaplasticity (Abraham and Bear, 1996). Uncontrollable stimulation induces a lasting 
alteration that undermines spinal learning, that can be described as a metaplastic inhibition 
of adaptive plasticity. Importantly, the same stimulation parameters that induce spinal 
learning deficits also undermine long-term recovery of locomotor function following a 
spinal contusion injury (Grau et al., 2004). Thus, a better understanding of the neurobiology 
underlying metaplastic inhibition of adaptive plasticity in the spinal cord will aid in the 
development of strategies to aid in functional recovery after spinal cord injury. 
 
Fig. 1. Instrumental learning model of spinal plasticity, and the role of mGluRs in this 
phenomenon. A) Spinalized rat subjects are given an electrical shock each time their hindlimb 
is in an unflexed position (controllable stimulation). Over time, they learn to increase their 
response durations in order to reduce exposure to the stimulation, thus encoding an 
instrumental (response-outcome) relationship. B) If uncontrollable, intermittent stimulation is 
administered prior to instrumental testing, the subjects are unable to learn the relationship. C) 
In subjects that are given vehicle treatment (0.0 nmol of mGluR antagonist CPCCOEt), 
intermittent stimulation produces a significant spinal learning deficit. D) Treatment with 100 
nmol CPCCOEt blocks the deficit induced by intermittent stimulation, suggesting a necessary 
role for mGluR activity in this effect. Adapted from Ferguson et al., 2008a. 
Previous work has shown that metaplasticity in the hippocampus involves ionotropic 
glutamate receptor trafficking (Hellier et al., 2007). Given that mGluRs modulate ionotropic 
receptor function and trafficking through a PKC-mediated mechanism, we recently 
investigated the role of this mechanism in the metaplastic inhibition of spinal instrumental 
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learning (Ferguson et al., 2008a). We first tested whether group I mGluRs are necessary for 
the metaplastic inhibition of spinal learning. We found that intermittent stimulation had no 
effect on future spinal learning if given after an intrathecal injection of an mGluR antagonist 
(CPCCOEt or MPEP, Fig. 1D). We next considered the contribution of PKC to this learning 
deficit. We found that in response to intermittent stimulation (which produces a lasting 
metaplastic inhibition of spinal learning) PKC activity in the spinal cord was significantly 
increased (Figure 2A). Similarly, if PKC inhibitors (bisindolylmaleimide or chelerythrine) 
were delivered intrathecally prior to intermittent stimulation, subjects exhibited no 
metaplastic inhibition of learning when tested 24 hours later. These data provided strong 
evidence that both mGluR and PKC activity are necessary in producing this form of spinal 
metaplasticity. To further examine the role of mGluR/PKC in this phenomenon, we tested 
whether pharmacological activation of mGluRs was sufficient to produce metaplastic 
inhibition of spinal learning. We found that a single bolus of the mGluR agonist DHPG was 
able to produce a spinal learning deficit that lasted at least 24 hours. We also found that 
PKC activity blockade (with chelerythrine or bisindolylmaleimide) prior to administration 
of DHPG, prevented metaplastic inhibition of spinal learning. These findings suggest an 
essential role for the mGluR/PKC pathway in mediating metaplasticity in the spinal cord.  
 
Fig. 2. Role for PKC in the metaplastic inhibition of spinal learning. A) Intermittent 
stimulation (which induces a lasting metaplastic inhibition of spinal learning) produces an 
increase in the expression of activated PKC that is significantly greater than unstimulated 
controls at 1 hour. B) When tested for spinal instrumental learning, vehicle-treated subjects 
that had received intermittent stimulation fail to learn; intrathecal injection of the PKC 
inhibitor chelerythrine blocks intermittent stimulation from producing a learning deficit. 
Adapted from Ferguson et al., 2008a. 
As discussed above, PKC is known to alter the open-channel probability of NMDARs. Spinal 
learning, like many other forms of plasticity, has been characterized by its dependence on 
subtle, precise alterations in NMDAR function. Thus, it is likely that increased potentiation of 
NMDARs by the mGluR/PKC pathway upsets a delicate balance, pushing NMDARs (and 
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subsequent intracellular calcium levels) beyond the range in which spinal learning can 
occur. Other work has also implicated other protein kinase activity in both the adaptive and 
maladaptive metaplastic changes in spinal learning. Inhibition of calcium/calmodulin-
dependent protein kinase II (CaMKII) has been shown to block the development of the long-
term inhibition of spinal learning if given after uncontrollable shock, and also blocks the 
facilitation effect of instrumental training if given prior to training (Baumbauer et al., 2007; 
Gomez-Pinilla et al., 2007). These findings suggest that protein kinase activity may engage a 
common mechanism in different forms of spinal metaplasticity. Future work will be 
necessary to elucidate how the various protein kinases interact and integrate to produce 
these lasting behavioral changes. Further, if these mechanisms are at work in the injured 
spinal cord, we can begin to develop therapeutic strategies that can reduce maladaptive 
metaplasticity, and promote the adaptive plasticity necessary for successful rehabilitation.  
 
Fig. 3. Possible cellular mechanism for A) spinal learning and B) metaplastic inhibition of 
spinal learning. Both forms of spinal plasticity have been shown to involve protein kinase 
signaling. In contrast to controllable stimulation, uncontrollable stimulation is believed to 
engage group I metabotropic glutamate receptors, which leads to the downstream activation 
of PKC. PKC in turn alters ionotropic glutamate receptor function, which is believed to 
induce a lasting saturation of the synapse, inhibiting future learning. Adapted from 
Ferguson et al., 2008a. 
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4. Spinal cord injury: Protein kinase modulation as therapy 
The previous sections have focused on spinal plasticity in isolated systems: how the 
mGluR/PKC pathway modulates nociceptive processing in the dorsal horn, and how it 
mediates the metaplastic inhibition of a ventral motor learning task. These models yield 
insight into the mechanisms by which plasticity in the spinal cord occur, and demonstrate 
that protein kinase activity is an essential step in mediating long-term neural modifications. 
In this final section, we will consider the therapeutic potential in altering protein kinase 
activity for spinal cord injury and related CNS disorders.  
Within the wave of secondary processes following spinal cord injury, high levels of 
glutamate release can have a devastating effect on cell survival (Crowe et al., 1997; McAdoo 
et al., 1999; Ferguson et al., 2008b). As mGluR activation leads to PLC-mediated release of 
intracellular calcium stores, PKC activity increases, and in turn ionotropic glutamate 
receptors can be further potentiated. While this pathway can induce long-term spinal 
plasticity, the neural microenvironment around the spinal lesion is more vulnerable to 
excitotoxicity, and this cascade can ultimately lead to cellular degradation and excitotoxic 
cell death (Choi, 1992; Gereau & Heinemann, 1998; Mills et al., 2001). This has lead 
researchers to investigate the effect of PKC inhibition on cell survival after injury. Hara et al. 
showed that following ischemic injury, treatment with the PKC inhibitor staurosporine 
produced a neuroprotective effect (Hara et al. 1990). This group later showed that the broad 
protein kinase inhibitor fasudil was also effective in improving locomotor function and 
tissue sparing following a spinal cord injury (Hara et al., 2000). 
As secondary injury processes develop, a glial scar formed by chondroitin sulfate 
proteoglycans (CSPGs) is created to protect the damaged tissue (Fawcett & Asher, 1999). 
This scar formation, along with myelin-associated proteins, exerts inhibitory effects on 
axonal regeneration (McKerracher et al. 1994; Chen et al. 2000). Interestingly, PKC has been 
shown to be a key signaling mediator that is activated by these inhibitory agents 
(Sivanskaran et al., 2004). Sivasankaran and colleagues used immobilized substrates coated 
in either inhibitory myelin proteins or CSPGs to assay neurite outgrowth. They tested a 
range of PKC inhibitors, and found that inhibiting PKC activity stimulated neurite 
outgrowth on both the inhibitory myelin protein and CSPG substrates. Further, they were 
able to confirm these in vitro findings in an in vivo model of spinal cord injury. Rat subjects 
were given a dorsal hemisection, followed by an osmotic infusion of the PKC inhibitor 
Go6976 over the next 14 days. Results showed axonal regeneration in the dorsal column, 
with fibers crossing the lesion gap and extending as far as 6 mm (Sivasankaran et al., 2004). 
While this treatment appears promising, they showed very little axonal regeneration of the 
the corticospinal tract (CST), which is thought to be necessary in order to maximize 
functional recovery of descending motor control in primates, including humans (Blesch & 
Tuszynski, 2009). Further work will be needed to determine whether the regeneration 
promoted by PKC inhibition results in functional connectivity and improved behavioral 
outcomes.  
Recently, many spinal cord researchers have begun focusing on the signaling pathways that 
are activated by the inhibitory myelin proteins. Interestingly, many of these inhibitory 
proteins act through their receptors to activate a small GTPase called Rho (Niederost et al. 
2002). Rho is known to be important for regulating cytoskeletal structure and guiding axons 
in the developing CNS, and thus has been become a target of interest for those that seek to 
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promote the regeneration of axons across spinal cord lesions after injury (Hall, 1998; 
Dubreuil et al., 2003). Many researchers have focused on inhibiting or altering Rho function 
after spinal cord injury, and have shown this treatment to be effective in blocking the 
growth inhibitory factors that are rampant after spinal cord injury (McKerracher et al. 2006; 
Fehlings et al., 2011). Others have looked further downstream, to the protein kinase that is 
activated by Rho. Rho-associated protein kinase (ROCK) has been shown to mediate the 
retraction of neurites in vitro, and experimental activation of ROCK is known to regulate 
myelin phosphotase, an essential component of axonal sprouting (Hirose et al., 1998; 
Kimura et al. 1996). Thus, ROCK has become an attractive therapeutic target, as specific 
ROCK inhibition is believed to mitigate the inhibitory effects of those myelin-derived 
proteins that undermine axonal regeneration. In 2000, Bito and colleagues used cultured, 
immature cerebellar granule neurons to directly study the effects of ROCK inhibition on 
neurite outgrowth. By co-transfecting these cells with green fluorescent protein (GFP) and 
an active form of Rho (V14Rho), they observed a marked retardation of axonal growth. 
When they then introduced the ROCK inhibitor Y-27632, they found that inhibiting ROCK 
attenuated the stunted growth, and produced significant axon genesis.  
Building on these findings, Dergham and colleagues (2002) tested this same ROCK inhibitor 
on a variety of substrates coated with myelin inhibitory proteins or CSPG. They too found 
that in vitro administration of Y-27632 promoted the growth of primary neurons across these 
substrates. Further, they extended these findings to an in vivo spinal cord injury model. They 
gave mouse subjects dorsal hemisections, followed by spinal injection of Y-27632. They 
found that this ROCK inhibitor not only attenuated axonal dieback, but promoted the 
regeneration of neurons within the corticospinal tract, generating sprouting that stretched 2-
3 mms across the lesion site. The ROCK-inhibited subjects also exhibited a long-term 
improvement in locomotor function. In 2003, Fournier published a study that extended 
these findings to rats, showing similar results (Fournier et al., 2003). They found that ROCK 
inhibition with Y-27632 was not only sufficient to promote neurite outgrowth in vitro, but as 
with the Dergham study, they showed that ROCK inhibition after hemisection could 
promote CST axons to regenerate across the lesion, as well as produce significant behavioral 
improvement in comparision to vehicle-treated subjects. 
Taken together as a group, these data indicate a strong role for PKC as well as Rho kinases 
in morphological regeneration of the CST that is thought to be necessary for recovery of 
function after spinal cord injury (Blesch & Tuszynski, 2009; Nielson et al., 2010). However, 
recent findings have revealed that, even in the absence of CST regeneration through a spinal 
cord lesion, there may be substantial sprouting of surviving CST fibers below the lesion site 
in primates, which has been linked to improved recovery of function in forelimb control 
(Rosenzweig et al., 2010). This suggests a role for local spinal plasticity in restoring recovery 
of function in CST-dependent function. The role of mGluRs and PKC flux in these effects is 
largely unknown, and may represent a fruitful area for further study. 
5. Conclusions 
This chapter has reviewed the role of mGluRs and down-stream PKC activity as a major 
factor in a number of forms of plasticity throughout the spinal cord. Its ubiquity indicates a 
potential common mechanism for a host of complex processes, in both the intact and injured 
spinal cord. As a critical link between mGluR activation and ionotropic GluR trafficking and 
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phosphorylation, PKC activity can mediate either the potentiation or depression of synaptic 
strength, the promotion of neural regeneration or the exacerbation of excitotoxicity. In the 
future, targeting PKC activity within the appropriate circumstances, and at the right time, 
will be essential to tailoring effective treatments for both central and peripheral injuries, as 
well as in the promotion of use-dependent spinal plasticity. 
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regeneration of neurons within the corticospinal tract, generating sprouting that stretched 2-
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improvement in comparision to vehicle-treated subjects. 
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in morphological regeneration of the CST that is thought to be necessary for recovery of 
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recent findings have revealed that, even in the absence of CST regeneration through a spinal 
cord lesion, there may be substantial sprouting of surviving CST fibers below the lesion site 
in primates, which has been linked to improved recovery of function in forelimb control 
(Rosenzweig et al., 2010). This suggests a role for local spinal plasticity in restoring recovery 
of function in CST-dependent function. The role of mGluRs and PKC flux in these effects is 
largely unknown, and may represent a fruitful area for further study. 
5. Conclusions 
This chapter has reviewed the role of mGluRs and down-stream PKC activity as a major 
factor in a number of forms of plasticity throughout the spinal cord. Its ubiquity indicates a 
potential common mechanism for a host of complex processes, in both the intact and injured 
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phosphorylation, PKC activity can mediate either the potentiation or depression of synaptic 
strength, the promotion of neural regeneration or the exacerbation of excitotoxicity. In the 
future, targeting PKC activity within the appropriate circumstances, and at the right time, 
will be essential to tailoring effective treatments for both central and peripheral injuries, as 
well as in the promotion of use-dependent spinal plasticity. 
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1. Introduction 
There is abundant evidence that protein kinases are involved in the physiopathology of 
acute and chronic pain. In the first section, we discuss the role of protein kinases in pain and 
the signalling pathways involved in both the acute and chronic states. The second section 
will present evidence supporting the contribution of protein kinase inhibition to pain 
control by different classes of drugs. Both well-known drugs and new molecules can control 
pain in the peripheral and central nervous systems. The third section highlights the progress 
in pharmaceutical development and protein kinase research for new pain control drugs in 
the first decade of the 21st century.  
2. Role of protein kinases in acute and chronic pain  
In this section, we will discuss the differential activation of protein kinases by pain 
mediators and the modulation of the acute and chronic pain processes by several kinases.  
2.1 PKC 
Protein Kinase C (PKC) is a family of phospholipid-dependent serine/threonine 
phosphotransferases; it can be divided into the following groups of isoforms: a) conventional 
or classical (, I, II, ), b) novel (, , , ), and c) atypical (,  (mouse)/ (human)) isoforms 
(Nishizuka, 1992). Five subspecies of PKC, PKC-I, PKC-II, PKC-, PKC-, and PKC-, are 
expressed in the dorsal root ganglion (DRG) of rats (Cesare et al. 1999). The PKC isoforms 
that are expressed in the DRG of mice include PKC-, PKC-I, PKC-II, PKC-, PKC-, PKC-
, PKC-, PKC-, and PKC- (Khasar et al., 1999a). Thus, there are some differences in the 
expression of DRG PKC isoforms between species.  
Signal transduction through the PKC pathway has been strongly linked to pain. 
Inflammatory stimuli and mediators can activate PKC to induce pain. Nociceptive response 
caused by formalin injection into the mouse paw is characterised by two phases; the 
neurogenic response, which is due to direct nociceptor activation, and the inflammatory 
response, which is caused by inflammatory mediators (Hunskaar and Hole, 1987). In this 
model, PKC blockade by local treatment with chelerythrine inhibited the second phase of 
nociceptive response (Souza et al., 2002), which is driven largely by tissue inflammation, 
indicating a relationship between PKC activation and the inflammatory process. In the same 
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1. Introduction 
There is abundant evidence that protein kinases are involved in the physiopathology of 
acute and chronic pain. In the first section, we discuss the role of protein kinases in pain and 
the signalling pathways involved in both the acute and chronic states. The second section 
will present evidence supporting the contribution of protein kinase inhibition to pain 
control by different classes of drugs. Both well-known drugs and new molecules can control 
pain in the peripheral and central nervous systems. The third section highlights the progress 
in pharmaceutical development and protein kinase research for new pain control drugs in 
the first decade of the 21st century.  
2. Role of protein kinases in acute and chronic pain  
In this section, we will discuss the differential activation of protein kinases by pain 
mediators and the modulation of the acute and chronic pain processes by several kinases.  
2.1 PKC 
Protein Kinase C (PKC) is a family of phospholipid-dependent serine/threonine 
phosphotransferases; it can be divided into the following groups of isoforms: a) conventional 
or classical (, I, II, ), b) novel (, , , ), and c) atypical (,  (mouse)/ (human)) isoforms 
(Nishizuka, 1992). Five subspecies of PKC, PKC-I, PKC-II, PKC-, PKC-, and PKC-, are 
expressed in the dorsal root ganglion (DRG) of rats (Cesare et al. 1999). The PKC isoforms 
that are expressed in the DRG of mice include PKC-, PKC-I, PKC-II, PKC-, PKC-, PKC-
, PKC-, PKC-, and PKC- (Khasar et al., 1999a). Thus, there are some differences in the 
expression of DRG PKC isoforms between species.  
Signal transduction through the PKC pathway has been strongly linked to pain. 
Inflammatory stimuli and mediators can activate PKC to induce pain. Nociceptive response 
caused by formalin injection into the mouse paw is characterised by two phases; the 
neurogenic response, which is due to direct nociceptor activation, and the inflammatory 
response, which is caused by inflammatory mediators (Hunskaar and Hole, 1987). In this 
model, PKC blockade by local treatment with chelerythrine inhibited the second phase of 
nociceptive response (Souza et al., 2002), which is driven largely by tissue inflammation, 
indicating a relationship between PKC activation and the inflammatory process. In the same 
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way, mechanical sensitisation induced by the inflammatory mediator bradykinin in rats is 
inhibited by a PKC inhibitor (Souza et al., 2002). In vitro experiments conducted in DRG 
neurons strongly suggest that bradykinin-induced heat sensitisation is dependent on PKC 
activation because it can be reversed by pharmacological inhibition with staurosporine or 
phosphatase inhibitors (Burguess et al., 1989; Cesare and McNaughton, 1996). In vitro 
experiments have shown noticeable PKC-activity in rat DRGs after 3 hours of prostaglandin 
E2 (PGE2) paw administration. This activity was accompanied by paw sensitisation to 
mechanical stimuli, as measured by behavioural experiments (Sachs et al., 2009).  
Carrageenan injection in rat or mouse paws is another tool used to study inflammatory 
sensitisation. In the same way, pharmacological inhibition of PKC reduces carrageenan-
induced mechanical sensitisation in mice (Khasar et al., 1999a). Phosphorylation of PKCε in 
DRG neurons is increased after carrageenan-induced acute sensitisation (Zhou et al. 2003), 
and a PKC agonist sensitises nociceptors to mechanical stimuli (Aley and Levine, 2003). 
Inflammatory sensitisation has a “sympathetic” component that involves the release of 
amines such as epinephrine and dopamine (Coderre et al. 1984; Nakamura and Ferreira 
1987). Evidence suggests that mechanical sensitisation induced either by epinephrine in rats 
(Khasar et al. 1999b) or dopamine in mice (Villarreal et al., 2009b) is blocked by PKCε-
selective inhibition. Cesare et al. (1999) found that bradykinin exposure induces PKCε 
translocation from the cytosol to a membrane-associated position in cultured DRG neurons, 
thus contributing to heat sensitisation.  
The mechanical sensitisation induced by PGE2 involves the peripheral activation of PKCε in 
rats and mice, as shown by specific pharmacological inhibition (Sachs et al., 2009; Villareal et 
al., 2009b). In PKCε-mutant mice, the nociceptive threshold is preserved, whereas the 
nociceptive response was significantly impaired, as evaluated in a model of visceral pain 
using peritoneal administration of acetic acid (Khasar et al. 1999a). Kassuya et al. (2007), 
found a noticeable increase in membrane-bound PKC expression of mouse paw tissue after 
PGE2 administration (Kassuya et al., 2007). Thus, the PGE2–induced pain-related effects 
during inflammation may be mediated by PKC and PKC. 
Multiple voltage-gated sodium channel (VGSC) isoforms are expressed in DRG neurons. For 
example, isoforms Nav 1.8 and Nav 1.9 are responsible for tetrodotoxin-resistant (TTX-
resistant) currents due to Na+ channel blocker insensitivity. These sodium currents can be 
modulated by PKC phosphorylation, which is induced by inflammatory mediators (Gold et 
al., 1998; Khasar et al., 1999a). Using whole-cell voltage-clamp recordings from DRG 
neurons, Gold et al. (1998) found that PKC inhibitors decreased the density of tetrodotoxin-
resistant sodium current, whereas the PKC activator PMA produces changes that are 
opposite, suggesting that PKC modulates it. In addition, it was show a relationship between 
inflammatory mediators-induced changes in TTX-resistant sodium currents and PKC 
activity (Gold et al., 1998; Khasar et al., 1999a).  
PKC peripheral activation contributes to central pain processing. During serotonin-induced 
rat paw sensitisation, another pain-sensitising mediator associated with inflammation, the 
response of animals to thermal stimulation and c-fos activation in the dorsal horn is 
attenuated by intraplantar application of the PKC inhibitor chelerythrine (Chen et al., 2006). 
During inflammation or in naïve animals, activation of glutamate receptors mGluRs in the 
spinal dorsal horn modulates acute nociception. These receptors are coupled to Gq/II 
protein phospholipase C (PLC)-phosphoinositide (PI) hydrolysis and PKC pre- and post-
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synaptic activation (Neugebauer, 2002; Giles et al., 2007), suggesting that PKC modulates 
the synaptic transmission at the spinal level.  
PKC activation is associated with chronic pain conditions. Mao et al. (1992) found an 
increase in membrane-bound PKC in the spinal cord of rats in a model of post-injury 
neuropathic pain. The role of PKC was confirmed using an intracellular inhibitor of PKC 
translocation/activation and analysing membrane-bound PKC translocation and pain 
behaviour. The data suggest a role for PKC in neuropathic pain states. Ahlgren and Levine 
(1994) found a reduction in streptozotocin-induced diabetic rat pain sensitisation after 
treatment with PKC inhibitors.  
Using the partial sciatic nerve section model, Malmberg et al. (1997) verified that mice 
lacking PKC completely fail to develop neuropathic-associated sensitisation even though 
they respond normally to acute pain stimuli. In addition, PKC expression is restricted to a 
subset of dorsal horn neurons. Malmberg and co-workers suggest that targeting PKC is a 
promising tool for treating chronic pain. This isoform inhibition also attenuates opioid 
tolerance in the spinal cord (section 3). 
The physiopathology of alcoholic neuropathy in rats seems to depend on PKC activation 
and up-regulation in DRG neurons, as shown by selective pharmacological inhibition and 
western blot analysis performed after 70 days of ethanol administration (Dina et al., 2000). 
In addition, the role of PKC in pain sensitisation is associated with neuropathy induced by 
the antineoplastic agent paclitaxel in rats (Dina et al., 2001).  
The role of PKC is well demonstrated during chronic inflammatory pain conditions. Aley et 
al. (2000) developed a model to study chronic inflammatory sensitisation that can be 
induced by a single episode of acute inflammation; after the induction, in a time-lapse of 5 
days there is inflammatory-mediator prolonged-response. During this state, PKC seems to 
be responsible for the maintenance of this “primed state” and the prolonged response to 
inflammatory mediators (Aley et al. 2000). Accordingly, the phosphorylation of PKC in 
DRG neurons correlated with pain-associated prolonged inflammation after 3 days of the 
administration of Complete Freund’s Adjuvant (CFA) to rat paws (Zhou et al., 2003). 
Mechanical persistent inflammatory sensitisation can also be induced by intraplantar 
administration of inflammatory mediators like prostaglandins and sympathetic amines in 
rats and mice (Ferreira et al., 1990; Villarreal et al., 2009b). Studies suggest that PKC activity 
in the DRG is up-regulated by and is at least partially responsible for the persistent 
condition, as shown by analyses of PKC activity in rat DRGs (Villarreal et al. 2009a). 
Moreover, the local administration of a selective PKC inhibitor abolished the persistent 
state induced by PGE2 in rats and mice (Villarreal et al. 2009a; Villarreal et al., 2009b). 
Evaluation of the mechanisms downstream of PKC activation found that Nav1.8 mRNA 
levels in the DRG from rats was up-regulated and inhibition of PKC activity reduced these 
levels (Villarreal et al., 2009a).  
2.2 PKA  
Cyclic adenosine-monophosphate (cAMP)-dependent protein kinase (PKA) is a 
serine/threonine phosphotransferase; in its inactive form, it is a tetrameric holoenzyme 
composed of two regulatory and two catalytic subunits (Taylor et al., 1990). When the 
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serine/threonine phosphotransferase; in its inactive form, it is a tetrameric holoenzyme 
composed of two regulatory and two catalytic subunits (Taylor et al., 1990). When the 
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second messenger cAMP is generated the PKA-regulatory subunits bind cAMP, and the 
holoenzyme separates into the regulatory subunits and the catalytic subunits (Taylor et al., 
1990). The catalytic subunits can phosphorylate their biological targets and regulate many 
cellular functions. There are different regulatory (RI, RI, RII, RII) and catalytic (C, C) 
subunits;  subunits are expressed in non-neuronal and neuronal tissue, whereas  subunits 
are expressed predominantly in neuronal cells (Cadd and McKnight, 1989). 
cAMP/PKA signalling is involved in nociceptor sensitisation by inflammatory mediators. 
Ferreira and Nakamura (1979) provided evidence that sensitisation of rat hind-paws by 
prostaglandins is dependent on cAMP generation. Since this original study, many subsequent 
studies have shown that cAMP generation is induced by a plethora of inflammatory stimuli. 
The mechanical nociceptor sensitisation that occurs during inflammation or induced by 
either inflammatory mediators (PGE2, dopamine, serotonin) is blocked by treatment with 
PKA inhibitors in rats and mice (Taiwo and Levine 1991; Taiwo et al., 1992; Aley and Levine, 
1999; Aley et al., 2000; Sachs et al., 2009; Villarreal et al., 2009b). 
Adenylyl cyclase (AC)/cAMP/PKA activation may be necessary to induce and maintain 
mechanical nociceptor sensitisation (Aley and Levine, 1999). Moreover, PGE2–induced 
inflammatory sensitisation increased PKA activity in mouse paws (Kassuya et al., 2007); and 
in rat DRGs (Sachs et al., 2009), which correlates with the behavioural data. Accordingly, the 
intraplantar administration of the catalytic subunit of PKA (PKACS) induces mechanical 
nociceptor sensitisation (Aley and Levine, 1999; Aley and Levine, 2003). Supporting the 
animal model data, in vitro studies using sensory neurons that were cultured and bathed in 
classic inflammatory mediators showed that prostaglandins can sensitise these cells to 
bradykinin and that this effect is dependent on PKA activation (Cui and Nicol, 1995; Smith 
et al., 2000). The role of PKA in formalin-induced nociceptive pain and inflammatory 
sensitisation was demonstrated in experiments in mice with a null mutation in the type I 
regulatory subunit (RI) of PKA. This mutation dampens the response during nociceptive 
pain and thermal stimulation (Malmberg et al., 1997). 
Once activated, the PKA substrate in the nociceptive pathways can be voltage-gated sodium 
channels. In fact, in vitro studies have shown that TTX-resistant sodium current is 
modulated via PKA activation during inflammation (England et al., 1996; Gold et al., 1998). 
Additionally, during inflammation, PKA enhances the gating of transient receptor potential 
vanilloid channel-1 (TRPV-1) via direct phosphorylation (Lopshire and Nicol, 1998; Rathee 
et al., 2002). Therefore, PKA can directly phosphorylate ion channels, thus increasing the 
excitability of sensory neurons and contributing to some pain conditions. Studies using a 
model of persistent inflammatory sensitisation in rats and mice show that PKA could exert a 
role in the maintenance of the chronic state. The persistent sensitisation is abolished by 
injection of PKA inhibitors, and PKA expression and activity were up-regulated in DRG 
(Villarreal et al., 2009a, 2009b). The contribution of PKA to sensitisation maintenance seems 
to be due to the regulation of the Nav1.8 sodium channel expression (Villarreal et al., 2009a).  
In the neuropathic pain model of sciatic nerve ligature, PKARI-null animals present 
nociceptive responses that are similar to control animals (Malmberg et al., 1997). However, 
in a model of paclitaxel-induced pain neuropathy, pharmacological inhibition of PKA 
attenuates the response to thermal stimulation (Dina et al., 2001). Other subunits of PKA, 
different from PKARI, may be activated during neuropathy because PKA inhibitors do not 
present selectivity.  
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2.3 MAPKs 
Mitogen-Activated Protein Kinases (MAPKs) are protein-serine/threonine kinases. There 
are many subfamily isoforms known, and are currently 14 mammalian members. They are 
important for pain regulation and control and are divided in extracellular-signal-regulated 
kinases (ERKs, 7 isoforms), stress-activated protein kinases or c-Jun N-terminal kinases 
(JNKs, 3 isoforms) and p38 mitogen-activated protein kinases (p38 MAPK, 4 isoforms). 
These enzymes are activated by direct phosphorylation of two sites in the kinase activation 
loop, at a tyrosine and a threonine residue; separated by a single, variable residue (Pearson 
et al. 2001). 
Classically, upon receptor-dependent tyrosine kinase activation on the cellular surface, a 
cascade of biochemical reactions culminates in small GTPase (Ras) activation. This 
molecular event initiates a series of catalytic phosphorylation-based signalling, involving 
kinases such as the proto-oncogene serine/threonine-protein kinase (C-Raf), mitogen-
activated protein kinase kinase 1 (MEK1), MEK2 and MAPKs. The dual phosphorylation of 
these proteins leads to conformational changes, allowing their respective catalytic domains 
to be accessible to their substrates, which are mainly transcription factors that regulate 
diverse genes, and others proteins that are regulated by phosphorylation. In addition, the 
MAPKs interact with inactivating phosphatases, which finely tunes their cellular activity. 
The same hierarchical cascade exists for JNK and p38 MAPK activation, consisting of three 
consecutive steps of phosphorylation and activation of different kinases (MAPKKK  
MAPKK  MAPK). 
Extracellular mitogens such as growth factors (cytokines and hormones) and phorbol esters 
(e.g., 12-O-tetradecanoylphorbol-13-acetate, TPA) activate ERK1 and ERK2, which regulates 
cell proliferation and promotes effects such as induction or inhibition of differentiation, 
stimulation of secretory responses in a variety of cell types such as neutrophils, modulating 
membrane activity, and generating active oxygen species (Blumberg, 1988). The stress-
activated protein kinases, or JNKs, and p38 MAPK signalling pathways are responsive to 
stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, osmotic shock and 
cellular redox state, and are involved in cell differentiation and apoptosis. There are 10 
isoforms of the three JNKs due to alternative splicing of JNK-1, JNK-2, and JNK-3, and there 
are four p38 MAPK isoforms.  
These MAPKs are involved in processing cellular pain. Dai et al. (2002) demonstrated that 
ERK is activated in DRG neurons by electrical, thermal and chemical stimuli using 
electrophysiological recordings and western blot analysis. The peripheral stimulation of 
ERK1/2 and p38 MAPKs is involved in the nociceptor sensitisation produced by epinephrine, 
nerve grow factor (NGF) and capsaicin (Aley & Levine 2003, Zhu & Oxford, 2007). Activation 
of nuclear factor-kappaB (NF-κB), a transcription factor linked to inflammation, and p38 
MAPK leads to the formation of various pro-inflammatory cytokines, such as TNF-α, IL-1β, 
and IL-6 (Doyle et al. 2011). TNF-α may induce acute peripheral mechanical sensitisation by 
acting directly on its receptor TNFR1, which is localised in primary afferent neurons, 
resulting in the p38-dependent modulation of TTX-resistant Na+ channel currents (Jin & 
Gereau 2006; Zhang et al. 2011). 
In neurons, synaptic activity-induced increases in the intracellular Ca2+ concentration 
activate MAPKs. Ca2+/calmodulin-activated protein kinase (CaMKII) is essential for 
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The same hierarchical cascade exists for JNK and p38 MAPK activation, consisting of three 
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membrane activity, and generating active oxygen species (Blumberg, 1988). The stress-
activated protein kinases, or JNKs, and p38 MAPK signalling pathways are responsive to 
stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, osmotic shock and 
cellular redox state, and are involved in cell differentiation and apoptosis. There are 10 
isoforms of the three JNKs due to alternative splicing of JNK-1, JNK-2, and JNK-3, and there 
are four p38 MAPK isoforms.  
These MAPKs are involved in processing cellular pain. Dai et al. (2002) demonstrated that 
ERK is activated in DRG neurons by electrical, thermal and chemical stimuli using 
electrophysiological recordings and western blot analysis. The peripheral stimulation of 
ERK1/2 and p38 MAPKs is involved in the nociceptor sensitisation produced by epinephrine, 
nerve grow factor (NGF) and capsaicin (Aley & Levine 2003, Zhu & Oxford, 2007). Activation 
of nuclear factor-kappaB (NF-κB), a transcription factor linked to inflammation, and p38 
MAPK leads to the formation of various pro-inflammatory cytokines, such as TNF-α, IL-1β, 
and IL-6 (Doyle et al. 2011). TNF-α may induce acute peripheral mechanical sensitisation by 
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In neurons, synaptic activity-induced increases in the intracellular Ca2+ concentration 
activate MAPKs. Ca2+/calmodulin-activated protein kinase (CaMKII) is essential for 
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synaptic plasticity because it regulates transcriptional and translational modifications in 
gene expression and regulation. MAPKs are downstream effectors of multiple kinases, 
including CaMKII. Membrane depolarisation and calcium influx activate MAPK/ERK 
kinases. ERK and p38 MAPKs are up-regulated both in primary afferent nerves and the 
spinal cord in response to noxious stimulation, nerve injury and tissue injury. Inhibition of 
ERK or p38 MAPK phosphorylation or activity induces an antinociceptive effect in many of 
the animal pain models described throughout this section. Thus, in addition to the PKA and 
PKC signalling pathways, some cross-talk may exist with MAPK cascades upon inflammation 
or injury. 
As an example, IL-6 exerts an important role in the development and maintenance of 
muscular sensitisation to nociception. The IL-6-mediated muscular pain response involves 
resident cell activation, polymorphonuclear cell infiltration, cytokine production, 
prostanoids and sympathomimetic amines release (Manjavachi et al. 2010). This response to 
IL-6 triggers the activation of intracellular pathways, especially MAPKs. Upon IL-6 
stimulation, ERK, p38 MAPK and JNK phosphorylation is measurable by flux cytometry, 
and selective inhibitors of ERK and p38 MAPK partially reduced mechanical nociceptive 
behaviour (Manjavachi et al. 2010). Inflamed tissues release NGF that act upon nociceptors, 
activating the p38 MAPK cascade and leading to an increase of TRPV-1 translation and 
transport to nerve terminals, which contributes to the maintenance of nociceptive behaviour 
in animal models (Ji et al. 2002). Additionally, two separate p38 MAPK pharmacological 
inhibitors were effective at inhibiting the development of burn-induced sensitisation when 
administered as intrathecal pre-treatments (Sorkin et al. 2009).  
A screen of MAPK activation in the dorsal horn in both phases of the formalin test 
demonstrated that p38 MAPK is activated in spinal microglia. Thus, a reduction in the level 
of spinal p38β, but not p38α, prevented the development of sensitisation following 
peripheral inflammation (Li et al., 2010). Any study of MAPK signalling must also consider 
the effect of nervous system cells other than neurons in the pain process. 
The same kind of consideration is needed for chronic pain. Synaptic and nerve plasticity is a 
key element in pain chronification. Changes in structure and function as a result of input 
from the environment, lesions and pathologies may lead to neuropathic pain. These changes 
depend upon transcriptional and translational modifications in cell function that are 
mediated by MAPK signalling. Thus, MAPK modulation became a natural choice for 
research and the development of new drugs and pharmacological tools. 
Pfizer Global Research and Development published a research paper in 2003 showing that 
the development of neuropathic pain is associated with an increase in the activity of the 
MAPK/ERK-kinase cascade within the spinal cord. They explored the chronic constriction 
injury model and the streptozocin-induced diabetic model to mimic neuropathic pain states. 
Global changes in gene expression and the effect of MAPK/ERK-kinase (MEK) inhibitor 
were analysed (Ciruela et al., 2003). These efforts lead to the selection of these kinases as 
targets of drug design for pain, with a focus on neuropathic pain.  
The MAPK intracellular signalling cascades are also associated with synaptic long-term 
potentiation and memory and are associated with nociceptive behaviour in spinal cord 
injury (Crown et al., 2006). ERK 1/2 and p38 MAPK phosphorylation levels are up-
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regulated in rat-spinal cords during mechanical sensitisation after spinal cord injury. 
Neurons are not the only cells involved in this process; microglial but not astrocytic p38α 
contributes to the maintenance of neuronal hyperexcitability in caudal areas after spinal 
cord injury (Gwak et al. 2009). 
The IL-6/p38 MAPK/CX3C Receptor 1 signalling cascade is involved in neural–glial 
communication and plays an important role in triggering spinal glial activation and 
facilitating pain processing following peripheral nerve injury. Up-regulation of CX3CR1 
expression by IL-6-p38 MAPK signalling enhances the responsiveness of microglia to 
chemokine CXCL1, or fractalkine, after nerve injury (Lee et al., 2010). TNF-α is important 
during the development of neuropathic pain by spinal nerve ligature (SNL) (Schäfers et al., 
2003). The inhibition of spinal p38 MAPK activation prevents this event. However, the 
activation of ERK but not p38 MAPK is critically involved in the TNFα-induced increase in 
TRPV1 expression in cultured DRG neurons (Hensellek et al., 2007). 
Injury to peripheral nerves may result in the formation of neuromas. Elevated levels of 
phosphorylated ERK1/2 can be identified in individual neuroma axons that also possess the 
voltage-gated sodium channel Nav1.7. Painful human neuromas show accumulation of this 
sodium channel, and its function is modulated by ERK1/2 phosphorylation (Persson et al., 
2011). 
MAPK expression analysed in the spinal cord after SNL showed differential activation in 
injured and uninjured DRG neurons. Uninjured neurons had only p38 MAPK detectable 
induction. In contrast ERK, p38 MAPK and JNK were activated in several populations of 
injured DRG neurons (Obata et al., 2004). Differential activation of MAPK in lesioned and 
sound primary nerve afferents may be linked to the pathogenesis of neuropathic pain after 
partial nerve injury (Svensson et al., 2003). 
2.4 Interplay between pathways 
The specificity of activation for each signalling pathway may be determined by the stimuli 
(Juntilla et al., 2008), and the crosstalk between them could be induced during pathological 
states (Noselli, 2000). Pimienta and Pascual (2007) described MAPK intracellular signalling 
as “different signalling cascades crosstalk with each other in a way that their functional 
compensation makes possible the simultaneous integration of multiple inputs”. 
Considering only one inflammatory mediator, PGE2, in three models performed in the same 
species (mice) with analyses of not the same tissue, differences between the signalling 
pathways involved can be detected: 
a. Acute nociception induced by high-dose PGE2 administration is dependent on ERK 
signalling mechanisms because its overexpression was detected in hind paw by western 
immunoblotting analyses (Kassuya et al., 2007). This effect was reversed by EP receptor 
antagonists (Kassuya et al., 2007).  
b. In the same way, PGE2 is a final mediator of nociceptor sensitisation that acts on the 
peripheral nerve endings through the prostanoid receptors, leading to sensitisation of 
sensory nerves. PGE2-induced acute mechanical sensitisation, which is also associated 
with kinase activation, was completely prevented by PKA and PKCε, but not by ERK, 
pharmacological inhibition (Villarreal et al. 2009b). The persistent pain state induced by 
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synaptic plasticity because it regulates transcriptional and translational modifications in 
gene expression and regulation. MAPKs are downstream effectors of multiple kinases, 
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or injury. 
As an example, IL-6 exerts an important role in the development and maintenance of 
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activating the p38 MAPK cascade and leading to an increase of TRPV-1 translation and 
transport to nerve terminals, which contributes to the maintenance of nociceptive behaviour 
in animal models (Ji et al. 2002). Additionally, two separate p38 MAPK pharmacological 
inhibitors were effective at inhibiting the development of burn-induced sensitisation when 
administered as intrathecal pre-treatments (Sorkin et al. 2009).  
A screen of MAPK activation in the dorsal horn in both phases of the formalin test 
demonstrated that p38 MAPK is activated in spinal microglia. Thus, a reduction in the level 
of spinal p38β, but not p38α, prevented the development of sensitisation following 
peripheral inflammation (Li et al., 2010). Any study of MAPK signalling must also consider 
the effect of nervous system cells other than neurons in the pain process. 
The same kind of consideration is needed for chronic pain. Synaptic and nerve plasticity is a 
key element in pain chronification. Changes in structure and function as a result of input 
from the environment, lesions and pathologies may lead to neuropathic pain. These changes 
depend upon transcriptional and translational modifications in cell function that are 
mediated by MAPK signalling. Thus, MAPK modulation became a natural choice for 
research and the development of new drugs and pharmacological tools. 
Pfizer Global Research and Development published a research paper in 2003 showing that 
the development of neuropathic pain is associated with an increase in the activity of the 
MAPK/ERK-kinase cascade within the spinal cord. They explored the chronic constriction 
injury model and the streptozocin-induced diabetic model to mimic neuropathic pain states. 
Global changes in gene expression and the effect of MAPK/ERK-kinase (MEK) inhibitor 
were analysed (Ciruela et al., 2003). These efforts lead to the selection of these kinases as 
targets of drug design for pain, with a focus on neuropathic pain.  
The MAPK intracellular signalling cascades are also associated with synaptic long-term 
potentiation and memory and are associated with nociceptive behaviour in spinal cord 
injury (Crown et al., 2006). ERK 1/2 and p38 MAPK phosphorylation levels are up-
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regulated in rat-spinal cords during mechanical sensitisation after spinal cord injury. 
Neurons are not the only cells involved in this process; microglial but not astrocytic p38α 
contributes to the maintenance of neuronal hyperexcitability in caudal areas after spinal 
cord injury (Gwak et al. 2009). 
The IL-6/p38 MAPK/CX3C Receptor 1 signalling cascade is involved in neural–glial 
communication and plays an important role in triggering spinal glial activation and 
facilitating pain processing following peripheral nerve injury. Up-regulation of CX3CR1 
expression by IL-6-p38 MAPK signalling enhances the responsiveness of microglia to 
chemokine CXCL1, or fractalkine, after nerve injury (Lee et al., 2010). TNF-α is important 
during the development of neuropathic pain by spinal nerve ligature (SNL) (Schäfers et al., 
2003). The inhibition of spinal p38 MAPK activation prevents this event. However, the 
activation of ERK but not p38 MAPK is critically involved in the TNFα-induced increase in 
TRPV1 expression in cultured DRG neurons (Hensellek et al., 2007). 
Injury to peripheral nerves may result in the formation of neuromas. Elevated levels of 
phosphorylated ERK1/2 can be identified in individual neuroma axons that also possess the 
voltage-gated sodium channel Nav1.7. Painful human neuromas show accumulation of this 
sodium channel, and its function is modulated by ERK1/2 phosphorylation (Persson et al., 
2011). 
MAPK expression analysed in the spinal cord after SNL showed differential activation in 
injured and uninjured DRG neurons. Uninjured neurons had only p38 MAPK detectable 
induction. In contrast ERK, p38 MAPK and JNK were activated in several populations of 
injured DRG neurons (Obata et al., 2004). Differential activation of MAPK in lesioned and 
sound primary nerve afferents may be linked to the pathogenesis of neuropathic pain after 
partial nerve injury (Svensson et al., 2003). 
2.4 Interplay between pathways 
The specificity of activation for each signalling pathway may be determined by the stimuli 
(Juntilla et al., 2008), and the crosstalk between them could be induced during pathological 
states (Noselli, 2000). Pimienta and Pascual (2007) described MAPK intracellular signalling 
as “different signalling cascades crosstalk with each other in a way that their functional 
compensation makes possible the simultaneous integration of multiple inputs”. 
Considering only one inflammatory mediator, PGE2, in three models performed in the same 
species (mice) with analyses of not the same tissue, differences between the signalling 
pathways involved can be detected: 
a. Acute nociception induced by high-dose PGE2 administration is dependent on ERK 
signalling mechanisms because its overexpression was detected in hind paw by western 
immunoblotting analyses (Kassuya et al., 2007). This effect was reversed by EP receptor 
antagonists (Kassuya et al., 2007).  
b. In the same way, PGE2 is a final mediator of nociceptor sensitisation that acts on the 
peripheral nerve endings through the prostanoid receptors, leading to sensitisation of 
sensory nerves. PGE2-induced acute mechanical sensitisation, which is also associated 
with kinase activation, was completely prevented by PKA and PKCε, but not by ERK, 
pharmacological inhibition (Villarreal et al. 2009b). The persistent pain state induced by 
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chronic PGE2 administration is completely abolished by PKA or PKCε inhibitors, but 
not by ERK inhibitors (Villarreal et al. 2009b).  
Thus, we conclude that PKA, PKC and ERK are involved in the effects of PGE2 (including 
nociceptor sensitisation and nociception). The inflammatory processes include several 
others mediators in addition to PGE2. In the same work, Villarreal et al. (2009b) showed that 
dopamine-induced acute sensitisation involves PKA, PKC and ERK activation, whereas the 
dopamine-induced persistent sensitisation state is abolished by ERK inhibition and 
temporarily inhibited by PKA or PKCε inhibitors, suggesting that ERK plays the major role. 
So, what is the real meaning of these results?  
The study of MAPK and other kinases must keep its momentum. The interplay between 
different signalling pathways is challenging to understand. The available experimental 
models allow individual probing of each mediator and the kinase transduction of its 
signalling. Biological systems and pathological states have multiple variables in a complex 
regulated environment that hinder our understanding of each molecule and their combined 
role. Nevertheless, the continuous efforts have already achieved interesting findings. In the 
next sections, additional mechanisms and protein kinases will be described in discussing the 
pharmacological mechanisms of different drug classes in pain control.  
3. Role of protein kinases in pain control 
Both acute and chronic pain are usually controlled by administration of pharmacological 
agents (analgesics and adjuvants) that attempt to tackle pain in both the central and peripheral 
divisions of the nociceptive pathway. Although a classical mechanism of action is well 
described for most drugs, additional mechanisms link their analgesic effects with some 
kinases-dependent pathways, mainly pathways related to PKA, PKC, MAPKs and cyclic 
guanosine monophosphate (cGMP)-dependent protein kinase (PKG). In this section, the 
involvement of protein kinases in the mechanisms of action of drugs used for pain control, 
such as opioids, dipyrone, general and local anaesthetics and antidepressants will be analysed.  
3.1 Opioids 
Among opioids, morphine is widely used as a classical opioid analgesic for the clinical 
management of acute and chronic pain. Despite its wide use, tolerance to the analgesic 
actions of morphine is an important side effect of prolonged exposure. Individuals who are 
tolerant to the effects of morphine require larger doses to elicit the same amount of 
analgesia. Thus, antinociceptive tolerance and the high doses required to achieve effects 
have limited the use of morphine.  
Many factors have been related to morphine tolerance, such as a change of the descending 
pain modulatory pathway, receptor desensitisation, down-regulation of opioid functional 
receptors, release of excitatory neurotransmission and other adaptive changes in cell 
signalling pathways. Interestingly, PKC, especially PKCγ, plays a major role in the changes 
associated with morphine tolerance. Song et al. (2010) demonstrated that an isoform-specific 
inhibitor could successfully down-regulate PKCγ in the spinal cord and reverse the 
development of morphine tolerance in rats. This result not only implicates this PKC isoform 
in the opioid tolerance mechanism but also has potential applications in pain management. 
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Beyond the involvement of PKC in opioid tolerance, PKC is involved in inflammatory and 
neuropathic pain. The capacity of opioids to alleviate inflammatory pain is negatively 
regulated by the glutamate-binding N-methyl-D-aspartate receptor (NMDAR). And 
increased activity of this receptor complicates the clinical use of opioids for treating 
neuropathic pain. Rodríguez-Muñoz et al. (2011) indicated that morphine disrupts the 
glutamate-binding NMDAR complex by PKC-mediated phosphorylation and potentiates 
the NMDAR-CaMKII pathway, which is implicated in morphine tolerance. Inhibition of 
PKC restored the antinociceptive effect of morphine on the -opioid receptor (MOR). Thus, 
the opposing activities of the MOR and NMDAR in pain control affect their relation within 
neurons of structures such as the periaqueductal grey (PAG), a region that is implicated in 
the opioid control of nociception. This finding could be exploited in developing bifunctional 
drugs that would act exclusively on NMDARs associated with MORs. 
MORs are not the only opioid receptors that influence PKC. Berg et al. (2011), who were 
investigating the regulation of the κ-opioid receptor (KOR) in rat primary sensory neurons 
in vitro and in a rat model of thermal sensitisation, showed that the application of a KOR 
agonist (U50488) did not inhibit AC activity or release of calcitonin gene-related peptide 
(CGRP) in vitro and did not inhibit thermal sensitisation in vivo. It is important to note that 
AC activity, CGRP release, and thermal sensitisation process are related to PKC activation 
(see section 2). However, after a 15-min pretreatment with bradykinin, the agonist became 
capable of inhibiting AC activity, CGRP release, and thermal sensitisation. The in vitro 
effects of bradykinin on the KOR agonist were abolished by a PKC inhibitor; thus, Berg and 
co-workers suggest that PKC activation mediates BK-induced regulation of the KOR system. 
More studies are necessary to understand the mechanisms by which peripheral KOR agonist 
efficacy is regulated and the relationship of the KOR agonist effects with PKC activation.  
In this regard, formalin-induced inflammatory nociception may inhibit morphine tolerance 
in mice. In this model, conventional PKC (cPKC) is up-regulated and treatment with an 
antisense oligonucleotide (AS-ODN) directed against cPKC abolished the development of 
morphine tolerance, suggesting that cPKC is involved in morphine tolerance development 
(Fujita-Hamabe et al., 2010). Additionally, formalin-induced inflammatory nociception 
inhibit morphine tolerance by a mechanism involving KOR activation, down-regulation of 
cPKC, and up-regulation of MOR activity (Fujita-Hamabe et al., 2010). The data suggest a 
key role to cPKC in opioid-induced tolerance and that nociception-activated mechanisms 
may modulate opioid-response, improving it. In addition, studying the effects of chronic 
ethanol–induced neuropathy in rats, Narita et al. (2007) showed that chronic ethanol 
exposure dysregulated MOR but not DOR and KOR, and was related to PKC up-regulation 
in the spinal cord, which may explain the reduced sensitivity to the morphine 
antinociceptive effect. Taken together, these findings suggest the PKC activation disrupts 
MOR function, which could be counteracted by the KOR system. How the DOR participates 
remains unclear. 
Like PKC, PKA may also play a role in morphine antinociceptive tolerance. Previous studies 
have shown that chronic exposure to morphine results in intracellular adaptations within 
neurons that cause an increase in PKA activity. Unexpectedly, sustained morphine 
treatment produces paradoxical pain sensitisation (opioid-induced hyperalgesia) and causes 
an increase in spinal pain-related neurotransmitter concentrations, such as CGRP, in 
experimental animals. Studies have also shown that PKA plays a major role in the 
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chronic PGE2 administration is completely abolished by PKA or PKCε inhibitors, but 
not by ERK inhibitors (Villarreal et al. 2009b).  
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dopamine-induced acute sensitisation involves PKA, PKC and ERK activation, whereas the 
dopamine-induced persistent sensitisation state is abolished by ERK inhibition and 
temporarily inhibited by PKA or PKCε inhibitors, suggesting that ERK plays the major role. 
So, what is the real meaning of these results?  
The study of MAPK and other kinases must keep its momentum. The interplay between 
different signalling pathways is challenging to understand. The available experimental 
models allow individual probing of each mediator and the kinase transduction of its 
signalling. Biological systems and pathological states have multiple variables in a complex 
regulated environment that hinder our understanding of each molecule and their combined 
role. Nevertheless, the continuous efforts have already achieved interesting findings. In the 
next sections, additional mechanisms and protein kinases will be described in discussing the 
pharmacological mechanisms of different drug classes in pain control.  
3. Role of protein kinases in pain control 
Both acute and chronic pain are usually controlled by administration of pharmacological 
agents (analgesics and adjuvants) that attempt to tackle pain in both the central and peripheral 
divisions of the nociceptive pathway. Although a classical mechanism of action is well 
described for most drugs, additional mechanisms link their analgesic effects with some 
kinases-dependent pathways, mainly pathways related to PKA, PKC, MAPKs and cyclic 
guanosine monophosphate (cGMP)-dependent protein kinase (PKG). In this section, the 
involvement of protein kinases in the mechanisms of action of drugs used for pain control, 
such as opioids, dipyrone, general and local anaesthetics and antidepressants will be analysed.  
3.1 Opioids 
Among opioids, morphine is widely used as a classical opioid analgesic for the clinical 
management of acute and chronic pain. Despite its wide use, tolerance to the analgesic 
actions of morphine is an important side effect of prolonged exposure. Individuals who are 
tolerant to the effects of morphine require larger doses to elicit the same amount of 
analgesia. Thus, antinociceptive tolerance and the high doses required to achieve effects 
have limited the use of morphine.  
Many factors have been related to morphine tolerance, such as a change of the descending 
pain modulatory pathway, receptor desensitisation, down-regulation of opioid functional 
receptors, release of excitatory neurotransmission and other adaptive changes in cell 
signalling pathways. Interestingly, PKC, especially PKCγ, plays a major role in the changes 
associated with morphine tolerance. Song et al. (2010) demonstrated that an isoform-specific 
inhibitor could successfully down-regulate PKCγ in the spinal cord and reverse the 
development of morphine tolerance in rats. This result not only implicates this PKC isoform 
in the opioid tolerance mechanism but also has potential applications in pain management. 
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Beyond the involvement of PKC in opioid tolerance, PKC is involved in inflammatory and 
neuropathic pain. The capacity of opioids to alleviate inflammatory pain is negatively 
regulated by the glutamate-binding N-methyl-D-aspartate receptor (NMDAR). And 
increased activity of this receptor complicates the clinical use of opioids for treating 
neuropathic pain. Rodríguez-Muñoz et al. (2011) indicated that morphine disrupts the 
glutamate-binding NMDAR complex by PKC-mediated phosphorylation and potentiates 
the NMDAR-CaMKII pathway, which is implicated in morphine tolerance. Inhibition of 
PKC restored the antinociceptive effect of morphine on the -opioid receptor (MOR). Thus, 
the opposing activities of the MOR and NMDAR in pain control affect their relation within 
neurons of structures such as the periaqueductal grey (PAG), a region that is implicated in 
the opioid control of nociception. This finding could be exploited in developing bifunctional 
drugs that would act exclusively on NMDARs associated with MORs. 
MORs are not the only opioid receptors that influence PKC. Berg et al. (2011), who were 
investigating the regulation of the κ-opioid receptor (KOR) in rat primary sensory neurons 
in vitro and in a rat model of thermal sensitisation, showed that the application of a KOR 
agonist (U50488) did not inhibit AC activity or release of calcitonin gene-related peptide 
(CGRP) in vitro and did not inhibit thermal sensitisation in vivo. It is important to note that 
AC activity, CGRP release, and thermal sensitisation process are related to PKC activation 
(see section 2). However, after a 15-min pretreatment with bradykinin, the agonist became 
capable of inhibiting AC activity, CGRP release, and thermal sensitisation. The in vitro 
effects of bradykinin on the KOR agonist were abolished by a PKC inhibitor; thus, Berg and 
co-workers suggest that PKC activation mediates BK-induced regulation of the KOR system. 
More studies are necessary to understand the mechanisms by which peripheral KOR agonist 
efficacy is regulated and the relationship of the KOR agonist effects with PKC activation.  
In this regard, formalin-induced inflammatory nociception may inhibit morphine tolerance 
in mice. In this model, conventional PKC (cPKC) is up-regulated and treatment with an 
antisense oligonucleotide (AS-ODN) directed against cPKC abolished the development of 
morphine tolerance, suggesting that cPKC is involved in morphine tolerance development 
(Fujita-Hamabe et al., 2010). Additionally, formalin-induced inflammatory nociception 
inhibit morphine tolerance by a mechanism involving KOR activation, down-regulation of 
cPKC, and up-regulation of MOR activity (Fujita-Hamabe et al., 2010). The data suggest a 
key role to cPKC in opioid-induced tolerance and that nociception-activated mechanisms 
may modulate opioid-response, improving it. In addition, studying the effects of chronic 
ethanol–induced neuropathy in rats, Narita et al. (2007) showed that chronic ethanol 
exposure dysregulated MOR but not DOR and KOR, and was related to PKC up-regulation 
in the spinal cord, which may explain the reduced sensitivity to the morphine 
antinociceptive effect. Taken together, these findings suggest the PKC activation disrupts 
MOR function, which could be counteracted by the KOR system. How the DOR participates 
remains unclear. 
Like PKC, PKA may also play a role in morphine antinociceptive tolerance. Previous studies 
have shown that chronic exposure to morphine results in intracellular adaptations within 
neurons that cause an increase in PKA activity. Unexpectedly, sustained morphine 
treatment produces paradoxical pain sensitisation (opioid-induced hyperalgesia) and causes 
an increase in spinal pain-related neurotransmitter concentrations, such as CGRP, in 
experimental animals. Studies have also shown that PKA plays a major role in the 
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regulation of presynaptic neurotransmitter (such as CGRP and substance P) synthesis and 
release. Tumati et al. (2011) previously showed that in cultured DRG neurons, sustained in 
vitro opioid agonist treatment up-regulates cAMP levels (AC superactivation) and augments 
CGRP release in a PKA-dependent manner. The authors also showed that selective knock-
down of spinal PKA activity by intrathecal pretreatment of rats with a PKA-selective small 
interference RNA (siRNA) mixture significantly attenuates sustained morphine-mediated 
augmentation of spinal CGRP immunoreactivity, thermal and mechanical sensitisation and 
antinociceptive tolerance. These findings indicate that sustained morphine-mediated 
activation of spinal cAMP/PKA-dependent signalling may play an important role in opioid-
induced pain sensitisation. More specifically, morphine acts acutely on MORs, which couple 
with G-proteins to inhibit AC and reduce PKA activity. However, during tolerance, MORs 
become uncoupled from G-proteins, AC inhibition is reduced, and PKA activity is 
increased. These findings also provide potential molecular targets for pharmacological 
intervention to prevent the development of such paradoxical pain sensitisation. 
The majority of studies that have demonstrated an increase in PKA activity during opioid 
tolerance have been conducted in rats using brain regions associated with the reinforcing 
properties of opioids, such as the locus coeruleus and nucleus accumbens. Studying the 
expression of morphine antinociceptive tolerance at the behavioural level (tail-flick test) and 
the alterations in PKA activity at the cellular level in mouse brain (PAG, medulla, thalamus) 
and lumbar spinal cord, Dalton et al. (2005) support the hypothesis that an increase in PKA 
activity contributes to the tolerance to morphine-induced antinociception. However, the 
effect of chronic morphine treatment for 15 days on PKA activity was region-specific 
because increases in cytosolic PKA activity were observed in the lumbar spinal cord. In 
contrast, PKA activity/kinetics was not altered in the PAG, medulla or thalamus. These 
results demonstrate that spinal and supraspinal PKA activity are differentially altered 
during morphine tolerance. Thus, the neurons in mouse brain and lumbar spinal cord that 
make up the pain pathway from the brainstem to the spinal cord respond differently to 
chronic morphine treatment. To confirm these findings, future studies need to elucidate the 
differential responses to chronic morphine treatment using in vivo models of morphine 
antinociceptive tolerance concerning the PKA involvement. 
Using a behavioural paw pressure test in rats, Yamdeu et al. (2011) demonstrated that up-
regulation of NGF, through activation of the p38 MAPK pathway, lead to adaptive changes 
in sensory neuron opioid receptors that enhance susceptibility to local opioids. After 
intraplantar NGF treatment, this effect occurs in three consecutive steps: MOR expression is 
increased in DRG at 24 h, increased axonal MOR transport at 48 h, and increased MOR 
density at 96 h. Consequently, the dose-dependent peripheral antinociceptive effects of 
locally applied full opioid agonists such as fentanyl are potentiated, and the effects of partial 
opioid agonists such as buprenorphine are more efficacious, which is reversed by the 
intrathecal administration of p38 MAPK inhibitor SB203580. Thus, in rats, peripheral 
inflammation increases MOR expression in nociceptors by NGF activation of p38 MAPK. 
This mechanism may act as a counter-regulatory response to painful p38 MAPK–induced 
conditions, such as inflammatory pain, to facilitate exogenously or endogenously mediated 
opioid antinociception. 
Recently, the roles of several MAPKs, including p38 MAPK and ERK, have been 
investigated in animal models of morphine tolerance and postoperative nociceptive 
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sensitisation. It is unknown, however, whether prior morphine-induced MAPK activation 
affects the resolution of postoperative nociceptive sensitisation. Horvath et al. (2010) 
investigated the effect of morphine-induced antinociceptive tolerance on the resolution of 
postoperative nociceptive sensitisation. They hypothesised that prior chronic morphine 
administration would inhibit or delay the resolution of postoperative nociceptive 
sensitisation via enhanced spinal glial proteins expression and MAPK signalling. Chronic 
morphine treatment attenuated the resolution of postoperative nociceptive sensitisation, as 
determined by thermal and mechanical behavioural tests, and enhanced microglial p38 
MAPK and ERK phosphorylation. To better understand these results, prior chronic 
morphine exposure could prime microglia, causing exacerbated MAPK signalling pathway 
activation following subsequent paw incision injury. This would cause more robust 
microglial responses in rats with a history of morphine tolerance versus naïve rats, and this 
response is manifested by further neuronal sensitisation, behavioural hypersensitivity and 
inhibition of the resolution of the postoperative-associated nociceptive condition. The 
Horvath and co-workers study indicates that microglial MAPKs play a role in the 
mechanisms by which morphine attenuates the resolution of postoperative pain and 
suggests that patients who abuse opioids or are on chronic opioid therapy may be more 
susceptible to developing chronic pain syndromes following acute injury. 
In conclusion, protein kinases (PKs) exert a crucial role in pain control responses mediated 
by opioids, mainly in tolerance-induced mechanisms. Thus, PKs could be the key to better 
understanding opioid pharmacodynamics. 
3.2 General and local anaesthetics  
3.2.1 General anaesthetics 
Ketamine is an NMDAR antagonist that is available for clinical use as a general anaesthetic. 
Ketamine presents analgesic effect in acute and chronic pain models in both animals and 
humans (Mathisen et al. 1995, Rabben et al., 1999; Visser & Schug, 2006; Pascual et al., 2010).  
The involvement of kinases in the analgesic effect of ketamine has been investigated. Using 
a model of neuropathic pain induced by SNL in rats, Mei et al. (2011) showed that SNL 
induced ipsilateral JNK phosphorylation up-regulation in astrocytes, but not microglia or 
neurons, within the spinal dorsal horn. Intrathecal ketamine relieved SNL-induced 
mechanical sensitisation and produced a dose-dependent effect on the suppression of SNL-
induced spinal astrocytic JNK phosphorylation but had no effect on JNK protein expression, 
suggesting that the inhibition of spinal JNK activation may be involved in the analgesic 
effects of ketamine in this model.  
The inhibition of MAPK phosphorylation by ketamine has also been related to a reduction 
in cytokine gene expressions in lipopolysaccharide (LPS)-activated macrophages (Wu et al., 
2008). A therapeutic concentration of ketamine can decrease LPS-induced JNK 
phosphorylation, thus inhibiting TNF-α and IL-6 gene expression, which leads to the 
suppression of LPS-induced macrophage activation (Wu et al., 2008). In addition, ketamine 
reduced IL-1β biosynthesis in LPS-stimulated macrophages through the suppression of Ras, 
Raf, MEK1/2, and ERK1/2/IKK phosphorylation and the subsequent translocation and 
transactivation of the transcription factor NF-κB (Chen et al., 2009). The involvement of 
TNF-α, IL-6 and IL-1β in inflammatory nociceptive sensitisation is well known. Thus, the 
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regulation of presynaptic neurotransmitter (such as CGRP and substance P) synthesis and 
release. Tumati et al. (2011) previously showed that in cultured DRG neurons, sustained in 
vitro opioid agonist treatment up-regulates cAMP levels (AC superactivation) and augments 
CGRP release in a PKA-dependent manner. The authors also showed that selective knock-
down of spinal PKA activity by intrathecal pretreatment of rats with a PKA-selective small 
interference RNA (siRNA) mixture significantly attenuates sustained morphine-mediated 
augmentation of spinal CGRP immunoreactivity, thermal and mechanical sensitisation and 
antinociceptive tolerance. These findings indicate that sustained morphine-mediated 
activation of spinal cAMP/PKA-dependent signalling may play an important role in opioid-
induced pain sensitisation. More specifically, morphine acts acutely on MORs, which couple 
with G-proteins to inhibit AC and reduce PKA activity. However, during tolerance, MORs 
become uncoupled from G-proteins, AC inhibition is reduced, and PKA activity is 
increased. These findings also provide potential molecular targets for pharmacological 
intervention to prevent the development of such paradoxical pain sensitisation. 
The majority of studies that have demonstrated an increase in PKA activity during opioid 
tolerance have been conducted in rats using brain regions associated with the reinforcing 
properties of opioids, such as the locus coeruleus and nucleus accumbens. Studying the 
expression of morphine antinociceptive tolerance at the behavioural level (tail-flick test) and 
the alterations in PKA activity at the cellular level in mouse brain (PAG, medulla, thalamus) 
and lumbar spinal cord, Dalton et al. (2005) support the hypothesis that an increase in PKA 
activity contributes to the tolerance to morphine-induced antinociception. However, the 
effect of chronic morphine treatment for 15 days on PKA activity was region-specific 
because increases in cytosolic PKA activity were observed in the lumbar spinal cord. In 
contrast, PKA activity/kinetics was not altered in the PAG, medulla or thalamus. These 
results demonstrate that spinal and supraspinal PKA activity are differentially altered 
during morphine tolerance. Thus, the neurons in mouse brain and lumbar spinal cord that 
make up the pain pathway from the brainstem to the spinal cord respond differently to 
chronic morphine treatment. To confirm these findings, future studies need to elucidate the 
differential responses to chronic morphine treatment using in vivo models of morphine 
antinociceptive tolerance concerning the PKA involvement. 
Using a behavioural paw pressure test in rats, Yamdeu et al. (2011) demonstrated that up-
regulation of NGF, through activation of the p38 MAPK pathway, lead to adaptive changes 
in sensory neuron opioid receptors that enhance susceptibility to local opioids. After 
intraplantar NGF treatment, this effect occurs in three consecutive steps: MOR expression is 
increased in DRG at 24 h, increased axonal MOR transport at 48 h, and increased MOR 
density at 96 h. Consequently, the dose-dependent peripheral antinociceptive effects of 
locally applied full opioid agonists such as fentanyl are potentiated, and the effects of partial 
opioid agonists such as buprenorphine are more efficacious, which is reversed by the 
intrathecal administration of p38 MAPK inhibitor SB203580. Thus, in rats, peripheral 
inflammation increases MOR expression in nociceptors by NGF activation of p38 MAPK. 
This mechanism may act as a counter-regulatory response to painful p38 MAPK–induced 
conditions, such as inflammatory pain, to facilitate exogenously or endogenously mediated 
opioid antinociception. 
Recently, the roles of several MAPKs, including p38 MAPK and ERK, have been 
investigated in animal models of morphine tolerance and postoperative nociceptive 
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sensitisation. It is unknown, however, whether prior morphine-induced MAPK activation 
affects the resolution of postoperative nociceptive sensitisation. Horvath et al. (2010) 
investigated the effect of morphine-induced antinociceptive tolerance on the resolution of 
postoperative nociceptive sensitisation. They hypothesised that prior chronic morphine 
administration would inhibit or delay the resolution of postoperative nociceptive 
sensitisation via enhanced spinal glial proteins expression and MAPK signalling. Chronic 
morphine treatment attenuated the resolution of postoperative nociceptive sensitisation, as 
determined by thermal and mechanical behavioural tests, and enhanced microglial p38 
MAPK and ERK phosphorylation. To better understand these results, prior chronic 
morphine exposure could prime microglia, causing exacerbated MAPK signalling pathway 
activation following subsequent paw incision injury. This would cause more robust 
microglial responses in rats with a history of morphine tolerance versus naïve rats, and this 
response is manifested by further neuronal sensitisation, behavioural hypersensitivity and 
inhibition of the resolution of the postoperative-associated nociceptive condition. The 
Horvath and co-workers study indicates that microglial MAPKs play a role in the 
mechanisms by which morphine attenuates the resolution of postoperative pain and 
suggests that patients who abuse opioids or are on chronic opioid therapy may be more 
susceptible to developing chronic pain syndromes following acute injury. 
In conclusion, protein kinases (PKs) exert a crucial role in pain control responses mediated 
by opioids, mainly in tolerance-induced mechanisms. Thus, PKs could be the key to better 
understanding opioid pharmacodynamics. 
3.2 General and local anaesthetics  
3.2.1 General anaesthetics 
Ketamine is an NMDAR antagonist that is available for clinical use as a general anaesthetic. 
Ketamine presents analgesic effect in acute and chronic pain models in both animals and 
humans (Mathisen et al. 1995, Rabben et al., 1999; Visser & Schug, 2006; Pascual et al., 2010).  
The involvement of kinases in the analgesic effect of ketamine has been investigated. Using 
a model of neuropathic pain induced by SNL in rats, Mei et al. (2011) showed that SNL 
induced ipsilateral JNK phosphorylation up-regulation in astrocytes, but not microglia or 
neurons, within the spinal dorsal horn. Intrathecal ketamine relieved SNL-induced 
mechanical sensitisation and produced a dose-dependent effect on the suppression of SNL-
induced spinal astrocytic JNK phosphorylation but had no effect on JNK protein expression, 
suggesting that the inhibition of spinal JNK activation may be involved in the analgesic 
effects of ketamine in this model.  
The inhibition of MAPK phosphorylation by ketamine has also been related to a reduction 
in cytokine gene expressions in lipopolysaccharide (LPS)-activated macrophages (Wu et al., 
2008). A therapeutic concentration of ketamine can decrease LPS-induced JNK 
phosphorylation, thus inhibiting TNF-α and IL-6 gene expression, which leads to the 
suppression of LPS-induced macrophage activation (Wu et al., 2008). In addition, ketamine 
reduced IL-1β biosynthesis in LPS-stimulated macrophages through the suppression of Ras, 
Raf, MEK1/2, and ERK1/2/IKK phosphorylation and the subsequent translocation and 
transactivation of the transcription factor NF-κB (Chen et al., 2009). The involvement of 
TNF-α, IL-6 and IL-1β in inflammatory nociceptive sensitisation is well known. Thus, the 
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inhibition of cytokine production by ketamine in different cells may be an additional 
mechanism that contributes toward its analgesic effect. 
Beyond its own specific effects, ketamine also has analgesic effects when given in 
combination with opioids. As mentioned earlier, several studies have demonstrated that 
ERK1/2 is involved in nociception. However, activation of MOR by opioids leads to 
ERK1/2 phosphorylation (Fukuda et al. 1996; Gutstein et al. 1997; Gupta et al., 2011), and 
this can be potentiated by ketamine. Gupta et al. (2011) investigated whether the ability of 
ketamine to increase the duration of opioid-induced effects could be related to the 
modulation of opioid-induced signalling. The authors found that, in a cell culture model, 
ketamine increases the effectiveness of opioid-induced signalling by enhancing the level of 
opioid-induced ERK1/2 phosphorylation. Ketamine also delays the desensitisation and 
improves the resensitisation of ERK1/2 signalling. These effects were observed in 
heterologous cells expressing MOR, suggesting a non-NMDA receptor-mediated action of 
ketamine (Gupta et al., 2011). The authors concluded that the overall effect of ketamine 
appears to be keeping opioid-induced ERK1/2 signalling active for a longer time period, 
and this could account for the observed effects of ketamine on the duration of opioid-
induced analgesia. However, these data were obtained from in vitro experiments, and the 
link with analgesia is not clearly understood. Data provided from in vivo studies could 
contribute to improve the understanding of opioid-induced analgesia and its potentiation by 
ketamine.  
3.2.2 Local anaesthetics 
Systemic or topical administration of lidocaine and other local anaesthetics reduce 
hypersensitivity states induced by both acute inflammation and peripheral nerve injury in 
animals and brings significant relief in some patients with neuropathic pain syndromes 
(Mao & Chen, 2000; Ma et al., 2003; Gu et al., 2008; Fleming & O’Connor, 2009; Suter et al., 
2009; Buchanan& MacIvor, 2010; Suzuki et al., 2011). 
The analgesic effect of lidocaine in neuropathic pain can be partially explained by its ability to 
attenuate MAPK activation. Intrathecal injection of lidocaine in rats with chronic constriction 
injury suppressed the phosphorylation of p38 MAPK in the activated microglia in the spinal 
cord (Gu et al., 2008). In ATP-activated cultured rat microglia, lidocaine inhibited p38 MAPK 
activation and attenuated the production of proinflammatory cytokines, including TNF-α, IL-
1 and IL-6 (Su et al., 2010). Furthermore, lidocaine significantly inhibited LPS-induced Toll-
like receptor 4, NF-κB, ERK and p38 MAPK activation, but not JNK activation in LPS-
stimulated murine macrophages (Lee et al., 2008). 
Spared nerve injury (SNI) induces mechanical sensitisation and p38 MAPK activation in spinal 
microglia. Bupivacaine microspheres induced a complete sensory and motor blockade and 
significantly inhibited p38 MAPK activation and microglial proliferation in the spinal cords of 
rats (Suter et al., 2009). Carrageenan-induced hind paw inflammation and sensitisation triggers 
phosphorylation of spinal p38 MAPK and enhances TNF and IL-1 production in the bilateral 
DRGs and spinal cord. Although bupivacaine inhibits oedema, hyperalgesia and the 
carrageenan-induced production of systemic cytokines (Beloeil et al., 2006a; Combettes et al., 
2010), the inhibitory effects of bupivacaine on the expression of cytokines or phosphorylated 
p38 MAPK in spinal cord or DRGs have not been verified (Beloeil et al., 2006b). 
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ERK activation as a potential target for bupivacaine antinociception was also investigated. 
The activation of both ionotropic (AMPA, NMDA, TRPV1) and metabotropic (NK-1, 
bradykinin 2 receptor, mGluR) receptors results in ERK phosphorylation in superficial 
dorsal horn neurons in rats. Bupivacaine blocked ionotropic but not metabotropic, receptor–
induced ERK activation by apparently blocking Ca2+ influx through the plasma membrane 
in the spinal cord (Yanagidate & Strichartz, 2006). 
Taken together, the inhibition of MAPK activation by general and local anaesthetics seems 
to represent a common and important pathway to at least partially explain the mechanism 
of analgesic action exerted by these drugs through ion influx inhibition. 
3.3 Antidepressants 
Selected antidepressants suppress pain through diverse mechanisms and are now 
considered as an essential component of the therapeutic strategy for treatment of many 
types of persistent pain. Their main mechanism of action involves reinforcement of the 
descending inhibitory pathways by increasing the amount of norepinephrine and serotonin 
in the synaptic cleft at both the supraspinal and spinal levels. Based on this, tricyclic 
antidepressants (TCAs) are widely used for treating chronic pain, such as neuropathic and 
inflammatory pain. Intrathecal (i.t.) co-infusion of amitriptyline with morphine not only 
attenuates the development of morphine tolerance but also preserves its antinociceptive 
efficacy (Tai et al., 2006). Tai et al. (2007) showed that amitriptyline pretreatment reverses 
the spinal cord PKA and PKC upregulation and preserves morphine’s antinociceptive effect 
in morphine-tolerant rats submitted to thermal behaviour test; this reversal may occur via 
preventing the up-regulation of PKA and PKC protein expression. It results in the 
trafficking of glutamate transporters from the cytosol to the plasma membrane of glial cells, 
thus reducing the excitatory amino acid (EAA) concentration in the cerebrospinal fluid (CSF) 
spinal cord by the morphine challenge. This study suggested that amitriptyline is a useful 
analgesic adjuvant in the treatment of patients who need long-term opioid administration 
for pain relief.  
In addition to the traditionally used TCAs, such as amitriptyline, selective serotonin 
reuptake inhibitors (SSRIs) and mixed monoamine uptake inhibitors are also used as a first-
line treatment for managing pain syndromes. As mentioned above, voltage-gated sodium 
channels (VGSCs) are subject to modulation by G protein-coupled receptor signalling 
cascades involving PKA- and PKC-mediated phosphorylation. Depending on the neuron 
type and its anatomical location, phosphorylation of the VGSCs by PKC may facilitate slow 
inactivation (Cantrell and Catterall, 2001). Activating the 5-HT2C subtype of serotonin 
receptors in prefrontal cortex neurons results in a negative shift in the voltage-dependence 
of fast inactivation accompanied with a reduction of the peak current due to a PKC-
mediated phosphorylation process (Carr et al., 2002). Concurrent phosphorylation by PKA 
seems necessary for the maximal current reduction (Cantrell et al., 2002). These mechanisms 
can be activated by various neurotransmitters including serotonin (Cantrell and Catterall, 
2001). Because SSRIs increase the extracellular concentration of serotonin it is logical that 
they would indirectly modulate sodium channels in the central nervous system. This action 
mediated by increased serotonin and, PKA and PKC activity, could account for the analgesic 
effect of SSRIs.  
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inhibition of cytokine production by ketamine in different cells may be an additional 
mechanism that contributes toward its analgesic effect. 
Beyond its own specific effects, ketamine also has analgesic effects when given in 
combination with opioids. As mentioned earlier, several studies have demonstrated that 
ERK1/2 is involved in nociception. However, activation of MOR by opioids leads to 
ERK1/2 phosphorylation (Fukuda et al. 1996; Gutstein et al. 1997; Gupta et al., 2011), and 
this can be potentiated by ketamine. Gupta et al. (2011) investigated whether the ability of 
ketamine to increase the duration of opioid-induced effects could be related to the 
modulation of opioid-induced signalling. The authors found that, in a cell culture model, 
ketamine increases the effectiveness of opioid-induced signalling by enhancing the level of 
opioid-induced ERK1/2 phosphorylation. Ketamine also delays the desensitisation and 
improves the resensitisation of ERK1/2 signalling. These effects were observed in 
heterologous cells expressing MOR, suggesting a non-NMDA receptor-mediated action of 
ketamine (Gupta et al., 2011). The authors concluded that the overall effect of ketamine 
appears to be keeping opioid-induced ERK1/2 signalling active for a longer time period, 
and this could account for the observed effects of ketamine on the duration of opioid-
induced analgesia. However, these data were obtained from in vitro experiments, and the 
link with analgesia is not clearly understood. Data provided from in vivo studies could 
contribute to improve the understanding of opioid-induced analgesia and its potentiation by 
ketamine.  
3.2.2 Local anaesthetics 
Systemic or topical administration of lidocaine and other local anaesthetics reduce 
hypersensitivity states induced by both acute inflammation and peripheral nerve injury in 
animals and brings significant relief in some patients with neuropathic pain syndromes 
(Mao & Chen, 2000; Ma et al., 2003; Gu et al., 2008; Fleming & O’Connor, 2009; Suter et al., 
2009; Buchanan& MacIvor, 2010; Suzuki et al., 2011). 
The analgesic effect of lidocaine in neuropathic pain can be partially explained by its ability to 
attenuate MAPK activation. Intrathecal injection of lidocaine in rats with chronic constriction 
injury suppressed the phosphorylation of p38 MAPK in the activated microglia in the spinal 
cord (Gu et al., 2008). In ATP-activated cultured rat microglia, lidocaine inhibited p38 MAPK 
activation and attenuated the production of proinflammatory cytokines, including TNF-α, IL-
1 and IL-6 (Su et al., 2010). Furthermore, lidocaine significantly inhibited LPS-induced Toll-
like receptor 4, NF-κB, ERK and p38 MAPK activation, but not JNK activation in LPS-
stimulated murine macrophages (Lee et al., 2008). 
Spared nerve injury (SNI) induces mechanical sensitisation and p38 MAPK activation in spinal 
microglia. Bupivacaine microspheres induced a complete sensory and motor blockade and 
significantly inhibited p38 MAPK activation and microglial proliferation in the spinal cords of 
rats (Suter et al., 2009). Carrageenan-induced hind paw inflammation and sensitisation triggers 
phosphorylation of spinal p38 MAPK and enhances TNF and IL-1 production in the bilateral 
DRGs and spinal cord. Although bupivacaine inhibits oedema, hyperalgesia and the 
carrageenan-induced production of systemic cytokines (Beloeil et al., 2006a; Combettes et al., 
2010), the inhibitory effects of bupivacaine on the expression of cytokines or phosphorylated 
p38 MAPK in spinal cord or DRGs have not been verified (Beloeil et al., 2006b). 
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ERK activation as a potential target for bupivacaine antinociception was also investigated. 
The activation of both ionotropic (AMPA, NMDA, TRPV1) and metabotropic (NK-1, 
bradykinin 2 receptor, mGluR) receptors results in ERK phosphorylation in superficial 
dorsal horn neurons in rats. Bupivacaine blocked ionotropic but not metabotropic, receptor–
induced ERK activation by apparently blocking Ca2+ influx through the plasma membrane 
in the spinal cord (Yanagidate & Strichartz, 2006). 
Taken together, the inhibition of MAPK activation by general and local anaesthetics seems 
to represent a common and important pathway to at least partially explain the mechanism 
of analgesic action exerted by these drugs through ion influx inhibition. 
3.3 Antidepressants 
Selected antidepressants suppress pain through diverse mechanisms and are now 
considered as an essential component of the therapeutic strategy for treatment of many 
types of persistent pain. Their main mechanism of action involves reinforcement of the 
descending inhibitory pathways by increasing the amount of norepinephrine and serotonin 
in the synaptic cleft at both the supraspinal and spinal levels. Based on this, tricyclic 
antidepressants (TCAs) are widely used for treating chronic pain, such as neuropathic and 
inflammatory pain. Intrathecal (i.t.) co-infusion of amitriptyline with morphine not only 
attenuates the development of morphine tolerance but also preserves its antinociceptive 
efficacy (Tai et al., 2006). Tai et al. (2007) showed that amitriptyline pretreatment reverses 
the spinal cord PKA and PKC upregulation and preserves morphine’s antinociceptive effect 
in morphine-tolerant rats submitted to thermal behaviour test; this reversal may occur via 
preventing the up-regulation of PKA and PKC protein expression. It results in the 
trafficking of glutamate transporters from the cytosol to the plasma membrane of glial cells, 
thus reducing the excitatory amino acid (EAA) concentration in the cerebrospinal fluid (CSF) 
spinal cord by the morphine challenge. This study suggested that amitriptyline is a useful 
analgesic adjuvant in the treatment of patients who need long-term opioid administration 
for pain relief.  
In addition to the traditionally used TCAs, such as amitriptyline, selective serotonin 
reuptake inhibitors (SSRIs) and mixed monoamine uptake inhibitors are also used as a first-
line treatment for managing pain syndromes. As mentioned above, voltage-gated sodium 
channels (VGSCs) are subject to modulation by G protein-coupled receptor signalling 
cascades involving PKA- and PKC-mediated phosphorylation. Depending on the neuron 
type and its anatomical location, phosphorylation of the VGSCs by PKC may facilitate slow 
inactivation (Cantrell and Catterall, 2001). Activating the 5-HT2C subtype of serotonin 
receptors in prefrontal cortex neurons results in a negative shift in the voltage-dependence 
of fast inactivation accompanied with a reduction of the peak current due to a PKC-
mediated phosphorylation process (Carr et al., 2002). Concurrent phosphorylation by PKA 
seems necessary for the maximal current reduction (Cantrell et al., 2002). These mechanisms 
can be activated by various neurotransmitters including serotonin (Cantrell and Catterall, 
2001). Because SSRIs increase the extracellular concentration of serotonin it is logical that 
they would indirectly modulate sodium channels in the central nervous system. This action 
mediated by increased serotonin and, PKA and PKC activity, could account for the analgesic 
effect of SSRIs.  
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Thán et al. (2007) studied the pharmacological interaction between SSRIs and sodium 
channel blocking agents such as lamotrigine. They examined the interaction of VGSCs 
blockers and SSRIs at the level of spinal segmental neurotransmission in the rat hemisected 
spinal cord model. The reflex inhibitory action of VGSCs blocker was markedly enhanced 
when SSRI compounds were co-applied; and it was found serotonin receptors and PKC 
involvement in the modulation of sodium channel function (Thán et al., 2007). 
In conclusion, it seems that antidepressants exert analgesic effects by a mechanism involving 
serotonin, PKA and PKC activation, and modulation of VGSCs. Understanding the PK 
dynamics in these processes would be key to improve pain management. 
3.4 PKG signalling and pain control 
As described in section 1, the activation of signalling pathways that are dependent on PKA, 
PKC and MAPKs is important for the sensitisation of nociceptors and pain processing. The 
PKG pathway, in turn, is related to the nitric oxide (NO)/cGMP/PKG/ATP-sensitive K+ 
channel pathway, which plays an important role in peripheral antinociception (Rodrigues & 
Duarte, 2000; Sachs et al., 2004).  
The relationship between the NO/cGMP pathway and peripheral antinociception was first 
demonstrated by Ferreira and co-workers (Durate et al., 1990; Ferreira et al., 1991). They 
showed that the antinociceptive effect of acetylcholine and morphine was blocked by a 
guanylyl cyclase inhibitor and an NO synthase inhibitor, and was potentiated by a specific 
cGMP phosphodiesterase inhibitor. Moreover, the antinociception achieved with these 
drugs was mimicked by NO donors such as sodium nitroprusside. The involvement of this 
pathway has also been demonstrated for other analgesics, such as dipyrone (Duarte et al., 
1992), diclofenac (Tonussi et al., 1994), and some antinociceptive agents, such as Crotalus 
durissus terrificus snake-venom (Picolo et al., 2000), the potent κ-opioid receptor agonist 
bremazocine (Amarante & Duarte, 2002), xylazine (Romero & Duarte, 2009), the 
cannabinoid receptor agonist anandamida (Reis et al., 2009) and ketamine (Romero et al., 
2011). In agreement with in vivo studies, data from electrophysiological experiments 
studying inflammatory sensitisation showed that capsaicin-induced elevations in 
intracellular Ca2+ levels of rat sensory neurons lead to an enhanced production of cGMP via 
the NO pathway. The elevated cGMP levels and the subsequent activation of PKG appear to 
inactivate the sensitisation, confirming the important regulatory role of this kinase in 
reversing the neuronal sensitisation (Lopshire & Nicol, 1997). 
In addition to studies on the mechanism of antinociceptive action of analgesics, Duarte and 
co-workers showed that the ability of morphine and dipyrone to induce peripheral 
antinociception is dependent on the activation of ATP-sensitive K+ channels (Rodrigues & 
Duarte, 2000). cGMP can directly or indirectly (via PKG stimulation) modulate the activity 
of ion channels. PKG is a protein kinase that is stimulated selectively but not exclusively by 
cGMP. Once stimulated, PKG inhibits phospholipase C activity, stimulates Ca2+-ATPase 
activity, inhibits inositol 1,4,5-triphosphate, inhibits Ca2+ channels, and/or stimulates K+ 
channels activity (Cury et al., 2011). Furthermore, Sachs et al. (2004) demonstrated that the 
antinociceptive effect of dipyrone on persistent inflammatory sensitisation is dependent on 
the PKG activation and its modulation of ATP-sensitive K+ channels.  
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Taken together, these findings suggest the relevant role of PKG as an intermediate between 
cGMP generation and the opening of ATP-sensitive K+ channels. The activation of this 
modulatory pathway may be an interesting target for new drug development.  
4. Conclusions: A perspective of promising drug targets 
In this section, protein kinases will be viewed as targets for pain control drug development. 
Several pre-clinical and clinical trials will be reviewed, focusing on the effectiveness and 
adverse effects of such drugs. 
The genomic analysis of the eukaryotic protein kinase superfamily together with drug 
design approaches such as the bioisosteric replacement of pharmacophoric groups of lead 
compounds and 3D-quantitative structure-activity relationship analysis provide several new 
chemical entities to be tested and developed as drug candidates.  
The continuous progress in protein structure determination and improved resolution allows 
the identification of pharmacological targets. The experimental results from genetically 
modified animals support new hypotheses and help to validate new concepts to better 
understand the pathological genesis and natural processes of our body. 
Such progress in medicinal chemistry, biochemistry and pharmacology paradoxically leads to 
poor results in terms of new pharmaceutical entities and therapeutics. The pharmaceutical 
innovation decrease in recent decades is due to many aspects that are beyond the scope of this 
chapter. As targets of pharmaceutics, protein kinases play an important role in this history, 
providing several new therapeutic cancer targets. Drug discovery companies have targeted 
protein kinase inhibitors, which have led to billion dollar merges and a new branch of research 
and development that spread beyond the boundaries of cancer therapeutics (Garber, 2003). 
At the beginning of the second decade of the 21st century, there are synthetic and medicinal 
chemistry service companies with strong backgrounds in kinase targets and kinase inhibitor 
drug discovery; these companies can develop new compounds on demand. There are 
sixteen pharmaceuticals actually licensed as protein kinase inhibitors, mainly to treat 
different cancers. The first drug, Trastuzumab, was licensed in 1998; this drug is a 
monoclonal antibody targeting membrane receptors that activates the MAPK pathway as 
well as the PI3 Kinase/AKT pathways. After this initial drug, many small molecules 
followed, targeting kinases as mechanism of action, mainly as ATP competitors. 
The International Federation of Pharmaceutical Manufacturers & Associations has listed in 
its Clinical Trials Portal three entries for clinical trials focusing on pain and protein kinases. 
Two of these trials involve p38 MAPK inhibitors from a large pharmaceutical company and 
are testing for neuropathic pain following nerve trauma and from lumbosacral 
radiculopathy. The third trial involves tyrosine kinase (TrkA) receptor expression in 
children with retrosternal pain. 
Experimental evidence suggests that p38 MAPK is activated in spinal microglia after nerve 
injury and contributes to neuropathic pain development and maintenance (Ji & Suter, 2007). 
p38 MAPK phosphorylates targets that transduce cellular signals to molecules and 
transcription factors that are involved in regulating the biosynthesis of inflammatory 
cytokines such as IL-1 and TNF-α. The inhibitor dilmapimod was associated with a 
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Thán et al. (2007) studied the pharmacological interaction between SSRIs and sodium 
channel blocking agents such as lamotrigine. They examined the interaction of VGSCs 
blockers and SSRIs at the level of spinal segmental neurotransmission in the rat hemisected 
spinal cord model. The reflex inhibitory action of VGSCs blocker was markedly enhanced 
when SSRI compounds were co-applied; and it was found serotonin receptors and PKC 
involvement in the modulation of sodium channel function (Thán et al., 2007). 
In conclusion, it seems that antidepressants exert analgesic effects by a mechanism involving 
serotonin, PKA and PKC activation, and modulation of VGSCs. Understanding the PK 
dynamics in these processes would be key to improve pain management. 
3.4 PKG signalling and pain control 
As described in section 1, the activation of signalling pathways that are dependent on PKA, 
PKC and MAPKs is important for the sensitisation of nociceptors and pain processing. The 
PKG pathway, in turn, is related to the nitric oxide (NO)/cGMP/PKG/ATP-sensitive K+ 
channel pathway, which plays an important role in peripheral antinociception (Rodrigues & 
Duarte, 2000; Sachs et al., 2004).  
The relationship between the NO/cGMP pathway and peripheral antinociception was first 
demonstrated by Ferreira and co-workers (Durate et al., 1990; Ferreira et al., 1991). They 
showed that the antinociceptive effect of acetylcholine and morphine was blocked by a 
guanylyl cyclase inhibitor and an NO synthase inhibitor, and was potentiated by a specific 
cGMP phosphodiesterase inhibitor. Moreover, the antinociception achieved with these 
drugs was mimicked by NO donors such as sodium nitroprusside. The involvement of this 
pathway has also been demonstrated for other analgesics, such as dipyrone (Duarte et al., 
1992), diclofenac (Tonussi et al., 1994), and some antinociceptive agents, such as Crotalus 
durissus terrificus snake-venom (Picolo et al., 2000), the potent κ-opioid receptor agonist 
bremazocine (Amarante & Duarte, 2002), xylazine (Romero & Duarte, 2009), the 
cannabinoid receptor agonist anandamida (Reis et al., 2009) and ketamine (Romero et al., 
2011). In agreement with in vivo studies, data from electrophysiological experiments 
studying inflammatory sensitisation showed that capsaicin-induced elevations in 
intracellular Ca2+ levels of rat sensory neurons lead to an enhanced production of cGMP via 
the NO pathway. The elevated cGMP levels and the subsequent activation of PKG appear to 
inactivate the sensitisation, confirming the important regulatory role of this kinase in 
reversing the neuronal sensitisation (Lopshire & Nicol, 1997). 
In addition to studies on the mechanism of antinociceptive action of analgesics, Duarte and 
co-workers showed that the ability of morphine and dipyrone to induce peripheral 
antinociception is dependent on the activation of ATP-sensitive K+ channels (Rodrigues & 
Duarte, 2000). cGMP can directly or indirectly (via PKG stimulation) modulate the activity 
of ion channels. PKG is a protein kinase that is stimulated selectively but not exclusively by 
cGMP. Once stimulated, PKG inhibits phospholipase C activity, stimulates Ca2+-ATPase 
activity, inhibits inositol 1,4,5-triphosphate, inhibits Ca2+ channels, and/or stimulates K+ 
channels activity (Cury et al., 2011). Furthermore, Sachs et al. (2004) demonstrated that the 
antinociceptive effect of dipyrone on persistent inflammatory sensitisation is dependent on 
the PKG activation and its modulation of ATP-sensitive K+ channels.  
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Taken together, these findings suggest the relevant role of PKG as an intermediate between 
cGMP generation and the opening of ATP-sensitive K+ channels. The activation of this 
modulatory pathway may be an interesting target for new drug development.  
4. Conclusions: A perspective of promising drug targets 
In this section, protein kinases will be viewed as targets for pain control drug development. 
Several pre-clinical and clinical trials will be reviewed, focusing on the effectiveness and 
adverse effects of such drugs. 
The genomic analysis of the eukaryotic protein kinase superfamily together with drug 
design approaches such as the bioisosteric replacement of pharmacophoric groups of lead 
compounds and 3D-quantitative structure-activity relationship analysis provide several new 
chemical entities to be tested and developed as drug candidates.  
The continuous progress in protein structure determination and improved resolution allows 
the identification of pharmacological targets. The experimental results from genetically 
modified animals support new hypotheses and help to validate new concepts to better 
understand the pathological genesis and natural processes of our body. 
Such progress in medicinal chemistry, biochemistry and pharmacology paradoxically leads to 
poor results in terms of new pharmaceutical entities and therapeutics. The pharmaceutical 
innovation decrease in recent decades is due to many aspects that are beyond the scope of this 
chapter. As targets of pharmaceutics, protein kinases play an important role in this history, 
providing several new therapeutic cancer targets. Drug discovery companies have targeted 
protein kinase inhibitors, which have led to billion dollar merges and a new branch of research 
and development that spread beyond the boundaries of cancer therapeutics (Garber, 2003). 
At the beginning of the second decade of the 21st century, there are synthetic and medicinal 
chemistry service companies with strong backgrounds in kinase targets and kinase inhibitor 
drug discovery; these companies can develop new compounds on demand. There are 
sixteen pharmaceuticals actually licensed as protein kinase inhibitors, mainly to treat 
different cancers. The first drug, Trastuzumab, was licensed in 1998; this drug is a 
monoclonal antibody targeting membrane receptors that activates the MAPK pathway as 
well as the PI3 Kinase/AKT pathways. After this initial drug, many small molecules 
followed, targeting kinases as mechanism of action, mainly as ATP competitors. 
The International Federation of Pharmaceutical Manufacturers & Associations has listed in 
its Clinical Trials Portal three entries for clinical trials focusing on pain and protein kinases. 
Two of these trials involve p38 MAPK inhibitors from a large pharmaceutical company and 
are testing for neuropathic pain following nerve trauma and from lumbosacral 
radiculopathy. The third trial involves tyrosine kinase (TrkA) receptor expression in 
children with retrosternal pain. 
Experimental evidence suggests that p38 MAPK is activated in spinal microglia after nerve 
injury and contributes to neuropathic pain development and maintenance (Ji & Suter, 2007). 
p38 MAPK phosphorylates targets that transduce cellular signals to molecules and 
transcription factors that are involved in regulating the biosynthesis of inflammatory 
cytokines such as IL-1 and TNF-α. The inhibitor dilmapimod was associated with a 
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significant reduction in pain intensity in patients with neuropathic pain following nerve 
injury (Anand et al., 2011). The clinical efficacy of p38 MAPK inhibitors in acute pain was 
also demonstrated in an assay of acute postsurgical dental pain; these inhibitors increased 
the time to rescue medication and decreased pain intensity when compared with the 
placebo group (Tong et al. 2011). 
Despite these clinical assays that are directly associated with pain, many other clinical and 
pre-clinical studies have some degree of relevance when pain management is the goal. The 
action of different protein kinases inhibitors in cancer, rheumatoid arthritis, postsurgical 
conditions, diabetes and so forth has significant impact on decreasing pain in subjects 
suffering from these pathologies. 
In addition to these efforts, one long-sought goal is the development of inhibitors of PKC 
isoforms because this family of protein kinases is involved in the cellular signalling of 
nociception, anxiety and cognition (Van Kolen et al., 2008). Non-isoform-specific PKC 
inhibitors have proven to be too toxic for in vivo use. PKCε is the primary target for drug 
design. This isoform is activated during nerve sensitisation and phosphorylates ion channels 
in the peripheral nervous system such as TRPV-1, and N-type voltage-dependent calcium 
channels (VDCCs) in isolectin B4-positive nociceptors; in addition, it mediates interplay 
between other kinases that are important to nociceptor function, such as PKA and MAPK 
(Hucho et al., 2005). There are no specific ATP-binding competitors for PKCε. There are 
other compounds that target alternative domains, such as the pseudosubstrate sequence, 
which is responsible for keeping the kinase in an inactivate state. The lipid-binding, cellular 
localisation and actin-binding domains are also valid targets. The main goal is to develop 
isoform-specific inhibitors among the ten known isozymes and to provide tissue specificity 
because cardiac-specific PKCε inhibition blocks norepinephrine-mediated regulation of 
heart contraction (Johnson et al., 1996). 
The pharmaceutical paradigm of “new targets for old drugs”, where known medications are 
employed in new pathologies as an innovation strategy to keep new products flowing to the 
market also applies to protein kinases and pain control because many drugs utilised for 
chronic and neuropathic pain management, such as antidepressants and anaesthetics, 
depend on protein kinases for their mechanisms of action.  
New lead drugs are also being proposed; these drugs utilise molecular hybridisation and 
bioisosteric replacement of pharmacophoric groups, where different bioactive molecular 
moieties of mechanistically diverse drugs are fused, giving birth to new chemical entities 
with dual activity profiles (Brando Lima et al., 2011) that incorporate protein kinase 
inhibition with another type of biological activity. The challenge of developing new 
molecular approaches to create drugs that manage pain is great, and as seen throughout this 
chapter, protein kinases are an important aspect of this problem. 
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significant reduction in pain intensity in patients with neuropathic pain following nerve 
injury (Anand et al., 2011). The clinical efficacy of p38 MAPK inhibitors in acute pain was 
also demonstrated in an assay of acute postsurgical dental pain; these inhibitors increased 
the time to rescue medication and decreased pain intensity when compared with the 
placebo group (Tong et al. 2011). 
Despite these clinical assays that are directly associated with pain, many other clinical and 
pre-clinical studies have some degree of relevance when pain management is the goal. The 
action of different protein kinases inhibitors in cancer, rheumatoid arthritis, postsurgical 
conditions, diabetes and so forth has significant impact on decreasing pain in subjects 
suffering from these pathologies. 
In addition to these efforts, one long-sought goal is the development of inhibitors of PKC 
isoforms because this family of protein kinases is involved in the cellular signalling of 
nociception, anxiety and cognition (Van Kolen et al., 2008). Non-isoform-specific PKC 
inhibitors have proven to be too toxic for in vivo use. PKCε is the primary target for drug 
design. This isoform is activated during nerve sensitisation and phosphorylates ion channels 
in the peripheral nervous system such as TRPV-1, and N-type voltage-dependent calcium 
channels (VDCCs) in isolectin B4-positive nociceptors; in addition, it mediates interplay 
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because cardiac-specific PKCε inhibition blocks norepinephrine-mediated regulation of 
heart contraction (Johnson et al., 1996). 
The pharmaceutical paradigm of “new targets for old drugs”, where known medications are 
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market also applies to protein kinases and pain control because many drugs utilised for 
chronic and neuropathic pain management, such as antidepressants and anaesthetics, 
depend on protein kinases for their mechanisms of action.  
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bioisosteric replacement of pharmacophoric groups, where different bioactive molecular 
moieties of mechanistically diverse drugs are fused, giving birth to new chemical entities 
with dual activity profiles (Brando Lima et al., 2011) that incorporate protein kinase 
inhibition with another type of biological activity. The challenge of developing new 
molecular approaches to create drugs that manage pain is great, and as seen throughout this 
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